FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Cohen, LA
Gutierrez, L
Weiss, A
Leichtmann-Bardoogo, Y
Zhang, DL
Crooks, DR
Sougrat, R
Morgenstern, A
Galy, B
Hentze, MW
Lazaro, FJ
Rouault, TA
Meyron-Holtz, EG
AF Cohen, Lyora A.
Gutierrez, Lucia
Weiss, Avital
Leichtmann-Bardoogo, Yael
Zhang, De-liang
Crooks, Daniel R.
Sougrat, Rachid
Morgenstern, Avigail
Galy, Bruno
Hentze, Matthias W.
Lazaro, Francisco J.
Rouault, Tracey A.
Meyron-Holtz, Esther G.
TI Serum ferritin is derived primarily from macrophages through a
nonclassical secretory pathway
SO BLOOD
LA English
DT Article
ID HUMAN ERYTHROID PRECURSORS; TRANSFERRIN IRON DELIVERY;
ENDOPLASMIC-RETICULUM; REGULATORY PROTEIN-2; DIAGNOSTIC-VALUE;
CONCANAVALIN-A; H-FERRITIN; METABOLISM; CELLS; RECEPTOR
AB The serum ferritin concentration is a clinical parameter measured widely for the differential diagnosis of anemia. Its levels increase with elevations of tissue iron stores and with inflammation, but studies on cellular sources of serum ferritin as well as its subunit composition, degree of iron loading and glycosylation have given rise to conflicting results. To gain further understanding of serum ferritin, we have used traditional and modern methodologies to characterize mouse serum ferritin. We find that both splenic macrophages and proximal tubule cells of the kidney are possible cellular sources for serum ferritin and that serum ferritin is secreted by cells rather than being the product of a cytosolic leak from damaged cells. Mouse serum ferritin is composed mostly of L-subunits, whereas it contains few H-subunits and iron content is low. L-subunits of serum ferritin are frequently truncated at the C-terminus, giving rise to a characteristic 17-kD band that has been previously observed in lysosomal ferritin. Taken together with the fact that mouse serum ferritin is not detectably glycosylated, we propose that mouse serum ferritin is secreted through the nonclassical lysosomal secretory pathway. (Blood. 2010; 116(9):1574-1584)
C1 [Cohen, Lyora A.; Weiss, Avital; Leichtmann-Bardoogo, Yael; Morgenstern, Avigail; Meyron-Holtz, Esther G.] Technion Israel Inst Technol, Fac Biotechnol & Food Engn, Lab Mol Nutr, IL-32000 Technion, Haifa, Israel.
[Gutierrez, Lucia; Lazaro, Francisco J.] Univ Zaragoza, Dept Ciencia & Tecnol Mat & Fluidos, Zaragoza, Spain.
[Zhang, De-liang; Crooks, Daniel R.; Rouault, Tracey A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Mol Med, NIH, Bethesda, MD USA.
[Sougrat, Rachid] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cell Biol & Metab Program, NIH, Bethesda, MD USA.
[Galy, Bruno; Hentze, Matthias W.] European Mol Biol Lab, Heidelberg, Germany.
RP Meyron-Holtz, EG (reprint author), Technion Israel Inst Technol, Fac Biotechnol & Food Engn, Lab Mol Nutr, IL-32000 Technion, Haifa, Israel.
EM meyron@tx.technion.ac.il
RI Gutierrez, Lucia/A-4305-2008; Meyron-Holtz, Esther/B-5991-2013; Lazaro,
Francisco/K-5100-2014
OI Gutierrez, Lucia/0000-0003-2366-3598; Sougrat,
Rachid/0000-0001-6476-1886; Zhang, Deliang/0000-0001-9478-5344; Hentze,
Matthias/0000-0002-4023-7876; Lazaro, Francisco/0000-0003-3130-4237
FU US-Israel Binational Science Foundation [2007466]; Instituto de Salud
Carlos III (Spain) [PI060549]
FX This work was funded by the US-Israel Binational Science Foundation,
Grant no. 2007466 (E.M.-H. and T.R.) and the Instituto de Salud Carlos
III (Spain), project PI060549 (F.J.L.)
NR 50
TC 111
Z9 117
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD SEP 2
PY 2010
VL 116
IS 9
BP 1574
EP 1584
DI 10.1182/blood-2009-11-253815
PG 11
WC Hematology
SC Hematology
GA 646VT
UT WOS:000281572700026
PM 20472835
ER
PT J
AU Connolly, BM
Choi, EY
Gardsvoll, H
Bey, AL
Currie, BM
Chavakis, T
Liu, SH
Molinolo, A
Ploug, M
Leppla, SH
Bugge, TH
AF Connolly, Brian M.
Choi, Eun Young
Gardsvoll, Henrik
Bey, Alexandra L.
Currie, Brooke M.
Chavakis, Triantafyllos
Liu, Shihui
Molinolo, Alfredo
Ploug, Michael
Leppla, Stephen H.
Bugge, Thomas H.
TI Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel
role in suppression of fibrin-associated inflammation
SO BLOOD
LA English
DT Article
ID UROKINASE PLASMINOGEN-ACTIVATOR; LIGNEOUS CONJUNCTIVITIS; DEFICIENT
MICE; CELL RECRUITMENT; ANTHRAX TOXIN; RECEPTOR; GENE; FIBROSIS;
BINDING; PROTEOLYSIS
AB The urokinase plasminogen activator receptor (uPAR) has emerged as a potential regulator of cell adhesion, cell migration, proliferation, differentiation, and cell survival in multiple physiologic and pathologic contexts. The urokinase plasminogen activator (uPA) was the first identified ligand for uPAR, but elucidation of the specific functions of the uPA-uPAR interaction in vivo has been difficult because uPA has important physiologic functions that are independent of binding to uPAR and because uPAR engages multiple ligands. Here, we developed a new mouse strain (Plau(GFDhu/GFDhu)) in which the interaction between endogenous uPA and uPAR is selectively abrogated, whereas other functions of both the protease and its receptor are retained. Specifically, we introduced 4 amino acid substitutions into the growth factor domain (GFD) of uPA that abrogate uPAR binding while preserving the overall structure of the domain. Analysis of Plau(GFDhu/GFDhu) mice revealed an unanticipated role of the uPAuPAR interaction in suppressing inflammation secondary to fibrin deposition. In contrast, leukocyte recruitment and tissue regeneration were unaffected by the loss of uPA binding to uPAR. This study identifies a principal in vivo role of the uPA-uPAR interaction in cell-associated fibrinolysis critical for suppression of fibrin accumulation and fibrin-associated inflammation and provides a valuable model for further exploration of this multifunctional receptor. (Blood. 2010; 116(9):1593-1603)
C1 [Bugge, Thomas H.] Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.
[Choi, Eun Young; Chavakis, Triantafyllos] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Gardsvoll, Henrik; Ploug, Michael] Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark.
[Liu, Shihui; Leppla, Stephen H.] NIAID, Lab Bacterial Dis, NIH, Bethesda, MD 20892 USA.
RP Bugge, TH (reprint author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Rm 211, Bethesda, MD 20892 USA.
EM thomas.bugge@nih.gov
FU National Institute of Dental and Craniofacial Research; National
Institutes of Health; National Institute of Cancer Intramural Research;
Danish National Research Foundation (Danish-Chinese Center for Proteases
and Cancer); Lundbeck Foundation
FX This study was supported by the National Institute of Dental and
Craniofacial Research, National Institutes of Health, and National
Institute of Cancer Intramural Research Programs, and grants from the
Danish National Research Foundation (Danish-Chinese Center for Proteases
and Cancer), and the Lundbeck Foundation. PlauGFDhu/GFDhu
mice can be obtained by contacting Thomas Bugge (thomas.bugge@nih.gov).
NR 50
TC 47
Z9 48
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD SEP 2
PY 2010
VL 116
IS 9
BP 1593
EP 1603
DI 10.1182/blood-2010-03-276642
PG 11
WC Hematology
SC Hematology
GA 646VT
UT WOS:000281572700028
PM 20466854
ER
PT J
AU Dunn, JP
Cowan, RL
Volkow, ND
Feurer, ID
Li, R
Williams, DB
Kessler, RM
Abumrad, NN
AF Dunn, Julia P.
Cowan, Ronald L.
Volkow, Nora D.
Feurer, Irene D.
Li, Rui
Williams, D. Brandon
Kessler, Robert M.
Abumrad, Naji N.
TI Decreased dopamine type 2 receptor availability after bariatric surgery:
Preliminary findings
SO BRAIN RESEARCH
LA English
DT Article
DE Dopamine; Obesity; Bariatric surgery; Receptor
ID LAPAROSCOPIC SLEEVE GASTRECTOMY; POSITRON-EMISSION-TOMOGRAPHY; MORBIDLY
OBESE SUBJECTS; GASTRIC BYPASS-SURGERY; EXTRASTRIATAL REGIONS; F-18
FALLYPRIDE; DORSAL STRIATUM; FOOD REWARD; WEIGHT-LOSS; PEPTIDE-YY
AB Background: Diminished dopaminergic neurotransmission contributes to decreased reward and negative eating behaviors in obesity. Bariatric surgery is the most effective therapy for obesity and rapidly reduces hunger and improves satiety through unknown mechanisms. We hypothesized that dopaminergic neurotransmission would be enhanced after Roux-en-Y-Gastric Bypass (RYGB) and Vertical Sleeve Gastrectomy (VSG) surgery and that these changes would influence eating behaviors and contribute to the positive outcomes from bariatric surgery. Methods: Five females with obesity were studied preoperatively and at 7 weeks after RYGB or VSG surgery. Subjects underwent positron emission tomography (PET) imaging with a dopamine type 2 (DA D2) receptor radioligand whose binding is sensitive to competition with endogenous dopamine. Regions of interest (ROI) relevant to eating behaviors were delineated. Fasting enteroendocrine hormones were quantified at each time point. Results: Body weight decreased as expected after surgery. DA D2 receptor availability decreased after surgery. Regional decreases (mean +/- SEM) were caudate 10 +/- 3%, putamen 9 +/- 4%, ventral striatum 8 +/- 4%, hypothalamus 9 +/- 3%, substantia nigra 10 +/- 2%, medial thalamus 8 2%, and amygdala 9 3%. These were accompanied by significant decreases in plasma insulin (62%) and leptin (41%). Conclusion: The decreases in DA D2 receptor availability after RYGB and VSG most likely reflect increases in extracellular dopamine levels. Enhanced dopaminergic neurotransmission may contribute to improved eating behavior (e.g. reduced hunger and improved satiety) following these bariatric procedures. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Dunn, Julia P.] Vanderbilt Univ, Sch Med, Dept Med, Div Diabet Endocrinol & Metab, Nashville, TN 37232 USA.
[Cowan, Ronald L.] Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37232 USA.
[Feurer, Irene D.; Williams, D. Brandon; Abumrad, Naji N.] Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA.
[Cowan, Ronald L.; Li, Rui; Kessler, Robert M.] Vanderbilt Univ, Sch Med, Dept Radiol, Nashville, TN 37232 USA.
[Feurer, Irene D.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA.
[Volkow, Nora D.] Natl Inst Drug Abuse, Bethesda, MD USA.
RP Dunn, JP (reprint author), Vanderbilt Univ, Sch Med, Dept Med, Div Diabet Endocrinol & Metab, 2213 Garland Ave,7465 MRBIV, Nashville, TN 37232 USA.
EM julia.dunn@vanderbilt.edu
FU Vanderbilt Environmental Health Science Scholars Program [NIEHS K12
ESO15855]; NIH [R01-DK070860]; NIDDK; NCRR/NIH [1 UL1 RR024975];
Vanderbilt Diabetes Research and Training Center [DK20593]; Vanderbilt
Digestive Diseases Research Center [DK058404]
FX We would like to thank Pamela Marks-Shulman, M.S., R.D. and Joan Kaiser,
R.N. for their hard work in support of this study. J.P.D. received
support from the Vanderbilt Environmental Health Science Scholars
Program (NIEHS K12 ESO15855). This work was supported by NIH grants
R01-DK070860, NIDDK to N.N.A. This work was also supported in part by
Vanderbilt CTSA grant 1 UL1 RR024975 from NCRR/NIH, the Vanderbilt
Diabetes Research and Training Center (DK20593), and the Vanderbilt
Digestive Diseases Research Center (DK058404).
NR 50
TC 64
Z9 65
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD SEP 2
PY 2010
VL 1350
SI SI
BP 123
EP 130
DI 10.1016/j.brainres.2010.03.064
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 653EA
UT WOS:000282069500014
PM 20362560
ER
PT J
AU Altshuler, DM
Gibbs, RA
Peltonen, L
Dermitzakis, E
Schaffner, SF
Yu, FL
Bonnen, PE
de Bakker, PIW
Deloukas, P
Gabriel, SB
Gwilliam, R
Hunt, S
Inouye, M
Jia, XM
Palotie, A
Parkin, M
Whittaker, P
Chang, K
Hawes, A
Lewis, LR
Ren, YR
Wheeler, D
Muzny, DM
Barnes, C
Darvishi, K
Hurles, M
Korn, JM
Kristiansson, K
Lee, C
McCarroll, SA
Nemesh, J
Keinan, A
Montgomery, SB
Pollack, S
Price, AL
Soranzo, N
Gonzaga-Jauregui, C
Anttila, V
Brodeur, W
Daly, MJ
Leslie, S
McVean, G
Moutsianas, L
Nguyen, H
Zhang, QR
Ghori, MJR
McGinnis, R
McLaren, W
Takeuchi, F
Grossman, SR
Shlyakhter, I
Hostetter, EB
Sabeti, PC
Adebamowo, CA
Foster, MW
Gordon, DR
Licinio, J
Manca, MC
Marshall, PA
Matsuda, I
Ngare, D
Wang, VO
Reddy, D
Rotimi, CN
Royal, CD
Sharp, RR
Zeng, CQ
Brooks, LD
McEwen, JE
AF Altshuler, David M.
Gibbs, Richard A.
Peltonen, Leena
Dermitzakis, Emmanouil
Schaffner, Stephen F.
Yu, Fuli
Bonnen, Penelope E.
de Bakker, Paul I. W.
Deloukas, Panos
Gabriel, Stacey B.
Gwilliam, Rhian
Hunt, Sarah
Inouye, Michael
Jia, Xiaoming
Palotie, Aarno
Parkin, Melissa
Whittaker, Pamela
Chang, Kyle
Hawes, Alicia
Lewis, Lora R.
Ren, Yanru
Wheeler, David
Muzny, Donna Marie
Barnes, Chris
Darvishi, Katayoon
Hurles, Matthew
Korn, Joshua M.
Kristiansson, Kati
Lee, Charles
McCarroll, Steven A.
Nemesh, James
Keinan, Alon
Montgomery, Stephen B.
Pollack, Samuela
Price, Alkes L.
Soranzo, Nicole
Gonzaga-Jauregui, Claudia
Anttila, Verneri
Brodeur, Wendy
Daly, Mark J.
Leslie, Stephen
McVean, Gil
Moutsianas, Loukas
Nguyen, Huy
Zhang, Qingrun
Ghori, Mohammed J. R.
McGinnis, Ralph
McLaren, William
Takeuchi, Fumihiko
Grossman, Sharon R.
Shlyakhter, Ilya
Hostetter, Elizabeth B.
Sabeti, Pardis C.
Adebamowo, Clement A.
Foster, Morris W.
Gordon, Deborah R.
Licinio, Julio
Manca, Maria Cristina
Marshall, Patricia A.
Matsuda, Ichiro
Ngare, Duncan
Wang, Vivian Ota
Reddy, Deepa
Rotimi, Charles N.
Royal, Charmaine D.
Sharp, Richard R.
Zeng, Changqing
Brooks, Lisa D.
McEwen, Jean E.
CA Int HapMap 3 Consortium
TI Integrating common and rare genetic variation in diverse human
populations
SO NATURE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COPY NUMBER VARIATION; POSITIVE SELECTION;
HAPLOTYPE MAP; VARIANTS; DISEASES; SIGNALS; REGIONS; SNPS
AB Despite great progress in identifying genetic variants that influence human disease, most inherited risk remains unexplained. A more complete understanding requires genome-wide studies that fully examine less common alleles in populations with a wide range of ancestry. To inform the design and interpretation of such studies, we genotyped 1.6 million common single nucleotide polymorphisms (SNPs) in 1,184 reference individuals from 11 global populations, and sequenced ten 100-kilobase regions in 692 of these individuals. This integrated data set of common and rare alleles, called 'HapMap 3', includes both SNPs and copy number polymorphisms (CNPs). We characterized population-specific differences among low-frequency variants, measured the improvement in imputation accuracy afforded by the larger reference panel, especially in imputing SNPs with a minor allele frequency of <= 5%, and demonstrated the feasibility of imputing newly discovered CNPs and SNPs. This expanded public resource of genome variants in global populations supports deeper interrogation of genomic variation and its role in human disease, and serves as a step towards a high-resolution map of the landscape of human genetic variation.
C1 [Altshuler, David M.; Schaffner, Stephen F.; de Bakker, Paul I. W.; Gabriel, Stacey B.; Jia, Xiaoming; Parkin, Melissa; Korn, Joshua M.; McCarroll, Steven A.; Pollack, Samuela; Brodeur, Wendy; Nguyen, Huy; Shlyakhter, Ilya] Broad Inst, Cambridge, MA 02138 USA.
[Gibbs, Richard A.; Yu, Fuli; Bonnen, Penelope E.; Chang, Kyle; Hawes, Alicia; Lewis, Lora R.; Ren, Yanru; Wheeler, David; Muzny, Donna Marie; Gonzaga-Jauregui, Claudia] Baylor Coll Med, Human Genome Sequencing Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Dermitzakis, Emmanouil; Montgomery, Stephen B.] Univ Geneva, Sch Med, Dept Genet Med & Dev, Fac Med, CH-1211 Geneva, Switzerland.
[de Bakker, Paul I. W.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Genet, Boston, MA 02115 USA.
[Deloukas, Panos; Gwilliam, Rhian; Hunt, Sarah; Inouye, Michael; Palotie, Aarno; Whittaker, Pamela; Barnes, Chris; Hurles, Matthew; Kristiansson, Kati; Soranzo, Nicole; Anttila, Verneri; Zhang, Qingrun; Ghori, Mohammed J. R.; McGinnis, Ralph; McLaren, William; Takeuchi, Fumihiko] Wellcome Trust Sanger Inst, Dept Human Genet, Cambridge CB10 1HH, England.
[Palotie, Aarno; Anttila, Verneri] Univ Helsinki, Inst Mol Med Finland, FIN-00290 Helsinki, Finland.
[Palotie, Aarno; Anttila, Verneri] Univ Helsinki, Dept Med Genet, FIN-00290 Helsinki, Finland.
[Palotie, Aarno; Anttila, Verneri] Univ Cent Hosp, Helsinki 00290, Finland.
[Darvishi, Katayoon; Lee, Charles] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Keinan, Alon] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA.
[Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Simches Res Ctr, Boston, MA 02114 USA.
[Leslie, Stephen; McVean, Gil; Moutsianas, Loukas] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
[Grossman, Sharon R.; Hostetter, Elizabeth B.; Sabeti, Pardis C.] Harvard Univ, Dept Organism & Evolutionary Biol, Ctr Syst Biol, Cambridge, MA 02215 USA.
[Adebamowo, Clement A.] Univ Maryland, Sch Med, Dept Epidemiol & Preventat Med, Inst Human Virol N406, Baltimore, MD 21201 USA.
[Foster, Morris W.] Univ Oklahoma, Dept Anthropol, Norman, OK 73019 USA.
[Gordon, Deborah R.] Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA.
[Licinio, Julio] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2603, Australia.
[Manca, Maria Cristina] Inst Oncol Study & Prevent, I-50139 Florence, Italy.
[Marshall, Patricia A.] Case Western Reserve Univ, Dept Bioeth, Sch Med TA200, Cleveland, OH 44106 USA.
[Matsuda, Ichiro] Hlth Sci Univ Hokkaido, Tobetsu, Hokkaido 0610293, Japan.
[Ngare, Duncan] Moi Univ, Dept Populat & Family Hlth, Eldoret 30100, Kenya.
[Wang, Vivian Ota; Brooks, Lisa D.; McEwen, Jean E.] NHGRI, NIH, Bethesda, MD 20892 USA.
[Reddy, Deepa] Univ Houston Clear Lake City, Dept Anthropol, Houston, TX 77058 USA.
[Rotimi, Charles N.] NHGRI, Ctr Res Genom & Global Hlth, Bethesda, MD 20892 USA.
[Royal, Charmaine D.] Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA.
[Sharp, Richard R.] Cleveland Clin, Dept Bioeth, Cleveland, OH 44124 USA.
[Zeng, Changqing] Chinese Acad Sci, Beijing Inst Genom, Beijing 101300, Peoples R China.
RP Altshuler, DM (reprint author), Broad Inst, 7 Cambridge Ctr, Cambridge, MA 02138 USA.
EM altshuler@molbio.mgh.harvard.edu; agibbs@bcm.edu
RI Altshuler, David/A-4476-2009; Schaffner, Stephen/D-1189-2011; Deloukas,
Panos/B-2922-2013; Dermitzakis, Emmanouil/B-7687-2013; Licinio,
Julio/L-4244-2013; de Bakker, Paul/B-8730-2009;
OI Adebamowo, Clement/0000-0002-6571-2880; Altshuler,
David/0000-0002-7250-4107; Deloukas, Panos/0000-0001-9251-070X; Hunt,
Sarah/0000-0002-8350-1235; Barnes, Chris/0000-0002-9459-1395; Licinio,
Julio/0000-0001-6905-5884; de Bakker, Paul/0000-0001-7735-7858; Anttila,
Verneri/0000-0002-0073-4675; Soranzo, Nicole/0000-0003-1095-3852;
Kristiansson, Kati/0000-0003-4688-107X; McLaren,
William/0000-0001-6218-1116; Gonzaga-Jauregui,
Claudia/0000-0002-4667-3679
FU USA National Institutes of Health; National Human Genome Research
Institute; National Institute on Deafness and Other Communication
Disorders; Wellcome Trust [068545/Z/02, 076113]; Louis-Jeantet
Foundation; NCCR 'Frontiers in Genetics' (Swiss National Science
Foundation); UK Medical Research Council [G0000934]
FX We dedicate this work to Leena Peltonen for her vital leadership role in
this study, and in memory of a valued friend and colleague. We thank E.
Boerwinkle and R. Durbin for critical reading of the manuscript. We
thank the USA National Institutes of Health, the National Human Genome
Research Institute, the National Institute on Deafness and Other
Communication Disorders and the Wellcome Trust for supporting the
majority of this work. Funding was also provided by the Louis-Jeantet
Foundation and the NCCR 'Frontiers in Genetics' (Swiss National Science
Foundation). We thank the people from the following communities who were
generous in donating their blood samples to be studied in this project:
the Yoruba in Ibadan, Nigeria; the Maasai in Kinyawa, Kenya; the Luhya
in Webuye, Kenya; the Han Chinese in Beijing, China; the Japanese in
Tokyo, Japan; the Chinese in metropolitan Denver, Colorado; the Gujarati
Indians in Houston, Texas; the Toscani in Italia; the community of
African ancestry in the southwestern USA; and the community of Mexican
ancestry in Los Angeles, California. We also thank the people in the
Utah Centre d'Etude du Polymorphisme Humain community who allowed the
samples they donated earlier to be used for the project. The authors
acknowledge use of DNA from the 1958 British birth cohort collection,
funded by the UK Medical Research Council grant G0000934 and the
Wellcome Trust grant 068545/Z/02. The Illumina 550K genotype data for
the 1958 British birth cohort samples were made available by the Sanger
Institute. For the 1958 British birth cohort Affymetrix 500K genotype
data, we thank the Wellcome Trust Case Control Consortium
(http://www.wtccc.org.uk), which was funded by Wellcome Trust award
076113.
NR 27
TC 1087
Z9 1100
U1 10
U2 105
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD SEP 2
PY 2010
VL 467
IS 7311
BP 52
EP 58
DI 10.1038/nature09298
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 645MB
UT WOS:000281461200033
ER
PT J
AU Appel, LJ
Wright, JT
Greene, T
Agodoa, LY
Astor, BC
Bakris, GL
Cleveland, WH
Charleston, J
Contreras, G
Faulkner, ML
Gabbai, FB
Gassman, JJ
Hebert, LA
Jamerson, KA
Kopple, JD
Kusek, JW
Lash, JP
Lea, JP
Lewis, JB
Lipkowitz, MS
Massry, SG
Miller, ER
Norris, K
Phillips, RA
Pogue, VA
Randall, OS
Rostand, SG
Smogorzewski, MJ
Toto, RD
Wang, XL
AF Appel, Lawrence J.
Wright, Jackson T., Jr.
Greene, Tom
Agodoa, Lawrence Y.
Astor, Brad C.
Bakris, George L.
Cleveland, William H.
Charleston, Jeanne
Contreras, Gabriel
Faulkner, Marquetta L.
Gabbai, Francis B.
Gassman, Jennifer J.
Hebert, Lee A.
Jamerson, Kenneth A.
Kopple, Joel D.
Kusek, John W.
Lash, James P.
Lea, Janice P.
Lewis, Julia B.
Lipkowitz, Michael S.
Massry, Shaul G.
Miller, Edgar R.
Norris, Keith
Phillips, Robert A.
Pogue, Velvie A.
Randall, Otelio S.
Rostand, Stephen G.
Smogorzewski, Miroslaw J.
Toto, Robert D.
Wang, Xuelei
CA AASK Collaborative Res Grp
TI Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID STAGE RENAL-DISEASE; AFRICAN-AMERICAN; PROGRESSION; TRIAL; AASK;
PROTEINURIA; OUTCOMES; DESIGN; DIET; RISK
AB BACKGROUND
In observational studies, the relationship between blood pressure and end-stage renal disease (ESRD) is direct and progressive. The burden of hypertension-related chronic kidney disease and ESRD is especially high among black patients. Yet few trials have tested whether intensive blood-pressure control retards the progression of chronic kidney disease among black patients.
METHODS
We randomly assigned 1094 black patients with hypertensive chronic kidney disease to receive either intensive or standard blood-pressure control. After completing the trial phase, patients were invited to enroll in a cohort phase in which the blood-pressure target was less than 130/80 mm Hg. The primary clinical outcome in the cohort phase was the progression of chronic kidney disease, which was defined as a doubling of the serum creatinine level, a diagnosis of ESRD, or death. Follow-up ranged from 8.8 to 12.2 years.
RESULTS
During the trial phase, the mean blood pressure was 130/78 mm Hg in the intensive-control group and 141/86 mm Hg in the standard-control group. During the cohort phase, corresponding mean blood pressures were 131/78 mm Hg and 134/78 mm Hg. In both phases, there was no significant between-group difference in the risk of the primary outcome (hazard ratio in the intensive-control group, 0.91; P = 0.27). However, the effects differed according to the baseline level of proteinuria (P = 0.02 for interaction), with a potential benefit in patients with a protein-to-creatinine ratio of more than 0.22 (hazard ratio, 0.73; P = 0.01).
CONCLUSIONS
In overall analyses, intensive blood-pressure control had no effect on kidney disease progression. However, there may be differential effects of intensive blood-pressure control in patients with and those without baseline proteinuria.
C1 [Appel, Lawrence J.] Johns Hopkins Univ, Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA.
[Wright, Jackson T., Jr.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
[Gassman, Jennifer J.; Wang, Xuelei] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA.
[Greene, Tom] Univ Utah, Sch Med, Div Clin Epidemiol, Salt Lake City, UT USA.
[Agodoa, Lawrence Y.; Kusek, John W.] NIDDK, Div Kidney Urol & Hematol Dis, Bethesda, MD USA.
[Bakris, George L.] Univ Chicago, Pritzker Sch Med, Dept Med, Hypertens Dis Unit, Chicago, IL 60637 USA.
[Lash, James P.] Univ Illinois, Dept Med, Chicago, IL USA.
[Cleveland, William H.] Morehouse Sch Med, Multidisciplinary Res Ctr, Atlanta, GA 30310 USA.
[Lea, Janice P.] Emory Univ, Sch Med, Emory Ctr Hypertens & Renal Dis Res, Atlanta, GA USA.
[Contreras, Gabriel] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
[Faulkner, Marquetta L.] Meharry Med Coll, Nashville, TN 37208 USA.
[Lewis, Julia B.] Vanderbilt Univ, Sch Med, Div Nephrol, Nashville, TN 37212 USA.
[Gabbai, Francis B.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
[Gabbai, Francis B.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
[Hebert, Lee A.] Ohio State Univ, Med Ctr, Div Nephrol, Columbus, OH 43210 USA.
[Jamerson, Kenneth A.] Univ Michigan, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.
[Kopple, Joel D.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA.
[Kopple, Joel D.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Massry, Shaul G.] Los Angeles Cty Univ So Calif, Med Ctr, Los Angeles, CA USA.
[Smogorzewski, Miroslaw J.] Univ So Calif, Keck Sch Med, Div Nephrol, Los Angeles, CA 90033 USA.
[Norris, Keith] Charles Drew Univ Med & Sci, Dept Internal Med, Los Angeles, CA USA.
[Lipkowitz, Michael S.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Pogue, Velvie A.] Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Dept Med, New York, NY 10032 USA.
[Pogue, Velvie A.] Columbia Univ, New York, NY USA.
[Phillips, Robert A.] Univ Massachusetts, Sch Med, Cardiovasc Res Fdn, Worcester, MA USA.
[Randall, Otelio S.] Howard Univ, Washington, DC 20059 USA.
[Randall, Otelio S.] Howard Univ Hosp, Washington, DC USA.
[Rostand, Stephen G.] Univ Alabama, Div Nephrol, Birmingham, AL USA.
[Toto, Robert D.] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA.
RP Appel, LJ (reprint author), Johns Hopkins Univ, Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-618, Baltimore, MD 21205 USA.
EM lappel@jhmi.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases;
National Center on Minority Health and Health Disparities; National
Institutes of Health [M01 RR-00080, M01 RR-00071, M0100032, P20-RR11145,
M01 RR00827, M01 RR00052, 2P20 RR11104, RR029887, DK 2818-02]; King
Pharmaceuticals
FX Supported by grants to each clinical center and the coordinating center
from the National Institute of Diabetes and Digestive and Kidney
Diseases; by the Office of Research in Minority Health (now the National
Center on Minority Health and Health Disparities); by institutional
grants from the National Institutes of Health (M01 RR-00080, M01
RR-00071, M0100032, P20-RR11145, M01 RR00827, M01 RR00052, 2P20 RR11104,
RR029887, and DK 2818-02); by King Pharmaceuticals, which provided
monetary support and antihypertensive medications to each clinical
center; and by Pfizer, AstraZeneca, GlaxoSmithKline, Forest
Laboratories, Pharmacia, and Upjohn, which donated antihypertensive
medications.
NR 29
TC 267
Z9 281
U1 3
U2 28
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 2
PY 2010
VL 363
IS 10
BP 918
EP 929
DI 10.1056/NEJMoa0910975
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 645GW
UT WOS:000281441500005
PM 20818902
ER
PT J
AU Probstfield, JL
Cushman, WC
Davis, BR
Pressel, S
Cutler, JA
Einhorn, P
Ford, C
Oparil, S
Whelton, P
Wright, JT
AF Probstfield, J. L.
Cushman, W. C.
Davis, B. R.
Pressel, S.
Cutler, J. A.
Einhorn, P.
Ford, C.
Oparil, S.
Whelton, P.
Wright, J. T.
TI Mortality and morbidity during and after the antihypertensive and
lipid-lowering treatment to prevent heart attack trial (ALLHAT)
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology
CY AUG 28-SEP 01, 2010
CL Stockholm, SWEDEN
SP European Soc Cardiol
C1 [Probstfield, J. L.] Univ Washington, Seattle, WA 98195 USA.
[Cushman, W. C.] Memphis VAMC, Memphis, TN USA.
[Davis, B. R.; Pressel, S.; Ford, C.] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Houston, TX USA.
[Cutler, J. A.; Einhorn, P.] NHLBI, NIH, Bethesda, MD 20892 USA.
[Oparil, S.] Univ Alabama Birmingham, Birmingham, AL USA.
[Whelton, P.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
[Wright, J. T.] Univ Hosp Cleveland, Cleveland, OH USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD SEP
PY 2010
VL 31
SU 1
BP 321
EP 321
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 646ID
UT WOS:000281531902083
ER
PT J
AU Wang, KL
Cheng, HM
Chuang, SY
Sung, SH
Huang, CM
Yu, WC
Ting, CT
Lakatta, EG
Yin, FCP
Chen, CH
AF Wang, K. L.
Cheng, H. M.
Chuang, S. Y.
Sung, S. H.
Huang, C. M.
Yu, W. C.
Ting, C. T.
Lakatta, E. G.
Yin, F. C. P.
Chen, C. H.
TI Prehypertension or white-coat hypertension: which best relates to
target-organs and future cardiovascular mortality?
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT ESC Congress
CY AUG 28-SEP 01, 2010
CL Stockholm, SWEDEN
C1 [Wang, K. L.; Cheng, H. M.; Sung, S. H.; Huang, C. M.; Yu, W. C.; Chen, C. H.] Taipei Vet Gen Hosp, Taipei, Taiwan.
[Chuang, S. Y.] Acad Sinica, Taipei 115, Taiwan.
[Ting, C. T.] Taichung Vet Gen Hosp, Taichung, Taiwan.
[Lakatta, E. G.] NIA, Baltimore, MD 21224 USA.
[Yin, F. C. P.] Washington Univ, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD SEP
PY 2010
VL 31
SU 1
BP 449
EP 449
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 646ID
UT WOS:000281531903002
ER
PT J
AU Ugander, M
Booker, OJ
Hsu, LY
Oki, AJ
Aletras, AH
Arai, AE
AF Ugander, M.
Booker, O. J.
Hsu, L. Y.
Oki, A. J.
Aletras, A. H.
Arai, A. E.
TI Edematous peri-infarct myocardium has a greater extracellular volume
fraction compared with normal myocardium - implications for late
gadolinium enhancement
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT ESC Congress
CY AUG 28-SEP 01, 2010
CL Stockholm, SWEDEN
C1 [Ugander, M.; Booker, O. J.; Hsu, L. Y.; Oki, A. J.; Aletras, A. H.; Arai, A. E.] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD SEP
PY 2010
VL 31
SU 1
BP 585
EP 585
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 646ID
UT WOS:000281531903540
ER
PT J
AU Briest, W
Cooper, TK
Tae, HJ
Krawczyk, M
Mcdonnell, NB
Talan, MI
AF Briest, W.
Cooper, T. K.
Tae, H. -J.
Krawczyk, M.
Mcdonnell, N. B.
Talan, M. I.
TI MMP-inhibition: a treatment for the vascular type of the Ehlers-Danlos
syndrome?
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT ESC Congress
CY AUG 28-SEP 01, 2010
CL Stockholm, SWEDEN
C1 [Briest, W.] Univ Leipzig, Ctr Heart, Dept Internal Med & Cardiol, Leipzig, Germany.
[Cooper, T. K.] Penn State Milton S Hershey Med Ctr, Hershey, PA USA.
[Tae, H. -J.; Krawczyk, M.; Talan, M. I.] NIA, Cardiovasc Sci Lab, Baltimore, MD 21224 USA.
[Mcdonnell, N. B.] NIA, Clin Invest Lab, Baltimore, MD 21224 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD SEP
PY 2010
VL 31
SU 1
BP 701
EP 701
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 646ID
UT WOS:000281531904432
ER
PT J
AU Roysland, R
Omland, T
Sabatine, MS
Hsia, J
Christophi, C
Rice, MM
Rouleau, JL
Domanski, MJ
Solomon, SD
Braunwald, E
AF Roysland, R.
Omland, T.
Sabatine, M. S.
Hsia, J.
Christophi, C.
Rice, M. M.
Rouleau, J. L.
Domanski, M. J.
Solomon, S. D.
Braunwald, E.
TI N-terminal pro-B-type natriuretic peptide is associated with the
incidence of sudden cardiac death in patients with stable coronary
artery disease and preserved left ventricular systolic function
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT ESC Congress
CY AUG 28-SEP 01, 2010
CL Stockholm, SWEDEN
C1 [Roysland, R.; Omland, T.] Univ Oslo, Lorenskog, Norway.
[Sabatine, M. S.; Solomon, S. D.; Braunwald, E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Christophi, C.; Rice, M. M.] George Washington Univ, Rockville, MD USA.
[Rouleau, J. L.] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Domanski, M. J.] NHLBI, NIH, Bethesda, MD 20892 USA.
RI Solomon, Scott/I-5789-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD SEP
PY 2010
VL 31
SU 1
BP 840
EP 840
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 646ID
UT WOS:000281531905407
ER
PT J
AU Briest, W
Muller, GA
Hansen, U
Mcdonnell, NB
Talan, MI
AF Briest, W.
Muller, G. A.
Hansen, U.
Mcdonnell, N. B.
Talan, M. I.
TI Selective suppression of the mutated form of collagen 3A1 by siRNA in
fibroblasts from a patient with the vascular form of the Ehlers-Danlos
syndrome
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT ESC Congress
CY AUG 28-SEP 01, 2010
CL Stockholm, SWEDEN
C1 [Briest, W.] Univ Leipzig, Ctr Heart, Dept Internal Med & Cardiol, Leipzig, Germany.
[Muller, G. A.] Univ Hosp Leipzig, Leipzig, Germany.
[Hansen, U.] Univ Hosp Muenster, Inst Pathol Chem & Pathobiochem, Munster, Germany.
[Mcdonnell, N. B.] NIA, Clin Invest Lab, Baltimore, MD 21224 USA.
[Talan, M. I.] NIA, Cardiovasc Sci Lab, Baltimore, MD 21224 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD SEP
PY 2010
VL 31
SU 1
BP 908
EP 908
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 646ID
UT WOS:000281531906125
ER
PT J
AU Borraccino, A
Iannotti, RJ
Lemma, P
Cavallo, F
AF Borraccino, A.
Iannotti, R. J.
Lemma, P.
Cavallo, F.
TI INFLUENCES OF PHYSICAL ACTIVITY AND SEDENTARY BEHAVIOR ON ADOLESCENT
MEDICINE USE IN 17 COUNTRIES
SO EPIDEMIOLOGIA & PREVENZIONE
LA English
DT Meeting Abstract
C1 [Borraccino, A.; Lemma, P.; Cavallo, F.] Univ Turin, Dipartimento Sanita Pubbl & Microbiol, I-10124 Turin, Italy.
[Iannotti, R. J.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
RI Borraccino, Alberto/C-9013-2012
OI Borraccino, Alberto/0000-0001-8235-8775
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INFERENZE SCARL
PI MILANO
PA VIA RICCIARELLI N 29, MILANO, 20148, ITALY
SN 1120-9763
J9 EPIDEMIOL PREV
JI Epidemiol. Prev.
PD SEP-DEC
PY 2010
VL 34
IS 5-6
SU 1
BP 60
EP 60
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 701MF
UT WOS:000285821300066
ER
PT J
AU Consonni, D
De Matteis, S
Pesatori, AC
Lubin, JH
Wacholder, S
Tucker, M
Caporaso, NE
Bertazzi, PA
Landi, MT
AF Consonni, D.
De Matteis, S.
Pesatori, A. C.
Lubin, J. H.
Wacholder, S.
Tucker, M.
Caporaso, N. E.
Bertazzi, P. A.
Landi, M. T.
TI LUNG CANCER AMONG CONSTRUCTION WORKERS IN A POPULATION-BASED
CASE-CONTROL STUDY
SO EPIDEMIOLOGIA & PREVENZIONE
LA English
DT Meeting Abstract
C1 [Consonni, D.; Pesatori, A. C.; Bertazzi, P. A.] Univ Milan, Milan, Italy.
[Consonni, D.; Pesatori, A. C.; Bertazzi, P. A.] Fdn IRCCS Ca Granda Osped Maggiore, Epidemiol Unit, Milan, Italy.
[De Matteis, S.; Lubin, J. H.; Wacholder, S.; Tucker, M.; Caporaso, N. E.; Landi, M. T.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
RI Tucker, Margaret/B-4297-2015
NR 0
TC 0
Z9 0
U1 1
U2 1
PU INFERENZE SCARL
PI MILANO
PA VIA RICCIARELLI N 29, MILANO, 20148, ITALY
SN 1120-9763
J9 EPIDEMIOL PREV
JI Epidemiol. Prev.
PD SEP-DEC
PY 2010
VL 34
IS 5-6
SU 1
BP 71
EP 71
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 701MF
UT WOS:000285821300089
ER
PT J
AU Goedert, JJ
Lauria, C
Vitale, F
Buscema, G
Leggio, L
Arena, G
Graubard, IB
Preiss, L
Whitby, D
Bonura, F
Perna, A
Viviano, E
Gafa, L
Messina, A
Romano, N
AF Goedert, J. J.
Lauria, C.
Vitale, F.
Buscema, G.
Leggio, L.
Arena, G.
Graubard, Barry, I
Preiss, L.
Whitby, D.
Bonura, F.
Perna, A.
Viviano, E.
Gafa, L.
Messina, A.
Romano, N.
TI EXPOSURES TO PLANTS AND CLASSIC KAPOSI SARCOMA: A STUDY IN SICILY
SO EPIDEMIOLOGIA & PREVENZIONE
LA English
DT Meeting Abstract
C1 [Goedert, J. J.; Graubard, Barry, I] NIH, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Lauria, C.; Buscema, G.; Leggio, L.; Arena, G.; Gafa, L.; Romano, N.] Sez Ragusa, Ragusa, Italy.
[Vitale, F.; Bonura, F.; Perna, A.; Viviano, E.] Univ Palermo, Dip Igiene Microbiol G DAlessandro, I-90133 Palermo, Italy.
[Preiss, L.] RTI Int, Res Triangle Pk, NC USA.
[Whitby, D.] NCI, Viral Oncol Sect, AIDS & Canc Virus Program, SAIC Frederick, Frederick, MD 21701 USA.
[Messina, A.] Univ Catania, Dip Sci Biomed, I-95124 Catania, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INFERENZE SCARL
PI MILANO
PA VIA RICCIARELLI N 29, MILANO, 20148, ITALY
SN 1120-9763
J9 EPIDEMIOL PREV
JI Epidemiol. Prev.
PD SEP-DEC
PY 2010
VL 34
IS 5-6
SU 1
BP 134
EP 134
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 701MF
UT WOS:000285821300228
ER
PT J
AU Ukegbu, UJ
Onumah, BM
Tambay, AV
Ricks, M
Miller, BV
Tulloch-Reid, MK
Sumner, AE
AF Ukegbu, U. J.
Onumah, B. M.
Tambay, A. V.
Ricks, M.
Miller, B. V., III
Tulloch-Reid, M. K.
Sumner, A. E.
TI RISK FOR KETOSIS-PRONE TYPE 2 DIABETES APPEARS TO BE GREATER IN
BLACK-AFRICAN THAN AFRICAN-AMERICAN MEN
SO ETHNICITY & DISEASE
LA English
DT Meeting Abstract
C1 [Ukegbu, U. J.; Tambay, A. V.; Ricks, M.; Miller, B. V., III; Sumner, A. E.] NIH, Bethesda, MD 20892 USA.
[Onumah, B. M.] Washington Hosp Ctr, Washington, DC 20010 USA.
[Tulloch-Reid, M. K.] Univ W Indies, Kingston 7, Jamaica.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
J9 ETHNIC DIS
JI Ethn. Dis.
PD FAL
PY 2010
VL 20
IS 4
MA 022
BP S312
EP S312
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 702RK
UT WOS:000285911600050
ER
PT J
AU Albert, PS
Shih, JH
AF Albert, Paul S.
Shih, Joanna H.
TI AN APPROACH FOR JOINTLY MODELING MULTIVARIATE LONGITUDINAL MEASUREMENTS
AND DISCRETE TIME-TO-EVENT DATA
SO ANNALS OF APPLIED STATISTICS
LA English
DT Article
DE Joint models; shared random parameter models; informative dropout;
regression calibration
ID SURVIVAL-DATA; ERROR; BIOMARKERS; PROFILES
AB In many medical studies, patients are followed longitudinally and interest is on assessing the relationship between longitudinal measurements and time to an event. Recently, various authors have proposed joint modeling approaches for longitudinal and time-to-event data for a single longitudinal variable. These joint modeling approaches become intractable with even a few longitudinal variables. In this paper we propose a regression calibration approach for jointly modeling multiple longitudinal measurements and discrete time-to-event data. Ideally, a two-stage modeling approach could be applied in which the multiple longitudinal measurements are modeled in the first stage and the longitudinal model is related to the time-to-event data in the second stage. Biased parameter estimation due to informative dropout makes this direct two-stage modeling approach problematic. We propose a regression calibration approach which appropriately accounts for informative dropout. We approximate the conditional distribution of the multiple longitudinal measurements given the event time by modeling all pairwise combinations of the longitudinal measurements using a bivariate linear mixed model which conditions on the event time. Complete data are then simulated based on estimates from these pairwise conditional models, and regression calibration is used to estimate the relationship between longitudinal data and time-to-event data using the complete data. We show that this approach performs well in estimating the relationship between multivariate longitudinal measurements and the time-to-event data and in estimating the parameters of the multiple longitudinal process subject to informative dropout. We illustrate this methodology with simulations and with an analysis of primary biliary cirrhosis (PBC) data.
C1 [Albert, Paul S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD 20892 USA.
[Shih, Joanna H.] NCI, Biometr Res Branch, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
RP Albert, PS (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD 20892 USA.
EM albertp@mail.nih.gov
FU National Institutes of Health; Eunice Kennedy Shriver National Institute
of Child Health and Human Development
FX Supported by the Intramural Research Program of the National Institutes
of Health, Eunice Kennedy Shriver National Institute of Child Health and
Human Development.
NR 25
TC 4
Z9 4
U1 1
U2 7
PU INST MATHEMATICAL STATISTICS
PI CLEVELAND
PA 3163 SOMERSET DR, CLEVELAND, OH 44122 USA
SN 1932-6157
J9 ANN APPL STAT
JI Ann. Appl. Stat.
PD SEP
PY 2010
VL 4
IS 3
BP 1517
EP 1532
DI 10.1214/10-AOAS339
PG 16
WC Statistics & Probability
SC Mathematics
GA 674YL
UT WOS:000283787900018
PM 21938267
ER
PT J
AU Bhatia, PA
Moaddel, R
Wainer, IW
AF Bhatia, Prateek A.
Moaddel, Ruin
Wainer, Irving W.
TI Application of cellular membrane affinity chromatography in determining
stereoselective interactions with ATP-binding cassette transporters
SO CHIMICA OGGI-CHEMISTRY TODAY
LA English
DT Article
ID MULTIDRUG-RESISTANCE; BREAST-CANCER; ABC TRANSPORTERS; P-GLYCOPROTEIN;
PROTEIN; VERAPAMIL; PHASE; MRP1; LOCALIZATION; METABOLISM
AB The ATP-binding cassette (ABC) efflux transporters plays a key role in drug absorption and excretion hence the determination of a compound's interaction with these transporters becomes a key element in drug discovery programs. ABC transporters also play a role in multiple drug resistance (MDR), a common obstacle in chemotherapeutic management of most neoplastic tumours as well as a number of other diseases such as malaria and tuberculosis. While there are a variety of approaches to the determination of drug interactions with ABC transporters, the direct measurement of stereoselective interactions remains a difficult task. In this review we address this issue and demonstrate that cellular membrane affinity chromatography (CMAC) utilizing columns containing immobilized ABC transporters can be used as a direct online method for the determination of stereoselective small molecule-drug transporter interactions. The CMAC columns discussed in this work contain the ABC transporter P-glycoprotein; the CMAC (Pgp) column, multiple drug resistant protein 1; the CMAC (MRP1) column, multiple drug resistance protein 2; the CMAC (MRP2) column and breast cancer resistant protein; the CMAC (BCRP) column.
C1 [Bhatia, Prateek A.; Moaddel, Ruin; Wainer, Irving W.] NIA, NIH, Clin Invest Lab, Biomed Res Ctr, Baltimore, MD 21224 USA.
RP Wainer, IW (reprint author), NIA, NIH, Clin Invest Lab, Biomed Res Ctr, 251 Bayview Blvd,Room 8B133, Baltimore, MD 21224 USA.
FU National Institute on Aging
FX This work was supported by funding from the National Institute on Aging
Intramural Research Program.
NR 27
TC 0
Z9 0
U1 1
U2 4
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1973-8250
J9 CHIM OGGI
JI Chim. Oggi-Chem. Today
PD SEP-OCT
PY 2010
VL 28
IS 5
BP 32
EP 36
PG 4
WC Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary
SC Biotechnology & Applied Microbiology; Chemistry
GA 672KJ
UT WOS:000283581600004
ER
PT J
AU Zhang, J
Ng, KY
Ho, PC
AF Zhang, Jing
Ng, Ka-Yun
Ho, Paul C.
TI Interaction of Oxazaphosphorines with Multidrug Resistance-Associated
Protein 4 (MRP4)
SO AAPS JOURNAL
LA English
DT Article
DE cyclophosphamide; cytotoxicity; drug transporter; ifosfamide; multidrug
resistance-associated protein 4
ID BREAST-CANCER; DRUG-RESISTANCE; SUBSTRATE-SPECIFICITY; REDUCED
GLUTATHIONE; CONFERS RESISTANCE; HEPATIC MRP4; TRANSPORTERS; EXPRESSION;
INDUCTION; RECEPTOR
AB Multidrug resistance-associated protein 4 (MRP4) is an organic anion efflux pump capable of transporting nucleoside, nucleotide analogs, and cyclic nucleotide. MRP4 could have an influence on the resistance and transport of the two oxazaphosphorines, cyclophosphamide (CP) and ifosfamide (IF). V/HepG2 (HepG2, hepatoma cells stably transfected with an empty vehicle plasmid) and MRP4/HepG2 (HepG2 cells stably expressing MRP4) were exposed to CP and IF in the absence or presence of various MRP4 inhibitors. HepG2 and HEK293 human kidney cells were also used to investigate the inducing potency of oxazaphosphorines on the MRP4 expression. In this study, insertion of MRP4 gene in HepG2 cells was found to confer significant resistance to CP and IF in the 48-h drug-exposure assays. In the presence of various MRP4 inhibitors, the resistance to CP and IF was then partially reversed. These indicate that CP and IF are highly possible substrates of MRP4. In addition, CP and clofibrate (CFB), a reported MRP4 inducer, in vivo significantly increased the MRP4 expression at both protein level and mRNA level in HEK293 cells at higher concentrations, while IF significantly decreased the MRP4 expression at mRNA level at lower concentration and had no effect at higher concentrations. However, all tested compounds (CP, IF, and CFB) did not change the MRP4 protein expression in HepG2 cells. CP and CFB are cell-specific and concentration-dependent MRP4 inducers. The finding may have implications in the CP- r IF-based chemotherapy.
C1 [Zhang, Jing; Ng, Ka-Yun; Ho, Paul C.] Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 117543, Singapore.
[Ng, Ka-Yun] NIH, Ctr Sci Review, Bethesda, MD 20892 USA.
RP Ho, PC (reprint author), Natl Univ Singapore, Fac Sci, Dept Pharm, 18 Sci Dr 4, Singapore 117543, Singapore.
EM phahocl@nus.edu.sg
RI Ho, Paul/O-9652-2014
OI Ho, Paul/0000-0001-9213-7116
FU National University of Singapore [R148-000-066-112]
FX We would like to thank Dr. Theresa Tan from the Department of
Biochemistry, National University of Singapore for providing the MRP4
transfected HepG2 cells for this study. We would also like to
acknowledge the scholarship for J. Zhang and the Academic Research Fund,
R148-000-066-112, from the National University of Singapore.
NR 35
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1550-7416
J9 AAPS J
JI AAPS J.
PD SEP
PY 2010
VL 12
IS 3
BP 300
EP 308
DI 10.1208/s12248-010-9189-x
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 735NU
UT WOS:000288425000006
PM 20405259
ER
PT J
AU Tian, J
Atkinson, NL
Portnoy, B
Lowitt, NR
AF Tian, Jing
Atkinson, Nancy L.
Portnoy, Barry
Lowitt, Nancy R.
TI The Development of a Theory-Based Instrument to Evaluate the
Effectiveness of Continuing Medical Education
SO ACADEMIC MEDICINE
LA English
DT Article
ID HEALTH-CARE; PHYSICIAN BEHAVIOR; PLANNED BEHAVIOR; OUTCOMES
AB Purpose
To determine the psychometric properties of a theoretically based continuing medical education (CME) evaluation instrument examining attitudinal determinants of physicians' changes in medical practices after a CME intervention. The instrument's scales represented constructs from the theory of planned behavior.
Method
The authors based the template instrument on educational objectives of the CME intervention and adapted it to the clinical domain of preoperative breast cancer therapy. Development of the initial survey involved cognitive testing, pilot tests, and expert reviews. The authors asked 269 clinicians to complete the 35-item instrument before the CME intervention. Factor analysis and item analysis guided the development of the final six subscales: positive behavioral beliefs, negative behavioral beliefs, attitude toward the behavior, perceived behavior control (self-efficacy), subjective norms, and behavioral intention.
Results
Cognitive testing and pilot tests ensured the accuracy and clarity of the language and a reasonable survey length. Of the 269 clinicians, 168 (134 physicians) responded. Scales clustered according to the theoretical constructs. Items not loading in any subscales were eliminated. The final 25 items loaded on six subscales with loadings >0.54. Reliability for the subscales ranged from 0.73 to 0.93 (good for the scale development stage). The authors revised the instrument template and protocol after this initial study to increase the possibility of use in future CME evaluations.
Conclusions
The levels of content and construct validity and reliability of the CME evaluation instrument are acceptable for evaluation of CME activities targeting physicians. Instruments adapted from this template could potentially evaluate future CME activities.
C1 [Tian, Jing] Univ Maryland, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21201 USA.
[Atkinson, Nancy L.] Univ Maryland, Sch Publ Hlth, Dept Publ & Community Hlth, College Pk, MD 20742 USA.
[Portnoy, Barry] NIH, Off Dis Prevent, Off Director, Bethesda, MD 20892 USA.
[Lowitt, Nancy R.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
RP Tian, J (reprint author), Univ Maryland, Sch Med, Dept Med, Div Cardiol, 22 S Greene St N3W77, Baltimore, MD 21201 USA.
EM tianjing@umd.edu
FU National Institutes of Health/Office of Director Evaluation Express
[07-1005 OD-ODP]
FX This study was supported by National Institutes of Health/Office of
Director Evaluation Express Award no. 07-1005 OD-ODP.
NR 31
TC 10
Z9 10
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD SEP
PY 2010
VL 85
IS 9
BP 1518
EP 1525
DI 10.1097/ACM.0b013e3181eac3fb
PG 8
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 647IH
UT WOS:000281611300026
PM 20736680
ER
PT J
AU Wlodawer, A
Lubkowski, J
Minor, W
Jaskolski, M
AF Wlodawer, Alexander
Lubkowski, Jacek
Minor, Wladek
Jaskolski, Mariusz
TI Is too 'creative' language acceptable in crystallography?
SO ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
LA English
DT Letter
DE letters to the editor; crystallographic terminology
AB While figures of speech are often useful and even educational, flashy titles combined with hyperbolae and imprecise language can mislead or deceive non-specialist readers and should therefore be avoided. The possibility of such confusion exists when poorly defined terms like `structure quality' or `super-resolution' are used to describe a protein structure.
C1 [Wlodawer, Alexander; Lubkowski, Jacek] NCI, Macromol Crystallog Lab, Frederick, MD 21701 USA.
[Minor, Wladek] Univ Virginia, Charlottesville, VA USA.
[Jaskolski, Mariusz] Adam Mickiewicz Univ Poznan, Poznan, Poland.
RP Wlodawer, A (reprint author), NCI, Macromol Crystallog Lab, Frederick, MD 21701 USA.
EM wlodawer@nih.gov
RI Minor, Wladek/F-3096-2014;
OI Minor, Wladek/0000-0001-7075-7090
NR 4
TC 2
Z9 2
U1 0
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0907-4449
J9 ACTA CRYSTALLOGR D
JI Acta Crystallogr. Sect. D-Biol. Crystallogr.
PD SEP
PY 2010
VL 66
BP 1041
EP 1042
DI 10.1107/S090744491002799X
PN 9
PG 2
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Biophysics; Crystallography
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA 647RE
UT WOS:000281635500011
PM 20823556
ER
PT J
AU Yang, JY
Qi, J
Han, WY
Wang, F
Wu, CF
AF Yang, Jing-yu
Qi, Jia
Han, Wen-yan
Wang, Fang
Wu, Chun-fu
TI Inhibitory role of oxytocin in psychostimulant-induced psychological
dependence and its effects on dopaminergic and glutaminergic
transmission
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Review
DE psychostimulants; oxytocin; cocaine; methamphetamine; dopamine;
glutamate
ID CONDITIONED PLACE PREFERENCE; MEDIAL PREFRONTAL CORTEX;
NUCLEUS-ACCUMBENS; EXTRACELLULAR LEVELS; CROSS-TOLERANCE; COCAINE; RATS;
MICE; METHAMPHETAMINE; ADDICTION
AB Psychostimulants are frequently abused as a result of their stimulatory effects on several neurotransmitter systems within the central nervous system. Both dopaminergic and glutaminergic neurotransmissions have been closely associated with psychostimulant dependence. In addition to its classical endocrine function in the periphery, oxytocin, an important neurohypophyseal neuropeptide in the central nervous system, has a wide range of behavioral effects, including regulating drug abuse. The present paper reviews the progress of research into the role of oxytocin in reducing psychostimulant-induced psychological dependence and the mechanisms by which oxytocin mediates its effects.
C1 [Qi, Jia] NIDA, NIH, Baltimore, MD 21224 USA.
[Yang, Jing-yu; Qi, Jia; Han, Wen-yan; Wang, Fang; Wu, Chun-fu] Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang 110016, Peoples R China.
RP Wu, CF (reprint author), Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang 110016, Peoples R China.
EM chunfuw@gmail.com
RI QI, JIA/A-6337-2014
FU Key Laboratory for New Drug Screening and Key Laboratory for
Pharmacodynamics of Liaoning Province; Outstanding Youth Fund of
Liaoning province; National Key Scientific Project for New Drug
Discovery and Development, China [2009ZX09301-012]
FX This research was partially supported by the Project of Key Laboratory
for New Drug Screening and Key Laboratory for Pharmacodynamics of
Liaoning Province, the Outstanding Youth Fund of Liaoning province, and
the National Key Scientific Project for New Drug Discovery and
Development (2009ZX09301-012), 2009-2010, China.
NR 46
TC 9
Z9 9
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671-4083
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD SEP
PY 2010
VL 31
IS 9
BP 1071
EP 1074
DI 10.1038/aps.2010.140
PG 4
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 646SK
UT WOS:000281562900011
PM 20729875
ER
PT J
AU Bumb, A
Brechbiel, MW
Choyke, P
AF Bumb, Ambika
Brechbiel, Martin W.
Choyke, Peter
TI Macromolecular and dendrimer-based magnetic resonance contrast agents
SO ACTA RADIOLOGICA
LA English
DT Review
DE MRI; magnetic resonance imaging; molecular imaging; comparative studies
ID NEPHROGENIC SYSTEMIC FIBROSIS; AFFINITY FOLATE RECEPTOR; WATER-PROTON
RELAXATION; DTPA-LABELED DEXTRAN; HUMAN SERUM-ALBUMIN; BLOOD-POOL AGENT;
GD-DTPA; POLYAMIDOAMINE DENDRIMER; MR-ANGIOGRAPHY; PHARMACOKINETIC
PROPERTIES
AB Magnetic resonance imaging (MRI) is a powerful imaging modality that can provide an assessment of function or molecular expression in tandem with anatomic detail. Over the last 20-25 years, a number of gadolinium-based MR contrast agents have been developed to enhance signal by altering proton relaxation properties. This review explores a range of these agents from small molecule chelates, such as Gd-DTPA and Gd-DOTA, to macromolecular structures composed of albumin, polylysine, polysaccharides (dextran, inulin, starch), poly(ethylene glycol), copolymers of cystamine and cystine with GD-DTPA, and various dendritic structures based on poly-amidoamine and polylysine (Gadomers). The synthesis, structure, biodistribution, and targeting of dendrimer-based MR contrast agents are also discussed.
C1 [Choyke, Peter] NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA.
[Bumb, Ambika; Brechbiel, Martin W.] NCI, Radiat Oncol Branch, NIH, Bethesda, MD 20892 USA.
RP Choyke, P (reprint author), NCI, Mol Imaging Program, NIH, Bldg 10,Room B3B69F,10 Ctr Dr, Bethesda, MD 20892 USA.
EM pchoyke@mail.nih.gov
FU NIH, National Cancer Institute, Center for Cancer Research
FX This research was supported by the Intramural Research Program of the
NIH, National Cancer Institute, Center for Cancer Research.
NR 98
TC 43
Z9 46
U1 2
U2 46
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0284-1851
EI 1600-0455
J9 ACTA RADIOL
JI Acta Radiol.
PD SEP
PY 2010
VL 51
IS 7
BP 751
EP 767
DI 10.3109/02841851.2010.491091
PG 17
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 649LM
UT WOS:000281771500005
PM 20590365
ER
PT J
AU Dawson, DA
Grant, BF
AF Dawson, Deborah A.
Grant, Bridget F.
TI Should symptom frequency be factored into scalar measures of alcohol use
disorder severity?
SO ADDICTION
LA English
DT Article
DE AUD severity; symptom frequency; validity
ID DSM-IV ALCOHOL; IDENTIFICATION TEST AUDIT; NATIONAL EPIDEMIOLOGIC
SURVEY; SUBSTANCE USE DISORDERS; SCREENING-TEST ASSIST; DEPENDENCE
SCALE; CONSEQUENCES QUESTIONNAIRE; PREDICTIVE-VALIDITY;
POPULATION-SAMPLE; AUDADIS-ADR
AB Aims
To evaluate whether weighting counts of alcohol use disorder (AUD) criteria or symptoms by their frequency of occurrence improves their association with correlates of AUD.
Design and participants
Data were collected in personal interviews with a representative sample of US adults interviewed in 1991-92. Analyses were conducted among past-year drinkers (12+ drinks, n = 18 352) and individuals with past-year DSM-IV AUD (n = 2770).
Measurements
Thirty-one symptom item indicators, whose frequency of occurrence was measured in eight categories, were used to create unweighted and frequency-weighted counts of DSM-IV past-year AUD symptoms and criteria. Correlates included density of familial alcoholism and past-year volume of ethanol intake, frequency of intoxication and utilization of alcohol treatment.
Findings
Although the AUD correlates were associated strongly and positively with the frequency of AUD symptom occurrence, weighting for symptom frequency did not strengthen their association consistently with AUD severity scores. Improved performance of the weighted scores was observed primarily among AUD correlates linked closely with the frequency of heavy drinking and among individuals with AUD. Criterion counts were correlated nearly as strongly as symptom counts with the AUD correlates.
Conclusions
Frequency weighting may add somewhat to the validity of AUD severity measures, especially those that are intended for use among individuals with AUD, e.g. in clinical settings. For studying the etiology and course of AUD in the general population, an equally effective and less time-consuming alternative to obtaining symptom frequency may be the use of unweighted criterion counts accompanied by independent measures of frequency of heavy drinking.
C1 [Dawson, Deborah A.; Grant, Bridget F.] NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, NIH, Bethesda, MD 20892 USA.
RP Dawson, DA (reprint author), NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, NIH, 5635 Fishers Lane,Room 3071, Bethesda, MD 20892 USA.
EM ddawson@mail.nih.gov
FU National Institutes of Health, National Institute on Alcohol Abuse and
Alcoholism
FX The study on which this paper is based, the National Longitudinal
Alcohol Epidemiologic Survey, was sponsored by the National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, US
Department of Health and Human Services. This research was supported in
part by the Intramural Program of the National Institutes of Health,
National Institute on Alcohol Abuse and Alcoholism. The views and
opinions expressed in this paper are those of the authors and should not
be construed to represent the views of any of the sponsoring
organizations, agencies or the US government.
NR 56
TC 5
Z9 5
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0965-2140
J9 ADDICTION
JI Addiction
PD SEP
PY 2010
VL 105
IS 9
BP 1568
EP 1579
DI 10.1111/j.1360-0443.2010.02994.x
PG 12
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 635PK
UT WOS:000280668200014
PM 20569231
ER
PT J
AU Nelson, DE
Naimi, TS
Brewer, RD
Roeber, J
AF Nelson, David E.
Naimi, Timothy S.
Brewer, Robert D.
Roeber, James
TI US state alcohol sales compared to survey data, 1993-2006
SO ADDICTION
LA English
DT Article
DE Alcohol abuse; alcohol drinking; cross-sectional studies; drinking
behaviors; health surveys; statistics
ID LIVER-CIRRHOSIS MORTALITY; MEASURING QUANTITY; POPULATION-LEVEL;
TELEPHONE SURVEY; CONSUMPTION; DRINKING; FREQUENCY; VALIDITY;
PREVENTION; EXPERIENCE
AB Aims Assess long-term trends of the correlation between alcohol sales data and survey data. Design Analyses of state alcohol consumption data from the US Alcohol Epidemiologic Data System based on sales, tax receipts or alcohol shipments. Cross-sectional, state annual estimates of alcohol-related measures for adults from the US Behavioral Risk Factor Surveillance System using telephone surveys. Setting United States. Participants State alcohol tax authorities, alcohol vendors, alcohol industry (sales data) and randomly selected adults aged >= 18 years 1993-2006 (survey data). Measurements State-level per capita annual alcohol consumption estimates from sales data. Self-reported alcohol consumption, current drinking, heavy drinking, binge drinking and alcohol-impaired driving from surveys. Correlation coefficients were calculated using linear regression models. Findings State survey estimates of consumption accounted for amedian of 22% to 32% of state sales data across years. Nevertheless, state consumption estimates from both sources were strongly correlated with annual r-values ranging from 0.55-0.71. State sales data had moderate-to-strong correlations with survey estimates of current drinking, heavy drinking and binge drinking (range of r-values across years: 0.57-0.65; 0.33-0.70 and 0.45-0.61, respectively), but a weaker correlation with alcoholimpaired driving (range of r-values: 0.24-0.56). There were no trends in the magnitude of correlation coefficients. Conclusions Although state surveys substantially underestimated alcohol consumption, the consistency of the strength of the association between sales consumption and survey data for most alcohol measures suggest both data sources continue to provide valuable information. These findings support and extend the distribution of consumption model and single distribution theory, suggesting that both sales and survey data are useful for monitoring population changes in alcohol use.
C1 [Nelson, David E.] NCI, Canc Prevent Fellowship Program, Ctr Canc Training, Bethesda, MD 20892 USA.
[Nelson, David E.; Naimi, Timothy S.; Brewer, Robert D.] Ctr Dis Control & Prevent, Alcohol Team, Emerging Invest & Analyt Methods Branch, Div Adult & Community Hlth,Natl Ctr Chron Dis Pre, Atlanta, GA USA.
[Roeber, James] New Mexico Dept Hlth, Albuquerque, NM USA.
RP Nelson, DE (reprint author), NCI, Canc Prevent Fellowship Program, Ctr Canc Training, 6120 Execut Blvd,Suite 150E,MSC 7105, Bethesda, MD 20892 USA.
EM nelsonde@mail.nih.gov
RI Stockwell, Tim/B-6662-2012
NR 50
TC 39
Z9 42
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0965-2140
J9 ADDICTION
JI Addiction
PD SEP
PY 2010
VL 105
IS 9
BP 1589
EP 1596
DI 10.1111/j.1360-0443.2010.03007.x
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 635PK
UT WOS:000280668200017
PM 20626370
ER
PT J
AU Schulze, S
Huang, GS
Krause, M
Aubyn, D
Quinones, VAB
Schmidt, CK
Mei, YF
Schmidt, OG
AF Schulze, Sabine
Huang, Gaoshan
Krause, Matthias
Aubyn, Deborah
Quinones, Vladimir A. Bolanos
Schmidt, Christine K.
Mei, Yongfeng
Schmidt, Oliver G.
TI Morphological Differentiation of Neurons on Microtopographic Substrates
Fabricated by Rolled-Up Nanotechnology
SO ADVANCED ENGINEERING MATERIALS
LA English
DT Article
ID RAT HIPPOCAMPAL-NEURONS; CONTACT GUIDANCE; CELL-MIGRATION; CULTURE;
GROWTH; SCAFFOLDS; SURFACES; ADHESION; CHANNELS; INVITRO
AB Arrays of transparent rolled-up microtubes can easily be mass-produced using a combination of conventional photolithography, electron beam depositioning, and chemical etching techniques. Here, we culture primary mouse motor neurons and immortalised CAD cells, a cell line derived from the central nervous system, on various microtube substrates to investigate the influence of topographical surface features on the growth and differentiation behaviour of these cells. Our results indicate that the microtube chips not only support growth of both cell types but also provide a well-defined, geometrically confined 3D cell culture scaffold. Strikingly, our micropatterns act as a platform for axon guidance with protruding cell extensions aligning in the direction of the microtubes and forming complex square-shaped grid-like neurite networks. Our experiments open up a cost-efficient and bio-compatible way of analysing single cell behaviour in the context of advanced micro-/nanostructures with various biological applications ranging from neurite protection studies to cell sensor development.
C1 [Schulze, Sabine; Huang, Gaoshan; Quinones, Vladimir A. Bolanos; Mei, Yongfeng; Schmidt, Oliver G.] IFW Dresden, Inst Integrat Nanosci, D-01069 Dresden, Germany.
[Schmidt, Oliver G.] Tech Univ Chemnitz, D-09107 Chemnitz, Germany.
[Schmidt, Christine K.] London Res Inst, Chromosome Segregat Lab, Canc Res UK, London WC2A 3PX, England.
[Schmidt, Christine K.] NCI, Bethesda, MD 20892 USA.
[Aubyn, Deborah] London Res Inst, Light Microscopy Lab, Canc Res UK, London WC2A 3PX, England.
[Krause, Matthias] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England.
RP Schulze, S (reprint author), IFW Dresden, Inst Integrat Nanosci, Helmholtzstr 20, D-01069 Dresden, Germany.
EM schmidtck@mail.nih.gov; mei@ifw-dresden.de
RI Huang, GaoShan/C-3629-2008; Krause, Matthias/D-9814-2013;
OI Krause, Matthias/0000-0002-3200-3199; Schmidt,
Christine/0000-0002-8363-7933; Mei, Yongfeng/0000-0002-3314-6108
FU Volkswagen Foundation [I/84 072]; Germany/Hong Kong Joint Research
Scheme [426/hk-PPP-cab]; Wellcome Trust [077429/Z/05/Z]
FX We acknowledge Dr. Frank Uhlmann for hosting our biological experiments,
Dr. Ina Weisswange for imaging advice, Emica Coric and Anne Weston for
SEM measurements and Guillermo Menendez and Anna Wade for kindly
providing us with primary mouse neurons. This work was financially
supported by a grant from the Volkswagen Foundation (I/84 072) and
partial support from the Germany/Hong Kong Joint Research Scheme (Grant
No. 426/hk-PPP-cab). MK is supported by funds from a Wellcome Trust
University Award (077429/Z/05/Z).
NR 37
TC 29
Z9 30
U1 4
U2 28
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1438-1656
J9 ADV ENG MATER
JI Adv. Eng. Mater.
PD SEP
PY 2010
VL 12
IS 9
SI SI
BP B558
EP B564
DI 10.1002/adem.201080023
PG 7
WC Materials Science, Multidisciplinary
SC Materials Science
GA 677ML
UT WOS:000283996400018
ER
PT J
AU Pinto, LA
Sullivan, EL
Rosenbaum, A
Wyngarden, N
Umhau, JC
Miller, MW
Taft, CT
AF Pinto, Lavinia A.
Sullivan, Eric L.
Rosenbaum, Alan
Wyngarden, Nicole
Umhau, John C.
Miller, Mark W.
Taft, Casey T.
TI Biological correlates of intimate partner violence perpetration
SO AGGRESSION AND VIOLENT BEHAVIOR
LA English
DT Article
DE Intimate partner violence; Biological factors; Neuropsychology;
Psychophysiology; Neurochemistry; Genetics
ID MONOAMINE-OXIDASE-A; PHYSICAL HEALTH CONSEQUENCES; YOUNG-ADULT
PRISONERS; HEART-RATE REACTIVITY; AL. 1995 TYPOLOGY; DOMESTIC VIOLENCE;
AGGRESSIVE-BEHAVIOR; INTERGENERATIONAL TRANSMISSION; CONFLICT-TACTICS;
FUNCTIONAL POLYMORPHISM
AB An extensive literature documents biological correlates of general aggression, but there has been less focus on biological correlates of intimate partner violence (IPV). The purpose of this review is to summarize the research literature to date that has reported on biological factors in IPV perpetration. We review the existing literature on four domains of biological processes that have been examined with respect to IPV perpetration, including: head injury and neuropsychology; psychophysiology; neurochemistry, metabolism and endocrinology; and genetics. We critique the literature, discuss the clinical relevance of research findings, and provide some recommendations for future biologically-oriented IPV research. Published by Elsevier Ltd.
C1 [Pinto, Lavinia A.; Miller, Mark W.; Taft, Casey T.] VA Boston Healthcare Syst, Behav Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA.
[Sullivan, Eric L.] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA.
[Rosenbaum, Alan; Wyngarden, Nicole] No Illinois Univ, Dept Psychol, De Kalb, IL 60115 USA.
[Umhau, John C.] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD USA.
[Miller, Mark W.; Taft, Casey T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Taft, CT (reprint author), VA Boston Healthcare Syst, Behav Sci Div, Natl Ctr PTSD, 150 S Huntington Ave 116B-4, Boston, MA 02130 USA.
EM Casey.Taft@va.gov
FU NIMH NIH HHS [R01 MH079806]
NR 111
TC 27
Z9 27
U1 11
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-1789
J9 AGGRESS VIOLENT BEH
JI Aggress. Violent Behav.
PD SEP-OCT
PY 2010
VL 15
IS 5
BP 387
EP 398
DI 10.1016/j.avb.2010.07.001
PG 12
WC Criminology & Penology; Psychology, Multidisciplinary
SC Criminology & Penology; Psychology
GA 660VS
UT WOS:000282675200008
PM 23393423
ER
PT J
AU Mittelman, M
Alperson, SY
Arcari, PM
Donnelly, GF
Ford, LC
Koithan, M
Kreitzer, MJ
AF Mittelman, Michele
Alperson, Sunny Yim
Arcari, Patricia Martin
Donnelly, Gloria Ferraro
Ford, Loretta C.
Koithan, Mary
Kreitzer, Mary Jo
TI NURSING AND INTEGRATIVE HEALTH CARE
SO ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
LA English
DT Editorial Material
C1 [Alperson, Sunny Yim] NINR, Washington, DC USA.
[Alperson, Sunny Yim] NIH, Ctr Clin, Washington, DC USA.
[Arcari, Patricia Martin] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Arcari, Patricia Martin] Benson Henry Inst Mind Body Med, Mind Body Program Mothers, Boston, MA USA.
[Donnelly, Gloria Ferraro] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19104 USA.
[Ford, Loretta C.] Univ Rochester, Med Ctr, Rochester, NY 14627 USA.
[Koithan, Mary] Univ Arizona, Coll Nursing, Tucson, AZ 85721 USA.
[Kreitzer, Mary Jo] Univ Minnesota, Ctr Spiritual & Healing, Minneapolis, MN USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU INNOVISION COMMUNICATIONS
PI ALISO VIEJO
PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA
SN 1078-6791
J9 ALTERN THER HEALTH M
JI Altern. Ther. Health Med.
PD SEP-OCT
PY 2010
VL 16
IS 5
BP 74
EP 84
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA V28TS
UT WOS:000208703700014
PM 20882736
ER
PT J
AU Goldberger, JJ
Bonow, RO
Cuffe, M
Dyer, A
Rosenberg, Y
O'Rourke, R
Shah, PK
Smith, SC
AF Goldberger, Jeffrey J.
Bonow, Robert O.
Cuffe, Michael
Dyer, Alan
Rosenberg, Yves
O'Rourke, Robert
Shah, Prediman K.
Smith, Sidney C., Jr.
CA PACE-MI Investigators
TI beta-Blocker use following myocardial infarction: Low prevalence of
evidence-based dosing
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID ASSOCIATION TASK-FORCE; CHRONIC HEART-FAILURE; DEVELOP
PERFORMANCE-MEASURES; MEASURES WRITING COMMITTEE; RANDOMIZED-TRIAL;
AMERICAN-COLLEGE; NORWEGIAN MULTICENTER; SECONDARY PREVENTION; PRACTICE
GUIDELINES; HOSPITAL DISCHARGE
AB Background Quality improvement programs have shown increased use of beta-blockers post-myocardial infarction (MI), but there are no data on whether appropriate doses are administered.
Methods In a prospective registry that enrolled consecutive patients with MI, we evaluated beta-blocker dosing at discharge after MI and 3 weeks later and assessed clinical predictors for treatment with very low doses. We studied 1,971 patients (70.8% male) with a mean age of 63.9 +/- 13.7 years, of whom 48.2% had an ST-elevation MI.
Results beta-Blocker utilization rates following MI were 93.2% at discharge: 20.1% received < 25% of target dose, 36.5% received < 25% of target dose, 26.4% received 26% to 50% of target dose, and 17.0% received >50% of target dose. Between discharge and 3 weeks, 76.4% had no change in beta-blocker dose, with 11.9% and 11.6% having their dose reduced and increased, respectively. Absence of hypertension, acute percutaneous coronary intervention, older age, and no angiotensin-converting enzyme inhibitor therapy were consistent predictors of treatment with very low beta-blocker doses.
Conclusions Underdosing of beta-blockers is highly prevalent among patients post-MI. This represents an important opportunity in quality improvement for the care of patients who have suffered an MI. (Am Heart J 2010; 160:435-442.e1.)
C1 [Goldberger, Jeffrey J.; Bonow, Robert O.; Dyer, Alan] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Cuffe, Michael] Duke Univ, Med Ctr, Durham, NC USA.
[Rosenberg, Yves] NHLBI, NIH, Bethesda, MD 20892 USA.
[O'Rourke, Robert] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Shah, Prediman K.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Smith, Sidney C., Jr.] Univ N Carolina, Chapel Hill, NC USA.
RP Goldberger, JJ (reprint author), Northwestern Univ, Feinberg Sch Med, 251 E Huron,Feinberg Pavil 8-503, Chicago, IL 60611 USA.
EM j-goldberger@northwestern.edu
OI Subacius, Haris/0000-0003-4061-1220
FU NHLBI NIH HHS [U01 HL080416, U01 HL080416-02]
NR 40
TC 14
Z9 14
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD SEP
PY 2010
VL 160
IS 3
BP 435
EP U86
DI 10.1016/j.ahj.2010.06.023
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 647YH
UT WOS:000281656300009
PM 20826250
ER
PT J
AU Yan, RT
Fernandes, V
Yan, AT
Cushman, M
Redheuil, A
Tracy, R
Vogel-Claussen, J
Bahrami, H
Nasir, K
Bluemke, DA
Lima, JAC
AF Yan, Raymond T.
Fernandes, Veronica
Yan, Andrew T.
Cushman, Mary
Redheuil, Alban
Tracy, Russell
Vogel-Claussen, Jens
Bahrami, Hossein
Nasir, Khurram
Bluemke, David A.
Lima, Joao A. C.
TI Fibrinogen and left ventricular myocardial systolic function: The
Multi-Ethnic Study of Atherosclerosis (MESA)
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID INDIVIDUAL PARTICIPANT METAANALYSIS; INTIMA-MEDIA THICKNESS;
CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE;
RISK-FACTORS; ASYMPTOMATIC INDIVIDUALS; HARP MRI; ARTERY; INFLAMMATION
AB Background Increasing evidence suggests that elevated plasma fibrinogen is associated with incident heart failure. However, the underlying pathophysiological mechanisms have not been well elucidated.
Methods We examined the relationship between plasma fibrinogen level and peak systolic midwall circumferential strain (Ecc) at the base, mid cavity, and apex of the left ventricle measured by magnetic resonance imaging myocardial tagging in 1096 participants without clinical cardiovascular disease enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA).
Results After adjustment for demographics, established risk factors and body mass index, elevated fibrinogen was independently associated with reductions in absolute Ecc indicative of impaired systolic function in all regions (all P <= .015). The relationships were consistently significant upon further adjustment for measures of atherosclerosis (all P < .024) and were modestly attenuated with regional heterogeneity after additional adjustment for other inflammatory biomarker and N-terminal pro-brain natriuretic peptide. In this fully-adjusted model, every 1-SD (74 mg/dL) increment in plasma fibrinogen was independently associated with a reduction in left ventricular absolute Ecc of 0.29% (95% CI 0.03%-0.59%, P = .048) at the base, 0.22% (95% CI 0.006%-0.43%, P = .044) at mid cavity, 0.20% (95% CI = -0.035% to 0.43%, P = .097) at the apex, and 0.24% (95% CI = 0.05%-0.43%, P = .015) overall.
Conclusions Among asymptomatic individuals without clinical cardiovascular disease, elevated fibrinogen is independently associated with impaired myocardial systolic function. These findings support roles of inflammation, procoagulation, and hyperviscosity underlying hyperfibrinogenemia in the pathogenesis of incipient myocardial dysfunction. (Am Heart J 2010;160:479-86.)
C1 [Yan, Raymond T.; Redheuil, Alban; Lima, Joao A. C.] Johns Hopkins Univ Hosp, Div Cardiol, Baltimore, MD 21287 USA.
[Fernandes, Veronica] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
[Yan, Andrew T.] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON M5B 1W8, Canada.
[Cushman, Mary; Tracy, Russell] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA.
[Vogel-Claussen, Jens] Johns Hopkins Univ Hosp, Dept Radiol, Baltimore, MD 21287 USA.
[Bahrami, Hossein] Yale Univ, Dept Med, New Haven, CT 06520 USA.
[Nasir, Khurram] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Bluemke, David A.] NIH, Bethesda, MD 20892 USA.
RP Lima, JAC (reprint author), Johns Hopkins Univ Hosp, Div Cardiol, Blalock 524,600 N Wolfe St, Baltimore, MD 21287 USA.
EM jlima@jhmi.edu
OI Bluemke, David/0000-0002-8323-8086
FU National Heart, Lung, and Blood Institute [RO1-HL66075-01]; Multi-Ethnic
Study of Atherosclerosis study [NO1-HC-95162, NO1-HC-95168,
NO1-HC-95169]; Canadian Institutes of Health Research; Royal College of
Physicians and Surgeons of Canada
FX This study was supported by the National Heart, Lung, and Blood
Institute grant (RO1-HL66075-01) and the Multi-Ethnic Study of
Atherosclerosis study contracts (NO1-HC-95162, NO1-HC-95168 and
NO1-HC-95169). Dr Raymond Yan was supported by fellowship awards from
the Canadian Institutes of Health Research and the Royal College of
Physicians and Surgeons of Canada.
NR 45
TC 12
Z9 14
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD SEP
PY 2010
VL 160
IS 3
BP 479
EP 486
DI 10.1016/j.ahj.2010.06.001
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 647YH
UT WOS:000281656300015
PM 20826256
ER
PT J
AU Cheng, S
Larson, MG
Keyes, MJ
McCabe, EL
Newton-Cheh, C
Levy, D
Benjamin, EJ
Vasan, RS
Wang, TJ
AF Cheng, Susan
Larson, Martin G.
Keyes, Michelle J.
McCabe, Elizabeth L.
Newton-Cheh, Christopher
Levy, Daniel
Benjamin, Emelia J.
Vasan, Ramachandran S.
Wang, Thomas J.
TI Relation of QRS Width in Healthy Persons to Risk of Future Permanent
Pacemaker Implantation
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID BUNDLE-BRANCH-BLOCK; COMPLETE ATRIOVENTRICULAR-BLOCK;
MYOCARDIAL-INFARCTION; INTRAVENTRICULAR-CONDUCTION; ELDERLY PATIENTS;
VALVE SURGERY; HEART-DISEASE; PATHOLOGY; DURATION; LOCATIONS
AB In the setting of acute myocardial infarction, prolongation of the QRS interval on electrocardiography identifies patients at risk for needing permanent pacemaker implantation. However, the implications of prolonged QRS intervals in healthy subjects are unclear, especially given that the QRS prolongation encountered in this setting is typically mild. The aim of this study was to assess the relation between QRS duration and incident pacemaker implantation in a community-based cohort of 8,311 subjects (mean age 54 years, 55% women) who attended 17,731 routine examinations with resting 12-lead electrocardiography. QRS duration was analyzed as a continuous and a categorical variable (<100, 100 to <120, and >= 120 ms). During up to 35 years of follow-up, 157 participants (56 women) developed need for permanent pacemakers. In multivariable Cox regression models adjusting for cardiovascular risk factors and previous myocardial infarction or heart failure, mild QRS prolongation was associated with a threefold risk for pacemaker implantation (adjusted hazard ratio 2.90, 95% confidence interval 1.81 to 4.66, p < 0.0001), and bundle branch block was associated with a fourfold risk for pacemaker implantation (hazard ratio 4.43, 95% confidence interval 2.94 to 6.68, p < 0.0001). Each standard deviation increment in QRS duration (11 ms) was associated with an adjusted hazard ratio of 1.14 (95% confidence interval 1.11 to 1.18, p < 0.0001) for pacemaker placement. This association remained significant after excluding subjects with QRS durations >= 120 ms. In conclusion, subjects with prolonged QRS durations, even without bundle branch block, are at increased risk for future pacemaker implantation. Such individuals may warrant monitoring for progressive conduction disease. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 20102010;106:668-672)
C1 [Cheng, Susan; Larson, Martin G.; Keyes, Michelle J.; McCabe, Elizabeth L.; Newton-Cheh, Christopher; Levy, Daniel; Benjamin, Emelia J.; Vasan, Ramachandran S.; Wang, Thomas J.] Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
[Cheng, Susan; McCabe, Elizabeth L.; Newton-Cheh, Christopher; Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Larson, Martin G.; Newton-Cheh, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA.
[Cheng, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Cardiovasc Med, Boston, MA 02115 USA.
[Keyes, Michelle J.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Newton-Cheh, Christopher] Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA USA.
[Newton-Cheh, Christopher] MIT, Cambridge, MA 02139 USA.
[Levy, Daniel] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA.
[Levy, Daniel; Benjamin, Emelia J.; Vasan, Ramachandran S.] Boston Univ, Sch Med, Prevent Med Sect, Boston, MA 02118 USA.
[Levy, Daniel; Benjamin, Emelia J.; Vasan, Ramachandran S.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
RP Wang, TJ (reprint author), Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
OI Larson, Martin/0000-0002-9631-1254; Ramachandran,
Vasan/0000-0001-7357-5970; Benjamin, Emelia/0000-0003-4076-2336
FU Framingham Heart Study of the National Heart, Lung, and Blood Institute,
Bethesda, Maryland [N01-HC-25195]
FX This work was supported by the Framingham Heart Study of the National
Heart, Lung, and Blood Institute, Bethesda, Maryland (Contract Number
N01-HC-25195)
NR 22
TC 11
Z9 12
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD SEP 1
PY 2010
VL 106
IS 5
BP 668
EP 672
DI 10.1016/j.amjcard.2010.04.021
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 647JW
UT WOS:000281615800012
PM 20723643
ER
PT J
AU Grant, JE
Potenza, MN
Weinstein, A
Gorelick, DA
AF Grant, Jon E.
Potenza, Marc N.
Weinstein, Aviv
Gorelick, David A.
TI Introduction to Behavioral Addictions
SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
LA English
DT Article
DE behavioral addiction; classification; diagnosis; impulse control
disorder; substance use disorder
ID OBSESSIVE-COMPULSIVE DISORDER; IMPULSE CONTROL DISORDERS; GENDER-RELATED
DIFFERENCES; PLACEBO-CONTROLLED TRIAL; PATHOLOGICAL GAMBLERS;
CLINICAL-FEATURES; DOUBLE-BLIND; PSYCHIATRIC COMORBIDITY;
PARKINSONS-DISEASE; ALCOHOL DEPENDENCE
AB Background: Several behaviors, besides psychoactive substance ingestion, produce short-term reward that may engender persistent behavior, despite knowledge of adverse consequences, i.e., diminished control over the behavior. These disorders have historically been conceptualized in several ways. One view posits these disorders as lying along an impulsive-compulsive spectrum, with some classified as impulse control disorders. An alternate, but not mutually exclusive, conceptualization considers the disorders as non-substance or "behavioral" addictions. Objectives: Inform the discussion on the relationship between psychoactive substance and behavioral addictions. Methods: We review data illustrating similarities and differences between impulse control disorders or behavioral addictions and substance addictions. This topic is particularly relevant to the optimal classification of these disorders in the forthcoming fifth edition of the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSMV). Results: Growing evidence suggests that behavioral addictions resemble substance addictions in many domains, including natural history, phenomenology, tolerance, comorbidity, overlapping genetic contribution, neurobiologicalmechanisms, and response to treatment, supporting the DSM-V Task Force proposed new category of Addiction and Related Disorders encompassing both substance use disorders and non-substance addictions. Current data suggest that this combined categorymay be appropriate for pathological gambling and a few other better studied behavioral addictions, e. g., Internet addiction. There is currently insufficient data to justify any classification of other proposed behavioral addictions. Conclusions and Scientific Significance: Proper categorization of behavioral addictions or impulse control disorders has substantial implications for the development of improved prevention and treatment strategies.
C1 [Grant, Jon E.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
[Potenza, Marc N.] Yale Univ, Sch Med, New Haven, CT USA.
[Weinstein, Aviv] Hadassah Univ Hosp, IL-91120 Jerusalem, Israel.
[Gorelick, David A.] NIDA, Intramural Res Program, NIH, Baltimore, MD USA.
RP Gorelick, DA (reprint author), 251 Bayview Blvd, Baltimore, MD 21224 USA.
EM dgorelic@intra.nida.nih.gov
FU Intramural NIH HHS [ZIA DA000240-18]; NIDA NIH HHS [RC1 DA028279, ZIA
DA000240-19, R01 DA019139]
NR 102
TC 210
Z9 213
U1 12
U2 140
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0095-2990
J9 AM J DRUG ALCOHOL AB
JI Am. J. Drug Alcohol Abuse
PD SEP
PY 2010
VL 36
IS 5
BP 233
EP 241
DI 10.3109/00952990.2010.491884
PG 9
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 663UY
UT WOS:000282916900001
PM 20560821
ER
PT J
AU Khoury, MJ
Gwinn, M
Ioannidis, JPA
AF Khoury, Muin J.
Gwinn, Marta
Ioannidis, John P. A.
TI The Emergence of Translational Epidemiology: From Scientific Discovery
to Population Health Impact
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
DE epidemiology; genomics; medicine; public health; translational research
ID GENOME-WIDE ASSOCIATION; CLINICAL-RESEARCH; UNITED-STATES; PERSONALIZED
MEDICINE; PUBLIC-HEALTH; DISEASE; RISK; CHALLENGES; PREVENTION; PROFILES
AB Recent emphasis on translational research (TR) is highlighting the role of epidemiology in translating scientific discoveries into population health impact. The authors present applications of epidemiology in TR through 4 phases designated T1-T4, illustrated by examples from human genomics. In T1, epidemiology explores the role of a basic scientific discovery (e.g., a disease risk factor or biomarker) in developing a "candidate application" for use in practice (e.g., a test used to guide interventions). In T2, epidemiology can help to evaluate the efficacy of a candidate application by using observational studies and randomized controlled trials. In T3, epidemiology can help to assess facilitators and barriers for uptake and implementation of candidate applications in practice. In T4, epidemiology can help to assess the impact of using candidate applications on population health outcomes. Epidemiology also has a leading role in knowledge synthesis, especially using quantitative methods (e.g., meta-analysis). To explore the emergence of TR in epidemiology, the authors compared articles published in selected issues of the Journal in 1999 and 2009. The proportion of articles identified as translational doubled from 16% (11/69) in 1999 to 33% (22/66) in 2009 (P = 0.02). Epidemiology is increasingly recognized as an important component of TR. By quantifying and integrating knowledge across disciplines, epidemiology provides crucial methods and tools for TR.
C1 [Khoury, Muin J.; Gwinn, Marta] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA.
[Khoury, Muin J.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.
[Ioannidis, John P. A.] Biomed Res Inst, Ioannina, Greece.
[Ioannidis, John P. A.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA.
[Ioannidis, John P. A.] Tufts Med Ctr, Tufts Clin & Translat Sci Inst, Boston, MA USA.
[Ioannidis, John P. A.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Ioannidis, John P. A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Khoury, MJ (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM muk1@cdc.gov
RI Ioannidis, John/G-9836-2011
NR 58
TC 108
Z9 117
U1 2
U2 16
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 1
PY 2010
VL 172
IS 5
BP 517
EP 524
DI 10.1093/aje/kwq211
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 643UF
UT WOS:000281324100003
PM 20688899
ER
PT J
AU Khoury, MJ
Gwinn, M
Ioannidis, JPA
AF Khoury, Muin J.
Gwinn, Marta
Ioannidis, John P. A.
TI Khoury et al. Respond to "The Epicenter of Translational Science":
Crossing All the T's
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
ID EPIDEMIOLOGY
C1 [Khoury, Muin J.; Gwinn, Marta] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA.
[Khoury, Muin J.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.
[Ioannidis, John P. A.] Biomed Res Inst, Ioannina, Greece.
[Ioannidis, John P. A.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA.
[Ioannidis, John P. A.] Tufts Med Ctr, Tufts Clin & Translat Sci Inst, Boston, MA USA.
[Ioannidis, John P. A.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Ioannidis, John P. A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Khoury, MJ (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM muk1@cdc.gov
RI Ioannidis, John/G-9836-2011
NR 8
TC 1
Z9 1
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 1
PY 2010
VL 172
IS 5
BP 528
EP 529
DI 10.1093/aje/kwq214
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 643UF
UT WOS:000281324100005
ER
PT J
AU Alley, DE
Metter, EJ
Griswold, ME
Harris, TB
Simonsick, EM
Longo, DL
Ferrucci, L
AF Alley, Dawn E.
Metter, E. Jeffrey
Griswold, Michael E.
Harris, Tamara B.
Simonsick, Eleanor M.
Longo, Dan L.
Ferrucci, Luigi
TI Changes in Weight at the End of Life: Characterizing Weight Loss by Time
to Death in a Cohort Study of Older Men
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE aged; cachexia; cause of death; cohort studies; mortality; weight loss
ID ALL-CAUSE MORTALITY; BODY-MASS INDEX; RISK-FACTOR; AGE; OVERWEIGHT;
HEALTH; WOMEN
AB The purpose of this analysis was to characterize the natural history of weight change in the years prior to death among older persons and to examine how this pattern varies according to longevity and cause of death. Weight trajectories were analyzed by using data from 800 male decedents from the Baltimore Longitudinal Study of Aging (Maryland, 1958-2005) observed beginning an average of 19 years before death. A model including 3 distinct periods of weight change (weight stability/gain, mild weight loss, and accelerated weight loss before death) provided the best fit for all age-at-death groups. Approximately 9 years before death, the rate of weight loss increased to an average of 0.39 kg/year (P < 0.001) for all-cause mortality. For cancer deaths, weight loss accelerated significantly 3 years before death, regardless of age group. For cardiovascular deaths, the best-fitting inflection point increased with age, from 5 years for participants aged 60-69 years to 9-10 years before death for those aged 80 years or older. Results suggest that weight loss in older persons may begin earlier than previously believed. The duration of weight loss for noncancer deaths suggests that even distal changes in energy balance may be linked to risk of death.
C1 [Alley, Dawn E.] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA.
[Metter, E. Jeffrey; Simonsick, Eleanor M.; Longo, Dan L.; Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Griswold, Michael E.] Univ Mississippi, Med Ctr, Ctr Biostat, Jackson, MS 39216 USA.
[Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
RP Alley, DE (reprint author), 660 W Redwood St,221B, Baltimore, MD 21201 USA.
EM dalley@epi.umaryland.edu
FU National Institute on Aging Intramural Research Program; Robert Wood
Johnson Foundation Health and Society Scholars Program; Organized
Research Center on Aging at the University of Maryland, Baltimore
FX This work was supported by the National Institute on Aging Intramural
Research Program; the Robert Wood Johnson Foundation Health and Society
Scholars Program; and the Organized Research Center on Aging at the
University of Maryland, Baltimore.
NR 26
TC 21
Z9 24
U1 3
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 1
PY 2010
VL 172
IS 5
BP 558
EP 565
DI 10.1093/aje/kwq168
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 643UF
UT WOS:000281324100010
PM 20682520
ER
PT J
AU Kristal, AR
Arnold, KB
Neuhouser, ML
Goodman, P
Platz, EA
Albanes, D
Thompson, IM
AF Kristal, Alan R.
Arnold, Kathryn B.
Neuhouser, Marian L.
Goodman, Phyllis
Platz, Elizabeth A.
Albanes, Demetrius
Thompson, Ian M.
TI Diet, Supplement Use, and Prostate Cancer Risk: Results From the
Prostate Cancer Prevention Trial
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE diet; dietary supplements; food; micronutrients; prostatic neoplasms
ID FOOD-FREQUENCY QUESTIONNAIRE; DAIRY-PRODUCTS; VITAMIN-E; SELENIUM
SUPPLEMENTATION; ALCOHOL-CONSUMPTION; MULTIETHNIC COHORT; SCREENING
TRIAL; CALCIUM INTAKE; BREAST-CANCER; FAT
AB The authors examined nutritional risk factors for prostate cancer among 9,559 participants in the Prostate Cancer Prevention Trial (United States and Canada, 1994-2003). The presence or absence of cancer was determined by prostate biopsy, which was recommended during the trial because of an elevated prostate-specific antigen level or an abnormal digital rectal examination and was offered to all men at the trial's end. Nutrient intake was assessed using a food frequency questionnaire and a structured supplement-use questionnaire. Cancer was detected in 1,703 men; 127 cancers were high-grade (Gleason score 8-10). There were no associations of any nutrient or supplement with prostate cancer risk overall. Risk of high-grade cancer was associated with high intake of polyunsaturated fats (quartile 4 vs. quartile 1: odds ratio = 2.41, 95% confidence interval (CI): 1.33, 4.38). Dietary calcium was positively associated with low-grade cancer but inversely associated with high-grade cancer (for quartile 4 vs. quartile 1, odds ratios were 1.27 (95% CI: 1.02, 1.57) and 0.43 (95% CI: 0.21, 0.89), respectively). Neither dietary nor supplemental intakes of nutrients often suggested for prostate cancer prevention, including lycopene, long-chain n-3 fatty acids, vitamin D, vitamin E, and selenium, were significantly associated with cancer risk. High intake of n-6 fatty acids, through their effects on inflammation and oxidative stress, may increase prostate cancer risk.
C1 [Kristal, Alan R.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Kristal, Alan R.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA.
[Platz, Elizabeth A.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Albanes, Demetrius] NCI, Bethesda, MD 20892 USA.
[Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
RP Kristal, AR (reprint author), Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Div Publ Hlth Sci, 1100 Fairview Ave N,M4-B402,POB 19024, Seattle, WA 98109 USA.
EM akristal@fhcrc.org
RI Albanes, Demetrius/B-9749-2015;
OI Kristal, Alan/0000-0002-7329-1617
FU National Cancer Institute [R01 CA63164, P01 CA37429, P01 CA108964]
FX This work was supported by the following grants from the National Cancer
Institute: R01 CA63164 (Prospective Cohort Study of Diet and Prostate
Cancer), P01 CA37429 (Prostate Cancer Prevention Trial), and P01
CA108964 (Biology of the Prostate Cancer Prevention Trial).
NR 56
TC 68
Z9 71
U1 4
U2 20
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 1
PY 2010
VL 172
IS 5
BP 566
EP 577
DI 10.1093/aje/kwq148
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 643UF
UT WOS:000281324100011
PM 20693267
ER
PT J
AU Salinas, CA
Kwon, EM
FitzGerald, LM
Feng, ZD
Nelson, PS
Ostrander, EA
Peters, U
Stanford, JL
AF Salinas, Claudia A.
Kwon, Erika M.
FitzGerald, Liesel M.
Feng, Ziding
Nelson, Peter S.
Ostrander, Elaine A.
Peters, Ulrike
Stanford, Janet L.
TI Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in
Relation to Prostate Cancer Risk
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE anti-inflammatory agents; non-steroidal; aspirin; odds ratio;
polymorphism; genetic; prostaglandin-endoperoxide synthases; prostatic
neoplasms
ID INVERSE ASSOCIATION; GENETIC-VARIATION; LARGE COHORT; COX-2 GENE;
DRUG-USE; CYCLOOXYGENASE-2; NSAIDS; EXPRESSION; PREVENTION; BREAST
AB Recent interest has focused on the role that inflammation may play in the development of prostate cancer and whether use of aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) affects risk. In a population-based case-control study designed to investigate the relation between these medications and prostate cancer risk, detailed exposure data were analyzed from 1,001 cases diagnosed with prostate cancer between January 1, 2002, and December 31, 2005, and 942 age-matched controls from King County, Washington. A significant 21% reduction in the risk of prostate cancer was observed among current users of aspirin compared with nonusers (95% confidence interval (CI): 0.65, 0.96). Long-term use of aspirin (> 5 years: odds ratio = 0.76, 95% CI: 0.61, 0.96) and daily use of low-dose aspirin (odds ratio = 0.71, 95% CI: 0.56, 0.90) were also associated with decreased risk. There was no evidence that the association with aspirin use varied by disease aggressiveness, but there was effect modification (P(interaction) = 0.02) with a genetic variant in prostaglandin-endoperoxide synthase 2 (PTGS2) (rs12042763). Prostate cancer risk was not related to use of either nonaspirin NSAIDs or acetaminophen. These results contribute further evidence that aspirin may have chemopreventive activity against prostate cancer and highlight the need for additional research.
C1 [Salinas, Claudia A.; FitzGerald, Liesel M.; Feng, Ziding; Peters, Ulrike; Stanford, Janet L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Salinas, Claudia A.; Peters, Ulrike; Stanford, Janet L.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Kwon, Erika M.; Ostrander, Elaine A.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.
[Feng, Ziding] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA.
[Nelson, Peter S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
RP Stanford, JL (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Mailstop M4-B874,POB 19024, Seattle, WA 98109 USA.
EM jstanfor@fhcrc.org
OI Ostrander, Elaine/0000-0001-6075-9738
FU National Cancer Institute [R01 CA092579, R03 CA121871, N01-PC-35142]; US
Department of Defense [PC06445]; Fred Hutchinson Cancer Research Center;
National Human Genome Research Institute
FX This work was supported by grants R01 CA092579 and R03 CA121871 and
contract N01-PC-35142 from the National Cancer Institute, as well as by
training grant PC06445 from the US Department of Defense (C. A. S.).
Additional support was provided by the Fred Hutchinson Cancer Research
Center and the Intramural Program of the National Human Genome Research
Institute.
NR 45
TC 42
Z9 43
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 1
PY 2010
VL 172
IS 5
BP 578
EP 590
DI 10.1093/aje/kwq175
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 643UF
UT WOS:000281324100012
PM 20688905
ER
PT J
AU Patton, HM
Yates, K
Unalp-Arida, A
Behling, CA
Huang, TTK
Rosenthal, P
Sanyal, AJ
Schwimmer, JB
Lavine, JE
AF Patton, Heather M.
Yates, Katherine
Unalp-Arida, Aynur
Behling, Cynthia A.
Huang, Terry T. -K.
Rosenthal, Philip
Sanyal, Arun J.
Schwimmer, Jeffrey B.
Lavine, Joel E.
CA NASH CRN
TI Association Between Metabolic Syndrome and Liver Histology Among
Children With Nonalcoholic Fatty Liver Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID TRIGLYCERIDE TRANSFER PROTEIN; NUTRITION EXAMINATION SURVEY;
CARDIOVASCULAR RISK-FACTORS; US ADOLESCENTS; ALANINE AMINOTRANSFERASE;
INSULIN-RESISTANCE; NATIONAL-HEALTH; STEATOHEPATITIS; DEFINITION;
PREVALENCE
AB OBJECTIVES: Nonalcoholic steatohepatitis (NASH) is considered the hepatic manifestation of metabolic syndrome (MetS) among adults. Emerging data suggest that MetS may be associated with nonalcoholic fatty liver disease (NAFLD) in children as well. We sought to determine whether MetS or its component features are associated with specific histological features or severity of NAFLD.
METHODS: Children and adolescents aged 6-17 years enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) with clinical data obtained within 6 months of liver biopsy were included. MetS was defined as the presence of three or more of the following features as determined by application of age-adjusted normative values: central obesity, dyslipidemia, impaired fasting glucose, and elevated blood pressure. Liver biopsies were evaluated by the Pathology Committee of the NASH CRN.
RESULTS: Two hundred fifty four children were included in the analysis, of whom 65 (26%) met specified criteria for MetS. Among children with MetS, there is a higher proportion of females who were on average older in age and pubertal. The risk of MetS was greatest among those with severe steatosis (odds ratio (OR)=2.58 for grade 3 vs. grade 1 steatosis, P=0.001). The presence of hepatocellular ballooning was also significantly associated with MetS (OR=2.10, P=0.03). Those with advanced fibrosis (stage 3/4) had an OR for MetS of 3.21 (P=0.04) vs. those without fibrosis (stage 0). Borderline zone 1 or definite NASH patterns compared with "not NASH" were strongly associated with MetS (OR=4.44, P=0.005 and OR=4.07, P=0.002, respectively). The mean NAFLD Activity Score (NAS) was greater among children with MetS vs. those without (4.8 +/- 1.4 vs. 4.3 +/- 1.4, P=0.01). Central obesity was significantly associated with steatosis, fibrosis, hepatocellular ballooning, and NAFLD pattern. Insulin resistance was significantly associated with steatosis, fibrosis, hepatocellular ballooning, NAS, and NAFLD pattern.
CONCLUSIONS: MetS is common among children with NAFLD and is associated with severity of steatosis, hepatocellular ballooning, NAS, NAFLD pattern, and the presence of advanced fibrosis. Individual MetS features, particularly central obesity and insulin resistance, were also associated with severity of NAFLD. MetS features should be considered in children with NAFLD as individually and collectively they help identify children with more advanced disease.
C1 [Patton, Heather M.; Schwimmer, Jeffrey B.; Lavine, Joel E.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
[Patton, Heather M.; Schwimmer, Jeffrey B.; Lavine, Joel E.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA.
[Yates, Katherine; Unalp-Arida, Aynur] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Behling, Cynthia A.] Pacific Rim Pathol Grp, San Diego, CA USA.
[Huang, Terry T. -K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
[Rosenthal, Philip] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.
[Sanyal, Arun J.] Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA.
RP Lavine, JE (reprint author), Morgan Stanley Childrens Hosp New York, 3959 Broadway,CHN7-702, New York, NY 10032 USA.
EM jl3553@columbia.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734,
U01DK061737, U01DK061738, U01DK061730, U01DK061713]; National Institute
of Child Health and Human Development; General Clinical Research Centers
[UL1RR024989, M01RR000750, M01RR00188, RR02413101, M01RR000827,
UL1RR02501401, M01RR000065, M01RR020359]; National Institutes of Health,
National Cancer Institute
FX The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) is
supported by the National Institute of Diabetes and Digestive and Kidney
Diseases (Grants U01DK061718, U01DK061728, U01DK061731, U01DK061732,
U01DK061734, U01DK061737, U01DK061738, U01DK061730, U01DK061713), and
the National Institute of Child Health and Human Development. Several
clinical centers use support from General Clinical Research Centers or
Clinical and Translational Science Awards in the conduct of Nonalcoholic
Steatohepatitis Clinical Research Network studies (Grants UL1RR024989,
M01RR000750, M01RR00188, RR02413101, M01RR000827, UL1RR02501401,
M01RR000065, M01RR020359). This study was supported in part by the
Intramural Research Program of the National Institutes of Health,
National Cancer Institute.
NR 50
TC 65
Z9 70
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD SEP
PY 2010
VL 105
IS 9
BP 2093
EP 2102
DI 10.1038/ajg.2010.152
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 646SM
UT WOS:000281563100026
PM 20372110
ER
PT J
AU Shebl, FM
El-Kamary, SS
AF Shebl, Fatma M.
El-Kamary, Samer S.
TI Diabetes Mellitus, Obesity, and Hepatocellular Carcinoma: The Jury Is
Still Out
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
C1 [Shebl, Fatma M.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Rockville, MD 20852 USA.
[El-Kamary, Samer S.] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA.
RP Shebl, FM (reprint author), NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, 6120 Execut Blvd,EPS 7074, Rockville, MD 20852 USA.
EM sheblf@mail.nih.gov
NR 5
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD SEP
PY 2010
VL 105
IS 9
BP 2116
EP 2117
DI 10.1038/ajg.2010.184
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 646SM
UT WOS:000281563100039
PM 20818365
ER
PT J
AU Stevens, LA
Schmid, CH
Greene, T
Zhang, YP
Beck, GJ
Froissart, M
Hamm, LL
Lewis, JB
Mauer, M
Navis, GJ
Steffes, MW
Eggers, PW
Coresh, J
Levey, AS
AF Stevens, Lesley A.
Schmid, Christopher H.
Greene, Tom
Zhang, Yaping (Lucy)
Beck, Gerald J.
Froissart, Marc
Hamm, Lee L.
Lewis, Julia B.
Mauer, Michael
Navis, Gerjan J.
Steffes, Michael W.
Eggers, Paul W.
Coresh, Josef
Levey, Andrew S.
TI Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI)
and the Modification of Diet in Renal Disease (MDRD) Study Equations for
Estimating GFR Levels Above 60 mL/min/1.73 m(2)
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Estimating equations; glomerular filtration rate; performance
ID GLOMERULAR-FILTRATION-RATE; RENIN-ANGIOTENSIN SYSTEM; TYPE-1
DIABETIC-PATIENTS; SERUM CYSTATIN-C; COCKCROFT-GAULT; PREDICTIVE
PERFORMANCE; AFRICAN-AMERICANS; KIDNEY-DISEASE; DUAL BLOCKADE;
CREATININE
AB Background: The Modification of Diet in Renal Disease (MDRD) Study equation underestimates measured glomerular filtration rate (GFR) at levels >60 mL/min/1.73 m(2), with variable accuracy among subgroups; consequently, estimated GFR (eGFR) >= 60 mL/min/1.73 m(2) is not reported by clinical laboratories. Here, performance of a more accurate GFR-estimating equation, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, is reported by level of GFR and clinical characteristics.
Study Design: Test of diagnostic accuracy.
Setting & Participants: Pooled data set of 3,896 people from 16 studies with measured GFR (not used for the development of either equation). Subgroups were defined by eGFR, age, sex, race, diabetes, prior solid-organ transplant, and body mass index.
Index Tests: eGFR from the CKD-EPI and MDRD Study equations and standardized serum creatinine.
Reference Test: Measured GFR using urinary or plasma clearance of exogenous filtration markers.
Results: Mean measured GFR was 68 +/- 36 (SD) mL/min/1.73 m(2). For eGFR <30 mL/min/1.73 m(2), both equations have similar bias (median difference compared with measured GFR). For eGFR of 30-59 mL/min/1.73 m(2), bias was decreased from 4.9 to 2.1 mL/min/1.73 m(2) (57% improvement). For eGFR of 60-89 mL/min/1.73 m(2), bias was decreased from 11.9 to 4.2 mL/min/1.73 m(2) (61% improvement). For eGFR of 90-119 mL/min/1.73 m(2), bias was decreased from 10.0 to 1.9 mL/min/1.73 m(2) (75% improvement). Similar or improved performance was noted for most subgroups with eGFR <90 mL/min/1.73 m(2), other than body mass index <20 kg/m(2), with greater variation noted for some subgroups with eGFR >= 90 mL/min/1.73 m(2).
Limitations: Limited number of elderly people and racial and ethnic minorities with measured GFR.
Conclusions: The CKD-EPI equation is more accurate than the MDRD Study equation overall and across most subgroups. In contrast to the MDRD Study equation, eGFR >= 60 mL/min/1.73 m(2) can be reported using the CKD-EPI equation. Am J Kidney Dis 56: 486-495. (C) 2010 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Stevens, Lesley A.] Tufts Med Ctr, Div Nephrol, Boston, MA 02111 USA.
[Greene, Tom] Univ Utah, Salt Lake City, UT USA.
[Beck, Gerald J.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Froissart, Marc] Paris Descartes Univ, Georges Pompidou European Hosp, Paris, France.
[Hamm, Lee L.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA.
[Lewis, Julia B.] Vanderbilt Univ, Nashville, TN USA.
[Mauer, Michael; Steffes, Michael W.] Univ Minnesota, Minneapolis, MN USA.
[Navis, Gerjan J.] Univ Groningen Hosp, Groningen, Netherlands.
[Eggers, Paul W.] NIDDK, Bethesda, MD USA.
[Coresh, Josef] Johns Hopkins Univ, Baltimore, MD USA.
RP Stevens, LA (reprint author), Tufts Med Ctr, Div Nephrol, 800 Washington St,Box 391, Boston, MA 02111 USA.
EM lstevens1@tuftsmedicalcenter.org
OI Froissart, Marc/0000-0002-4010-3173
FU [UO1 DK 053869]; [UO1 DK 067651]; [UO1 DK 35073]; [K23-DK081017]
FX This study was supported by grants UO1 DK 053869, UO1 DK 067651, UO1 DK
35073, and K23-DK081017.
NR 48
TC 246
Z9 260
U1 1
U2 24
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD SEP
PY 2010
VL 56
IS 3
BP 486
EP 495
DI 10.1053/j.ajkd.2010.03.026
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 642IH
UT WOS:000281203200011
PM 20557989
ER
PT J
AU Solomon, BD
Pineda-Alvarez, DE
Raam, MS
Bous, SM
Keaton, AA
Velez, JI
Cummings, DAT
AF Solomon, Benjamin D.
Pineda-Alvarez, Daniel E.
Raam, Manu S.
Bous, Sophia M.
Keaton, Amelia A.
Velez, Jorge I.
Cummings, Derek A. T.
TI Analysis of Component Findings in 79 Patients Diagnosed With VACTERL
Association
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE VACTERL; VACTERL association; VATER; VATER association
ID RESPIRATORY-CHAIN DEFICIENCY; VATER-ASSOCIATION; CONGENITAL-ANOMALIES;
ESOPHAGEAL ATRESIA; SONIC HEDGEHOG; SPECTRUM; MUTATION; DELINEATION;
DEFINITION; FISTULA
AB VACTERL association is a relatively common condition, though the causes remain poorly understood. We present data on 79 patients diagnosed with VACTERL association and perform statistical analysis on a selected subset of 60 patients with at least three component features, and who, after review, did not meet criteria for a likely alternate diagnosis. Considered individually, no two component features are significantly associated, but several multivariate statistical techniques suggest novel patterns of the co-occurrence of component features, and latent class cluster analysis demonstrates the presence of five major subgroups of patients. These findings have implications for both our understanding of VACTERL association and for the approach to research involving this condition. Published 2010 (C) Wiley-Liss, Inc.
C1 [Solomon, Benjamin D.] NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA.
[Raam, Manu S.] NIH, Res Scholars Program, Howard Hughes Med Inst, Chevy Chase, MD USA.
[Cummings, Derek A. T.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Solomon, BD (reprint author), NHGRI, Med Genet Branch, NIH, MSC 3717, Bethesda, MD 20892 USA.
FU Intramural NIH HHS [Z99 HG999999]
NR 28
TC 25
Z9 29
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4825
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD SEP
PY 2010
VL 152A
IS 9
BP 2236
EP 2244
DI 10.1002/ajmg.a.33572
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 645XF
UT WOS:000281498800013
PM 20683998
ER
PT J
AU Gyamfi, C
Mele, L
Wapner, RJ
Spong, CY
Peaceman, A
Sorokin, Y
Dudley, DJ
Johnson, F
Leveno, KJ
Caritis, SN
Mercer, BM
Thorp, JM
O'Sullivan, MJ
Ramin, SM
Carpenter, M
Rouse, DJ
Miodovnik, M
Sibai, B
AF Gyamfi, Cynthia
Mele, Lisa
Wapner, Ronald J.
Spong, Catherine Y.
Peaceman, Alan
Sorokin, Yoram
Dudley, Donald J.
Johnson, Francee
Leveno, Kenneth J.
Caritis, Steve N.
Mercer, Brian M.
Thorp, John M., Jr.
O'Sullivan, Mary J.
Ramin, Susan M.
Carpenter, Marshall
Rouse, Dwight J.
Miodovnik, Menachem
Sibai, Baha
TI The effect of plurality and obesity on betamethasone concentrations in
women at risk for preterm delivery
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Proceedings Paper
CT 29th Annual Meeting of the Society-for-Maternal-Fetal-Medicine
CY JAN 26-31, 2009
CL San Diego, CA
SP Soc Maternal Fetal Med
DE betamethasone concentration; obesity; twins
ID PHARMACOKINETICS; CORTICOSTEROIDS
AB OBJECTIVE: Antenatal corticosteroids (ACS) decrease respiratory distress syndrome in singleton gestations. Twin data are less clear. Obesity and body mass index (BMI) also affect medication distribution volume. We evaluated whether maternal or neonatal cord betamethasone concentrations differed in twin gestations or obese patients.
STUDY DESIGN: Participants receiving betamethasone in a randomized controlled trial of weekly ACS were identified. We analyzed maternal delivery and cord serum betamethasone concentrations comparing singletons with twins and obese (BMI >= 30 kg/m(2)) with nonobese women.
RESULTS: Fifty-five maternal and 45 cord blood samples were available. Unadjusted median maternal serum concentrations appeared paradoxically higher in both twin gestations and the obese. However, after controlling for confounders, there were no differences in betamethasone concentrations in maternal serum or cord blood between singletons and twins (P = .61 vs P = .14) or nonobese and obese women (P = .67 vs .12).
CONCLUSION: Maternal and umbilical cord blood serum betamethasone concentrations are not different in twin gestations or obese women.
C1 [Gyamfi, Cynthia] Columbia Univ, Med Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, New York, NY 10032 USA.
[Wapner, Ronald J.] Drexel Univ, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA.
[Peaceman, Alan] Northwestern Univ, Dept Obstet & Gynecol, Chicago, IL 60611 USA.
[Sorokin, Yoram] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA.
[Dudley, Donald J.] Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT USA.
[Johnson, Francee] Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA.
[Leveno, Kenneth J.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA.
[Caritis, Steve N.] Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA USA.
[Mercer, Brian M.] Case Western Reserve Univ, Dept Obstet & Gynecol, Cleveland, OH 44106 USA.
[Thorp, John M., Jr.] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC USA.
[O'Sullivan, Mary J.] Univ Miami, Miller Sch Med, Dept Obstet & Gynecol, Miami, FL 33136 USA.
[Ramin, Susan M.] Univ Texas Hlth Sci Ctr Houston, Dept Obstet & Gynecol, Houston, TX USA.
[Carpenter, Marshall] Brown Univ, Dept Obstet & Gynecol, Providence, RI 02912 USA.
[Rouse, Dwight J.] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA.
[Miodovnik, Menachem] Univ Cincinnati, Dept Obstet & Gynecol, Cincinnati, OH USA.
[Sibai, Baha] Univ Tennessee, Dept Obstet & Gynecol, Memphis, TN 38103 USA.
[Mele, Lisa] George Washington Univ, Ctr Biostat, Dept Obstet & Gynecol, Washington, DC USA.
[Spong, Catherine Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Dept Obstet & Gynecol, Bethesda, MD USA.
RP Gyamfi, C (reprint author), Columbia Univ, Med Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, 622 W 168th St,PH 16, New York, NY 10032 USA.
EM cg2231@columbia.edu
OI caritis, steve/0000-0002-2169-0712; Peaceman, Alan/0000-0002-4515-4850;
Berghella, Vincenzo/0000-0003-2854-0239
FU NCATS NIH HHS [UL1 TR000005]; NCRR NIH HHS [M01 RR000080,
M01-RR-000080]; NICHD NIH HHS [HD21410, HD21414, HD27860, HD27861,
HD27869, HD27915, HD27917, HD34116, HD34136, HD34208, HD36801, HD40485,
HD40500, HD40512, HD40544, HD40545, HD40560, R24 HD050924, U01 HD036801,
U10 HD021410, U10 HD027860, U10 HD027869, U10 HD027905, U10 HD027915,
U10 HD027917, U10 HD034116, U10 HD034122, U10 HD034136, U10 HD034208,
U10 HD036801, U10 HD040485, U10 HD040485-13, U10 HD040500, U10 HD040512,
U10 HD040544, U10 HD040545, U10 HD040560, UG1 HD027869, UG1 HD027915,
UG1 HD034116, UG1 HD034208, UG1 HD040485, UG1 HD040500, UG1 HD040512,
UG1 HD040544, UG1 HD040545, UG1 HD040560]
NR 12
TC 3
Z9 3
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2010
VL 203
IS 3
AR 219.e1
DI 10.1016/j.ajog.2010.04.047
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 647FH
UT WOS:000281602700013
PM 20579955
ER
PT J
AU Kominiarek, MA
VanVeldhuisen, P
Hibbard, J
Landy, H
Haberman, S
Learman, L
Wilkins, I
Bailit, J
Branch, W
Burkman, R
Gonzalez-Quintero, VH
Gregory, K
Hatjis, C
Hoffman, M
Ramirez, M
Reddy, UM
Troendle, J
Zhang, J
AF Kominiarek, Michelle A.
VanVeldhuisen, Paul
Hibbard, Judith
Landy, Helain
Haberman, Shoshana
Learman, Lee
Wilkins, Isabelle
Bailit, Jennifer
Branch, Ware
Burkman, Ronald
Gonzalez-Quintero, Victor Hugo
Gregory, Kimberly
Hatjis, Christos
Hoffman, Matthew
Ramirez, Mildred
Reddy, Uma M.
Troendle, James
Zhang, Jun
CA Consortium Safe Labor
TI The maternal body mass index: a strong association with delivery route
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Proceedings Paper
CT 30th Annual Clinical Meeting of the Society-for-Maternal-Fetal-Medicine
CY JAN 31-FEB 06, 2010
CL Chicago, IL
SP Soc Maternal Fetal Med, Univ Texas Med Branch, Dept Obstet & Gynecol
DE body mass index; cesarean delivery; obesity
ID PREVIOUS CESAREAN DELIVERY; WEIGHT-GAIN; NULLIPAROUS WOMEN; OBESE WOMEN;
RISK-FACTOR; LABOR; POPULATION; MORBIDITY; SECTION; IMPACT
AB OBJECTIVE: We sought to assess body mass index (BMI) effect on cesarean risk during labor.
STUDY DESIGN: The Consortium on Safe Labor collected electronic data from 228,668 deliveries. Women with singletons >= 37 weeks and known BMI at labor admission were analyzed in this cohort study. Regression analysis generated relative risks for cesarean stratifying for parity and prior cesarean while controlling for covariates.
RESULTS: Of the 124,389 women, 14.0% had cesareans. Cesareans increased with increasing BMI for nulliparas and multiparas with and without a prior cesarean. Repeat cesareans were performed in > 50% of laboring women with a BMI > 40 kg/m(2). The risk for cesarean increased as BMI increased for all subgroups, P < .001. The risk for cesarean increased by 5%, 2%, and 5% for nulliparas and multiparas with and without a prior cesarean, respectively, for each 1-kg/m(2) increase in BMI.
CONCLUSION: Admission BMI is significantly associated with delivery route in term laboring women. Parity and prior cesarean are other important predictors.
C1 [Kominiarek, Michelle A.; Learman, Lee] Indiana Univ Clarian Hlth, Indianapolis, IN USA.
[VanVeldhuisen, Paul] EMMES Corp, Rockville, MD USA.
[Hibbard, Judith; Wilkins, Isabelle] Univ Illinois, Chicago, IL USA.
[Landy, Helain] Georgetown Univ Hosp, Washington, DC 20007 USA.
[Haberman, Shoshana] Maimonides Hosp, Brooklyn, NY 11219 USA.
[Bailit, Jennifer] Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH USA.
[Branch, Ware] Univ Utah, Salt Lake City, UT USA.
[Branch, Ware] Intermt Healthcare, Salt Lake City, UT USA.
[Burkman, Ronald] Tufts Univ, Baystate Med Ctr, Springfield, MA USA.
[Gonzalez-Quintero, Victor Hugo] Univ Miami, Miami, FL USA.
[Gregory, Kimberly] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Hatjis, Christos] Akron City Hosp, Summa Hlth Syst, Akron, OH USA.
[Hoffman, Matthew] Christiana Care Hlth Syst, Newark, DE USA.
[Ramirez, Mildred] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
[Reddy, Uma M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pregnancy & Perinatol Branch, NIH, Bethesda, MD USA.
[Troendle, James; Zhang, Jun] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD USA.
RP Kominiarek, MA (reprint author), Indiana Univ Clarian Hlth, Indianapolis, IN USA.
FU Intramural NIH HHS; NICHD NIH HHS [HHSN267200603425C]; PHS HHS
[HHSN267200603425C]
NR 28
TC 15
Z9 15
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2010
VL 203
IS 3
AR 264.e1
DI 10.1016/j.ajog.2010.06.024
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 647FH
UT WOS:000281602700033
PM 20673867
ER
PT J
AU Oh, KJ
Lee, KA
Sohn, YK
Park, CW
Hong, JS
Romero, R
Yoon, BH
AF Oh, Kyung Joon
Lee, Kyung A.
Sohn, Yoo-Kyung
Park, Chan-Wook
Hong, Joon-Seok
Romero, Roberto
Yoon, Bo Hyun
TI Intraamniotic infection with genital mycoplasmas exhibits a more intense
inflammatory response than intraamniotic infection with other
microorganisms in patients with preterm premature rupture of membranes
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE chorioamnionitis; CRP; interleukin-6; IL-6; intraamniotic inflammation;
mycoplasmas; preterm birth; ureaplasma
ID POLYMERASE-CHAIN-REACTION; BLOOD-CELL COUNT; UREAPLASMA-UREALYTICUM;
AMNIOTIC-FLUID; CLINICAL-SIGNIFICANCE; MICROBIAL INVASION; CAVITY;
FETAL; LABOR; CULTURES
AB OBJECTIVE: The objective of the study was to compare the intensity of inflammatory responses between intraamniotic infection with genital mycoplasmas and intraamniotic infection with other microorganisms.
STUDY DESIGN: We examined the intensity of intraamniotic and maternal inflammatory responses in 99 patients with preterm premature rupture of membranes and a positive amniotic fluid (AF) culture. AF was obtained by transabdominal amniocentesis or at the time of cesarean delivery. Patients were divided according to the recovered microorganisms: (1) genital mycoplasmas (n = 62); (2) other microorganisms (n = 31); or (3) mixed infection (n = 6).
RESULTS: The median AF white blood cell (WBC) count, maternal blood WBC count, and plasma C-reactive protein concentrations were significantly higher in patients with intraamniotic infection with genital mycoplasmas than in those with intraamniotic infection with other microorganisms (P < .05 for each).
CONCLUSION: Intraamniotic and maternal inflammatory responses are more intense in intraamniotic infection with genital mycoplasmas than in intraamniotic infection with other microorganisms in patients with preterm premature rupture of membranes.
C1 [Oh, Kyung Joon; Lee, Kyung A.; Sohn, Yoo-Kyung; Park, Chan-Wook; Hong, Joon-Seok; Yoon, Bo Hyun] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 110744, South Korea.
[Romero, Roberto] NICHHD, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Romero, Roberto] NICHHD, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Detroit, MI USA.
RP Yoon, BH (reprint author), Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 110744, South Korea.
EM yoonbh@snu.ac.kr
RI Yoon, Bo Hyun/H-6344-2011; Park, Chan-Wook/J-5498-2012
FU Seoul National University; Eunice Kennedy Shriver National Institute of
Child Health and Human Development, National Institutes of Health,
Department of Health and Human Services
FX This work was supported in part by Grant 03-2006-011-0 from the Seoul
National University Hospital Research Fund and in part by the Intramural
Research Program of the Eunice Kennedy Shriver National Institute of
Child Health and Human Development, National Institutes of Health,
Department of Health and Human Services.
NR 36
TC 13
Z9 13
U1 1
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2010
VL 203
IS 3
AR 211.e1
DI 10.1016/j.ajog.2010.03.035
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 647FH
UT WOS:000281602700009
PM 20678747
ER
PT J
AU Graham, BB
Mentink-Kane, MM
I-Haddad, HE
Purnell, S
Zhang, L
Zaiman, A
Redente, EF
Riches, DWH
Hassoun, PM
Bandeira, A
Champion, HC
Butrous, G
Wynn, TA
Tuder, RM
AF Graham, Brian B.
Mentink-Kane, Margaret M.
I-Haddad, Hazim E.
Purnell, Shawn
Zhang, Li
Zaiman, An
Redente, Elizabeth F.
Riches, David W. H.
Hassoun, Paul M.
Bandeira, Angela
Champion, Hunter C.
Butrous, Ghazwan
Wynn, Thomas A.
Tuder, Rubin M.
TI Schistosomiasis-Induced Experimental Pulmonary Hypertension Role of
Interleukin-13 Signaling
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID SMOOTH-MUSCLE-CELLS; ARTERIAL-HYPERTENSION; CHRONIC HYPOXIA; MICE
LACKING; TISSUE FIBROSIS; IMMUNE-RESPONSE; PROTEIN-KINASE; RECEPTOR;
INHIBITION; IL-13
AB The mechanisms underlying schistosomiasis-induced pulmonary hypertension (PH), one of the most common causes of PH worldwide, remain unclear. We sought to determine whether Schistosoma mansoni causes experimental PH associated with pulmonary vascular remodeling in an interleukin (IL)-13-dependent manner. IL-13R alpha 1 is the canonical IL-13 signaling receptor, whereas IL-13R alpha 2 is a competitive non-signaling decoy receptor. Wild-type, IL-13R alpha 1(-/-), and IL-13R alpha 2(-/-) C57BL/6J mice were percutaneously infected with S. mansoni cercariae, followed by i.v. injection of eggs. We assessed PH with right ventricular catheterization, histological evaluation of pulmonary vascular remodeling, and detection of IL-13 and transforming growth factor-beta signaling. Infected mice developed pulmonary pen-egg granulomas and arterial remodeling involving predominantly the vascular media. In addition, gain-of-function IL-13Ra2-/- mice had exacerbated vascular remodeling and PH. Mice with loss of IL-13R alpha 1 function did not develop PH and had reduced pulmonary vascular remodeling. Moreover, the expression of resistin-like molecule-a, a target of IL-13 signaling, was increased in infected wild-type and IL-13R alpha 2(-/-) but not IL-13R alpha 1(-/-) mice. Phosphorylated Smad2/3, a target of transforming growth factor-beta signaling, was increased in both infected mice and humans with the disease. Our data indicate that experimental schistosomiasis causes PH and potentially relics on up-regulated IL-13 signaling. (Am J Pathol 2014 177:1549-1561: DO!: 10.2353/ajpath.2010.100063)
C1 [Graham, Brian B.] Univ Colorado Denver, Program Translat Lung Research, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA.
NIAID, Colorado Immunopathogenesis Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
Johns Hopkins Univ, Dept Cardiol, Baltimore, MD USA.
Johns Hopkins Univ, Dept Pulmanary & Crit Care Med, Baltimore, MD USA.
[Purnell, Shawn] Univ Calif Davis, Dept Pathol & Lab Med, Davis, CA 95616 USA.
[Redente, Elizabeth F.] Natl Jewish Hlth, Program Cell Biol, Denver, CO USA.
[Bandeira, Angela] Univ Fed Pernambuco, Dept Cardiol, Recife, PE, Brazil.
[Champion, Hunter C.] Univ Pittsburgh, Dept Cardiol, Pittsburgh, PA USA.
[Butrous, Ghazwan] Univ Kent, Pulm Vasc Res Inst, Canterbury CT2 7NZ, Kent, England.
RP Graham, BB (reprint author), Univ Colorado Denver, Program Translat Lung Research, Div Pulm Sci & Crit Care Med, Res 2,9th Floor,Mail Stop C-272,12700 E 19th Ave, Aurora, CO 80045 USA.
RI Wynn, Thomas/C-2797-2011
FU Cardiovascular Medical Research Fund; University of Colorado; National
Institute of Allergy and Infectious Diseases; National Institutes of
Health [F32HL095274, NIH R01HL068628]
FX Supported by Cardiovascular Medical Research Fund, the Translational
Lung Research Program at the University of Colorado, the Parker B
Francis Fellowship Program, the Intramural Research Program of National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, and National Institutes of Health grants F32HL095274 and NIH
R01HL068628
NR 54
TC 33
Z9 33
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD SEP
PY 2010
VL 177
IS 3
BP 1549
EP 1561
DI 10.2353/ajpath.2010.100063
PG 13
WC Pathology
SC Pathology
GA 648TR
UT WOS:000281717700047
PM 20671265
ER
PT J
AU Sorokin, Y
Romero, R
Mele, L
Wapner, RJ
Iams, JD
Dudley, DJ
Spong, CY
Peaceman, AM
Leveno, KJ
Harper, M
Caritis, SN
Miodovnik, M
Mercer, BM
Thorp, JM
O'Sullivan, MJ
Ramin, SM
Carpenter, MW
Rouse, DJ
Sibai, B
AF Sorokin, Yoram
Romero, Roberto
Mele, Lisa
Wapner, Ronald J.
Iams, Jay D.
Dudley, Donald J.
Spong, Catherine Y.
Peaceman, Alan M.
Leveno, Kenneth J.
Harper, Margaret
Caritis, Steve N.
Miodovnik, Menachem
Mercer, Brian M.
Thorp, John M.
O'Sullivan, Mary Jo
Ramin, Susan M.
Carpenter, Marshall W.
Rouse, Dwight J.
Sibai, Baha
TI Maternal Serum Interleukin-6, C-Reactive Protein, and Matrix
Metalloproteinase-9 Concentrations as Risk Factors for Preterm Birth <
32 Weeks and Adverse Neonatal Outcomes
SO AMERICAN JOURNAL OF PERINATOLOGY
LA English
DT Article
DE Maternal serum; cytokines; preterm birth; neonatal morbidity
ID UMBILICAL-CORD PLASMA; BLOOD-CELL COUNT; AMNIOTIC-FLUID INTERLEUKIN-6;
NECROSIS-FACTOR-ALPHA; WHITE-MATTER LESIONS; PREMATURE RUPTURE;
INTRAVENTRICULAR HEMORRHAGE; PERIVENTRICULAR LEUKOMALACIA; INFLAMMATORY
RESPONSE; CEREBRAL-PALSY
AB Elevated concentrations of interleukin-6 (IL-6), C-reactive protein (CRP), and matrix metalloproteinase-9 (MMP-9) in fetal and neonatal compartments have been associated with an increased risk for preterm birth (PTB) and/or neonatal morbidity. The purpose of this study was to determine if the maternal serum concentration of IL-6, CRP, and MMP-9 in women at risk for PTB, who are not in labor and have intact membranes, are associated with an increased risk for PTB < 32 weeks and/or neonatal morbidity. Maternal serum samples collected from 475 patients enrolled in a multicenter randomized controlled trial of single versus weekly corticosteroids for women at increased risk for preterm delivery were assayed. Serum was collected at randomization (24 to 32 weeks' gestation). Maternal serum concentrations of IL-6, CRP, and MMP-9 were subsequently determined using enzyme-linked immunoassays. Multivariate logistic regression analysis was performed to explore the relationship between maternal serum concentrations of IL-6, CRP, and MMP-9 and PTB <32 weeks, respiratory distress syndrome (RDS), chronic lung disease (CLD), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and any sepsis. Maternal serum concentrations of IL-6 and CRP, but not MMP-9, above the 90th percentile at the time of randomization were associated with PTB <32 weeks. In contrast, there was no significant relationship between RDS and NEC and the maternal serum concentration of IL-6, CRP, or MMP-9 (univariate analysis). The development of CLD was associated with a high (above 90th percentile) IL-6 and CRP in maternal serum, even after adjustment for gestational age (GA) at randomization and treatment group. However, when GA at delivery was added to the model, this finding was nonsignificant. Neonatal sepsis was more frequent in neonates born to mothers with a high maternal serum concentration of CRP (>90th percentile). However, there was no significant association after adjustment for GA at randomization and treatment group. Logistic regression analysis for each analyte indicated that high maternal serum concentrations of IL-6 and CRP, but not MMP-9, were associated with an increased risk of IVH (odds ratio [OR] 4.60, 95% confidence interval [CI] 1.86 to 10.68; OR 4.07, 95% CI 1.63 to 9.50) after adjusting for GA at randomization and treatment group. Most babies (25/30) had grade I IVH. When GA at delivery was included, elevated IL-6 remained significantly associated with IVH (OR 2.77, 95% CI 1.02 to 7.09). An elevated maternal serum concentration of IL-6 and CRP are risk factors for PTB <32 weeks and subsequent development of neonatal IVH. An elevated maternal serum IL-6 appears to confer additional risk for IVH even after adjusting for GA at delivery.
C1 Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA.
Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, Detroit, MI USA.
George Washington Univ, Ctr Biostat, Washington, DC USA.
Drexel Univ, Coll Med, Philadelphia, PA 19104 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Univ Utah, Salt Lake City, UT USA.
RP Sorokin, Y (reprint author), Hutzel Womens Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, 3990 John R,Mailbox 163, Detroit, MI 48201 USA.
EM ysorokin@med.wayne.edu
OI caritis, steve/0000-0002-2169-0712; Peaceman, Alan/0000-0002-4515-4850
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development [HD21410, HD21414, HD27869, HD27917, HD27905, HD27860,
HD27861, HD27915, HD34122, HD34116, HD34208, HD34136, HD40500, HD40485,
HD40544, HD40545, HD40560, HD40512, HD36801]; National Center for
Research Resources [M01-RR-000080]
FX Supported by grants from the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (HD21410, HD21414, HD27869,
HD27917, HD27905, HD27860, HD27861, HD27915, HD34122, HD34116, HD34208,
HD34136, HD40500, HD40485, HD40544, HD40545, HD40560, HD40512, HD40485,
HD36801) and M01-RR-000080 from the National Center for Research
Resources.
NR 39
TC 53
Z9 60
U1 0
U2 4
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0735-1631
J9 AM J PERINAT
JI Am. J. Perinatol.
PD SEP
PY 2010
VL 27
IS 8
BP 631
EP 639
DI 10.1055/s-0030-1249366
PG 9
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA 637GE
UT WOS:000280804100007
PM 20195952
ER
PT J
AU Laroche, G
Giguere, PM
Roth, BL
Trejo, J
Siderovski, DP
AF Laroche, Genevieve
Giguere, Patrick M.
Roth, Bryan L.
Trejo, JoAnn
Siderovski, David P.
TI RNA interference screen for RGS protein specificity at muscarinic and
protease-activated receptors reveals bidirectional modulation of
signaling
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE calcium flux; muscarinic acetylcholine receptor; protease-activated
receptor-1; regulators of G protein signaling; short interfering RNA
duplexes
ID 3RD INTRACELLULAR LOOP; COUPLED-RECEPTORS; ALPHA-SUBUNITS; STRUCTURAL
DIVERSITY; M3 RECEPTOR; COMPLEX; CELLS; BINDING; FAMILY; DOMAIN
AB Laroche G, Giguere PM, Roth BL, Trejo J, Siderovski DP. RNA interference screen for RGS protein specificity at muscarinic and protease-activated receptors reveals bidirectional modulation of signaling. Am J Physiol Cell Physiol 299: C654-C664, 2010. First published June 23, 2010; doi: 10.1152/ajpcell.00441.2009.-Regulator of G protein signaling (RGS) proteins are considered key modulators of G protein-coupled receptor (GPCR)-mediated signal transduction. These proteins act directly on G alpha subunits in vitro to increase their intrinsic rate of GTP hydrolysis; this activity is central to the prevailing view of RGS proteins as negative regulators of agonist-initiated GPCR signaling. However, the specificities of action of particular RGS proteins toward specific GPCRs in an integrated cellular context remain unclear. Here, we developed a medium-throughput assay to address this question in a wholly endogenous context using RNA interference. We performed medium-throughput calcium mobilization assays of agonist-stimulated muscarinic acetylcholine and protease-activated receptors in human embryonic kidney 293 (HEK293) cells transfected with individual members of a "pooled duplex" short interfering RNA library targeting all conventional human RGS transcripts. Only knockdown of RGS11 increased both carbachol-mediated calcium mobilization and inositol phosphate accumulation. Surprisingly, we found that knockdown of RGS8 and RGS9, but not other conventional RGS proteins, significantly decreased carbachol-mediated calcium mobilization, whereas only RGS8 knockdown decreased protease-activated receptor-1 (PAR-1)-mediated calcium mobilization. Loss of responsiveness toward carbachol and PAR-1 agonist peptide upon RGS8 knockdown appears due, at least in part, to a loss in respective receptor cell surface expression, although this is not the case for RGS9 knockdown. Our data suggest a cellular role for RGS8 in the stable surface expression of M3 muscarinic acetylcholine receptor and PAR-1, as well as a specific and opposing set of functions for RGS9 and RGS11 in modulating carbachol responsiveness similar to that seen in Caenorhabditis elegans.
C1 [Laroche, Genevieve; Giguere, Patrick M.; Roth, Bryan L.; Siderovski, David P.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.
[Laroche, Genevieve; Giguere, Patrick M.; Roth, Bryan L.; Siderovski, David P.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Laroche, Genevieve; Giguere, Patrick M.; Roth, Bryan L.; Siderovski, David P.] Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA.
[Roth, Bryan L.] Univ N Carolina, Natl Inst Mental Hlth Psychoact Drug Screening Pr, Chapel Hill, NC 27599 USA.
[Trejo, JoAnn] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA.
RP Siderovski, DP (reprint author), Univ N Carolina, Dept Pharmacol, 4073 Genet Med Bldg,120 Mason Farm Rd,Suite 4010, Chapel Hill, NC 27599 USA.
EM dsiderov@med.unc.edu
RI Roth, Bryan/F-3928-2010;
OI Siderovski, David/0000-0002-0688-8210
FU National Institute of General Medical Sciences [R01 GM062338]; Heart &
Stroke Foundation of Canada
FX This study was supported by National Institute of General Medical
Sciences Grant R01 GM062338 (to D. P. Siderovski), postdoctoral
fellowships from the Heart & Stroke Foundation of Canada (to G. Laroche
and P. M. Giguere), and infrastructure support from the NIMH
Psychoactive Drug Screening Program (to B. L. Roth).
NR 44
TC 9
Z9 9
U1 0
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD SEP
PY 2010
VL 299
IS 3
BP C654
EP C664
DI 10.1152/ajpcell.00441.2009
PG 11
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 644OR
UT WOS:000281389100014
PM 20573995
ER
PT J
AU Varu, VN
Ahanchi, SS
Hogg, ME
Bhikhapurwala, HA
Chen, A
Popowich, DA
Vavra, AK
Martinez, J
Jiang, Q
Saavedra, JE
Hrabie, JA
Keefer, LK
Kibbe, MR
AF Varu, Vinit N.
Ahanchi, Sadie S.
Hogg, Melissa E.
Bhikhapurwala, Hussein A.
Chen, Amy
Popowich, Daniel A.
Vavra, Ashley K.
Martinez, Janet
Jiang, Qun
Saavedra, Joseph E.
Hrabie, Joseph A.
Keefer, Larry K.
Kibbe, Melina R.
TI Insulin enhances the effect of nitric oxide at inhibiting neointimal
hyperplasia in a rat model of type 1 diabetes
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE proliferation; arterial injury; vascular smooth muscle cells
ID SMOOTH-MUSCLE-CELLS; ANGIOTENSIN-II; INTIMAL HYPERPLASIA; ARTERIAL
INJURY; IN-VIVO; GUANOSINE-MONOPHOSPHATE; PERIVASCULAR DELIVERY;
METABOLIC SYNDROME; GENE-TRANSFER; HIGH GLUCOSE
AB Varu VN, Ahanchi SS, Hogg ME, Bhikhapurwala HA, Chen A, Popowich DA, Vavra AK, Martinez J, Jiang Q, Saavedra JE, Hrabie JA, Keefer LK, Kibbe MR. Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes. Am J Physiol Heart Circ Physiol 299: H772-H779, 2010. First published June 18, 2010; doi:10.1152/ajpheart.01234.2009.-Diabetes confers greater restenosis from neointimal hyperplasia following vascular interventions. While localized administration of nitric oxide (NO) is known to inhibit neointimal hyperplasia, the effect of NO in type 1 diabetes is unknown. Thus the aim of this study was to determine the efficacy of NO following arterial injury, with and without exogenous insulin administration. Vascular smooth muscle cells (VSMC) from lean Zucker (LZ) rats were exposed to the NO donor, DETA/NO, following treatment with different glucose and/or insulin concentrations. DETA/NO inhibited VSMC proliferation in a concentration-dependent manner to a greater extent in VSMC exposed to normal-glucose vs. high-glucose environments, and even more effectively in normal-glucose/high-insulin and high-glucose/high-insulin environments. G(0)/G(1) cell cycle arrest and cell death were not responsible for the enhanced efficacy of NO in these environments. Next, type 1 diabetes was induced in LZ rats with streptozotocin. The rat carotid artery injury model was performed. Type 1 diabetic rats experienced no significant reduction in neointimal hyperplasia following arterial injury and treatment with the NO donor PROLI/NO. However, daily administration of insulin to type 1 diabetic rats restored the efficacy of NO at inhibiting neointimal hyperplasia (60% reduction, P < 0.05). In conclusion, these data demonstrate that NO is ineffective at inhibiting neointimal hyperplasia in an uncontrolled rat model of type 1 diabetes; however, insulin administration restores the efficacy of NO at inhibiting neointimal hyperplasia. Thus insulin may play a role in regulating the downstream beneficial effects of NO in the vasculature.
C1 [Varu, Vinit N.; Ahanchi, Sadie S.; Hogg, Melissa E.; Bhikhapurwala, Hussein A.; Chen, Amy; Popowich, Daniel A.; Vavra, Ashley K.; Martinez, Janet; Jiang, Qun; Kibbe, Melina R.] Northwestern Univ, Div Vasc Surg, Chicago, IL 60611 USA.
[Varu, Vinit N.; Ahanchi, Sadie S.; Hogg, Melissa E.; Bhikhapurwala, Hussein A.; Chen, Amy; Popowich, Daniel A.; Vavra, Ashley K.; Martinez, Janet; Jiang, Qun; Kibbe, Melina R.] Northwestern Univ, Inst BioNanotechnol Med, Chicago, IL 60611 USA.
[Varu, Vinit N.] Northwestern Univ, Dept Surg, Chicago, IL 60611 USA.
[Ahanchi, Sadie S.] Univ Illinois Mt Sinai, Dept Surg, Chicago, IL USA.
[Saavedra, Joseph E.; Hrabie, Joseph A.] SAIC Frederick Inc, Basic Res Program, Frederick, MD USA.
[Keefer, Larry K.] Natl Canc Inst Frederick, Comparat Carcinogenesis Lab, Ctr Canc Res, Frederick, MD USA.
[Kibbe, Melina R.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA.
RP Kibbe, MR (reprint author), Northwestern Univ, Div Vasc Surg, 676 N St Clair St 650, Chicago, IL 60611 USA.
EM mkibbe@nmh.org
RI Keefer, Larry/N-3247-2014
OI Keefer, Larry/0000-0001-7489-9555
FU National Institutes of Health (NIH) [1 K08HL084203, 5 R0 1 EB003806-02];
Department of Veterans Affairs; Veterans Affairs Merit Review Grant;
American Vascular Association; American Medical Association Foundation;
Eleanor Prince Wood Grant; University of Illinois; Hilda Rosenbloom and
Eleanor Baldwin; National Cancer Institute, NIH [N01-CO-2008-00001];
NIH, National Cancer Institute, Center for Cancer Research
FX This work was supported, in part, by funding from the National
Institutes of Health (NIH; 1 K08HL084203 and 5 R0 1 EB003806-02), the
Department of Veterans Affairs, Veterans Affairs Merit Review Grant, the
American Vascular Association, the American Medical Association
Foundation 2007 Seed Grant, the Eleanor Prince Wood Grant, the Eleanor
B. Pillsbury Grant-University of Illinois, and by the generosity of
Hilda Rosenbloom and Eleanor Baldwin. In addition, part of this research
was supported with federal funds from the National Cancer Institute,
NIH, under contract N01-CO-2008-00001 with SAIC-Frederick, Inc. and by
the Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research.
NR 46
TC 14
Z9 14
U1 1
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD SEP
PY 2010
VL 299
IS 3
BP H772
EP H779
DI 10.1152/ajpheart.01234.2009
PG 8
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA 646JZ
UT WOS:000281537400023
PM 20562340
ER
PT J
AU Hwang, S
Gunaratne, R
Rinschen, MM
Yu, MJ
Pisitkun, T
Hoffert, JD
Fenton, RA
Knepper, MA
Chou, CL
AF Hwang, Shelly
Gunaratne, Ruwan
Rinschen, Markus M.
Yu, Ming-Jiun
Pisitkun, Trairak
Hoffert, Jason D.
Fenton, Robert A.
Knepper, Mark A.
Chou, Chung-Lin
TI Vasopressin increases phosphorylation of Ser84 and Ser486 in Slc14a2
collecting duct urea transporters
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE phospho-specific antibody; confocal microscopy; immunofluorescence
immunocytochemistry; immuno-electron microscopy
ID LIGHT-CHAIN KINASE; SMOOTH-MUSCLE MYOSIN; RAT-KIDNEY; UT-A; MEMBRANE
ACCUMULATION; GENOMIC ORGANIZATION; PLASMA-MEMBRANES; UT-A1;
AQUAPORIN-2; EXPRESSION
AB Hwang S, Gunaratne R, Rinschen MM, Yu M-J, Pisitkun T, Hoffert JD, Fenton RA, Knepper MA, Chou C-L. Vasopressin increases phosphorylation of Ser84 and Ser486 in Slc14a2 collecting duct urea transporters. Am J Physiol Renal Physiol 299: F559-F567, 2010. First published June 24, 2010; doi:10.1152/ajprenal. 00617.2009.-Vasopressin-regulated urea transport in the renal inner medullary collecting duct (IMCD) is mediated by two urea channel proteins, UT-A1 and UT-A3, derived from the same gene (Slc14a2) by alternative splicing. The NH2-terminal 459 amino acids are the same in both proteins. To study UT-A1/3 phosphorylation, we made phosphospecific antibodies to UT-A sequences targeting phospho-serines at positions 84 and 486, sites identified previously by protein mass spectrometry. Both antibodies proved specific, recognizing only the phosphorylated forms of UT-A1 and -A3. Immunoblotting of rat IMCD suspensions or whole inner medullas showed that the V2R-selective vasopressin analog 1-deamino-8-D-arginine vasopressin (dDAVP) increases phosphorylation at Ser84 (in UT-A1 and UT-A3) and Ser486 (in UT-A1) by about eightfold. Time course studies in rat IMCD suspensions showed maximum phosphorylation within 1 min of dDAVP exposure, consistent with the time course of vasopressin-stimulated phosphorylation of the vasopressin-sensitive water channel aquaporin-2 at Ser256. Confocal immunofluorescence in Brattleboro rat medullary tissue showed labeling limited to the IMCD, which increased markedly in response to dDAVP. Immuno-electron microscopy studies showed that both phosphorylated forms were present mainly in intracellular compartments in the presence of vasopressin. These studies demonstrate regulated phosphorylation of both UT-A1 and UT-A3 in response to vasopressin in a manner consistent with coordinate regulation of UT-A and aquaporin-2 in the renal IMCD. The findings add to prior evidence for vasopressin-induced phosphorylation of UT-A1, providing evidence that UT-A3 may be regulated by phosphorylation as well.
C1 [Hwang, Shelly; Gunaratne, Ruwan; Rinschen, Markus M.; Yu, Ming-Jiun; Pisitkun, Trairak; Hoffert, Jason D.; Knepper, Mark A.; Chou, Chung-Lin] NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA.
[Fenton, Robert A.] Aarhus Univ, Dept Anat, Water & Salt Res Ctr, Aarhus, Denmark.
RP Knepper, MA (reprint author), NHLBI, Kidney & Electrolyte Metab Lab, NIH, 10 Ctr Dr,MSC 1603,Bldg 10,Rm 6N260, Bethesda, MD 20892 USA.
EM knep@helix.nih.gov
OI Pisitkun, Trairak/0000-0001-6677-2271; YU, MING-JIUN/0000-0003-0393-4696
FU Intramural Budget of the NHLBI [Z01-HL-001285]; American Physiological
Society; Biomedical Exchange Program, Hannover; Braun Foundation,
Melsungen; Danish Medical Research Council; Lundbeck Foundation; Novo
Nordisk Foundation
FX This study was supported by the Intramural Budget of the NHLBI (Project
Z01-HL-001285). S. Hwang was supported by an American Physiological
Society Undergraduate Summer Research Fellowship. M. M. Rinschen was
supported by the Biomedical Exchange Program, Hannover and the Braun
Foundation, Melsungen. R. A. Fenton is funded by the Danish Medical
Research Council, The Lundbeck Foundation, and the Novo Nordisk
Foundation.
NR 44
TC 15
Z9 15
U1 0
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD SEP
PY 2010
VL 299
IS 3
BP F559
EP F567
DI 10.1152/ajprenal.00617.2009
PG 9
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 646KC
UT WOS:000281537700010
PM 20576681
ER
PT J
AU Parry, M
AF Parry, Manon
TI Betty Friedan: Feminist Icon and Founder of the National Organization
for Women
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Biographical-Item
C1 [Parry, Manon] Univ Maryland, College Pk, MD 20742 USA.
RP Parry, M (reprint author), Natl Lib Med, Exhibit Program, 8600 Rockville Pike,Bldg 38,Room 1E-21, Bethesda, MD 20894 USA.
EM parrym@mail.nlm.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD SEP
PY 2010
VL 100
IS 9
BP 1584
EP 1585
DI 10.2105/AJPH.2009.187534
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 638AY
UT WOS:000280863100012
PM 20634444
ER
PT J
AU Garofalo, ME
Fee, E
AF Garofalo, Mary E.
Fee, Elizabeth
TI Florence Nightingale (1820-1910): Feminism and Hospital Reform
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Biographical-Item
C1 [Garofalo, Mary E.] NIAID, Lab Host Defenses, NIH, Bethesda, MD 20892 USA.
[Fee, Elizabeth] NIH, Hist Med Div, Natl Lib Med, Bethesda, MD 20892 USA.
RP Garofalo, ME (reprint author), NIAID, Lab Host Defenses, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 1
U1 1
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD SEP
PY 2010
VL 100
IS 9
BP 1588
EP 1588
DI 10.2105/AJPH.2009.188722
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 638AY
UT WOS:000280863100014
PM 20671260
ER
PT J
AU Theerman, P
AF Theerman, Paul
TI Julia Lathrop and the Children's Bureau
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Biographical-Item
C1 NIH, Hist Med Div, Natl Lib Med, Bethesda, MD 20894 USA.
RP Theerman, P (reprint author), NIH, Hist Med Div, Natl Lib Med, Bldg 38,Room 1E-21,8600 Rockville Pike, Bethesda, MD 20894 USA.
EM paul_theerman@nlm.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD SEP
PY 2010
VL 100
IS 9
BP 1589
EP 1590
DI 10.2105/APH.2009.188185
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 638AY
UT WOS:000280863100015
PM 20634442
ER
PT J
AU Fee, E
Garofalo, ME
AF Fee, Elizabeth
Garofalo, Mary E.
TI Florence Nightingale and the Crimean War
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
C1 [Fee, Elizabeth] NIH, Hist Med Div, Natl Lib Med, Bethesda, MD 20892 USA.
[Garofalo, Mary E.] NIAID, Lab Host Defenses, NIH, Bethesda, MD 20892 USA.
RP Fee, E (reprint author), NIH, Hist Med Div, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA.
NR 5
TC 6
Z9 7
U1 0
U2 1
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD SEP
PY 2010
VL 100
IS 9
BP 1591
EP 1591
DI 10.2105/AJPH.2009.188607
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 638AY
UT WOS:000280863100016
PM 20671261
ER
PT J
AU Mani, H
Climent, F
Colomo, L
Pittaluga, S
Raffeld, M
Jaffe, ES
AF Mani, Haresh
Climent, Fina
Colomo, Lluis
Pittaluga, Stefania
Raffeld, Mark
Jaffe, Elaine S.
TI Gall Bladder and Extrahepatic Bile Duct Lymphomas: Clinicopathological
Observations and Biological Implications
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE lymphoma; gallbladder; bile duct; hepatic duct; cystic duct;
cholecystitis; cholelithiasis; extranodal; intestinal follicular
lymphoma; in situ mantle cell lymphoma; HHV-8/KSHV; plasmablastic
lymphoma; primary effusion lymphoma; lymphomatous polyposis
ID B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA;
ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PRIMARY EFFUSION LYMPHOMA;
OF-THE-LITERATURE; FOLLICULAR LYMPHOMA; MALIGNANT-LYMPHOMA; T-CELL;
OBSTRUCTIVE-JAUNDICE; SOLID LYMPHOMAS
AB Lymphomas of the gall bladder and extrahepatic bile ducts are exceedingly rare. We present the clinicopathological features of 19 cases from our files; 14 patients had primary lymphoma (13 involving gall bladder and 1 involving common hepatic duct), while 5 had systemic lymphoma on further workup. Most patients presented with symptoms mimicking cholecystitis. The most common primary lymphoma types were diffuse large B-cell lymphoma, extranodal marginal zone lymphoma, B-lymphoblastic lymphoma, and follicular lymphoma. Two cases had features of lymphomatous polyposis, one a case of follicular lymphoma and the second a case of mantle cell lymphoma, with disease limited to the mantle zones, so-called in situ mantle cell lymphoma. Other rare lymphoma subtypes not described earlier in this site included the extracavitary variant of primary effusion lymphoma and plasmablastic lymphoma. Patients with diffuse large B-cell lymphoma and extranodal marginal zone lymphoma were older (mean age 75.8 y) than those with other subtypes (mean age 47 y) and more likely to have gallstones (60% vs. 12.5%). A comprehensive literature review revealed 36 primary gall bladder and 16 primary extrahepatic bile duct lymphomas. When compared with primary gall bladder lymphomas, those involving the extrahepatic bile ducts present at a younger age (47 y vs. 63 y) usually with obstructive jaundice, and are less often associated with gallstones (17% vs. 50%) or regional lymph node involvement (6% vs. 31%). In conclusion, primary lymphomas of the gall bladder and extrahepatic bile ducts show a broad spectrum of disease types, but in many respects mirror the spectrum of primary lymphomas of the gastrointestinal tract.
C1 [Jaffe, Elaine S.] NCI, Hematopathol Sect, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
[Climent, Fina] Hosp Univ Bellvitge, Barcelona, Spain.
[Colomo, Lluis] Hosp Clin Barcelona, Barcelona, Spain.
RP Jaffe, ES (reprint author), NCI, Hematopathol Sect, Pathol Lab, Ctr Canc Res,NIH, 10 Ctr Dr,Room 2B-40,MSC-1500, Bethesda, MD 20892 USA.
EM ejaffe@mail.nih.gov
RI Colomo, Luis/A-2259-2016;
OI Colomo, Luis/0000-0001-5236-5085; Jaffe, Elaine/0000-0003-4632-0301
FU Center for Clinical Research, National Cancer Institute, National
Institutes of Health
FX This research was supported by the Intramural Research Program of the
Center for Clinical Research, National Cancer Institute, National
Institutes of Health.
NR 74
TC 14
Z9 15
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD SEP
PY 2010
VL 34
IS 9
BP 1277
EP 1286
DI 10.1097/PAS.0b013e3181e9bb8b
PG 10
WC Pathology; Surgery
SC Pathology; Surgery
GA 646XW
UT WOS:000281579800006
PM 20679881
ER
PT J
AU Lehmann, T
Dao, A
Yaro, AS
Adamou, A
Kassogue, Y
Diallo, M
Sekou, T
Coscaron-Arias, C
AF Lehmann, Tovi
Dao, Adama
Yaro, Alpha Seydou
Adamou, Abdoulaye
Kassogue, Yaya
Diallo, Moussa
Sekou, Traore
Coscaron-Arias, Cecilia
TI Aestivation of the African Malaria Mosquito, Anopheles gambiae in the
Sahel
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID EFFECTIVE POPULATION-SIZE; DRY SEASON; CULEX-PIPIENS; SUDAN SAVANNA;
COMPLEX MOSQUITOS; WESTERN KENYA; SURVIVAL; SENEGAL; MALI; TRANSMISSION
AB The African malaria mosquito. Anopheles gambiae, inhabits diverse environments including dry savannas, where surface waters required for larval development are absent for 4-8 months per year Under such conditions, An gambiae virtually disappears Whether populations survive the long dry season by aestivation (a dormant state promoting extended longevity during the summer) or are reestablished by migrants from distant locations where larval sites persist has remained an enigma for over 60 years Resolving this question is important, because fragile dry season populations may be more susceptible to control. Here, we show unequivocally that An gambiae aestivates based on a demographic study and a mark release recapture experiment spanning the period from the end of one wet season to the beginning of the next. During the dry season. An. gambiae was barely detectable in Sahehan villages of Mali. Five days after the first rain. before a new generation of adults could be produced. mosquito abundance surged 10-fold, implying that most mosquitoes were concealed locally until the rain Four clays after the first rain, a marked female An gambiae s.s was recaptured Initially captured, marked, and released at the end of the previous wet season, she has survived the 7-month-long dry season These results provide evidence that An. gambiae persists throughout the dry season by aestivation and open new questions for mosquito and parasite research Improved malaria control by targeting aestivating mosquitoes using existing or novel strategies may be possible.
C1 [Lehmann, Tovi; Coscaron-Arias, Cecilia] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
[Dao, Adama; Yaro, Alpha Seydou; Adamou, Abdoulaye; Kassogue, Yaya; Diallo, Moussa; Sekou, Traore] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali.
RP Lehmann, T (reprint author), NIAID, Lab Malaria & Vector Res, NIH, MS 8132,12735 Twinbrook Pkwy, Rockville, MD 20852 USA.
FU National Institutes of Health, National Institute of Allergy and
Infectious Diseases
FX This study was supported by the Intramural Research Program in National
Institutes of Health, National Institute of Allergy and Infectious
Diseases
NR 37
TC 44
Z9 44
U1 1
U2 12
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD SEP
PY 2010
VL 83
IS 3
BP 601
EP 606
DI 10.4269/ajtmh.2010.09-0779
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 645SZ
UT WOS:000281487800028
PM 20810827
ER
PT J
AU Concheiro, M
Gray, TR
Shakleya, DM
Huestis, MA
AF Concheiro, Marta
Gray, Teresa R.
Shakleya, Diaa M.
Huestis, Marilyn A.
TI High-throughput simultaneous analysis of buprenorphine, methadone,
cocaine, opiates, nicotine, and metabolites in oral fluid by liquid
chromatography tandem mass spectrometry
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Oral fluid; Liquid chromatography tandem mass spectrometry;
Buprenorphine; Bioanalytical methods; Forensics/toxicology
ID SOLID-PHASE EXTRACTION; MULTIPLE ILLICIT DRUGS; QUANTITATIVE-ANALYSIS;
HUMAN URINE; VALIDATION; BENZOYLECGONINE; AMPHETAMINES; COTININE;
SALIVA; ABUSE
AB A method for simultaneous determination of buprenorphine (BUP), norbuprenorphine (NBUP), methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), cocaine, benzoylecgonine (BE), ecgonine methyl ester (EME), anhydroecgonine methyl ester (AEME), morphine, codeine, 6-acetylmorphine (6AM), heroin, 6-acetylcodeine (6AC), nicotine, cotinine, and trans-3'-hydroxycotinine (OH-cotinine) by liquid chromatography tandem mass spectrometry in oral fluid (OF) was developed and extensively validated. Acetonitrile (800 mu L) and OF (250 mu L) were added to a 96-well Isolute-PPT+protein precipitation plate. Reverse-phase separation was achieved in 16 min and quantification was performed by multiple reaction monitoring. The assay was linear from 0.5 or 1 to 500 mu g/L. Intraday, interday, and total imprecision were less than 13% (n = 20), analytical recovery was 92-114% (n = 20), extraction efficiencies were more than 77% (n = 5), and process efficiencies were more than 45% (n = 5). Although ion suppression was detected for EME, cocaine, morphine, 6AC, and heroin (less than 56%) and enhancement was detected for BE and nicotine (less than 316%), deuterated internal standards compensated for these effects. The method was sensitive (limit of detection 0.2-0.8 mu g/L) and specific (no interferences) except that 3-hydroxy-4-methoxyamphetamine interfered with AEME. No carryover was detected, and all analytes were stable for 24 h at 22 A degrees C, for 72 h at 4 A degrees C, and after three freeze-thaw cycles, except cocaine, 6AC, and heroin (22-97% loss). The method was applied to 41 OF specimens collected throughout pregnancy with a SalivetteA (R) OF collection device from an opioid-dependent BUP-maintained pregnant woman. BUP ranged from 0 to 7,400 mu g/L, NBUP from 0 to 71 mu g/L, methadone from 0 to 3 mu g/L, nicotine from 32 to 5,020 mu g/L, cotinine from 125 to 508 mu g/L, OH-cotinine from 11 to 51 mu g/L, cocaine from 0 to 419 mu g/L, BE from 0 to 351 mu g/L, EME from 0 to 286 mu g/L, AEME from 0 to 7 mu g/L, morphine from 0 to 22 mu g/L, codeine from 0 to 1 mu g/L, 6AM from 0 to 4 mu g/L, and heroin from 0 to 2 mu g/L. All specimens tested negative for EDDP and 6AC. This method permits a fast and simultaneous quantification of 16 drugs and metabolites in OF, with good selectivity and sensitivity.
C1 [Concheiro, Marta; Gray, Teresa R.; Shakleya, Diaa M.; Huestis, Marilyn A.] NIDA, Intramural Res Program, NIH, BRC, Baltimore, MD 21224 USA.
[Concheiro, Marta] Univ Santiago de Compostela, Fac Med, Serv Toxicol Forense, Dpto Anat Patol & Ciencias Forenses, Santiago De Compostela 15782, A Coruna, Spain.
RP Huestis, MA (reprint author), NIDA, Intramural Res Program, NIH, BRC, 251 Bayview Blvd,Suite 200,Room 05A721, Baltimore, MD 21224 USA.
EM mhuestis@intra.nida.nih.gov
FU National Institutes of Health, National Institute on Drug Abuse
FX This research was supported by the National Institutes of Health,
Intramural Research Program, National Institute on Drug Abuse.
NR 23
TC 28
Z9 29
U1 3
U2 27
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD SEP
PY 2010
VL 398
IS 2
BP 915
EP 924
DI 10.1007/s00216-010-3903-5
PG 10
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 650IL
UT WOS:000281842400029
PM 20652688
ER
PT J
AU Ryschkewitsch, CF
Jensen, PN
Monaco, MC
Major, EO
AF Ryschkewitsch, Caroline F.
Jensen, Peter N.
Monaco, Maria Chiara
Major, Eugene O.
TI JC Virus Persistence Following Progressive Multifocal
Leukoencephalopathy in Multiple Sclerosis Patients Treated with
Natalizumab
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID BK VIRUS; ANTIBODY
AB JC virus (JCV) DNA in the cerebrospinal fluid (CSF) provides the laboratory confirmatory diagnosis of progressive multifocal leukoencephalopathy (PML) in patients whose clinical symptoms and magnetic resonance imaging findings are consistent with PML. The Laboratory of Molecular Medicine and Neuroscience (LMMN), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), made the confirmatory laboratory diagnosis in 35 multiple sclerosis (MS) patients treated with natalizumab. Thirteen patients had 3 or more CSF samples taken from weeks to months following PML diagnosis. Seven of the 13 patients demonstrated persistence of JCV DNA in the CSF even though all patients experienced immune reconstitution inflammatory syndrome (IRIS), 11 patients had plasma exchange, and 2 had immunoabsorption. Specific anti-JCV antibody was measured in plasma/sera samples from 25 of the 35 patients. Most of the samples showed moderate to high or rising antibody levels from the time of PML diagnosis. However, plasma from 1 patient at or near the time of PML diagnosis had a titer considered seronegative and 2 other plasma samples from patients had titers considered at baseline for seropositivity. In several PML cases, viral persistence and neurological deficits have continued for several years, indicating that once initiated, JCV infection may not entirely clear, even with IRIS. ANN NEUROL 2010;68:384-391
C1 [Ryschkewitsch, Caroline F.; Jensen, Peter N.; Monaco, Maria Chiara; Major, Eugene O.] NINDS, LMMN, NIH, Bethesda, MD 20892 USA.
RP Major, EO (reprint author), NINDS, LMMN, NIH, Bethesda, MD 20892 USA.
EM majorg@ninds.nih.gov
FU Division of Intramural Research, NINDS
FX We thank all Laboratory of Molecular Medicine and Neuroscience (LMMN)
members; K. Johnson, PhD, Senior Statistician, National Institute of
Neurological Disorders and Stroke (NINDS) for data analysis in Fig 2;
the staff at the Centers that provided the samples; and the cooperation
of Biogen/Idec in their acquisition. LMMN, NINDS, receives support from
the Division of Intramural Research, NINDS. There is no cost for the
assays nor does the LMMN receive any form of compensation. All reports
on sample tests go directly to the Centers and physicians who send the
samples.
NR 15
TC 54
Z9 54
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD SEP
PY 2010
VL 68
IS 3
BP 384
EP 391
DI 10.1002/ana.22137
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 644ZX
UT WOS:000281421800018
PM 20818792
ER
PT J
AU Cobb, BL
Fei, Y
Jonsson, R
Bolstad, AI
Brun, JG
Rischmueller, M
Lester, SE
Witte, T
Illei, G
Brennan, M
Bowman, S
Moser, KL
Harley, JB
Sawalha, AH
AF Cobb, Beth L.
Fei, Yiping
Jonsson, Roland
Bolstad, Anne Isine
Brun, Johan G.
Rischmueller, Maureen
Lester, Susan E.
Witte, Torsten
Illei, Gabor
Brennan, Michael
Bowman, Simon
Moser, Kathy L.
Harley, John B.
Sawalha, Amr H.
TI Genetic association between methyl-CpG binding protein 2 (MECP2) and
primary Sjogren's syndrome
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Editorial Material
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; OVEREXPRESSION; EXPRESSION; VARIANTS
C1 [Cobb, Beth L.; Fei, Yiping; Moser, Kathy L.; Harley, John B.; Sawalha, Amr H.] Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA.
[Fei, Yiping; Harley, John B.; Sawalha, Amr H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Jonsson, Roland; Bolstad, Anne Isine] Univ Bergen, Gade Inst, Broegelmann Res Lab, Bergen, Norway.
[Bolstad, Anne Isine] Univ Bergen, Dept Clin Dent, Bergen, Norway.
[Brun, Johan G.] Haukeland Hosp, Dept Rheumatol, N-5021 Bergen, Norway.
[Brun, Johan G.] Univ Bergen, Rheumatol Sect, Bergen, Norway.
[Rischmueller, Maureen] Queen Elizabeth Hosp, Dept Rheumatol, Adelaide, SA, Australia.
[Lester, Susan E.] Hanson Inst, Arthritis Res Lab, Adelaide, SA, Australia.
[Witte, Torsten] Hannover Med Sch, Clin Immunol & Rheumatol, D-3000 Hannover, Germany.
[Illei, Gabor] Natl Inst Dent & Craniofacial Res, Sjogrens Syndrome Clin, Gene Therapy & Therapeut Branch, Natl Inst Hlth, Bethesda, MD USA.
[Brennan, Michael] Carolinas Med Ctr, Dept Oral Med, Charlotte, NC 28203 USA.
[Bowman, Simon] Univ Hosp Birmingham NHS Fdn Trust, Dept Rheumatol, Birmingham, W Midlands, England.
[Harley, John B.; Sawalha, Amr H.] US Dept Vet Affairs Med Ctr, Oklahoma City, OK USA.
RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA.
EM amr-sawalha@omrf.ouhsc.edu
RI Witte, Torsten/B-5783-2016
FU Intramural NIH HHS; NCRR NIH HHS [P20 RR015577, P20 RR020143, P20
RR020143-06, P20 RR020143-07, P20-RR015577, P20-RR020143]; NIAID NIH HHS
[R03 AI076729, R03 AI076729-01, R03 AI076729-02, R03AI076729, U19
AI082714]; NIAMS NIH HHS [P30 AR053483, P30-AR053483]; NIDCR NIH HHS
[DE015223, R01 DE015223, R01 DE015223-05]
NR 10
TC 15
Z9 16
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD SEP
PY 2010
VL 69
IS 9
BP 1731
EP 1732
DI 10.1136/ard.2009.122903
PG 2
WC Rheumatology
SC Rheumatology
GA 636XB
UT WOS:000280776700029
PM 20215141
ER
PT J
AU Mo, LJ
Zhang, J
Shi, JD
Xuan, QA
Yang, XL
Qin, M
Lee, C
Klocker, H
Li, QQ
Mo, ZN
AF Mo, Linjian
Zhang, Ju
Shi, Jiandang
Xuan, Qiang
Yang, Xiaoli
Qin, Min
Lee, Chung
Klocker, Helmut
Li, Qingdi Quentin
Mo, Zengnan
TI Human Kallikrein 7 Induces Epithelial-Mesenchymal Transition-like
Changes in Prostate Carcinoma Cells: A Role in Prostate Cancer Invasion
and Progression
SO ANTICANCER RESEARCH
LA English
DT Article
DE Human tissue kallikrein 7; morphological change; vimentin; prostate
cancer; invasion; metastasis
ID CORNEUM CHYMOTRYPTIC ENZYME; E-CADHERIN; STRATUM-CORNEUM; TGF-BETA;
PROTEINASE; ACTIVATION; EXPRESSION; RECEPTORS; GROWTH; ASSAY
AB Human tissue kallikrein 7 (hK7), a chymotrypsin-like secreted serine protease, catalyzes the degradation of intercellular adhesive structures in the cornified layer of the skin, leading to desquamation. Thus, hK7 is implicated in cancer invasion and metastasis. Although hK7 is highly expressed in prostate tissues, its biological role in prostate cancer progression is poorly understood. In the current study, we established an hK7-expressing cell model for prostate tumors by stably transfecting prostate carcinoma 22RV1 and DU145 cells with an expression vector encoding hK7. We found that there were no obvious differences in cell proliferation between cells overexpressing hK7 and cells transfected with empty vector (p>0.05). Intriguingly, a Matrigel invasion assay revealed that hK7 remarkably increased the migration and invasion of prostate cancer cells (p<0.01). Furthermore, hK7 induced epithelial mesenchymal transition-like changes in prostate carcinoma cells, as evidenced by scattered cellular growth, mesenchyma-like morphology, and up-regulated expression of vimentin, a mesenchymal marker. These novel findings suggest that hK7 plays an important role in mediating prostate cancer progression and that hK7 promotes invasion and metastasis, at least in part, through inducing the epithelial mesenchymal transition of prostatic carcinoma cells.
C1 [Mo, Linjian; Xuan, Qiang; Yang, Xiaoli; Qin, Min; Mo, Zengnan] Guangxi Med Univ, Univ Hosp 1, Inst Urol, Nanning 530021, Peoples R China.
[Zhang, Ju; Shi, Jiandang] Nankai Univ, Inst Mol Biol, Tianjin 300071, Peoples R China.
[Lee, Chung] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Klocker, Helmut] Innsbruck Med Univ, Dept Urol, A-6010 Innsbruck, Austria.
[Li, Qingdi Quentin] NIH, Bethesda, MD 20892 USA.
RP Mo, ZN (reprint author), Guangxi Med Univ, Univ Hosp 1, Inst Urol, Nanning 530021, Peoples R China.
EM liquenti@mail.nih.gov; mozengnan@gmail.com
FU National Natural Science Foundation of China [30260110/C03030305]; First
University Hospital of Guangxi Medical University
FX This project was carried out at the Institute of Urology, First
University Hospital of Guangxi Medical University and the Institute for
Molecular Biology, Nankai University. This work was supported by grants
from the National Natural Science Foundation of China (No.
30260110/C03030305) and the First University Hospital of Guangxi Medical
University.
NR 19
TC 16
Z9 16
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP
PY 2010
VL 30
IS 9
BP 3413
EP 3420
PG 8
WC Oncology
SC Oncology
GA 665BI
UT WOS:000283009400026
PM 20944116
ER
PT J
AU Chung, SM
Wendeler, M
Rausch, JW
Beilhartz, G
Gotte, M
O'Keefe, BR
Bermingham, A
Beutler, JA
Liu, SX
Zhuang, XW
Le Grice, SFJ
AF Chung, Suhman
Wendeler, Michaela
Rausch, Jason W.
Beilhartz, Greg
Gotte, Matthias
O'Keefe, Barry R.
Bermingham, Alun
Beutler, John A.
Liu, Shixin
Zhuang, Xiaowei
Le Grice, Stuart F. J.
TI Structure-Activity Analysis of Vinylogous Urea Inhibitors of Human
Immunodeficiency Virus-Encoded Ribonuclease H
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HIV-1 REVERSE-TRANSCRIPTASE; RNASE-H; SIGNIFICANT DISCREPANCIES;
CALORIMETRIC ENTHALPIES; THUMB SUBDOMAIN; DNA-POLYMERASE; VANT-HOFF;
TYPE-1; ACID; DERIVATIVES
AB Vinylogous ureas 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b] thiophene-3-carboxamide and N-[3-(aminocarbonyl)- 4,5-dimethyl-2-thienyl]-2-furancarboxamide (compounds 1 and 2, respectively) were recently identified to be modestly potent inhibitors of the RNase H activity of HIV-1 and HIV-2 reverse transcriptase (RT). Both compounds shared a 3-CONH(2)-substituted thiophene ring but were otherwise structurally unrelated, which prevented a precise definition of the pharmacophore. We have therefore examined a larger series of vinylogous ureas carrying amide, amine, and cycloalkane modifications of the thiophene ring of compound 1. While cycloheptane-and cyclohexane-substituted derivatives retained potency, cyclopentane and cyclooctane substitutions eliminated activity. In the presence of a cycloheptane ring, modifying the 2-NH(2) or 3-CONH(2) functions decreased the potency. With respect to compound 2, vinylogous ureas whose dimethylthiophene ring contained modifications of the 2-NH(2) and 3-CONH(2) functions were investigated. 2-NH(2)-modified analogs displayed potency equivalent to or enhanced over that of compound 2, the most active of which, compound 16, reflected intramolecular cyclization of the 2-NH(2) and 3-CONH(2) groups. Molecular modeling was used to define an inhibitor binding site in the p51 thumb subdomain, suggesting that an interaction with the catalytically conserved His539 of the p66 RNase H domain could underlie inhibition of RNase H activity. Collectively, our data indicate that multiple functional groups of vinylogous ureas contribute to their potencies as RNase H inhibitors. Finally, single-molecule spectroscopy indicates that vinylogous ureas have the property of altering the reverse transcriptase orientation on a model RNA-DNA hybrid mimicking initiation plus-strand DNA synthesis.
C1 [Chung, Suhman; Wendeler, Michaela; Rausch, Jason W.; Le Grice, Stuart F. J.] NCI, RT Biochem Sect, HIV Drug Resistance Program, Frederick, MD 21702 USA.
[Beilhartz, Greg; Gotte, Matthias] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
[O'Keefe, Barry R.; Bermingham, Alun; Beutler, John A.] NCI, Mol Targets Program, Frederick, MD 21702 USA.
[Liu, Shixin; Zhuang, Xiaowei] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Zhuang, Xiaowei] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.
[Zhuang, Xiaowei] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.
RP Le Grice, SFJ (reprint author), NCI, RT Biochem Sect, HIV Drug Resistance Program, Bldg 525,Room 312, Frederick, MD 21702 USA.
EM legrices@mail.nih.gov
RI Liu, Shixin/A-4560-2012; Beutler, John/B-1141-2009
OI Beutler, John/0000-0002-4646-1924
FU National Cancer Institute, National Institutes of Health; Canadian
Foundation for AIDS Research; NIH [GM 068518]; National Cancer
Institute, National Institutes of Health [N01-CO-12400]
FX S.F.J.L.G. is supported by the Intramural Research Program of the
National Cancer Institute, National Institutes of Health; M. G. is
supported by a grant from the Canadian Foundation for AIDS Research; and
X.Z. is supported by NIH grant GM 068518. X.Z. is a Howard Hughes
Medical Institute investigator. This project was supported in whole or
in part with federal funds from the National Cancer Institute, National
Institutes of Health, under contract N01-CO-12400.
NR 35
TC 29
Z9 30
U1 0
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2010
VL 54
IS 9
BP 3913
EP 3921
DI 10.1128/AAC.00434-10
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 639WC
UT WOS:000281005900053
PM 20547794
ER
PT J
AU Shi, ZH
Nie, GJ
Duan, XL
Rouault, T
Wu, WS
Ning, B
Zhang, N
Chang, YZ
Zhao, BL
AF Shi, Zhen-Hua
Nie, Guangjun
Duan, Xiang-Lin
Rouault, Tracey
Wu, Wen-Shuang
Ning, Bo
Zhang, Nan
Chang, Yan-Zhong
Zhao, Bao-Lu
TI Neuroprotective Mechanism of Mitochondrial Ferritin on
6-Hydroxydopamine-Induced Dopaminergic Cell Damage: Implication for
Neuroprotection in Parkinson's Disease
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
ID GREEN TEA POLYPHENOLS; ENDOPLASMIC-RETICULUM STRESS; NEUROBLASTOMA
SH-SY5Y CELLS; CENTRAL-NERVOUS-SYSTEM; LABILE IRON POOL; ROS-NO PATHWAY;
OXIDATIVE STRESS; COMPLEX-I; NEURODEGENERATIVE DISORDERS; INDUCED
NEUROTOXICITY
AB Neuronal iron homeostasis disruption and oxidative stress are closely related to the pathogenesis of Parkinson's disease (PD). Adult iron-regulatory protein 2 knockout (Ireb2(-/-)) mice develop iron accumulation in white matter tracts and nuclei in different brain area and display severe neurodegeneration in Purkinje cells of the cerebrum. Mitochondrial ferritin (MtFt), a newly discovered ferritin, specifically expresses in high energy-consuming cells, including neurons of brain and spinal cord. Interestingly, the decreased expression of MtFt in cerebrum, but not in striatum, matches the differential neurodegeneration pattern in these Ireb2(-/-) mice. To explore its effect on neurodegeneration, the effects of MtFt expression on 6-hydrodopamine (6-OHDA)-induced neuronal damage was examined. The overexpression of MtFt led to a cytosolic iron deficiency in the neuronal cells and significantly prevented the alteration of iron redistribution induced by 6-OHDA. Importantly, MtFt strongly inhibited mitochondrial damage, decreased production of the reactive oxygen species and lipid peroxidation, and dramatically rescued apoptosis by regulating Bcl-2, Bax and caspase-3 pathways. In conclusion, this study demonstrates that MtFt plays an important role in preventing neuronal damage in an 6-OHDA-induced parkinsonian phenotype by maintaining iron homeostasis. Regulation of MtFt expression in neuronal cells may provide a new neuroprotective strategy for PD. Antioxid. Redox Signal. 13, 783-796.
C1 [Shi, Zhen-Hua; Duan, Xiang-Lin; Wu, Wen-Shuang; Zhang, Nan; Chang, Yan-Zhong] Hebei Normal Univ, Coll Life Sci, Lab Mol Iron Metab, Shijiazhuang 050016, Hebei, Peoples R China.
[Shi, Zhen-Hua; Zhao, Bao-Lu] Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100080, Peoples R China.
[Nie, Guangjun; Ning, Bo] Natl Ctr Nanosci & Technol China, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing, Peoples R China.
[Rouault, Tracey] NICHHD, Program Mol Med, NIH, Bethesda, MD 20892 USA.
RP Chang, YZ (reprint author), Hebei Normal Univ, Coll Life Sci, Lab Mol Iron Metab, Shijiazhuang 050016, Hebei, Peoples R China.
EM frankyzchang@yahoo.com.hk; zhaobl@sun5.ibp.ac.cn
RI Nie, Guangjun/A-9954-2011;
OI nie, guangjun/0000-0001-5040-9793
FU National Natural Sciences Foundation of China [30871260, 10979011,
30900278]; Natural Science Foundation of Hebei Province [C2007000251];
High Technology Research and Development Project of China
[2009AA03Z335]; State Key Development Program for Basic Research of
China [2010CB933600]; Chinese Academy of Sciences
FX This work was supported by grants from the National Natural Sciences
Foundation of China (30871260; 10979011; 30900278), Natural Science
Foundation of Hebei Province (C2007000251), High Technology Research and
Development Project of China (2009AA03Z335) and the State Key
Development Program for Basic Research of China (2010CB933600). GN
gratefully acknowledges the support of Chinese Academy of Sciences,
Hundred Talents Program. We also thank Dr. Manik Ghosh and Hayden
Ollivierre-Wilson for preparation of the IRP-knockout mouse. Anti-MtFt
antibody was a generous gift from Professor Sonia Levi and Dr. Paolo
Santambrogio, Milan.
NR 53
TC 30
Z9 34
U1 0
U2 19
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD SEP
PY 2010
VL 13
IS 6
BP 783
EP 796
DI 10.1089/ars.2009.3018
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 628KY
UT WOS:000280119800006
PM 20121342
ER
PT J
AU Sastalla, I
Rosovitz, MJ
Leppla, SH
AF Sastalla, Inka
Rosovitz, M. J.
Leppla, Stephen H.
TI Accidental Selection and Intentional Restoration of
Sporulation-Deficient Bacillus anthracis Mutants
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID ILLEGITIMATE RECOMBINATION; SUBTILIS; GENE; BACTERIA; TRANSCRIPTION;
EXPRESSION; PROMOTERS; REGULATOR; PROTEINS; MUTATION
AB We demonstrate the frequent accidental enrichment of spontaneous sporulation-deficient mutants of Bacillus anthracis on solid medium and identify contributing factors. Mutations in spo0A, encoding the master regulator of sporulation initiation, were found in 38 of 53 mutants. Transductions using bacteriophage CP51 propagated on sporogenic bacteria allowed for the restoration of sporulation phenotypes.
C1 [Sastalla, Inka; Rosovitz, M. J.; Leppla, Stephen H.] NIAID, Lab Bacterial Dis, NIH, Bethesda, MD 20892 USA.
RP Leppla, SH (reprint author), NIAID, Lab Bacterial Dis, NIH, Bldg 33, Bethesda, MD 20892 USA.
EM sleppla@niaid.nih.gov
FU NIH, National Institute of Allergy and Infectious Diseases
FX This work was supported by the Intramural Research Program of the NIH,
National Institute of Allergy and Infectious Diseases.
NR 28
TC 7
Z9 7
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD SEP
PY 2010
VL 76
IS 18
BP 6318
EP 6321
DI 10.1128/AEM.00950-10
PG 4
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 648EV
UT WOS:000281674100040
PM 20639373
ER
PT J
AU Zhang, HF
Lountos, GT
Ching, CB
Jiang, RR
AF Zhang, Hongfang
Lountos, George T.
Ching, Chi Bun
Jiang, Rongrong
TI Engineering of glycerol dehydrogenase for improved activity towards 1,
3-butanediol
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Glycerol dehydrogenase; Protein engineering; 1, 3-butanediol;
4-hydroxy-2-butanone
ID SECONDARY ALCOHOL-DEHYDROGENASE; ESCHERICHIA-COLI; 4-HYDROXY-2-BUTANONE;
OXIDATION; PURIFICATION; EXPRESSION; POLYMERS; CATALYST; CLONING
AB The objective of this study was to use protein engineering techniques to enhance the catalytic activity of glycerol dehydrogenase (GlyDH) on racemic 1, 3-butanediol (1, 3-BDO) for the bioproduction of the important pharmaceutical intermediate 4-hydroxy-2-butanone. Three GlyDH genes (gldA) from Escherichia coli K-12, Salmonella enterica, and Klebsiella pneumoniae MGH78578 were shuffled to generate a random mutagenesis library. The nitroblue tetrazolium/phenazine methosulfate high throughput screening protocol was used to select four chimeric enzymes with up to a 2.6-fold improved activity towards 1, 3-BDO. A rational design method was also employed to further improve the enzyme activity after DNA shuffling. Based on the homology model of GlyDH (Escherichia coli), Asp121 was predicted to influence 1, 3-BDO binding and replaced with Ala by site-directed mutagenesis. Combination of the mutations from both DNA shuffling and rational design produced the best mutant with a V(max) value of 126.6 U/mg, a 26-fold activity increase compared with that of the wild type GlyDH from E. coli.
C1 [Zhang, Hongfang; Ching, Chi Bun; Jiang, Rongrong] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 637459, Singapore.
[Lountos, George T.] NCI, Macromol Crystallog Lab, Frederick, MD 21702 USA.
RP Jiang, RR (reprint author), Nanyang Technol Univ, Sch Chem & Biomed Engn, 62 Nanyang Dr, Singapore 637459, Singapore.
EM rrjiang@ntu.edu.sg
RI Jiang , Rongrong/G-6217-2010; Lountos, George/B-3983-2015
NR 28
TC 19
Z9 21
U1 2
U2 30
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD SEP
PY 2010
VL 88
IS 1
BP 117
EP 124
DI 10.1007/s00253-010-2735-8
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 638RZ
UT WOS:000280914900013
PM 20585771
ER
PT J
AU Pati, HN
Das, U
Sakagami, H
Kawase, M
Chu, Q
Wang, QT
Stables, JP
Dimmock, JR
AF Pati, Hari N.
Das, Umashankar
Sakagami, Hiroshi
Kawase, Masame
Chu, Qing
Wang, Qintao
Stables, James P.
Dimmock, Jonathan R.
TI 1,3-Diaryl-2-propenones and 2-Benzylidene-1,3-indandiones: A Quest for
Compounds Displaying Greater Toxicity to Neoplasms than Normal Cells
SO ARCHIV DER PHARMAZIE
LA English
DT Article
DE Apoptosis; Cytotoxicity; Neurotoxicity; Structure-activity
relationships; Unsaturated ketones
ID MULTIDRUG-RESISTANCE REVERSAL; ANTIMITOTIC CHALCONES;
2-ARYLIDENEBENZOCYCLOALKANONES; PHARMACOPHORE; CYTOTOXICITY; ANTICANCER;
DRUGS
AB A series of 1,3-diaryl-2-propenones 2a-j and analogous 2-benzylidene-1,3-indandiones 3a-j were evaluated against various neoplasms and normal cells. In general, greater cytotoxic potencies and selective toxicity to human malignant cells were observed by the compounds in series 2 rather than 3. In particular, 2i emerged as a lead molecule having an average CC(50) figure of 8.6 mu M and a selective index value of 18. Various physicochemical features of 2a-j were correlated with the cytotoxic potencies to neoplastic cell lines which provide guidelines for expansion of this series of compounds. The enone 2i induced internucleosomal DNA fragmentation and activated caspase-3 in HL-60 cells suggesting that one of the ways in which the cytotoxicity of the compounds in series 2 is mediated towards some of the cell lines used in this study is by apoptosis. Neurotoxicity in mice was generally lower in series 2 than 3a-j.
C1 [Pati, Hari N.; Das, Umashankar; Dimmock, Jonathan R.] Univ Saskatchewan, Drug Design & Discovery Res Grp, Coll Pharm & Nutr, Saskatoon, SK S7N 5C9, Canada.
[Sakagami, Hiroshi; Chu, Qing] Meikai Univ Sch Dent, Dept Diagnost & Therapeut Sci, Saitama, Japan.
[Kawase, Masame] Matsuyama Univ, Fac Pharmaceut Sci, Matsuyama, Ehime, Japan.
[Chu, Qing; Wang, Qintao] Fourth Mil Med Univ, Dept Periodontol & Oral Med, Sch Stomatol, Xian 710032, Peoples R China.
[Stables, James P.] NINDS, Rockville, MD USA.
RP Dimmock, JR (reprint author), Univ Saskatchewan, Drug Design & Discovery Res Grp, Coll Pharm & Nutr, Saskatoon, SK S7N 5C9, Canada.
EM jr.dimmock@usask.ca
FU Canadian Institutes of Health Research; Ministry of Education, Science,
Sports and Culture of Japan [19592156]
FX The authors thank the Canadian Institutes of Health Research for a grant
to J. R. Dimmock and the Ministry of Education, Science, Sports and
Culture of Japan for a Grant-in-Aid (No. 19592156) to H. Sakagami. The
National Institute of Neurological Disorders and Stroke, USA kindly
undertook the in-vivo experimentation with mice and rats. Erin Watson is
thanked for assisting with some of the literature retrieval.
NR 28
TC 3
Z9 3
U1 0
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0365-6233
J9 ARCH PHARM
JI Arch. Pharm.
PD SEP
PY 2010
VL 343
IS 9
BP 535
EP 541
DI 10.1002/ardp.200900308
PG 7
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 662FS
UT WOS:000282793400006
PM 20806272
ER
PT J
AU Bigos, KL
Mattay, VS
Callicott, JH
Straub, RE
Vakkalanka, R
Kolachana, B
Hyde, TM
Lipska, BK
Kleinman, JE
Weinberger, DR
AF Bigos, Kristin L.
Mattay, Venkata S.
Callicott, Joseph H.
Straub, Richard E.
Vakkalanka, Radhakrishna
Kolachana, Bhaskar
Hyde, Thomas M.
Lipska, Barbara K.
Kleinman, Joel E.
Weinberger, Daniel R.
TI Genetic Variation in CACNA1C Affects Brain Circuitries Related to Mental
Illness
SO ARCHIVES OF GENERAL PSYCHIATRY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BIPOLAR-DISORDER; NEURAL MECHANISMS; AMYGDALA
ACTIVITY; SCHIZOPHRENIA; RISK; MEMORY; VARIANTS; SIBLINGS; AUTISM
AB Context: The CACNA1C gene (alpha-1C subunit of the L-type voltage-gated calcium channel) has been identified as a risk gene for bipolar disorder and schizophrenia, but the mechanism of association has not been explored.
Objective: To identify the neural system mechanism that explains the genetic association between the CACNA1C gene and psychiatric illness using neuroimaging and human brain expression.
Design: We used blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) to measure brain activation in circuitries related to bipolar disorder and schizophrenia by comparing CACNA1C genotype groups among healthy subjects. We tested the effect of genotype on messenger RNA (mRNA) levels of CACNA1C in postmortem human brain. A case-control analysis was used to determine the association of CACNA1C genotype with schizophrenia.
Setting: National Institutes of Health Clinical Center.
Patients: Healthy men and women of white race/ethnicity participated in the fMRI study. Postmortem samples from normal human brains were used for the brain expression study. Patients with schizophrenia and healthy subjects were used in the case-control analysis.
Main Outcome Measures: BOLD fMRI, mRNA levels in postmortem brain samples, and genetic association with schizophrenia.
Results: The risk-associated single-nucleotide polymorphism (SNP rs1006737) in CACNA1C predicted increased hippocampal activity during emotional processing (P=.001 uncorrected, P((false recovery rate [FDR]))=.05, z=3.20) and increased prefrontal activity during executive cognition (P=2.8e-05 uncorrected, P(FDR)=.01, z=4.03). The risk-associated SNP also predicted increased expression of CACNA1C mRNA in human brain (P=.002). CACNA1C was associated with schizophrenia in our case-control sample (odds ratio, 1.77; P=.03).
Conclusions: The risk-associated SNP in CACNA1C maps to circuitries implicated in genetic risk for bipolar disorder and schizophrenia. Its effects in human brain expression implicate a molecular and neural system mechanism for the clinical genetic association.
C1 [Bigos, Kristin L.; Mattay, Venkata S.; Straub, Richard E.; Weinberger, Daniel R.] NIMH, Genes Cognit & Psychosis Program, Div Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Mattay, Venkata S.; Callicott, Joseph H.; Straub, Richard E.; Vakkalanka, Radhakrishna; Kolachana, Bhaskar; Hyde, Thomas M.; Lipska, Barbara K.; Kleinman, Joel E.] NIMH, Clin Brain Disorders Branch, Div Intramural Res Program, NIH, Bethesda, MD 20892 USA.
RP Weinberger, DR (reprint author), NIMH, Genes Cognit & Psychosis Program, Div Intramural Res Program, NIH, 10 Ctr Dr,MSC 1379, Bethesda, MD 20892 USA.
EM weinberd@mail.nih.gov
RI Lipska, Barbara/E-4569-2017;
OI Callicott, Joseph/0000-0003-1298-3334
FU National Institute of Mental Health, National Institutes of Health
FX This research was supported by the Intramural Research Program of the
National Institute of Mental Health, National Institutes of Health.
NR 41
TC 128
Z9 133
U1 1
U2 19
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-990X
J9 ARCH GEN PSYCHIAT
JI Arch. Gen. Psychiatry
PD SEP
PY 2010
VL 67
IS 9
BP 939
EP 945
PG 7
WC Psychiatry
SC Psychiatry
GA 649JD
UT WOS:000281764000009
PM 20819988
ER
PT J
AU Khoury, SJ
Healy, BC
Kivisakk, P
Viglietta, V
Egorova, S
Guttmann, CRG
Wedgwood, JF
Hafler, DA
Weiner, HL
Buckle, G
Cook, S
Reddy, S
AF Khoury, Samia J.
Healy, Brian C.
Kivisakk, Pia
Viglietta, Vissia
Egorova, Svetlana
Guttmann, Charles R. G.
Wedgwood, Josiah F.
Hafler, David A.
Weiner, Howard L.
Buckle, Guy
Cook, Sandra
Reddy, Susheel
TI A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy
in Patients With Multiple Sclerosis
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; GLATIRAMER ACETATE; T-CELLS;
NEUROTROPHIC FACTOR; LONGITUDINAL DATA; BRAIN; INTERLEUKIN-12; DISEASE;
MECHANISMS; RESPONSES
AB Background:Interleukin 12 (IL-12), a cytokine that promotes generation of helper T cells subtype 1, is increased in multiple sclerosis. Albuterol sulfate, a beta 2-adrenergic agonist, reduces IL-12 expression, so we tested the effect of albuterol as an add-on treatment to glatiramer acetate therapy.
Objectives: To investigate the clinical and immunologic effects of albuterol treatment as an add-on therapy in patients starting glatiramer acetate treatment.
Design: Single-center double-masked clinical trial.
Setting: Academic research.
Patients: Subjects with relapsing-remitting multiple sclerosis.
Main Outcome Measures: In this single-center double-masked clinical trial, subjects with relapsing-remitting multiple sclerosis were randomized to receive a subcutaneous injection of glatiramer acetate (20 mg) plus an oral dose of placebo daily for 2 years or a subcutaneous injection of glatiramer acetate (20 mg) plus an oral dose of albuterol daily for 2 years. The primary clinical efficacy measurement was the change in Multiple Sclerosis Functional Composite at 2 years, and the primary immunologic end point was the change in expression of IL-13 and interferon gamma at each study time point. The clas-sification level of evidence from this trial is C for each question, as this is the first class II clinical trial addressing the efficacy of glatiramer acetate plus albuterol.
Results: Forty-four subjects were randomized to receive glatiramer acetate plus albuterol or glatiramer acetate plus placebo, and 39 subjects contributed to the analysis. Improvement in the Multiple Sclerosis Functional Composite was observed in the glatiramer acetate plus albuterol group at the 6-month (P=.005) and 12-month (P=.04) time points but not at the 24-month time point. A delay in the time to first relapse was also observed in the glatiramer acetate plus albuterol group (P=.03). Immunologically, IL-13 and interferon-gamma production decreased in both treatment groups, and a treatment effect on IL-13 production was observed at the 12-month time point (P<.05). Adverse events were generally mild, and only 3 moderate or severe events were considered related to the treatment.
Conclusion: Treatment with glatiramer acetate plus albuterol is well tolerated and improves clinical outcomes in patients with multiple sclerosis.
C1 [Khoury, Samia J.; Kivisakk, Pia; Viglietta, Vissia; Hafler, David A.; Weiner, Howard L.; Buckle, Guy; Cook, Sandra] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Ctr Neurol Dis, Boston, MA 02115 USA.
[Egorova, Svetlana; Guttmann, Charles R. G.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol,Ctr Neurol Imaging, Boston, MA 02115 USA.
[Healy, Brian C.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Wedgwood, Josiah F.] NIAID, NIH, Bethesda, MD 20892 USA.
[Reddy, Susheel] Rho Inc, Chapel Hill, NC USA.
RP Khoury, SJ (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Ctr Neurol Dis, Room 710,77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM skhoury@rics.bwh.harvard.edu
OI khoury, samia/0000-0003-3198-6063
FU National Institute of Allergy and Infectious Diseases [U19A1046130];
EpiVax; LifeCycle Pharmaceutical; PDL; BioPharma; Repligen; Wyeth
Pharmaceuticals; Allozyne, Inc; EISAI Research Institute; Xceed
Molecular Corporation; Actelion; AutoImmune; Biogen Idec; EMD Serono;
Enzo; Gen-. entech; Teva Neuroscience; Vascular Biogenics; Millennium
Pharmaceuticals; Bayer; Pfizer
FX This study was supported in part by Autoimmunity Center of Excellence
Study grant U19A1046130 from the National Institute of Allergy and
Infectious Diseases (Dr Khoury).; Dr Khoury has received consulting or
lecture fees from EpiVax, LifeCycle Pharmaceutical, PDL, BioPharma,
Repligen, and Wyeth Pharmaceuticals. Dr Hafler has received consulting
or lecture fees from Allozyne, Inc, EISAI Research Institute, Xceed
Molecular Corporation, and Actelion. Dr Weiner has received consulting
or lecture fees from AutoImmune, Biogen Idec, EMD Serono, Enzo, Gen-.
entech, Teva Neuroscience, and Vascular Biogenics and has received grant
support from Millennium Pharmaceuticals. Dr Buckle has received
consulting or lecture fees from Bayer, Biogen Idec, EMD Serono, Pfizer,
and Teva Neuroscience.
NR 32
TC 20
Z9 21
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD SEP
PY 2010
VL 67
IS 9
BP 1055
EP 1061
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 653OW
UT WOS:000282102800002
PM 20837847
ER
PT J
AU Tobian, AAR
Gray, RH
Quinn, TC
AF Tobian, Aaron A. R.
Gray, Ronald H.
Quinn, Thomas C.
TI When Is a Review Article Not a Review Article? Reply
SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE
LA English
DT Editorial Material
ID RANDOMIZED CONTROLLED-TRIAL; MALE CIRCUMCISION; HUMAN-PAPILLOMAVIRUS;
HPV INFECTIONS; HIV PREVENTION; YOUNG MEN; METAANALYSIS; HSV-2; RISK
C1 [Tobian, Aaron A. R.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
[Gray, Ronald H.] Johns Hopkins Univ, Dept Populat Family & Reprod Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
[Quinn, Thomas C.] Johns Hopkins Univ, Dept Med, Sch Med, Baltimore, MD 21205 USA.
[Quinn, Thomas C.] NIAID, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
RP Quinn, TC (reprint author), Johns Hopkins Univ, Dept Med, Sch Med, Rangos Bldg,Room 530,855 N Wolfe St, Baltimore, MD 21205 USA.
EM tquinn@jhmi.edu
NR 15
TC 0
Z9 0
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 1072-4710
J9 ARCH PEDIAT ADOL MED
JI Arch. Pediatr. Adolesc. Med.
PD SEP
PY 2010
VL 164
IS 9
BP 884
EP 884
PG 1
WC Pediatrics
SC Pediatrics
GA 646SX
UT WOS:000281564200018
ER
PT J
AU Lieb, W
Gona, P
Larson, MG
Massaro, JM
Lipinska, I
Keaney, JF
Rong, JA
Corey, D
Hoffmann, U
Fox, CS
Vasan, RS
Benjamin, EJ
O'Donnell, CJ
Kathiresan, S
AF Lieb, Wolfgang
Gona, Philimon
Larson, Martin G.
Massaro, Joseph M.
Lipinska, Izabella
Keaney, John F., Jr.
Rong, Jian
Corey, Diane
Hoffmann, Udo
Fox, Caroline S.
Vasan, Ramachandran S.
Benjamin, Emelia J.
O'Donnell, Christopher J.
Kathiresan, Sekar
TI Biomarkers of the Osteoprotegerin Pathway Clinical Correlates,
Subclinical Disease, Incident Cardiovascular Disease, and Mortality
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE coronary heart disease; vascular biology; osteoprotegerin; receptor
activator of nuclear factor-kappa B ligand
ID SERUM OSTEOPROTEGERIN; CORONARY-ARTERY; VASCULAR CALCIFICATION; RECEPTOR
ACTIVATOR; DEFICIENT MICE; BONE-DENSITY; RANKL; LIGAND; RISK;
OSTEOPOROSIS
AB Objective-Experimental evidence identified the osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B (RANK)/RANK ligand (RANKL) pathway as a candidate system modulating vascular remodeling and cardiovascular disease (CVD).
Methods and Results-Serum concentrations of OPG and RANKL were measured in 3250 Framingham Study participants (54% women, 61 +/- 9 years). During a mean follow-up of 4.6 years, 143 (of 3084 free of CVD at baseline) participants developed a first CVD event, and 235 died. In multivariable models, OPG was associated with increased hazards for incident CVD and mortality (hazard ratio, 1.27; 95% CI, 1.04 to 1.54; and hazard ratio, 1.25; 95% CI, 1.07 to 1.47, per 1-SD increment in log-OPG, respectively). Log-OPG was positively related to multiple CVD risk factors, including age, smoking, diabetes, systolic blood pressure, and prevalent CVD. In a subsample (n=1264), the prevalence of coronary artery calcification, measured by computed tomography, increased nonsignificantly with OPG quartiles. RANKL concentrations displayed inverse associations with multiple CVD risk factors, including smoking, diabetes, and antihypertensive treatment, and were not related to coronary artery calcification or incident CVD or mortality.
Conclusion-Our prospective data reinforce OPG as marker for CVD risk factor burden and predictor for CVD and mortality in the community. (Arterioscler Thromb Vasc Biol. 2010; 30: 1849-1854.)
C1 [Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Lieb, Wolfgang; Gona, Philimon; Larson, Martin G.; Massaro, Joseph M.; Rong, Jian; Corey, Diane; Fox, Caroline S.; Vasan, Ramachandran S.; Benjamin, Emelia J.; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Keaney, John F., Jr.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
[Fox, Caroline S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrinol, Boston, MA 02115 USA.
[O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA.
[Gona, Philimon; Larson, Martin G.; Massaro, Joseph M.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Benjamin, Emelia J.] Boston Univ, Dept Epidemiol, Boston, MA 02215 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Publ Hlth, Prevent Med & Epidemiol Sect, Boston, MA 02215 USA.
[Lipinska, Izabella; Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA.
[O'Donnell, Christopher J.; Kathiresan, Sekar] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Kathiresan, S (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 185 Cambridge St,CPZN 5-252, Boston, MA 02114 USA.
EM skathiresan@partners.org
RI Lieb, Wolfgang/C-1990-2012;
OI Massaro, Joseph/0000-0002-2682-4812; Larson, Martin/0000-0002-9631-1254;
Ramachandran, Vasan/0000-0001-7357-5970; Benjamin,
Emelia/0000-0003-4076-2336
FU National Heart, Lung, and Blood Institute [N01-HC-25195]; Doris Duke
Charitable Foundation; [R01-HL076784]; [1R01-AG028321];
[R01-HL064753]
FX This work was supported by the National Heart, Lung, and Blood
Institute's Framingham Heart Study (contract no. N01-HC-25195) and by
R01-HL076784, 1R01-AG028321, and R01-HL064753 (to E.J.B.). Dr Kathiresan
was funded by a Clinical Scientist Development Award from the Doris Duke
Charitable Foundation and by a Mentored Patient-Oriented Research Career
Development Award from the National Heart, Lung, and Blood Institute.
NR 27
TC 70
Z9 76
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD SEP
PY 2010
VL 30
IS 9
BP 1849
EP U386
DI 10.1161/ATVBAHA.109.199661
PG 11
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 641NX
UT WOS:000281135900025
PM 20448212
ER
PT J
AU Dhingra, R
Gona, P
Wang, TJ
Fox, CS
D'Agostino, RB
Vasan, RS
AF Dhingra, Ravi
Gona, Philimon
Wang, Thomas J.
Fox, Caroline S.
D'Agostino, Ralph B., Sr.
Vasan, Ramachandran S.
TI Serum gamma-Glutamyl Transferase and Risk of Heart Failure in the
Community
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE epidemiology; heart failure; risk factors; oxidative stress;
gamma-glutamyl transferase
ID CORONARY MICROVASCULAR FUNCTION; C-REACTIVE PROTEIN;
CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; GENERAL-POPULATION;
METABOLIC SYNDROME; OXIDATIVE STRESS; PROGNOSTIC VALUE; BLOOD-PRESSURE;
TRANSPEPTIDASE
AB Objective-To examine the association of serum gamma-glutamyltransferase (GGT) with incident heart failure.
Methods and Results-We related serum GGT to the incidence of heart failure in 3544 (mean age, 44.5 years; 1833 women and 1711 men) Framingham Study participants who were free of heart failure and myocardial infarction. On follow-up (mean, 23.6 years), 188 participants (77 women) developed new-onset heart failure. In multivariable Cox proportional hazards regression models adjusting for standard risk factors and alcohol consumption as time-varying covariates (updated every 4 years), each SD increase in log-GGT was associated with a 1.39-fold risk of heart failure (95% CI, 1.20 to 1.62). The linearity of the association was confirmed by multivariable-adjusted splines, and the relations remained robust on additional adjustment for hepatic aminotransferases and C-reactive protein. Participants with a serum GGT level at the median or greater had a 1.71-fold risk of heart failure (95% CI, 1.21 to 2.41) compared with individuals with GGT concentrations less than the median. GGT marginally increased the model C-statistic from 0.85 to 0.86 but improved the risk reclassification modestly (net reclassification index, 5.7%; P = 0.01).
Conclusion-In this prospective study of a large community-based sample, higher serum GGT concentrations within the "normal" range were associated with greater risk of heart failure and incrementally improved prediction of heart failure risk. (Arterioscler Thromb Vasc Biol. 2010;30:1855-1860.)
C1 [Dhingra, Ravi; Wang, Thomas J.; Fox, Caroline S.; D'Agostino, Ralph B., Sr.; Vasan, Ramachandran S.] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA.
[Dhingra, Ravi] Dartmouth Hitchcock Med Ctr, Div Cardiol, Lebanon, NH 03766 USA.
[Dhingra, Ravi] Harvard Univ, Sch Publ Hlth, Masters Publ Hlth Program, Boston, MA 02115 USA.
[Gona, Philimon; D'Agostino, Ralph B., Sr.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Fox, Caroline S.] NHLBI, Bethesda, MD 20892 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Prevent Med & Epidemiol, Boston, MA 02118 USA.
RP Vasan, RS (reprint author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Ste 2, Framingham, MA 01702 USA.
EM vasan@bu.edu
RI Max, Mad/E-5238-2010;
OI Max, Mad/0000-0001-6966-6829; Ramachandran, Vasan/0000-0001-7357-5970
FU National Heart, Lung, and Blood Institute [N01-HC-25195, N01HV28178,
R01HL71039, R01HL67288]
FX This study was supported by contracts N01-HC-25195, N01HV28178 (Dr
Vasan), R01HL71039 (Dr Vasan), and R01HL67288 (Dr Vasan) from the
National Heart, Lung, and Blood Institute's Framingham Heart Study.
NR 40
TC 30
Z9 35
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD SEP
PY 2010
VL 30
IS 9
BP 1855
EP 1860
DI 10.1161/ATVBAHA.110.207340
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 641NX
UT WOS:000281135900026
PM 20539015
ER
PT J
AU Rider, LG
Miller, FW
AF Rider, Lisa G.
Miller, Frederick W.
TI Mast Cells and Type I Interferon Responses in the Skin of Patients With
Juvenile Dermatomyositis: Are Current Therapies Just Scratching the
Surface?
SO ARTHRITIS AND RHEUMATISM
LA English
DT Editorial Material
ID PERIPHERAL-BLOOD; DISEASE-ACTIVITY; GENE-EXPRESSION; POLYMYOSITIS;
AUTOANTIBODIES; ASSOCIATION; INVOLVEMENT; ARTHRITIS; MUSCLE
C1 [Rider, Lisa G.; Miller, Frederick W.] NIEHS, NIH, Dept Hlth & Human Serv, Bethesda, MD USA.
RP Rider, LG (reprint author), CRC 4-2352,MSC 1301,10 Ctr Dr, Bethesda, MD 20892 USA.
EM riderl@mail.nih.gov
OI Rider, Lisa/0000-0002-6912-2458; Miller, Frederick/0000-0003-2831-9593
FU Intramural NIH HHS [ZIA ES101081-08]
NR 29
TC 3
Z9 3
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD SEP
PY 2010
VL 62
IS 9
BP 2619
EP 2622
DI 10.1002/art.27525
PG 4
WC Rheumatology
SC Rheumatology
GA 665TT
UT WOS:000283059100008
PM 20506242
ER
PT J
AU Ertem, G
Steudel, A
Emmerich, K
Lagaly, G
Schuhmann, R
AF Ertem, Goezen
Steudel, Annett
Emmerich, Katja
Lagaly, Gerhard
Schuhmann, Rainer
TI Correlation Between the Extent of Catalytic Activity and Charge Density
of Montmorillonites
SO ASTROBIOLOGY
LA English
DT Article
DE Mars; Origin of life; Montmorillonite; Mineral catalysis; Layer charge
density; X-ray diffractometry
ID ALKYLAMMONIUM LAYER-SILICATES; PARAFFIN-LIKE STRUCTURES; PHOENIX LANDING
SITE; CLAY-MINERALS; OLIGOMERIZATION REACTIONS; CATIONIC TENSIDES;
MARTIAN SOIL; MARS; SURFACES; ARRANGEMENT
AB The clay mineral montmorillonite is a member of the phyllosilicate group of minerals, which has been detected on martian soil. Montmorillonite catalyzes the condensation of activated monomers to form RNA-like oligomers. Extent of catalysis, that is, the yield of oligomers, and the length of the longest oligomer formed in these reactions widely varies with the source of montmorillonite (i.e., the locality where the mineral is mined). This study was undertaken to establish whether there exists a correlation between the extent of catalytic property and the charge density of montmorillonites. Charge density was determined by saturating the montmorillonites with alkyl ammonium cations that contained increasing lengths of alkyl chains, [CH(3)-(CH(2))(n)-NH(3)](+), where n = 3-16 and 18, and then measuring d((001)), interlayer spacing of the resulting montmorillonite-alkyl ammonium-montmorillonite complex by X-ray diffractometry (XRD).
Results demonstrate that catalytic activity of montmorillonites with lower charge density is superior to that of higher charge density montmorillonite. They produce longer oligomers that contain 9 to 10 monomer units, while montmorillonite with high charge density catalyzes the formation of oligomers that contain only 4 monomer units.
The charge density of montmorillonites can also be calculated from the chemical composition if elemental analysis data of the pure mineral are available. In the next mission to Mars, CheMin (Chemistry and Mineralogy), a combined X-ray diffraction/X-ray fluorescence instrument, will provide information on the mineralogical and elemental analysis of the samples. Possible significance of these results for planning the future missions to Mars for the search of organic compounds and extinct or extant life is discussed.
C1 [Ertem, Goezen] NIH, Bethesda, MD 20892 USA.
[Ertem, Goezen] Carl Sagan Ctr, SETI Inst, Mountain View, CA USA.
[Steudel, Annett; Emmerich, Katja; Schuhmann, Rainer] Karlsruhe Inst Technol, Competence Ctr Mat Moisture, Karlsruhe, Germany.
[Steudel, Annett; Emmerich, Katja; Schuhmann, Rainer] Karlsruhe Inst Technol, Inst Funct Interfaces, Karlsruhe, Germany.
[Lagaly, Gerhard] Univ Kiel, Inst Organ Chem, D-2300 Kiel, Germany.
RP Ertem, G (reprint author), NIH, 10 Ctr Dr 3N322, Bethesda, MD 20892 USA.
EM ertemg@mail.nih.gov
NR 41
TC 3
Z9 3
U1 4
U2 13
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1531-1074
J9 ASTROBIOLOGY
JI Astrobiology
PD SEP
PY 2010
VL 10
IS 7
BP 743
EP 749
DI 10.1089/ast.2009.0436
PG 7
WC Astronomy & Astrophysics; Biology; Geosciences, Multidisciplinary
SC Astronomy & Astrophysics; Life Sciences & Biomedicine - Other Topics;
Geology
GA 671EM
UT WOS:000283483100007
PM 20854214
ER
PT J
AU Gogtay, N
AF Gogtay, Nitin
TI PROGRESSIVE GM ABNORMALITIES IN CHILDHOOD-ONSET SCHIZOPHRENIA (COS):
INSIGHTS FROM GENETIC AND IMAGING STUDIES
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Gogtay, Nitin] NIMH, Child Psychiat Branch, Bethesda, MD 20892 USA.
RI Gogtay, Nitin/A-3035-2008
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0004-8674
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD SEP
PY 2010
VL 44
SU 1
BP A8
EP A8
PG 1
WC Psychiatry
SC Psychiatry
GA 664IX
UT WOS:000282954700015
ER
PT J
AU Lenroot, RK
Giedd, JN
AF Lenroot, Rhoshel K.
Giedd, Jay N.
TI THE STRUCTURAL AND FUNCTIONAL DEVELOPMENTAL TRAJECTORY OF THE FRONTAL
CORTEX
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Lenroot, Rhoshel K.] Univ New S Wales, Sydney, NSW, Australia.
[Lenroot, Rhoshel K.] Neurosci Res Australia, Sydney, NSW, Australia.
[Lenroot, Rhoshel K.; Giedd, Jay N.] NIMH, Child Psychiat Branch, Bethesda, MD 20892 USA.
RI Giedd, Jay/A-3080-2008; Giedd, Jay/B-7302-2012; Giedd, Jay/J-9644-2015
OI Giedd, Jay/0000-0003-0827-3460; Giedd, Jay/0000-0003-2002-8978
NR 6
TC 1
Z9 1
U1 0
U2 1
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0004-8674
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD SEP
PY 2010
VL 44
SU 1
BP A7
EP A7
PG 1
WC Psychiatry
SC Psychiatry
GA 664IX
UT WOS:000282954700012
ER
PT J
AU Subbiah, M
Xiao, S
Khattar, SK
Dias, FM
Collins, PL
Samal, SK
AF Subbiah, Madhuri
Xiao, Sa
Khattar, Sunil K.
Dias, Flavia Militino
Collins, Peter L.
Samal, Siba K.
TI Pathogenesis of Two Strains of Avian Paramyxovirus Serotype 2, Yucaipa
and Bangor, in Chickens and Turkeys
SO AVIAN DISEASES
LA English
DT Article
DE avian paramyxovirus serotype 2; APMV-2 strain Yucaipa; APMV-2 strain
Bangor; pathogenesis; chickens and turkeys; immunohistochemistry
ID NEWCASTLE-DISEASE VIRUS; COMPLETE NUCLEOTIDE-SEQUENCE;
RESPIRATORY-DISEASE; GENOME SEQUENCE; WILD BIRDS; SEROLOGICAL SURVEY;
MALLARD DUCK; PROTEIN; POULTRY; ISRAEL
AB Nine serologic types of avian paramyxovirus (APMV) have been recognized. Newcastle disease virus (APMV-1) is the most extensively characterized virus, while relatively little information is available for the other APMV serotypes. In the present study, we examined the pathogenicity of two strains of APMV-2, Yucaipa and Bangor, in 9-day-old embryonated chicken eggs, 1-day-old specific-pathogen-free (SPF) chicks, and 4-wk-old SPF chickens and turkeys. The mean death time in 9-day-old embryonated chicken eggs was more than 168 hr for both strains, and their intracerebral pathogenicity index (ICPI) was zero, indicating that these viruses are nonpathogenic in chickens. When inoculated intracerebrally in 1-day-old chicks, neither strain caused disease or replicated detectably in the brain. This suggests that the zero ICPI value of APMV-2 reflects the inability of the virus to grow in neural cells. Groups of twelve 4-wk-old SPF chickens and turkeys were inoculated oculonasally with either strain, and three birds per group were euthanatized on days 2, 4, 6, and 14 postinoculation for analysis. There were no overt clinical signs of illnesses, although all birds seroconverted by day 6. The viruses were isolated predominantly from the respiratory and alimentary tracts. Immunohistochemistry studies also showed the presence of a large amount of viral antigens in epithelial linings of respiratory and alimentary tracts. There also was evidence of systemic spread even though the cleavage site of the viral fusion glycoprotein does not contain the canonical furin protease cleavage site.
C1 [Subbiah, Madhuri; Xiao, Sa; Khattar, Sunil K.; Dias, Flavia Militino; Samal, Siba K.] Univ Maryland, Virginia Maryland Reg Coll Vet Med, College Pk, MD 20742 USA.
[Collins, Peter L.] NIAID, Infect Dis Lab, Bethesda, MD 20892 USA.
RP Samal, SK (reprint author), Univ Maryland, Virginia Maryland Reg Coll Vet Med, 8075 Greenmead Dr, College Pk, MD 20742 USA.
EM ssamal@umd.edu
FU National Institute of Allergy and Infectious Diseases (NIAID)
[N01A060009]
FX We thank Daniel Rockemann and all our laboratory members for their
excellent technical assistance; LaShae Green, Shin-Hee Kim, Arthur
Samuel, and Anandan Paldurai for critical reading of this manuscript.
This research was supported in part by National Institute of Allergy and
Infectious Diseases (NIAID) contract no. N01A060009 (85% support) and
the NIAID, National Institute of Health Intramural Research Program (15%
support).
NR 57
TC 6
Z9 6
U1 1
U2 4
PU AMER ASSOC AVIAN PATHOLOGISTS
PI ATHENS
PA 953 COLLEGE STATION RD, ATHENS, GA 30602-4875 USA
SN 0005-2086
J9 AVIAN DIS
JI Avian Dis.
PD SEP
PY 2010
VL 54
IS 3
BP 1050
EP 1057
DI 10.1637/9380-041910-Reg.1
PG 8
WC Veterinary Sciences
SC Veterinary Sciences
GA 658XS
UT WOS:000282528600012
PM 20945787
ER
PT J
AU Grave, GD
Huang, TTK
Maddox, YT
AF Grave, Gilman D.
Huang, Terry T-K.
Maddox, Yvonne T.
TI Working Together to Reduce Pediatric Obesity
SO BARIATRIC NURSING AND SURGICAL PATIENT CARE
LA English
DT Editorial Material
ID CHILDHOOD OBESITY; UNITED-STATES; FATTY LIVER; ADOLESCENTS; CHILDREN;
EPIDEMIC
C1 [Grave, Gilman D.; Maddox, Yvonne T.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
[Huang, Terry T-K.] Univ Nebraska Med Ctr, Omaha, NE USA.
RP Grave, GD (reprint author), NICHD, Ctr Res Mothers & Children, 6100 Execut Blvd,Room 4B-05, Bethesda, MD 20892 USA.
EM gg37v@nih.gov
NR 18
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1557-1459
J9 BARIAT NURS SURG PAT
JI Bariatr. Nurs. Surg. Patient Care
PD SEP
PY 2010
VL 5
IS 3
BP 197
EP 202
DI 10.1089/bar.2010.9902
PG 6
WC Nursing
SC Nursing
GA 646BT
UT WOS:000281510600002
ER
PT J
AU Klaiber, M
Kruse, M
Volker, K
Schroter, J
Feil, R
Freichel, M
Gerling, A
Feil, S
Dietrich, A
Londono, JEC
Baba, HA
Abramowitz, J
Birnbaumer, L
Penninger, JM
Pongs, O
Kuhn, M
AF Klaiber, Michael
Kruse, Martin
Voelker, Katharina
Schroeter, Juliane
Feil, Robert
Freichel, Marc
Gerling, Andrea
Feil, Susanne
Dietrich, Alexander
Londono, Juan Eduardo Camacho
Baba, Hideo A.
Abramowitz, Joel
Birnbaumer, Lutz
Penninger, Josef M.
Pongs, Olaf
Kuhn, Michaela
TI Novel insights into the mechanisms mediating the local antihypertrophic
effects of cardiac atrial natriuretic peptide: role of cGMP-dependent
protein kinase and RGS2
SO BASIC RESEARCH IN CARDIOLOGY
LA English
DT Article
DE ANP; Angiotensin II; cGMP-dependent protein kinase; RGS2; Cardiac
hypertrophy
ID GUANYLYL CYCLASE-A; DEFICIENT MICE; BLOOD-PRESSURE; TRPC3 CHANNELS;
HYPERTROPHY; RECEPTOR; HEART; HYPERTENSION; MYOCYTES; SYSTEM
AB Cardiac atrial natriuretic peptide (ANP) locally counteracts cardiac hypertrophy via the guanylyl cyclase-A (GC-A) receptor and cGMP production, but the downstream signalling pathways are unknown. Here, we examined the influence of ANP on beta-adrenergic versus Angiotensin II (Ang II)-dependent (G(s) vs. G(alpha q) mediated) modulation of Ca(2+) (i)-handling in cardiomyocytes and of hypertrophy in intact hearts. L-type Ca(2+) currents and Ca(2+) (i) transients in adult isolated murine ventricular myocytes were studied by voltage-clamp recordings and fluorescence microscopy. ANP suppressed Ang II-stimulated Ca(2+) currents and transients, but had no effect on isoproterenol stimulation. Ang II suppression by ANP was abolished in cardiomyocytes of mice deficient in GC-A, in cyclic GMP-dependent protein kinase I (PKG I) or in the regulator of G protein signalling (RGS) 2, a target of PKG I. Cardiac hypertrophy in response to exogenous Ang II was significantly exacerbated in mice with conditional, cardiomyocyte-restricted GC-A deletion (CM GC-A KO). This was concomitant to increased activation of the Ca(2+)/calmodulin-dependent prohypertrophic signal transducer CaMKII. In contrast, beta-adrenoreceptor-induced hypertrophy was not enhanced in CM GC-A KO mice. Lastly, while the stimulatory effects of Ang II on Ca(2+)-handling were absent in myocytes of mice deficient in TRPC3/TRPC6, the effects of isoproterenol were unchanged. Our data demonstrate a direct myocardial role for ANP/GC-A/cGMP to antagonize the Ca(2+) (i)-dependent hypertrophic growth response to Ang II, but not to beta-adrenergic stimulation. The selectivity of this interaction is determined by PKG I and RGS2-dependent modulation of Ang II/AT(1) signalling. Furthermore, they strengthen published observations in neonatal cardiomyocytes showing that TRPC3/TRPC6 channels are essential for Ang II, but not for beta-adrenergic Ca(2+) (i)-stimulation in adult myocytes.
C1 [Klaiber, Michael; Voelker, Katharina; Schroeter, Juliane; Kuhn, Michaela] Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany.
[Kruse, Martin; Pongs, Olaf] Univ Hamburg, Inst Neurale Signalverarbeitung, Zentrum Mol Neurobiol, Hamburg, Germany.
[Feil, Robert; Gerling, Andrea; Feil, Susanne] Univ Tubingen, Interfak Inst Biochem, Tubingen, Germany.
[Freichel, Marc; Londono, Juan Eduardo Camacho] Univ Saarland, Homburg, Germany.
[Dietrich, Alexander] Univ Marburg, Inst Pharmakol & Toxikol, D-3550 Marburg, Germany.
[Baba, Hideo A.] Univ Duisburg Essen, Univ Hosp Essen, Inst Pathol, Essen, Germany.
[Abramowitz, Joel; Birnbaumer, Lutz] Natl Inst Environm Hlth Sci, Neurobiol Lab, NIH, Res Triangle Pk, NC USA.
[Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1010 Vienna, Austria.
RP Kuhn, M (reprint author), Univ Wurzburg, Inst Physiol, Rontgenring 9, D-97070 Wurzburg, Germany.
EM michaela.kuhn@mail.uni-wuerzburg.de
RI Dietrich, Alexander/G-8619-2013; Penninger, Josef/I-6860-2013; Feil,
Robert/B-8918-2014; Abramowitz, Joel/A-2620-2015;
OI Penninger, Josef/0000-0002-8194-3777; Feil, Robert/0000-0002-7335-4841;
Dietrich, Alexander/0000-0002-1168-8707
FU Deutsche Forschungsgemeinschaft [SFB 487]; NIH [Z01-ES101684]
FX This study was supported by the Deutsche Forschungsgemeinschaft (SFB 487
to Michaela Kuhn). HEK293 cells stably expressing rat GC-A were
generously provided by Dr. RueyBing Yang, Academia Sinica, Taipei,
Taiwan. The plasmids for expression of human RGS2 and PKG I alpha were
kindly provided by Dr. Thomas Wieland (Institute of Pharmacology,
University of Mannheim-Heidelberg, Germany) and Dr. Stepan Gambaryan
(Department of Clinical Biochemistry, University of Wurzburg, Germany),
respectively.; Michael Klaiber performed and evaluated the fluorometric
calcium measurements, western blotting, and heart morphometry. Martin
Kruse performed and evaluated the electrophysiological calcium
measurements. Katharina Volker performed the isolation of myocytes and
in vivo studies. Juliane Schroter provided some technical help with the
western blot analyses. Drs. Robert, Susanne Feil and Gerling generated
and provided the PKG I deficient ("rescue") mice and anti-PKG I
antibody. Drs. Freichel, Dietrich, Camacho Londono, Joel Abramowitz, and
Lutz Birnbaumer generated or provided the TRPC3/C6 knockout mice. The
generation of these mice was supported by the Intramural Research
Program of the NIH (Z01-ES101684 to JA and LB). Dr. Baba prepared the
cardiac tissues for histology. Dr. Penninger provided RGS2 knockout
mice. Michaela Kuhn conceived of and directed the study, analyzed the
data, and wrote the manuscript, having helpful discussions with Dr.
Pongs.
NR 51
TC 40
Z9 40
U1 1
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8428
J9 BASIC RES CARDIOL
JI Basic Res. Cardiol.
PD SEP
PY 2010
VL 105
IS 5
BP 583
EP 595
DI 10.1007/s00395-010-0098-z
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 635HZ
UT WOS:000280647500003
PM 20352235
ER
PT J
AU Lipska, BK
AF Lipska, Barbara K.
TI ANTIPSYCHOTICS AND ADULT NEUROGENESIS
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Meeting Abstract
CT Meeting on Drugs, Psychiatric Disorders and Neurogenesis
CY SEP 03-05, 2010
CL Tours, FRANCE
C1 [Lipska, Barbara K.] NIMH, NIH, CBDB, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0955-8810
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD SEP
PY 2010
VL 21
IS 5-6
BP 582
EP 582
PG 1
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 641IS
UT WOS:000281119000033
ER
PT J
AU Turanov, AA
Kehr, S
Marino, SM
Yoo, MH
Carlson, BA
Hatfield, DL
Gladyshev, VN
AF Turanov, Anton A.
Kehr, Sebastian
Marino, Stefano M.
Yoo, Min-Hyuk
Carlson, Bradley A.
Hatfield, Dolph L.
Gladyshev, Vadim N.
TI Mammalian thioredoxin reductase 1: roles in redox homoeostasis and
characterization of cellular targets
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE cellular target; redox control; thioredoxin; thioredoxin reductase 1
ID EARLY EMBRYONIC LETHALITY; MITOCHONDRIAL THIOREDOXIN; SELENOCYSTEINE;
LIVER; GENE; SELENOPROTEINS; APOPTOSIS; SYSTEM
AB The classical Trx (thioredoxin) system, composed of TR (Trx reductase), Trx and NADPH, defines a major pathway of cellular thiol-based redox regulation. Three TRs have been identified in mammals: (i) cytosolic TR1, (ii) mitochondrial TR3 and (iii) testes-specific TGR (Trx-glutathione reductase). All three are selenocysteine-containing enzymes with broad substrate specificity in in vitro assays, but which protein substrates are targeted by TRs in vivo is not well understood. In the present study, we used a mechanism-based approach to characterize the molecular targets of TR1 Cytosolic Trx1 was the major target identified in rat and mouse liver, as well as in rat brain and mouse serum. The results suggest that the main function of TR1 is to reduce Trx1. We also found that TR1-based affinity resins provide a convenient tool for specific isolation of Trxs from a variety of biological samples. To better assess the role of TRs in redox homoeostasis, we comparatively analysed TR1- and TR3-knockdown cells. Although cells deficient in TR1were particularly sensitive to diamide, TR3-knockdown cells were more sensitive to hydrogen peroxide. To further examine the TR1-Trx1 redox pair, we used mice with a liver-specific knockout of selenocysteine tRNA. In this model, selenocysteine insertion into TR1 was blocked, but the truncated form of this protein was not detected. Instead, TR I and TR3 levels were decreased in the knockout samples. Diminished hepatic TR I function was associated with elevated Trx1 levels, but this protein was mostly in the oxidized state. Overall, this study provides evidence for the key role of the TR1-Trx1 pair in redox homoeostasis.
C1 [Turanov, Anton A.; Kehr, Sebastian; Marino, Stefano M.; Gladyshev, Vadim N.] Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.
[Turanov, Anton A.; Kehr, Sebastian; Marino, Stefano M.; Gladyshev, Vadim N.] Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA.
[Turanov, Anton A.; Marino, Stefano M.; Gladyshev, Vadim N.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA.
[Turanov, Anton A.; Marino, Stefano M.; Gladyshev, Vadim N.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Yoo, Min-Hyuk; Carlson, Bradley A.; Hatfield, Dolph L.] NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
RP Gladyshev, VN (reprint author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.
EM vgladyshev@rics.bwh.harvard.edu
RI Gladyshev, Vadim/A-9894-2013
FU National Institutes of Health [GM065204]; Center for Cancer Research,
NCI, NIH
FX This work was supported by the National Institutes of Health [grant
number GM065204 (to V.N.G.)] and the Intramural Program of the Center
for Cancer Research, NCI, NIH (to D.L.H.).
NR 23
TC 34
Z9 37
U1 0
U2 5
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD SEP 1
PY 2010
VL 430
BP 285
EP 293
DI 10.1042/BJ20091378
PN 2
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 645TX
UT WOS:000281490200012
PM 20536427
ER
PT J
AU Kolli, N
Mikolajczyk, J
Drag, M
Mukhopadhyay, D
Moffatt, N
Dasso, M
Salvesen, G
Wilkinson, KD
AF Kolli, Nagamalleswari
Mikolajczyk, Jowita
Drag, Marcin
Mukhopadhyay, Debaditya
Moffatt, Nela
Dasso, Mary
Salvesen, Guy
Wilkinson, Keith D.
TI Distribution and paralogue specificity of mammalian deSUMOylating
enzymes
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE deSUMOylating enzyme; small ubiquitin-related modifier (SUMO); substrate
specificity; SUMO-specific processing protease (SENP)
ID SUMO-SPECIFIC PROTEASE; UBIQUITIN-LIKE PROTEINS; OXIDATIVE STRESS;
STRUCTURAL BASIS; NUCLEAR-PORE; C-TERMINUS; HEAT-SHOCK; SENP1;
NUCLEOLAR; COMPLEX
AB The covalent attachment of SUMO (small ubiquitin-like protein modifier) to target proteins results in modifications in their activity, binding interactions, localization or half-life. The reversal of this modification is catalysed by SENPs (SUMO-specific processing proteases). Mammals contain four SUMO paralogues and six SENP enzymes. In the present paper, we describe a systematic analysis of human SENPs, integrating estimates of relative selectivity for SUMO 1 and SUMO2, and kinetic measurements of recombinant C-terminal cSENPs (SENP catalytic domains). We first characterized the reaction of each endogenous SENP and cSENPs with HA SUMO-VS [HA (haemagglutinin)-tagged SUMO-vinyl sulfones], active-site-directed irreversible inhibitors of SENPs. We found that all cSENPs and endogenous SENP I react with both SUMO paralogues, whereas all other endogeneous SENPs in mammalian cells and tissues display high selectivity for SUMO2-VS. To obtain more quantitative data, the kinetic properties of purified cSENPs were determined using SUMO1- or SUMO2-AMC (7-amino-4-methylcoumarin) as substrate. All enzymes bind their respective substrates with high affinity. cSENP1 and cSENP2 process either SUMO substrate with similar affinity and catalytic efficiency; cSENP5 and cSENP6 show marked catalytic specificity for SUMO2 as measured by K(m) and k(cat) whereas cSENP7 works only on SUMO2. Compared with cSENPs, recombinant full-length SENP1 and SENP2 show differences in SUMO selectivity, indicating that paralogue specificity is influenced by the presence of the variable N-terminal domain of each SENP. Our data suggest that SUMO2 metabolism is more dynamic than that of SUMO1 since most SENPs display a marked preference for SUMO2.
C1 [Kolli, Nagamalleswari; Moffatt, Nela; Wilkinson, Keith D.] Emory Univ, Dept Biochem, Atlanta, GA 30322 USA.
[Mikolajczyk, Jowita; Drag, Marcin; Salvesen, Guy] Burnham Inst Med Res, La Jolla, CA 92037 USA.
[Mukhopadhyay, Debaditya; Dasso, Mary] NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.
RP Wilkinson, KD (reprint author), Emory Univ, Dept Biochem, Atlanta, GA 30322 USA.
EM keith.wilkinson@emory.edu
OI Dasso, Mary/0000-0002-5410-1371
FU National Institutes of Health [5RO1GM066355]
FX This work was supported by the National Institutes of Health [grant
number 5RO1GM066355].
NR 58
TC 49
Z9 49
U1 1
U2 2
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD SEP 1
PY 2010
VL 430
BP 335
EP 344
DI 10.1042/BJ20100504
PN 2
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 645TX
UT WOS:000281490200017
PM 20590526
ER
PT J
AU Camilli, TC
Weeraratna, AT
AF Camilli, Tura C.
Weeraratna, Ashani T.
TI Striking the target in Wnt-y conditions: Intervening in Wnt signaling
during cancer progression
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE Wnt; Wnt5A; Calcium; PCP; beta-Catenin; Cancer
ID PROTEIN-KINASE-C; GLYCOGEN-SYNTHASE KINASE-3-BETA; RECEPTOR TYROSINE
KINASE; HUMAN COLORECTAL-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS;
CONVERGENT EXTENSION MOVEMENTS; ACUTE LYMPHOBLASTIC-LEUKEMIA;
BETA-CATENIN MUTATIONS; PLANAR CELL POLARITY; CHRONIC MYELOID-LEUKEMIA
AB Wnt signaling can be divided into three pathways, namely the canonical Wnt/beta-catenin pathway, and the non-canonical (or heretical) Wnt/Ca(2+) and planar cell polarity (PCP) pathways. Although the canonical Wnt/beta-catenin pathway is the best described in cancer, increasing data points to the importance of the heretical Wnt pathways in several aspects of tumor progression. The recent advances in understanding the players and mechanisms by which these Wnt pathways contribute to cancer progression have led to the identification of numerous molecules that are already, or could be considered, targets for cancer therapy. Published by Elsevier Inc.
C1 [Weeraratna, Ashani T.] NIA, Immunol Lab, NIH, Baltimore, MD 21224 USA.
NIA, Res Resources Branch, NIH, Baltimore, MD 21224 USA.
RP Weeraratna, AT (reprint author), NIA, Immunol Lab, NIH, 251 Bayview Blvd,Suite 100,Rm08C226, Baltimore, MD 21224 USA.
EM weerarat@mail.nih.gov
FU National Institute on Aging
FX TCC and ATVV are supported by the Intramural Research Program of the
National Institute on Aging. We regret that we were unable to cite all
of the work of many great scientists in the Wnt signaling field due to
space constraints.
NR 218
TC 28
Z9 30
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD SEP 1
PY 2010
VL 80
IS 5
SI SI
BP 702
EP 711
DI 10.1016/j.bcp.2010.03.002
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 627FL
UT WOS:000280024800018
PM 20211149
ER
PT J
AU Lisk, G
Pain, M
Sellers, M
Gurnev, PA
Pillai, AD
Bezrukov, SM
Desai, SA
AF Lisk, Godfrey
Pain, Margaret
Sellers, Morgan
Gurnev, Philip A.
Pillai, Ajay D.
Bezrukov, Sergey M.
Desai, Sanjay A.
TI Altered plasmodial surface anion channel activity and in vitro
resistance to permeating antimalarial compounds
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Article
DE Ion channel mutants; Gating; Selectivity; Noise analysis; Plasmodium
falciparum; PSAC
ID FALCIPARUM-INFECTED ERYTHROCYTES; RED-BLOOD-CELLS; MALARIA PARASITE;
BLASTICIDIN-S; PROTEIN-SYNTHESIS; MAMMALIAN-CELLS; TRANSPORT;
INHIBITORS; PERMEABILITY; METABOLITES
AB Erythrocytes infected with malaria parasites have increased permeability to various solutes. These changes may be mediated by an unusual small conductance ion channel known as the plasmodial surface anion channel (PSAC). While channel activity benefits the parasite by permitting nutrient acquisition, it can also be detrimental because water-soluble antimalarials may more readily access their parasite targets via this channel. Recently, two such toxins, blasticidin S and leupeptin, were used to select mutant parasites with altered PSAC activities, suggesting acquired resistance via reduced channel-mediated toxin uptake. Surprisingly, although these toxins have similar structures and charge, we now show that reduced permeability of one does not protect the intracellular parasite from the other. Leupeptin accumulation in the blasticidin S-resistant mutant was relatively preserved, consistent with retained in vitro susceptibility to leupeptin. Subsequent in vitro selection with both toxins generated a double mutant parasite having additional changes in PSAC, implicating an antimalarial resistance mechanism for water-soluble drugs requiring channel-mediated uptake at the erythrocyte membrane. Characterization of these mutants revealed a single conserved channel on each mutant, albeit with distinct gating properties. These findings are consistent with a shared channel that mediates uptake of ions, nutrients and toxins. This channel's gating and selectivity properties can be modified in response to in vitro selective pressure. Published by Elsevier B.V.
C1 [Lisk, Godfrey; Pain, Margaret; Sellers, Morgan; Pillai, Ajay D.; Desai, Sanjay A.] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
[Gurnev, Philip A.; Bezrukov, Sergey M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Lab Phys & Struct Biol, Program Phys Biol, NIH, Rockville, MD 20852 USA.
RP Desai, SA (reprint author), NIAID, Lab Malaria & Vector Res, NIH, Room 3W-01,12735 Twinbrook Pkwy, Rockville, MD 20852 USA.
EM sdesai@niaid.nih.gov
FU National Institutes of Health; NIAID; NICHD; Medicines for Malaria
Venture (MMV)
FX We thank Ian Bathurst, the Medicines for Malaria Venture Project
Director for these studies, and Michael Fay for help with statistical
analysis. This research was funded by the Intramural Research Programs
of the National Institutes of Health, NIAID and NICHD, and by the
Medicines for Malaria Venture (MMV).
NR 55
TC 10
Z9 10
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD SEP
PY 2010
VL 1798
IS 9
BP 1679
EP 1688
DI 10.1016/j.bbamem.2010.04.013
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 636PY
UT WOS:000280752100005
PM 20451492
ER
PT J
AU Kumar, A
Shukla, S
Mandal, A
Shukla, S
Ambudkar, SV
Prasad, R
AF Kumar, Antresh
Shukla, Suneet
Mandal, Ajeet
Shukla, Sudhanshu
Ambudkar, Suresh V.
Prasad, Rajendra
TI Divergent signature motifs of nucleotide binding domains of ABC
multidrug transporter, CaCdr1p of pathogenic Candida albicans, are
functionally asymmetric and noninterchangeable
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Article
DE ABC transporter; Nucleotide binding domain; Signature motif; Drug
resistance; Drug transport; ATPase activity
ID TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR CHLORIDE CHANNELS;
ATP-BINDING; DRUG TRANSPORTER; P-GLYCOPROTEIN; SACCHAROMYCES-CEREVISIAE;
WALKER-B; RESISTANCE; CDR1P; HYDROLYSIS
AB Nucleotide binding domains (NBDs) of the multidrug transporter of Candida albicans, CaCdr1p, possess unique divergent amino acids in their conserved motifs. For example, NBD1 (N-terminal-NBD) possesses conserved signature motifs, while the same motif is divergent in NBD2 (C-terminal-NBD). In this study, we have evaluated the contribution of these conserved and divergent signature motifs of CaCdr1p in ATP catalysis and drug transport. By employing site-directed mutagenesis, we made three categories of mutant variants. These included mutants where all the signature motif residues were replaced with either alanines or mutants with exchanged equipositional residues to mimic the conservancy and degeneracy in opposite domain. In addition, a set of mutants where signature motifs were swapped to have variants with either both the conserved or degenerated entire signature motif. We observed that conserved and equipositional residues of NBD1 and NBD2 and swapped signature motif mutants showed high susceptibility to all the tested drugs with simultaneous abrogation in ATPase and R6G efflux activities. However, some of the mutants displayed a selective increase in susceptibility to the drugs. Notably, none of the mutant variants and WT-CaCdr1p showed any difference in drug and nucleotide binding. Our mutational analyses show not only that certain conserved residues of NBD1 signature sequence (S304, G306, and E307) are important in ATP hydrolysis and R6G efflux but also that a few divergent residues (N1002 and E1004) of NBD2 signature motif have evolved to be functionally relevant and are not interchangeable. Taken together, our data suggest that the signature motifs of CaCdr1p, whether it is divergent or conserved, are nonexchangeable and are functionally critical for ATP hydrolysis. (C) 2010 Elsevier By. All rights reserved.
C1 [Kumar, Antresh; Mandal, Ajeet; Prasad, Rajendra] Jawaharlal Nehru Univ, Sch Life Sci, Membrane Biol Lab, New Delhi 110067, India.
[Shukla, Suneet; Ambudkar, Suresh V.] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Shukla, Sudhanshu] NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA.
RP Prasad, R (reprint author), Jawaharlal Nehru Univ, Sch Life Sci, Membrane Biol Lab, New Delhi 110067, India.
EM rp47jnu@gmail.com
RI shukla, suneet/B-4626-2012;
OI Shukla, Sudhanshu/0000-0002-7091-7215
FU University Grants Commission, India; Department of Biotechnology
[BT/PR9100/Med/29/03/2007, BT/PR9563/BRB/10/567/2007,
BT/PR11158/BRB/10/640/2008]; National Institutes of Health, National
Cancer Institute, Centre for Cancer Research
FX We thank R.D. Cannon for the gifts of the plasmid. We thank Ranbaxy
Laboratories Ltd., New Delhi, India, for providing fluconazole. AK
acknowledges the University Grants Commission, India for the support in
the form of Senior Research Fellowship.; The work presented in this
paper has been supported in part by grants to R.P. from the Department
of Biotechnology (BT/PR9100/Med/29/03/2007, BT/PR9563/BRB/10/567/2007,
and BT/PR11158/BRB/10/640/2008). SS and SVA were supported by the
intramural research program from the National Institutes of Health,
National Cancer Institute, Centre for Cancer Research.
NR 55
TC 7
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD SEP
PY 2010
VL 1798
IS 9
BP 1757
EP 1766
DI 10.1016/j.bbamem.2010.05.017
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 636PY
UT WOS:000280752100014
PM 20546701
ER
PT J
AU Galan, C
Woodard, GE
Dionisio, N
Salido, GM
Rosado, JA
AF Galan, Carmen
Woodard, Geoffrey E.
Dionisio, Natalia
Salido, Gines M.
Rosado, Juan A.
TI Lipid rafts modulate the activation but not the maintenance of
store-operated Ca2+ entry
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE Orai1; TRPC1; TRPC6; STIM1; Lipid rafts; Lanthanum
ID INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; HUMAN PLATELETS; CALCIUM-ENTRY;
ACTIN CYTOSKELETON; CHANNEL FUNCTION; PLASMA-MEMBRANE; TRPC CHANNELS;
CRAC CHANNEL; KEY ROLE; STIM1
AB Different studies have reported that proteins involved in Ca2+ entry are localized in discrete plasma membrane domains known as lipid rafts, which have been suggested to support store-operated Ca2+ entry by facilitating STIM1 clustering in endoplasmic reticulum-plasma membrane junctions as well as the interaction of STIM1 with TRPC1. Here we report that treatment of HEK293 cells with thapsigargin (TG) results in the activation of Ca2+ entry with two components, an early, La3+-sensitive, component and a late component that shows both La3+-sensitive and -insensitive constituents. Preincubation with methyl-beta-cyclodextrin (M beta CD) prevented TG-induced activation of Ca2+ entry but, in contrast, enhanced this process after its activation. Addition of M beta CD after store depletion did not modify the La3+-sensitive store-operated divalent cation entry but increased La3+-insensitive non-capacitative Ca2+ entry. Cell stimulation with TG results in a transient increase in Orai1 co-immunoprecipitation with STIM1, TRPC1 and TRPC6. TG-induced association of these proteins was significantly attenuated by preincubation for 30 min with m beta CD, without altering surface expression of Orai1 or TRPCs. In contrast, the association of Orai1 with STIM1 or TRPC1 was unaffected when M beta CD was added after store depletion with TG. Addition of M beta CD to TG-treated cells promoted dissociation between Orai1 and TRPC6, as well as non-capacitative Ca2+ entry. TRPC6 expression silencing indicates that M beta CD-enhanced non-capacitative Ca2+ entry was mediated by TRPC6. In conclusion, lipid raft domains are necessary for the activation but not the maintenance of SOCE probably due to the support of the formation of Ca2+ signalling complexes involving Orai1. TRPCs and STIM1. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Galan, Carmen; Dionisio, Natalia; Salido, Gines M.; Rosado, Juan A.] Univ Extremadura, Dept Physiol, Cell Physiol Res Grp, Caceres 10071, Spain.
[Woodard, Geoffrey E.] NIDDK, NIH, Bethesda, MD 20892 USA.
RP Rosado, JA (reprint author), Univ Extremadura, Dept Physiol, Cell Physiol Res Grp, Caceres 10071, Spain.
EM jarosado@unex.es
RI Woodard, Geoffrey/A-8608-2009; Salido, Gines/A-4292-2009; rosado,
juan/H-3488-2015
OI Salido, Gines/0000-0002-8687-2445; rosado, juan/0000-0002-9749-2325
FU MEC [BFU2007-60104]; Junta de Extremadura-FEDER [GRU090]; Spanish
Ministry of Science and Innovation [PTA2008-0870-P]; Junta de
Extremadura [PRE09020]
FX Supported by MEC grant BFU2007-60104. G.E.W. hold a visit grant from
Junta de Extremadura-FEDER (GRU090). C.G. and N.D. are supported by
Spanish Ministry of Science and Innovation (PTA2008-0870-P) and Junta de
Extremadura (PRE09020), respectively. We are grateful to Dr. Indu
Ambudkar for generously providing plasmids.
NR 54
TC 24
Z9 27
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD SEP
PY 2010
VL 1803
IS 9
BP 1083
EP 1093
DI 10.1016/j.bbamcr.2010.06.006
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 638VM
UT WOS:000280925600012
PM 20600358
ER
PT J
AU Petrucci, R
Saso, L
Kumar, V
Prasad, AK
Malhotra, SV
Parmar, VS
Marrosu, G
AF Petrucci, Rita
Saso, Luciano
Kumar, Vineet
Prasad, Ashok K.
Malhotra, Sanjay V.
Parmar, Virinder S.
Marrosu, Giancarlo
TI A spectroelectrochemical and chemical study on oxidation of
7,8-dihydroxy-4-methylcoumarin (DHMC) and some related compounds in
aprotic medium
SO BIOCHIMIE
LA English
DT Article
DE Antioxidants; Polyphenols oxidation; Radical anions; Semiquinones;
Spectroelectrochemistry
ID LOW-DENSITY-LIPOPROTEIN; NITROGEN-CENTERED RADICALS; SUBSTITUTED
4-METHYLBENZOPYRAN-2-ONES; ANTIOXIDANT ACTIVITY; LIPID-PEROXIDATION;
BIOCHEMICAL-ACTION; IN-VITRO; HYDROXYCINNAMIC ACIDS; PROTEIN
FRAGMENTATION; PHENOLIC-COMPOUNDS
AB Electrochemical and chemical oxidation of 7,8-hydroxy-4-methylcoumarin (DHMC 1) and 7,8-diacetoxy-4-methylcoumarin (DAMC 4) were studied to investigate the mechanisms occurring in their antioxidant activities in acetonitrile, under electron transfer and H-atom transfer conditions. Electrolysis and chemical reactions were followed on-line by monitoring the UV spectral changes with time.
The anodic oxidation of DHMC, studied by cyclic voltammetry and controlled potential electrolysis, occurs via a reversible one-step two-electrons process, yielding the corresponding stable phenoxonium cation. Moreover, the chemical oxidation with an H-atom acceptor also follows a similar path, yielding the stable neutral quinonic product. Intermediates were never evidenced in both cases. Only in the presence of a strong base, an anodic oxidation product mono-electronic was evidenced, likely the DHMC radical anion.
However, the anodic oxidation of the acetoxy derivative DAMC occurs at very high potential values, ruling out the possibility that the antioxidant activity observed in vivo might occur via an electron transfer mechanism; no reactions were evidenced with an H-atom acceptor. (C) 2010 Elsevier Masson SAS. All rights reserved.
C1 [Petrucci, Rita; Marrosu, Giancarlo] Univ Roma La Sapienza, Dipartimento Ingn Chim Mat Ambiente, I-00161 Rome, Italy.
[Saso, Luciano] Univ Roma La Sapienza, Dipartimento Fisiol & Farmacol Vittorio Erspamer, I-00185 Rome, Italy.
[Kumar, Vineet; Prasad, Ashok K.; Parmar, Virinder S.] Univ Delhi, Dept Chem, Bioorgan Lab, Delhi 110007, India.
[Kumar, Vineet; Malhotra, Sanjay V.] Natl Canc Inst Frederick, Lab Synthet Chem, Dev Therapeut Program Support, SAIC Frederick, Frederick, MD 21702 USA.
RP Petrucci, R (reprint author), Univ Roma La Sapienza, Dipartimento Ingn Chim Mat Ambiente, Via Castro Laurenziano 7, I-00161 Rome, Italy.
EM rita.petrucci@uniroma1.it
RI saso, luciano/F-6306-2012;
OI saso, luciano/0000-0003-4530-8706; MARROSU,
Giancarlo/0000-0002-0462-3809
FU Ministero dell'Universita e dellaRicerca Scientifica e Tecnologica
(MURST)
FX We thank the Ministero dell'Universita e dellaRicerca Scientifica e
Tecnologica (MURST) for financial support.
NR 52
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0300-9084
J9 BIOCHIMIE
JI Biochimie
PD SEP
PY 2010
VL 92
IS 9
BP 1123
EP 1129
DI 10.1016/j.biochi.2010.06.008
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 652GM
UT WOS:000281991400006
PM 20600572
ER
PT J
AU Kumar, V
Parmar, VS
Malhotra, SV
AF Kumar, Vineet
Parmar, Virinder S.
Malhotra, Sanjay V.
TI Structural modifications of nucleosides in ionic liquids
SO BIOCHIMIE
LA English
DT Review
DE Nucleosides; Ionic liquids; Solubility; Anti-viral drugs
ID PYRIMIDINE NUCLEOSIDES; EFFICIENT METHOD; ANTIVIRAL DRUGS; SELECTIVE
BENZOYLATION; ENZYMATIC RESOLUTION; BETA-ELIMINATION; CATALYSIS;
ANALOGS; OLIGONUCLEOTIDES; CHEMISTRY
AB Nucleoside chemistry represents an important research area for drug discovery, as many nucleoside analogs are prominent drugs and have been widely applied for cancer and viral chemotherapy. However, the synthesis of modified nucleosides presents a major challenge, which is further aggravated by poor solubility of these compounds in common organic solvents. Most of the currently available methods for nucleoside modification employ toxic high boiling solvents; require long reaction time and tedious workup methods. As such, there is constant effort to develop process chemistry in alternative medium to limit the use of organic solvents that are hazardous to the environment and can be deleterious to human health. One such approach is to use ionic liquids, which are 'designer materials' with unique and tunable physico-chemical properties. Studies have shown that methodologies using ionic liquids are highly efficient and convenient for the synthesis of nucleoside analogs, as demonstrated by the preparation of pharmaceutically important anti-viral drugs. This article summarizes recent efforts on nucleoside modification using ionic liquids. (C) 2010 Elsevier Masson SAS. All rights reserved.
C1 [Kumar, Vineet; Malhotra, Sanjay V.] NCI, Lab Synthet Chem, SAIC Frederick Inc, Frederick, MD 21702 USA.
[Parmar, Virinder S.] Univ Delhi, Dept Chem, Delhi 110007, India.
RP Malhotra, SV (reprint author), NCI, Lab Synthet Chem, SAIC Frederick Inc, 1050 Boyles St, Frederick, MD 21702 USA.
EM malhotrasa@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX The authors acknowledge financial support from the National Cancer
Institute, National Institutes of Health, under Contract No.
HHSN261200800001E. The content of this publication does not necessarily
reflect the views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial products, or
organizations imply endorsement by the U.S. Government.
NR 48
TC 10
Z9 10
U1 0
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0300-9084
J9 BIOCHIMIE
JI Biochimie
PD SEP
PY 2010
VL 92
IS 9
BP 1260
EP 1265
DI 10.1016/j.biochi.2010.02.019
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 652GM
UT WOS:000281991400023
PM 20178825
ER
PT J
AU Volkow, ND
Wang, GJ
Fowler, JS
Tomasi, D
Telang, F
Baler, R
AF Volkow, Nora D.
Wang, Gene-Jack
Fowler, Joanna S.
Tomasi, Dardo
Telang, Frank
Baler, Ruben
TI Addiction: Decreased reward sensitivity and increased expectation
sensitivity conspire to overwhelm the brain's control circuit
SO BIOESSAYS
LA English
DT Review
DE addiction; brain disease; dopamine; reward circuit
ID STRIATAL DOPAMINE RELEASE; NUCLEUS-ACCUMBENS; COCAINE ABUSERS;
DRUG-ADDICTION; METHYLPHENIDATE; HUMANS; RECEPTORS; OCCUPANCY; SYSTEMS;
RATS
AB Based on brain imaging findings, we present a model according to which addiction emerges as an imbalance in the information processing and integration among various brain circuits and functions. The dysfunctions reflect (a) decreased sensitivity of reward circuits, (b) enhanced sensitivity of memory circuits to conditioned expectations to drugs and drug cues, stress reactivity, and (c) negative mood, and a weakened control circuit. Although initial experimentation with a drug of abuse is largely a voluntary behavior, continued drug use can eventually impair neuronal circuits in the brain that are involved in free will, turning drug use into an automatic compulsive behavior. The ability of addictive drugs to co-opt neurotransmitter signals between neurons (including dopamine, glutamate, and GABA) modifies the function of different neuronal circuits, which begin to falter at different stages of an addiction trajectory. Upon exposure to the drug, drug cues or stress this results in unrestrained hyperactivation of the motivation/drive circuit that results in the compulsive drug intake that characterizes addiction.
C1 [Volkow, Nora D.; Baler, Ruben] Natl Inst Drug Abuse, NIH, Bethesda, MD USA.
[Wang, Gene-Jack; Fowler, Joanna S.; Tomasi, Dardo; Telang, Frank] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA.
RP Volkow, ND (reprint author), Natl Inst Drug Abuse, NIH, Bethesda, MD USA.
EM nvolkow@nida.nih.gov
RI Tomasi, Dardo/J-2127-2015
FU Intramural NIH HHS [ZIA AA000550-06]
NR 54
TC 127
Z9 131
U1 3
U2 27
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0265-9247
J9 BIOESSAYS
JI Bioessays
PD SEP
PY 2010
VL 32
IS 9
BP 748
EP 755
DI 10.1002/bies.201000042
PG 8
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics
GA 647NK
UT WOS:000281625000005
PM 20730946
ER
PT J
AU Pruim, RJ
Welch, RP
Sanna, S
Teslovich, TM
Chines, PS
Gliedt, TP
Boehnke, M
Abecasis, GR
Willer, CJ
AF Pruim, Randall J.
Welch, Ryan P.
Sanna, Serena
Teslovich, Tanya M.
Chines, Peter S.
Gliedt, Terry P.
Boehnke, Michael
Abecasis, Goncalo R.
Willer, Cristen J.
TI LocusZoom: regional visualization of genome-wide association scan
results
SO BIOINFORMATICS
LA English
DT Article
ID COMMON VARIANTS; IDENTIFICATION; SNPS; TOOL
AB Genome-wide association studies (GWAS) have revealed hundreds of loci associated with common human genetic diseases and traits. We have developed a web-based plotting tool that provides fast visual display of GWAS results in a publication-ready format. LocusZoom visually displays regional information such as the strength and extent of the association signal relative to genomic position, local linkage disequilibrium (LD) and recombination patterns and the positions of genes in the region.
C1 [Welch, Ryan P.; Teslovich, Tanya M.; Gliedt, Terry P.; Boehnke, Michael; Abecasis, Goncalo R.; Willer, Cristen J.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
[Welch, Ryan P.; Teslovich, Tanya M.; Gliedt, Terry P.; Boehnke, Michael; Abecasis, Goncalo R.; Willer, Cristen J.] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Pruim, Randall J.] Calvin Coll, Dept Math & Stat, Grand Rapids, MI 49546 USA.
[Welch, Ryan P.] Univ Michigan, Sch Med, Bioinformat Grad Program, Ann Arbor, MI 48109 USA.
[Sanna, Serena] Cittadella Univ Monserrato, CNR, INN, I-09042 Cagliari, Italy.
[Chines, Peter S.] NHGRI, NIH, Bethesda, MD 20892 USA.
RP Willer, CJ (reprint author), Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
EM cristen@umich.edu
RI Abecasis, Goncalo/B-7840-2010;
OI Willer, Cristen/0000-0001-5645-4966; sanna, serena/0000-0002-3768-1749;
Abecasis, Goncalo/0000-0003-1509-1825
FU Calvin College; National Institue of Diabetes and Digestive and Kidney
Diseases [DK062370]; National Human Genome Research Institute [HG000376,
HG000040, HG002651, HG005214]; National Institute of Mental Health
[MH084698]; National Heart, Lung and Blood Institute [K99HL094535]
FX R.J.P. is supported by a Research Fellowship from Calvin College. M. B.
and T. M. T. are supported by grants from the National Institue of
Diabetes and Digestive and Kidney Diseases (DK062370, PI M. B.). M. B.,
T.N.T. and G. R. A. are supported by the National Human Genome Research
Institute (HG000376, PI M. B.; for T. M. T. HG000040, PI M. B.;
HG002651, PI G. R. A. and HG005214, PI G. R. A.). G. R. A. is
additionally funded by the National Institute of Mental Health
(MH084698). C.J.W. is funded by a Pathway to Independence Award from the
National Heart, Lung and Blood Institute (K99HL094535, PI C.J.W.).
NR 8
TC 667
Z9 673
U1 2
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
J9 BIOINFORMATICS
JI Bioinformatics
PD SEP
PY 2010
VL 26
IS 18
BP 2336
EP 2337
DI 10.1093/bioinformatics/btq419
PG 2
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Computer Science, Interdisciplinary Applications; Mathematical &
Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Computer Science; Mathematical & Computational Biology; Mathematics
GA 648SK
UT WOS:000281714100054
PM 20634204
ER
PT J
AU Thomason, ME
Henry, ML
Hamilton, JP
Joormann, J
Pine, DS
Ernst, M
Goldman, D
Mogg, K
Bradley, BP
Britton, JC
Lindstrom, KM
Monk, CS
Sankin, LS
Louro, HMC
Gotlib, IH
AF Thomason, Moriah E.
Henry, Melissa L.
Hamilton, J. Paul
Joormann, Jutta
Pine, Daniel S.
Ernst, Monique
Goldman, David
Mogg, Karin
Bradley, Brendan P.
Britton, Jennifer C.
Lindstrom, Kara M.
Monk, Christopher S.
Sankin, Lindsey S.
Louro, Hugo M. C.
Gotlib, Ian H.
TI Neural and behavioral responses to threatening emotion faces in children
as a function of the short allele of the serotonin transporter gene
SO BIOLOGICAL PSYCHOLOGY
LA English
DT Article
DE Attention; Emotion; Children; Serotonin; Gene; fMRI; 5-HTTLPR;
Adolescence
ID STRESSFUL LIFE EVENTS; PREFRONTAL CORTEX ACTIVATION; GENERALIZED ANXIETY
DISORDER; PROMOTER POLYMORPHISM; MAJOR DEPRESSION; ATTENTIONAL BIAS;
ANGRY FACES; 5-HTTLPR POLYMORPHISM; FACIAL EXPRESSIONS; TRAIT ANXIETY
AB Recent evidence suggests that a genetic polymorphism in the promoter region (5-HTTLPR) of the serotonin transporter gene (SLC6A4) mediates stress reactivity in adults. Little is known, however, about this gene-brain association in childhood and adolescence, generally conceptualized as a time of heightened stress reactivity. The present study examines the association between 5-HTTLPR allelic variation and responses to fearful and angry faces presented both sub- and supraliminally in participants, ages 9-17. Behaviorally, carriers of the 5-HTTLPR short (s) allele exhibited significantly greater attentional bias to subliminally presented fear faces than did their long (l)-allele homozygous counterparts. Moreover, s-allele carriers showed greater neural activations to fearful and angry faces than did l-allele homozygotes in various regions of association cortex previously linked to attention control in adults. These results indicate that in children and adolescents, s-allele carriers can be distinguished from l-allele homozygotes on the basis of hypervigilant behavioral and neural processing of negative material. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Thomason, Moriah E.; Henry, Melissa L.; Hamilton, J. Paul; Louro, Hugo M. C.; Gotlib, Ian H.] Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.
[Joormann, Jutta] Univ Miami, Dept Psychol, Miami, FL USA.
[Pine, Daniel S.; Ernst, Monique; Goldman, David; Britton, Jennifer C.; Lindstrom, Kara M.; Sankin, Lindsey S.] NIMH, Mood & Anxiety Disorders Program, NIH, Bethesda, MD USA.
[Mogg, Karin; Bradley, Brendan P.] Univ Southampton, Dept Psychol, Southampton SO9 5NH, Hants, England.
[Monk, Christopher S.] Univ Michigan, Dept Psychol, Ann Arbor, MI USA.
RP Thomason, ME (reprint author), Stanford Univ, Dept Psychol, Jordan Hall,Bldg 420, Stanford, CA 94305 USA.
EM moriah@stanford.edu
RI Mogg, Karin/C-1181-2008; Bradley, Brendan/B-9724-2008; Britton,
Jennifer/J-4501-2013; Monk, Christopher/J-1805-2014; Goldman,
David/F-9772-2010;
OI Mogg, Karin/0000-0002-2738-7378; Goldman, David/0000-0002-1724-5405;
Bradley, Brendan/0000-0003-2801-4271
FU National Institute of Mental Health [MH081583, MH074849]; NARSAD Young
Investigator Award
FX This project was supported by awards from the National Institute of
Mental Health [MH081583 to MET, and MH074849 to IHG], and by a NARSAD
Young Investigator Award to MET, and by funding from the NIMH-Intramural
Research Program. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health. The authors thank Melissa Henry, Sarah
Victor, Emily Dennis, Rebecca Johnson, Meggy Wang, and Hannah Kang for
their assistance in acquiring the scan data, and Yamanda Wright, Kirsten
Gilbert, and Lindsey Sherdell for their assistance in participant
recruitment, screening, and conducting structured behavioral interviews.
NR 57
TC 39
Z9 40
U1 7
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-0511
J9 BIOL PSYCHOL
JI Biol. Psychol.
PD SEP
PY 2010
VL 85
IS 1
BP 38
EP 44
DI 10.1016/j.biopsycho.2010.04.009
PG 7
WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology,
Experimental
SC Psychology; Behavioral Sciences
GA 642DB
UT WOS:000281182600005
PM 20493234
ER
PT J
AU Kroger, N
Bacher, U
Bader, P
Bottcher, S
Borowitz, MJ
Dreger, P
Khouri, I
Macapintac, H
Olavarria, E
Radich, J
Stock, W
Vose, JM
Weisdorf, D
Willasch, A
Giralt, S
Bishop, MR
Wayne, AS
AF Kroeger, Nicolaus
Bacher, Ulrike
Bader, Peter
Boettcher, Sebastian
Borowitz, Michael J.
Dreger, Peter
Khouri, Issa
Macapintac, Homer
Olavarria, Eduardo
Radich, Jerald
Stock, Wendy
Vose, Julie M.
Weisdorf, Daniel
Willasch, Andre
Giralt, Sergio
Bishop, Michael R.
Wayne, Alan S.
TI NCI First International Workshop on the Biology, Prevention, and
Treatment of Relapse after Allogeneic Hematopoietic Stem Cell
Transplantation: Report from the Committee on Disease-Specific Methods
and Strategies for Monitoring Relapse following Allogeneic Stem Cell
Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic
Syndromes
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Allogeneic stem cell transplantation; Minimal residual disease;
Chimerism; Acute leukemia; Myelodysplastic syndrome
ID MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE
MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION;
POLYMERASE-CHAIN-REACTION; WT1 GENE-EXPRESSION; TIME QUANTITATIVE PCR;
MULTIPARAMETER FLOW-CYTOMETRY; SINGLE-NUCLEOTIDE POLYMORPHISMS; CHRONIC
MYELOGENOUS LEUKEMIA
AB Relapse has become the major cause of treatment failure after allogeneic stem cell transplantation. Outcome of patients with clinical relapse after transplantation generally remains poor, but intervention prior to florid relapse improves outcome for certain hematologic malignancies. To detect early relapse or minimal residual disease, sensitive methods such as molecular genetics, tumor-specific molecular primers, fluorescein in situ hybridization, and multiparameter flow cytometry (MFC) are commonly used after allogeneic stem cell transplantation to monitor patients, but not all of them are included in the commonly employed disease-specific response criteria. The highest sensitivity and specificity can be achieved by molecular monitoring of tumor- or patient-specific markers measured by polymerase chain reaction-based techniques, but not all diseases have such targets for monitoring. Similar high sensitivity can be achieved by determination of donor chimerism, but its specificity regarding detection of relapse is low and differs substantially among diseases. Here, we summarize the current knowledge about the utilization of such sensitive monitoring techniques based on tumor-specific markers and donor cell chimerism and how these methods might augment the standard definitions of posttransplant remission, persistence, progression, relapse, and the prediction of relapse. Critically important is the need for standardization of the different residual disease techniques and to assess the clinical relevance of minimal residual disease and chimerism surveillance in individual diseases, which in turn, must be followed by studies to assess the potential impact of specific interventional strategies. Biol Blood Marrow Transplant 16: 1187-1211(2010) (C) 2010 American Society for Blood and Marrow Transplantation
C1 [Kroeger, Nicolaus] Univ Hamburg Hosp, Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, D-20246 Hamburg, Germany.
[Bader, Peter; Willasch, Andre] Univ Hosp Frankfurt, Dept Pediat Hematol Oncol, Frankfurt, Germany.
[Boettcher, Sebastian] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany.
[Borowitz, Michael J.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
[Dreger, Peter] Univ Heidelberg, Dept Med 5, D-6900 Heidelberg, Germany.
[Khouri, Issa; Giralt, Sergio] Univ Texas MD Anderson Canc Ctr, Div Hematol, Houston, TX 77030 USA.
[Macapintac, Homer] Univ Texas MD Anderson Canc Ctr, Div Nucl Med, Houston, TX 77030 USA.
[Olavarria, Eduardo] Hosp Navarra, Serv Hematol, Pamplona, Spain.
[Radich, Jerald] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Stock, Wendy] Univ Chicago, Chicago, IL 60637 USA.
[Vose, Julie M.] Univ Nebraska, Med Ctr, Omaha, NE USA.
[Weisdorf, Daniel] Univ Minnesota, Minneapolis, MN USA.
[Bishop, Michael R.] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Kroger, N (reprint author), Univ Hamburg Hosp, Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Martinstr 52, D-20246 Hamburg, Germany.
EM nkroeger@uke.de; waynea@mail.nih.gov
NR 250
TC 43
Z9 43
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD SEP
PY 2010
VL 16
IS 9
BP 1187
EP 1211
DI 10.1016/j.bbmt.2010.06.008
PG 25
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 643NS
UT WOS:000281304000001
PM 20558311
ER
PT J
AU Stringaris, K
Adams, S
Uribe, M
Eniafe, R
Wu, CO
Savani, BN
Barrett, AJ
AF Stringaris, Kate
Adams, Sharon
Uribe, Marcelo
Eniafe, Rhoda
Wu, Colin O.
Savani, Bipin N.
Barrett, A. John
TI Donor KIR Genes 2DL5A, 2DSI and 3DSI Are Associated with a Reduced Rate
of Leukemia Relapse After HLA-Identical Sibling Stem Cell
Transplantation for Acute Myeloid Leukemia but Not Other Hematologic
Malignancies
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE NK cells; Stem cell transplantation; Activatory KIR; Relapse; Acute
myelogenous leukemia
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; VERSUS-HOST-DISEASE;
BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; ABSOLUTE
LYMPHOCYTE COUNT; NATURAL-KILLER-CELLS; FREE SURVIVAL; NK CELLS;
RECOVERY; ALLOREACTIVITY
AB Stem cell transplantation (SCT) from a healthy donor can be curative for patients with hematologic malignancies resistant to other treatments. Elimination of malignant cells through a graft-versus-leukemia (GVL) effect involves donor T and natural killer (NK) cells, but their relative contribution to this process is poorly defined. NK cell alloreactivity and GVL effects are controlled by the nature of the interaction of NK activation receptors and killer-immunoglobulin-like-receptors (KIR) with major histocompatibility locus class I antigens on the target cell. We performed KIR-genotyping of HLA-identical sibling donors in 246 T cell-depleted SCTs to identify genetic factors affecting transplant outcome (treatment-related mortality [TRM], leukemic relapse, and survival). Univariate and multivariate analysis of transplant-related risk factors and KIR genotyping was performed to identify independent variables predictive of outcome for different forms of leukemia. Further to confirming known predictive factors for TRM and survival (CD34 cell dose, patient age, disease stage), statistical analysis revealed that 3 donor B haplotype KIR genes, 2DL5A, 2DSI, and 3DSI, were associated with significantly less relapse in patients with acute myelogenous leukemia (AML) (13% versus 57%) but not in patients with other myelogenous or lymphoid malignancies. AML patients receiving SCT from donors with these KIR genes relapsed 4 times less frequently than patients transplanted from donors with other KIR genotypes. These findings suggest specific, genetically determined, interactions between NK cells and AML cells that facilitate the GVL effect, and have implications for donor selection for AML patients. Biol Blood Marrow Transplant 16: 1257-1264 (2010) Published by Elsevier Inc.
C1 [Stringaris, Kate; Eniafe, Rhoda; Barrett, A. John] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
[Adams, Sharon; Uribe, Marcelo] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
[Wu, Colin O.] NHLBI, Off Biostat Res, Bethesda, MD 20892 USA.
[Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Hematol & Stem Cell Transplantat Sect, Div Hematol Oncol,Dept Med, Nashville, TN USA.
RP Barrett, AJ (reprint author), NHLBI, Hematol Branch, NIH, Bldg 10-CRC-3-5330, Bethesda, MD 20892 USA.
EM barrettjj@mail.nih.gov
FU Intramural NIH HHS [ZIA HL006105-02]
NR 22
TC 43
Z9 48
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD SEP
PY 2010
VL 16
IS 9
BP 1257
EP 1264
DI 10.1016/j.bbmt.2010.03.004
PG 8
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 643NS
UT WOS:000281304000007
PM 20302958
ER
PT J
AU Jeong, JW
Kwak, I
Lee, KY
Kim, TH
Large, MJ
Stewart, CL
Kaestner, KH
Lydon, JP
DeMayo, FJ
AF Jeong, Jae-Wook
Kwak, Inseok
Lee, Kevin Y.
Kim, Tae Hoon
Large, Michael J.
Stewart, Colin L.
Kaestner, Klaus H.
Lydon, John P.
DeMayo, Francesco J.
TI Foxa2 Is Essential for Mouse Endometrial Gland Development and Fertility
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE decidua; female reproductive tract; Foxa2; gland development;
implantation; uterus
ID LEUKEMIA INHIBITORY FACTOR; FEMALE REPRODUCTIVE-TRACT; FORKHEAD BOX A1;
TRANSCRIPTION FACTORS; BETA-CATENIN; PROGESTERONE-RECEPTOR; BLASTOCYST
IMPLANTATION; EMBRYO IMPLANTATION; LUNG MORPHOGENESIS; UTERINE GLANDS
AB During embryonic development, Foxa2 is required for the formation of the node and notochord, and ablation of this gene results in defects in gastrulation, neural tube patterning, and gut morphogenesis. Foxa2 has been shown to be expressed specifically in the glandular epithelium of the murine uterus. To study the uterine function of Foxa2, this gene was conditionally ablated in the mouse uterus by crossing mice with floxed Foxa2 alleles, Foxa2(IoxP/IoxP), with the Pgr(cre) mouse model. Pgr(cre/+) Foxa2(IoxP/IoxP) mice showed significantly reduced fertility. Analysis of the uterus on Day 5.5 of pregnancy showed disrupted blastocyst implantation. Pgr(cre/+) Foxa2(IoxP/IoxP) mice also showed a severe impairment of the uterus to respond to the artificial induction of the decidual response. Morphological examination of the uteri of these mice showed a severe reduction in the number of endometrial glands. The loss of endometrial glands resulted in the reduction of leukemia inhibitory factor (Lif) expression. The lack of a decidual response could be partially rescued by an intrauterine injection of LIF before the initiation of the decidual response. This analysis demonstrates that Foxa2 regulates endometrial gland development and that mice with a loss of endometrial glands cannot support implantation in part due to the loss of LIF, which is a requisite for fertility in the mouse.
C1 [Jeong, Jae-Wook; Lee, Kevin Y.; Kim, Tae Hoon; Large, Michael J.; Lydon, John P.; DeMayo, Francesco J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
[Kwak, Inseok] Silla Univ, Dept Biol Sci, Pusan, South Korea.
[Stewart, Colin L.] NCI, Canc & Dev Biol Lab, Frederick, MD 21701 USA.
[Kaestner, Klaus H.] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
RP DeMayo, FJ (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
EM fdemayo@bcm.tmc.edu
FU NIH [R01HD057873, R01CA77530, R01HD042311, U54HD0077495]
FX Supported by NIH grant R01HD057873 (to J.W.J.), NIH grant R01CA77530 (to
J.P.L.), and NIH grants R01HD042311 and U54HD0077495 (to F.J.D.).
NR 52
TC 62
Z9 63
U1 0
U2 4
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1603 MONROE ST, MADISON, WI 53711-2021 USA
SN 0006-3363
J9 BIOL REPROD
JI Biol. Reprod.
PD SEP
PY 2010
VL 83
IS 3
BP 396
EP 403
DI 10.1095/biolreprod.109.083154
PG 8
WC Reproductive Biology
SC Reproductive Biology
GA 641TY
UT WOS:000281153800011
PM 20484741
ER
PT J
AU Kang-Sickel, JCC
Stober, VP
French, JE
Nylander-French, LA
AF Kang-Sickel, Juei-Chuan C.
Stober, Vandy P.
French, John E.
Nylander-French, Leena A.
TI Exposure to naphthalene induces naphthyl-keratin adducts in human
epidermis in vitro and in vivo
SO BIOMARKERS
LA English
DT Article
DE Biomarkers; dermal exposure; jet fuel; keratin adducts; naphthalene (CAS
91-20-3)
ID POLYCYCLIC AROMATIC-HYDROCARBONS; XENOBIOTIC-METABOLIZING ENZYMES; JP-8
JET FUEL; HUMAN SKIN; DERMAL EXPOSURE; TERMINAL DIFFERENTIATION; GENETIC
POLYMORPHISMS; MAINTENANCE WORKERS; URINARY NAPHTHOLS; CYTOCHROMES P450
AB We observed naphthyl-keratin adducts and dose-related metabolic enzyme induction at the mRNA level in reconstructed human epidermis in vitro after exposure to naphthalene. Immunofluorescence detection of 2-naphthyl-keratin-1 adducts confirmed the metabolism of naphthalene and adduction of keratin. We also observed naphthyl-keratin adducts in dermal tape-strip samples collected from naphthalene-exposed workers at levels ranging from 0.004 to 6.104 pmol adduct mu g(-1) keratin. We have demonstrated the ability of the human skin to metabolize naphthalene and to form naphthyl-keratin adducts both in vitro and in vivo. The results indicate the potential use of keratin adducts as biomarkers of dermal exposure.
C1 [Kang-Sickel, Juei-Chuan C.; Stober, Vandy P.; Nylander-French, Leena A.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA.
[French, John E.] Natl Inst Environm Hlth Sci, Host Susceptibil Branch, Natl Toxicol Program, Res Triangle Pk, NC USA.
RP Nylander-French, LA (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Environm Sci & Engn, CB 7431,Rosenau Hall, Chapel Hill, NC 27599 USA.
EM leena_french@unc.edu
FU US Air Force (Texas Tech University) [1331/0489-01]; National Institute
of Environmental Health Sciences [P42ES05948, ES021134]; National
Institute for Occupational Safety and Health [T42/CCT422952, T42/008673]
FX The authors declare they have no competing financial interests. This
work was supported by US Air Force (Texas Tech University subcontract
1331/0489-01), National Institute of Environmental Health Sciences
(grant number P42ES05948 and the Division of Intramural Research
ES021134) and National Institute for Occupational Safety and Health
(grant numbers T42/CCT422952, T42/008673). The authors report no
conflicts of interest.
NR 50
TC 8
Z9 8
U1 2
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-750X
J9 BIOMARKERS
JI Biomarkers
PD SEP
PY 2010
VL 15
IS 6
BP 488
EP 497
DI 10.3109/1354750X.2010.485700
PG 10
WC Biotechnology & Applied Microbiology; Toxicology
SC Biotechnology & Applied Microbiology; Toxicology
GA 639LJ
UT WOS:000280976000002
PM 20500019
ER
PT J
AU Mukherjee, B
Ahn, J
Gruber, SB
Ghosh, M
Chatterjee, N
AF Mukherjee, Bhramar
Ahn, Jaeil
Gruber, Stephen B.
Ghosh, Malay
Chatterjee, Nilanjan
TI Case-Control Studies of Gene-Environment Interaction: Bayesian Design
and Analysis
SO BIOMETRICS
LA English
DT Article
DE Case-only design; Gene-environment independence; Highest posterior
density interval; Molecular epidemiology of colorectal cancer;
Multinomial-Dirichlet; Posterior odds
ID SAMPLE-SIZE DETERMINATION; MATCHED CASE-CONTROL; CASE-ONLY DESIGNS;
CONTINGENCY-TABLES; REQUIREMENTS; INDEPENDENCE; POWER; EXPOSURE; MODELS;
ERRORS
AB P>With increasing frequency, epidemiologic studies are addressing hypotheses regarding gene-environment interaction. In many well-studied candidate genes and for standard dietary and behavioral epidemiologic exposures, there is often substantial prior information available that may be used to analyze current data as well as for designing a new study. In this article, first, we propose a proper full Bayesian approach for analyzing studies of gene-environment interaction. The Bayesian approach provides a natural way to incorporate uncertainties around the assumption of gene-environment independence, often used in such an analysis. We then consider Bayesian sample size determination criteria for both estimation and hypothesis testing regarding the multiplicative gene-environment interaction parameter. We illustrate our proposed methods using data from a large ongoing case-control study of colorectal cancer investigating the interaction of N-acetyl transferase type 2 (NAT2) with smoking and red meat consumption. We use the existing data to elicit a design prior and show how to use this information in allocating cases and controls in planning a future study that investigates the same interaction parameters. The Bayesian design and analysis strategies are compared with their corresponding frequentist counterparts.
C1 [Mukherjee, Bhramar; Ahn, Jaeil] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
[Gruber, Stephen B.] Univ Michigan, Dept Epidemiol Human Genet & Internal Med, Ann Arbor, MI 48109 USA.
[Ghosh, Malay] Univ Florida, Dept Stat, Gainesville, FL 32611 USA.
[Chatterjee, Nilanjan] Natl Canc Inst, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA.
RP Mukherjee, B (reprint author), Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
EM bhramar@umich.edu
FU NSF [DMS 07-06935, SES-063426]; NIH [R03 CA130045-01, R01 CA81488];
National Heart Lung and Blood Institute [R01 HL091172-01]; National
Cancer Institute
FX The research of Bhramar Mukherjee was partially supported by NSF DMS
07-06935 and NIH grant R03 CA130045-01. The Molecular Epidemiology of
Colorectal Cancer Study is supported via NIH grant R01 CA81488. The
research of Nilanjan Chatterjee was supported by a Gene-Environment
Initiative (GEI) grant from the National Heart Lung and Blood Institute
(R01 HL091172-01) and by the Intramural research program of the National
Cancer Institute. Malay Ghosh's research was supported in part by NSF
grant SES-063426.
NR 49
TC 7
Z9 8
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0006-341X
J9 BIOMETRICS
JI Biometrics
PD SEP
PY 2010
VL 66
IS 3
BP 934
EP 948
DI 10.1111/j.1541-0420.2009.01357.x
PG 15
WC Biology; Mathematical & Computational Biology; Statistics & Probability
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
Biology; Mathematics
GA 651TM
UT WOS:000281950000029
PM 19930190
ER
PT J
AU Nason, M
Follmann, D
AF Nason, Martha
Follmann, Dean
TI Design and Analysis of Crossover Trials for Absorbing Binary Endpoints
SO BIOMETRICS
LA English
DT Article
DE Mantel-Haenszel; Mixture model; Time-varying covariates
ID PREVENTION; DISEASE
AB P>The crossover is a popular and efficient trial design used in the context of patient heterogeneity to assess the effect of treatments that act relatively quickly and whose benefit disappears with discontinuation. Each patient can serve as her own control as within-individual treatment and placebo responses are compared. Conventional wisdom is that these designs are not appropriate for absorbing binary endpoints, such as death or HIV infection. We explore the use of crossover designs in the context of these absorbing binary endpoints and show that they can be more efficient than the standard parallel group design when there is heterogeneity in individuals' risks. We also introduce a new two-period design where first period "survivors" are rerandomized for the second period. This design combines the crossover design with the parallel design and achieves some of the efficiency advantages of the crossover design while ensuring that the second period groups are comparable by randomization. We discuss the validity of the new designs and evaluate both a mixture model and a modified Mantel-Haenszel test for inference. The mixture model assumes no carryover or period effects while the Mantel-Haenszel approach conditions out period effects. Simulations are used to compare the different designs and an example is provided to explore practical issues in implementation.
C1 [Nason, Martha; Follmann, Dean] NIAID, Biostat Res Branch, Div Clin Res, Bethesda, MD 20892 USA.
RP Nason, M (reprint author), NIAID, Biostat Res Branch, Div Clin Res, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM mnason@niaid.nih.gov; dfollmann@niaid.nih.gov
NR 12
TC 13
Z9 13
U1 0
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0006-341X
J9 BIOMETRICS
JI Biometrics
PD SEP
PY 2010
VL 66
IS 3
BP 958
EP 965
DI 10.1111/j.1541-0420.2009.01358.x
PG 8
WC Biology; Mathematical & Computational Biology; Statistics & Probability
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
Biology; Mathematics
GA 651TM
UT WOS:000281950000031
PM 19930189
ER
PT J
AU Albert, PS
Shih, JH
AF Albert, Paul S.
Shih, Joanna H.
TI On Estimating the Relationship between Longitudinal Measurements and
Time-to-Event Data Using a Simple Two-Stage Procedure
SO BIOMETRICS
LA English
DT Article
DE Informative dropout; Joint model; Regression calibration; Two-stage
models
ID LIKELIHOOD APPROACH; MODELS
AB Ye, Lin, and Taylor (2008, Biometrics 64, 1238-1246) proposed a joint model for longitudinal measurements and time-to-event data in which the longitudinal measurements are modeled with a semiparametric mixed model to allow for the complex patterns in longitudinal biomarker data. They proposed a two-stage regression calibration approach that is simpler to implement than a joint modeling approach. In the first stage of their approach, the mixed model is fit without regard to the time-to-event data. In the second stage, the posterior expectation of an individual's random effects from the mixed-model are included as covariates in a Cox model. Although Ye et al. (2008) acknowledged that their regression calibration approach may cause a bias due to the problem of informative dropout and measurement error, they argued that the bias is small relative to alternative methods. In this article, we show that this bias may be substantial. We show how to alleviate much of this bias with an alternative regression calibration approach that can be applied for both discrete and continuous time-to-event data. Through simulations, the proposed approach is shown to have substantially less bias than the regression calibration approach proposed by Ye et al. (2008). In agreement with the methodology proposed by Ye et al. (2008), an advantage of our proposed approach over joint modeling is that it can be implemented with standard statistical software and does not require complex estimation techniques.
C1 [Albert, Paul S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA.
[Shih, Joanna H.] NCI, Biometr Res Branch, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
RP Albert, PS (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA.
EM albertp@mail.nih.gov
FU NCI NIH HHS [CA110518]
NR 11
TC 8
Z9 8
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-341X
EI 1541-0420
J9 BIOMETRICS
JI Biometrics
PD SEP
PY 2010
VL 66
IS 3
BP 983
EP 987
DI 10.1111/j.1541-0420.2009.01324.x
PG 5
WC Biology; Mathematical & Computational Biology; Statistics & Probability
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
Biology; Mathematics
GA 651TM
UT WOS:000281950000034
PM 20849547
ER
PT J
AU Chatterjee, N
Sinha, S
Diver, WR
Feigelson, HS
AF Chatterjee, Nilanjan
Sinha, Samiran
Diver, W. Ryan
Feigelson, Heather Spencer
TI Analysis of cohort studies with multivariate and partially observed
disease classification data
SO BIOMETRIKA
LA English
DT Article
DE Competing-risk; Etiologic heterogeneity; Influence function; Missing
cause of failure; Partial likelihood; Proportional hazard regression;
Two-stage model
ID COMPETING RISKS MODEL; MISSING CAUSE; FAILURE
AB Complex diseases like cancers can often be classified into subtypes using various pathological and molecular traits of the disease. In this article, we develop methods for analysis of disease incidence in cohort studies incorporating data on multiple disease traits using a two-stage semiparametric Cox proportional hazards regression model that allows one to examine the heterogeneity in the effect of the covariates by the levels of the different disease traits. For inference in the presence of missing disease traits, we propose a generalization of an estimating equation approach for handling missing cause of failure in competing-risk data. We prove asymptotic unbiasedness of the estimating equation method under a general missing-at-random assumption and propose a novel influence-function-based sandwich variance estimator. The methods are illustrated using simulation studies and a real data application involving the Cancer Prevention Study II nutrition cohort.
C1 [Chatterjee, Nilanjan] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20852 USA.
[Sinha, Samiran] Texas A&M Univ, Dept Stat, College Stn, TX 77843 USA.
[Diver, W. Ryan; Feigelson, Heather Spencer] Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30303 USA.
RP Chatterjee, N (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20852 USA.
EM chattern@mail.nih.gov; sinha@stat.tamu.edu
FU National Cancer Institute, National Institutes of Health, USA
FX The research of Dr. Chatterjee, and partially that of Dr. Sinha, was
supported by the intramural program of the National Cancer Institute,
National Institutes of Health, USA.
NR 9
TC 12
Z9 12
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-3444
J9 BIOMETRIKA
JI Biometrika
PD SEP
PY 2010
VL 97
IS 3
BP 683
EP 698
DI 10.1093/biomet/asq036
PG 16
WC Biology; Mathematical & Computational Biology; Statistics & Probability
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
Biology; Mathematics
GA 638OK
UT WOS:000280904000011
ER
PT J
AU Ghosh, AK
Dawson, ZL
Moon, DK
Bai, RL
Hamel, E
AF Ghosh, Arun K.
Dawson, Zachary L.
Moon, Deuk Kyu
Bai, Ruoli
Hamel, Ernest
TI Synthesis and biological evaluation of new jasplakinolide (jaspamide)
analogs
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Jasplakinolide; Actin filament; Natural product; Synthesis; Antitumor
activity
ID ENANTIOSELECTIVE TOTAL-SYNTHESIS; MARINE SPONGE; F-ACTIN;
(+)-JASPLAKINOLIDE JASPAMIDE; NATURAL-PRODUCT; CYCLODEPSIPEPTIDE;
POLYMERIZATION; PHALLOIDIN; (-)-DOLICULIDE; CELLS
AB Synthesis and biological evaluation of jasplakinolide analogs are described. The synthesis of analogs utilized a diastereoselective syn-aldol reaction and an orthoester Claisen rearrangement as key steps. All synthetic analogs were evaluated for their ability to disrupt the actin cytoskeleton. Compounds 2, 3, and 4 essentially displayed similar activity to jasplakinolide. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Ghosh, Arun K.; Dawson, Zachary L.; Moon, Deuk Kyu] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
[Ghosh, Arun K.; Dawson, Zachary L.; Moon, Deuk Kyu] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA.
[Bai, Ruoli; Hamel, Ernest] NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,NIH, Frederick, MD 21702 USA.
RP Ghosh, AK (reprint author), Purdue Univ, Dept Chem, 560 Oval Dr, W Lafayette, IN 47907 USA.
EM akghosh@purdue.edu
FU National Institutes of Health
FX This research was supported in part by the National Institutes of
Health.
NR 38
TC 8
Z9 8
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 1
PY 2010
VL 20
IS 17
BP 5104
EP 5107
DI 10.1016/j.bmcl.2010.07.023
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 642UT
UT WOS:000281247000026
PM 20678932
ER
PT J
AU Hu, KN
Tycko, R
AF Hu, Kan-Nian
Tycko, Robert
TI What can solid state NMR contribute to our understanding of protein
folding?
SO BIOPHYSICAL CHEMISTRY
LA English
DT Review
DE Protein folding; Freeze-trapping; Chemical denaturation; Conformational
ensembles; Solid state NMR; Villin; HP35
ID ANGLE-SPINNING NMR; NUCLEAR-MAGNETIC-RESONANCE; VILLIN HEADPIECE
SUBDOMAIN; X-RAY-SCATTERING; RESIDUAL DIPOLAR COUPLINGS; POLYPROLINE-II
HELIX; MOLECULAR TORSIONAL ANGLE; 3-HELIX BUNDLE PROTEINS; BETA-AMYLOID
PEPTIDE; PROTON-ENHANCED NMR
AB Complete understanding of the folding process that connects a structurally disordered state of a protein to an ordered, biochemically functional state requires detailed characterization of intermediate structural states with high resolution and site specificity. While the intrinsically inhomogeneous and dynamic nature of unfolded and partially folded states limits the efficacy of traditional X-ray diffraction and solution NMR in structural studies, solid state NMR methods applied to frozen solutions can circumvent the complications due to molecular motions and conformational exchange encountered in unfolded and partially folded states. Moreover, solid state NMR methods can provide both qualitative and quantitative structural information at the site-specific level, even in the presence of structural inhomogeneity. This article reviews relevant solid state NMR methods and their initial applications to protein folding studies. Using either chemical denaturation to prepare unfolded states at equilibrium or a rapid freezing apparatus to trap non-equilibrium, transient structural states on a sub-millisecond time scale, recent results demonstrate that solid state NMR can contribute essential information about folding processes that is not available from more familiar biophysical methods. Published by Elsevier B.V.
C1 [Hu, Kan-Nian; Tycko, Robert] NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
RP Tycko, R (reprint author), NIDDKD, Chem Phys Lab, NIH, Bldg 5,Room 112, Bethesda, MD 20892 USA.
EM robertty@mail.nih.gov
FU Intramural NIH HHS [ZIA DK029063-03]
NR 128
TC 14
Z9 14
U1 4
U2 43
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-4622
J9 BIOPHYS CHEM
JI Biophys. Chem.
PD SEP
PY 2010
VL 151
IS 1-2
BP 10
EP 21
DI 10.1016/j.bpc.2010.05.009
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA 633NO
UT WOS:000280510000002
PM 20542371
ER
PT J
AU Herring, AH
Reddy, UM
AF Herring, A. H.
Reddy, U. M.
TI Recurrence risk of stillbirth in the second pregnancy
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Editorial Material
ID SUBSEQUENT
C1 [Herring, A. H.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA.
[Herring, A. H.] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27599 USA.
[Reddy, U. M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pregnancy & Perinatol Branch, Bethesda, MD USA.
RP Herring, AH (reprint author), Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA.
EM amy_herring@unc.edu
FU NICHD NIH HHS [R24 HD050924]
NR 6
TC 3
Z9 3
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1470-0328
J9 BJOG-INT J OBSTET GY
JI BJOG
PD SEP
PY 2010
VL 117
IS 10
BP 1173
EP 1174
DI 10.1111/j.1471-0528.2010.02655.x
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 639QJ
UT WOS:000280989000001
PM 20722642
ER
PT J
AU Zhang, X
Mumford, SL
Cnattingius, S
Schisterman, EF
Kramer, MS
AF Zhang, X.
Mumford, S. L.
Cnattingius, S.
Schisterman, E. F.
Kramer, M. S.
TI Reduced birthweight in short or primiparous mothers: physiological or
pathological?
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article
DE Birthweight; directed acyclic graph; effect decomposition; gestational
age; maternal height; parity perinatal mortality
ID MARGINAL STRUCTURAL MODELS; FETAL-GROWTH; STANDARDS; PREGNANCIES; DEATH;
EPIDEMIOLOGY; DETERMINANTS; RETARDATION; ASSOCIATION; MORTALITY
AB Objective Customisation of birthweight-for-gestational-age standards for maternal characteristics assumes that variation in birth weight as a result of those characteristics is physiological, rather than pathological. Maternal height and parity are among the characteristics widely assumed to be physiological. Our objective was to test that assumption by using an association with perinatal mortality as evidence of a pathological effect.
Design Population-based cohort study.
Setting Sweden.
Population A total of 952 630 singletons born at 28 weeks of gestation in the period 1992-2001.
Methods We compared perinatal mortality among mothers of short stature (< 160 cm) versus those of normal height (160 cm), and primiparous versus multiparous mothers, using an internal reference of estimated fetal weight for gestational age. The total effects of maternal height and parity were estimated, as well as the effects of height and parity independent of birthweight (controlled direct effects). All analyses were based on fetuses at risk, using marginal structural Cox models for the estimation of total and controlled direct effects.
Main outcome measures Perinatal mortality, stillbirth, and early neonatal mortality.
Results The estimated total effect (HR; 95% CI) of short stature on perinatal death among short mothers was 1.2 (95% CI 1.1-1.3) compared with women of normal height; the effect of short stature independent of birthweight (controlled direct effect) was 0.8 (95% CI 0.6-1.0) among small-for-gestational-age (SGA) births, but 1.1 (95% CI 1.0-1.3) among non-SGA births. Similar results were observed for primiparous mothers.
Conclusions The effect of maternal short stature or primiparity on perinatal mortality is partly mediated through SGA birth. Thus, birthweight differences resulting from these maternal characteristics appear not only to be physiological, but also to have an important pathological component.
C1 [Zhang, X.; Kramer, M. S.] McGill Univ, Dept Pediat, Fac Med, Montreal, PQ H3A 2T5, Canada.
[Mumford, S. L.; Schisterman, E. F.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Bethesda, MD USA.
[Cnattingius, S.] Karolinska Inst, Clin Epidemiol Unit, Dept Med, Stockholm, Sweden.
[Kramer, M. S.] McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
RP Kramer, MS (reprint author), Montreal Childrens Hosp, 2300 Tupper St Les Tourelles, Montreal, PQ H3H 1P3, Canada.
EM michael.kramer@mcgill.ca
OI Schisterman, Enrique/0000-0003-3757-641X
FU Canadian Institutes of Health Research; Eunice Kennedy Shriver National
Institute of Child Health and Human Development, National Institutes of
Health
FX Supported by a grant from the Canadian Institutes of Health Research.
EFS and SLM are supported by the Intramural Research Program of the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health.
NR 40
TC 14
Z9 14
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1470-0328
J9 BJOG-INT J OBSTET GY
JI BJOG
PD SEP
PY 2010
VL 117
IS 10
BP 1248
EP 1254
DI 10.1111/j.1471-0528.2010.02642.x
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 639QJ
UT WOS:000280989000011
PM 20618317
ER
PT J
AU Pulanic, D
Cowen, EW
Baird, K
Bishop, MR
Pavletic, SZ
AF Pulanic, D.
Cowen, E. W.
Baird, K.
Bishop, M. R.
Pavletic, S. Z.
TI Development of severe sclerotic chronic GVHD during treatment with
dasatinib
SO BONE MARROW TRANSPLANTATION
LA English
DT Letter
ID VERSUS-HOST-DISEASE; IMATINIB MESYLATE; EFFICACY; FIBROSIS
C1 [Pulanic, D.; Bishop, M. R.; Pavletic, S. Z.] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Cowen, E. W.] NCI, Dermatol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Baird, K.] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Pulanic, D (reprint author), NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM pulanicd@mail.nih.gov
FU Intramural NIH HHS
NR 10
TC 5
Z9 5
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD SEP
PY 2010
VL 45
IS 9
BP 1469
EP 1470
DI 10.1038/bmt.2009.368
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 648CS
UT WOS:000281668600014
PM 20062096
ER
PT J
AU Costigan, M
Belfer, I
Griffin, RS
Dai, F
Barrett, LB
Coppola, G
Wu, TX
Kiselycznyk, C
Poddar, M
Lu, Y
Diatchenko, L
Smith, S
Cobos, EJ
Zaykin, D
Allchorne, A
Shen, PH
Nikolajsen, L
Karppinen, J
Mannikko, M
Kelempisioti, A
Goldman, D
Maixner, W
Geschwind, DH
Max, MB
Seltzer, Z
Woolf, CJ
AF Costigan, Michael
Belfer, Inna
Griffin, Robert S.
Dai, Feng
Barrett, Lee B.
Coppola, Giovanni
Wu, Tianxia
Kiselycznyk, Carly
Poddar, Minakshi
Lu, Yan
Diatchenko, Luda
Smith, Shad
Cobos, Enrique J.
Zaykin, Dmitri
Allchorne, Andrew
Shen, Pei-Hong
Nikolajsen, Lone
Karppinen, Jaro
Mannikko, Minna
Kelempisioti, Anthi
Goldman, David
Maixner, William
Geschwind, Daniel H.
max, Mitchell B.
Seltzer, Ze'ev
woolf, Clifford J.
TI Multiple chronic pain states are associated with a common amino
acid-changing allele in KCNS1
SO BRAIN
LA English
DT Article
DE neuropathic pain; phenotype; molecular genetics; axonal injury; gene
expression
ID DORSAL-ROOT GANGLION; MAINE LUMBAR SPINE; GATED POTASSIUM CHANNELS;
PERIPHERAL-NERVE INJURY; NONSURGICAL MANAGEMENT; NEUROPATHIC PAIN;
SCIATICA SECONDARY; DISC HERNIATION; ALPHA-SUBUNITS; SODIUM-CHANNEL
AB Not all patients with nerve injury develop neuropathic pain. The extent of nerve damage and age at the time of injury are two of the few risk factors identified to date. In addition, preclinical studies show that neuropathic pain variance is heritable. To define such factors further, we performed a large-scale gene profiling experiment which plotted global expression changes in the rat dorsal root ganglion in three peripheral neuropathic pain models. This resulted in the discovery that the potassium channel alpha subunit KCNS1, involved in neuronal excitability, is constitutively expressed in sensory neurons and markedly downregulated following nerve injury. KCNS1 was then characterized by an unbiased network analysis as a putative pain gene, a result confirmed by single nucleotide polymorphism association studies in humans. A common amino acid changing allele, the 'valine risk allele', was significantly associated with higher pain scores in five of six independent patient cohorts assayed (total of 1359 subjects). Risk allele prevalence is high, with 18-22% of the population homozygous, and an additional 50% heterozygous. At lower levels of nerve damage (lumbar back pain with disc herniation) association with greater pain outcome in homozygote patients is P = 0.003, increasing to P = 0.0001 for higher levels of nerve injury (limb amputation). The combined P-value for pain association in all six cohorts tested is 1.14 E-08. The risk profile of this marker is additive: two copies confer the most, one intermediate and none the least risk. Relative degrees of enhanced risk vary between cohorts, but for patients with lumbar back pain, they range between 2- and 3-fold. Although work still remains to define the potential role of this protein in the pathogenic process, here we present the KCNS1 allele rs734784 as one of the first prognostic indicators of chronic pain risk. Screening for this allele could help define those individuals prone to a transition to persistent pain, and thus requiring therapeutic strategies or lifestyle changes that minimize nerve injury.
C1 [Belfer, Inna; Dai, Feng; Poddar, Minakshi; max, Mitchell B.] Univ Pittsburgh, Dept Anesthesiol, Mol Epidemiol Pain Program, Pittsburgh, PA 15261 USA.
[Costigan, Michael; Griffin, Robert S.; Barrett, Lee B.; Cobos, Enrique J.; Allchorne, Andrew; woolf, Clifford J.] Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA.
[Costigan, Michael; Griffin, Robert S.; Barrett, Lee B.; Cobos, Enrique J.; Allchorne, Andrew; woolf, Clifford J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Coppola, Giovanni; Geschwind, Daniel H.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Wu, Tianxia] NIH, Ctr Informat Technol, Bethesda, MD 20892 USA.
[Kiselycznyk, Carly; Shen, Pei-Hong; Goldman, David] NIAAA, Neurogenet Lab, NIH, Rockville, MD 20892 USA.
[Lu, Yan; Seltzer, Ze'ev] Univ Toronto, Comparat Pain Phen & Genom Lab, Ctr Study Pain, Fac Dent, Toronto, ON M5G 1G6, Canada.
[Lu, Yan; Seltzer, Ze'ev] Univ Toronto, Comparat Pain Phen & Genom Lab, Ctr Study Pain, Fac Med, Toronto, ON M5G 1G6, Canada.
[Diatchenko, Luda; Smith, Shad; Maixner, William] Univ N Carolina, Ctr Neurosensory Disorders, Chapel Hill, NC 27599 USA.
[Zaykin, Dmitri] NIEHS, Durham, NC 27709 USA.
[Nikolajsen, Lone] Aarhus Univ Hosp, Danish Pain Res Ctr, DK-8000 Aarhus, Denmark.
[Karppinen, Jaro; Mannikko, Minna; Kelempisioti, Anthi] Univ Oulu, Dept Med Biochem & Mol Biol, Oulu 90014, Finland.
RP Belfer, I (reprint author), Univ Pittsburgh, Dept Anesthesiol, Mol Epidemiol Pain Program, 3550 Terrace St,Scaife Hall A-1310, Pittsburgh, PA 15261 USA.
EM belferi@upmc.edu
RI Cobos, Enrique/E-9077-2016; Goldman, David/F-9772-2010
OI Goldman, David/0000-0002-1724-5405
FU National Institutes of Health (NIH), National Institute of Environmental
Health Sciences; Spanish Ministry for Science and Innovation; NIH [R01
NS038253, NS058870]; Canada Research Chair Programme
FX Intramural Research Programme of the National Institutes of Health
(NIH), National Institute of Environmental Health Sciences to D.Z.;
Spanish Ministry for Science and Innovation/Fulbright programme to
E.J.C.; NIH support R01 NS038253 and NS058870 (C.J.W.); Canada Research
Chair Programme to Z.S.
NR 43
TC 113
Z9 114
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD SEP
PY 2010
VL 133
BP 2519
EP 2527
DI 10.1093/brain/awq195
PN 9
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 646HE
UT WOS:000281529000005
PM 20724292
ER
PT J
AU Singh, A
Mishra, A
Hewitt, S
Sharma, KC
Saxena, S
AF Singh, A.
Mishra, A.
Hewitt, S.
Sharma, Chand K.
Saxena, Sunita
TI Identification of immunohistochemical markers that differentiate
fibroblastic meningioma from schwannoma: a tissue microarray based
approach
SO BRAIN PATHOLOGY
LA English
DT Meeting Abstract
CT 17th International Congress of Neuropathology (ICN 2010)
CY SEP 11-15, 2010
CL Salzburg, AUSTRIA
C1 [Singh, A.; Mishra, A.; Saxena, Sunita] Inst Pathol ICMR, New Delhi, India.
[Hewitt, S.] NCI, NIH, Bethesda, MD 20892 USA.
[Sharma, Chand K.] VMMC, Dept Neurosurg, New Delhi, India.
[Sharma, Chand K.] Safdarjang Hosp, New Delhi, India.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1015-6305
J9 BRAIN PATHOL
JI Brain Pathol.
PD SEP
PY 2010
VL 20
SU 1
BP 67
EP 67
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 649TZ
UT WOS:000281798100238
ER
PT J
AU Ruiz-Narvaez, EA
Rosenberg, L
Rotimi, CN
Cupples, LA
Boggs, DA
Adeyemo, A
Cozier, YC
Adams-Campbell, LL
Palmer, JR
AF Ruiz-Narvaez, Edward A.
Rosenberg, Lynn
Rotimi, Charles N.
Cupples, L. Adrienne
Boggs, Deborah A.
Adeyemo, Adebowale
Cozier, Yvette C.
Adams-Campbell, Lucile L.
Palmer, Julie R.
TI Genetic variants on chromosome 5p12 are associated with risk of breast
cancer in African American women: the Black Women's Health Study
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Chromosome 5p12; African Americans; SNP
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; COMMON VARIANTS;
POPULATIONS; ADMIXTURE; ALLELES; LINKAGE
AB Two single nucleotide polymorphisms (SNPs), rs4415084, and rs10941679 on chromosome 5p12 were associated with risk of breast cancer in a recent genome-wide association study (GWAS) of women of European ancestry. Both SNPs are located in a large high-LD region and the causal variant(s) are still unknown. We conducted a nested case-control study in a cohort of African American women to replicate and narrow the region carrying the causal variant(s). We evaluated 14 tagging SNPs in a 98 kb LD block surrounding the index SNPs in 886 breast cancer cases and 1,089 controls from the Black Women's Health Study. We used the Cochran-Armitage trend test to assess association with breast cancer risk. Odds ratios were derived from logistic regression analyses adjusted for potential confounders including percent European admixture. We confirmed the reported association of rs4415084 SNP with overall risk of breast cancer (P = 0.06), and, as in the original study, observed a stronger association with estrogen receptor positive tumors (P = 0.03). We identified four other SNPs (rs6451770, rs12515012, rs13156930, and rs16901937) associated with risk of breast cancer at the nominal alpha value of 0.05; all of them were located in a 59 kb HapMap YRI LD block. After correction for multiple testing, the association with SNP rs16901937 remained significant (P permutated = 0.038). The G allele was associated with a 21% increased risk of breast cancer overall and with a 32% increase in tumors positive for both estrogen and progesterone receptors. The present results from an African ancestry (AA) population confirm the presence of breast cancer susceptibility genetic variants in the chromosome 5p12 region. We successfully used the shorter range of LD in our AA sample to refine the localization of the putative causal variant.
C1 [Ruiz-Narvaez, Edward A.; Rosenberg, Lynn; Boggs, Deborah A.; Cozier, Yvette C.; Palmer, Julie R.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA.
[Ruiz-Narvaez, Edward A.; Rosenberg, Lynn; Cozier, Yvette C.; Palmer, Julie R.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
[Rotimi, Charles N.; Adeyemo, Adebowale] NHGRI, Ctr Res Genom & Global Hlth, NIH, Bethesda, MD USA.
[Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
[Adams-Campbell, Lucile L.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA.
RP Palmer, JR (reprint author), Boston Univ, Slone Epidemiol Ctr, 1010 Commonwealth Ave, Boston, MA 02215 USA.
EM jpalmer@bu.edu
OI Ruiz-Narvaez, Edward/0000-0002-0339-5824; Palmer,
Julie/0000-0002-6534-335X; Cupples, L. Adrienne/0000-0003-0273-7965;
Cozier, Yvette/0000-0003-0625-7256; Adeyemo,
Adebowale/0000-0002-3105-3231
FU National Cancer Institute, Division of Cancer Control and Population
Science [R01CA058420, R01CA098663]; National Center for Research
Resources [U54 RR020278]
FX We thank the Black Women's Health Study participants for their
continuing participation in this research effort. This work was
supported by grants R01CA058420 and R01CA098663 from the National Cancer
Institute, Division of Cancer Control and Population Science
(http://www.cancercontrol.cancer.gov). The Broad Institute Center for
Genotyping and Analysis is supported by grant U54 RR020278 from the
National Center for Research Resources
(http://www.broadinstitute.org/sections/science/projects/broad/ncrr-cent
er-genotyping-analysis).
NR 21
TC 22
Z9 22
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2010
VL 123
IS 2
BP 525
EP 530
DI 10.1007/s10549-010-0775-5
PG 6
WC Oncology
SC Oncology
GA 637HK
UT WOS:000280807900022
PM 20140701
ER
PT J
AU Maurex, L
Lekander, M
Nilsonne, A
Andersson, EE
Asberg, M
Ohman, A
AF Maurex, Liselotte
Lekander, Mats
Nilsonne, Asa
Andersson, Eva E.
Asberg, Marie
Ohman, Arne
TI Social problem solving, autobiographical memory, trauma, and depression
in women with borderline personality disorder and a history of suicide
attempts
SO BRITISH JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
ID PSYCHOPATHOLOGICAL RATING-SCALE; DELIBERATE SELF-HARM; DSM-III-R; MAJOR
DEPRESSION; NONDEPRESSED PATIENTS; DECISION-MAKING; SPECIFICITY;
RUMINATION; MOOD; PARASUICIDE
AB Objectives. The primary aim of this study was to compare the retrieval of autobiographical memory and the social problem-solving performance of individuals with borderline personality disorder (BPD) and a history of suicide attempts, with and without concurrent diagnoses of depression and/or post-traumatic stress disorder (PTSD), to that of controls. Additionally, the relationships between autobiographical memory, social problem-solving skills, and various clinical characteristics were examined in the BPD group.
Design. Individuals with BPD who had made at least two suicide attempts were compared to controls with regard to specificity of autobiographical memory and social problem-solving skills. Autobiographical memory specificity and social problem-solving skills were further studied in the BPD group by comparing depressed participants to non-depressed participants; and autobiographical memory specificity was also studied by comparing participants with and without PTSD.
Method. A total of 47 women with a diagnosis of BPD and 30 controls completed the Autobiographical Memory Test, assessing memory specificity, and the means-end problem solving-procedure, measuring social problem-solving skills. The prevalence of suicidal/self-injurious behaviour, and the exposure to violence, was also assessed in the BPD group.
Results. Compared to controls, participants with BPD showed reduced specificity of autobiographical memory, irrespective of either concurrent depression, previous depression, or concurrent PTSD. The depressed BPD group displayed poor problem-solving skills. Further, an association between unspecific memory and poor problem-solving was displayed in the BPD group.
Conclusion. Our results confirmed that reduced specificity of autobiographical memory is an important characteristic of BPD individuals with a history of suicide attempt, independent of depression, or PTSD. Reduced specificity of autobiographical memory was further related to poor social problem-solving capacity in the BPD group.
C1 [Maurex, Liselotte; Lekander, Mats; Nilsonne, Asa; Ohman, Arne] Karolinska Inst, Psychol Sect, Dept Clin Neurosci, S-17177 Stockholm, Sweden.
[Lekander, Mats] Karolinska Inst, Osher Ctr Integrat Med, S-17177 Stockholm, Sweden.
[Andersson, Eva E.] Karolinska Inst, Sect Psychiat, Dept Clin Neurosci, S-17177 Stockholm, Sweden.
[Asberg, Marie] Karolinska Inst, Dept Clin Sci, S-17177 Stockholm, Sweden.
[Ohman, Arne] Stockholm Brain Inst, Stockholm, Sweden.
[Ohman, Arne] Univ Florida, NIMH Ctr Res Emot & Attent, Gainesville, FL USA.
RP Maurex, L (reprint author), Karolinska Inst, Psychol Sect, Dept Clin Neurosci, S-17177 Stockholm, Sweden.
EM Liselotte.Maurex@ki.se
NR 50
TC 19
Z9 19
U1 2
U2 18
PU BRITISH PSYCHOLOGICAL SOC
PI LEICESTER
PA ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND
SN 0144-6657
J9 BRIT J CLIN PSYCHOL
JI Br. J. Clin. Psychol.
PD SEP
PY 2010
VL 49
BP 327
EP 342
DI 10.1348/014466509X454831
PN 3
PG 16
WC Psychology, Clinical
SC Psychology
GA 651XI
UT WOS:000281960500004
PM 19555523
ER
PT J
AU Li, Y
Seifert, MF
Lim, SY
Salem, N
Watkins, BA
AF Li, Yong
Seifert, Mark F.
Lim, Sun-Young
Salem, Norman, Jr.
Watkins, Bruce A.
TI Bone mineral content is positively correlated to n-3 fatty acids in the
femur of growing rats
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE n-3 Fatty acids; DHA; Docosapentaenoic acid n-6; Rat femur
ID CONJUGATED LINOLEIC-ACID; DOCOSAHEXAENOIC ACID; TOOTH MOVEMENT; DIETARY
RATIO; DENSITY; CALCIUM; ALTERS; SUPPLEMENTATION; PHOSPHOLIPIDS;
METABOLISM
C1 [Li, Yong; Watkins, Bruce A.] Purdue Univ, Lipid Chem & Mol Biol Lab, W Lafayette, IN 47907 USA.
[Seifert, Mark F.; Watkins, Bruce A.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
[Lim, Sun-Young] Korea Maritime Univ, Div Marine Environm & Biosci, Pusan 606791, South Korea.
[Salem, Norman, Jr.] NIAAA, Lab Membrane Biochem & Biophys, Div Intramural Clin & Biol Res, NIH, Rockville, MD 20852 USA.
RP Watkins, BA (reprint author), Purdue Univ, Lipid Chem & Mol Biol Lab, 745 Agr Mall Dr, W Lafayette, IN 47907 USA.
EM baw@purdue.edu
FU National Institutes of Health, National Institute on Alcohol Abuse and
Alcoholism
FX The present study was supported by the Intramural Research Program of
the National Institutes of Health, National Institute on Alcohol Abuse
and Alcoholism.
NR 30
TC 32
Z9 32
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD SEP
PY 2010
VL 104
IS 5
BP 674
EP 685
DI 10.1017/S0007114510001133
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 650XP
UT WOS:000281887900008
PM 20420751
ER
PT J
AU Song, XY
Sun, LQ
Mu, XY
Dinse, GE
AF Song, Xinyuan
Sun, Liuquan
Mu, Xiaoyun
Dinse, Gregg E.
TI Additive hazards regression with censoring indicators missing at random
SO CANADIAN JOURNAL OF STATISTICS-REVUE CANADIENNE DE STATISTIQUE
LA English
DT Article
DE Additive hazards model; censoring; kernel smoother; missing at random;
weighted estimating equation
ID PRODUCT-LIMIT ESTIMATORS; COMPETING RISKS MODEL; EFFICIENT ESTIMATION;
SURVIVAL FUNCTION; FAILURE; COEFFICIENTS; INFORMATION; KERNELS
AB In this article, the authors consider a semiparametric additive hazards regression model for right-censored data that allows some censoring indicators to be missing at random. They develop a class of estimating equations and use an inverse probability weighted approach to estimate the regression parameters. Nonparametric smoothing techniques are employed to estimate the probability of non-missingness and the conditional probability of an uncensored observation. The asymptotic properties of the resulting estimators are derived. Simulation studies show that the proposed estimators perform well. They motivate and illustrate their methods with data from a brain cancer clinical trial. The Canadian Journal of Statistics 38: 333 351; 2010 (C) 2010 Statistical Society of Canada
C1 [Song, Xinyuan] Dept Stat, Shatin, Hong Kong, Peoples R China.
[Sun, Liuquan; Mu, Xiaoyun] Chinese Acad Sci, Acad Math & Syst Sci, Inst Appl Math, Beijing 100190, Peoples R China.
[Dinse, Gregg E.] NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA.
RP Song, XY (reprint author), Dept Stat, Shatin, Hong Kong, Peoples R China.
EM xysong@sta.cuhk.edu.hk
FU Research Grant Council of the Hong Kong Special Administration Region;
National Natural Science Foundation of China; National Basic Research
Program of China (973 Program); Key Laboratory of RCSDS, CAS; NIH,
National Institute of Environmental Health Sciences
FX The authors would like to thank the Editor (Paul Gustafson), the
Associate Editor, two reviewers and Shyamal Peddada for their
constructive and insightful comments and suggestions that greatly
improved the article. Xinyuan Song's research was fully supported by two
grants from the Research Grant Council of the Hong Kong Special
Administration Region. Liuquan Sun's research was fully supported by the
National Natural Science Foundation of China Grants, the National Basic
Research Program of China (973 Program) and Key Laboratory of RCSDS,
CAS. Gregg Dinse's research was supported by the Intramural Research
Program of the NIH, National Institute of Environmental Health Sciences.
NR 29
TC 6
Z9 7
U1 2
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0319-5724
J9 CAN J STAT
JI Can. J. Stat.-Rev. Can. Stat.
PD SEP
PY 2010
VL 38
IS 3
BP 333
EP 351
PG 19
WC Statistics & Probability
SC Mathematics
GA 642BW
UT WOS:000281179300002
PM 21197117
ER
PT J
AU Schlom, J
AF Schlom, Jeffrey
TI The MUC1-C oncoprotein as a target in hematologic malignancies
SO CANCER BIOLOGY & THERAPY
LA English
DT Editorial Material
DE MUC1; CML; Bcr-Abl; myeloid blasts; differentiation; self-renewal;
targeted therapies; peptide drugs
ID THERAPY
C1 NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Schlom, J (reprint author), NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA.
EM js141c@nih.gov
NR 12
TC 2
Z9 2
U1 0
U2 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4047
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD SEP 1
PY 2010
VL 10
IS 5
DI 10.4161/cbt.10.5.13150
PG 3
WC Oncology
SC Oncology
GA 651EZ
UT WOS:000281909400012
PM 20716962
ER
PT J
AU Ruder, EH
Hartman, TJ
Rovine, MJ
Dorgan, JF
AF Ruder, Elizabeth H.
Hartman, Terryl J.
Rovine, Michael J.
Dorgan, Joanne F.
TI Birth characteristics and age at menarche: results from the dietary
intervention study in children (DISC)
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Menarche; Birth weight; Birth length; Gestational age; Puberty; Breast
cancer
ID BREAST-CANCER RISK; UNITED-STATES; BODY-SIZE; OPPOSING INFLUENCES;
PREGNANCY ESTRIOL; POSTNATAL-GROWTH; CHILDHOOD GROWTH; HORMONE-LEVELS;
EARLY PUBERTY; GIRLS
AB Objective To examine whether birth weight, birth length, and gestational age are individually associated with age at menarche.
Methods Analyses were conducted using data from n = 278 female participants in the Dietary Intervention Study in Children (DISC). Age at menarche was prospectively collected as part of the original DISC investigation. DISC participants self-reported birth weight, birth length, and gestational age with assistance from their mothers and other records as part of the DISC06 Follow-up Study at ages 25-29. Linear regression was used to estimate the association of birth characteristics and age at menarche.
Results Birth weight was positively associated with age at menarche (p <= 0.01) in multiple regression analyses after controlling for BMI-for-age percentile, race and DISC treatment group. No statistically significant relationships were detected between either length or gestational age and age at menarche.
Conclusions Higher birth weight may be associated with a modest delay in age at menarche.
C1 [Ruder, Elizabeth H.] NCI, Canc Prevent Fellowship Program, NIH, Bethesda, MD 20892 USA.
[Hartman, Terryl J.] Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA.
[Rovine, Michael J.] Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA.
[Dorgan, Joanne F.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
RP Ruder, EH (reprint author), NCI, Canc Prevent Fellowship Program, NIH, 6120 Execut Blvd,Suite 320,MSC 7236, Bethesda, MD 20892 USA.
EM rudereh@mail.nih.gov
FU National Cancer Institute [R01CA104670]
FX The work described was supported by Grant Number R01CA104670 from the
National Cancer Institute. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
National Cancer Institute or the National Institutes of Health.
NR 48
TC 7
Z9 7
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD SEP
PY 2010
VL 21
IS 9
BP 1379
EP 1386
DI 10.1007/s10552-010-9565-y
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 638NQ
UT WOS:000280902000003
PM 20495859
ER
PT J
AU Carsin, AE
Drummond, FJ
Black, A
van Leeuwen, PJ
Sharp, L
Murray, LJ
Connolly, D
Egevad, L
Boniol, M
Autier, P
Comber, H
Gavin, A
AF Carsin, A-E.
Drummond, F. J.
Black, A.
van Leeuwen, P. J.
Sharp, L.
Murray, L. J.
Connolly, D.
Egevad, L.
Boniol, M.
Autier, P.
Comber, H.
Gavin, A.
TI Impact of PSA testing and prostatic biopsy on cancer incidence and
mortality: comparative study between the Republic of Ireland and
Northern Ireland
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Prostate cancer; Trends; PSA tests; Incidence; Mortality
ID INTERPRETING TRENDS; SURVEILLANCE SERIES; UNITED-STATES; THERAPY; RATES;
RISK; MEN; GUIDELINES; CARCINOMA; COUNTRIES
AB Objectives To investigate the impact of different PSA testing policies and health-care systems on prostate cancer incidence and mortality in two countries with similar populations, the Republic of Ireland (RoI) and Northern Ireland (NI).
Methods Population-level data on PSA tests, prostate biopsies and prostate cancer cases 1993-2005 and prostate cancer deaths 1979-2006 were compiled. Annual percentage change (APC) was estimated by join-point regression.
Results Prostate cancer rates were similar in both areas in 1994 but increased rapidly in RoI compared to NI. The PSA testing rate increased sharply in RoI (APC = +23.3%), and to a lesser degree in NI (APC = +9.7%) to reach 412 and 177 tests per 1,000 men in 2004, respectively. Prostatic biopsy rates rose in both countries, but were twofold higher in RoI. Cancer incidence rates rose significantly, mirroring biopsy trends, in both countries reaching 440 per 100,000 men in RoI in 2004 compared to 294 in NI. Median age at diagnosis was lower in RoI (71 years) compared to NI (73 years) (p < 0.01) and decreased significantly over time in both countries. Mortality rates declined from 1995 in both countries (APC = -1.5% in RoI, -1.3% in NI) at a time when PSA testing was not widespread.
Conclusions Prostatic biopsy rates, rather than PSA testing per se, were the main driver of prostate cancer incidence. Because mortality decreases started before screening became widespread in RoI, and mortality remained low in NI, PSA testing is unlikely to be the explanation for declining mortality.
C1 [Carsin, A-E.; Drummond, F. J.; Sharp, L.; Comber, H.] Natl Canc Registry Ireland, Cork, Ireland.
[Black, A.] NCI, Early Detect Res Grp, Canc Prevent Div, NIH, Bethesda, MD 20892 USA.
[van Leeuwen, P. J.] Erasmus Univ, Med Ctr, Rotterdam, Netherlands.
[Murray, L. J.] Queens Univ Belfast, Canc Epidemiol & Prevent Res Grp, Belfast, Antrim, North Ireland.
[Connolly, D.] Belfast City Hosp, Dept Urol, Belfast BT9 7AD, Antrim, North Ireland.
[Egevad, L.; Boniol, M.; Autier, P.] Int Agcy Res Canc, F-69372 Lyon, France.
[Gavin, A.] Queens Univ Belfast, No Ireland Canc Registry, Belfast, Antrim, North Ireland.
RP Carsin, AE (reprint author), Natl Canc Registry Ireland, Bldg 6800,Cork Airport Business Pk,Kinsale Rd, Cork, Ireland.
EM acarsin@creal.cat
RI Boniol, Mathieu/F-9623-2011; Autier, Philippe/A-4402-2014
OI Boniol, Mathieu/0000-0003-1052-5604; Autier,
Philippe/0000-0003-1538-5321
FU Public Health Agency Northern Ireland; Department of Health and Children
(Republic of Ireland); Northern Ireland Research & Development Office
and the Health Research Board (Dublin) [NS/2004/20]
FX The Northern Ireland Cancer Registry is funded by the Public Health
Agency Northern Ireland, and the National Cancer Registry of Ireland is
funded by the Department of Health and Children (Republic of Ireland).
Some aspects of the data collection for this study were funded by a
grant from the Northern Ireland Research & Development Office and the
Health Research Board (Dublin) [grant number NS/2004/20]. The study
funders had no role in the study design, the collection, analysis and
interpretation of the data. All authors were independent from the
funding source.
NR 38
TC 12
Z9 12
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD SEP
PY 2010
VL 21
IS 9
BP 1523
EP 1531
DI 10.1007/s10552-010-9581-y
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 638NQ
UT WOS:000280902000019
PM 20514514
ER
PT J
AU Fox, E
Maris, JM
Cohn, SL
Goodspeed, W
Goodwin, A
Kromplewski, M
Medina, D
Xiong, H
Krivoshik, A
Widemann, B
Adamson, PC
Balis, FM
AF Fox, Elizabeth
Maris, John M.
Cohn, Susan L.
Goodspeed, Wendy
Goodwin, Anne
Kromplewski, Marie
Medina, Diane
Xiong, Hao
Krivoshik, Andrew
Widemann, Brigitte
Adamson, Peter C.
Balis, Frank M.
TI Pharmacokinetics of orally administered ABT-751 in children with
neuroblastoma and other solid tumors
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Pharmacokinetics; Tubulin binding agent; Neuroblastoma
ID BIOAVAILABLE TUBULIN INHIBITOR; PEDIATRIC-PATIENTS; CELL-LINES; PHASE-1;
BINDING; AGENT; E7010
AB To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes.
Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m(2)/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed.
ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t (1/2) of 5.1 h. The apparent clearance was 33 ml/min/m(2) and was age-independent. The AUC(0-a) increased in proportion to the dose, and at 200 mg/m(2) the median AUC(0-a) was 91 mcg h/ml and the C (ave) was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min post-dose and peaked 3-5 h after the dose. The glucuronide:sulfate molar AUC(0-a) ratio was 0.57. Less than 1% of the dose was excreted in urine as parent drug; 13% of the dose was excreted as sulfate metabolite and 10% as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93%, respectively. AUC(0-a) was higher in patients experiencing dose-limiting toxicity.
Oral ABT-751 pharmacokinetics was dose-proportional and age-independent with minimal intra- and inter-patient variability in children.
C1 [Fox, Elizabeth; Goodspeed, Wendy; Goodwin, Anne; Widemann, Brigitte; Balis, Frank M.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Maris, John M.; Kromplewski, Marie; Adamson, Peter C.; Balis, Frank M.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA.
[Maris, John M.; Kromplewski, Marie; Adamson, Peter C.; Balis, Frank M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Cohn, Susan L.] Univ Chicago, Chicago, IL 60637 USA.
[Medina, Diane; Xiong, Hao; Krivoshik, Andrew] Abbott Labs, Abbott Pk, IL 60064 USA.
RP Fox, E (reprint author), NCI, Pediat Oncol Branch, 10 Ctr Dr,Bldg 10,Rm 1-5750, Bethesda, MD 20892 USA.
EM foxb@mail.nih.gov
OI Cohn, Susan/0000-0001-5749-7650
FU National Institutes of Health, National Cancer Institute, Center for
Cancer Research.; Abbott Laboratories
FX This research was supported, in part, by the Intramural Research Program
of the National Institutes of Health, National Cancer Institute, Center
for Cancer Research. Additional funding to Children's Hospital of
Philadelphia and Children's Memorial Hospital was provided by Abbott
Laboratories.
NR 10
TC 13
Z9 13
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD SEP
PY 2010
VL 66
IS 4
BP 737
EP 743
DI 10.1007/s00280-009-1218-z
PG 7
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA 627TP
UT WOS:000280066100013
PM 20044751
ER
PT J
AU Fletcher, O
Johnson, N
Silva, ID
Orr, N
Ashworth, A
Nevanlinna, H
Heikkinen, T
Aittomaki, K
Blomqvist, C
Burwinkel, B
Bartram, CR
Meindl, A
Schmutzler, RK
Cox, A
Brock, I
Elliott, G
Reed, MWR
Southey, MC
Smith, L
Spurdle, AB
Hopper, JL
Couch, FJ
Olson, JE
Wang, XS
Fredericksen, Z
Schurmann, P
Waltes, R
Bremer, M
Dork, T
Devilee, P
van Asperen, CJ
Tollenaar, RAEM
Seynaeve, C
Hall, P
Czene, K
Humphreys, K
Liu, JJ
Ahmed, S
Dunning, AM
Maranian, M
Pharoah, PDP
Chenevix-Trench, G
Beesley, J
Bogdanova, NV
Antonenkova, NN
Zalutsky, IV
Anton-Culver, H
Ziogas, A
Brauch, H
Ko, YD
Hamann, U
Fasching, PA
Strick, R
Ekici, AB
Beckmann, MW
Giles, GG
Severi, G
Baglietto, L
English, DR
Milne, RL
Benitez, J
Arias, JI
Pita, G
Nordestgaard, BG
Bojesen, SE
Flyger, H
Kang, D
Yoo, KY
Noh, DY
Mannermaa, A
Kataja, V
Kosma, VM
Garcia-Closas, M
Chanock, S
Lissowska, J
Brinton, LA
Chang-Claude, J
Wang-Gohrke, S
Broeks, A
Schmidt, MK
van Leeuwen, FE
Van't Veer, LJ
Margolin, S
Lindblom, A
Humphreys, MK
Morrison, J
Platte, R
Easton, DF
Peto, J
AF Fletcher, Olivia
Johnson, Nichola
Silva, Isabel dos Santos
Orr, Nick
Ashworth, Alan
Nevanlinna, Heli
Heikkinen, Tuomas
Aittomaki, Kristiina
Blomqvist, Carl
Burwinkel, Barbara
Bartram, Claus R.
Meindl, Alfons
Schmutzler, Rita K.
Cox, Angela
Brock, Ian
Elliott, Graeme
Reed, Malcolm W. R.
Southey, Melissa C.
Smith, Letitia
Spurdle, Amanda B.
Hopper, John L.
Couch, Fergus J.
Olson, Janet E.
Wang, Xianshu
Fredericksen, Zachary
Schuermann, Peter
Waltes, Regina
Bremer, Michael
Doerk, Thilo
Devilee, Peter
van Asperen, Christie J.
Tollenaar, Rob A. E. M.
Seynaeve, Caroline
Hall, Per
Czene, Kamila
Humphreys, Keith
Liu, Jianjun
Ahmed, Shahana
Dunning, Alison M.
Maranian, Melanie
Pharoah, Paul D. P.
Chenevix-Trench, Georgia
Beesley, Jonathan
Bogdanova, Natalia V.
Antonenkova, Natalia N.
Zalutsky, Iosif V.
Anton-Culver, Hoda
Ziogas, Argyrios
Brauch, Hiltrud
Ko, Yon-Dschun
Hamann, Ute
Fasching, Peter A.
Strick, Reiner
Ekici, Arif B.
Beckmann, Matthias W.
Giles, Graham G.
Severi, Gianluca
Baglietto, Laura
English, Dallas R.
Milne, Roger L.
Benitez, Javier
Ignacio Arias, Jose
Pita, Guillermo
Nordestgaard, Borge G.
Bojesen, Stig E.
Flyger, Henrik
Kang, Daehee
Yoo, Keun-Young
Noh, Dong Young
Mannermaa, Arto
Kataja, Vesa
Kosma, Veli-Matti
Garcia-Closas, Montserrat
Chanock, Stephen
Lissowska, Jolanta
Brinton, Louise A.
Chang-Claude, Jenny
Wang-Gohrke, Shan
Broeks, Annegien
Schmidt, Marjanka K.
van Leeuwen, Flora E.
Van't Veer, Laura J.
Margolin, Sara
Lindblom, Annika
Humphreys, Manjeet K.
Morrison, Jonathan
Platte, Radka
Easton, Douglas F.
Peto, Julian
CA KConFab Investigators
AOCS Grp
GENICA Consortium
Breast Canc Assoc Consortium
TI Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842
Controls
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ATAXIA-TELANGIECTASIA; SUSCEPTIBILITY ALLELES;
CONFER SUSCEPTIBILITY; TRUNCATING MUTATIONS; COMMON VARIANTS; RISK;
GENE; SPECTRUM; PROTEIN
AB Background: Truncating mutations in ATM have been shown to increase the risk of breast cancer but the effect of missense variants remains contentious.
Methods: We have genotyped five polymorphic (minor allele frequency, 0.9-2.6%) missense single nucleotide polymorphisms (SNP) in ATM (S49C, S707P, F858L, P1054R, and L1420F) in 26,101 breast cancer cases and 29,842 controls from 23 studies in the Breast Cancer Association Consortium.
Results: Combining the data from all five SNPs, the odds ratio (OR) was 1.05 for being a heterozygote for any of the SNPs and 1.51 for being a rare homozygote for any of the SNPs with an overall trend OR of 1.06 (P(trend) = 0.04). The trend OR among bilateral and familial cases was 1.12 (95% confidence interval, 1.02-1.23; P(trend) = 0.02).
Conclusions: In this large combined analysis, these five missense ATM SNPs were associated with a small increased risk of breast cancer, explaining an estimated 0.03% of the excess familial risk of breast cancer.
Impact: Testing the combined effects of rare missense variants in known breast cancer genes in large collaborative studies should clarify their overall contribution to breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev; 19(9); 2143-51. (C) 2010 AACR.
C1 [Fletcher, Olivia; Johnson, Nichola; Orr, Nick; Ashworth, Alan] Inst Canc Res, Breakthrough Breast Canc Res Ctr, BBCS, London SW3 6JB, England.
[Fletcher, Olivia; Silva, Isabel dos Santos; Peto, Julian] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
[Peto, Julian] Inst Canc Res, Surrey, England.
[Nevanlinna, Heli; Heikkinen, Tuomas] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, Helsinki Breast Canc Study HEBCS, FIN-00290 Helsinki, Finland.
[Aittomaki, Kristiina] Univ Helsinki, Cent Hosp, Dept Clin Genet, Helsinki Breast Canc Study HEBCS, Helsinki, Finland.
[Blomqvist, Carl] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki Breast Canc Study HEBCS, Helsinki, Finland.
[Bartram, Claus R.] Univ Heidelberg, Inst Human Genet, GC HBOC, Heidelberg, Germany.
[Burwinkel, Barbara] German Canc Res Ctr, Mol Epidemiol Grp, Heidelberg, Germany.
[Meindl, Alfons] Tech Univ Munich, Dept Obstet & Gynaecol, Munich, Germany.
[Schmutzler, Rita K.] Univ Cologne, Dept Obstet & Gynaecol, Ctr Clin, Cologne, Germany.
[Reed, Malcolm W. R.] Univ Sheffield, Sch Med, Acad Unit Surg Oncol, SBCS, Sheffield, S Yorkshire, England.
[Cox, Angela; Brock, Ian; Elliott, Graeme] Univ Sheffield, Sch Med, Inst Canc Studies, SBCS, Sheffield, S Yorkshire, England.
[Southey, Melissa C.; Smith, Letitia; Hopper, John L.; Bojesen, Stig E.; Flyger, Henrik] Univ Melbourne, ABCFS, Melbourne, Vic 3010, Australia.
[Spurdle, Amanda B.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[Couch, Fergus J.; Wang, Xianshu] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Couch, Fergus J.; Olson, Janet E.; Fredericksen, Zachary] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Schuermann, Peter; Doerk, Thilo] Hannover Med Sch, Dept Obstet & Gynaecol, Hannover Breast Canc Study HABCS, D-3000 Hannover, Germany.
[Waltes, Regina; Bremer, Michael] Hannover Med Sch, Dept Radiat Oncol, Hannover Breast Canc Study HABCS, D-3000 Hannover, Germany.
[Devilee, Peter] Leiden Univ, Dept Human Genet, Med Ctr, Breast Canc Study ORIGO, NL-2300 RA Leiden, Netherlands.
[Devilee, Peter] Leiden Univ, Dept Pathol, Med Ctr, Breast Canc Study ORIGO, Leiden, Netherlands.
[van Asperen, Christie J.] Leiden Univ, Dept Clin Genet, Med Ctr, Breast Canc Study ORIGO, Leiden, Netherlands.
[Tollenaar, Rob A. E. M.] Leiden Univ, Dept Surg, Med Ctr, Breast Canc Study ORIGO, Leiden, Netherlands.
[Seynaeve, Caroline] Erasmus MC Daniel Hoed Canc Ctr, Rotterdam Family Canc Clin, Dept Med Oncol, Rotterdam, Netherlands.
[Hall, Per; Czene, Kamila; Humphreys, Keith] Karolinska Inst, Dept Med Epidemiol & Biostat, Singapore & Swedish Breast Canc Study SASBAC, Stockholm, Sweden.
[Liu, Jianjun] Genome Inst Singapore, Human Genet Lab, Singapore, Singapore.
[Ahmed, Shahana; Dunning, Alison M.; Maranian, Melanie; Pharoah, Paul D. P.] Univ Cambridge, Dept Oncol, Studies Epidemiol & Risk Factors Canc Hered SEARC, Cambridge, England.
[Pharoah, Paul D. P.] Univ Cambridge, Dept Publ Hlth & Primary Care, Studies Epidemiol & Risk Factors Canc Hered SEARC, Cambridge, England.
[Chenevix-Trench, Georgia; Beesley, Jonathan] Queensland Inst Med Res, Kathleen Cuningham Fdn Consortium Res Familial Br, Brisbane, Qld 4006, Australia.
[Chenevix-Trench, Georgia; Beesley, Jonathan] Peter MacCallum Canc Ctr, Australian Ovarian Canc Study AOCS, Melbourne, Vic, Australia.
[Bogdanova, Natalia V.] Hannover Med Sch, HMBCS, Dept Obstet & Gynaecol, D-3000 Hannover, Germany.
[Bogdanova, Natalia V.] Hannover Med Sch, HMBCS, Dept Radiat Oncol, D-3000 Hannover, Germany.
[Bogdanova, Natalia V.; Antonenkova, Natalia N.; Zalutsky, Iosif V.] NN Alexandrov Res Inst Oncol & Med Radiol, Minsk, Byelarus.
[Anton-Culver, Hoda; Ziogas, Argyrios] Univ Calif Irvine, Dept Epidemiol, Breast Canc Study, Irvine, CA USA.
[Brauch, Hiltrud] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Gene Environm Interact & Breast Canc Germany GENI, D-7000 Stuttgart, Germany.
[Hamann, Ute] Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany.
[Brauch, Hiltrud] Univ Tubingen, Tubingen, Germany.
[Ko, Yon-Dschun] Johanniter Krankenhaus, Evangel Kliniken Bonn gGmbH, Dept Internal Med, Bonn, Germany.
Univ Bochum, Inst Ruhr, BGFA Res Inst Occupat Med,German Social Accid Ins, Bochum, Germany.
[Fasching, Peter A.; Strick, Reiner; Beckmann, Matthias W.] Univ Hosp Erlangen, Bavarian Breast Canc Cases & Controls BBCC, Univ Breast Ctr, Erlangen, Germany.
[Ekici, Arif B.] Univ Hosp Erlangen, Bavarian Breast Canc Cases & Controls BBCC, Inst Human Genet, Erlangen, Germany.
[Fasching, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Gynecol & Obstet, Los Angeles, CA 90095 USA.
[Giles, Graham G.; Severi, Gianluca; Baglietto, Laura] Canc Council Victoria, Melbourne Collaborat Cohort Study MCCS, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
[English, Dallas R.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
[Milne, Roger L.; Benitez, Javier; Pita, Guillermo] Spanish Natl Canc Ctr, Breast Canc Study CNIO BCS Study, Madrid, Spain.
[Benitez, Javier] CIBERER, Valencia, Spain.
[Ignacio Arias, Jose] Monte Naranco Hosp, Oviedo, Spain.
[Nordestgaard, Borge G.] Univ Copenhagen, Herlev Univ Hosp, Copenhagen Breast Canc Study, Dept Clin Biochem, Copenhagen, Denmark.
[Nordestgaard, Borge G.] Univ Copenhagen, Herlev Univ Hosp, Copenhagen Breast Canc Study, Dept Breast Surg, Copenhagen, Denmark.
[Nordestgaard, Borge G.] Univ Copenhagen, Herlev Univ Hosp, CGPS, Dept Breast Surg, Copenhagen, Denmark.
[Nordestgaard, Borge G.] Univ Copenhagen, Herlev Univ Hosp, CGPS, Dept Clin Biochem, Copenhagen, Denmark.
[Kang, Daehee; Yoo, Keun-Young; Noh, Dong Young] Seoul Natl Univ, Coll Med, Seoul Breast Canc Study SEBCS, Seoul, South Korea.
[Mannermaa, Arto; Kosma, Veli-Matti] Univ Kuopio, KBCP, Inst Clin Med Pathol & Forens Med, FIN-70211 Kuopio, Finland.
[Mannermaa, Arto; Kosma, Veli-Matti] Kuopio Univ Hosp, Dept Pathol, SF-70210 Kuopio, Finland.
[Mannermaa, Arto; Kataja, Vesa; Kosma, Veli-Matti] Bioctr Kuopio, Kuopio, Finland.
[Kataja, Vesa] Kuopio Univ Hosp, Dept Oncol, SF-70210 Kuopio, Finland.
[Kataja, Vesa] Vaasa Cent Hosp, Dept Oncol, Vaasa, Finland.
[Garcia-Closas, Montserrat; Chanock, Stephen; Brinton, Louise A.] NCI, PBCS, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Lissowska, Jolanta] M Sklodowska Curie Canc Ctr, Dept Epidemiol & Canc Prevent, Warsaw, Poland.
[Lissowska, Jolanta] Inst Oncol, Warsaw, Poland.
[Chang-Claude, Jenny] German Canc Res Ctr DFKZ, Genet Epidemiol Study Breast Canc Age 50, Heidelberg, Germany.
[Wang-Gohrke, Shan] Ulm Med Sch, Dept Gynecol & Obstet, Ulm, Germany.
[Broeks, Annegien; Schmidt, Marjanka K.; van Leeuwen, Flora E.; Van't Veer, Laura J.] Netherlands Canc Inst, ABCS, Amsterdam, Netherlands.
[Margolin, Sara; Lindblom, Annika] Karolinska Inst, Dept Pathol & Oncol, Dept Mol Med & Surg, Karloinska Breast Canc Study KARBAC, Stockholm, Sweden.
[Humphreys, Manjeet K.; Morrison, Jonathan; Platte, Radka; Easton, Douglas F.] Univ Cambridge, Dept Publ Hlth & Primary Care, Canc Res UK Genet Epidemiol Unit, BCAC, Cambridge, England.
[Burwinkel, Barbara] Univ Heidelberg, Dept Obstet & Gynecol, GC HBOC, Heidelberg, Germany.
RP Fletcher, O (reprint author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, BBCS, 237 Fulham Rd, London SW3 6JB, England.
EM olivia.fletcher@icr.ac.uk
RI Noh, Dong-Young/G-5531-2011; Kang, Dae Hee/E-8631-2012; Yoo,
Keun-Young/J-5548-2012; Ekici, Arif/C-3971-2013; Smith, Letitia
/J-9035-2014; Garcia-Closas, Montserrat /F-3871-2015; Brinton,
Louise/G-7486-2015; Dork, Thilo/J-8620-2012; Bowtell, David/H-1007-2016;
Spurdle, Amanda/A-4978-2011;
OI Dunning, Alison Margaret/0000-0001-6651-7166; Nevanlinna,
Heli/0000-0002-0916-2976; dos Santos Silva, Isabel/0000-0002-6596-8798;
Cox, Angela/0000-0002-5138-1099; Giles, Graham/0000-0003-4946-9099;
English, Dallas/0000-0001-7828-8188; Czene, Kamila/0000-0002-3233-5695;
Garcia-Closas, Montserrat /0000-0003-1033-2650; Brinton,
Louise/0000-0003-3853-8562; Bowtell, David/0000-0001-9089-7525; Spurdle,
Amanda/0000-0003-1337-7897; Lissowska, Jolanta/0000-0003-2695-5799
FU Breakthrough Breast Cancer; NHS; National Cancer Research Network;
Helsinki University Central Hospital; Academy of Finland [110663];
Finnish Cancer Society; Sigrid Juselius Foundation; Deutsche Krebshilfe
[107054]; Center of Molecular Medicine; Cologne; Helmholtz Society;
Dietmar-Hopp Foundation; Yorkshire Cancer Research and the Breast Cancer
Campaign; National Health and Medical Research Council of Australia
(NHMRC) [145604, 145684, 288704, 454508, 199600, 209057, 251533,
396414]; NIH [CA102740-01A2, CA122340, CA128978, CA116201]; National
Cancer Institute, NIH [CA-95-011, CA-58860]; Cancer Care Ontario
[CA69467]; Columbia University [CA69398]; Fox Chase Cancer Center
[CA69631]; Huntsman Cancer Institute [CA69446]; Northern California
Cancer Center [CA69417]; University of Melbourn [CA69638]; New South
Wales Cancer Council; Victorian Health Promotion Foundation; Prostate
Cancer Foundation of Australia; Susan G. Komen Breast Cancer Foundation;
Hannover Medical School; German Research Foundation (DFG) [Do761/2-1];
German Academic Exchange Program; Dutch Cancer Society [NKI 2001-2423,
2007-3839]; Agency for Science, Technology and Research of Singapore
(A*STAR); National Breast Cancer Foundation; Chief Physician Johan
Boserup and Queensland Cancer Fund; Cancer Council of New South Wales;
Cancer Council of Victoria; Cancer Council of Tasmania; Cancer Council
of South Australia; Cancer Foundation of Western Australia; U.S. Army
[DAMD17-01-1-0729]; Lon V Smith Foundation [LVS-18840]; German Human
Genome Project; German Federal Ministry of Education and Research (BMBF)
[01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114]; Robert Bosch Foundation
of Medical Research, Stuttgart, Germany; Deutsches
Krebsforschungszentrum, Heidelberg, Germany; University Hospital of
Erlangen; VicHealth; Genome Spain Foundation; Red Tematica de
Investigacion Cooperativa en Cancer; Asociacion Espanola Contra Cancer;
Fondo de Investigacion Sanitario [PI081120, PI081583]; Lise Boserup
Fund; Danish Medical Research Council; Copenhagen University Hospital;
Herlev Hospital; National Research and Development (R&D) Program for
Cancer Control [0620410-1]; Ministry of Health and Welfare, Republic of
Korea [AO30001]; Kuopio University Hospital; Finnish Cancer Foundation;
National Cancer Institute, Department of Health and Human Services;
Deutsche Krebshilfe e.V. [70492]; Dutch National Genomics Initiative;
Swedish Cancer Society; Gustav V Julilee Foundation; European Union
[BM0606]; Cancer Research UK (CR-UK) [C490/A11021, C8197/A10865,
C1287/A10118, C1287/A7497]
FX The BBCS is funded by Cancer Research UK (CR-UK) and Breakthrough Breast
Cancer and acknowledges NHS funding to the NIHR Biomedical Research
Centre and the National Cancer Research Network. The HEBCS study has
been financially supported by the Helsinki University Central Hospital
Research Fund, Academy of Finland grant 110663, the Finnish Cancer
Society, and the Sigrid Juselius Foundation. The GC-HBOC study was
supported by Deutsche Krebshilfe grant 107054, the Center of Molecular
Medicine, Cologne, the Helmholtz Society, and the Dietmar-Hopp
Foundation. The SBCS was supported by Yorkshire Cancer Research and the
Breast Cancer Campaign. The ABCFS was supported by National Health and
Medical Research Council of Australia (NHMRC) grant 145604, NIH grant
CA102740-01A2, and National Cancer Institute, NIH grant CA-95-011
through cooperative agreements with members of the Breast Cancer Family
Registry and principal investigators, Cancer Care Ontario grant CA69467,
Columbia University grant CA69398, Fox Chase Cancer Center grant
CA69631, Huntsman Cancer Institute grant CA69446, Northern California
Cancer Center grant CA69417, and University of Melbourne grant CA69638.
The content of this manuscript does not necessarily reflect the views or
policies of the National Cancer Institute or any of collaborating
centers in the Breast CFR, nor does mention of trade names, commercial
products, or organizations imply endorsement by the U.S. Government or
the Breast CFR. The ABCFS was initially supported by the NHMRC, the New
South Wales Cancer Council, and the Victorian Health Promotion
Foundation. J.L. Hopper is an Australia Fellow of the NHMRC and
Victorian Breast Cancer Research Consortium Group Leader. M. C. Southey
and A. B. Spurdle are Senior Research Fellows of the NHMRC. Genotyping
was in part supported by the Prostate Cancer Foundation of Australia.
The MCBCS was supported by NIH grants CA122340 and CA128978, an NIH
Breast Cancer Specialized Program of Research Excellence award to the
Mayo Clinic (CA116201), and a Susan G. Komen Breast Cancer Foundation
award. The HABCS was supported by an intramural grant from Hannover
Medical School and German Research Foundation (DFG) grant Do761/2-1. The
HMBCS was supported by short-term fellowships from the German Academic
Exchange Program (N. Bogdanova) and the Friends of Hannover Medical
School (N. Bogdanova). The ORIGO study was supported by the Dutch Cancer
Society. The SASBAC study was supported by the Agency for Science,
Technology and Research of Singapore (A*STAR), the NIH, and the Susan G.
Komen Breast Cancer Foundation. SEARCH is funded by CR-UK programme
grant C490/A11021. A. M. Dunning is supported by CR-UK grant
C8197/A10865 and P. D. P. Pharoah is a Senior Clinical Research Fellow
of CR-UK. kConFab is supported by grants from the National Breast Cancer
Foundation, the NHMRC, the Queensland Cancer Fund, the Cancer Councils
of New South Wales, Victoria, Tasmania, and South Australia, and the
Cancer Foundation of Western Australia. The kConFab Clinical Follow-Up
Study was funded by NHMRC grants 145684, 288704, and 454508. Financial
support for the AOCS was provided by U.S. Army Medical Research and
Materiel Command grant DAMD17-01-1-0729, the Cancer Council of Tasmania,
Cancer Foundation of Western Australia, and NHMRC grant 199600. G.
Chenevix-Trench is supported by the NHMRC. The UCIBCS is supported by
NIH, National Cancer Institute grant CA-58860 and Lon V Smith Foundation
grant LVS-18840.; The GENICA study was supported by the German Human
Genome Project and German Federal Ministry of Educaton and Research
(BMBF) grants 01KW9975/5, 01KW9976/8, 01KW9977/0, and 01KW0114.
Genotyping analysis was supported by the Robert Bosch Foundation of
Medical Research, Stuttgart, Germany, and the Deutsches
Krebsforschungszentrum, Heidelberg, Germany. The work of the BBCC was
partly funded by ELAN-Fond of the University Hospital of Erlangen.
Infrastructure support for the MCCS recruitment and follow-up is
provided by The Cancer Council Victoria, whereas cohort recruitment was
partly funded by VicHealth. This work using the MCCS was supported by
NHMRC grants 209057, 251533, and 396414 and genotyping was in part
supported by the Prostate Cancer Foundation of Australia. The CNIO-BCS
was supported by the Genome Spain Foundation, the Red Tematica de
Investigacion Cooperativa en Cancer, the Asociacion Espanola Contra
Cancer, and Fondo de Investigacion Sanitario grants PI081120 (J.
Beesley) and PI081583 (R.L. Milne.). The CGPS was supported by the Chief
Physician Johan Boserup and Lise Boserup Fund, the Danish Medical
Research Council, and Copenhagen University Hospital, Herlev Hospital.
The SEBCS was supported National Research and Development (R&D) Program
for Cancer Control grant 0620410-1 and Korea Health 21 R&D Project grant
AO30001, Ministry of Health and Welfare, Republic of Korea. The KBCP is
supported by the EVO funds of Kuopio University Hospital and the Finnish
Cancer Foundation. The PBCS was funded by Intramural Research Funds of
the National Cancer Institute, Department of Health and Human Services.
The GESBC was supported by Deutsche Krebshilfe e.V. grant 70492. Funding
for the ABCS was provided by Dutch Cancer Society grants NKI 2001-2423
and 2007-3839 and the Dutch National Genomics Initiative. KARBAC
acknowledges funding from the Swedish Cancer Society and the Gustav V
Julilee Foundation. The BCAC is funded by CR-UK grants C1287/A10118 and
C1287/A7497. Meetings of the BCAC have been funded by the European Union
COST Programme (BM0606). D. F. Easton is a Principal Research Fellow of
CR-UK.
NR 36
TC 16
Z9 16
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD SEP
PY 2010
VL 19
IS 9
BP 2143
EP 2151
DI 10.1158/1055-9965.EPI-10-0374
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 648HS
UT WOS:000281683800004
PM 20826828
ER
PT J
AU George, SM
Neuhouser, ML
Mayne, ST
Irwin, ML
Albanes, D
Gail, MH
Alfano, CM
Bernstein, L
McTiernan, A
Reedy, J
Smith, AW
Ulrich, CM
Ballard-Barbash, R
AF George, Stephanie M.
Neuhouser, Marian L.
Mayne, Susan T.
Irwin, Melinda L.
Albanes, Demetrius
Gail, Mitchell H.
Alfano, Catherine M.
Bernstein, Leslie
McTiernan, Anne
Reedy, Jill
Smith, Ashley W.
Ulrich, Cornelia M.
Ballard-Barbash, Rachel
TI Postdiagnosis Diet Quality Is Inversely Related to a Biomarker of
Inflammation among Breast Cancer Survivors
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID C-REACTIVE PROTEIN; OBESE POSTMENOPAUSAL WOMEN; HEALTHY EATING
INDEX-2005; PHYSICAL-ACTIVITY; SOLEUS MUSCLE; WEIGHT-LOSS; ADIPONECTIN;
ADIPOKINES; PATTERNS; QUESTIONNAIRE
AB Background: Inflammation and immune response have potential prognostic implications for breast cancer survivors. We examined how postdiagnosis diet quality is cross-sectionally related to biomarkers of inflammation and adipose-derived hormones among breast cancer survivors and determined whether physical activity or body size modified any observed associations.
Methods: Participants included 746 women diagnosed with stage 0 to IIIA breast cancer. Thirty months after diagnosis, the women completed food frequency questionnaires. We scored diet quality with the Healthy Eating Index (HEI)-2005. Serum concentrations of C-reactive protein (CRP), serum amyloid A, leptin, and adiponectin were measured in fasting 30 mL blood samples. Log biomarker values were regressed on quartiles of HEI-2005 scores in multivariate models, and beta scores were exponentiated and expressed as geometric means within quartiles of HEI-2005 scores.
Results: Women with better versus poor quality postdiagnosis diets, as defined by higher HEI-2005 scores (Q4 versus Q1), had lower concentrations of CRP (1.6 mg/L versus 2.5 mg/L), but no significant difference in concentrations of serum amyloid A, leptin, or adiponectin. Among women not engaging in recreational physical activity after diagnosis, better diet quality was associated with lower CRP concentrations (2.5 mg/L versus 5.0 mg/L), but no association was observed among women engaging in any recreational physical activity (1.4 mg/L versus 1.6 mg/L; P heterogeneity = 0.03).
Conclusions: Among breast cancer survivors, a better-quality diet seems to be associated with lower levels of chronic inflammation.
Impact: Lower levels of chronic inflammation have been associated with improved survival after breast cancer. Cancer Epidemiol Biomarkers Prev; 19(9); 2220-8. (C) 2010 AACR.
C1 [George, Stephanie M.; Mayne, Susan T.; Irwin, Melinda L.] Yale Univ, Sch Publ Hlth, Div Chron Dis Epidemiol, New Haven, CT USA.
[George, Stephanie M.; Albanes, Demetrius] NCI, Nutr Epidemiol Branch, Rockville, MD USA.
[Gail, Mitchell H.] NCI, Biostat Branch, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Alfano, Catherine M.] NCI, Off Canc Survivorship, Rockville, MD USA.
[Reedy, Jill; Smith, Ashley W.; Ballard-Barbash, Rachel] NCI, Appl Res Program, Div Canc Control & Populat Sci, Rockville, MD USA.
[Neuhouser, Marian L.; McTiernan, Anne; Ulrich, Cornelia M.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA USA.
[Ulrich, Cornelia M.] German Canc Res Ctr, D-6900 Heidelberg, Germany.
[Ulrich, Cornelia M.] Natl Ctr Tumor Dis, Heidelberg, Germany.
RP George, SM (reprint author), NCI, 6120 Execut Blvd,Suite 320,MSC 7232, Bethesda, MD 20892 USA.
EM materess@mail.nih.gov
RI Albanes, Demetrius/B-9749-2015
FU National Cancer Institute [N01-CN-75036-20, NO1-CN-05228, NO1-PC-67010,
T32 CA09661, T32 CA105666]; National Institutes of Health
[M01-RR-00037]; University of New Mexico [NCRR M01-RR-0997]; National
Institute of Child Health and Human Development [N01-HD-3-3175];
California Department of Health Services [050Q-8709-S1528]
FX National Cancer Institute Grants N01-CN-75036-20, NO1-CN-05228,
NO1-PC-67010, T32 CA09661 and T32 CA105666. A portion of this work was
conducted through the Clinical Research Center at the University of
Washington and supported by the National Institutes of Health Grant
M01-RR-00037 and the University of New Mexico Grant NCRR M01-RR-0997.
Data collection for the Women's Contraceptive and Reproductive
Experiences Study at the University of Southern California was supported
by Contract No. N01-HD-3-3175 from the National Institute of Child
Health and Human Development, and patient identification was supported
in part by Contract 050Q-8709-S1528 from the California Department of
Health Services.
NR 40
TC 27
Z9 28
U1 2
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD SEP
PY 2010
VL 19
IS 9
BP 2220
EP 2228
DI 10.1158/1055-9965.EPI-10-0464
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 648HS
UT WOS:000281683800011
PM 20716617
ER
PT J
AU Douglas, JB
Silverman, DT
Pollak, MN
Tao, YZ
Soliman, AS
Stolzenberg-Solomon, RZ
AF Douglas, Jason B.
Silverman, Debra T.
Pollak, Michael N.
Tao, Yuzhen
Soliman, Amr S.
Stolzenberg-Solomon, Rachael Z.
TI Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of
Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GROWTH-FACTOR-I; BINDING-PROTEINS; FACTOR SYSTEM; INSULIN; AUTOCRINE;
RECEPTOR; TUMORIGENESIS; EXPRESSION; HEALTH; CELLS
AB Background: Experimental evidence suggests that an overexpression of insulin-like growth factor (IGF)-I is implicated in human pancreatic tumors. Increased IGF-II and decreased IGF binding protein (IGFBP)-3 serum concentrations have been linked to a number of other cancers.
Methods: We conducted a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial cohort of men and women 55 to 74 years of age at baseline to test whether prediagnostic circulating IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio concentrations were associated with exocrine pancreatic cancer risk. Between 1994 and 2006, 187 incident cases of pancreatic adenocarcinoma occurred (follow-up of up to 11.7 years). Two controls (n = 374), who were alive at the time the case was diagnosed, were selected for each case and matched by age, race, sex, and date of blood draw. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) with the use of conditional logistic regression, adjusting for smoking.
Results: IGF-I, IGF-II, and IGFBP-3 concentrations were not significantly associated with pancreatic cancer (highest compared with lowest quartile: OR, 1.58; 95% CI, 0.91-2.76; and P-trend = 0.25; OR, 0.86; 95% CI, 0.49-1.50; and P-trend = 0.31; and OR, 0.88; 95% CI, 0.51-1.51; and P-trend = 0.47, respectively). However, a significant positive trend was observed with high IGF-I/IGFBP-3 molar ratio levels (highest compared with lowest quartile: OR, 1.54; 95% CI, 0.89-2.66; P-trend = 0.04).
Conclusion: A higher IGF-I/IGFBP-3 molar ratio represents increased free IGF-I, which may be a risk factor for pancreatic cancer.
Impact: Our results highlight the importance of this biomarker for further investigation in large prospective cohort studies and pooled analysis with other prospective cohorts. Cancer Epidemiol Biomarkers Prev; 19(9); 2298-306. (C) 2010 AACR.
C1 [Douglas, Jason B.; Stolzenberg-Solomon, Rachael Z.] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv, Rockville, MD USA.
[Silverman, Debra T.] NCI, Occupat Epidemiol Branch, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv, Rockville, MD USA.
[Douglas, Jason B.; Soliman, Amr S.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
[Pollak, Michael N.; Tao, Yuzhen] McGill Univ, Jewish Gen Hosp, Canc Prevent Program, Montreal, PQ H3T 1E2, Canada.
[Pollak, Michael N.; Tao, Yuzhen] McGill Univ, Montreal, PQ, Canada.
RP Stolzenberg-Solomon, RZ (reprint author), Suite 320,6120 Execut Blvd, Rockville, MD 20852 USA.
EM rs221z@nih.gov
RI Pollak, Michael/G-9094-2011
OI Pollak, Michael/0000-0003-3047-0604
FU NIH, Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Department of Health and Human Services
FX NIH Intramural Research Program, Division of Cancer Epidemiology and
Genetics, National Cancer Institute, Department of Health and Human
Services.
NR 32
TC 37
Z9 38
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD SEP
PY 2010
VL 19
IS 9
BP 2298
EP 2306
DI 10.1158/1055-9965.EPI-10-0400
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 648HS
UT WOS:000281683800020
PM 20699371
ER
PT J
AU Bradford, PT
Anderson, WF
Purdue, MP
Goldstein, AM
Tucker, MA
AF Bradford, Porcia T.
Anderson, William F.
Purdue, Mark P.
Goldstein, Alisa M.
Tucker, Margaret A.
TI Rising Melanoma Incidence Rates of the Trunk among Younger Women in the
United States
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID CUTANEOUS MALIGNANT-MELANOMA; PERIOD-COHORT MODELS; SUN EXPOSURE;
AGE-PERIOD; SITE DISTRIBUTION; ANATOMIC SITE; TRENDS; ASSOCIATION; SEX
AB Background: Melanoma rates are rising among young women, possibly due to increasing UV radiation to previously protected body sites. Therefore, we examined melanoma incidence trends by age, gender, and body site. Descriptive methods were complemented with the age-period-cohort parameters net drift and longitudinal age trend.
Methods: Case and population data were obtained from the Surveillance, Epidemiology, and End Results (SEER) 9 Registries Database (1975-2006). Net drift summarized the average annual percentage change in log-linear rates per year of calendar-time (or year of diagnosis). Longitudinal age trend summarized the average annual percentage change by attained age at diagnosis. Early-and late-onset melanomas have low and high longitudinal age trends, respectively.
Results: There were 105,829 melanomas diagnosed in the SEER 9 Registries. The overall age-adjusted incidence rate (IR) for melanoma was 17.7/100,000 person-years. Age-specific IRs were greater among women than men prior to age 40 years. Among women, IRs decreased for all anatomic sites relative to the trunk. The highest net drift occurred in truncal lesions among women (net drift, 3.8%/year of calendar time; 95% confidence interval, 3.5-4.0%). The lowest longitudinal age trends also were observed for truncal lesions among women (longitudinal age trend, 5.4%/year of attained age; 95% confidence interval, 5.1-5.7).
Conclusions: Although melanoma IRs overall have risen for decades, the combination of high net drift and low longitudinal age trend show that melanomas are rising preferentially on the trunk among young women.
Impact: Future surveillance and analytic studies should consider melanoma effect modification by age, gender, and body site. Cancer Epidemiol Biomarkers Prev; 19(9); 2401-6. (C) 2010 AACR.
C1 [Bradford, Porcia T.; Goldstein, Alisa M.; Tucker, Margaret A.] NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Anderson, William F.; Purdue, Mark P.] NCI, Biostat Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
RP Bradford, PT (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, 6120 Execut Blvd,EPS,Room 7005, Rockville, MD 20852 USA.
EM bradfordp@mail.nih.gov
RI Tucker, Margaret/B-4297-2015; Purdue, Mark/C-9228-2016
OI Purdue, Mark/0000-0003-1177-3108
FU National Institutes of Health; National Cancer Institute, Division of
Cancer Epidemiology and Genetics
FX Grant Support; Intramural Research Program of the National Institutes of
Health and the National Cancer Institute, Division of Cancer
Epidemiology and Genetics. The SEER Program is operated by the National
Cancer Institute Surveillance Research Program.
NR 25
TC 40
Z9 40
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD SEP
PY 2010
VL 19
IS 9
BP 2401
EP 2406
DI 10.1158/1055-9965.EPI-10-0503
PG 6
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 648HS
UT WOS:000281683800031
PM 20826837
ER
PT J
AU Amaral, AFS
Cantor, KP
Silverman, DT
Malats, N
AF Amaral, Andre F. S.
Cantor, Kenneth P.
Silverman, Debra T.
Malats, Nuria
TI Selenium and Bladder Cancer Risk: a Meta-analysis
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID PROSTATE-CANCER; TOENAIL SELENIUM; SELENIFEROUS AREA; SERUM SELENIUM;
PREVENTION; SUPPLEMENTATION; TRIAL; HETEROGENEITY; MECHANISMS;
BIOMARKERS
AB Background: Selenium is considered to be an antioxidant, and its high levels have been inversely associated with cancer risk of several sites. This meta-analysis examined the relationship between levels of selenium measured in serum and toenails, and the risk of bladder cancer.
Methods: A meta-analysis using data from seven published epidemiologic studies (three case-control, three nested case-control, one case-cohort) published before March 2010 was done to examine the association between levels of selenium and bladder cancer. Fixed and random effects analyses were done to calculate meta-odds ratio (mOR) and 95% confidence intervals (CI). Heterogeneity among studies was measured by the I(2) statistic.
Results: Overall, the risk of bladder cancer was inversely associated with elevated levels of selenium according to a random-effects model (mOR = 0.61; 95% CI, 0.42-0.87). The mORs were 0.95 (95% CI, 0.69-1.27) and 0.55 (95% CI, 0.32-0.95) among men and women, respectively. Sex, type of sample specimen, smoking status, and study design were found to be potential sources of heterogeneity.
Conclusions: A significant protective effect of selenium, observed mainly among women, may result from gender-specific differences in its accumulation and excretion. The heterogeneity found among studies was mainly linked to the different biological sample specimens used to measure the selenium concentrations and the small size of the studies. Although these results suggest a protective effect of selenium for bladder cancer risk, additional large studies are warranted to support these preliminary evidence.
Impact: The present results suggest a beneficial effect of high selenium intake for bladder cancer risk. Cancer Epidemiol Biomarkers Prev; 19(9); 2407-15. (C) 2010 AACR.
C1 [Amaral, Andre F. S.; Malats, Nuria] Spanish Natl Canc Res Ctr, Genet & Mol Epidemiol Grp, Madrid 28029, Spain.
[Silverman, Debra T.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Malats, N (reprint author), Spanish Natl Canc Res Ctr, Genet & Mol Epidemiol Grp, C Melchor Fernandez Almagro 3, Madrid 28029, Spain.
EM nmalats@cnio.es
RI Malats, Nuria/H-7041-2015; Amaral, Andre/A-7662-2008
OI Malats, Nuria/0000-0003-2538-3784; Amaral, Andre/0000-0002-0369-9449
FU Red Tematica de Investigacion Cooperativa en Cancer; Instituto de Salud
Carlos III; Spanish Ministry of Science and Innovation; Association for
International Cancer Research [AICR09-0780]
FX Grant Support; Red Tematica de Investigacion Cooperativa en Cancer,
Instituto de Salud Carlos III, Spanish Ministry of Science and
Innovation, and by the Association for International Cancer Research
(AICR09-0780).
NR 40
TC 49
Z9 52
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD SEP
PY 2010
VL 19
IS 9
BP 2407
EP 2415
DI 10.1158/1055-9965.EPI-10-0544
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 648HS
UT WOS:000281683800032
PM 20807831
ER
PT J
AU Memmott, RM
Mercado, JR
Maier, CR
Kawabata, S
Fox, SD
Dennis, PA
AF Memmott, Regan M.
Mercado, Jose R.
Maier, Colleen R.
Kawabata, Shigeru
Fox, Stephen D.
Dennis, Phillip A.
TI Metformin Prevents Tobacco Carcinogen-Induced Lung Tumorigenesis
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; A/J MICE; DIABETES-MELLITUS; DEFICIENT MICE;
BREAST-CANCER; T-CELLS; IN-VIVO; DIET; GROWTH; MECHANISM
AB Activation of the mammalian target of rapamycin (mTOR) pathway is an important and early event in tobacco carcinogen-induced lung tumorigenesis, and therapies that target mTOR could be effective in the prevention or treatment of lung cancer. The biguanide metformin, which is widely prescribed for the treatment of type II diabetes, might be a good candidate for lung cancer chemoprevention because it activates AMP-activated protein kinase (AMPK), which can inhibit the mTOR pathway. To test this, A/J mice were treated with oral metformin after exposure to the tobacco carcinogen 4-(methylnitrosamino)1-(3-pyridyl)-1-butanone (NNK). Metformin reduced lung tumor burden by up to 53% at steady-state plasma concentrations that are achievable in humans. mTOR was inhibited in lung tumors but only modestly. To test whether intraperitoneal administration of metformin might improve mTOR inhibition, we injected mice and assessed biomarkers in liver and lung tissues. Plasma levels of metformin were significantly higher after injection than oral administration. In liver tissue, metformin activated AMPK and inhibited mTOR. In lung tissue, metformin did not activate AMPK but inhibited phosphorylation of insulin-like growth factor-I receptor/insulin receptor (IGF-1R/IR), Akt, extracellular signal-regulated kinase (ERK), and mTOR. This suggested that metformin indirectly inhibited mTOR in lung tissue by decreasing activation of insulin-like growth factor-I receptor/insulin receptor and Akt upstream of mTOR. Based on these data, we repeated the NNK-induced lung tumorigenesis study using intraperitoneal administration of metformin. Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition of mTOR in tumors. These studies show that metformin prevents tobacco carcinogen-induced lung tumorigenesis and support clinical testing of metformin as a chemopreventive agent. Cancer Prev Res; 3(9); 1066-76. (C) 2010 AACR.
C1 [Memmott, Regan M.; Mercado, Jose R.; Maier, Colleen R.; Kawabata, Shigeru; Dennis, Phillip A.] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Fox, Stephen D.] Sci Applicat Int Corp Frederick Inc, Lab Prote & Analyt Technol, Frederick, MD USA.
RP Dennis, PA (reprint author), Natl Canc Inst Navy Med Oncol, Room 5101,Bldg 8,8901 Wisconsin Ave, Bethesda, MD 20889 USA.
EM pdennis@nih.gov
NR 40
TC 193
Z9 201
U1 2
U2 23
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD SEP
PY 2010
VL 3
IS 9
BP 1066
EP 1076
DI 10.1158/1940-6207.CAPR-10-0055
PG 11
WC Oncology
SC Oncology
GA 646KH
UT WOS:000281538400005
PM 20810672
ER
PT J
AU Tichelaar, JW
Yan, Y
Tan, Q
Wang, YA
Estensen, RD
Young, MR
Colburn, NH
Yin, HL
Goodin, C
Anderson, MW
You, M
AF Tichelaar, Jay W.
Yan, Ying
Tan, Qing
Wang, Yian
Estensen, Richard D.
Young, Matthew R.
Colburn, Nancy H.
Yin, Hulian
Goodin, Colleen
Anderson, Marshall W.
You, Ming
TI A Dominant-Negative c-jun Mutant Inhibits Lung Carcinogenesis in Mice
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID TRANSCRIPTION FACTOR; AP-1 ACTIVITY; CANCER CELLS; PULMONARY
CARCINOGENESIS; AEROSOLIZED BUDESONIDE; CHEMOPREVENTIVE AGENTS; INDUCED
TRANSFORMATION; GENE-EXPRESSION; TRANSGENIC MICE; TARGET GENES
AB Lung cancer is the leading cause of cancer mortality in the United States and worldwide. The identification of key regulatory and molecular mechanisms involved in lung tumorigenesis is therefore critical to increase our understanding of this disease and could ultimately lead to targeted therapies to improve prevention and treatment. Induction of members of the activator protein-1 (AP-1) transcription factor family has been described in human non-small cell lung carcinoma. Activation of AP-1 can either stimulate or repress transcription of multiple gene targets, ultimately leading to increased cell proliferation and inhibition of apoptosis. In the present study, we show induction of AP-1 in carcinogen-induced mouse lung tumors compared with surrounding normal lung tissue. We then used a transgenic mouse model directing conditional expression of the dominant-negative c-jun mutant TAM67 in lung epithelial cells to determine the effect of AP-1 inhibition on mouse lung tumorigenesis. Consistent with low AP-1 activity in normal lung tissue, TAM67 expression had no observed effects in adult mouse lung. TAM67 decreased tumor number and overall lung tumor burden in chemically induced mouse lung tumor models. The most significant inhibitory effect was observed on carcinoma burden compared with lower-grade lesions. Our results support the concept that AP-1 is a key regulator of mouse lung tumorigenesis, and identify AP-1-dependent transcription as a potential target to prevent lung tumor progression. Cancer Prev Res; 3(9); 1148-56. (C) 2010 AACR.
C1 [Tichelaar, Jay W.; Yan, Ying; Tan, Qing; Wang, Yian; You, Ming] Washington Univ, Dept Surg, Alvin J Siteman Canc Ctr, Sch Med, St Louis, MO 63110 USA.
[Estensen, Richard D.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
[Young, Matthew R.; Colburn, Nancy H.] NCI, Lab Canc Prevent, Frederick, MD 21701 USA.
[Yin, Hulian] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH USA.
[Goodin, Colleen; Anderson, Marshall W.] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH USA.
RP Tichelaar, JW (reprint author), Washington Univ, Dept Surg, Alvin J Siteman Canc Ctr, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA.
EM tichelaarj@wustl.edu
RI Tichelaar, Jay/B-9148-2011
FU NIH [P01CA096964, R03CA137819, R01CA139959]
FX NIH grants P01CA096964, R03CA137819, and R01CA139959.
NR 55
TC 6
Z9 6
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD SEP
PY 2010
VL 3
IS 9
BP 1148
EP 1156
DI 10.1158/1940-6207.CAPR-10-0023
PG 9
WC Oncology
SC Oncology
GA 646KH
UT WOS:000281538400014
PM 20716630
ER
PT J
AU Chow, HHS
Garland, LL
Hsu, CH
Vining, DR
Chew, WM
Miller, JA
Perloff, M
Crowell, JA
Alberts, DS
AF Chow, H-H. Sherry
Garland, Linda L.
Hsu, Chiu-Hsieh
Vining, Donna R.
Chew, Wade M.
Miller, Jessica A.
Perloff, Marjorie
Crowell, James A.
Alberts, David S.
TI Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a
Healthy Volunteer Study
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; ARYL-HYDROCARBON RECEPTOR; OXIDATIVE
DNA-DAMAGE; HUMAN PLASMA; CHEMOPREVENTIVE AGENT; TRANS-RESVERATROL;
CANCER PREVENTION; EPITHELIAL-CELLS; RED WINE; PHASE-I
AB Resveratrol has been shown to exhibit cancer-preventive activities in preclinical studies. We conducted a clinical study to determine the effect of pharmacologic doses of resveratrol on drug-and carcinogen-metabolizing enzymes. Forty-two healthy volunteers underwent baseline assessment of cytochrome P450 (CYP) and phase II detoxification enzymes. CYP1A2, CYP2D6, CYP2C9, and CYP3A4 enzyme activities were measured by the metabolism of caffeine, dextromethorphan, losartan, and buspirone, respectively. Blood lymphocyte glutathione S-transferase (GST) activity and GST-pi level and serum total and direct bilirubin, a surrogate for UDP-glucuronosyl transferase (UGT) 1A1 activity, were measured to assess phase II enzymes. After the baseline evaluation, study participants took 1 g of resveratrol once daily for 4 weeks. Enzyme assessment was repeated upon intervention completion. Resveratrol intervention was found to inhibit the phenotypic indices of CYP3A4, CYP2D6, and CYP2C9 and to induce the phenotypic index of 1A2. Overall, GST and UGT1A1 activities were minimally affected by the intervention, although an induction of GST-pi level and UGT1A1 activity was observed in individuals with low baseline enzyme level/activity. We conclude that resveratrol can modulate enzyme systems involved in carcinogen activation and detoxification, which may be one mechanism by which resveratrol inhibits carcinogenesis. However, pharmacologic doses of resveratrol could potentially lead to increased adverse drug reactions or altered drug efficacy due to inhibition or induction of certain CYPs. Further clinical development of resveratrol for cancer prevention should consider evaluation of lower doses of resveratrol to minimize adverse metabolic drug interactions. Cancer Prev Res; 3(9); 1168-75. (C) 2010 AACR.
C1 [Chow, H-H. Sherry; Garland, Linda L.; Hsu, Chiu-Hsieh; Vining, Donna R.; Chew, Wade M.; Miller, Jessica A.; Alberts, David S.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA.
[Perloff, Marjorie] NCI, Canc Prevent Div, Bethesda, MD 20892 USA.
[Crowell, James A.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
RP Chow, HHS (reprint author), Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA.
EM schow@azcc.arizona.edu
FU National Cancer Institute [N01-CN-35158]
FX National Cancer Institute contract N01-CN-35158.
NR 34
TC 96
Z9 98
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD SEP
PY 2010
VL 3
IS 9
BP 1168
EP 1175
DI 10.1158/1940-6207.CAPR-09-0155
PG 8
WC Oncology
SC Oncology
GA 646KH
UT WOS:000281538400016
PM 20716633
ER
PT J
AU Saleiro, D
Murillo, G
Lubahn, DB
Kopelovich, L
Korach, KS
Mehta, RG
AF Saleiro, Diana
Murillo, Genoveva
Lubahn, Dennis B.
Kopelovich, Levy
Korach, Kenneth S.
Mehta, Rajendra G.
TI Enhanced Induction of Mucin-Depleted Foci in Estrogen Receptor beta
Knockout Mice
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID COLORECTAL-CANCER RISK; ER-BETA; COLON CARCINOGENESIS; EXPRESSION; GENE;
LESIONS; IDENTIFICATION; TUMORIGENESIS; METHYLATION; DISRUPTION
AB The role of the estrogen receptor beta (ER beta) in the colon has received considerable interest, yet in vivo models are needed to better define its protective actions. In the present study, wild-type (WT), ER alpha, and ER beta knockout (alpha ERKO and beta ERKO) mice were injected with azoxymethane, a colon chemical carcinogen. Fourteen weeks after azoxymethane exposure, the incidence of aberrant crypt foci (ACF) was assessed by methylene blue staining. beta ERKO mice showed significantly higher incidence (P < 0.001) of ACF (15.0 +/- 2.5) compared with alpha ERKO (3.4 +/- 1.0) and WT (4.6 +/- 1.0) mice. The colons in several beta ERKO mice had increased thickness and loss of normal morphology. It has been reported that ER beta plays a role in the maintenance of the colonic crypt architecture; this may explain the loss of crypt organization in the colonic epithelium of beta ERKO mice. The presence of mucin-depleted foci (MDF) has been shown, both in humans and in rodents, as an early event in colon cancer. Therefore, to surpass the limitations with ACF scoring, we performed Alcian blue-neutral red staining to assess the presence of MDF. This assay allowed the assessment of precancerous lesions on all the beta ERKO mice colons (38.3 +/- 4.0; P < 0.001), comparing to WT and alpha ERKO mice (6.6 +/- 1.5 and 10.0 +/- 1.9, respectively), and served to confirm the ACF results. Together, these data support the use of MDF staining as a biomarker for precancerous lesions and the protective role of ER beta in colon carcinogenesis. Cancer Prev Res; 3(9); 1198-204. (C) 2010 AACR.
C1 [Saleiro, Diana; Murillo, Genoveva; Mehta, Rajendra G.] IIT Res Inst, Div Canc Biol, Chicago, IL 60616 USA.
[Saleiro, Diana] Univ Porto, Grad Program Areas Basic & Appl Biol, P-4100 Oporto, Portugal.
[Lubahn, Dennis B.] Univ Missouri, Columbia, MO USA.
[Kopelovich, Levy] NCI, Bethesda, MD 20892 USA.
[Korach, Kenneth S.] Natl Inst Environm Hlth Sci, NIH, Res Triangle Pk, NC USA.
RP Murillo, G (reprint author), IIT Res Inst, Div Canc Biol, 10 W 35th St, Chicago, IL 60616 USA.
EM gmurillo@iitri.org
OI Korach, Kenneth/0000-0002-7765-418X
FU Business Development Agency-Global Portugal (AICEP); Fulbright Portugal
Commission; FCT [MCET, FSE-SFRH/BD/33544/2008]; NIH [K01 CA103861]
FX Business Development Agency-Global Portugal (AICEP), Fulbright Portugal
Commission, and FCT (MCET and FSE-SFRH/BD/33544/2008; D. Saleiro), NIH
K01 CA103861 (G. Murillo), R01 CA121157 (R. G. Mehta), and research
support provided by the Division of Intramural Research of NIEHS/NIH (K.
S. Korach).
NR 38
TC 9
Z9 9
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD SEP
PY 2010
VL 3
IS 9
BP 1198
EP 1204
DI 10.1158/1940-6207.CAPR-10-0044
PG 7
WC Oncology
SC Oncology
GA 646KH
UT WOS:000281538400019
PM 20716634
ER
PT J
AU Kerkar, SP
Muranski, P
Kaiser, A
Boni, A
Sanchez-Perez, L
Yu, ZY
Palmer, DC
Reger, RN
Borman, ZA
Zhang, L
Morgan, RA
Gattinoni, L
Rosenberg, SA
Trinchieri, G
Restifo, NP
AF Kerkar, Sid P.
Muranski, Pawel
Kaiser, Andrew
Boni, Andrea
Sanchez-Perez, Luis
Yu, Zhiya
Palmer, Douglas C.
Reger, Robert N.
Borman, Zachary A.
Zhang, Ling
Morgan, Richard A.
Gattinoni, Luca
Rosenberg, Steven A.
Trinchieri, Giorgio
Restifo, Nicholas P.
TI Tumor-Specific CD8(+) T Cells Expressing Interleukin-12 Eradicate
Established Cancers in Lymphodepleted Hosts
SO CANCER RESEARCH
LA English
DT Article
ID IFN-GAMMA PRODUCTION; INTERFERON-GAMMA; SUPPRESSOR-CELLS; IN-VIVO;
ANTITUMOR IMMUNITY; MURINE TUMORS; GENE-THERAPY; IL-12; IMMUNOTHERAPY;
CYTOKINE
AB T-cell-based immunotherapies can be effective in the treatment of large vascularized tumors, but they rely on adoptive transfer of substantial numbers (similar to 20 million) of tumor-specific T cells administered together with vaccination and high-dose interleukin (IL)-2. In this study, we report that similar to 10,000 T cells gene-engineered to express a single-chain IL-12 molecule can be therapeutically effective against established tumors in the absence of exogenous IL-2 and vaccine. Although IL-12-engineered cells did not perist long-term in hosts, they exhibited enhanced functionality and were detected in higher numbers intratumorally along with increased numbers of endogenous natural killer and CD8(+) T cells just before regression. Importantly, transferred T cells isolated from tumors stably overproduced supraphysiologic amounts of IL-12, and the therapeutic effect of IL-12 produced within the tumor microenvironment could not be mimicked with high doses of exogenously provided IL-12. Furthermore, antitumor effects could be recapitulated by engineering wild-type open-repertoire splenocytes to express both the single-chain IL-12 and a recombinant tumor-specific T-cell receptor (TCR), but only when individual cells expressed both the TCR and IL-12, indicating that arrested migration of T cells at the tumor site was required for their activities. Successful tumor eradication was dependent on a lymphodepleting preconditioning regimen that reduced the number of intratumoral CD4(+) Foxp3(+) T regulatory cells. Our findings reveal an approach to genetically modify T cells to reduce the cell number needed, eliminate the need for vaccines or systemic IL-2, and improve immunotherapy efficacy based on adoptive transfer of gene-engineered T cells. Cancer Res; 70(17); 6725-34. (C)2010 AACR.
C1 [Kerkar, Sid P.; Muranski, Pawel; Kaiser, Andrew; Boni, Andrea; Sanchez-Perez, Luis; Yu, Zhiya; Palmer, Douglas C.; Reger, Robert N.; Borman, Zachary A.; Zhang, Ling; Morgan, Richard A.; Gattinoni, Luca; Rosenberg, Steven A.; Restifo, Nicholas P.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Trinchieri, Giorgio] NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA.
RP Kerkar, SP (reprint author), NCI, Ctr Canc Res, NIH, Room 3-5762,10 Ctr Dr, Bethesda, MD 20892 USA.
EM kerkars@mail.nih.gov; restifon@nih.gov
RI Gattinoni, Luca/A-2281-2008; Restifo, Nicholas/A-5713-2008; Kaiser,
Andrew/C-2617-2012; Palmer, Douglas/B-9454-2008;
OI Gattinoni, Luca/0000-0003-2239-3282; Palmer,
Douglas/0000-0001-5018-5734; Restifo, Nicholas P./0000-0003-4229-4580
FU NIH, National Cancer Institute, Center for Cancer Research
FX Grant Support; Intramural Research Program of the NIH, National Cancer
Institute, Center for Cancer Research.
NR 50
TC 104
Z9 104
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2010
VL 70
IS 17
BP 6725
EP 6734
DI 10.1158/0008-5472.CAN-10-0735
PG 10
WC Oncology
SC Oncology
GA 651GF
UT WOS:000281914600006
PM 20647327
ER
PT J
AU Terzuoli, E
Puppo, M
Rapisarda, A
Uranchimeg, B
Cao, LA
Burger, AM
Ziche, M
Melillo, G
AF Terzuoli, Erika
Puppo, Maura
Rapisarda, Annamaria
Uranchimeg, Badarch
Cao, Liang
Burger, Angelika M.
Ziche, Marina
Melillo, Giovanni
TI Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1
alpha Expression in an AhR-Independent Fashion
SO CANCER RESEARCH
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BREAST-CANCER CELLS; TUMOR-GROWTH;
FACTOR 1-ALPHA; PROTEIN ACCUMULATION; DEPENDENT INHIBITION; CYTOCHROME
P4501A1; SIGNALING PATHWAYS; ANTITUMOR AGENT; MESSENGER-RNA
AB Aminoflavone (AF), the active component of a novel anticancer agent (AFP464) in phase I clinical trials, is a ligand of the aryl hydrocarbon receptor (AhR). AhR dimerizes with HIF-1 beta/AhR, which is shared with HIF-1 alpha, a transcription factor critical for the response of cells to oxygen deprivation. To address whether pharmacologic activation of the AhR pathway might be a potential mechanism for inhibition of HIF-1, we tested the effects of AF on HIF-1 expression. AF inhibited HIF-1 alpha transcriptional activity and protein accumulation in MCF-7 cells. However, inhibition of HIF-1 alpha by AF was independent from a functional AhR pathway. Indeed, AF inhibited HIF-1 alpha expression in Ah(R100) cells, in which the AhR pathway is functionally impaired, yet did not induce cytotoxicity, providing evidence that these effects are mediated by distinct signaling pathways. Moreover, AF was inactive in MDA-MB-231 cells, yet inhibited HIF-1 alpha in MDA-MB-231 cells transfected with the SULT1A1 gene. AF inhibited HIF-1 alpha mRNA expression by similar to 50%. Notably, actinomycin-D completely abrogated the ability of AF to downregulate HIF-1 alpha mRNA, indicating that active transcription was required for the inhibition of HIF-1 alpha expression. Finally, AF inhibited HIF-1a protein accumulation and the expression of HIF-1 target genes in MCF-7 xenografts. These results show that AF inhibits HIF-1 alpha in an AhR-independent fashion, and they unveil additional activities of AF that may be relevant for its further clinical development. Cancer Res; 70(17); 6837-48. (C)2010 AACR.
C1 [Melillo, Giovanni] NCI, Dev Therapeut Program, Tumor Hypoxia Lab, SAIC Frederick Inc, Frederick, MD 21702 USA.
[Terzuoli, Erika; Ziche, Marina] Univ Siena, Dept Mol Biol, I-53100 Siena, Italy.
[Puppo, Maura] G Gaslini Inst Children, Mol Biol Lab, Genoa, Italy.
[Cao, Liang] NCI, Mol Targets Core Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Burger, Angelika M.] Barbara Ann Karmanos Canc Inst, Detroit, MI USA.
RP Melillo, G (reprint author), NCI, Dev Therapeut Program, Tumor Hypoxia Lab, SAIC Frederick Inc, Bldg 432,Room 218, Frederick, MD 21702 USA.
EM melillog@mail.nih.gov
FU NCI, NIH [N01-CO-12400]
FX Grant Support; Federal funds from the NCI, NIH, under contract no.
N01-CO-12400. The content of this publication does not necessarily
reflect the views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial products, or
organizations imply endorsement by the U. S. Government. This research
was supported by the Developmental Therapeutics Program, DCTD, of the
NCI, NIH.
NR 50
TC 37
Z9 37
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2010
VL 70
IS 17
BP 6837
EP 6848
DI 10.1158/0008-5472.CAN-10-1075
PG 12
WC Oncology
SC Oncology
GA 651GF
UT WOS:000281914600017
PM 20736373
ER
PT J
AU Lan, Q
Zhang, LP
Tang, XJ
Shen, M
Smith, MT
Qiu, CY
Ge, YC
Ji, ZY
Xiong, J
He, JA
Reiss, B
Hao, ZY
Liu, SW
Xie, YX
Guo, WH
Purdue, MP
Galvan, N
Xin, KX
Hu, W
Freeman, LEB
Blair, AE
Li, LY
Rothman, N
Vermeulen, R
Huang, HL
AF Lan, Qing
Zhang, Luoping
Tang, Xiaojiang
Shen, Min
Smith, Martyn T.
Qiu, Chuangyi
Ge, Yichen
Ji, Zhiying
Xiong, Jun
He, Jian
Reiss, Boris
Hao, Zhenyue
Liu, Songwang
Xie, Yuxuan
Guo, Weihong
Purdue, Mark P.
Galvan, Noe
Xin, Kerry X.
Hu, Wei
Freeman, Laura E. Beane
Blair, Aaron E.
Li, Laiyu
Rothman, Nathaniel
Vermeulen, Roel
Huang, Hanlin
TI Occupational exposure to trichloroethylene is associated with a decline
in lymphocyte subsets and soluble CD27 and CD30 markers
SO CARCINOGENESIS
LA English
DT Article
ID CANCER-RISK; ANTIRETROVIRAL THERAPY; MULTIPLE-SCLEROSIS; BONE-MARROW;
ACTIVATION; WORKERS; CD27-CD70; COHORT; EXPRESSION; RESPONSES
AB Occupational cohort and case-control studies suggest that trichloroethylene (TCE) exposure may be associated with non-Hodgkin lymphoma (NHL) but findings are not consistent. There is a need for mechanistic studies to evaluate the biologic plausibility of this association. We carried out a cross-sectional molecular epidemiology study of 80 healthy workers that used TCE and 96 comparable unexposed controls in Guangdong, China. Personal exposure measurements were taken over a three-week period before blood collection. Ninety-six percent of workers were exposed to TCE below the current US Occupational Safety and Health Administration Permissible Exposure Limit (100 p.p.m. 8 h time-weighted average), with a mean (SD) of 22.2 (36.0) p.p.m. The total lymphocyte count and each of the major lymphocyte subsets including CD4+ T cells, CD8+ T cells, natural killer (NK) cells and B cells were significantly decreased among the TCE-exposed workers compared with controls (P < 0.05), with evidence of a dose-dependent decline. Further, there was a striking 61% decline in sCD27 plasma level and a 34% decline in sCD30 plasma level among TCE-exposed workers compared with controls. This is the first report that TCE exposure under the current Occupational Safety and Health Administration workplace standard is associated with a decline in all major lymphocyte subsets and sCD27 and sCD30, which play an important role in regulating cellular activity in subsets of T, B and NK cells and are associated with lymphocyte activation. Given that altered immunity is an established risk factor for NHL, these results add to the biologic plausibility that TCE is a possible lymphomagen.
C1 [Lan, Qing] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Zhang, Luoping; Smith, Martyn T.; Ji, Zhiying; Guo, Weihong; Galvan, Noe; Xin, Kerry X.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
[Tang, Xiaojiang; Qiu, Chuangyi; Ge, Yichen; Xie, Yuxuan; Li, Laiyu; Huang, Hanlin] Guangdong Poison Control Ctr, Guangzhou 510300, Guangdong, Peoples R China.
[Xiong, Jun] Dongguan Ctr Dis Control & Prevent, Dongguan 523016, Guangdong, Peoples R China.
[He, Jian] Zhongshan Ctr Dis Control & Prevent, Zhongshan 528403, Guangdong, Peoples R China.
[Reiss, Boris; Vermeulen, Roel] Univ Utrecht, NL-3508 TC Utrecht, Netherlands.
[Hao, Zhenyue] Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada.
[Hao, Zhenyue] Univ Hlth Network, Toronto, ON M5G 2C1, Canada.
[Liu, Songwang] Qiaotou Hosp, Dongguan 523523, Guangdong, Peoples R China.
RP Lan, Q (reprint author), NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, MSC 7240,6120 Execut Blvd,EPS 8109, Bethesda, MD 20892 USA.
EM qingl@mail.nih.gov
RI Hu, Wei/M-3524-2013; Vermeulen, Roel/F-8037-2011; Purdue,
Mark/C-9228-2016; Beane Freeman, Laura/C-4468-2015
OI Vermeulen, Roel/0000-0003-4082-8163; Purdue, Mark/0000-0003-1177-3108;
Beane Freeman, Laura/0000-0003-1294-4124
FU National Institutes of Health and National Cancer Institute; National
Institute of Environmental Health Sciences [P42ES04705, P30ES01896];
Northern California Center for Occupational and Environmental Health;
Department of Science and Technology of Guangdong Province, China
[2007A050100004]; Department of Science and Technology of Guangdong
Province, People's Republic of China [2007A050100004]
FX Intramural funds from the National Institutes of Health and National
Cancer Institute; National Institute of Environmental Health Sciences
(P42ES04705, P30ES01896); Northern California Center for Occupational
and Environmental Health; Department of Science and Technology of
Guangdong Province, China (2007A050100004); Department of Science and
Technology of Guangdong Province, People's Republic of China
(2007A050100004 to X. T.).
NR 28
TC 21
Z9 25
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD SEP
PY 2010
VL 31
IS 9
BP 1592
EP 1596
DI 10.1093/carcin/bgq121
PG 5
WC Oncology
SC Oncology
GA 646HP
UT WOS:000281530400012
PM 20530238
ER
PT J
AU Nakamura, AJ
Redon, CE
Bonner, WM
AF Nakamura, Asako J.
Redon, Christophe E.
Bonner, William M.
TI gamma H2AX Applications for the evaluation of telomerase-based cancer
therapy
SO CELL CYCLE
LA English
DT Editorial Material
ID CELLS
C1 [Nakamura, Asako J.; Redon, Christophe E.; Bonner, William M.] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Nakamura, AJ (reprint author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM nakamuraa@mail.nih.gov
NR 11
TC 1
Z9 2
U1 0
U2 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD SEP 1
PY 2010
VL 9
IS 17
BP 3385
EP 3386
DI 10.4161/cc.9.17.13003
PG 2
WC Cell Biology
SC Cell Biology
GA 647MD
UT WOS:000281621700001
PM 20703091
ER
PT J
AU Assayag, M
Gerstenblith, G
Stern, MD
Horowitz, M
AF Assayag, Miri
Gerstenblith, Gary
Stern, Michael D.
Horowitz, Michal
TI Long- but not short-term heat acclimation produces an
apoptosis-resistant cardiac phenotype: a lesson from heat stress and
ischemic/reperfusion insults
SO CELL STRESS & CHAPERONES
LA English
DT Article
DE Heat acclimation-mediated cross-tolerance; Apoptosis; Heat stress;
Mitochondria; Ischemia/reperfusion
ID ISCHEMIC CROSS-TOLERANCE; CELL-DEATH; MEMBRANE PERMEABILIZATION;
THERMOREGULATORY ACTIVITY; RAT; HYPOHYDRATION; REPERFUSION; INHIBITION;
MECHANISMS; RESPONSES
AB Long-term heat acclimation (AC, 30d/34 degrees C) is a phenotypic adaptation leading to increased thermotolerance during heat stress (HS, 2 h 41 degrees C). AC also renders protection against ischemic/reperfusion (I/R, 30' global ischemia/40' reperfusion) insult via cross-tolerance mechanisms. In contrast to the protected AC phenotype, the onset of acclimation (34 degrees C, AC2d) is characterized by cellular perturbations, suggesting increased susceptibility to HS and I/R insults. In this investigation, we tested the hypothesis that apoptosis resistance is part of the AC repertoire and that, at the initial phase of acclimation (AC2d), cytoprotection is impaired. TUNEL staining and caspase 3 levels in HS and I/R insulted hearts affirmed this hypothesis. To examine the role of the mitochondria in life/death decision in AC2d and 30d AC settings vs. control hearts, we studied the Bcl-2 apoptotic cascade and found increased levels of the anti-apoptotic Bcl-X-L and decreased levels of the pro-apoptotic death promoter Bad in hearts from AC2d and AC animals. In these groups, cytochrome c (cyt c) was elevated in the mitochondria and remained unchanged in the cytosol. This adaptation was insufficient to negate apoptosis in AC2d rats. At this early acclimation phase (and in controls), increased caspase 8 activity confirmed activation of the extrinsic (Fas ligand) apoptosis pathway. In conclusion, the elevated Bcl-X-L/Bad ratio and decreased cyt c leakage to the cytosol are insufficient to protect the heart and interactions with additional cytoprotective pathways involved in acclimation (elevated HSP70, ROS, and sarcolemmal adaptations to abolish extrinsic apoptosis pathways) are required to induce the apoptosis-resistant AC phenotype.
C1 [Horowitz, Michal] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel.
[Assayag, Miri; Horowitz, Michal] Hebrew Univ Jerusalem, Fac Med Dent, Environm Physiol Lab, IL-91120 Jerusalem, Israel.
[Gerstenblith, Gary] Johns Hopkins Univ, Dept Med, Div Cardiol, Baltimore, MD USA.
[Stern, Michael D.] NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, Baltimore, MD 21224 USA.
RP Horowitz, M (reprint author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, POB 12272, IL-91120 Jerusalem, Israel.
EM horowitz@cc.huji.ac.il
FU USA-Israel Binational Fund BSF [2003-298]; NIH National Institute on
Aging
FX This study was supported by the USA-Israel Binational Fund BSF Grant
2003-298 and (in part) by the Intramural Research Program of the NIH
National Institute on Aging.
NR 40
TC 14
Z9 14
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
EI 1466-1268
J9 CELL STRESS CHAPERON
JI Cell Stress Chaperones
PD SEP
PY 2010
VL 15
IS 5
BP 651
EP 664
DI 10.1007/s12192-010-0178-x
PG 14
WC Cell Biology
SC Cell Biology
GA 636YQ
UT WOS:000280781800018
PM 20221856
ER
PT J
AU Gardner, MK
Sprague, BL
Pearson, CG
Cosgrove, BD
Bicek, AD
Bloom, K
Salmon, ED
Odde, DJ
AF Gardner, Melissa K.
Sprague, Brian L.
Pearson, Chad G.
Cosgrove, Benjamin D.
Bicek, Andrew D.
Bloom, Kerry
Salmon, E. D.
Odde, David J.
TI Model Convolution: A Computational Approach to Digital Image
Interpretation (vol 3, pg 163, 2010)
SO CELLULAR AND MOLECULAR BIOENGINEERING
LA English
DT Correction
C1 [Gardner, Melissa K.; Cosgrove, Benjamin D.; Bicek, Andrew D.; Odde, David J.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA.
[Bloom, Kerry; Salmon, E. D.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA.
[Sprague, Brian L.] NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA.
[Pearson, Chad G.] Univ Colorado, MCD Biol, Boulder, CO 80309 USA.
RP Odde, DJ (reprint author), Univ Minnesota, Dept Biomed Engn, 7-132 Nils Hasselmo Hall,312 Church St SE, Minneapolis, MN 55455 USA.
EM oddex002@umn.edu
RI Odde, David/H-4925-2011
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1865-5025
J9 CELL MOL BIOENG
JI Cell. Mol. Bioeng.
PD SEP
PY 2010
VL 3
IS 3
BP 331
EP 332
DI 10.1007/s12195-010-0126-y
PG 2
WC Cell & Tissue Engineering; Biophysics; Cell Biology
SC Cell Biology; Biophysics
GA 638MZ
UT WOS:000280900300012
ER
PT J
AU Malachowa, N
DeLeo, FR
AF Malachowa, Natalia
DeLeo, Frank R.
TI Mobile genetic elements of Staphylococcus aureus
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Mobile genetic elements; Staphylococcus aureus; Virulence; Antibiotic
resistance; Horizontal gene transfer
ID PANTON-VALENTINE LEUKOCIDIN; COAGULASE-NEGATIVE STAPHYLOCOCCI; CADMIUM
RESISTANCE DETERMINANTS; CHEMOTAXIS INHIBITORY PROTEIN; COMPLETE
NUCLEOTIDE-SEQUENCE; STREPTOGRAMIN-B RESISTANCE; LEVEL MUPIROCIN
RESISTANCE; METHICILLIN-RESISTANT; PATHOGENICITY ISLANDS; BETA-LACTAMASE
AB Bacteria such as Staphylococcus aureus are successful as commensal organisms or pathogens in part because they adapt rapidly to selective pressures imparted by the human host. Mobile genetic elements (MGEs) play a central role in this adaptation process and are a means to transfer genetic information (DNA) among and within bacterial species. Importantly, MGEs encode putative virulence factors and molecules that confer resistance to antibiotics, including the gene that confers resistance to beta-lactam antibiotics in methicillin-resistant S. aureus (MRSA). Inasmuch as MRSA infections are a significant problem worldwide and continue to emerge in epidemic waves, there has been significant effort to improve diagnostic assays and to develop new antimicrobial agents for treatment of disease. Our understanding of S. aureus MGEs and the molecules they encode has played an important role toward these ends and has provided detailed insight into the evolution of antimicrobial resistance mechanisms and virulence.
C1 [Malachowa, Natalia; DeLeo, Frank R.] NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.
RP DeLeo, FR (reprint author), NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, 903 S 4th St, Hamilton, MT 59840 USA.
EM fdeleo@niaid.nih.gov
OI DeLeo, Frank/0000-0003-3150-2516
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health
FX We thank James M. Musser (The Methodist Hospital Research Institute,
Houston TX, USA) for critical reading of the manuscript. This article
was supported by the Intramural Research Program of the National
Institute of Allergy and Infectious Diseases, National Institutes of
Health.
NR 171
TC 114
Z9 129
U1 12
U2 60
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD SEP
PY 2010
VL 67
IS 18
BP 3057
EP 3071
DI 10.1007/s00018-010-0389-4
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 644QY
UT WOS:000281395800002
PM 20668911
ER
PT J
AU Bao, JJ
Sack, MN
AF Bao, Jianjun
Sack, Michael N.
TI Protein deacetylation by sirtuins: delineating a post-translational
regulatory program responsive to nutrient and redox stressors
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Sirtuins; Lysine acetylation/deacetylation; Post-translational
modifications; NAD(+); Biological functions
ID DEPENDENT GENE-EXPRESSION; III HISTONE DEACETYLASE; NAD(+) SALVAGE
PATHWAY; FATTY-ACID OXIDATION; DNA-DAMAGE RESPONSE; SIR2 HOMOLOG;
CALORIE RESTRICTION; NEGATIVE REGULATOR; LYSINE ACETYLATION; LIFE-SPAN
AB Lysine acetylation/deacetylation is increasingly being recognized as common post-translational modification that appears to be broadly operational throughout the cell. The functional roles of these modifications, outside of the nucleus, have not been extensively studied. Moreover, as acetyl-CoA donates the acetyl group for acetylation, nutrient availability and energetic status may be pivotal in this modification. Similarly, nutrient limitation is associated with the deacetylation reaction. This modification is orchestrated by a novel family of sirtuin deacetylases that function in a nutrient and redox dependent manner and targets non-histone protein deacetylation. In compartment-specific locations, candidate target proteins undergoing lysine-residue deacetylation are being identified. Through these investigations, the functional role of this post-translational modification is being delineated. We review the sirtuin family proteins, discuss their functional effects on target proteins, and postulate on potential biological programs and disease processes that may be modified by sirtuin-mediated deacetylation of target proteins.
C1 [Bao, Jianjun; Sack, Michael N.] NHLBI, Translat Med Branch, NIH, Bethesda, MD 20892 USA.
RP Sack, MN (reprint author), NHLBI, Translat Med Branch, NIH, 10 Ctr Dr,MSC 1454, Bethesda, MD 20892 USA.
EM sackm@nhlbi.nih.gov
FU National Heart Lung and Blood Institute of the National Institutes of
Health
FX The authors of this manuscript are funded by the Division of Intramural
Research of the National Heart Lung and Blood Institute of the National
Institutes of Health.
NR 176
TC 33
Z9 34
U1 0
U2 4
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD SEP
PY 2010
VL 67
IS 18
BP 3073
EP 3087
DI 10.1007/s00018-010-0402-y
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 644QY
UT WOS:000281395800003
PM 20680393
ER
PT J
AU Mital, J
Miller, NJ
Fischer, ER
Hackstadt, T
AF Mital, Jeffrey
Miller, Natalie J.
Fischer, Elizabeth R.
Hackstadt, Ted
TI Specific chlamydial inclusion membrane proteins associate with active
Src family kinases in microdomains that interact with the host
microtubule network
SO CELLULAR MICROBIOLOGY
LA English
DT Article
ID INVASIVE CERVICAL-CANCER; TRACHOMATIS INFECTION; TYROSINE KINASES;
DEVELOPMENTAL CYCLE; CELL PROTEINS; III SECRETION; PHOSPHORYLATION;
DYNEIN; TRAFFICKING; DIVISION
AB P>Chlamydiae are Gram-negative obligate intracellular bacteria that cause diseases with significant medical and economic impact. Chlamydia trachomatis replicates within a vacuole termed an inclusion, which is extensively modified by the insertion of a number of bacterial effector proteins known as inclusion membrane proteins (Incs). Once modified, the inclusion is trafficked in a dynein-dependent manner to the microtubule-organizing centre (MTOC), where it associates with host centrosomes. Here we describe a novel structure on the inclusion membrane comprised of both host and bacterial proteins. Members of the Src family of kinases are recruited to the chlamydial inclusion in an active form. These kinases display a distinct, localized punctate microdomain-like staining pattern on the inclusion membrane that colocalizes with four chlamydial inclusion membrane proteins (Incs) and is enriched in cholesterol. Biochemical studies show that at least two of these Incs stably interact with one another. Furthermore, host centrosomes associate with these microdomain proteins in C. trachomatis-infected cells and in uninfected cells exogenously expressing one of the chlamydial effectors. Together, the data suggest that a specific structure on the C. trachomatis inclusion membrane may be responsible for the known interactions of chlamydiae with the microtubule network and resultant effects on centrosome stability.
C1 [Mital, Jeffrey; Miller, Natalie J.; Hackstadt, Ted] NIAID, Host Parasite Interact Sect, Intracellular Parasites Lab, Rocky Mt Labs,NIH, Hamilton, MT 59840 USA.
[Fischer, Elizabeth R.] NIAID, Microscopy Unit, NIH, Hamilton, MT 59840 USA.
RP Hackstadt, T (reprint author), NIAID, Host Parasite Interact Sect, Intracellular Parasites Lab, Rocky Mt Labs,NIH, 903 S 4th St, Hamilton, MT 59840 USA.
EM ted_hackstadt@nih.gov
FU NIAID/NIH
FX This work was supported by the intramural research programme of the
NIAID/NIH. We thank Janet Sager for technical assistance and Drs R.
Heinzen and J. Celli for critical review of the manuscript.
NR 63
TC 60
Z9 62
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1462-5814
J9 CELL MICROBIOL
JI Cell Microbiol.
PD SEP
PY 2010
VL 12
IS 9
BP 1235
EP 1249
DI 10.1111/j.1462-5822.2010.01465.x
PG 15
WC Cell Biology; Microbiology
SC Cell Biology; Microbiology
GA 639KB
UT WOS:000280972600005
PM 20331642
ER
PT J
AU Kim, YS
Harry, GJ
Kang, HS
Goulding, D
Wine, RN
Kissling, GE
Liao, G
Jetten, AM
AF Kim, Yong-Sik
Harry, G. Jean
Kang, Hong Soon
Goulding, David
Wine, Rob N.
Kissling, Grace E.
Liao, Grace
Jetten, Anton M.
TI Altered Cerebellar Development in Nuclear Receptor TAK1/TR4 Null Mice Is
Associated with Deficits in GLAST(+) Glia, Alterations in Social
Behavior, Motor Learning, Startle Reactivity, and Microglia
SO CEREBELLUM
LA English
DT Article
DE Cerebellum; Behavior; GLAST; Granule cells; Motor activity; Prepulse
startle
ID NEURONAL MIGRATION; ORPHAN RECEPTOR; MOUSE CEREBELLUM; PREPULSE
INHIBITION; GRANULE CELLS; MUTANT MICE; GENE; TR4; MODELS; AUTISM
AB Previously, deficiency in the expression of the nuclear orphan receptor TAK1 was found to be associated with delayed cerebellar granule cell migration and Purkinje cell maturation with a permanent deficit in foliation of lobules VI-VII, suggesting a role for TAK1 in cerebellum development. In this study, we confirm that TAK1-deficient (TAK1(-/-)) mice have a smaller cerebellum and exhibit a disruption of lobules VI-VII. We extended these studies and show that at postnatal day 7, TAK1(-/-) mice exhibit a delay in monolayer maturation of dysmorphic calbindin 28K-positive Purkinje cells. The astrocyte-specific glutamate transporter (GLAST) was expressed within Bergmann fibers and internal granule cell layer at significantly lower levels in the cerebellum of TAK1(-/-) mice. At PND21, Golgi-positive Purkinje cells in TAK1(-/-) mice displayed a smaller soma (18%) and shorter distance to first branch point (35%). Neuronal death was not observed in TAK1(-/-) mice at PND21; however, activated microglia were present in the cerebellum, suggestive of earlier cell death. These structural deficits in the cerebellum were not sufficient to alter motor strength, coordination, or activity levels; however, deficits in acoustic startle response, prepulse startle inhibition, and social interactions were observed. Reactions to a novel environment were inhibited in a light/dark chamber, open-field, and home-cage running wheel. TAK1(-/-) mice displayed a plateau in performance on the running wheel, suggesting a deficit in learning to coordinate performance on a motor task. These data indicate that TAK1 is an important transcriptional modulator of cerebellar development and neurodevelopmentally regulated behavior.
C1 [Kim, Yong-Sik; Kang, Hong Soon; Liao, Grace; Jetten, Anton M.] NIEHS, Lab Resp Biol, Cell Biol Sect, Div Intramural Res,NIH, Durham, NC 27709 USA.
[Harry, G. Jean; Wine, Rob N.] NIEHS, Mol Toxicol Lab, Div Intramural Res, NIH, Durham, NC 27709 USA.
[Goulding, David] NIEHS, Comparat Med Branch, Div Intramural Res, NIH, Durham, NC 27709 USA.
[Kissling, Grace E.] NIEHS, Biostat Branch, Div Intramural Res, NIH, Durham, NC 27709 USA.
RP Jetten, AM (reprint author), NIEHS, Lab Resp Biol, Cell Biol Sect, Div Intramural Res,NIH, POB 12233, Durham, NC 27709 USA.
EM jetten@niehs.nih.gov
OI Jetten, Anton/0000-0003-0954-4445
FU Division of Intramural Research at the National Institute of
Environmental Health Sciences, NIH [Z01-ES-101586, Z01-ES-021164]
FX The authors thank Dr. Randy Thresher, UNC/Chapel Hill, NC for generating
TAK1-/- mice; Ms. Laura M. Degraff for technical assistance;
Dr. Fu Du for the Golgi staining, and Drs. Gordon Flake (NIEHS) and
Robert Berman (University of California/Davis) for comments. This
research was supported by the Division of Intramural Research at the
National Institute of Environmental Health Sciences, NIH (Z01-ES-101586;
Z01-ES-021164).
NR 62
TC 15
Z9 16
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1473-4222
J9 CEREBELLUM
JI Cerebellum
PD SEP
PY 2010
VL 9
IS 3
BP 310
EP 323
DI 10.1007/s12311-010-0163-z
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 658SD
UT WOS:000282508800007
PM 20393820
ER
PT J
AU da Guarda, SNF
Cohen, LG
Pinho, MDC
Yamamoto, FI
Marchiori, PE
Scaff, M
Conforto, AB
AF Farias da Guarda, Suzete Nascimento
Cohen, Leonardo G.
Pinho, Marco da Cunha
Yamamoto, Fabio Iuji
Marchiori, Paulo Euripedes
Scaff, Milberto
Conforto, Adriana Bastos
TI Interhemispheric Asymmetry of Corticomotor Excitability After Chronic
Cerebellar Infarcts
SO CEREBELLUM
LA English
DT Article
DE Transcranial magnetic stimulation; Paired pulse; Cerebellar disease;
Stroke
ID TRANSCRANIAL MAGNETIC STIMULATION; MOTOR CORTEX EXCITABILITY; CHRONIC
STROKE; MECHANISMS; MODULATION; PLASTICITY; HUMANS; SYSTEM; ATAXIA;
SCALE
AB Early after stroke, there is loss of intracortical facilitation (ICF) and increase in short-interval intracortical inhibition (SICI) in the primary motor cortex (M1) contralateral to a cerebellar infarct. Our goal was to investigate intracortical M1 function in the chronic stage following cerebellar infarcts (> 4 months). We measured resting motor threshold (rMT), SICI, ICF, and ratios between motor-evoked potential amplitudes (MEP) and supramaximal M response amplitudes (MEP/M; %), after transcranial magnetic stimulation was applied to the M1 contralateral (M1(contralesional)) and ipsilateral (M1(ipsilesional)) to the cerebellar infarct in patients and to both M1s of healthy age-matched volunteers. SICI was decreased in M1(contralesional) compared to M1(ipsilesional) in the patient group in the absence of side-to-side differences in controls. There were no significant interhemispheric or between-group differences in rMT, ICF, or MEP/M (%). Our results document disinhibition of M1(contralesional) in the chronic phase after cerebellar stroke.
C1 [Farias da Guarda, Suzete Nascimento; Yamamoto, Fabio Iuji; Marchiori, Paulo Euripedes; Scaff, Milberto; Conforto, Adriana Bastos] Univ Sao Paulo, Clin Hospital, Dept Neurol, Sao Paulo, Brazil.
[Farias da Guarda, Suzete Nascimento; Conforto, Adriana Bastos] Univ Sao Paulo, Clin Hospital, Neurostimulat Lab, Sao Paulo, Brazil.
[Cohen, Leonardo G.] NINDS, Human Cort Physiol & Stroke Neurorehabil Sect, NIH, Bethesda, MD 20892 USA.
[Pinho, Marco da Cunha] Univ Sao Paulo, Dept Radiol, Clin Hospital, Sao Paulo, Brazil.
[Conforto, Adriana Bastos] Inst Israelita Ensino & Pesquisa Albert Einstein, Sao Paulo, Brazil.
RP da Guarda, SNF (reprint author), Rua Oito Dezembro,291 Ap 1202, BR-40150000 Salvador, Brazil.
EM suzetefarias@terra.com.br
OI Pinho, Marco/0000-0002-4645-1638
FU Fundacao Faculdade de Medicina, Clinics Hospital/Sao Paulo University
FX Dr. Suzete N. Farias received a research scholarship from Fundacao
Faculdade de Medicina, Clinics Hospital/Sao Paulo University. We thank
Michael Dimyan for helpful comments and suggestions.
NR 36
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1473-4222
J9 CEREBELLUM
JI Cerebellum
PD SEP
PY 2010
VL 9
IS 3
BP 398
EP 404
DI 10.1007/s12311-010-0176-7
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 658SD
UT WOS:000282508800014
ER
PT J
AU Mur, M
Ruff, DA
Bodurka, J
Bandettini, PA
Kriegeskorte, N
AF Mur, Marieke
Ruff, Douglas A.
Bodurka, Jerzy
Bandettini, Peter A.
Kriegeskorte, Nikolaus
TI Face-Identity Change Activation Outside the Face System: "Release from
Adaptation" May Not Always Indicate Neuronal Selectivity
SO CEREBRAL CORTEX
LA English
DT Article
DE attention; face-identity; fMRI-adaptation; fusiform face area; neuronal
representation
ID HUMAN VISUAL-CORTEX; HUMAN FUSIFORM GYRUS; FMRI-ADAPTATION; DISTINCT
REPRESENTATIONS; FUNCTIONAL ARCHITECTURE; ACQUIRED PROSOPAGNOSIA;
PARAHIPPOCAMPAL CORTEX; REPETITION SUPPRESSION; SPATIAL ATTENTION;
CORTICAL ACTIVITY
AB Face recognition is a complex cognitive process that requires distinguishable neuronal representations of individual faces. Previous functional magnetic resonance imaging (fMRI) studies using the "fMRI-adaptation" technique have suggested the existence of face-identity representations in face-selective regions, including the fusiform face area (FFA). Here, we present face-identity adaptation findings that are not well explained in terms of face-identity representations. We performed blood-oxygen level-dependent (BOLD) fMRI measurements, while participants viewed familiar faces that were shown repeatedly throughout the experiment. We found decreased activation for repeated faces in face-selective regions, as expected based on previous studies. However, we found similar effects in regions that are not face-selective, including the parahippocampal place area (PPA) and early visual cortex (EVC). These effects were present for exact-image (same view and lighting) as well as different-image (different view and/or lighting) repetition, but more widespread for exact-image repetition. Given the known functional properties of PPA and EVC, it appears unlikely that they contain domain-specific face-identity representations. Alternative interpretations include general attentional effects and carryover of activation from connected regions. These results remind us that fMRI stimulus-change effects can have a range of causes and do not provide conclusive evidence for a neuronal representation of the changed stimulus property.
C1 [Mur, Marieke; Ruff, Douglas A.; Bandettini, Peter A.; Kriegeskorte, Nikolaus] NIMH, Sect Funct Imaging Methods, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA.
[Mur, Marieke] Maastricht Univ, Fac Psychol & Neurosci, Dept Cognit Neurosci, NL-6229 ER Maastricht, Netherlands.
[Bodurka, Jerzy; Bandettini, Peter A.] NIMH, Funct Magnet Resonance Imaging Facil, NIH, Bethesda, MD 20892 USA.
RP Mur, M (reprint author), Univ Singel 40,Room 4-777, NL-6229 ER Maastricht, Netherlands.
EM marieke.mur@maastrichtuniversity.nl
OI Kriegeskorte, Nikolaus/0000-0001-7433-9005; Ruff,
Douglas/0000-0001-7228-8822
FU National Institute of Mental Health at the National Institutes of Health
FX Intramural Research Program of the National Institute of Mental Health
at the National Institutes of Health.
NR 76
TC 42
Z9 43
U1 2
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
J9 CEREB CORTEX
JI Cereb. Cortex
PD SEP
PY 2010
VL 20
IS 9
BP 2027
EP 2042
DI 10.1093/cercor/bhp272
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA 646RP
UT WOS:000281560200002
PM 20051364
ER
PT J
AU Tanaka, S
Honda, M
Hanakawa, T
Cohen, LG
AF Tanaka, Satoshi
Honda, Manabu
Hanakawa, Takashi
Cohen, Leonardo G.
TI Differential Contribution of the Supplementary Motor Area to
Stabilization of a Procedural Motor Skill Acquired through Different
Practice Schedules
SO CEREBRAL CORTEX
LA English
DT Article
DE magnetic stimulation; memory and learning; motor cortex; motor learning;
training
ID TRANSCRANIAL MAGNETIC STIMULATION; EXPERIENCE-DEPENDENT CHANGES; MEDIAL
FRONTAL-CORTEX; CONTEXTUAL INTERFERENCE; MEMORY CONSOLIDATION; TEMPORAL
ORGANIZATION; SEQUENTIAL-PROCEDURES; INTERMANUAL TRANSFER; MULTIPLE
MOVEMENTS; NEURONAL-ACTIVITY
AB Behavioral studies have suggested that the stabilization of motor memory varies depending on the practice schedule. The neural substrates underlying this schedule-dependent difference in memory stabilization are not known. Here, we evaluated the effects of 1-Hz repetitive transcranial magnetic stimulation (rTMS) applied to different cortical regions and sham after one session of training (Day 1) of sequential motor skills acquired through blocked (each sequence was completely trained before training the next)-practice schedules and random (random training of 3 sequences)-practice schedules. The recall of sequences learned on Day 1 by Day 2 was measured in different groups of healthy volunteers. The rTMS over the supplementary motor area (SMA) but not over control regions or over the primary motor cortex (M1) immediately after practice or over SMA 6 h later reduced recall relative to sham only in the blocked-practice group. In contrast, recall in the random-practice group was unaffected by rTMS. These results document a differential contribution of the SMA to the stabilization of motor memories acquired through different practice schedules. More generally, they indicate that the anatomical substrates underlying motor-memory stabilization (or their temporal operation) do differ depending on the practice schedule.
C1 [Tanaka, Satoshi; Cohen, Leonardo G.] NINDS, Human Cort Physiol & Stroke Neurorehabil Sect, NIH, Bethesda, MD 20892 USA.
[Tanaka, Satoshi; Honda, Manabu; Hanakawa, Takashi] Natl Inst Neurosci, Dept Cort Funct Disorders, Kodaira, Tokyo 1878502, Japan.
[Honda, Manabu] Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Saitama 3310012, Japan.
[Hanakawa, Takashi] Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Saitama 3310012, Japan.
RP Cohen, LG (reprint author), NINDS, Human Cort Physiol & Stroke Neurorehabil Sect, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.
EM cohenl@ninds.nih.gov
FU National Institute of Neurological Disorder and Stroke, National
Institute of Health (NIH); Japan Society for the Promotion of Science
Research Fellowship for Japanese Biomedical and Behavioral Researchers
at NIH; Exploratory Research for Advanced Technology Shimojo Implicit
Brain Function Project; Ministry of Education, Culture, Sports, Science
and Technology, Japan [20019041, 20033030]
FX Intramural Research Program of the National Institute of Neurological
Disorder and Stroke, National Institute of Health (NIH); Japan Society
for the Promotion of Science Research Fellowship for Japanese Biomedical
and Behavioral Researchers at NIH; Exploratory Research for Advanced
Technology Shimojo Implicit Brain Function Project; KAKENHI (20019041,
20033030) from the Ministry of Education, Culture, Sports, Science and
Technology, Japan.
NR 65
TC 21
Z9 21
U1 1
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
J9 CEREB CORTEX
JI Cereb. Cortex
PD SEP
PY 2010
VL 20
IS 9
BP 2114
EP 2121
DI 10.1093/cercor/bhp276
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 646RP
UT WOS:000281560200009
PM 20038545
ER
PT J
AU Nelson, TM
LopezJimenez, ND
Tessarollo, L
Inoue, M
Bachmanov, AA
Sullivan, SL
AF Nelson, Theodore M.
LopezJimenez, Nelson D.
Tessarollo, Lino
Inoue, Masashi
Bachmanov, Alexander A.
Sullivan, Susan L.
TI Taste Function in Mice with a Targeted Mutation of the Pkd1l3 Gene
SO CHEMICAL SENSES
LA English
DT Article
DE gene knockout; gustatory nerves; polycystic kidney disease-like ion
channel; preference; taste; threshold
ID GUSTATORY NEURAL RESPONSES; RECEPTOR-CELLS; SOUR-TASTE; CHORDA TYMPANI;
129P3/J MICE; SALT TASTE; NULL MICE; SACCHARIN PREFERENCE; ALLELIC
VARIATION; MAMMALIAN TASTE
AB Recent studies, both in vitro and in vivo, have suggested the involvement of the polycystic kidney disease-1 and -2 like genes, Pkd1l3 and Pkd2l1, in acid taste transduction. In mice, disruption of taste cells expressing PKD2L1 eliminates gustatory neural responses to acids. However, no previous data exist on taste responses in the absence of PKD1L3 or on behavioral responses in mice lacking either of these proteins. In order to assess the function of PKD1L3, we genetically engineered mice with a targeted mutation of the Pkd1l3 gene. We then examined taste responsiveness of mutant and wild-type mice using several different approaches. In separate groups of mice, we measured preference scores in 48-h 2-bottle tests, determined NaCl or citric acid taste thresholds using a conditioned taste aversion technique, and conducted electrophysiological recordings of activity in the chorda tympani and glossopharyngeal nerves. Multiple taste compounds representing all major taste qualities were used in the preference tests and nerve-recording experiments. We found no significant reduction in taste responsiveness in Pkd1l3 mutant mice in behavioral or electrophysiologic:al tests when compared with wild-type controls. Therefore, further studies are needed to elucidate the function of PKD1L3 in taste bud cells.
C1 [Nelson, Theodore M.; Bachmanov, Alexander A.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA.
[LopezJimenez, Nelson D.; Sullivan, Susan L.] Natl Inst Deafness & Other Commun Disorders, Mol Biol Lab, NIH, Rockville, MD 20850 USA.
[Tessarollo, Lino] NCI, Neural Dev Grp, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA.
[Inoue, Masashi] Tokyo Univ Pharm & Life Sci, Dept Life Sci, Lab Cellular Neurobiol, Tokyo 1920392, Japan.
RP Nelson, TM (reprint author), Monell Chem Senses Ctr, 3500 Market St, Philadelphia, PA 19104 USA.
EM tnelson@monell.org
OI Bachmanov, Alexander/0000-0002-2861-3322
FU National Institutes of Health (NIH) [R01 DC00882, R01 AA11028]; NIH,
National Cancer Institute; NIH, NIDCD
FX This work was supported in part by National Institutes of Health (NIH)
grants (R01 DC00882 and R01 AA11028 to A.A.B.) and Intramural Research
Program of the NIH (National Cancer Institute to L.T. and NIDCD to
S.L.S.).
NR 61
TC 37
Z9 40
U1 2
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0379-864X
J9 CHEM SENSES
JI Chem. Senses
PD SEP
PY 2010
VL 35
IS 7
BP 565
EP 577
DI 10.1093/chemse/bjq070
PG 13
WC Behavioral Sciences; Food Science & Technology; Neurosciences;
Physiology
SC Behavioral Sciences; Food Science & Technology; Neurosciences &
Neurology; Physiology
GA 647SJ
UT WOS:000281639100006
PM 20605874
ER
PT J
AU Fushan, AA
Simons, CT
Slack, JP
Drayna, D
AF Fushan, Alexey A.
Simons, Christopher T.
Slack, Jay P.
Drayna, Dennis
TI Association between Common Variation in Genes Encoding Sweet Taste
Signaling Components and Human Sucrose Perception
SO CHEMICAL SENSES
LA English
DT Article
DE association; genetic variations; gustducin; sucrose
ID ALPHA-GUSTDUCIN; INSULIN-RESISTANCE; ESSENTIAL-HYPERTENSION;
NATURAL-SELECTION; RECEPTOR-CELLS; TRAIT LOCUS; UMAMI TASTE; HAPLOTYPE;
GENOME; SENSITIVITY
AB Variation in taste perception of different chemical substances is a well-known phenomenon in both humans and animals. Recent advances in the understanding of sweet taste signaling have identified a number of proteins involved in this signal transduction. We evaluated the hypothesis that sequence variations occurring in genes encoding taste signaling molecules can influence sweet taste perception in humans. Our population consisted of unrelated individuals (n = 160) of Caucasian, African-American, and Asian descent. Threshold and suprathreshold sensitivities of participants for sucrose were estimated using a sorting test and signal detection analysis that produced cumulative R-index area under the curve (AUC) scores. Genetic association analysis revealed significant correlation of sucrose AUC scores with genetic variation occurring in the GNAT3 gene (single point P = 10(-3) to 10(-4)), which encodes the taste-specific Go, protein subunit gustducin. Subsequent sequencing identified additional GNAT3 variations having significant association with sucrose AUC scores. Collectively, GNAT3 polymorphisms explain 13% of the variation in sucrose perception. Our findings underscore the importance of common genetic variants influencing human taste perception.
C1 [Fushan, Alexey A.; Drayna, Dennis] Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD 20892 USA.
[Simons, Christopher T.; Slack, Jay P.] Givaudan Flavors Corp, Dept Sci & Technol, Cincinnati, OH 45216 USA.
RP Drayna, D (reprint author), Natl Inst Deafness & Other Commun Disorders, NIH, 5 Res Court, Rockville, MD 20850 USA.
EM drayna@nidcd.nih.gov
RI Simons, Christopher/B-3036-2013
FU National Institute on Deafness and Other Communication
Disorders/National Institutes of Health [Z01-000046-09]; Givaudan
Flavors Corporation [CRADA DC-CR-06-01]
FX This work was supported by National Institute on Deafness and Other
Communication Disorders/National Institutes of Health (Z01-000046-09)
and Givaudan Flavors Corporation (CRADA DC-CR-06-01).
NR 55
TC 31
Z9 31
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0379-864X
J9 CHEM SENSES
JI Chem. Senses
PD SEP
PY 2010
VL 35
IS 7
BP 579
EP 592
DI 10.1093/chemse/bjq063
PG 14
WC Behavioral Sciences; Food Science & Technology; Neurosciences;
Physiology
SC Behavioral Sciences; Food Science & Technology; Neurosciences &
Neurology; Physiology
GA 647SJ
UT WOS:000281639100007
PM 20660057
ER
PT J
AU Young, LR
VanDyke, R
Gulleman, PM
Inoue, Y
Brown, KK
Schmidt, LS
Linehan, WM
Hajjar, F
Kinder, BW
Trapnell, BC
Bissler, JJ
Franz, DN
McCormack, FX
AF Young, Lisa R.
VanDyke, Rhonda
Gulleman, Peter M.
Inoue, Yoshikazu
Brown, Kevin K.
Schmidt, Laura S.
Linehan, W. Marston
Hajjar, Fuad
Kinder, Brent W.
Trapnell, Bruce C.
Bissler, John J.
Franz, David N.
McCormack, Francis X.
TI Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes
Lymphangioleiomyomatosis From Other Diseases
SO CHEST
LA English
DT Article
ID TUBEROUS SCLEROSIS COMPLEX; VEGF-D; CONSENSUS CONFERENCE; CELL CLUSTERS;
LYMPHANGIOGENESIS; LAM; CT
AB Objectives: The majority of women with lymphangioleiomyomatosis (LAM) present with cystic lung disease, and most require lung biopsy for definitive diagnosis. The purpose of this study was to determine the prospective diagnostic usefulness of a serologic test for vascular endothelial growth factor-D (VEGF-D), a lymphangiogenic growth factor.
Methods: We prospectively measured serum VEGF-D levels by enzyme-linked immunoassay in 48 women presenting with cystic lung disease. Diagnostic test performance was determined from a cohort of 195 women, with tuberous sclerosis complex (TSC), TSC-LAM, sporadic LAM (S-LAM), and other cystic lung diseases in the differential diagnosis, including biopsy-proven or genetically proven pulmonary Langerhans cell histiocytosis, emphysema, Sjogren syndrome, or Birt-Hogg-Dube syndrome.
Results: Serum VEGF-D levels were significantly greater in S-LAM (median 1,175 [interquartile range (IQR): 780-2,013] pg/mL; n = 56) than in other cystic lung diseases (median 281 [IQR 203-351] pg/mL; n=44, P <.001). In the cohort evaluated prospectively, 12 of the 15 individuals ultimately diagnosed with LAM by biopsy had VEGF-D levels of > 800 pg/mL, whereas levels were <600 pg/mL in all 18 subjects later diagnosed with other causes of cystic lung disease. Receiver operating characteristic curves demonstrated that VEGF-D effectively identified LAM, with an area under the curve of 0.961(95% CI, 0.923-0.992). A VEGF-D level of > 600 pg/mL was highly associated with a diagnosis of LAM (specificity 97.6%, likelihood ratio 35.2) and values >800 pg/mL were diagnostically specific. Serum VEGF-D levels were significantly elevated in women with TSC-LAM (median 3,465 [IQR 1,970-7,1951 pg/mL) compared with women with TSC only (median 370 [IQR 291-5201 pg/mL), P<.001).
Conclusions: A serum VEGF-D level of > 800 pg/mL in a woman with typical cystic changes on high-resolution CT (HRCT) scan is diagnostically specific for S-LAM and identifies LAM in women with TSC. A negative VEGF-D result does not exclude the diagnosis of LAM. The usefulness of serum VEGF-D testing in men or in women who do not have cystic lung disease on HRCT scan is unknown. CHEST 2010; 138(3):674-681
C1 [Young, Lisa R.; Hajjar, Fuad; Kinder, Brent W.; McCormack, Francis X.] Univ Cincinnati, Coll Med, Div Pulm Crit Care & Sleep Med, Cincinnati, OH 45267 USA.
[Young, Lisa R.; VanDyke, Rhonda; Gulleman, Peter M.] Cincinnati Childrens Hosp, Med Ctr, Div Pulm Med, Cincinnati, OH USA.
[VanDyke, Rhonda] Cincinnati Childrens Hosp, Med Ctr, Div Biostat, Cincinnati, OH USA.
[Trapnell, Bruce C.] Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH USA.
[Bissler, John J.] Cincinnati Childrens Hosp, Med Ctr, Div Nephrol, Cincinnati, OH USA.
[Franz, David N.] Cincinnati Childrens Hosp, Med Ctr, Div Neurol, Cincinnati, OH USA.
[Inoue, Yoshikazu] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Osaka, Japan.
[Brown, Kevin K.] Natl Jewish Hlth, Dept Med, Denver, CO USA.
[Schmidt, Laura S.] SAIC Frederick Inc, NCI Frederick, Basic Res Program, Frederick, MD USA.
[Schmidt, Laura S.; Linehan, W. Marston] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA.
RP McCormack, FX (reprint author), Univ Cincinnati, Coll Med, Div Pulm Crit Care & Sleep Med, 231 Albert Sabin Way,Med Sci Bldg,Room 6114,MLC 0, Cincinnati, OH 45267 USA.
EM Frank.McCormack@uc.edu
RI Szczesniak, Rhonda/M-4446-2015;
OI McCormack, Francis/0000-0001-7168-9464
FU LAM Foundation; The Tante Mela Foundation; National institutes of
Health, National Cancer Institute, Center for Cancer Research; National
Cancer Institute, National Institutes of Health [HHSN261200800001E];
Wyeth for clinical trials in LAM; [NIH/NHLB1 RR19498]
FX This study was funded in pie by a pilot project grant from The LAM
Foundation, The Tante Mela Foundation, and NIH/NHLB1 RR19498. This
research was also supported in part by the Intramural Research Program
of the National institutes of Health, National Cancer Institute, Center
for Cancer Research. This project has been funded in part with federal
funds from the National Cancer Institute, National Institutes of Health,
under contract HHSN261200800001E (to L. S. S.).; The authors have
reported to CHEST the following conflicts of interest: Dr Kinder
received grant monies of > $1.00,000 from the National Institutes of
Health. Drs Young and McCormack have received federal and university
grant monies and funding from Wyeth for clinical trials in LAM. They
have filed a patent application for the development of the VEGF-D assay
as a diagnostic tool. They have waived their rights to royalties
generated by the performance of the assay. Mr Gulleman and Drs VanDyke,
Inoue, Brown, Schmidt, Linehan, Hajjar, Trapnell, Bissler, and Franz
have reported that no potential conflicts of interest exist with any
companies/organizations whose products or services may be discussed in
this article.
NR 21
TC 64
Z9 67
U1 1
U2 4
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD SEP
PY 2010
VL 138
IS 3
BP 674
EP 681
DI 10.1378/chest.10-0573
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 659IZ
UT WOS:000282561500033
PM 20382711
ER
PT J
AU Castriotta, RJ
Eldadah, BA
Foster, WM
Halter, JB
Hazzard, WR
Kiley, JP
King, TE
Horne, FM
Nayfield, SG
Reynolds, HY
Schmader, KE
Toews, GB
High, KP
AF Castriotta, Richard J.
Eldadah, Basil A.
Foster, W. Michael
Halter, Jeffrey B.
Hazzard, William R.
Kiley, James P.
King, Talmadge E., Jr.
Horne, Frances McFarland
Nayfield, Susan G.
Reynolds, Herbert Y.
Schmader, Kenneth E.
Toews, Galen B.
High, Kevin P.
TI Workshop on Idiopathic Pulmonary Fibrosis in Older Adults
SO CHEST
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; INTERSTITIAL LUNG-DISEASE; ALVEOLAR
EPITHELIAL-CELLS; GASTROESOPHAGEAL-REFLUX DISEASE; GENE-EXPRESSION
PROFILES; PLACEBO-CONTROLLED TRIAL; MESENCHYMAL STEM-CELLS;
ARTERIAL-HYPERTENSION; ACUTE EXACERBATIONS; DIABETES-MELLITUS
AB Idiopathic pulmonary fibrosis (IPF), a heterogeneous disease with respect to clinical presentation and rates of progression, disproportionately affects older adults. The diagnosis of IPF is descriptive, based on clinical, radiologic, and histopathologic examination, and definitive diagnosis is hampered by poor interobserver agreement and lack of a consensus definition. There are no effective treatments. Cellular, molecular, genetic, and environmental risk factors have been identified for IPF, but the initiating event and the characteristics of preclinical stages are not known. IPF is predominantly a disease of older adults, and the processes underlying normal aging might significantly influence the development of IPF. Yet, the biology of aging and the principles of medical care for this population have been typically ignored in basic, translational, or clinical IPF research. In August 2009, the Association of Specialty Professors, in collaboration with the American College of Chest Physicians, the American Geriatrics Society, the National Institute on Aging, and the National Heart, Lung, and Blood Institute, held a workshop, summarized herein, to review what is known, to identify research gaps at the interface of aging and IPF, and to suggest priority areas for future research. Efforts to answer the questions identified will require the integration of geriatrics, gerontology, and pulmonary, research, but these efforts have great potential to improve care for patients with IPF. CHEST 2010; 138(3):693-703
C1 [High, Kevin P.] Wake Forest Univ, Bowman Gray Sch Med, Infect Dis Sect, Winston Salem, NC 27157 USA.
[Castriotta, Richard J.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
[Eldadah, Basil A.] NIA, Bethesda, MD 20892 USA.
[Foster, W. Michael] Duke Univ, Sch Med, Durham, NC USA.
[Halter, Jeffrey B.; Toews, Galen B.] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Hazzard, William R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Kiley, James P.; Reynolds, Herbert Y.] NHLBI, Bethesda, MD 20892 USA.
[King, Talmadge E., Jr.] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA USA.
[Horne, Frances McFarland] Assoc Specialty Prof, Washington, DC USA.
[Nayfield, Susan G.] Univ Florida, Sch Med, Gainesville, FL USA.
[Schmader, Kenneth E.] Duke Univ, Med Ctr, Durham, NC USA.
[Schmader, Kenneth E.] GRECC Durham VA Med Ctr, Durham, NC USA.
RP High, KP (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Infect Dis Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM khigh@wfubmc.edu
OI Castriotta, Richard/0000-0003-3502-4558
FU John A. Hartford Foundation [2006-0239]; Cephalon, Inc.; Merck; Wyeth;
Pfizer; Optimer; Chimerix; Afexa Life Sciences
FX This workshop was supported by a grant from the John A. Hartford
Foundation to the Association of Specialty Professors [Grant
2006-0239].; The authors have reported to CHEST the following conflicts
of interest: Dr Castriotta is a consultant for Blue Cross and Blue
Shield of Texas and has received past research support from Cephalon,
Inc. Dr Eldadah is a federal employee with the National Institutes of
Health. Dr King serves as a consultant to the following pharmaceutical
or medical device companies: Actelion, AstraZeneca, Boehringer
Ingelheim, Centocor, Chronoger, CV Therapeutics, Domantis Limited,
FibroGen, Genzyme, Human Genome Sciences, Huya Bioscience, InterMune,
Millennium Pharmaceuticals, Merck, GlaxoSmithKline, Gilead, Novartis,
Hoffman-La Roche, Inc., and Serono. He also serves on the advisory
committees for Actelion and InterMune and on the data safety monitoring
boards for Centocor and GlaxoSmithKline. Dr Nayfield is a federal
employee with the National Institutes of Health. Dr Reynolds is a
federal employee with the National Institutes of Health. Dr Schmader has
received grant support from Merck and Wyeth and serves as a consultant
for Merck and GlaxoSmithKline. Dr High has received grant support from
Merck, Pfizer, Optimer, Chimerix, and Afexa Life Sciences, and serves as
a consultant for Optimer and GlaxoSmithKline. Drs Foster, Halter,
Hazzard, Kiley, McFarland Home, and Toews have reported that no
potential conflicts of interest exist with any companies/organizations
whose products or services may be discussed in this article.
NR 106
TC 25
Z9 25
U1 1
U2 9
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD SEP
PY 2010
VL 138
IS 3
BP 693
EP 703
DI 10.1378/chest.09-3006
PG 11
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 659IZ
UT WOS:000282561500035
PM 20822991
ER
PT J
AU Amaruchkul, K
AF Amaruchkul, Kannapha
TI Stochastic Orders in Risk-Based Overbooking
SO CHIANG MAI JOURNAL OF SCIENCE
LA English
DT Article
DE stochastic model applications; operations research; revenue management
ID YIELD-MANAGEMENT; REVENUE MANAGEMENT; DECISION
AB In this article, we propose a risk-based overbooking model, in which an overbooking limit is chosen such that an expected profit is maximized. We derive an optimality condition, when a show demand given a total number of reservations follows a binomial distribution. We also determine a directional change of the optimal overbooking limit with respect to various model parameters, such as a show-up probability, a per-unit revenue and a per-unit oversale cost. Finally, we show that the optimal expected profit decreases, if the show-up probability increases.
C1 NIDA, Sch Appl Stat, Bangkok 10240, Thailand.
RP Amaruchkul, K (reprint author), NIDA, Sch Appl Stat, 118 Serithai Rd, Bangkok 10240, Thailand.
EM kamaruchkul@gmail.com
NR 15
TC 0
Z9 0
U1 0
U2 2
PU CHIANG MAI UNIV
PI CHIANG MAI
PA FACULTY SCIENCE, CHIANG MAI, 50200, THAILAND
SN 0125-2526
J9 CHIANG MAI J SCI
JI Chiang Mai J. Sci.
PD SEP
PY 2010
VL 37
IS 3
BP 377
EP 383
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 669GO
UT WOS:000283336100003
ER
PT J
AU Kulemzina, AI
Trifonov, VA
Perelman, PL
Ferguson-Smith, MA
Stanyon, R
Yang, F
Graphodatsky, AS
AF Kulemzina, A. I.
Trifonov, V. A.
Perelman, P. L.
Ferguson-Smith, M. A.
Stanyon, R.
Yang, F.
Graphodatsky, A. S.
TI Chromosome evolution in key Cetartiodactyl families
SO CHROMOSOME RESEARCH
LA English
DT Meeting Abstract
CT 19th International Colloquium on animal cytogenetics and gene mapping
CY JUN 06-09, 2010
CL Natl Res Inst Anim Prod, Krakow, POLAND
HO Natl Res Inst Anim Prod
C1 [Kulemzina, A. I.; Trifonov, V. A.; Graphodatsky, A. S.] Inst Chem Biol & Fundamental Med SB RAS, Dept Mol & Cell Biol, Novosibirsk, Russia.
[Perelman, P. L.] NCI, Frederick, MA USA.
[Ferguson-Smith, M. A.] Resource Ctr Comparat Genom, Dept Vet Med, Cambridge, England.
[Stanyon, R.] Univ Florence, Dept Evolutionary Biol, Florence, Italy.
[Yang, F.] Wellcome Trust Sanger Inst, Cambridge, England.
RI Trifonov, Vladimir/E-4907-2012; Perelman, Polina/N-8088-2015; Kulemzina,
Anastasia/N-8554-2015; Graphodatsky, Alexander/B-4922-2010
OI Trifonov, Vladimir/0000-0003-0454-8359; Perelman,
Polina/0000-0002-0982-5100; Graphodatsky, Alexander/0000-0002-8282-1085
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0967-3849
J9 CHROMOSOME RES
JI Chromosome Res.
PD SEP
PY 2010
VL 18
IS 6
BP 722
EP 723
PG 2
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 651NY
UT WOS:000281935600033
ER
PT J
AU Trifonov, VA
Kulemzina, AI
Stanyon, R
Perelman, PL
Ferguson-Smith, MA
Yang, F
Graphodatsky, AS
AF Trifonov, V. A.
Kulemzina, A. I.
Stanyon, R.
Perelman, P. L.
Ferguson-Smith, M. A.
Yang, F.
Graphodatsky, A. S.
TI Chromosome evolution in Perissodactyla
SO CHROMOSOME RESEARCH
LA English
DT Meeting Abstract
CT 19th International Colloquium on animal cytogenetics and gene mapping
CY JUN 06-09, 2010
CL Natl Res Inst Anim Prod, Krakow, POLAND
HO Natl Res Inst Anim Prod
C1 [Trifonov, V. A.; Kulemzina, A. I.; Graphodatsky, A. S.] Inst Chem Biol & Fundamental Med SB RAS, Novosibirsk, Russia.
[Stanyon, R.] Univ Florence, Dept Anim Biol & Genet, Florence, Italy.
[Perelman, P. L.] NCI, Frederick, MA USA.
[Ferguson-Smith, M. A.] Cambridge Resource Ctr Comparat Genom, Dept Vet Med, Cambridge, England.
[Yang, F.] Wellcome Trust Sanger Inst, Cambridge, England.
RI Trifonov, Vladimir/E-4907-2012; Perelman, Polina/N-8088-2015; Kulemzina,
Anastasia/N-8554-2015; Graphodatsky, Alexander/B-4922-2010
OI Trifonov, Vladimir/0000-0003-0454-8359; Perelman,
Polina/0000-0002-0982-5100; Graphodatsky, Alexander/0000-0002-8282-1085
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0967-3849
J9 CHROMOSOME RES
JI Chromosome Res.
PD SEP
PY 2010
VL 18
IS 6
BP 722
EP 722
PG 1
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 651NY
UT WOS:000281935600032
ER
PT J
AU Fox, CS
Massaro, JM
Schlett, CL
Lehman, SJ
Meigs, JB
O'Donnell, CJ
Hoffmann, U
Murabito, JM
AF Fox, Caroline S.
Massaro, Joseph M.
Schlett, Christopher L.
Lehman, Sam J.
Meigs, James B.
O'Donnell, Christopher J.
Hoffmann, Udo
Murabito, Joanne M.
TI Periaortic Fat Deposition Is Associated With Peripheral Arterial Disease
The Framingham Heart Study
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Article
DE obesity; atherosclerosis; peripheral vascular diseases
ID NUTRITION EXAMINATION SURVEY; ANKLE-BRACHIAL INDEX; ADIPOSE-TISSUE;
RISK-FACTORS; INTERMITTENT CLAUDICATION; METABOLIC SYNDROME;
PERIVASCULAR FAT; NATIONAL-HEALTH; OBESITY; PREVALENCE
AB Background-Central obesity is associated with peripheral arterial disease, suggesting that ectopic fat depots may be associated with localized diseases of the aorta and lower-extremity arteries. We hypothesized that persons with greater amounts of periaortic fat are more likely to have clinical PAD and a low ankle-brachial index.
Methods and Results-We quantified periaortic fat surrounding the thoracic aorta using a novel volumetric quantitative approach in 1205 participants from the Framingham Heart Study Offspring cohort (mean age, 65.9 years; women, 54%); visceral abdominal fat also was measured. Clinical peripheral arterial disease was defined as a history of intermittent claudication, and ankle-brachial index was dichotomized as low (<= 0.9) or lower-extremity revascularization versus normal (>0.9 to <1.4). Regression models were created to examine the association between periaortic fat and intermittent claudication or low ankle-brachial index (n = 66). In multivariable logistic regression, per 1 SD increase in periaortic fat, the odds ratio for the combined end point was 1.52 (P = 0.004); these results were strengthened with additional adjustment for body mass index (odds ratio, 1.69; P = 0.002) or visceral abdominal fat (odds ratio, 1.67; P = 0.009), whereas no association was observed for visceral abdominal fat (P = 0.16). Similarly, per SD increase in body mass index or waist circumference, no association was observed after accounting for visceral abdominal fat (body mass index, P = 0.35; waist circumference, P = 0.49).
Conclusions-Periaortic fat is associated with low ABI and intermittent claudication. (Circ Cardiovasc Imaging. 2010;3:515-519.)
C1 [Fox, Caroline S.; O'Donnell, Christopher J.; Murabito, Joanne M.] NHLBI, Framingham Heart Study, Bethesda, MD 20892 USA.
[Fox, Caroline S.; O'Donnell, Christopher J.; Murabito, Joanne M.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Schlett, Christopher L.; Lehman, Sam J.; Hoffmann, Udo] Massachusetts Gen Hosp, Dept Cardiac MR PET CT, Boston, MA 02114 USA.
[Massaro, Joseph M.] Massachusetts Gen Hosp, Dept Gen Internal Med, Boston, MA 02114 USA.
[Fox, Caroline S.; Schlett, Christopher L.; Lehman, Sam J.; Hoffmann, Udo] Harvard Univ, Sch Med, Boston, MA USA.
[Lehman, Sam J.] Flinders Univ S Australia, Dept Cardiol, Adelaide, SA 5001, Australia.
[Massaro, Joseph M.] Boston Univ, Dept Math, Boston, MA 02215 USA.
[Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA.
RP Fox, CS (reprint author), 73 Mt Wayte Ave,Ste 2, Framingham, MA 01702 USA.
EM foxca@nhlbi.nih.gov
OI Murabito, Joanne/0000-0002-0192-7516; Massaro,
Joseph/0000-0002-2682-4812
FU National Heart, Lung, and Blood Institute [N01-HC-25195]; General
Clinical Research Centers Program [M01-RR-01066]; American Diabetes
Association; National Institute of Diabetes and Digestive and Kidney
Diseases [K24 DK080140]; GlaxoSmithKline; Sanofi-Aventis
FX This work was supported by the National Heart, Lung, and Blood Institute
Framingham Heart Study (N01-HC-25195), the General Clinical Research
Centers Program (grant number M01-RR-01066), and a Career Development
Award from the American Diabetes Association and National Institute of
Diabetes and Digestive and Kidney Diseases (K24 DK080140) to Dr
Massaro.; Dr Massaro currently has research grants from GlaxoSmithKline
and Sanofi-Aventis, and has consulting agreements with Eli Lilly and
Interleukin Genetics. The other authors report no conflicts.
NR 24
TC 35
Z9 39
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD SEP
PY 2010
VL 3
IS 5
BP 515
EP 519
DI 10.1161/CIRCIMAGING.110.958884
PG 5
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 649RH
UT WOS:000281790000006
PM 20639302
ER
PT J
AU Berry, C
Kellman, P
Mancini, C
Chen, MY
Bandettini, WP
Lowrey, T
Hsu, LY
Aletras, AH
Arai, AE
AF Berry, Colin
Kellman, Peter
Mancini, Christine
Chen, Marcus Y.
Bandettini, W. Patricia
Lowrey, Tracy
Hsu, Li-Yueh
Aletras, Anthony H.
Arai, Andrew E.
TI Magnetic Resonance Imaging Delineates the Ischemic Area at Risk and
Myocardial Salvage in Patients With Acute Myocardial Infarction
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Article
DE myocardial infarction; MRI; edema; myocardial ischemia
ID AUTOMATED FEATURE ANALYSIS; CORONARY-ARTERY OCCLUSION; DELAYED
ENHANCEMENT MRI; NO-REFLOW PHENOMENON; SIZING ALGORITHM;
RELAXATION-TIMES; VALIDATION; REPERFUSION; EDEMA; SIZE
AB Background-The area at risk (AAR) is a key determinant of myocardial infarction (MI) size. We investigated whether magnetic resonance imaging (MRI) measurement of AAR would be correlated with an angiographic AAR risk score in patients with acute MI.
Methods and Results-Bright-blood, T2-prepared, steady-state, free-precession MRI was used to depict the AAR in 50 consecutive acute MI patients, whereas infarct size was measured on gadolinium late-contrast-enhancement images. AAR was also estimated by the APPROACH and DUKE angiographic jeopardy scores and ST-segment elevation score. Myocardial salvage was calculated as AAR minus infarct size. Results are mean +/- SD unless specified otherwise. Patients were 61 +/- 12 years of age, 76% had an ST-segment elevation MI, and 20% had a prior MI. All underwent MRI 4 +/- 2 days after initial presentation. The relation between MRI and the APPROACH angiographic estimates of AAR was similar (overall size relative to left ventricular mass was 32 +/- 12% vs 30 +/- 12%, respectively, P = 0.33), correlated well (r = 0.78, P < 0.0001), and had a 2.5% bias on Bland-Altman analysis. The DUKE jeopardy score underestimated AAR relative to infarct size and was correlated less well with MRI (r = 0.39, P = 0.0055). ST-segment elevation score underestimated infarct size in 19 subjects (50%) and was not correlated with MRI (r = 0.27, P = 0.06). Myocardial salvage varied according to Thrombolysis in Myocardial Infarction flow grade at the end of angiography/percutaneous coronary intervention (P = 0.04), and Thrombolysis in Myocardial Infarction flow grade was a univariable predictor of myocardial salvage (P = 0.011). In multivariable analyses, infarct size was predicted by T2-prepared, steady-state, free-precession MRI (P < 0.0001).
Conclusions-T2-prepared, steady-state, free-precession MRI delineates the AAR and enables estimation of myocardial salvage when coupled with a measurement of infarct size. (Circ Cardiovasc Imaging. 2010;3:527-535.)
C1 [Berry, Colin; Kellman, Peter; Chen, Marcus Y.; Bandettini, W. Patricia; Lowrey, Tracy; Hsu, Li-Yueh; Aletras, Anthony H.; Arai, Andrew E.] NHLBI, NIH, US Dept HHS, Bethesda, MD 20892 USA.
[Berry, Colin] Univ Glasgow, Fac Med, Glasgow, Lanark, Scotland.
RP Arai, AE (reprint author), NHLBI, NIH, US Dept HHS, Bldg 10,Room B1D 416,MSC 1061,10 Ctr Dr, Bethesda, MD 20892 USA.
EM araia@nih.gov
OI Aletras, Anthony/0000-0002-3786-3817
FU Division of Intramural Research of the National Institutes of Health;
University of Glasgow; Scottish Funding Council
FX This research was funded by the Division of Intramural Research of the
National Institutes of Health. Dr Berry was supported by a University of
Glasgow Lord Kelvin Adam Smith Fellowship (2005-2009) and is currently
supported by a Senior Fellowship from the Scottish Funding Council.
NR 30
TC 75
Z9 75
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD SEP
PY 2010
VL 3
IS 5
BP 527
EP 535
DI 10.1161/CIRCIMAGING.109.900761
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 649RH
UT WOS:000281790000008
PM 20631034
ER
PT J
AU Thanassoulis, G
Massaro, JM
Hoffmann, U
Mahabadi, AA
Vasan, RS
O'Donnell, CJ
Fox, CS
AF Thanassoulis, George
Massaro, Joseph M.
Hoffmann, Udo
Mahabadi, Amir A.
Vasan, Ramachandran S.
O'Donnell, Christopher J.
Fox, Caroline S.
TI Prevalence, Distribution, and Risk Factor Correlates of High Pericardial
and Intrathoracic Fat Depots in the Framingham Heart Study
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Article
DE pericardial fat; obesity; epidemiology
ID EPICARDIAL ADIPOSE-TISSUE; VISCERAL ABDOMINAL FAT; METABOLIC SYNDROME;
OBESE SUBJECTS; DISEASE; MEN; ASSOCIATION; COMMUNITY
AB Background-Pericardial and intrathoracic fat depots may represent novel risk factors for obesity-related cardiovascular disease. We sought to determine the prevalence, distribution, and risk factor correlates of high pericardial and intrathoracic fat deposits.
Methods and Results-Participants from the Framingham Heart Study (n = 3312; mean age, 52 years; 48% women) underwent multidetector CT imaging in 2002 to 2005; high pericardial and high intrathoracic fat were defined on the basis of the sex-specific 90th percentile for these fat depots in a healthy reference sample. For men and women, the prevalence of high pericardial fat was 29.3% and 26.3%, respectively, and high intrathoracic fat was 31.4% and 35.3%, respectively. Overall, 22.1% of the sample was discordant for pericardial and intrathoracic fat depots: 8.3% had high pericardial but normal intrathoracic fat and 13.8% had high intrathoracic but normal pericardial fat. Higher body mass index, higher waist circumference, and increased prevalence of metabolic syndrome were more prevalent in participants with high intrathoracic fat depots than with high pericardial fat (P < 0.05 for all comparisons). High abdominal visceral adipose tissue was more frequent in participants with high intrathoracic adipose tissue compared with those with high pericardial fat (P < 0.001). Intrathoracic fat but not waist circumference was more highly correlated with visceral adipose tissue (r = 0.76 and 0.78 in men and women, respectively; P < 0.0001) than with subcutaneous adipose tissue (SAT) (r = 0.46 and 0.54 in men and women, respectively; P < 0.0001).
Conclusions-Although prevalence of pericardial fat and intrathoracic fat were comparable at 30%, intrathoracic fat correlated more closely with metabolic risk and visceral fat. Intrathoracic fat may be a potential marker of metabolic risk and visceral fat on thoracic imaging. (Circ Cardiovasc Imaging. 2010;3:559-566.)
C1 [Thanassoulis, George; Vasan, Ramachandran S.; O'Donnell, Christopher J.; Fox, Caroline S.] NHLBI, NIH, Framingham Heart Study, Framingham, MA 01702 USA.
[Thanassoulis, George] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Massaro, Joseph M.; Vasan, Ramachandran S.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.
[Hoffmann, Udo; Mahabadi, Amir A.; O'Donnell, Christopher J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Fox, Caroline S.] Harvard Univ, Sch Med, Div Endocrinol, Boston, MA USA.
[O'Donnell, Christopher J.] NIH, Div Intramural Res, Bethesda, MD USA.
[Fox, Caroline S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Fox, CS (reprint author), NHLBI, NIH, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.
EM foxca@nhlbi.nih.gov
RI 王, 强/F-4212-2011;
OI Massaro, Joseph/0000-0002-2682-4812; Ramachandran,
Vasan/0000-0001-7357-5970
FU Canadian Institute of Health Research; Fonds de Recherche en Sante du
Quebec; National Institutes of Health [N01-HC-25195]; [R01-DK-080739]
FX Dr Thanassoulis is supported by a Research Fellowship from the Canadian
Institute of Health Research and the Fonds de Recherche en Sante du
Quebec. The Framingham Heart Study is supported by National Institutes
of Health Contract No. N01-HC-25195. Dr Vasan was supported in part by
grant R01-DK-080739.
NR 21
TC 32
Z9 32
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD SEP
PY 2010
VL 3
IS 5
BP 559
EP U85
DI 10.1161/CIRCIMAGING.110.956706
PG 11
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 649RH
UT WOS:000281790000012
PM 20525769
ER
PT J
AU Gray, TR
Eiden, RD
Leonard, KE
Connors, GJ
Shisler, S
Huestis, MA
AF Gray, Teresa R.
Eiden, Rina D.
Leonard, Kenneth E.
Connors, Gerard J.
Shisler, Shannon
Huestis, Marilyn A.
TI Identifying Prenatal Cannabis Exposure and Effects of Concurrent Tobacco
Exposure on Neonatal Growth
SO CLINICAL CHEMISTRY
LA English
DT Article
ID MARIJUANA EXPOSURE; ORAL FLUID; MAJOR METABOLITES; FETAL-GROWTH;
GENERATION R; MECONIUM; PREGNANCY; DELTA(9)-TETRAHYDROCANNABINOL; USERS;
QUANTIFICATION
AB BACKGROUND: Cannabis is the most frequently used illicit drug among pregnant women, but data describing the effects of prenatal cannabis exposure and concurrent nicotine and cannabis exposures on neonatal growth are inconsistent. Testing of meconium, the first neonatal feces, offers objective evidence of prenatal cannabis exposure, but the relative ability of meconium testing and maternal self-report to identify affected neonates remains unclear.
METHODS: Eighty-six pregnant women provided detailed self-reports of daily cannabis and tobacco consumption throughout pregnancy. Cannabinoids and tobacco biomarkers were identified in oral fluid samples collected each trimester and quantified in meconium at birth.
RESULTS: Cannabis-using women were significantly more likely to also consume tobacco, and smoked similar numbers of cigarettes as non-cannabis-using tobacco smokers. As pregnancy progressed, fewer women smoked cannabis and those who continued to use cannabis reported smoking a smaller number of cannabis joints, but positive maternal oral fluid tests cast doubt on the veracity of some maternal self-reports. More neonates were identified as cannabis exposed by maternal self-report than meconium analysis, because many women quit cannabis use after the first or second trimester; meconium was more likely to be positive if cannabis use continued into the third trimester. Cannabis exposure was associated with decreased birth weight, reduced length, and smaller head circumference, even after data were controlled for tobacco coexposure.
CONCLUSIONS: Prenatal cannabis exposure was associated with fetal growth reduction. Meconium testing primarily identifies prenatal cannabis exposure occurring in the third trimester of gestation. (C) 2010 American Association for Clinical Chemistry
C1 [Gray, Teresa R.; Huestis, Marilyn A.] NIDA, Intramural Res Program, NIH, Baltimore, MD USA.
[Eiden, Rina D.; Leonard, Kenneth E.; Connors, Gerard J.; Shisler, Shannon] SUNY Buffalo, Res Inst Addict, Buffalo, NY 14260 USA.
RP Huestis, MA (reprint author), NIDA, Intramural Res Program, NIH, 251 Bayview Blvd, Baltimore, MD USA.
EM mhuestis@intra.nida.nih.gov
FU National Institute on Drug Abuse, NIH; NIH [R01 DA 013190]
FX This research was funded by the Intramural Research Program of the
National Institute on Drug Abuse, NIH, and NIH extramural grant R01 DA
013190, given to the Growing Up Healthy Study.
NR 33
TC 31
Z9 32
U1 1
U2 10
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD SEP
PY 2010
VL 56
IS 9
BP 1442
EP 1450
DI 10.1373/clinchem.2010.147876
PG 9
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 644SP
UT WOS:000281400600014
PM 20628142
ER
PT J
AU Ray, S
Chhabra, A
Chakraborty, NG
Hegde, U
Dorsky, DI
Chodon, T
von Euw, E
Comin-Anduix, B
Koya, RC
Ribas, A
Economou, JS
Rosenberg, SA
Mukherji, B
AF Ray, Swagatam
Chhabra, Arvind
Chakraborty, Nitya G.
Hegde, Upendra
Dorsky, David I.
Chodon, Thinle
von Euw, Erika
Comin-Anduix, Begonya
Koya, Richard C.
Ribas, Antoni
Economou, James S.
Rosenberg, Steven A.
Mukherji, Bijay
CA UCLA-CALTECH-CHLA-USC-UCONN Consor
TI MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+T
cells exhibit multifunctional effector and helper responses, in vitro
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Cancer immunotherapy; TCR; Multi functional CD4 T cells
ID CD4(+) T-CELLS; GENE-TRANSFER; DENDRITIC CELLS; ESTABLISHED MELANOMA;
ANTITUMOR IMMUNITY; CANCER REGRESSION; REACTIVE TCR; LYMPHOCYTES;
GENERATION; RECEPTOR
AB MHC class I-restricted human melanoma epitope MART-1(27-35) specific TCR-engineered CD4+CD25- T cells synthesize Th1 type cytokines and exhibit cytolytic effector function upon cognate stimulation. A detailed characterization of such TCR-engineered CD4+CD25- T cells now reveals that they are multifunctional. For example, they undergo multiple rounds of division, synthesize cytokines (IFN-gamma, TNF-alpha, IL-2, and MIP1 beta), lyse target cells, and "help" the expansion of the MART-1(27-35) specific CD8+ T cells when stimulated by the MART-1(27-35) peptide pulsed DC. Multiparametric analyses reveal that a single TCR-engineered CD4+ T cell can perform as many as five different functions. Nearly 100% MART-1(27-35) specific TCR expressing CD4+ T cells can be generated through retroviral vector-based transduction and one round of in vitro stimulation by the peptide pulsed DC. MHC class I-restricted tumor epitope specific TCR transduced CD4+ T cells, therefore, could be useful in immunotherapeutic strategies for melanoma or other human malignancies. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Ray, Swagatam; Chhabra, Arvind; Chakraborty, Nitya G.; Hegde, Upendra; Dorsky, David I.; Mukherji, Bijay] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA.
[Chodon, Thinle; von Euw, Erika; Comin-Anduix, Begonya; Koya, Richard C.; Ribas, Antoni; Economou, James S.] Univ Calif Los Angeles, Dept Surg, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Chodon, Thinle; von Euw, Erika; Comin-Anduix, Begonya; Koya, Richard C.; Ribas, Antoni; Economou, James S.] Univ Calif Los Angeles, Dept Med, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Economou, James S.] Univ Calif Los Angeles, Dept Microbiol, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Economou, James S.] Univ Calif Los Angeles, Dept Immunol & Mol Genet, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Economou, James S.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Rosenberg, Steven A.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA.
RP Chhabra, A (reprint author), Univ Connecticut, Ctr Hlth, Dept Med, 263 Farmington Ave, Farmington, CT 06030 USA.
EM arvindac@yahoo.com; mukherji@NSO2.uchc.edu
FU PHS [CA 83130, CA 88059, CA 129816]; Dowling Foundation; Samuel Waxman
Cancer Research Foundation; W.M. Keck Foundation; Joy and Jerry Monkarsh
Fund; Breast Cancer Alliance; Connecticut; GCRC, UCHC [MO 1RR06192]
FX The work was supported by PHS grants CA 83130 (BM), CA 88059 (BM), and
CA 129816 (JSE) and grants from the Dowling Foundation (BM), Samuel
Waxman Cancer Research Foundation, W.M. Keck Foundation, Joy and Jerry
Monkarsh Fund (JSE for UCLA-CALTECH-CHLA-USC-UCONN Consortium on
Translational Program in Engineered Immunity), Breast Cancer Alliance,
Connecticut (AC) and MO 1RR06192 from GCRC, UCHC.
NR 33
TC 28
Z9 28
U1 5
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD SEP
PY 2010
VL 136
IS 3
BP 338
EP 347
DI 10.1016/j.clim.2010.04.013
PG 10
WC Immunology
SC Immunology
GA 638PM
UT WOS:000280907000004
PM 20547105
ER
PT J
AU Porter, BO
Ouedraogo, GL
Hodge, JN
Smith, MA
Pau, A
Roby, G
Kwan, R
Bishop, RJ
Rehm, C
Mican, J
Sereti, I
AF Porter, Brian O.
Ouedraogo, G. Laissa
Hodge, Jessica N.
Smith, Margo A.
Pau, Alice
Roby, Gregg
Kwan, Richard
Bishop, Rachel J.
Rehm, Catherine
Mican, JoAnn
Sereti, Irini
TI D-Dimer and CRP levels are elevated prior to antiretroviral treatment in
patients who develop IRIS (vol 136, pg 42, 2010)
SO CLINICAL IMMUNOLOGY
LA English
DT Correction
C1 [Sereti, Irini] NIAID, NIH, Ctr Clin, Bethesda, MD 20892 USA.
[Ouedraogo, G. Laissa] NCI, Clin Monitoring Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA.
[Bishop, Rachel J.] NEI, NIH, Bethesda, MD 20892 USA.
[Smith, Margo A.] Washington Hosp Ctr, Washington, DC 20010 USA.
RP Sereti, I (reprint author), NIAID, NIH, Ctr Clin, Bldg 10,Room 11B07A,10 Ctr Dr, Bethesda, MD 20892 USA.
EM isereti@niaid.nih.gov
NR 1
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD SEP
PY 2010
VL 136
IS 3
BP 462
EP 462
DI 10.1016/j.clim.2010.06.009
PG 1
WC Immunology
SC Immunology
GA 638PM
UT WOS:000280907000019
ER
PT J
AU Zaoutis, TE
Prasad, PA
Localio, AR
Coffin, SE
Bell, LM
Walsh, TJ
Gross, R
AF Zaoutis, Theoklis E.
Prasad, Priya A.
Localio, A. Russell
Coffin, Susan E.
Bell, Louis M.
Walsh, Thomas J.
Gross, Robert
TI Risk Factors and Predictors for Candidemia in Pediatric Intensive Care
Unit Patients: Implications for Prevention
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID COLONIZATION RESISTANCE; SURGICAL PATIENTS; CANCER-PATIENTS;
EPIDEMIOLOGY; THERAPY; STATES; INFECTIONS; CHILDREN; LEUKEMIA; SPECTRUM
AB Background. Candida species are the leading cause of invasive fungal infections in hospitalized children and are the third most common isolates recovered from patients with healthcare-associated bloodstream infection in the United States. Few data exist on risk factors for candidemia in pediatric intensive care unit (PICU) patients.
Methods. We conducted a population-based case-control study of PICU patients at Children's Hospital of Philadelphia during the period from 1997 through 2004. Case patients were identified using laboratory records, and control patients were selected from PICU rosters. Control patients were matched to case patients by incidence density sampling, adjusting for time at risk. Following conditional multivariate analysis, we performed weighted multivariate analysis to determine predicted probabilities for candidemia given certain risk factor combinations.
Results. We identified 101 case patients with candidemia (incidence, 3.5 cases per 1000 PICU admissions). Factors independently associated with candidemia included presence of a central venous catheter (odds ratio [OR], 30.4; 95% confidence interval [CI], 7.7-119.5), malignancy (OR, 4.0; 95% CI, 1.23-13.1), use of vancomycin for >3 days in the prior 2 weeks (OR, 6.2; 95% CI, 2.4-16), and receipt of agents with activity against anaerobic organisms for >3 days in the prior 2 weeks (OR, 3.5; 95% CI, 1.5-8.4). Predicted probability of having various combinations of the aforementioned factors ranged from 10.7% to 46%. The 30-day mortality rate was 44% among case patients and 14% among control patients (OR, 4.22; 95% CI, 2.35-7.60).
Conclusions. To our knowledge, this is the first study to evaluate independent risk factors and to determine a population of children in PICUs at high risk for developing candidemia. Future efforts should focus on validation of these risk factors identified in a different PICU population and development of interventions for prevention of candidemia in critically ill children.
C1 [Zaoutis, Theoklis E.] Childrens Hosp Philadelphia, Div Infect Dis, CHOP N, Philadelphia, PA 19104 USA.
[Zaoutis, Theoklis E.; Coffin, Susan E.] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA.
[Zaoutis, Theoklis E.; Coffin, Susan E.; Bell, Louis M.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Zaoutis, Theoklis E.; Localio, A. Russell; Gross, Robert] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Walsh, Thomas J.] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA.
RP Zaoutis, TE (reprint author), Childrens Hosp Philadelphia, Div Infect Dis, CHOP N, 34th & Civ Ctr Blvd,Ste 1527, Philadelphia, PA 19104 USA.
EM Zaoutis@email.chop.edu
FU National Institutes of Health [1K23 AI0629753-01]; Merck; National
Cancer Institute; Enzon; Schering-Plough; AstraZeneca; Wyeth-Ayerst
Laboratories; Cephalon
FX Financial support. National Institutes of Health (grant 1K23
AI0629753-01 to T.E.Z); Merck Research Funding; the intramural research
program of the National Cancer Institute.; Potential conflicts of
interest. T.E.Z reports that he has received research funding from
Merck, Enzon, Schering-Plough, AstraZeneca, and Wyeth-Ayerst
Laboratories and has received speaking honoraria from Cephalon. All
other authors: no conflicts.
NR 39
TC 59
Z9 65
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2010
VL 51
IS 5
BP E38
EP E45
DI 10.1086/655698
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 634ZC
UT WOS:000280623900031
PM 20636126
ER
PT J
AU Chawla, V
Greene, T
Beck, GJ
Kusek, JW
Collins, AJ
Sarnak, MJ
Menon, V
AF Chawla, Varun
Greene, Tom
Beck, Gerald J.
Kusek, John W.
Collins, Allan J.
Sarnak, Mark J.
Menon, Vandana
TI Hyperlipidemia and Long-Term Outcomes in Nondiabetic Chronic Kidney
Disease
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC RENAL-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE;
HEMODIALYSIS-PATIENTS; CHOLESTEROL LEVEL; DIALYSIS PATIENTS; MORTALITY
RISK; LIPID-LEVELS; ASSOCIATION; DEATH
AB Background and objectives: Dyslipidemia confers a paradoxical survival advantage in patients with kidney failure. Data are limited in the earlier stages of chronic kidney disease (CKD).
Design, setting, participants, and measurements: This was a cohort study in 840 subjects with stage 3 to 4 CKD enrolled in the Modification of Diet in Renal Disease study. Cox models were used to examine the relationship of total cholesterol (TC), non-HDL-cholesterol (NHDL-C), triglycerides (TG), and HDL-cholesterol (HDL-C) with all-cause and cardiovascular disease (CVD) mortality and progression to kidney failure.
Results: During a mean follow-up of 10 years, there were 208 deaths, 128 deaths from CVD, and 554 subjects reached kidney failure. There was no association between tertiles of any of the lipid variables and mortality; the lowest HDL-C tertile (1.44, 1.18 to 1.78) had increased risk of kidney failure but covariate adjustment abolished this association. In analyses with lipids as continuous variables, there was a significant association with all-cause mortality for TC (hazard ratio [HR] per 10-mg/dl increase, 95% confidence intervals [CI] = 1.03, 1.0 to 1.06) that disappeared with covariate adjustment; there was no association of TG, HDL-C, and NHDL-C as continuous variables with all-cause or CVD mortality. There was a significant inverse association between HDL-C and kidney failure (HR = 0.93, CI = 0.87 to 0.99) in an unadjusted Cox model that was attenuated after adjustment for covariates (HR = 0.98 CI = 0.91 to 1.06).
Conclusions: In this cohort, with predominantly nondiabetic CKD patients, hyperlipidemia is not an independent predictor of long-term outcomes. Clin J Am Soc Nephrol 5: 1582-1587, 2010. doi: 10.2215/CJN.01450210
C1 [Sarnak, Mark J.; Menon, Vandana] Tufts Med Ctr, Div Nephrol, Boston, MA 02111 USA.
[Chawla, Varun] Mt Auburn Hosp, Dept Med, Cambridge, MA USA.
[Greene, Tom] Univ Utah, Div Clin Epidemiol, Salt Lake City, UT USA.
[Beck, Gerald J.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Kusek, John W.] NIH, Bethesda, MD 20892 USA.
[Collins, Allan J.] Hennepin Cty Med Ctr, Div Nephrol, Minneapolis, MN 55415 USA.
RP Menon, V (reprint author), Tufts Med Ctr, Div Nephrol, 800 Washington St,Box 391, Boston, MA 02111 USA.
EM vmenon@tuftsmedicalcenter.org
FU National Institute of Diabetes and Digestive and Kidney Diseases [K23
DK067303, K23DK02904, K24 DK078204]
FX This study was supported through grants K23 DK067303, K23DK02904, and
K24 DK078204 from the National Institute of Diabetes and Digestive and
Kidney Diseases. Part of this material was presented in abstract form at
the annual meeting of the American Society of to Nephrology; November 4
through 9, 2008; Philadelphia, PA.
NR 24
TC 24
Z9 24
U1 0
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP
PY 2010
VL 5
IS 9
BP 1582
EP 1587
DI 10.2215/CJN.01450210
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 648II
UT WOS:000281685600008
PM 20558558
ER
PT J
AU Pipkin, M
Eggers, PW
Larive, B
Rocco, MV
Stokes, JB
Suri, RS
Lockridge, RS
AF Pipkin, Mary
Eggers, Paul W.
Larive, Brett
Rocco, Michael V.
Stokes, John B.
Suri, Rita S.
Lockridge, Robert S., Jr.
CA Frequent Hemodialysis Network Tria
TI Recruitment and Training for Home Hemodialysis: Experience and Lessons
from the Nocturnal Dialysis Trial
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID SELF-CARE DIALYSIS; CONVENTIONAL HEMODIALYSIS; PERSPECTIVES; ESRD
AB Background and objectives: We assessed perceived barriers and incentives to home hemodialysis and evaluated potential correlates with the duration of home hemodialysis training.
Design, settings, participants, & measurements: Surveys were sent to the principal investigator and study coordinator for each clinical center in the Frequent Hemodialysis Network Nocturnal Trial. Baseline data were obtained on medical comorbidities, cognitive and physical functioning, sessions required for home hemodialysis training, and costs of home renovations.
Results: The most commonly perceived barriers included lack of patient motivation, unwillingness to change from in-center modality, and fear of self-cannulation. The most common incentives were greater scheduling flexibility and reduced travel time. The median costs for home renovations varied between $1191 and $4018. The mean number of home hemodialysis training sessions was 27.7 +/- 10.4 (11-59 days). Average training time was less for patients with experience in either self-care or both self-care and cannulation. The number of training sessions was unrelated to the score on the Modified Mini Mental Status or Trailmaking B tests or patient's education level. Training time also did not correlate with the SF-36 Physical Function subscale but did with the modified Charlson comorbidity score and older patient age.
Conclusions: Lack of patient or family motivation and fear of the dialysis process are surmountable barriers for accepting home hemodialysis as a modality for renal replacement therapy. Formal education and scores on cognitive function tests are not predictors of training time. Clin J Am Soc Nephrol 5: 1614-1620, 2010. doi: 10.2215/CJN.02440310
C1 [Stokes, John B.] Univ Iowa, Dept Internal Med, Div Nephrol, Iowa City, IA 52242 USA.
[Pipkin, Mary; Lockridge, Robert S., Jr.] Univ Virginia, Nephrol Clin Res Ctr, Charlottesville, VA USA.
[Pipkin, Mary; Lockridge, Robert S., Jr.] Univ Virginia, Div Nephrol, Charlottesville, VA USA.
[Pipkin, Mary; Lockridge, Robert S., Jr.] Lynchburg Nephrol Phys, Lynchburg, VA USA.
[Eggers, Paul W.] NIDDKD, Bethesda, MD 20892 USA.
[Larive, Brett] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA.
[Rocco, Michael V.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA.
[Stokes, John B.] VA Med Ctr, Iowa City, IA USA.
[Suri, Rita S.] Univ Western Ontario, London, ON, Canada.
RP Stokes, JB (reprint author), Univ Iowa, Dept Internal Med, Div Nephrol, 200 Hawkins Dr,E300 GH, Iowa City, IA 52242 USA.
EM john-stokes@uiowa.edu
RI Suri, Rita/G-3348-2011
OI Suri, Rita/0000-0002-0519-3927
FU National Institutes of Health (NIH) [DK66597, DK066480]; Centers for
Medicare and Medicaid Services, Fresenius Medical Care; Renal Research
Institute, Satellite Health Care, NKF of Iowa; NIH Foundation
FX We thank Susan Sherer for assistance with the data analysis. Funding for
this study was received from the National Institutes of Health (NIH;
Grants DK66597 and DK066480), Centers for Medicare and Medicaid
Services, Fresenius Medical Care, the Renal Research Institute,
Satellite Health Care, NKF of Iowa, and a grant from the NIH Foundation.
NR 21
TC 46
Z9 46
U1 0
U2 4
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP
PY 2010
VL 5
IS 9
BP 1614
EP 1620
DI 10.2215/CJN.02440310
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 648II
UT WOS:000281685600013
PM 20576829
ER
PT J
AU Chakkera, HA
Knowler, WC
Devarapalli, Y
Weil, EJ
Heilman, RL
Dueck, A
Mulligan, DC
Reddy, KS
Moss, AA
Mekeel, KL
Mazur, MJ
Hamawi, K
Castro, JC
Cook, CB
AF Chakkera, Harini A.
Knowler, William C.
Devarapalli, Yugandhara
Weil, E. Jennifer
Heilman, Raymond L.
Dueck, Amylou
Mulligan, David C.
Reddy, Kunam S.
Moss, Adyr A.
Mekeel, Kristin L.
Mazur, Marek J.
Hamawi, Khaled
Castro, Janna C.
Cook, Curtiss B.
TI Relationship between Inpatient Hyperglycemia and Insulin Treatment after
Kidney Transplantation and Future New Onset Diabetes Mellitus
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID IMPAIRED GLUCOSE-TOLERANCE; RENAL-ALLOGRAFT RECIPIENTS; LIFE-STYLE;
CLINICAL INERTIA; CARE; PREVENTION; METFORMIN; RISK
AB Background and objectives: Approximately two-thirds of kidney transplant recipients with no previous history of diabetes experience inpatient hyperglycemia immediately after kidney transplant surgery; whether inpatient hyperglycemia predicts future new onset diabetes after transplant (NODAT) is not established.
Design, setting, participants, & measurements: A retrospective study was conducted to determine the risk conferred by inpatient hyperglycemia on development of NODAT within 1 year posttransplant. All adult nondiabetic kidney transplant recipients between June 1999 and January 2008 were included. Posttransplant inpatient hyperglycemia was defined as any bedside capillary blood glucose >= 200 mg/dl or insulin therapy during hospitalization. NODAT was defined as HbA1C >= 6.5%, fasting venous serum glucose >= 126 mg/dl, or prescribed diet or medical therapy for diabetes mellitus.
Results: The study cohort included 377 patients. NODAT developed in 1 (4%) of the 28 patients without inpatient hyperglycemia, 4 (18%) of the 22 patients with inpatient hyperglycemia but not treated with insulin, and in 98 (30%) of the 327 of the patients who were diagnosed with inpatient hyperglycemia and were treated with insulin. In adjusted analyses, requirement of insulin therapy during hospitalization posttransplant was associated with a 4-fold increase in NODAT (relative risk 4.01; confidence interval, 1.49 to 10.7; P = 0.006).
Conclusion: Development of inpatient hyperglycemia after kidney transplantation in nondiabetic patients significantly increased the risk of NODAT. Additionally, we observed a significantly increased risk of cardiovascular events in patients who developed NODAT. Clin J Am Soc Nephrol 5: 1669-1675, 2010. doi: 10.2215/CJN.09481209
C1 [Chakkera, Harini A.; Devarapalli, Yugandhara; Heilman, Raymond L.; Mazur, Marek J.; Hamawi, Khaled] Mayo Clin, Div Nephrol & Transplantat, Phoenix, AZ USA.
[Mulligan, David C.; Reddy, Kunam S.; Moss, Adyr A.; Mekeel, Kristin L.] Mayo Clin, Div Surg, Phoenix, AZ USA.
[Castro, Janna C.; Cook, Curtiss B.] Mayo Clin, Div Endocrinol, Phoenix, AZ USA.
[Dueck, Amylou] Mayo Clin, Div Biostat, Phoenix, AZ USA.
[Knowler, William C.; Weil, E. Jennifer] NIDDKD, NIH, Phoenix, AZ USA.
RP Chakkera, HA (reprint author), Mayo Clin Hosp, Div Transplantat, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA.
EM chakkera.harini@mayo.edu
FU National Center for Research Resources (NCRR) [1 KL2 RR024151]; National
Institutes of Health (NIH); NIH Roadmap for Medical Research; National
Institute of Diabetes and Digestive and Kidney Diseases
FX This publication was made possible by grant number 1 KL2 RR024151 from
the National Center for Research Resources (NCRR), a component of the
National Institutes of Health (NIH), and the NIH Roadmap for Medical
Research. Its contents are solely the responsibility of the authors and
do not necessarily represent the official view of NCRR or NIH.
Information on NCRR is available at http://www. ncrr.nih.gov/.
Additionally, this research was supported by the Intramural Research
Program of the National Institute of Diabetes and Digestive and Kidney
Diseases.
NR 21
TC 35
Z9 35
U1 0
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP
PY 2010
VL 5
IS 9
BP 1669
EP 1675
DI 10.2215/CJN.09481209
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 648II
UT WOS:000281685600021
PM 20558559
ER
PT J
AU Reddy, UM
AF Reddy, Uma M.
TI Stillbirth Foreword
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Editorial Material
C1 [Reddy, Uma M.] NICHHD, Pregnancy & Perinatol Branch, NIH, Bethesda, MD 20892 USA.
RP Reddy, UM (reprint author), NICHD, Pregnancy & Perinatol Branch, NIH, 6100 Execut Blvd,Room 4B03,MSC 7510, Bethesda, MD 20892 USA.
EM reddyu@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-9201
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD SEP
PY 2010
VL 53
IS 3
BP 586
EP 587
DI 10.1097/GRF.0b013e3181eb6308
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 631TO
UT WOS:000280371500011
PM 20661042
ER
PT J
AU McClure, EM
Dudley, DJ
Reddy, UM
Goldenberg, RL
AF McClure, Elizabeth M.
Dudley, Donald J.
Reddy, Uma M.
Goldenberg, Robert L.
TI Infectious Causes of Stillbirth: A Clinical Perspective
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE stillbirth; infection; chorioamnionitis
ID SPONTANEOUS-ABORTION; PERINATAL-MORTALITY; CLASSIFICATION; PREGNANCY;
COXSACKIE; SYPHILIS; VIRUSES; DEATHS; WOMEN
AB Untreated infection may cause stillbirth by several mechanisms, including direct fetal infection, placental damage, and severe maternal illness. Many bacteria, viruses, and protozoa have been associated with stillbirth. In developed countries, up to 24% of stillbirths have been attributed to infection, although with increased availability of sophisticated diagnostics and rigorous screening, it appears likely that higher numbers may actually be associated with infection. In developed countries, ascending bacterial infection is usually the most common infectious cause of stillbirth, with a number of viral infections also an important factor. Screening, prevention, and treatment of maternal infections are important to reduce stillbirth risk.
C1 [Goldenberg, Robert L.] Drexel Univ, Dept Obstet Gynecol, Coll Med, Philadelphia, PA 19102 USA.
[McClure, Elizabeth M.] Univ N Carolina, Dept Epidemiol, Global Sch Publ Hlth, Chapel Hill, NC USA.
[Dudley, Donald J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA.
[Reddy, Uma M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Rockville, MD USA.
RP Goldenberg, RL (reprint author), Drexel Univ, Dept Obstet Gynecol, Coll Med, 245 N 15th St,17th Floor,Room 17113, Philadelphia, PA 19102 USA.
EM rgoldenb@drexelmed.edu
FU NICHD NIH HHS [U01 HD040607, U01 HD040636]
NR 29
TC 9
Z9 9
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-9201
EI 1532-5520
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD SEP
PY 2010
VL 53
IS 3
BP 635
EP 645
DI 10.1097/GRF.0b013e3181eb6620
PG 11
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 631TO
UT WOS:000280371500017
PM 20661048
ER
PT J
AU Reddy, UM
AF Reddy, Uma M.
TI Management of Pregnancy After Stillbirth
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE stillbirth; recurrence; management; risk factors
ID ALPHA-FETOPROTEIN; RISK; SUBSEQUENT; POPULATION; RECURRENCE; BIRTHS;
DEATH
AB It is difficult for clinicians to counsel, evaluate, and manage subsequent pregnancies after stillbirth as little is known about pregnancy outcome after a stillbirth. In a significant number of cases, either the evaluation was incomplete or the prior stillbirth remains unexplained despite a complete work-up. In addition, there are important psychological and emotional issues when dealing with a pregnancy resulting in a stillbirth. The overall recurrence risk for stillbirth is increased 2 to 10 folds in the next pregnancy, depending on the circumstances. Understanding the circumstances of the previous stillbirth is important for counseling about stillbirth recurrence risk. Categorization of the cause of the previous stillbirth will allow better estimation of individual recurrence risk of the condition that is associated with stillbirth and help guide management.
C1 [Reddy, Uma M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pregnancy & Perinatol Branch, NIH, Bethesda, MD USA.
RP Reddy, UM (reprint author), NICHD, Pregnancy & Perinatol Branch, NIH, 6100 Execut Blvd,Room 4B03,MSC 7510, Bethesda, MD 20892 USA.
EM reddyu@mail.nih.gov
NR 21
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-9201
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD SEP
PY 2010
VL 53
IS 3
BP 700
EP 709
DI 10.1097/GRF.0b013e3181eba25e
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 631TO
UT WOS:000280371500023
PM 20661054
ER
PT J
AU Yang, MA
Dunson, DB
Baird, D
AF Yang, Mingan
Dunson, David B.
Baird, Donna
TI Semiparametric Bayes hierarchical models with mean and variance
constraints
SO COMPUTATIONAL STATISTICS & DATA ANALYSIS
LA English
DT Article
DE Dirichlet process; Latent variables; Moment constraints; Nonparametric
Bayes; Parameter expansion; Random effects
ID LATENT VARIABLE MODELS; DIRICHLET PROCESS; NONPARAMETRIC-ESTIMATION;
PRIOR DISTRIBUTIONS; MEDIAN REGRESSION; PRIORS; FUNCTIONALS; MIXTURES;
OUTCOMES; DENSITY
AB In parametric hierarchical models, it is standard practice to place mean and variance constraints on the latent variable distributions for the sake of identifiability and interpretability. Because incorporation of such constraints is challenging in semiparametric models that allow latent variable distributions to be unknown, previous methods either constrain the median or avoid constraints. In this article, we propose a centered stick-breaking process (CSBP), which induces mean and variance constraints on an unknown distribution in a hierarchical model. This is accomplished by viewing an unconstrained stick-breaking process as a parameter-expanded version of a CSBP. An efficient blocked Gibbs sampler is developed for approximate posterior computation. The methods are illustrated through a simulated example and an epidemiologic application. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Yang, Mingan] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA.
[Dunson, David B.] Duke Univ, Dept Stat Sci, Durham, NC 27706 USA.
[Baird, Donna] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA.
RP Yang, MA (reprint author), St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA.
EM mingany@yahoo.com; dunson@stat.duke.edu; baird@niehs.nih.gov
RI Baird, Donna/D-5214-2017
OI Baird, Donna/0000-0002-5544-2653
FU NIEHS NIH HHS [R01 ES017240]
NR 37
TC 20
Z9 20
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-9473
J9 COMPUT STAT DATA AN
JI Comput. Stat. Data Anal.
PD SEP 1
PY 2010
VL 54
IS 9
BP 2172
EP 2186
DI 10.1016/j.csda.2010.03.025
PG 15
WC Computer Science, Interdisciplinary Applications; Statistics &
Probability
SC Computer Science; Mathematics
GA 610IA
UT WOS:000278723900010
PM 24363478
ER
PT J
AU Spencer, RG
AF Spencer, Richard G.
TI Equivalence of the Time-Domain Matched Filter and the Spectral-Domain
Matched Filter in One-Dimensional NMR Spectroscopy
SO CONCEPTS IN MAGNETIC RESONANCE PART A
LA English
DT Article
DE matched filter; exponential multiplication; signal processing
AB A type of 'matched filter' (MF), used extensively in the processing of one-dimensional spectra, is defined by multiplication of a free-induction decay (FID) by a decaying exponential with the same time constant as that of the FID. This maximizes, in a sense to be defined, the signal-to-noise ratio (SNR) in the spectrum obtained after Fourier transformation. However, a different entity known also as the MF was introduced by van Vleck in the context of pulse detection in the 1940's and has become widely integrated into signal processing practice. These two types of MFs appear to be quite distinct. In the NMR case, the 'filter', that is, the exponential multiplication, is defined by the characteristics of, and applied to, a time domain signal to achieve improved SNR in the spectral domain. In signal processing, the filter is defined by the characteristics of a signal in the spectral domain, and applied to improve the SNR in the temporal (pulse) domain. We reconcile these two distinct implementations of the MF, demonstrating that the NMR 'MF' is a special case of the MF more rigorously defined in the signal processing literature. In addition, two limitations on the use of the MF are highlighted. First, application of the MF distorts resonance ratios as defined by amplitudes, although not as defined by areas. Second, the MF maximizes SNR with respect to resonance amplitude, while intensity is often more appropriately defined by area. Maximizing the SNR with respect to area requires a somewhat different approach to matched filtering. (C) 2010 Wiley Periodicals, Inc(dagger) Concepts Magn Reson Part A 36A: 255-265, 2010.
C1 NIA, NIH, Baltimore, MD 21224 USA.
RP Spencer, RG (reprint author), NIA, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.
EM spencer@helix.nih.gov
FU National Institute on Aging of the NIH
FX This work was supported by the Intramural Research Program of the
National Institute on Aging of the NIH.
NR 11
TC 4
Z9 4
U1 1
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1546-6086
J9 CONCEPT MAGN RESON A
JI Concepts Magn. Reson. Part A
PD SEP
PY 2010
VL 36A
IS 5
BP 255
EP 265
DI 10.1002/cmr.a.20162
PG 11
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical; Radiology,
Nuclear Medicine & Medical Imaging; Spectroscopy
SC Chemistry; Physics; Radiology, Nuclear Medicine & Medical Imaging;
Spectroscopy
GA 672WZ
UT WOS:000283619000001
PM 21765806
ER
PT J
AU Rubinstein, YR
Croft, SC
AF Rubinstein, Yaffa R.
Croft, Stephen C.
TI Patient registry for the overlooked patient
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Letter
C1 [Rubinstein, Yaffa R.; Croft, Stephen C.] NIH, Off Rare Dis Res, Bethesda, MD 20892 USA.
RP Rubinstein, YR (reprint author), NIH, Off Rare Dis Res, Bldg 10, Bethesda, MD 20892 USA.
EM rubinsty@mail.nih.gov
NR 0
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD SEP
PY 2010
VL 31
IS 5
BP 393
EP 393
DI 10.1016/j.cct.2010.07.002
PG 1
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 657CX
UT WOS:000282391000002
PM 20603228
ER
PT J
AU Rubinstein, YR
Groft, SC
Bartek, R
Brown, K
Christensen, RA
Collier, E
Farber, A
Farmer, J
Ferguson, JH
Forrest, CB
Lockhart, NC
McCurdy, KR
Moore, H
Pollen, GB
Richesson, R
Miller, VR
Hull, S
Vaught, J
AF Rubinstein, Yaffa R.
Groft, Stephen C.
Bartek, Ronald
Brown, Kyle
Christensen, Ronald A.
Collier, Elaine
Farber, Amy
Farmer, Jennifer
Ferguson, John H.
Forrest, Christopher B.
Lockhart, Nicole C.
McCurdy, Kate R.
Moore, Helen
Pollen, Geraldine B.
Richesson, Rachel
Miller, Vanessa Rangel
Hull, Sara
Vaught, Jim
TI Creating a global rare disease patient registry linked to a rare
diseases biorepository database: Rare Disease-HUB (RD-HUB)
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Rare diseases; Patient registry; Disease registry; Rare disease; Patient
advocacy; Biospecimen; Biospecimen repositories; Clinical data;
Electronic health record
AB A movement to create a global patient registry for as many as 7,000 rare diseases was launched at a workshop, "Advancing Rare Disease Research: The Intersection of Patient Registries, Biospecimen Repositories, and Clinical Data." http://rarediseases.info.nih.gov/PATIENT_REGISTRIES_WORKSHOP/. The workshop was sponsored by the Office of Rare Diseases Research (ORDR). The focus was the building of an infrastructure for an internet-based global registry linking to biorepositories. Such a registry would serve the patients, investigators, and drug companies. To aid researchers the participants suggested the creation of a centralized database of biorepositories for rare biospecimens (RD-HUB)http://biospecimens.ordr.info.nih.gov/ that could be linked to the registry. Over two days of presentations and breakout sessions, several hundred attendees discussed government rules and regulations concerning privacy and patients' rights and the nature and scope of data to be entered into a central registry as well as concerns about how to validate patient and clinician-entered data to ensure data accuracy. Mechanisms for aggregating data from existing registries were also discussed. The attendees identified registry best practices, model coding systems, international systems for recruiting patients into clinical trials and novel ways of using the internet directly to invite participation in research. They also speculated about who would bear ultimate responsibility for the informatics in the registry and who would have access to the information. Hurdles associated with biospecimen collection and how to overcome them were detailed. The development of the recommendations was, in itself, an indication of the commitment of the rare disease community as never before. Published by Elsevier Inc.
C1 [Rubinstein, Yaffa R.; Groft, Stephen C.; Ferguson, John H.; Pollen, Geraldine B.] NIH, Off Rare Dis Res, Bethesda, MD 20892 USA.
[Bartek, Ronald; Farmer, Jennifer] FARA, Springfield, VA USA.
[Brown, Kyle] Innolyst Inc, San Mateo, CA USA.
[Christensen, Ronald A.] REGISTRAT MAPI, Scottsdale, AZ USA.
[Collier, Elaine] NIH, Natl Ctr Res Resources, Bethesda, MD 20892 USA.
[Farber, Amy] LAM Treatment Alliance, Cambridge, MA USA.
[Forrest, Christopher B.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Forrest, Christopher B.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Lockhart, Nicole C.; Moore, Helen; Vaught, Jim] NCI, Off Biorepositories & Biospecimen Res, NIH, Bethesda, MD 20892 USA.
[McCurdy, Kate R.] Barth Syndrome Fdn Inc, Larchmont, NY USA.
[Richesson, Rachel] Univ S Florida, Coll Med, Dept Pediat, Div Bioinformat & Biostat, Tampa, FL 33612 USA.
[Miller, Vanessa Rangel] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA.
[Hull, Sara] NHGRI, Off Clin Director, Dept Bioeth, Ctr Clin,NIH, Bethesda, MD 20892 USA.
RP Rubinstein, YR (reprint author), NIH, Off Rare Dis Res, 6100 Execut Blvd,Room 3A07,MSC 751, Bethesda, MD 20892 USA.
EM rubinsty@mail.nih.gov; gropts2@od.nih.gov
FU Intramural NIH HHS [Z99 OD999999]
NR 0
TC 44
Z9 44
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD SEP
PY 2010
VL 31
IS 5
BP 394
EP 404
DI 10.1016/j.cct.2010.06.007
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 657CX
UT WOS:000282391000003
PM 20609392
ER
PT J
AU Berger, VW
AF Berger, Vance W.
TI Minimization, by its nature, precludes allocation concealment, and
invites selection bias
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Letter
DE Allocation concealment; Clinical trial; Masking; Minimization; Selection
bias
C1 NCI, Biometry Res Grp, Bethesda, MD 20892 USA.
RP Berger, VW (reprint author), NCI, Biometry Res Grp, Execut Plaza N,Suite 3131,6130 Execut Blvd,MSC 73, Bethesda, MD 20892 USA.
EM vb78c@nih.gov
FU Intramural NIH HHS [Z99 CA999999]
NR 4
TC 17
Z9 17
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD SEP
PY 2010
VL 31
IS 5
BP 406
EP 406
DI 10.1016/j.cct.2010.05.001
PG 1
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 657CX
UT WOS:000282391000005
PM 20457277
ER
PT J
AU Resnik, DB
Miller, F
AF Resnik, David B.
Miller, Frank
TI The ethics of sham surgery on research subjects with cognitive
impairments that affect decision-making capacity
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Sham surgery; Ethics; Clinical trials; Vulnerable populations;
Decision-making capacity
ID PARKINSONS-DISEASE; CLINICAL-RESEARCH; PLACEBO SURGERY; TRIALS
AB Populations recruited to participate in sham surgery clinical trials sometimes include patients with cognitive impairments that affect decision-making capacity. In this commentary we examine arguments for and against including these patients in sham surgery clinical trials. We argue that patients with cognitive impairments that affect decision-making capacity should not be excluded from a sham surgery clinical trial if there are scientific reasons for including them in the study and basic ethical requirements for clinical research are met. Published by Elsevier Inc.
C1 [Resnik, David B.] Natl Inst Environm Hlth Sci, NIH, Res Triangle Pk, NC 27709 USA.
[Miller, Frank] NIH, Dept Bioeth, Bethesda, MD 20892 USA.
RP Resnik, DB (reprint author), Natl Inst Environm Hlth Sci, NIH, Box 12233,Mail Drop CU 03, Res Triangle Pk, NC 27709 USA.
EM resnikd@niehs.nih.gov
FU National Institute for Environmental Health Sciences; Department of
Bioethics, National Institutes of Health
FX This research was supported by the Intramural Programs of the National
Institute for Environmental Health Sciences and the Department of
Bioethics, National Institutes of Health. This research does not
represent the views of the National Institutes of Health or the U.S.
government.
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD SEP
PY 2010
VL 31
IS 5
BP 407
EP 410
DI 10.1016/j.cct.2010.05.009
PG 4
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 657CX
UT WOS:000282391000006
PM 20570755
ER
PT J
AU Kalil, AC
Murthy, MH
Hermsen, ED
Neto, FK
Sun, JF
Rupp, ME
AF Kalil, Andre C.
Murthy, Madhu H.
Hermsen, Elizabeth D.
Neto, Felipe K.
Sun, Junfeng
Rupp, Mark E.
TI Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A
systematic review and meta-analysis
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE pneumonia; vancomycin; linezolid; teicoplanin
ID RESISTANT STAPHYLOCOCCUS-AUREUS; GRAM-POSITIVE INFECTIONS;
CRITICALLY-ILL PATIENTS; VENTILATOR-ASSOCIATED PNEUMONIA; RANDOMIZED
CONTROLLED-TRIALS; DOUBLE-BLIND; LINING FLUID; MULTICENTER;
PHARMACOKINETICS
AB Introduction: Compared with glycopeptides, linezolid achieves higher lung epithelial lining fluid concentrations, which may correlate with improved efficacy in the treatment of nosocomial pneumonia. However, clinical superiority has not been demonstrated.
Objective: To test the hypothesis that linezolid may be superior to glycopeptides.
Methods: Prospective randomized trials that tested linezolid vs. vancomycin or teicoplanin for treatment of nosocomial pneumonia were included. Heterogeneity was analyzed by I(2) and Q statistics. Meta-analysis relative risks were based on fixed and random-effects models. Outcomes evaluated consisted of clinical cure, microbiological eradication, and side effects.
Results: Nine linezolid trials (vancomycin [7]; teicoplanin [2]) were included (n = 2329). The linezolid vs. glycopeptide analysis shows clinical cure relative risk of 1.01 (95% confidence interval, 0.93-1.10; p = .83; I(2) = 0%) and microbiological eradication relative risk of 1.10 (95% confidence interval, 0.98-1.22; p = .10; I(2) = 0%). Methicillin-resistant Staphylococcus aureus subgroup analysis yielded a microbiological eradication relative risk of 1.10 (95% confidence interval, 0.87-1.38; p = .44; I(2) = 16%). If linezolid is compared with vancomycin only, then clinical cure relative risk is 1.00 (95% confidence interval, 0.90-1.12), microbiological eradication and methicillin-resistant Staphylococcus aureus relative risks are 1.07 (95% confidence interval, 0.90-1.26; p = .45) and 1.05 (95% confidence interval, 0.82-1.33; p = .71). The risks of thrombocytopenia (relative risk, 1.93; 95% confidence interval, 1.30-2.87; p = .001) and gastrointestinal events (relative risk, 2.02; 95% confidence interval, 1.10-3.70; p = .02) are higher with linezolid, but no differences are seen for renal dysfunction (relative risk, 0.89; 95% confidence interval, 0.56-1.43; p = .64) or all-cause mortality (relative risk, 0.95; 95% confidence interval, 0.76-1.18; p = .63).
Conclusions: Our study does not demonstrate clinical superiority of linezolid vs. glycopeptides for the treatment of nosocomial pneumonia despite a statistical power of 95%. Linezolid shows a significant two-fold increase in the risk of thrombocytopenia and gastrointestinal events. Vancomycin and teicoplanin are not associated with more renal dysfunction than linezolid. (Crit Care Med 2010; 38:1802-1808)
C1 [Kalil, Andre C.; Hermsen, Elizabeth D.] Univ Nebraska Med Ctr, Coll Med, Omaha, NE USA.
[Murthy, Madhu H.] W Valley Hosp, Integrated Med Serv, Goodyear, AZ USA.
[Hermsen, Elizabeth D.] Nebraska Med Ctr, Omaha, NE USA.
[Hermsen, Elizabeth D.] Univ Nebraska Med Ctr, Coll Pharm, Omaha, NE USA.
[Neto, Felipe K.] Pontificia Univ Catolica, Hosp San Lucas Da Pucrs, Porto Alegre, RS, Brazil.
[Sun, Junfeng] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA.
[Rupp, Mark E.] Univ Nebraska Med Ctr, Dept Internal Med, Div Infect Dis, Omaha, NE USA.
RP Kalil, AC (reprint author), Univ Nebraska Med Ctr, Coll Med, Omaha, NE USA.
EM akalil@unmc.edu
NR 28
TC 64
Z9 83
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD SEP
PY 2010
VL 38
IS 9
BP 1802
EP 1808
DI 10.1097/CCM.0b013e3181eb3b96
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 646RK
UT WOS:000281559500005
PM 20639754
ER
PT J
AU Shaw, PA
AF Shaw, Pamela A.
TI Combination versus monotherapy for septic shock patients
SO CRITICAL CARE MEDICINE
LA English
DT Editorial Material
DE septic shock; monotherapy; antibiotic; combination therapy; propensity
scores; Cox model; multiple comparisons
ID PROPENSITY SCORE; SEVERE SEPSIS; BIAS
C1 NIAID, NIH, Biostat Res Branch, Bethesda, MD 20892 USA.
RP Shaw, PA (reprint author), NIAID, NIH, Biostat Res Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA.
NR 10
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD SEP
PY 2010
VL 38
IS 9
BP 1905
EP 1906
DI 10.1097/CCM.0b013e3181ee3549
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA 646RK
UT WOS:000281559500020
PM 20724887
ER
PT J
AU Fitzgerald, PJ
AF Fitzgerald, P. J.
TI Is Elevated Norepinephrine an Etiological Factor in Some Cases of
Alzheimer's Disease?
SO CURRENT ALZHEIMER RESEARCH
LA English
DT Article
DE Dementia; tricyclic antidepressant; desipramine; clonidine; guanfacine;
beta blocker; propranolol; bipolar disorder; hypertension; obesity;
psychological stress
ID ACTIVATED PROTEIN-KINASE; CEREBROSPINAL-FLUID NOREPINEPHRINE; VASCULAR
RISK-FACTORS; LOCUS-COERULEUS DEGENERATION; BIPOLAR SPECTRUM DISORDERS;
TYPE-2 DIABETES-MELLITUS; BODY-MASS INDEX; BLOOD-PRESSURE; DOUBLE-BLIND;
PREFRONTAL CORTEX
AB Loss of norepinephrine (NE) releasing neurons, in the locus coeruleus of the brainstem, is well documented to occur in Alzheimer's disease (AD). However, this process does not necessarily result in decreased release of NE, since compensatory mechanisms may produce increased release of this neurotransmitter. Independent of potential loss of locus coeruleus cells, brain NE levels may be elevated in some persons with AD, both before and during disease progression. Here I examine evidence that elevated, endogenous brain NE is an etiological factor in some cases of AD, and not merely an epiphenomenon of the disease. To explore this etiological hypothesis in AD, I examine the following eight lines of evidence: 1) direct evidence of elevated NE or its metabolites in AD; 2) studies of tricyclic antidepressants, which may principally boost NE; 3) studies of clonidine and other alpha2 adrenergic agonist drugs, which may principally lower the concentration of NE; 4) studies of beta adrenoceptor blocking drugs, including propranolol; 5) comorbidity of AD and bipolar disorder, where both disorders may involve elevated NE; 6) comorbidity of AD and hypertension; 7) comorbidity of AD and obesity; and 8) potential interaction between AD and psychological stress, where stressors are known to release NE. These lines of evidence tend to support the elevated NE etiological hypothesis.
C1 [Fitzgerald, P. J.] Johns Hopkins Univ, Zanvyl Krieger Mind Bran Inst, Solomon H Snyder Dept Neurosci, Baltimore, MD 21218 USA.
RP Fitzgerald, PJ (reprint author), NIAAA, 5625 Fishers Lane,Room 2N09, Rockville, MD 20852 USA.
EM pfitz@mbi.mb.jhu.edu
NR 133
TC 15
Z9 16
U1 2
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1567-2050
J9 CURR ALZHEIMER RES
JI Curr. Alzheimer Res.
PD SEP
PY 2010
VL 7
IS 6
BP 506
EP 516
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 633SK
UT WOS:000280525100003
PM 20626335
ER
PT J
AU Ozbabacan, SEA
Gursoy, A
Keskin, O
Nussinov, R
AF Ozbabacan, Saliha Ece Acuner
Gursoy, Attila
Keskin, Ozlem
Nussinov, Ruth
TI Conformational ensembles, signal transduction and residue hot spots:
Application to drug discovery
SO CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT
LA English
DT Review
DE Allosteric; cellular pathway; conformational selection; drug design;
drug target; molecular recognition; pharmacological research; protein
dynamics; protein network; signaling
ID PROTEIN-PROTEIN INTERACTIONS; P53 TUMOR-SUPPRESSOR; NITRIC-OXIDE
SYNTHASE; NERVE GROWTH-FACTOR; SMALL-MOLECULE; STRUCTURAL BASIS;
BINDING-SITE; MODULAR ARCHITECTURE; CONSERVED RESIDUES; ENERGY
LANDSCAPES
AB A key step in drug development is the identification of both a protein target and its topological cellular network location and interactions, with regard to information flow in disease-causing events and to medication effects. Information flow involves a cascade of binding or covalent modification processes, with each step being affected by those that occur previously. Proteins are flexible, and information flows via dynamic changes in the distribution of conformational protein ensembles; molecular recognition is mainly determined by these changes. Drug discovery often focuses on signaling proteins situated at the crossroads of cellular networks; such signaling proteins have multiple partners that bind through shared binding sites. This review highlights these shared binding sites, and describes research to suggest that partners binding at these sites could at least partly interact via different energetically dominant 'hot-spot' residues. The data also indicate that, despite dynamic changes in the distribution of the conformational ensembles, the hot-spot conformations are retained in their pre-organized states.
C1 [Nussinov, Ruth] NCI, SAIC Frederick Inc, Basic Sci Program, Ctr Canc Res Nanobiol Program, Frederick, MD 21702 USA.
[Ozbabacan, Saliha Ece Acuner; Gursoy, Attila; Keskin, Ozlem] Koc Univ, Ctr Computat Biol & Bioinformat, TR-34450 Istanbul, Turkey.
[Ozbabacan, Saliha Ece Acuner; Gursoy, Attila; Keskin, Ozlem] Koc Univ, Coll Engn, TR-34450 Istanbul, Turkey.
[Nussinov, Ruth] Tel Aviv Univ, Sackler Inst Mol Med, Dept Human Genet & Mol Med, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
RP Nussinov, R (reprint author), NCI, SAIC Frederick Inc, Basic Sci Program, Ctr Canc Res Nanobiol Program, 1050 Boyles St, Frederick, MD 21702 USA.
EM ruthnu@helix.nih.gov
RI Acuner Ozbabacan, Saliha Ece/I-3464-2012; Gursoy, Attila/E-9565-2015
OI Gursoy, Attila/0000-0002-2297-2113
FU Turkish Academy of Sciences; Scientific and Technological Research
Council of Turkey [109T343, 109E207]; NCI [HHSN261200800001E]; NIH, NCI,
Center for Cancer Research
FX The authors' research is supported by a Turkish Academy of Sciences
Distinguished Young Investigator Award (awarded to Ozlem Keskin); the
Scientific and Technological Research Council of Turkey Fellowship
(awarded to Saliha Ece Acuner Ozbabacan; Grant Numbers 109T343 and
109E207); Federal funds from the NCI, under contract number
HHSN261200800001E; and, in part, by the Intramural Research Program of
the NIH, NCI, Center for Cancer Research.
NR 95
TC 35
Z9 35
U1 2
U2 11
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1367-6733
EI 2040-3437
J9 CURR OPIN DRUG DISC
JI Curr. Opin. Drug Discov. Dev.
PD SEP
PY 2010
VL 13
IS 5
BP 527
EP 537
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 645DI
UT WOS:000281430700002
ER
PT J
AU Rerks-Ngarm, S
Pitisuttithum, P
Ganguly, N
Zhang, LQ
Tamashiro, H
Cooper, DA
Vun, MC
Bela, B
Ditangco, R
Kinh, NV
Bernstein, A
Osmanov, S
Mathieson, B
Kent, SJ
Shao, YM
AF Rerks-Ngarm, Supachai
Pitisuttithum, Punnee
Ganguly, Nirmal
Zhang, Linqi
Tamashiro, Hiko
Cooper, David A.
Mean Chhi Vun
Bela, Budiman
Ditangco, Rossana
Nguyen Van Kinh
Bernstein, Alan
Osmanov, Saladin
Mathieson, Bonnie
Kent, Stephen J.
Shao, Yiming
TI Defining the objectives of the AIDS vaccine for Asia network: report of
the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on
expanding AIDS vaccine research and development capacity in Asia
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Article
DE AIDS; Asia; HIV; vaccine
ID VIRUS-VACCINE; SUBTYPE; IMMUNOGENICITY; THAILAND; SAFETY; TRIAL; BOOST;
DNA; CANDIDATE; RESPONSES
C1 [Kent, Stephen J.] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
[Pitisuttithum, Punnee] Mahidol Univ, Fac Trop Med, Bangkok 10700, Thailand.
[Rerks-Ngarm, Supachai] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand.
[Ganguly, Nirmal] Indian Council Med Res, New Delhi, India.
[Zhang, Linqi] Tsinghua Univ, Chinese Acad Med Sci, Beijing 100084, Peoples R China.
[Zhang, Linqi] Peking Union Med Coll, Beijing 100021, Peoples R China.
[Tamashiro, Hiko] Hokkaido Univ, Sapporo, Hokkaido, Japan.
[Cooper, David A.] Univ NSW, Sydney, NSW, Australia.
[Mean Chhi Vun] Natl Ctr HIV AIDS Dermatol & STIs NCHADS, Phnom Penh, Cambodia.
[Bela, Budiman] Univ Indonesia, Jakarta, Indonesia.
[Ditangco, Rossana] Res Inst Trop Med, Manila, Philippines.
[Nguyen Van Kinh] Natl Inst Infect & Trop Dis NIITD, Hanoi, Vietnam.
[Bernstein, Alan] Global HIV Vaccine Enterprise, New York, NY USA.
[Osmanov, Saladin] Joint United Nations Programme HIV AIDS, WHO, Geneva, Switzerland.
[Mathieson, Bonnie] Off AIDS Res, NIH, Washington, DC USA.
[Shao, Yiming] Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.
RP Kent, SJ (reprint author), Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
EM skent@unimelb.edu.au
RI Tamashiro, Hidehiko/B-2403-2013;
OI Kent, Stephen/0000-0002-8539-4891
FU World Health Organization; National Institutes of Health Office of AIDS
Research; Global HIV Vaccine Enterprise (GHVE); China AIDS Vaccine
Initiative (CAVI); Deirdre
FX The Beijing meeting was sponsored by the World Health Organization, the
National Institutes of Health Office of AIDS Research, the Global HIV
Vaccine Enterprise (GHVE), and the China AIDS Vaccine Initiative (CAVI).
The World Health Organization and the Joint United Nations Programme on
HIV/AIDS (WHO-UNAIDS) and the Global HIV Vaccine Enterprise (GHVE) are
extremely grateful to all participants who made this regional
consultation a fruitful and successful meeting, in particular to the
Ministry of Health of the People's Republic of China, to the Chinese
Centre for Disease Control and Prevention for hosting this meeting.
Thanks are also given to Michael Benenson, Jorge Flores, Deirdre Grant,
Sonali Kochhar, Zarifah Reed, Candace Rosen, and Yiming Shao who served
as rapporteurs. The organizers also thank Jean Louis Excler for his
assistance at the meeting and preparing the first draft of the meeting
report. The authors also acknowledge the help of Tim France
(iniscommunication.com) for technical editing of the paper.
NR 31
TC 9
Z9 9
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1746-630X
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD SEP
PY 2010
VL 5
IS 5
BP 435
EP 452
DI 10.1097/COH.0b013e32833c95c1
PG 18
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 828NO
UT WOS:000295508900013
PM 20978386
ER
PT J
AU Henderson, C
Goldbach-Mansky, R
AF Henderson, Cailin
Goldbach-Mansky, Raphaela
TI Monogenic autoinflammatory diseases: new insights into clinical aspects
and pathogenesis
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE autoinflammatory diseases; cryopyrin-associated periodic syndromes;
deficiency of the IL-1 receptor antagonist; familial Mediterranean
fever; hyperimmunoglobulinemia D with periodic fevers syndrome; IL-1;
inflammasome; TNF-receptor-associated periodic syndrome
ID FAMILIAL MEDITERRANEAN FEVER; RECURRENT MULTIFOCAL OSTEOMYELITIS;
PEDIATRIC GRANULOMATOUS ARTHRITIS; KAPPA-B ACTIVATION;
HYPERIMMUNOGLOBULINEMIA-D SYNDROME; RILONACEPT INTERLEUKIN-1 TRAP;
RECEPTOR ANTAGONIST ANAKINRA; ENCODING MEVALONATE KINASE; EARLY-ONSET
SARCOIDOSIS; LOW-LEVEL MOSAICISM
AB Purpose of review
The genetic and clinical characterizations of monogenic autoinflammatory syndromes have led to ground breaking insights into the regulation of inflammatory responses to endogenous and exogenous inducers or triggers of inflammation and continue to uncover key inflammatory pathways of the innate immune system. This article summarizes recent progress in the clinical aspects and understanding of the pathogenesis of this growing spectrum of diseases.
Recent findings
The understanding of the spectrum of organ manifestations in autoinflammation was expanded by the discovery of two novel monogenic diseases both caused by the absence of an anti-inflammatory signal and added evidence that increased IL-1 signaling can cause aseptic osteolytic bone lesions and that the absence of IL-10 signaling causes inflammatory enterocolitis in neonates. New knock in animal models for TNF-receptor-associated periodic syndrome, and familial Mediterranean fever and cryopyrin-associated periodic syndromes allow insights into the complexity of the dysregulated immune pathways. Exploring 'triggers' of the NLRP3 inflammasome spurred studies of tissue inflammation in diseases including gout and those that previously have not been considered inflammatory in nature such as diabetes, fibrosing lung disease and possibly coronary artery disease.
Summary
The genetic characterization of a growing number of monogenic autoinflammatory diseases has provided important insights into the phenotypic expression of single gene disorders and the complexity of the dysregulated inflammatory pathways leading to clinical disease. Knowledge obtained from these disorders is pertinent to a number of common disorders and provides new targets for drug development.
C1 [Goldbach-Mansky, Raphaela] NIAMSD, Translat Autoinflammatory Dis Sect, NIH, Bethesda, MD 20892 USA.
RP Goldbach-Mansky, R (reprint author), NIAMSD, Translat Autoinflammatory Dis Sect, NIH, MSC 1616,10 Ctr Dr, Bethesda, MD 20892 USA.
EM goldbacr@mail.nih.gov
RI e-, a/F-9947-2012
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
program
FX Dr Henderson and Dr Goldbach-Mansky are employees of the National
Institutes of Health. Their research is funded through the intramural
National Institute of Arthritis and Musculoskeletal and Skin Diseases
program and they report no financial conflicts of interest.
NR 96
TC 41
Z9 46
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8711
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD SEP
PY 2010
VL 22
IS 5
BP 567
EP 578
DI 10.1097/BOR.0b013e32833ceff4
PG 12
WC Rheumatology
SC Rheumatology
GA 632VS
UT WOS:000280457800016
PM 20671522
ER
PT J
AU Colbert, RA
AF Colbert, Robert A.
TI Early axial spondyloarthritis
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE ankylosing spondylitis; axial; classification; preradiographic;
spondyloarthritis
ID SOCIETY CLASSIFICATION CRITERIA; JUVENILE IDIOPATHIC ARTHRITIS;
INFLAMMATORY BACK-PAIN; ANKYLOSING-SPONDYLITIS; EVIDENT SACROILIITIS;
EARLY DISEASE; WHOLE-BODY; SPONDYLARTHRITIS; VALIDATION; CYTOKINES
AB Purpose of review
To summarize recent advances in the classification of preradiographic axial spondyloarthritis (SpA).
Recent findings
Inflammation in the sacroiliac joints precedes radiographic damage that is necessary to establish a diagnosis of ankylosing spondylitis (AS). Preradiographic axial SpA refers to patients with SpA who exhibit signs and symptoms of axial involvement, but lack criteria for AS. Patients with axial SpA can have remarkably similar clinical features and disease activity as those with early AS. MRI is a sensitive method for detecting sacroiliac joint inflammation, which is useful in predicting the development of AS. Whole-body MRI has emerged as a means to visualize additional areas of involvement. However, it may be less sensitive than conventional MRI, and thus its added value will need to be further assessed. The incorporation of MRI evaluation of the sacroiliac joints and HLA-B27 testing into criteria for identifying individuals with preradiographic axial disease has led to the development of criteria for classifying axial SpA.
Summary
The development of classification criteria for axial SpA will aid in the identification of patients suitable for clinical trials testing whether early intervention will slow the development and/or progression of structural changes in that lead to AS.
C1 NIAMSD, Pediat Translat Res Branch, NIH, Bethesda, MD 20892 USA.
RP Colbert, RA (reprint author), NIAMSD, Pediat Translat Res Branch, NIH, Bldg 10,Room 1-5142,10 Ctr Dr, Bethesda, MD 20892 USA.
EM colbertr@mail.nih.gov
FU National Institute of Arthritis Musculoskeletal and Skin Diseases at the
NIH
FX R.A.C. is supported by the Intramural Research Program of the National
Institute of Arthritis Musculoskeletal and Skin Diseases at the NIH. He
thanks Dr M. Ward for critical evaluation of the manuscript. There are
no conflicts of interest.
NR 34
TC 8
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8711
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD SEP
PY 2010
VL 22
IS 5
BP 603
EP 607
DI 10.1097/BOR.0b013e32833c7255
PG 5
WC Rheumatology
SC Rheumatology
GA 632VS
UT WOS:000280457800021
PM 20592602
ER
PT J
AU Roederer, M
Tarnok, A
AF Roederer, Mario
Tarnok, Attila
TI OMIPs-Orchestrating Multiplexity In Polychromatic science
SO CYTOMETRY PART A
LA English
DT Editorial Material
ID FLOW-CYTOMETRY; B-CELLS; MIFLOWCYT
C1 [Tarnok, Attila] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, D-04289 Leipzig, Germany.
[Roederer, Mario] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
RP Tarnok, A (reprint author), Univ Leipzig, Heart Ctr Leipzig, Dept Pediat Cardiol, Strumpellstr 39, D-04289 Leipzig, Germany.
EM tarnok@medizin.uni-leipzig.de
NR 7
TC 15
Z9 15
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4922
J9 CYTOM PART A
JI Cytom. Part A
PD SEP
PY 2010
VL 77A
IS 9
BP 811
EP 812
DI 10.1002/cyto.a.20959
PG 2
WC Biochemical Research Methods; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 646AU
UT WOS:000281508100001
PM 20722007
ER
PT J
AU Mahnke, Y
Chattopadhyay, P
Roederer, M
AF Mahnke, Yolanda
Chattopadhyay, Pratip
Roederer, Mario
TI Publication of Optimized Multicolor Immunofluorescence Panels
SO CYTOMETRY PART A
LA English
DT Letter
ID FLOW-CYTOMETRY
C1 [Mahnke, Yolanda; Chattopadhyay, Pratip; Roederer, Mario] NIAID, ImmunoTechnoloy Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
RP Roederer, M (reprint author), NIAID, ImmunoTechnoloy Sect, Vaccine Res Ctr, NIH, 40 Convent Dr,Room 5509, Bethesda, MD 20892 USA.
EM Roederer@nih.gov
RI Chattopadhyay, Pratip/B-9227-2008;
OI Chattopadhyay, Pratip/0000-0002-5457-9666
NR 6
TC 13
Z9 14
U1 1
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4922
J9 CYTOM PART A
JI Cytom. Part A
PD SEP
PY 2010
VL 77A
IS 9
BP 814
EP 818
DI 10.1002/cyto.a.20916
PG 5
WC Biochemical Research Methods; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 646AU
UT WOS:000281508100002
PM 20722004
ER
PT J
AU Mahnke, YD
Roederer, M
AF Mahnke, Yolanda D.
Roederer, Mario
TI OMIP-001: Quality and Phenotype of Ag-Responsive Human T-Cells
SO CYTOMETRY PART A
LA English
DT Article
C1 [Mahnke, Yolanda D.; Roederer, Mario] NIAID, ImmunoTechnol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
RP Mahnke, YD (reprint author), NIAID, ImmunoTechnol Sect, Vaccine Res Ctr, NIH, 40 Convent Dr, Bethesda, MD 20892 USA.
EM mahnkey@mail.nih.gov
NR 3
TC 20
Z9 20
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4922
J9 CYTOM PART A
JI Cytom. Part A
PD SEP
PY 2010
VL 77A
IS 9
BP 819
EP 820
DI 10.1002/cyto.a.20944
PG 2
WC Biochemical Research Methods; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 646AU
UT WOS:000281508100003
PM 20722005
ER
PT J
AU Chattopadhyay, PK
Roederer, M
Price, DA
AF Chattopadhyay, Pratip K.
Roederer, Mario
Price, David A.
TI OMIP-002: Phenotypic Analysis of Specific Human CD8+ T-Cells Using
Peptide-MHC Class I Multimers for Any of Four Epitopes
SO CYTOMETRY PART A
LA English
DT Article
C1 [Chattopadhyay, Pratip K.; Roederer, Mario] NIAID, ImmunoTechnol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Price, David A.] Cardiff Univ Sch Med, Dept Infect Immun & Biochem, Cardiff, S Glam, Wales.
RP Chattopadhyay, PK (reprint author), NIAID, ImmunoTechnol Sect, Vaccine Res Ctr, NIH, 40 Convent Dr, Bethesda, MD 20892 USA.
EM pchattop@mail.nih.gov
RI Chattopadhyay, Pratip/B-9227-2008; Price, David/C-7876-2013;
OI Price, David/0000-0001-9416-2737; Chattopadhyay,
Pratip/0000-0002-5457-9666
FU Intramural NIH HHS [Z99 AI999999]; Medical Research Council [G0501963]
NR 3
TC 6
Z9 6
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1552-4922
J9 CYTOM PART A
JI Cytom. Part A
PD SEP
PY 2010
VL 77A
IS 9
BP 821
EP 822
DI 10.1002/cyto.a.20945
PG 2
WC Biochemical Research Methods; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 646AU
UT WOS:000281508100004
PM 20722006
ER
PT J
AU Kursawe, R
Eszlinger, M
Narayan, D
Liu, T
Bazuine, M
Cali, AMG
D'Adamo, E
Shaw, M
Pierpont, B
Shulman, GI
Cushman, SW
Sherman, A
Capriol, S
AF Kursawe, Romy
Eszlinger, Markus
Narayan, Deepak
Liu, Teresa
Bazuine, Merlijn
Cali, Anna M. G.
D'Adamo, Ebe
Shaw, Melissa
Pierpont, Bridget
Shulman, Gerald I.
Cushman, Samuel W.
Sherman, Arthur
Capriol, Sonia
TI Cellularity and Adipogenic Profile of the Abdominal Subcutaneous Adipose
Tissue From Obese Adolescents: Association With Insulin Resistance and
Hepatic Steatosis
SO DIABETES
LA English
DT Article
ID ACTIVATED-RECEPTOR-GAMMA; TYPE-2 DIABETES-MELLITUS; CELL-SIZE; ADIPOCYTE
DIFFERENTIATION; IMPAIRED ADIPOGENESIS; LIPOPROTEIN-LIPASE;
ETHNIC-DIFFERENCES; GLUCOSE-TOLERANCE; LIPIN EXPRESSION; IN-VITRO
AB OBJECTIVE We explored whether the distribution of adipose cell size, the estimated total number of adipose cells, and the expression of adipogenic genes in subcutaneous adipose tissue are linked to the phenotype of high visceral and low subcutaneous fat depots in obese adolescents.
RESEARCH DESIGN AND METHODS A total of 38 adolescents with similar degrees of obesity agreed to have a subcutaneous periumbilical adipose tissue biopsy, in addition to metabolic (oral glucose tolerance test and hyperinsulinemic euglycemic clamp) and imaging studies (MRI, DEXA, (1)H-NMR). Subcutaneous periumbilical adipose cell-size distribution and the estimated total number of subcutaneous adipose cells were obtained from tissue biopsy samples fixed in osmium tetroxide and analyzed by Beckman Coulter Multisizer. The adipogenic capacity was measured by Affymetrix Gene Chip and quantitative RT-PCR.
RESULTS Subjects were divided into two groups: high versus low ratio of visceral to visceral + subcutaneous fat (VAT/[VAT+SAT]). The cell-size distribution curves were significantly different between the high and low VAT/(VAT+SAT) groups, even after adjusting for age, sex, and ethnicity (MANOVA P = 0.035). Surprisingly, the fraction of large adipocytes was significantly lower (P < 0.01) in the group with high VAT/(VAT+SAT), along with the estimated total number of large adipose cells (P < 0.05), while the mean diameter was increased (P < 0.01). From the microarray analyses emerged a lower expression of lipogenesis/adipogenesis markers (sterol regulatory element binding protein-1, acetyl-CoA carboxylase, fatty acid synthase) in the group with high VAT/(VAT+SAT), which was confirmed by RT-PCR.
CONCLUSIONS A reduced lipo-/adipogenic capacity, fraction, and estimated number of large subcutaneous adipocytes may contribute to the abnormal distribution of abdominal fat and hepatic steatosis, as well as to insulin resistance in obese adolescents. Diabetes 59:2288-2296, 2010
C1 [Kursawe, Romy; Cali, Anna M. G.; D'Adamo, Ebe; Shaw, Melissa; Pierpont, Bridget; Capriol, Sonia] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.
[Eszlinger, Markus] Univ Leipzig, Dept Endocrinol, Leipzig, Germany.
[Narayan, Deepak] Yale Univ, Sch Med, Dept Plast Surg, New Haven, CT USA.
[Liu, Teresa; Bazuine, Merlijn; Cushman, Samuel W.] NIDDK, Diabet Branch, NIH, Bethesda, MD USA.
[Shulman, Gerald I.] Yale Univ, Sch Med, Dept Internal Med & Cellular & Mol Physiol, New Haven, CT USA.
[Sherman, Arthur] NIDDK, Lab Biol Modeling, NIH, Bethesda, MD USA.
RP Capriol, S (reprint author), Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.
EM sonia.caprio@yale.edu
OI Eszlinger, Markus/0000-0002-4732-2934
FU National Institutes of Health [R01-HD-40787, R01-HD-28016,
K24-HD-01464]; National Center for Research Resources (NCRR), National
Institutes of Health [UL1-RR-0249139]; American Diabetes Association
[R01-EB-006494]; National Institutes of Health, NIDDK
FX This study was supported by grants from the National Institutes of
Health (R01-HD-40787, R01-HD-28016, and K24-HD-01464) to S.C. and by
CTSA Grant No. UL1-RR-0249139 from the National Center for Research
Resources (NCRR), a component of the National Institutes of Health; and
R01-EB-006494 (Bioimage Suite), and Distinguished Clinical Scientist
Awards from the American Diabetes Association (S.C.). T.L., M.B., A.S.,
and S.W.C. were supported by the Intramural Research Program of the
National Institutes of Health, NIDDK. No potential conflicts of interest
relevant to this article were reported.
NR 45
TC 44
Z9 45
U1 0
U2 1
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD SEP
PY 2010
VL 59
IS 9
BP 2288
EP 2296
DI 10.2337/db10-0113
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 647IN
UT WOS:000281612000026
PM 20805387
ER
PT J
AU Klingensmith, GJ
Pyle, L
Arslanian, S
Copeland, KC
Cuttler, L
Kaufman, F
Laffel, L
Marcovina, S
Tollefsen, SE
Weinstock, RS
Linder, B
AF Klingensmith, Georgeanna J.
Pyle, Laura
Arslanian, Silva
Copeland, Kenneth C.
Cuttler, Leona
Kaufman, Francine
Laffel, Lori
Marcovina, Santica
Tollefsen, Sherida E.
Weinstock, Ruth S.
Linder, Barbara
CA TODAY Study Grp
TI The Presence of GAD and IA-2 Antibodies in Youth With a Type 2 Diabetes
Phenotype Results from the TODAY study
SO DIABETES CARE
LA English
DT Article
ID CHILDREN; ADOLESCENTS; AUTOIMMUNITY; MELLITUS; EUROPE; TRENDS; ONSET
AB OBJECTIVE - To determine the frequency of islet cell autoimmunity in youth clinically diagnosed with type 2 diabetes and describe associated clinical and laboratory findings.
RESEARCH DESIGN AND METHODS - Children (10-17 years) diagnosed with type 2 diabetes were screened for participation in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study. Measurements included GAD-65 and insulinoma-associated protein 2 autoantibodies using the new National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health (NIDDK/NIH) standardized assays, a physical examination, and fasting lipid, C-peptide, and A1C determinations.
RESULTS - Of the 1,206 subjects screened and considered clinically to have type 2 diabetes, 118 (9.8%) were antibody positive; of these, 71 (5.9%) were positive for a single antibody, and 47 were positive (3.9%) for both antibodies. Diabetes autoantibody (DAA) positivity was significantly associated with race (P < 0.0001), with positive subjects more likely to be white (40.7 vs. 19%) (P < 0.0001) and male (51.7 vs. 35.7%) (P = 0.0007). BMI, BMI z score, C-peptide, A1C, triglycerides, HDL cholesterol, and blood pressure were significantly different by antibody status. The antibody-positive subjects were less likely to display characteristics clinically associated with type 2 diabetes and a metabolic syndrome phenotype, although the range for BMI z score, blood pressure, fasting C-peptide, and serum lipids overlapped between antibody-positive and antibody-negative subjects.
CONCLUSIONS - Obese youth with a clinical diagnosis of type 2 diabetes may have evidence of islet autoimmunity contributing to insulin deficiency. As a group, patients with DAA have clinical characteristics significantly different from those without DAA. However, without islet autoantibody analysis, these characteristics cannot reliably distinguish between obese young individuals with type 2 diabetes and those with autoimmune diabetes.
C1 [Klingensmith, Georgeanna J.] Univ Colorado Denver, Barbara Davis Ctr, Aurora, CO 80202 USA.
[Klingensmith, Georgeanna J.] Univ Colorado Denver, Childrens Hosp, Aurora, CO USA.
[Pyle, Laura] George Washington Univ, Ctr Biostat, Rockville, MD USA.
[Arslanian, Silva] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA.
[Copeland, Kenneth C.] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA.
[Cuttler, Leona] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
[Kaufman, Francine] Univ So Calif, Los Angeles, CA USA.
[Kaufman, Francine] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Laffel, Lori] Harvard Univ, Sch Med, Boston, MA USA.
[Marcovina, Santica] Univ Washington, Dept Med, Seattle, WA USA.
[Tollefsen, Sherida E.] St Louis Univ, Hlth Sci Ctr, St Louis, MO 63103 USA.
[Weinstock, Ruth S.] SUNY Upstate Med Univ, Syracuse, NY USA.
[Weinstock, Ruth S.] Dept Vet Affairs Med Ctr, Syracuse, NY USA.
[Linder, Barbara] NIDDKD, NIH, Bethesda, MD 20892 USA.
RP Klingensmith, GJ (reprint author), Univ Colorado Denver, Barbara Davis Ctr, Aurora, CO 80202 USA.
EM georgeanna.klingensmith@ucdenver.edu
FU NIDDK, NIH [U01-DK-61212, U01-DK-61230, U01-DK-61239, U01-DK-61242,
U01-DK-61254]; National Center for Research Resources General Clinical
Research Centers [M01-RR-00036, M01-RR-00043-45, M01-RR-00069,
M01-RR-00084, M01-RR-01066, M01-RR-00125, M01-RR14467]
FX This work was completed with funding from NIDDK, NIH (grants
U01-DK-61212, U01-DK-61230, U01-DK-61239, U01-DK-61242, and
U01-DK-61254) and from the National Center for Research Resources
General Clinical Research Centers Program (grant M01-RR-00036
[Washington University in St. Louis School of Medicine], M01-RR-00043-45
[Children's Hospital Los Angeles], M01-RR-00069 [University of Colorado
Health Sciences Center], M01-RR-00084 [Children's Hospital of
Pittsburgh], M01-RR-01066 [Massachusetts General Hospital], M01-RR-00125
[Yale University], and M01-RR14467 [University of Oklahoma Health
Sciences Center]).
NR 19
TC 46
Z9 50
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD SEP
PY 2010
VL 33
IS 9
BP 1970
EP 1975
DI 10.2337/dc10-0373
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 659IN
UT WOS:000282560300014
PM 20519658
ER
PT J
AU Calles-Escandon, J
Light, L
Lovato, L
Getaneh, A
Simmons, D
Kirk, J
Bonds, D
Banerji, MA
Green, JB
Menon, L
Moogali, A
Bergenstal, RM
AF Calles-Escandon, J.
Light, L.
Lovato, L.
Getaneh, A.
Simmons, D.
Kirk, J.
Bonds, D.
Banerji, M. A.
Green, J. B.
Menon, L.
Moogali, A.
Bergenstal, R. M.
TI Glycaemia management of minority participants in ACCORD
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the European-Association-for-the-
Study-of-Diabetes (EASD)
CY SEP 20-24, 2010
CL Stockholm, SWEDEN
SP European Assoc Study Diabetes
C1 [Calles-Escandon, J.; Light, L.; Lovato, L.; Kirk, J.; Menon, L.; Moogali, A.] Wake Forest Univ, Winston Salem, NC 27109 USA.
[Getaneh, A.] Columbia Univ, New York, NY USA.
[Simmons, D.] Univ Arkansas, Little Rock, AR 72204 USA.
[Bonds, D.] NHLBI, Washington, DC USA.
[Banerji, M. A.] State Univ, Brooklyn, NY USA.
[Green, J. B.] Duke Univ, Durham, NC 27706 USA.
[Bergenstal, R. M.] ADA, Alexandria, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2010
VL 53
SU 1
MA 31
BP S19
EP S19
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 635XA
UT WOS:000280689700032
ER
PT J
AU Levetan, CS
Peters, AJ
Novelli, KJ
Marks, BE
Katz, AE
Peterson, RG
Upham, LV
AF Levetan, C. S.
Peters, A. J.
Novelli, K. J.
Marks, B. E.
Katz, A. E.
Peterson, R. G.
Upham, L. V.
TI Impact of a stabilized human reg3a protein on islet neogenesis and
glycaemic control
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the European-Association-for-the-
Study-of-Diabetes (EASD)
CY SEP 20-24, 2010
CL Stockholm, SWEDEN
SP European Assoc Study Diabetes
C1 [Levetan, C. S.] Chestnut Hill Hosp, Philadelphia, PA USA.
[Peters, A. J.] NIH, Unit Cognit Neurophysiol & Imaging, Bethesda, MD 20892 USA.
[Novelli, K. J.] Cabrini Coll, Rosemont, PA USA.
[Marks, B. E.; Katz, A. E.] Thomas Jefferson Univ, Sch Med, Philadelphia, PA 19107 USA.
[Peterson, R. G.] Univ Notre Dame, South Bend, IN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2010
VL 53
SU 1
MA 529
BP S215
EP S215
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 635XA
UT WOS:000280689700530
ER
PT J
AU Mather, KJ
Christophi, CA
Jablonski, KA
Knowler, WC
Goldberg, RB
Kahn, SE
Pi-Sunyer, FX
Pollin, TI
Florez, JC
Franks, PW
AF Mather, K. J.
Christophi, C. A.
Jablonski, K. A.
Knowler, W. C.
Goldberg, R. B.
Kahn, S. E.
Pi-Sunyer, F. X.
Pollin, T. I.
Florez, J. C.
Franks, P. W.
CA Diabet Prevention Program Res Grp
TI Associations of common variants of ADIPOQ, ADIPOR1 and ADIPOR2 with
adiponectin concentration and diabetes incidence in the Diabetes
Prevention Program
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the European-Association-for-the-
Study-of-Diabetes (EASD)
CY SEP 20-24, 2010
CL Stockholm, SWEDEN
SP European Assoc Study Diabetes
C1 [Mather, K. J.] Indiana Univ, Sch Med, Indianapolis, IN USA.
[Christophi, C. A.; Jablonski, K. A.] George Washington Univ, Ctr Biostat, Rockville, MD USA.
[Knowler, W. C.] NIDDKD, Phoenix, AZ USA.
[Goldberg, R. B.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Kahn, S. E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Pi-Sunyer, F. X.] St Lukes Roosevelt Hosp, New York, NY 10025 USA.
[Pollin, T. I.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Florez, J. C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Franks, P. W.] Umea Univ Hosp, S-90185 Umea, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2010
VL 53
SU 1
MA 303
BP S130
EP S131
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 635XA
UT WOS:000280689700304
ER
PT J
AU Rees, MG
Turner, C
Facio, FM
Beer, NL
McCarthy, MI
Biesecker, LG
Gloyn, AL
Collins, FS
AF Rees, M. G.
Turner, C.
Facio, F. M.
Beer, N. L.
McCarthy, M. I.
Biesecker, L. G.
Gloyn, A. L.
Collins, F. S.
CA NISC Comparative Sequencing Progra
TI Insights into glucokinase regulatory protein regulation from the
cellular and kinetic characterisation of rare coding variants
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the European-Association-for-the-
Study-of-Diabetes (EASD)
CY SEP 20-24, 2010
CL Stockholm, SWEDEN
SP European Assoc Study Diabetes
C1 [Rees, M. G.; Beer, N. L.; McCarthy, M. I.; Gloyn, A. L.] Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[Rees, M. G.; Turner, C.; Facio, F. M.; Biesecker, L. G.; Collins, F. S.] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2010
VL 53
SU 1
MA 54
BP S29
EP S29
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 635XA
UT WOS:000280689700055
ER
PT J
AU Schafer, MK
Eiden, LE
Weihe, E
AF Schafer, M. K.
Eiden, L. E.
Weihe, E.
TI Vesicular monoamine transporter 2 gene expression in beta cells of
primates but not of rodents: implications for developing radioligands
for imaging of beta cell mass in animal models
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the European-Association-for-the-
Study-of-Diabetes (EASD)
CY SEP 20-24, 2010
CL Stockholm, SWEDEN
SP European Assoc Study Diabetes
C1 [Schafer, M. K.; Weihe, E.] Univ Marburg, Inst Anat & Cell Biol, D-35032 Marburg, Germany.
[Eiden, L. E.] NIMH, Mol Neurosci Sect, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2010
VL 53
SU 1
MA 477
BP S195
EP S196
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 635XA
UT WOS:000280689700478
ER
PT J
AU Gonzalez, N
Ramos-Alvarez, I
Martin-Duce, A
Moreno, P
Nuche-Berenguer, B
Sanz, R
Portal-Nunez, S
Jensen, RT
Villanueva-Penacarrillo, ML
AF Gonzalez, N.
Ramos-Alvarez, I.
Martin-Duce, A.
Moreno, P.
Nuche-Berenguer, B.
Sanz, R.
Portal-Nunez, S.
Jensen, R. T.
Villanueva-Penacarrillo, M. L.
TI Bombesin receptor subtype-3 signalling and its role on glucose transport
in human myocytes
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the European-Association-for-the-
Study-of-Diabetes (EASD)
CY SEP 20-24, 2010
CL Stockholm, SWEDEN
SP European Assoc Study Diabetes
C1 [Gonzalez, N.; Ramos-Alvarez, I.; Moreno, P.; Nuche-Berenguer, B.; Sanz, R.; Portal-Nunez, S.; Villanueva-Penacarrillo, M. L.] HS Fdn Jimenez Diaz, Madrid, Spain.
[Martin-Duce, A.] Univ Alcala de Henares, Madrid, Spain.
[Jensen, R. T.] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2010
VL 53
SU 1
MA 702
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 635XA
UT WOS:000280689701145
ER
PT J
AU Gradmark, A
Pomeroy, J
Renstrom, F
Steiginga, S
Wright, A
Kahn, SE
Mogren, I
Domellof, M
Franks, PW
AF Gradmark, A.
Pomeroy, J.
Renstrom, F.
Steiginga, S.
Wright, A.
Kahn, S. E.
Mogren, I.
Domellof, M.
Franks, P. W.
TI Physical activity may offset pregnancy-related insulin resistance
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the European-Association-for-the-
Study-of-Diabetes (EASD)
CY SEP 20-24, 2010
CL Stockholm, SWEDEN
SP European Assoc Study Diabetes
C1 [Gradmark, A.; Renstrom, F.; Steiginga, S.; Franks, P. W.] GECRG, Umea, Sweden.
[Pomeroy, J.] NIDDK, NIH, Diabet Epidemiol & Clin Res Sect, Phoenix, AZ USA.
[Wright, A.] MRC Human Nutr Res, Cambridge, England.
[Kahn, S. E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Mogren, I.] Dept Clin Sci Obstet & Gynecol, Umea, Sweden.
[Domellof, M.] Dept Pediat, Umea, Sweden.
RI Domellof, Magnus/E-5307-2011
OI Domellof, Magnus/0000-0002-0726-7029
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2010
VL 53
SU 1
MA 688
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 635XA
UT WOS:000280689701131
ER
PT J
AU Simila, ME
Kontto, JP
Valsta, LM
Albanes, D
Virtamo, J
AF Simila, M. E.
Kontto, J. P.
Valsta, L. M.
Albanes, D.
Virtamo, J.
TI Carbohydrate substitution for protein, fat, and their subtypes and risk
of type 2 diabetes in men
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the European-Association-for-the-
Study-of-Diabetes (EASD)
CY SEP 20-24, 2010
CL Stockholm, SWEDEN
SP European Assoc Study Diabetes
C1 [Simila, M. E.; Kontto, J. P.; Valsta, L. M.; Virtamo, J.] Natl Inst Hlth & Welf, Helsinki, Finland.
[Albanes, D.] NCI, Bethesda, MD 20892 USA.
RI Albanes, Demetrius/B-9749-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2010
VL 53
SU 1
MA 937
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 635XA
UT WOS:000280689701379
ER
PT J
AU Turkbey, B
Thomasson, D
Pang, YX
Bernardo, M
Choyke, PL
AF Turkbey, Baris
Thomasson, David
Pang, Yuxi
Bernardo, Marcelino
Choyke, Peter L.
TI The role of dynamic contrast-enhanced MRI in cancer diagnosis and
treatment
SO DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY
LA English
DT Review
DE pathologic angiogenesis; angiogenic inhibitors; magnetic resonance
imaging
ID TUMOR ANGIOGENESIS; KINETIC-PARAMETERS; BREAST-CANCER; MICROCIRCULATION;
BEVACIZUMAB
AB Angiogenesis is a key step in the pathophysiology of tumor growth and metastatic spread. Recently, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has emerged as a method for assessing angiogenesis both during the initial diagnosis and for follow up of anti-angiogenic therapies. In this review, we discuss the technical aspects of implementing DCE-MRI in clinical practice with emphasis on acquisition methods and analytic techniques.
C1 [Turkbey, Baris; Bernardo, Marcelino; Choyke, Peter L.] NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA.
[Thomasson, David] NIH, Ctr Clin, Bethesda, MD 20892 USA.
[Pang, Yuxi] Philips Healthcare, Cleveland, OH USA.
RP Turkbey, B (reprint author), NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA.
EM bturkbey@yahoo.com
FU Intramural NIH HHS [Z01 BC010714-03]
NR 20
TC 40
Z9 46
U1 0
U2 7
PU TURKISH SOC RADIOLOGY
PI ANKARA
PA HOSDERE CAD, GUZELKENT SOK, CANKAYA EVLERI, F-2, ANKARA, 06540, TURKEY
SN 1305-3825
J9 DIAGN INTERV RADIOL
JI Diagn. Interv. Radiol.
PD SEP
PY 2010
VL 16
IS 3
BP 186
EP 192
DI 10.4261/1305-3825.DIR.2537-08.1
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 642RC
UT WOS:000281232900003
PM 19885783
ER
PT J
AU Matsuda, KM
Nobrega, R
Quezado, M
Schrump, DS
Filie, AC
AF Matsuda, Kant M.
Nobrega, Raissa
Quezado, Martha
Schrump, David S.
Filie, Armando C.
TI Melanocytic Bronchopulmonary Carcinoid Tumor in a Patient With Multiple
Endocrine Neoplasia Syndrome Type 1: A Case Report With Emphasis on
Intraoperative Cytological Findings
SO DIAGNOSTIC CYTOPATHOLOGY
LA English
DT Article
DE melanocytic bronchopulmonary carcinoid tumor; multiple endocrine
neoplasia syndrome type 1; melanin; intra-operative cytology
consultation; touch preparation
ID GERMLINE MUTATIONS; THYMIC CARCINOIDS; APUD SERIES; MEN1 GENE;
PATHOGENESIS; FEATURES; LESIONS; ORIGIN; CELLS
AB We present the cytological features along with histologic and imaging findings of a melanocytic bronchopulmonary carcinoid tumor in a patient with multiple endocrine neoplasia syndrome type 1 (MEN-1). Intraoperative touch preparations of the lung tumor showed single spindle cells and loosely cohesive aggregates of spindle cells with oval to elongated nuclei, "salt and pepper" chromatin pattern and inconspicuous nucleoli. The spindle cells occasionally contained cytoplasmic pigment, which revealed to be melanin by Fontana Masson stain on permanent processed material. Immunohistochemical stains for both synaptophysin and chromogranin were strongly positive in the spindle cells. The findings were consistent with melanocytic bronchopulmonary carcinoid tumor, which is relatively uncommon in MEN-1. Diagn. Cytopathol. 2010;38:669-674. (C) 2010 Wiley-Liss, Inc.
C1 [Matsuda, Kant M.; Nobrega, Raissa; Quezado, Martha; Filie, Armando C.] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA.
[Schrump, David S.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA.
RP Filie, AC (reprint author), NCI, Pathol Lab, NIH, 10 Ctr Dr,Bldg 10 Room 2A19, Bethesda, MD 20892 USA.
EM afilie@mail.nih.gov
FU NIH, National Cancer Institute
FX We thank the Clinical Imaging Processing (CIP) Department, Clinical
Center, National Institutes of Health for the 3D reconstruction images.
This research was supported in part by the Intramural Research Program
of the NIH, National Cancer Institute.
NR 30
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-1039
EI 1097-0339
J9 DIAGN CYTOPATHOL
JI Diagn. Cytopathol.
PD SEP
PY 2010
VL 38
IS 9
BP 669
EP 674
DI 10.1002/dc.21296
PG 6
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 645XE
UT WOS:000281498700009
PM 20196165
ER
PT J
AU Schug, TT
AF Schug, Thaddeus T.
TI The skinny on SIRT1 regulation
SO DISEASE MODELS & MECHANISMS
LA English
DT Editorial Material
ID CALORIE RESTRICTION; PGC-1-ALPHA; DEACETYLASE; DBC1
C1 Natl Inst Environm Hlth Sci, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA.
RP Schug, TT (reprint author), Natl Inst Environm Hlth Sci, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA.
EM schugt@niehs.nih.gov
NR 17
TC 0
Z9 0
U1 0
U2 0
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 1754-8403
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD SEP-OCT
PY 2010
VL 3
IS 9-10
BP 507
EP 508
DI 10.1242/dmm.005629
PG 2
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA 678FR
UT WOS:000284060000001
PM 20483999
ER
PT J
AU Ayala, JE
Samuel, VT
Morton, GJ
Obici, S
Croniger, CM
Shulman, GI
Wasserman, DH
McGuinness, OP
AF Ayala, Julio E.
Samuel, Varman T.
Morton, Gregory J.
Obici, Silvana
Croniger, Colleen M.
Shulman, Gerald I.
Wasserman, David H.
McGuinness, Owen P.
CA NIH Mouse Metab Phenotyping Ctr Co
TI Standard operating procedures for describing and performing metabolic
tests of glucose homeostasis in mice
SO DISEASE MODELS & MECHANISMS
LA English
DT Review
ID MUSCLE INSULIN SENSITIVITY; DIET-INDUCED OBESITY; HIGH-FAT-DIET; OB-OB
MICE; IN-VIVO; SKELETAL-MUSCLE; RECEPTOR SUBSTRATE-1; LIPOATROPHIC MICE;
TRANSGENIC MICE; BLOOD-GLUCOSE
AB The Mouse Metabolic Phenotyping Center (MMPC) Consortium was established to address the need to characterize the growing number of mouse models of metabolic diseases, particularly diabetes and obesity. A goal of the MMPC Consortium is to propose standard methods for assessing metabolic phenotypes in mice. In this article, we discuss issues pertaining to the design and performance of various tests of glucose metabolism. We also propose guidelines for the description of methods, presentation of data and interpretation of results. The recommendations presented in this article are based on the experience of the MMPC Consortium and other investigators.
C1 [Ayala, Julio E.; Wasserman, David H.; McGuinness, Owen P.] Vanderbilt NIH Mouse Metab Phenotyping Ctr, Nashville, TN 37232 USA.
[Ayala, Julio E.] Sanford Burnham Med Res Inst Lake Nona, Orlando, FL 32827 USA.
[Samuel, Varman T.; Shulman, Gerald I.] Yale NIH Mouse Metab Phenotyping Ctr, New Haven, CT 06520 USA.
[Morton, Gregory J.] Univ Washington, NIH Mouse Metab Phenotyping Ctr, Seattle, WA 98109 USA.
[Obici, Silvana] Univ Cincinnati, NIH Mouse Metab Phenotyping Ctr, Cincinnati, OH 45267 USA.
[Croniger, Colleen M.] Case Western Reserve Univ, NIH Mouse Metab Phenotyping Ctr, Cleveland, OH 44106 USA.
RP Ayala, JE (reprint author), Vanderbilt NIH Mouse Metab Phenotyping Ctr, Nashville, TN 37232 USA.
EM jayala@sanfordburnham.org
FU NIH [5-U24-DK059637-10, 5-U24-DK076169-05, 5-U24-DK076126-05,
5-U24DK059630-10]
FX We thank Stephen C. Woods for his editorial assistance in preparing this
manuscript. This work was supported by the following NIH grants:
5-U24-DK059637-10 (Vanderbilt University MMPC), 5-U24-DK076169-05 (Yale
University MMPC and Case Western Reserve University MMPC),
5-U24-DK076126-05 (University of Washington MMPC) and 5-U24DK059630-10
(University of Cincinnati MMPC). Deposited in PMC for release after 12
months.
NR 62
TC 183
Z9 185
U1 5
U2 38
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 1754-8403
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD SEP-OCT
PY 2010
VL 3
IS 9-10
BP 525
EP 534
DI 10.1242/dmm.006239
PG 10
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA 678FR
UT WOS:000284060000008
PM 20713647
ER
PT J
AU McMains, VC
Myre, M
Kreppel, L
Kimmel, AR
AF McMains, Vanessa C.
Myre, Michael
Kreppel, Lisa
Kimmel, Alan R.
TI Dictyostelium possesses highly diverged presenilin/gamma-secretase that
regulates growth and cell-fate specification and can accurately process
human APP: a system for functional studies of the
presenilin/gamma-secretase complex
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; C-TERMINAL
FRAGMENT; GAMMA-SECRETASE; INTRAMEMBRANE PROTEOLYSIS; BETA-CATENIN;
TRANSMEMBRANE ASPARTATES; INTRACELLULAR DOMAIN; LINKED MUTATIONS;
DISCOIDEUM
AB Presenilin (PS) is the catalytic moiety of the gamma-secretase complex. PS and other gamma-secretase components are well conserved among metazoa, but their presence and function in more-distant species are not resolved. Because inappropriate gamma-secretase processing of amyloid precursor protein (APP) in humans is associated with familial Alzheimer's disease, understanding essential elements within each gamma-secretase component is crucial to functional studies. Diverged proteins have been identified in primitive plants but experiments have failed to demonstrate gamma-secretase activity. We have identified highly diverged orthologs for each gamma-secretase component in the ancient eukaryote Dictyostelium, which lacks equivalents of APP, Notch and other characterized PS/gamma-secretase substrates. We show that wild-type (WT) Dictyostelium is capable of amyloidogenic processing of ectopically expressed human APP to generate amyloid-beta peptides A beta(40) and A beta(42); strains deficient in gamma-secretase cannot produce A beta peptides but accumulate processed intermediates of APP that co-migrate with the C-terminal fragments alpha-and beta-CTF of APP that are found in mammalian cells. We further demonstrate that Dictyostelium requires PS for phagocytosis and cell-fate specification in a cell-autonomous manner, and show that regulation of phagocytosis requires an active gamma-secretase, a pathway suggested, but not proven, to occur in mammalian and Drosophila cells. Our results indicate that PS signaling is an ancient process that arose prior to metazoan radiation, perhaps independently of Notch. Dictyostelium might serve to identify novel PS/gamma-secretase signaling targets and provide a unique system for high-throughput screening of small-molecule libraries to select new therapeutic targets for diseases associated with this pathway.
C1 [McMains, Vanessa C.; Kreppel, Lisa; Kimmel, Alan R.] NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.
[McMains, Vanessa C.] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
[Myre, Michael] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Human Genet Res,Richard B Simches Res Ctr, Boston, MA 02114 USA.
RP Kimmel, AR (reprint author), NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.
EM ark1@helix.nih.gov
FU National Institutes of Health; National Institute of Diabetes and
Digestive and Kidney Diseases
FX We thank Xiuli Huang, Xin-Hua Liao, Collette Young, Marielle Young,
Jonathan Buggey, Joseph Brzostowski and Taruna Khurana for insightful
discussions and expert technical advice. We also thank Konstantin
Chumakov for guidance on phylogenic analyses, and appreciate the
generosity of Wilma Wasco. This research was supported by the Intramural
Research Program of the National Institutes of Health and the National
Institute of Diabetes and Digestive and Kidney Diseases. Deposited in
PMC for release after 12 months.
NR 66
TC 20
Z9 20
U1 0
U2 1
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 1754-8403
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD SEP-OCT
PY 2010
VL 3
IS 9-10
BP 581
EP 594
DI 10.1242/dmm.004457
PG 14
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA 678FR
UT WOS:000284060000014
PM 20699477
ER
PT J
AU Conway, KP
Levy, J
Vanyukoy, M
Chandler, R
Rutter, J
Swan, GE
Neale, M
AF Conway, Kevin P.
Levy, Janet
Vanyukoy, Michael
Chandler, Redonna
Rutter, Joni
Swan, Gary E.
Neale, Michael
TI Measuring addiction propensity and severity: The need for a new
instrument
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Review
DE Tobacco; Cannabis assessment; Individual differences; Adolescents
ID SUBSTANCE USE DISORDERS; ENVIRONMENTAL RISK-FACTORS; ITEM RESPONSE
THEORY; ALCOHOL DEPENDENCE SCALE; GENOME-WIDE ASSOCIATION; DRUG-ABUSE;
NICOTINE DEPENDENCE; BEHAVIORAL DISINHIBITION; GENETIC INFLUENCES;
DSM-IV
AB Drug addiction research requires but lacks a valid and reliable way to measure both the risk (propensity) to develop addiction and the severity of manifest addiction. This paper argues for a new measurement approach and instrument to quantify propensity to and severity of addiction, based on the testable assumption that these constructs can be mapped onto the same dimension of liability to addiction. The case for this new direction becomes clear from a critical review of empirical data and the current instrumentation. The many assessment instruments in use today have proven utility, reliability, and validity, but they are of limited use for evaluating individual differences in propensity and severity. The conceptual and methodological shortcomings of instruments currently used in research and clinical practice can be overcome through the use of new technologies to develop a reliable, valid, and standardized assessment instrument(s) to measure and distinguish individual variations in expression of the underlying latent trait(s) that comprises propensity to and severity of drug addiction. Such instrumentation would enhance our capacity for drug addiction research on linkages and interactions among familial, genetic, psychosocial, and neurobiological factors associated with variations in propensity and severity. It would lead to new opportunities in substance abuse prevention, treatment, and services research, as well as in interventions and implementation science for drug addiction. Published by Elsevier Ireland Ltd.
C1 [Conway, Kevin P.; Chandler, Redonna] NIDA, DESPR, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Levy, Janet] Duke Univ, Sch Nursing, Durham, NC 27710 USA.
[Vanyukoy, Michael] Univ Pittsburgh, SALK 528, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA.
[Vanyukoy, Michael] Univ Pittsburgh, SALK 528, Dept Psychiat, Pittsburgh, PA 15260 USA.
[Vanyukoy, Michael] Univ Pittsburgh, SALK 528, Dept Human Genet, Pittsburgh, PA 15260 USA.
[Rutter, Joni] NIDA, Div Basic Neurosci & Behav Res, NIH, Dept Hlth & Human Serv, Rockville, MD 20852 USA.
[Swan, Gary E.] SRI Int, Ctr Hlth Sci, Menlo Pk, CA 94025 USA.
[Neale, Michael] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA.
RP Conway, KP (reprint author), NIDA, DESPR, NIH, Dept Hlth & Human Serv, 6001 Execut Blvd,Suite 5185, Bethesda, MD 20892 USA.
EM kconway@nida.nih.gov
OI Rutter, Joni/0000-0002-6502-2361; Conway, Kevin/0000-0002-7638-339X
FU Intramural NIH HHS [Z99 DA999999]
NR 126
TC 18
Z9 19
U1 9
U2 20
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD SEP 1
PY 2010
VL 111
IS 1-2
BP 4
EP 12
DI 10.1016/j.drugalcdep.2010.03.011
PG 9
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 658FU
UT WOS:000282476700003
PM 20462706
ER
PT J
AU Levin, KH
Copersino, ML
Heishman, SJ
Liu, F
Kelly, DL
Boggs, DL
Gorelick, DA
AF Levin, Kenneth H.
Copersino, Marc L.
Heishman, Stephen J.
Liu, Fang
Kelly, Deanna L.
Boggs, Douglas L.
Gorelick, David A.
TI Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis
smokers
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Cannabis; Marijuana; Withdrawal; Tolerance; Relapse
ID SUBSTANCE USE DISORDERS; LONG-TERM USERS; MARIJUANA WITHDRAWAL;
ABSTINENCE SYMPTOMS; TREATMENT SEEKERS; FOLLOW-UP; DEPENDENCE;
ADOLESCENTS; POPULATION; RELAPSE
AB Background: Cannabis withdrawal is not recognized in DSM-IV because of doubts about its clinical significance.
Objectives: Assess the phenomenon of cannabis withdrawal and its relationship to relapse in non-treatment-seeking adults.
Subjects: Convenience sample of 469 adult cannabis smokers who had made a quit attempt while not in a controlled environment.
Methods: Subjects completed a 176-item Marijuana Quit Questionnaire collecting information on sociodemographic characteristics, cannabis use history, and their "most difficult" cannabis quit attempt.
Results: 42.4% of subjects had experienced a lifetime withdrawal syndrome, of whom 70.4% reported using cannabis in response to withdrawal. During the index quit attempt, 95.5% of subjects reported >= 1 individual withdrawal symptom (mean [SD] 9.5 [6.1], median 9.0); 43.1% reported >= 10. Number of withdrawal symptoms was significantly associated with greater frequency and amount of cannabis use, but symptoms occurred even in those using less than weekly. Symptoms were usually of >= moderate intensity and often prompted actions to relieve them. Alcohol (41.5%) and tobacco (48.2%) were used more often than cannabis (33.3%) for this purpose. There was little change during withdrawal in use of other legal or illegal substances.
Conclusions: Cannabis withdrawal is a common syndrome among adults not seeking treatment. The intention to relieve withdrawal symptoms can drive relapse during quit attempts, giving cannabis withdrawal clinical significance as a target of treatment. Published by Elsevier Ireland Ltd.
C1 [Gorelick, David A.] NIDA, NIH, Intramural Res Program, Baltimore, MD 21224 USA.
[Copersino, Marc L.] Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA.
[Liu, Fang; Kelly, Deanna L.; Boggs, Douglas L.] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Catonsville, MD 21228 USA.
RP Gorelick, DA (reprint author), NIDA, NIH, Intramural Res Program, 251 Bayview Blvd,Suite 200, Baltimore, MD 21224 USA.
EM dgorelic@intra.nida.nih.gov
FU Intramural Research Program; National Institutes of Health; National
Institute on Drug Abuse; NIDA Residential Research Support Services
[HHSN271200599091CADB]
FX This study was supported by the Intramural Research Program, National
Institutes of Health, National Institute on Drug Abuse, and NIDA
Residential Research Support Services Contract HHSN271200599091CADB. The
funding sources had no further role in study design; in the collection,
analysis, and interpretation of data; in the writing of the report; or
in the decision to submit the paper for publication.
NR 55
TC 19
Z9 19
U1 4
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD SEP 1
PY 2010
VL 111
IS 1-2
BP 120
EP 127
DI 10.1016/j.drugalcdep.2010.04.010
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 658FU
UT WOS:000282476700018
PM 20510550
ER
PT J
AU Okuda, M
Hasin, DS
Olfson, M
Khan, SS
Nunes, EV
Montoya, I
Liu, SM
Grant, BF
Blanco, C
AF Okuda, Mayumi
Hasin, Deborah S.
Olfson, Mark
Khan, Sharaf S.
Nunes, Edward V.
Montoya, Ivan
Liu, Shang-Min
Grant, Bridget F.
Blanco, Carlos
TI Generalizability of clinical trials for cannabis dependence to community
samples
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Epidemiology; Generalizability; Cannabis dependence; Clinical trials;
Eligibility criteria; Inclusion criteria; Exclusion criteria
ID NATIONAL-EPIDEMIOLOGIC-SURVEY; ALCOHOL-USE DISORDER; RANDOMIZED
CONTROLLED-TRIAL; ANTIDEPRESSANT EFFICACY TRIALS; INTERVIEW SCHEDULE
AUDADIS; DRUG-USE DISORDERS; DSM-IV ALCOHOL; EXCLUSION CRITERIA;
UNITED-STATES; SUBSTANCE USE
AB There is growing concern that results of tightly controlled clinical trials may not generalize to broader community samples. To assess the proportion of community dwelling adults with cannabis dependence who would have been eligible for a typical cannabis dependence treatment study, we applied a standard set of eligibility criteria commonly used in cannabis outcome studies to a large (N = 43,093) representative US adult sample interviewed face-to-face, the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Approximately 80% of the community sample of adults with a diagnosis of cannabis dependence (N = 133) would be excluded from participating in clinical trials by one or more of the common eligibility criteria. Individual study criteria excluded from 0% to 41.0% of the community sample. Legal problems, other illicit drug use disorders, and current use of fewer than 5 joints/week excluded the largest percentage of individuals. These results extend to cannabis dependence concerns that typical clinical trials likely exclude most community dwelling adults with the disorder. The results also support the notion that clinical trials tend to recruit highly selective samples, rather than adults who are representative of typical patients. Clinical trials should carefully evaluate the effects of eligibility criteria on the generalizability of their results. Even in efficacy trials, stringent exclusionary criteria could limit the representativeness of study results. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Okuda, Mayumi; Hasin, Deborah S.; Olfson, Mark; Khan, Sharaf S.; Nunes, Edward V.; Liu, Shang-Min; Blanco, Carlos] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York State Psychiat Inst, New York, NY 10032 USA.
[Hasin, Deborah S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.
[Montoya, Ivan] NIDA, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Bethesda, MD 20892 USA.
[Grant, Bridget F.] NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, NIH, Bethesda, MD 20892 USA.
RP Blanco, C (reprint author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York State Psychiat Inst, 1051 Riverside Dr,Unit 69, New York, NY 10032 USA.
EM cb255@columbia.edu
RI Blanco, Carlos/I-4906-2013; Okuda, Mayumi/L-6210-2013
OI Blanco, Carlos/0000-0001-6187-3057; Okuda, Mayumi/0000-0002-3479-5599
FU National Institute on Alcohol Abuse and Alcoholism; NIAAA, National
Institutes of Health; National Institute of Drug Abuse; American
Foundation for Suicide Foundation; New York State Psychiatric Institute
FX The National Epidemiologic Survey on Alcohol and Related Conditions was
sponsored by the National Institute on Alcohol Abuse and Alcoholism and
funded, in part, by the Intramural Program, NIAAA, National Institutes
of Health, with supplementary funding from the National Institute of
Drug Abuse. This study was supported by a grant from the American
Foundation for Suicide Foundation (Dr. Blanco) and the New York State
Psychiatric Institute (Drs. Blanco, Olfson, Nunes and Hasin).
NR 60
TC 28
Z9 29
U1 3
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD SEP 1
PY 2010
VL 111
IS 1-2
BP 177
EP 181
DI 10.1016/j.drugalcdep.2010.04.009
PG 5
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 658FU
UT WOS:000282476700027
PM 20537813
ER
PT J
AU Griffin, JA
AF Griffin, James A.
TI Research on the implementation of preschool intervention programs:
Learning by doing
SO EARLY CHILDHOOD RESEARCH QUARTERLY
LA English
DT Editorial Material
DE Implementation research; Early intervention; School readiness
ID PROFESSIONAL-DEVELOPMENT; SCHOOL READINESS; BEHAVIOR; TRIAL
C1 [Griffin, James A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, US Dept HHS, Bethesda, MD USA.
RP Griffin, JA (reprint author), NICHD, NIH, Child Dev & Behav Branch, 6100 Execut Blvd,Suite 4B05, Rockville, MD 20852 USA.
EM james.griffin@nih.gov
FU Intramural NIH HHS [Z99 HD999999]
NR 14
TC 7
Z9 7
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-2006
J9 EARLY CHILD RES Q
JI Early Childhood Res. Q.
PD SEP
PY 2010
VL 25
IS 3
BP 267
EP 269
DI 10.1016/j.ecresq.2010.03.004
PG 3
WC Education & Educational Research; Psychology, Developmental
SC Education & Educational Research; Psychology
GA 616ML
UT WOS:000279213400001
PM 20657800
ER
PT J
AU Greenberg, DE
Shoffner, AR
Zelazny, AM
Fenster, ME
Zarember, KA
Stock, F
Ding, L
Marshall-Batty, KR
Wasserman, RL
Welch, DF
Kanakabandi, K
Sturdevant, DE
Virtaneva, K
Porcella, SF
Murray, PR
Malech, HL
Holland, SM
AF Greenberg, David E.
Shoffner, Adam R.
Zelazny, Adrian M.
Fenster, Michael E.
Zarember, Kol A.
Stock, Frida
Ding, Li
Marshall-Batty, Kimberly R.
Wasserman, Richard L.
Welch, David F.
Kanakabandi, Kishore
Sturdevant, Dan E.
Virtaneva, Kimmo
Porcella, Stephen F.
Murray, Patrick R.
Malech, Harry L.
Holland, Steven M.
TI Recurrent Granulibacter bethesdensis Infections and Chronic
Granulomatous Disease
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID ACETIC-ACID BACTERIUM; ASAIA-BOGORENSIS; SEQUENCE-ANALYSIS; REINFECTION;
PATIENT; TUBERCULOSIS; BACTEREMIA; CHILD
AB Chronic granulomatous disease (CGD)is characterized by frequent infections, most of which are curable. Granulibacter bethesdensis is an emerging pathogen in patients with CGD that causes fever and necrotizing lymphadenitis. However, unlike typical CGD organisms, this organism can cause relapse after clinical quiescence. To better define whether infections were newly acquired or recrudesced, we use comparative bacterial genomic hybridization to characterize 11 isolates obtained from 5 patients with CGD from North and Central America. Genomic typing showed that 3 patients had recurrent infection months to years after apparent clinical cure. Two patients were infected with the same strain as previously isolated, and 1 was infected with a genetically distinct strain. This organism is multidrug resistant, and therapy required surgery and combination antimicrobial drugs, including long-term ceftriaxone. G. bethesdensis causes necrotizing lymphadenitis in COD, which may recur or relapse.
C1 [Greenberg, David E.] NIAID, Labs Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
[Wasserman, Richard L.; Welch, David F.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Welch, David F.] Childrens Med Ctr, Dallas, TX 75235 USA.
[Welch, David F.] Med City Dallas Hosp, Dallas, TX USA.
[Kanakabandi, Kishore; Sturdevant, Dan E.; Virtaneva, Kimmo; Porcella, Stephen F.] NIH, Hamilton, MT USA.
RP Greenberg, DE (reprint author), NIAID, Labs Clin Infect Dis, NIH, 33 North Dr,2W10A3, Bethesda, MD 20892 USA.
EM degreenberg@niaid.nih.gov
OI Malech, Harry/0000-0001-5874-5775
FU Baxter Healthcare; CSL Behring; Talecris Biotherapeutics; Nabi
Biopharmaceuticals; Prodesse (Gen-Probe); National Institute of Allergy
and Infectious Diseases, NIH
FX David E. Greenberg, MD; Adam R. Shoffner, BS; Adrian M. Zelazny, PhD;
Michael E. Fenster, MD; Kol A. Zarember, PhD, BSc; Frida Stock, BS; Li
Ding, MD; Kimberly R. Marshall-Batty, PhD, MS, BS; Kishore Kanakabandi;
Dan E. Sturdevant, PhD; Kimmo Virtaneva; Stephen F. Porcella, PhD;
Patrick R. Murray, PhD; Harry L. Malech, MD; and Steven M. Holland, MD,
have disclosed no relevant financial relationships. Richard L.
Wasserman, MD, has disclosed the following relevant financial
relationships: served as an advisor or consultant for Baxter Healthcare,
CSL Behring, Talecris Biotherapeutics; served as a speaker or a member
of a speakers bureau for Baxter Healthcare, CSL Behring, Talecris
Biotherapeutics; received grants for clinical research from Baxter
Healthcare, CSL Behring, Talecris Biotherapeutics, Nabi
Biopharmaceuticals. David F. Welch, PhD, has disclosed the following
relevant financial relationships: received grants for clinical research
from: Prodesse (Gen-Probe); owns stock, stock options, or bonds from
Cepheid, Luminex Corporation, Merck & Co., Inc., Eli Lilly and Company,
Boston Scientific Corporation; Becton, Dickinson and Company.; This
study was supported by the Intramural Research Program of the National
Institute of Allergy and Infectious Diseases, NIH.
NR 19
TC 22
Z9 22
U1 0
U2 3
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2010
VL 16
IS 9
BP 1341
EP 1348
DI 10.3201/eid1609.091800
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 643YT
UT WOS:000281338000001
PM 20735916
ER
PT J
AU Lajous, M
Danon, L
Lopez-Ridaura, R
Astley, CM
Miller, JC
Dowell, SF
O'Hagan, JJ
Goldstein, E
Lipsitch, M
AF Lajous, Martin
Danon, Leon
Lopez-Ridaura, Ruy
Astley, Christina M.
Miller, Joel C.
Dowell, Scott F.
O'Hagan, Justin J.
Goldstein, Edward
Lipsitch, Marc
TI Mobile Messaging as Surveillance Tool during Pandemic (H1N1) 2009,
Mexico
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
C1 [Lajous, Martin] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Lajous, Martin; Lopez-Ridaura, Ruy] Natl Inst Publ Hlth, Ctr Populat Hlth Res, Cuernavaca, Morelos, Mexico.
[Danon, Leon] Univ Warwick, Coventry CV4 7AL, W Midlands, England.
[Miller, Joel C.] NIH, Bethesda, MD 20892 USA.
[Dowell, Scott F.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Lajous, M (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.
EM mlajous@hsph.harvard.edu
RI Danon, Leon/J-6324-2012; Miller, Joel/C-4229-2015;
OI Danon, Leon/0000-0002-7076-1871; Miller, Joel/0000-0003-4426-0405;
Lipsitch, Marc/0000-0003-1504-9213
FU NIGMS NIH HHS [U01 GM076497]
NR 5
TC 7
Z9 7
U1 0
U2 2
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2010
VL 16
IS 9
BP 1488
EP 1489
DI 10.3201/eid1609.100671
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 643YT
UT WOS:000281338000026
PM 20735942
ER
PT J
AU Lodish, MB
Adams, KT
Huynh, TT
Prodanov, T
Ling, A
Chen, C
Shusterman, S
Jimenez, C
Merino, M
Hughes, M
Cradic, KW
Milosevic, D
Singh, RJ
Stratakis, CA
Pacak, K
AF Lodish, Maya B.
Adams, Karen T.
Huynh, Thanh T.
Prodanov, Tamara
Ling, Alex
Chen, Clara
Shusterman, Suzanne
Jimenez, Camilo
Merino, Maria
Hughes, Marybeth
Cradic, Kendall W.
Milosevic, Dragana
Singh, Ravinder J.
Stratakis, Constantine A.
Pacak, Karel
TI Succinate dehydrogenase gene mutations are strongly associated with
paraganglioma of the organ of Zuckerkandl
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
ID MALIGNANT PHEOCHROMOCYTOMAS; FUNCTIONAL PARAGANGLIOMA; FAMILIAL
PARAGANGLIOMA; GERMLINE MUTATIONS; SUBUNIT-B; SDHB; SUSCEPTIBILITY;
PENETRANCE; NEOPLASIA; DISTINCT
AB Organ of Zuckerkandl paragangliomas (PGLs) are rare neuroendocrine tumors that are derived from chromaffin cells located around the origin of the inferior mesenteric artery extending to the level of the aortic bifurcation. Mutations in the genes encoding succinate dehydrogenase subunits (SDH) B, C, and D (SDHx) have been associated with PGLs, but their contribution to PGLs of the organ of Zuckerkandl PGLs is not known. We aimed to describe the clinical presentation of patients with PGLs of the organ of Zuckerkandl and investigate the prevalence of SDHx mutations and other genetic defects among them. The clinical characteristics of 14 patients with PGL of the organ of Zuckerkandl were analyzed retrospectively; their DNA was tested for SDHx mutations and deletions. Eleven out of 14 (79%) patients with PGLs of the organ of Zuckerkandl were found to have mutations in the SDHB (9) or SDHD (2) genes; one patient was found to have the Carney-Stratakis syndrome (CSS), and his PGL was discovered during surgery for gastrointestinal stromal tumor. Our results show that SDHx mutations are prevalent in pediatric and adult PGLs of the organ of Zuckerkandl. Patients with PGLs of the organ of Zuckerkandl should be screened for SDHx mutations and the CSS; in addition, asymptomatic carriers of an SDHx mutation among the relatives of affected patients may benefit from tumor screening for early PGL detection. Endocrine-Related Cancer (2010) 17 581-588
C1 [Lodish, Maya B.; Stratakis, Constantine A.] Natl Inst Child Hlth & Human Dev NICHD, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet PDEGEN, NIH,CRC, Bethesda, MD 20892 USA.
[Pacak, Karel] NICHD, Sect Med Neuroendocrinol, Reprod Biol & Adult Endocrinol Program, NIH,CRC, Bethesda, MD 20892 USA.
[Ling, Alex; Chen, Clara] NIH, Dept Diagnost Radiol, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA.
[Shusterman, Suzanne] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Jimenez, Camilo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Merino, Maria] NCI, Dept Pathol, NIH, Bethesda, MD 20892 USA.
[Hughes, Marybeth] NCI, Dept Surg, NIH, Bethesda, MD 20892 USA.
[Cradic, Kendall W.; Milosevic, Dragana; Singh, Ravinder J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
RP Pacak, K (reprint author), NICHD, Sect Med Neuroendocrinol, Reprod Biol & Adult Endocrinol Program, NIH,CRC, Bldg 10,Room 1E-3140,10 Ctr Dr,MSC 1109, Bethesda, MD 20892 USA.
EM karel@mail.nih.gov
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development of the National Institutes of Health
FX This work was supported by the Intramural Research funding of the Eunice
Kennedy Shriver National Institute of Child Health and Human Development
of the National Institutes of Health.
NR 37
TC 14
Z9 15
U1 0
U2 3
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD SEP
PY 2010
VL 17
IS 3
BP 581
EP 588
DI 10.1677/ERC-10-0004
PG 8
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 657VE
UT WOS:000282445100009
PM 20418362
ER
PT J
AU Meyer-Rochow, GY
Jackson, NE
Conaglen, JV
Whittle, DE
Kunnimalaiyaan, M
Chen, H
Westin, G
Sandgren, J
Stalberg, P
Khanafshar, E
Shibru, D
Duh, QY
Clark, OH
Kebebew, E
Gill, AJ
Clifton-Bligh, R
Robinson, BG
Benn, DE
Sidhu, SB
AF Meyer-Rochow, Goswin Y.
Jackson, Nicole E.
Conaglen, John V.
Whittle, Denis E.
Kunnimalaiyaan, Muthusamy
Chen, Herbert
Westin, Gunnar
Sandgren, Johanna
Stalberg, Peter
Khanafshar, Elham
Shibru, Daniel
Duh, Quan-Yang
Clark, Orlo H.
Kebebew, Electron
Gill, Anthony J.
Clifton-Bligh, Rory
Robinson, Bruce G.
Benn, Diana E.
Sidhu, Stan B.
TI MicroRNA profiling of benign and malignant pheochromocytomas identifies
novel diagnostic and therapeutic targets
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
ID NON-TUMOROUS TISSUES; HUMAN OVARIAN-CANCER; HEPATOCELLULAR-CARCINOMA;
DOWN-REGULATION; ADRENOCORTICAL TUMORS; EXPRESSION PROFILES;
THYROID-CARCINOMA; GENE-EXPRESSION; PROSTATE-CANCER; LUNG-CANCER
AB MicroRNAs (miRNAs) are small RNAs (similar to 22 bp) that post-transcriptionally regulate protein expression and are found to be differentially expressed in a number of human cancers. There is increasing evidence to suggest that miRNAs could be useful in cancer diagnosis, prognosis, and therapy. We performed miRNA microarray expression profiling on a cohort of 12 benign and 12 malignant pheochromocytomas and identified a number of differentially expressed miRNAs. These results were validated in a separate cohort of ten benign and ten malignant samples using real-time quantitative RT-PCR; benign samples had a minimum follow-up of at least 2 years. It was found that IGF2 as well as its intronic miR-483-5p was over-expressed, while miR-15a and miR-16 were under-expressed in malignant tumours compared with benign tumours. These miRNAs were found to be diagnostic and prognostic markers for malignant pheochromocytoma. The functional role of miR-15a and miR-16 was investigated in vitro in the rat PC12 pheochromocytoma cell line, and these miRNAs were found to regulate cell proliferation via their effect on cyclin D1 and apoptosis. These data indicate that miRNAs play a pivotal role in the biology of malignant pheochromocytoma, and represent an important class of diagnostic and prognostic biomarkers and therapeutic targets warranting further investigation. Endocrine-Related Cancer (2010) 17 835-846
C1 [Meyer-Rochow, Goswin Y.; Jackson, Nicole E.; Clifton-Bligh, Rory; Robinson, Bruce G.; Benn, Diana E.; Sidhu, Stan B.] Royal N Shore Hosp, Kolling Inst Med Res, Canc Genet Hormones & Canc Grp, St Leonards, NSW 2065, Australia.
[Sidhu, Stan B.] Royal N Shore Hosp, Dept Endocrine & Oncol Surg, St Leonards, NSW 2065, Australia.
[Clifton-Bligh, Rory; Robinson, Bruce G.] Royal N Shore Hosp, Dept Endocrinol, St Leonards, NSW 2065, Australia.
[Gill, Anthony J.] Royal N Shore Hosp, Dept Anat Pathol, St Leonards, NSW 2065, Australia.
[Meyer-Rochow, Goswin Y.; Jackson, Nicole E.; Gill, Anthony J.; Clifton-Bligh, Rory; Robinson, Bruce G.; Benn, Diana E.; Sidhu, Stan B.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia.
[Meyer-Rochow, Goswin Y.; Whittle, Denis E.] Univ Auckland, Dept Surg, Fac Med & Hlth Sci, Waikato Clin Sch, Auckland 1142, New Zealand.
[Conaglen, John V.] Univ Auckland, Dept Endocrinol, Fac Med & Hlth Sci, Waikato Clin Sch, Auckland 1142, New Zealand.
[Kunnimalaiyaan, Muthusamy; Chen, Herbert] Univ Wisconsin, Endocrine Surg Res Labs, Dept Surg, Madison, WI USA.
[Kunnimalaiyaan, Muthusamy; Chen, Herbert] UW Carbone Canc Ctr, Madison, WI USA.
[Westin, Gunnar; Sandgren, Johanna; Stalberg, Peter] Univ Hosp, Dept Surg Sci, SE-75185 Uppsala, Sweden.
[Khanafshar, Elham; Shibru, Daniel; Duh, Quan-Yang; Clark, Orlo H.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 93143 USA.
[Khanafshar, Elham; Shibru, Daniel; Duh, Quan-Yang; Clark, Orlo H.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 93143 USA.
[Kebebew, Electron] NCI, Endocrine Oncol Sect, Surg Branch, Bethesda, MD 20892 USA.
RP Sidhu, SB (reprint author), AMA House,202-69 Christie St, St Leonards, NSW 2065, Australia.
EM stansidhu@nebsc.com.au
RI Gill, Anthony/D-4215-2015
OI Gill, Anthony/0000-0002-9447-1967
FU National Health and Medical Research Council (NHMRC, Australia); Cancer
Institute of New South Wales (CINSW, Australia); Royal Australasian
College of Surgeons (RACS); Hillcrest Foundation
FX G Y Meyer-Rochow is a recipient of the National Health and Medical
Research Council (NHMRC, Australia) Postgraduate Research Scholarship,
the Cancer Institute of New South Wales (CINSW, Australia) Postgraduate
Scholarship and the Royal Australasian College of Surgeons (RACS)
Surgeon Scientist Scholarships. S B Sidhu is a NSW Cancer Institute
Clinical Research Fellow. D E Benn is supported by the Hillcrest
Foundation.
NR 46
TC 40
Z9 42
U1 1
U2 7
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD SEP
PY 2010
VL 17
IS 3
BP 835
EP 846
DI 10.1677/ERC-10-0142
PG 12
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 657VE
UT WOS:000282445100029
PM 20621999
ER
PT J
AU Lodish, MB
Stratakis, CA
AF Lodish, Maya B.
Stratakis, Constantine A.
TI Endocrine side effects of broad-acting kinase inhibitors
SO ENDOCRINE-RELATED CANCER
LA English
DT Review
ID RENAL-CELL CARCINOMA; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS
LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; PHASE-II TRIAL; SUNITINIB
INDUCES HYPOTHYROIDISM; MEDULLARY-THYROID CANCER; IMATINIB MESYLATE;
BONE-FORMATION; SECONDARY HYPERPARATHYROIDISM
AB Targeted therapy in oncology consists of drugs that specifically interfere with abnormal signaling pathways that are dysregulated in cancer cells. Tyrosine kinase inhibitors (TKIs) take advantage of unique oncogenes that are activated in certain types of cancer, and also target common mechanisms of growth, invasion, metastasis, and angiogenesis. However, many kinase inhibitors for cancer therapy are somewhat nonselective, and most have additional mechanisms of action at the cellular level, which are not completely understood. The use of these agents has increased our knowledge of important side effects, of which the practicing clinician must be aware. Recently, proposed endocrine-related side effects of these agents include alterations in thyroid function, bone metabolism, linear growth, gonadal function, fetal development, and glucose metabolism, and adrenal function. This review summarizes the most recent data on the endocrine side effects of TKIs. Endocrine-Related Cancer (2010) 17 R233-R244
C1 [Lodish, Maya B.; Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol Genet, Program Dev Endocrinol Genet, Bethesda, MD 20892 USA.
[Lodish, Maya B.; Stratakis, Constantine A.] NIH, Pediat Endocrinol Interinst Training Program, Bethesda, MD 20892 USA.
RP Lodish, MB (reprint author), 10 Ctr Dr,CRC Room 1-3330, Bethesda, MD 20892 USA.
EM lodishma@mail.nih.gov
FU Intramural Research Division of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development
FX Supported by the Intramural Research Division of the Eunice Kennedy
Shriver National Institute of Child Health and Human Development.
NR 88
TC 19
Z9 19
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
EI 1479-6821
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD SEP
PY 2010
VL 17
IS 3
BP R233
EP R244
DI 10.1677/ERC-10-0082
PG 12
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 657VE
UT WOS:000282445100006
PM 20603395
ER
PT J
AU Voutetakis, A
Cotrim, AP
Rowzee, A
Zheng, CY
Rathod, T
Yanik, T
Loh, YP
Baum, BJ
Cawley, NX
AF Voutetakis, Antonis
Cotrim, Ana P.
Rowzee, Anne
Zheng, Changyu
Rathod, Trushar
Yanik, Tulin
Loh, Y. Peng
Baum, Bruce J.
Cawley, Niamh X.
TI Systemic Delivery of Bioactive Glucagon-Like Peptide 1 after
Adenoviral-Mediated Gene Transfer in the Murine Salivary Gland
SO ENDOCRINOLOGY
LA English
DT Article
ID DEPENDENT INSULINOTROPIC POLYPEPTIDE; RAPAMYCIN CONTROL; IN-VIVO; IV;
DEFICIENCY; EXPRESSION; VECTOR; PEPTIDE-1(7-36)AMIDE; THERAPEUTICS;
TRAFFICKING
AB Anadenoviral (Ad) vector that expresses bioactive glucagon-like peptide 1 (GLP-1) was generated, and its effectiveness at modulating glucose homeostasis was evaluated after transduction of murine salivary glands. The construct was engineered with the signal sequence of mouse GH to direct the peptide into the secretory pathway, followed by a furin cleavage site and the GLP-1(7-37) sequence encoding an Ala to Gly substitution at position 8 to achieve resistance to degradation. When expressed in Neuro2A and COS7 cells, an active form of GLP-1 was specifically detected by RIA in the conditioned medium of transduced cells, showed resistance to degradation by dipeptidyl-peptidase IV, and induced the secretion of insulin from NIT1 pancreatic beta-cells in vitro. In vivo studies demonstrated that healthy mice transduced with Ad-GLP-1 in both submandibular glands had serum GLP-1 levels approximately 3 times higher than mice transduced with the control Ad-luciferase vector. In fasted animals, serum glucose levels were similar between Ad-GLP-1 and Ad-luciferase transduced mice in keeping with GLP-1's glucose-dependent action. However, when challenged with glucose, Ad-GLP-1 transduced mice cleared the glucose significantly faster than control mice. In an animal model of diabetes induced by alloxan, progression of hyperglycemia was significantly attenuated in mice given the Ad-GLP-1 vector compared with control mice. These studies demonstrate that the bioactive peptide hormone, GLP-1, normally secreted from endocrine cells in the gut through the regulated secretory pathway, can be engineered for secretion into the circulatory system from exocrine cells of the salivary gland to affect glucose homeostasis. (Endocrinology 151: 4566-4572, 2010)
C1 [Voutetakis, Antonis; Cotrim, Ana P.; Rowzee, Anne; Zheng, Changyu; Baum, Bruce J.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Mol Physiol & Therapeut Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Rathod, Trushar; Yanik, Tulin; Loh, Y. Peng; Cawley, Niamh X.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Natl Inst Dent & Craniofacial Res, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Rathod, Trushar; Yanik, Tulin; Loh, Y. Peng; Cawley, Niamh X.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cellular Neurobiol Sect, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
RP Cawley, NX (reprint author), 49 Convent Dr,Room 5A22, Bethesda, MD 20892 USA.
EM cawleyn@mail.nih.gov
OI Rowzee, Anne/0000-0003-1969-9133
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development; National Institute of Dental and Craniofacial Research,
National Institutes of Health (Bethesda, MD)
FX This work was supported by the Intramural Research Programs of the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development and the National Institute of Dental and Craniofacial
Research, National Institutes of Health (Bethesda, MD).
NR 34
TC 9
Z9 9
U1 1
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2010
VL 151
IS 9
BP 4566
EP 4572
DI 10.1210/en.2010-0193
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 642WP
UT WOS:000281252000052
PM 20610567
ER
PT J
AU Robertson, RP
AF Robertson, R. Paul
TI Update on Transplanting Beta Cells for Reversing Type 1 Diabetes
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Article
DE Pancreas transplantation; Islet transplantation; Type 1 diabetes; Beta
cells
ID QUALITY-OF-LIFE; PANCREAS-KIDNEY TRANSPLANTATION; CLINICAL ISLET
TRANSPLANTATION; STEROID-FREE IMMUNOSUPPRESSION; AUTONOMIC NEUROPATHY;
SYMPTOM RECOGNITION; FOLLOW-UP; MELLITUS; INSULIN; HYPOGLYCEMIA
AB Whole pancreas has been used successfully for transplantation for more than 30 years, and islets have been used reproducibly with success for 10 years; both procedures require drugs for immunosuppression. Success is judged by discontinuation of exogenous insulin-based treatment and maintenance of normal or nearly normal hemoglobin A1c. Successful pancreas transplantation has beneficial effects on retinopathy, nephropathy, neuropathy, macrovascular disease, and quality of life. Such findings are suggested for islet transplantation, but insufficient information is available to draw firm conclusions. Because of the paucity of annual pancreas donations, research for human beta cell surrogates is essential to provide a transplantation approach to therapy for a greater number of recipients.
C1 Univ Washington, NIH, Div Endocrinol & Metab, Pacific NW Diabet Res Inst, Seattle, WA 98122 USA.
RP Robertson, RP (reprint author), Univ Washington, NIH, Div Endocrinol & Metab, Pacific NW Diabet Res Inst, 720 Broadway, Seattle, WA 98122 USA.
EM rpr@pnri.org
FU National Institutes of Health [NIDDK RO1 39994]
FX This work was supported by Grant No. NIDDK RO1 39994 from the National
Institutes of Health.
NR 47
TC 13
Z9 13
U1 4
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8529
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD SEP
PY 2010
VL 39
IS 3
BP 655
EP +
DI 10.1016/j.ecl.2010.05.010
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 654CM
UT WOS:000282146100014
PM 20723826
ER
PT J
AU Lee, YC
Cook, MB
Bhatia, S
Chow, WH
El-Omar, EM
Goto, H
Lin, JT
Li, YQ
Rhee, PL
Sharma, P
Sung, JJY
Wong, JYY
Wu, JCY
Ho, KY
AF Lee, Y. C.
Cook, M. B.
Bhatia, S.
Chow, W. H.
El-Omar, E. M.
Goto, H.
Lin, J. T.
Li, Y. Q.
Rhee, P. L.
Sharma, P.
Sung, J. J. Y.
Wong, J. Y. Y.
Wu, J. C. Y.
Ho, K. Y.
CA Asian Barrett's Consortium
TI Interobserver reliability in the endoscopic diagnosis and grading of
Barrett's esophagus: an Asian multinational study
SO ENDOSCOPY
LA English
DT Article
ID GASTROESOPHAGEAL-REFLUX DISEASE; LOS-ANGELES CLASSIFICATION;
SQUAMOUS-CELL CARCINOMA; RISK-FACTORS; M CRITERIA; PRAGUE C;
ESOPHAGOGASTRIC JUNCTION; CHINESE POPULATION; METABOLIC SYNDROME;
PALISADE VESSELS
AB Background and study aim: The establishment of precise and valid diagnostic criteria is important for any disease. We determined the interobserver reliability in the endoscopic diagnosis and grading of Barrett's esophagus.
Patients and methods: Video clips of endoscopy in 21 patients with/without Barrett's esophagus were used for training (n = 3) and for diagnosis/grading (n = 18) of Barrett's esophagus by endoscopists from seven hospitals in Asia. Barrett's esophagus was graded using the Prague C & M Criteria whereby the circumferential extent of the Barrett's segment (C value), maximum extent of Barrett's segment (M value), location of the gastroesophageal junction, and location of the diaphragmatic hiatus were scored. The intraclass correlation coefficients (ICC) were calculated as a measure of interobserver reliability.
Results: A total of 34 endoscopists participated. ICC values for the scores of the C value, M value, location of the gastroesophageal junction, and location of the diaphragmatic hiatus were: 0.92 (95% confidence interval [CI] 0.88-0.97), 0.94 (95%CI 0.90-0.98), 0.86 (95%CI 0.78-0.94), and 0.81 (95%CI 0.71-0.92), respectively, indicating excellent interobserver agreement. The differences in region/country, endoscopists' experience, case volume of participating centers, or primary practice type had no significant effect on the reliability. The ICC values for recognition of Barrett's esophagus of >= 1 cm were 0.90 (95%CI 0.80-1.00) and 0.92 (95%CI 0.87-0.98) for the C and M values, respectively, whereas the corresponding ICC values for Barrett's segment of < 1 cm were 0.18 (95%CI 0.03-0.32) and 0.21 (95%CI 0.00-0.51), respectively.
Conclusions: Despite the uncommon occurrence of Barrett's esophagus in Asia, our endoscopists exhibited excellent agreement in the endoscopic diagnosis and grading of Barrett's esophagus using the Prague C & M Criteria. However, in view of the low interobserver reliability in recognizing Barrett's segments of < 1 cm, future studies in Asia should take this into account when selecting the study population.
C1 [Wong, J. Y. Y.; Ho, K. Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 65, Singapore.
[Lee, Y. C.] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Cook, M. B.; Chow, W. H.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Bhatia, S.] Seth GS Med Coll, Dept Gastroenterol, Bombay, Maharashtra, India.
[Bhatia, S.] King Edward Mem Hosp, Bombay, Maharashtra, India.
[El-Omar, E. M.] Univ Aberdeen, Div Appl Med, Inst Med Sci, Aberdeen, Scotland.
[Goto, H.] Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Nagoya, Aichi 4648601, Japan.
[Lin, J. T.] E DA Hosp, Dept Internal Med, Yan Chau Shiang, Kaohsiung Cty, Taiwan.
[Lin, J. T.] I Shou Univ, Yan Chau Shiang, Kaohsiung Cty, Taiwan.
[Li, Y. Q.] Shandong Univ, Qilu Hosp, Dept Gastroenterol, Jinan 250100, Peoples R China.
[Rhee, P. L.] Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr, Seoul, South Korea.
[Sharma, P.] Vet Affairs Med Ctr, Div Gastroenterol & Hepatol, Kansas City, MO USA.
[Sharma, P.] Univ Kansas, Sch Med, Kansas City, MO USA.
[Sung, J. J. Y.; Wu, J. C. Y.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
[Lee, Y. C.] Natl Taiwan Univ, Coll Publ Hlth, Div Biostat, Taipei 10764, Taiwan.
RP Ho, KY (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, 5 Lower Kent Ridge Rd, Singapore 65, Singapore.
EM khek_yu_ho@nuhs.edu.sg
RI Rhee, Poong Lyul/C-9655-2011; Hossain, Sarah /C-7332-2009; Cook,
Michael/A-5641-2009; Wu, Justin/N-6916-2015;
OI Hossain, Sarah /0000-0003-1355-0979; Cook, Michael/0000-0002-0533-7302;
LEE, YI-CHIA/0000-0002-8160-1216
FU Intramural NIH HHS [ZIA CP010136-15]
NR 53
TC 23
Z9 23
U1 0
U2 6
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0013-726X
J9 ENDOSCOPY
JI Endoscopy
PD SEP
PY 2010
VL 42
IS 9
BP 699
EP 704
DI 10.1055/s-0030-1255629
PG 6
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 644WT
UT WOS:000281413400002
PM 20806154
ER
PT J
AU Cao, Y
Blount, BC
Valentin-Blasini, L
Bernbaum, JC
Phillips, TM
Rogan, WJ
AF Cao, Yang
Blount, Benjamin C.
Valentin-Blasini, Liza
Bernbaum, Judy C.
Phillips, Terry M.
Rogan, Walter J.
TI Goitrogenic Anions, Thyroid-Stimulating Hormone, and Thyroid Hormone in
Infants
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE infant; iodide; nitrate; perchlorate; thiocyanate; thyrotropin;
thyroxine
ID TANDEM MASS-SPECTROMETRY; SODIUM-IODIDE SYMPORTER; PERCHLORATE EXPOSURE;
DRINKING-WATER; ENVIRONMENTAL PERCHLORATE; HUMAN-URINE; CONGENITAL
HYPOTHYROIDISM; ION CHROMATOGRAPHY; US POPULATION; UNITED-STATES
AB BACKGROUND: Environmental exposure of infants to perchlorate, thiocyanate, nitrate, might interfere with thyroid function. U.S. women with higher background perchlorate exposure have higher thyroid-stimulating hormone (TSH) and lower thyroxine (T-4). There are no studies with individual measures of thyroid function and these goitrogens available in infants.
OBJECTIVE: We examined the association of urinary perchlorate, nitrate, iodide, and thiocyanate with urinary T-4 and TSH in infants and whether that association differed by sex or iodide status.
METHODS: We used data and samples from the Study of Estrogen Activity and Development, which assessed hormone levels of full-term infants over the first 12 months of life. The study included 92 full-term infants between birth and 1 year of age seen up to four times. Perchlorate, thiocyanate, nitrate, and iodide were measured in 206 urine samples; TSH and T-4 and were measured in urines and in 50 blood samples.
RESULTS: In separate mixed models, adjusting for creatinine, age, sex, and body mass index, infants with higher urinary perchlorate, nitrate or thiocyanate had higher urinary TSH. With all three modeled, children with higher nitrate and thiocyanate had higher TSH, but higher perchlorate was associated with TSH only in children with low iodide. Unexpectedly, exposure to the three chemicals was generally associated with higher T-4.
CONCLUSIONS: The association of perchlorate exposure with increased urinary TSH in infants with low urinary iodide is consistent with previous findings. Higher thiocyanate and nitrate exposure were also associated with higher TSH in infants.
C1 [Cao, Yang; Rogan, Walter J.] Natl Inst Environm Hlth Sci, Epidemiol Branch, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
[Cao, Yang] Second Mil Med Univ, Fac Hlth Serv, Dept Hlth Stat, Shanghai, Peoples R China.
[Blount, Benjamin C.; Valentin-Blasini, Liza] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Bernbaum, Judy C.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Phillips, Terry M.] Natl Inst Biomed Imaging & Bioengn, Ultramicro Immunodiagnost Lab, Bethesda, MD USA.
RP Rogan, WJ (reprint author), Natl Inst Environm Hlth Sci, Epidemiol Branch, NIH, Dept Hlth & Human Serv, POB 12233,Mail Drop A3-05, Res Triangle Pk, NC 27709 USA.
EM rogan@niehs.nih.gov
RI Rogan, Walter/I-6034-2012;
OI Rogan, Walter/0000-0002-9302-0160; Cao, Yang/0000-0002-3552-9153
FU National Institutes of Health
FX This work was supported in part by the Intramural Research Program of
the National Institutes of Health.
NR 37
TC 15
Z9 17
U1 0
U2 5
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD SEP
PY 2010
VL 118
IS 9
BP 1332
EP 1337
DI 10.1289/ehp.0901736
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA 647MB
UT WOS:000281621500024
PM 20439182
ER
PT J
AU Hirschfeld, S
Kramer, B
Guttmacher, A
AF Hirschfeld, Steven
Kramer, Barnett
Guttmacher, Alan
TI Current Status of the National Children's Study
SO EPIDEMIOLOGY
LA English
DT Editorial Material
C1 [Hirschfeld, Steven] NICHD, Natl Childrens Hlth Study, NIH, Bethesda, MD 20814 USA.
[Kramer, Barnett] NIH, Off Director, Bethesda, MD 20892 USA.
[Guttmacher, Alan] Eunice Kennedy Shriver Natl Inst Child Hlth & Hu, Bethesda, MD USA.
RP Hirschfeld, S (reprint author), NICHD, Natl Childrens Hlth Study, NIH, 31 Ctr Dr,Room 2A03, Bethesda, MD 20814 USA.
EM hirschfs@mail.nih.gov
RI Hirschfeld, Steven/E-2987-2016
OI Hirschfeld, Steven/0000-0003-0627-7249
NR 1
TC 6
Z9 6
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1044-3983
J9 EPIDEMIOLOGY
JI Epidemiology
PD SEP
PY 2010
VL 21
IS 5
BP 605
EP 606
DI 10.1097/EDE.0b013e3181ea603b
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 640BC
UT WOS:000281021100006
PM 20631619
ER
PT J
AU Zelner, JL
King, AA
Moe, CL
Eisenberg, JNS
AF Zelner, Jonathan L.
King, Aaron A.
Moe, Christine L.
Eisenberg, Joseph N. S.
TI How Infections Propagate After Point-Source Outbreaks An Analysis of
Secondary Norovirus Transmission
SO EPIDEMIOLOGY
LA English
DT Article
ID VIRAL GASTROENTERITIS; NORWALK VIRUS; FOOD HANDLERS; DISEASE;
PARAMETERS; HOUSEHOLD; MODELS
AB Background: Secondary transmission after point-source outbreaks is an integral feature of the epidemiology of gastrointestinal pathogens such as norovirus. The household is an important site of these secondary cases. It can become the source of further community transmission as well as new point-source outbreaks. Consequently, time-series data from exposed households provide information for risk assessment and intervention.
Methods: Analysis of these data requires models that can address (1) dependencies in infection transmission, (2) random variability resulting from households with few members, and (3) unobserved state variables important to transmission. We use Monte Carlo maximum likelihood via data augmentation for obtaining estimates of the transmission rate and infectious period from household outbreaks with the 3 above features.
Results: We apply this parameter estimation technique to 153 infection sequences within households from a norovirus outbreak in Sweden and obtain maximum likelihood estimates of the daily rate of transmission ((beta) over cap = 0.14, 95% confidence interval [CI] = 0.08-0.24) and average infectious period (1/(gamma) over cap = 1.17 days, 95% CI = 1.00-1.88). We also demonstrate the robustness of the estimates to missing household sizes and asymptomatic infections.
Conclusions: Maximum likelihood techniques such as these can be used to estimate transmission parameters under conditions of unobserved states and missing household size data, and to aid in the understanding of secondary risks associated with point-source outbreaks.
C1 [Zelner, Jonathan L.; King, Aaron A.; Eisenberg, Joseph N. S.] Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA.
[Zelner, Jonathan L.] Univ Michigan, Dept Sociol, Ann Arbor, MI 48109 USA.
[Zelner, Jonathan L.] Univ Michigan, Gerald R Ford Sch Publ Policy, Ann Arbor, MI 48109 USA.
[King, Aaron A.] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.
[King, Aaron A.] Univ Michigan, Dept Math, Ann Arbor, MI 48109 USA.
[Eisenberg, Joseph N. S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Moe, Christine L.] Emory Univ, Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA.
[King, Aaron A.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Zelner, JL (reprint author), Univ Michigan, Ctr Study Complex Syst, 321A W Hall,1085 S Univ Ave, Ann Arbor, MI 48109 USA.
EM jzelner@umich.edu
RI Moe, Christine/G-6118-2012; King, Aaron/B-8092-2012
OI King, Aaron/0000-0001-6159-3207
FU US Environmental Protection Agency (EPA) [RD83172701]; Department of
Homeland Security (DHS); EPA [RD83236201]; Science & Technology
Directorate, Department of Homeland Security; Fogarty International
Center of the National Institutes of Health
FX Supported by US Environmental Protection Agency (EPA) STAR Grant #
RD83172701(to J.L.Z., C. L. M. and J.N.S.) and by CAMRA program of the
Department of Homeland Security (DHS) and EPA Grant # RD83236201(to
J.L.Z. and J.N.S.). RAPIDD program of the Science & Technology
Directorate, Department of Homeland Security and the Fogarty
International Center of the National Institutes of Health (to A. A. K.).
NR 32
TC 11
Z9 11
U1 1
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1044-3983
J9 EPIDEMIOLOGY
JI Epidemiology
PD SEP
PY 2010
VL 21
IS 5
BP 711
EP 718
DI 10.1097/EDE.0b013e3181e5463a
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 640BC
UT WOS:000281021100024
PM 20508526
ER
PT J
AU Bharti, N
Djibo, A
Ferrari, MJ
Grais, RF
Tatem, AJ
McCabe, CA
Bjornstad, ON
Grenfell, BT
AF Bharti, N.
Djibo, A.
Ferrari, M. J.
Grais, R. F.
Tatem, A. J.
McCabe, C. A.
Bjornstad, O. N.
Grenfell, B. T.
TI Measles hotspots and epidemiological connectivity
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Infectious disease control; infectious disease epidemiology; measles
(rubeola); spatial modelling; vaccine-preventable diseases
ID MASS VACCINATION; DYNAMICS; EPIDEMICS; MODEL; TRANSMISSION; PERSISTENCE;
ENGLAND; IMPACT; WALES; NIGER
AB Though largely controlled in developed countries, measles remains a major global public health issue. Regional and local transmission patterns are rooted in human mixing behaviour across spatial scales. Identifying spatial interactions that contribute to recurring epidemics helps define and predict outbreak patterns. Using spatially explicit reported cases from measles outbreaks in Niger, we explored how regional variations in movement and contact patterns relate to patterns of measles incidence. Because we expected to see lower rates of re-introductions in small, compared to large, populations, we measured the population-size corrected proportion of weeks with zero cases across districts to understand relative rates of measles re-introductions. We found that critical elements of spatial disease dynamics in Niger are agricultural seasonality, transnational contact clusters, and roads networks that facilitate host movement and connectivity. These results highlight the need to understand local patterns of seasonality, demographic characteristics, and spatial heterogeneities to inform vaccination policy.
C1 [Bharti, N.] Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA.
[Bharti, N.; Ferrari, M. J.; Bjornstad, O. N.; Grenfell, B. T.] Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA.
[Djibo, A.] Minist Hlth, Niamey, Niger.
[Grais, R. F.] Epicentre, Paris, France.
[Tatem, A. J.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA.
[Tatem, A. J.] Univ Florida, Dept Geog, Gainesville, FL USA.
[McCabe, C. A.] Penn State Univ, Dept Geog, University Pk, PA 16802 USA.
[McCabe, C. A.] Penn State Univ, GeoVISTA Ctr, University Pk, PA 16802 USA.
[Bjornstad, O. N.] Penn State Univ, Dept Entomol, University Pk, PA 16802 USA.
[Bjornstad, O. N.; Grenfell, B. T.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Bharti, N (reprint author), Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA.
EM nita@psu.edu
RI Bjornstad, Ottar/I-4518-2012
FU Bill and Melinda Gates Foundation [49446]; Science & Technology
Directorate, Department of Homeland Security; Forgarty International
Center, National Institutes of Health
FX This study was supported by the Bill and Melinda Gates Foundation.
M.J.F., O.N.B. and B.G. were also supported by the RAPIDD programme of
the Science & Technology Directorate, Department of Homeland Security,
and the Forgarty International Center, National Institutes of Health.
A.J.T. is supported by a grant from the Bill and Melinda Gates
Foundation (no. 49446). We thank Paolo Palermo from UNOCHA for his
assistance.
NR 38
TC 16
Z9 16
U1 0
U2 13
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD SEP
PY 2010
VL 138
IS 9
BP 1308
EP 1316
DI 10.1017/S0950268809991385
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 643DT
UT WOS:000281275300013
PM 20096146
ER
PT J
AU Koh, K
Quon, M
AF Koh, K.
Quon, M.
TI Effects of fenofibrate therapy on circulating adipocytokines in patients
with primary hypertriglyceridemia
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT ESC Congress
CY AUG 28-SEP 01, 2010
CL Stockholm, SWEDEN
C1 [Koh, K.] Gachon Univ, Inchon, South Korea.
[Quon, M.] NIH, Diabet Unit, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD SEP
PY 2010
VL 31
SU 1
BP 175
EP 176
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 646ID
UT WOS:000281531901173
ER
PT J
AU Kostek, MC
Devaney, JM
Gordish-Dressman, H
Harris, TB
Thompson, PD
Clarkson, PM
Angelopoulos, TJ
Gordon, PM
Moyna, NM
Pescatello, LS
Visich, PS
Zoeller, RF
Seip, RL
Garcia, M
Li, RL
Zmuda, JM
Delmonico, MJ
Kanaya, A
Hoffman, EP
AF Kostek, Matthew C.
Devaney, Joseph M.
Gordish-Dressman, Heather
Harris, Tamara B.
Thompson, Paul D.
Clarkson, Priscilla M.
Angelopoulos, Theodore J.
Gordon, Paul M.
Moyna, Niall M.
Pescatello, Linda S.
Visich, Paul S.
Zoeller, Robert F.
Seip, Richard L.
Garcia, Melissa
Li, Rongling
Zmuda, Joseph M.
Delmonico, Matthew J.
Kanaya, Alka
Hoffman, Eric P.
TI A polymorphism near IGF1 is associated with body composition and muscle
function in women from the Health, Aging, and Body Composition Study
SO EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE IGF1; Muscle; Body composition; Bone mineral density; Elderly; SNP
ID GROWTH-FACTOR-I; COMMON GENETIC-VARIATION; PROSTATE-CANCER RISK;
BONE-MINERAL DENSITY; FAT-FREE MASS; SKELETAL-MUSCLE; OLDER-ADULTS;
MYOFIBER HYPERTROPHY; PHYSICAL FUNCTION; TRANSGENIC MICE
AB Previous studies have reported associations of polymorphisms in the IGF1 gene with phenotypes of body composition (BC). The purpose of this study was to identify phenotypes of BC and physical function that were associated with the IGF1 promoter polymorphism (rs35767, -C1245T). Subjects from the Health, Aging, and Body Composition Study, white males and females (n = 925/836) and black males and females (533/705) aged 70-79 years were genotyped for the polymorphism. Phenotypes of muscle size and function, bone mineral density, and BC were analyzed for associations with this polymorphism. To validate and compare these findings, a cohort of young (mean age = 24.6, SD = 5.9) white men and women (n = 173/296) with similar phenotypic measurements were genotyped. An association with BC was identified in elderly females when significant covariates (physical activity, age, smoking status, body mass index) were included. White women with C/C genotype had 3% more trunk fat and 2% more total fat than those with C/T (P < 0.05). Black women with C/C genotype had 3% less total lean mass and 3% less muscle mass than their T/T counterparts (P < 0.05). Associations were identified with muscle strength in white women (P < 0.01) that were in agreement with the C/C genotype having lower muscle function. Thus, in an elderly population but not a young population, a polymorphism in the IGF1 gene may be predictive of differences in body composition, primarily in black females.
C1 [Devaney, Joseph M.; Gordish-Dressman, Heather; Hoffman, Eric P.] Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA.
[Kostek, Matthew C.] Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA.
[Harris, Tamara B.; Garcia, Melissa] NIA, NIH, Bethesda, MD 20892 USA.
[Thompson, Paul D.; Seip, Richard L.] Hartford Hosp, Div Cardiol, Henry Low Heart Ctr, Hartford, CT 06115 USA.
[Clarkson, Priscilla M.] Univ Massachusetts, Dept Kinesiol, Amherst, MA 01003 USA.
[Angelopoulos, Theodore J.] Univ Cent Florida, Ctr Lifestyle Med, Orlando, FL 32816 USA.
[Gordon, Paul M.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI USA.
[Moyna, Niall M.] Dublin City Univ, Dept Sport Sci & Hlth, Dublin 9, Ireland.
[Pescatello, Linda S.] Univ Connecticut, Dept Kinesiol, Sch Educ, Storrs, CT USA.
[Visich, Paul S.] Cent Michigan Univ, Human Performance Lab, Mt Pleasant, MI 48859 USA.
[Zoeller, Robert F.] Florida Atlantic Univ, Dept Exercise Sci & Hlth Promot, Davie, FL USA.
[Li, Rongling] Univ Tennessee, Dept Prevent Med, Memphis, TN USA.
[Zmuda, Joseph M.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA.
[Delmonico, Matthew J.] Univ Rhode Isl, Dept Kinesiol, Kingston, RI 02881 USA.
[Kanaya, Alka] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
RP Hoffman, EP (reprint author), Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA.
EM ericphoffman@gmail.com
RI gordon, paul/E-3862-2015
OI gordon, paul/0000-0003-4403-0888
FU NIH, National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103,
N01-AG-6-2106]
FX This research was supported in part by the Intramural Research Program
of the NIH, National Institute on Aging (NIA contract numbers:
N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106).
NR 38
TC 12
Z9 14
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1439-6319
J9 EUR J APPL PHYSIOL
JI Eur. J. Appl. Physiol.
PD SEP
PY 2010
VL 110
IS 2
BP 315
EP 324
DI 10.1007/s00421-010-1500-0
PG 10
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 644MD
UT WOS:000281380800011
PM 20490824
ER
PT J
AU Wong, HL
Peters, U
Hayes, RB
Huang, WY
Schatzkin, A
Bresalier, RS
Velie, EM
Brody, LC
AF Wong, Hui-Lee
Peters, Ulrike
Hayes, Richard B.
Huang, Wen-Yi
Schatzkin, Arthur
Bresalier, Robert S.
Velie, Ellen M.
Brody, Lawrence C.
TI Polymorphisms in the adenomatous polyposis coli (APC) gene and advanced
colorectal adenoma risk
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Adenomatous polyposis coli; SNPs; Advanced adenoma; Colorectal cancer
ID HORMONE-REPLACEMENT-THERAPY; CANCER SCREENING TRIAL; SPORADIC
BREAST-CANCER; CALCIUM SUPPLEMENTATION; ASYMPTOMATIC ADULTS; HAPLOTYPE
ANALYSIS; SOMATIC MUTATIONS; RANDOMIZED-TRIAL; COMMON VARIANTS; E1317Q
VARIANT
AB While germline mutations in the adenomatous polyposis coli (APC) gene cause the hereditary colon cancer syndrome (familial adenomatous polyposis (FAP)), the role of common germline APC variants in sporadic adenomatous polyposis remains unclear. We studied the association of eight APC single nucleotide polymorphisms (SNPs), possibly associated with functional consequences, and previously identified gene-environment (dietary fat intake and hormone replacement therapy (HRT) use) interactions, in relation to advanced colorectal adenoma in 758 cases and 767 sex- and race-matched controls, randomly selected from the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Cases had at least one verified advanced adenoma of the distal colon; controls, a negative sigmoidoscopy. We did not observe an association between genotypes for any of the eight APC SNPs and advanced distal adenoma risk (P(global) (gene-based) = 0.92). Frequencies of identified common haplotypes did not differ between cases and controls (P(global) (haplotype test) = 0.97). However, the risk for advanced distal adenoma was threefold higher for one rare haplotype (cases: 2.7%; controls: 1.6%) (odds ratio (OR) = 3.27; 95% confidence interval (CI) = 1.08-9.88). The genetic association between D1822V and advanced distal adenoma was confined to persons consuming a high-fat diet(P(interaction) = 0.03). Similar interactions were not observed with HRT use. In our large, nested case-control study of advanced distal adenoma and clinically verified adenoma-free controls, we observed no association between specific APC SNPs and advanced adenoma. Fat intake modified the APC D1822V-adenoma association, but further studies are warranted. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Velie, Ellen M.] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA.
[Wong, Hui-Lee; Peters, Ulrike; Hayes, Richard B.; Huang, Wen-Yi; Schatzkin, Arthur] NCI, Dept Hlth & Human Serv, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA.
[Peters, Ulrike] Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA.
[Peters, Ulrike] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA.
[Bresalier, Robert S.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Gastrointestinal Med & Nutr, Houston, TX 77030 USA.
[Velie, Ellen M.] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA.
[Brody, Lawrence C.] NHGRI, Dept Hlth & Human Serv, Genome Technol Branch, NIH, Bethesda, MD 20892 USA.
RP Velie, EM (reprint author), Michigan State Univ, Dept Epidemiol, B601 W Fee Hall, E Lansing, MI 48824 USA.
EM velie@epi.msu.edu
FU National Institutes of Health, National Cancer Institute, Division of
Cancer Epidemiology and Genetics
FX This research was supported by the Intramural Research Program of the
National Institutes of Health, National Cancer Institute, Division of
Cancer Epidemiology and Genetics. The content of this publication does
not necessarily reflect the views or policies of the Department of
Health and Human Services nor does mention of trade names, commercial
products or organisations imply endorsement by the US Government.
NR 67
TC 11
Z9 12
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2010
VL 46
IS 13
BP 2457
EP 2466
DI 10.1016/j.ejca.2010.04.020
PG 10
WC Oncology
SC Oncology
GA 652HJ
UT WOS:000281994100018
PM 20510605
ER
PT J
AU Freedman, ND
Derakhshan, MH
Abnet, CC
Schatzkin, A
Hollenbeck, AR
McColl, KEL
AF Freedman, N. D.
Derakhshan, M. H.
Abnet, C. C.
Schatzkin, A.
Hollenbeck, A. R.
McColl, K. E. L.
TI Male predominance of upper gastrointestinal adenocarcinoma cannot be
explained by differences in tobacco smoking in men versus women
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Oesophageal adenocarcinoma; Gastric cancer; Male predominance; Smoking
ID HELICOBACTER-PYLORI INFECTION; GASTRIC-CANCER RISK; LUNG-CANCER;
REPRODUCTIVE FACTORS; PROSPECTIVE COHORT; HISTOLOGIC TYPE; POPULATION;
ESOPHAGEAL; ALCOHOL; HEALTH
AB Background: Adenocarcinomas of the upper gastrointestinal tract (UGI) show remarkable male predominance. As smoking is a well-established risk factor, we investigated the role of tobacco smoking in the male predominance of UGI adenocarcinomas in the United States NIH-AARP Diet and Health Study.
Method: A questionnaire was completed by 281,422 men and 186,133 women in 1995-1996 who were followed until 31st December 2003. Incident UGI adenocarcinomas were identified by linkage to state cancer registries. We present age-standardised cancer incidence rates per 100,000-person years and male/female ratios (M/F) calculated from age-adjusted Cox proportional hazards models, both with 95% confidence intervals (Cl).
Results: After 2013,142-person years follow-up, 338 adenocarcinomas of the oesophagus, 261 of gastric cardia and 222 of gastric non-cardia occurred in men. In women, 23 tumours of oesophagus, 36 of gastric cardia and 88 of gastric non-cardia occurred in 1351,958-person years follow-up. The age-standardised incidence rate of all adenocarcinoma sites was 40.5 (37.8-43.3) and 11.0 (9.2-12.8) in men and women, respectively. Among smokers, the M/F of all UGI adenocarcinomas was 3.4 (2.7-4.1), with a M/F of 7.3 (4.6-11.7) for tumours in oesophagus, 3.7 (2.5-5.4) for gastric cardia and 1.7 (1.2-2.3) for gastric non-cardia. In nonsmokers, M/F ratios were 14.2 (5.1-39.5) for oesophagus, 6.1 (2.6-14.7) for gastric cardia and 1.3 (0.8-2.0) for gastric non-cardia. The overall M/F ratio was 3.0 (2.2-4.3).
Conclusion: The male predominance was similar in smokers and non-smokers for these cancer sites. These results suggest that the male predominance of upper GI adenocarcinomas cannot be explained by differences in smoking histories. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [McColl, K. E. L.] Univ Glasgow, Western Infirm, Gastroenterol Sect, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland.
[Freedman, N. D.; Abnet, C. C.; Schatzkin, A.] Natl Canc Inst, Nutrit Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Rockville, MD USA.
[Hollenbeck, A. R.] AARP, Washington, DC USA.
RP McColl, KEL (reprint author), Univ Glasgow, Western Infirm, Gastroenterol Sect, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland.
EM k.e.l.mccoll@clinmed.gla.ac.uk
RI Abnet, Christian/C-4111-2015; Freedman, Neal/B-9741-2015; Derakhshan,
Mohammad/K-8694-2016
OI Abnet, Christian/0000-0002-3008-7843; Freedman,
Neal/0000-0003-0074-1098;
FU Chief Scientist Office [CZB/4/709]; Intramural NIH HHS [ZIA CP000185-08]
NR 40
TC 19
Z9 21
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2010
VL 46
IS 13
BP 2473
EP 2478
DI 10.1016/j.ejca.2010.05.005
PG 6
WC Oncology
SC Oncology
GA 652HJ
UT WOS:000281994100020
PM 20605442
ER
PT J
AU Wang, L
Carr, T
Xiong, YM
Wildt, KF
Zhu, JF
Feigenbaum, L
Bendelac, A
Bosselut, R
AF Wang, Lie
Carr, Tiffany
Xiong, Yumei
Wildt, Kathryn F.
Zhu, Jinfang
Feigenbaum, Lionel
Bendelac, Albert
Bosselut, Remy
TI The sequential activity of Gata3 and Thpok is required for the
differentiation of CD1d-restricted CD4(+) NKT cells
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE CD4(+) T cells; NKT cells; Thymic selection; Transcription
ID CD4-CD8 LINEAGE DIFFERENTIATION; T-CELLS; EXPRESSION; COMMITMENT;
RECEPTORS; SELECTION; DIRECTS; CHOICE; CKROX; FATE
AB While most CD4(+) T cells are MHC class II-restricted, a small subset, including the CD1d-restricted 'invariant' NKT (iNKT) cells, are selected on non-classical MHC-I or MHC-I-like molecules. We previously showed that the sequential activity of two zinc finger transcription factors, Gata3 and Thpok, promotes the differentiation of conventional, MHC II-restricted thymocytes into CD4(+) T cells. In the current study, we show that a Gata3-Thpok cascade is required for the differentiation of CD4(+) iNKT cells. Gata3 is required for iNKT cells to express Thpok, whereas Thpok is needed for proper NKT cell differentiation, and notably for NKT cells to maintain CD4 and terminate CD8 expression. These findings identify the sequential activity of Gata3 and Thpok as a hallmark of CD4(+) T-cell differentiation, regardless of MHC restriction.
C1 [Bosselut, Remy] NCI, Lab Immune Cell Biol, CCR, NIH, Bethesda, MD 20892 USA.
[Carr, Tiffany; Bendelac, Albert] Univ Chicago, Howard Hughes Med Inst, Dept Pathol, Comm Immunol, Chicago, IL 60637 USA.
[Zhu, Jinfang] NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA.
[Feigenbaum, Lionel] NCI, SAIC, Frederick, MD 21701 USA.
RP Bosselut, R (reprint author), NCI, Lab Immune Cell Biol, CCR, NIH, Bldg 37,Room 3015,37 Convent Dr, Bethesda, MD 20892 USA.
EM remy@helix.nih.gov
RI Zhu, Jinfang/B-7574-2012
FU National Cancer Institute, Center for Cancer Research, and of the
National Institute of Allergy and Infectious Diseases, NIH; NIH [R01
AI038339]
FX The authors thank Ehydel Castro for expert mouse technical assistance,
Barbara Taylor for help with flow cytometry, Takeshi Egawa for insight
on the control of Cd4 expression, Renaud Lesourne, Paul Love and Bill
Paul for helpful discussions and reagents, and B.J. Fowlkes, Paul Love
and Al Singer for reading the manuscript. This work was supported in
part by the Intramural Research Programs of the National Cancer
Institute, Center for Cancer Research, and of the National Institute of
Allergy and Infectious Diseases, NIH and by NIH Grant R01 AI038339.
NR 29
TC 31
Z9 32
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD SEP
PY 2010
VL 40
IS 9
BP 2385
EP 2390
DI 10.1002/eji.201040534
PG 6
WC Immunology
SC Immunology
GA 656DD
UT WOS:000282305400007
PM 20706986
ER
PT J
AU Benninger, D
Berman, B
Houdayer, E
Pal, N
Luckenbaugh, D
Schneider, L
Miranda, S
Hallett, M
AF Benninger, D.
Berman, B.
Houdayer, E.
Pal, N.
Luckenbaugh, D.
Schneider, L.
Miranda, S.
Hallett, M.
TI Intermittent theta-burst transcranial magnetic stimulation for the
treatment of Parkinson's disease
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
CT 14th Congress of European-Federation-of-Neurological-Societies
CY SEP, 2010
CL Geneva, SWITZERLAND
SP European Federat Neurol Soc
C1 [Benninger, D.; Berman, B.; Houdayer, E.; Pal, N.; Luckenbaugh, D.; Schneider, L.; Miranda, S.; Hallett, M.] NINDS, NIH, Bethesda, MD 20892 USA.
RI Benninger, David/A-8157-2015
OI Benninger, David/0000-0002-1049-9533
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1351-5101
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD SEP
PY 2010
VL 17
SU 3
SI SI
BP 22
EP 22
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 800BD
UT WOS:000293331100045
ER
PT J
AU Giacone, S
Moglia, C
Calvo, A
Cammarosano, S
Ilardi, A
Gallo, S
Canosa, A
Montuschi, A
Restagno, G
Ossola, I
Brunetti, M
Cistaro, A
Ticca, A
Borghero, G
Traynor, BJ
Chio, A
AF Giacone, S.
Moglia, C.
Calvo, A.
Cammarosano, S.
Ilardi, A.
Gallo, S.
Canosa, A.
Montuschi, A.
Restagno, G.
Ossola, I.
Brunetti, M.
Cistaro, A.
Ticca, A.
Borghero, G.
Traynor, B. J.
Chio, A.
TI TARDBP A382T mutation and frontotemporal dementia: description of three
ALS families
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
CT 14th Congress of European-Federation-of-Neurological-Societies
CY SEP, 2010
CL Geneva, SWITZERLAND
SP European Federat Neurol Soc
C1 [Giacone, S.; Moglia, C.; Calvo, A.; Cammarosano, S.; Ilardi, A.; Gallo, S.; Canosa, A.; Montuschi, A.; Chio, A.] Univ Turin, Dept Neurosci, I-10124 Turin, Italy.
[Restagno, G.; Ossola, I.; Brunetti, M.] ASO OIRM St Anna, Mol Genet Lab, Turin, Italy.
[Cistaro, A.] IRMET, Positron Emiss Tomog Ctr, Turin, Italy.
[Ticca, A.] AO San Francesco, Nuoro, Italy.
[Borghero, G.] Univ Cagliari, Cagliari, Italy.
[Traynor, B. J.] NIA, Neuromuscular Dis Res Grp, Neurogenet Lab, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1351-5101
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD SEP
PY 2010
VL 17
SU 3
SI SI
BP 290
EP 290
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 800BD
UT WOS:000293331100546
ER
PT J
AU Sailer, A
Paisa-Puiz, C
Li, A
Paudel, R
Scholz, SW
Ahmed, Z
Revesz, T
Mathias, CJ
Wood, NW
Holton, J
Hardy, J
Houlden, H
AF Sailer, A.
Paisa-Puiz, C.
Li, A.
Paudel, R.
Scholz, S. W.
Ahmed, Z.
Revesz, T.
Mathias, C. J.
Wood, N. W.
Holton, J.
Hardy, J.
Houlden, H.
TI Genetic analysis of the MAPT locus in multiple system atrophy
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
CT 14th Congress of European-Federation-of-Neurological-Societies
CY SEP, 2010
CL Geneva, SWITZERLAND
SP European Federat Neurol Soc
C1 [Sailer, A.; Paisa-Puiz, C.; Li, A.; Paudel, R.; Ahmed, Z.; Revesz, T.; Mathias, C. J.; Wood, N. W.; Holton, J.; Hardy, J.; Houlden, H.] Inst Neurol, London WC1N 3BG, England.
[Scholz, S. W.] NIH, Bethesda, MD 20892 USA.
RI Holton, Janice/F-6831-2011; Hardy, John/C-2451-2009; Houlden,
Henry/C-1532-2008
OI Holton, Janice/0000-0002-3882-5249; Houlden, Henry/0000-0002-2866-7777
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1351-5101
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD SEP
PY 2010
VL 17
SU 3
SI SI
BP 598
EP 598
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 800BD
UT WOS:000293331101472
ER
PT J
AU Hu, HL
Lu, WN
Zhang, M
Zhang, XL
Argall, AJ
Patel, S
Lee, GE
Kim, YC
Jacobson, KA
Laties, AM
Mitchell, CH
AF Hu, Huiling
Lu, Wennan
Zhang, Mei
Zhang, Xiulan
Argall, Arthur J.
Patel, Shaun
Lee, Ga Eun
Kim, Yong-Chul
Jacobson, Kenneth A.
Laties, Alan M.
Mitchell, Claire H.
TI Stimulation of the P2X(7) receptor kills rat retinal ganglion cells in
vivo
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE P2X receptor; A(3) adenosine receptor; purinergic signaling; retinal
ganglion cells; neuroprotection; in vivo models
ID A(3) ADENOSINE RECEPTOR; MULLER GLIAL-CELLS; BRILLIANT-BLUE-G;
INTRAOCULAR-PRESSURE; PHARMACOLOGICAL CHARACTERIZATION; ATP;
NUCLEOSIDES; INVOLVEMENT; INHIBITION; ASTROCYTES
AB The P2X(7) receptor is associated with the death of many cell types, and growing evidence supports its presence on neurons. Activation of the P2X(7) receptor on isolated retinal ganglion cells increases intracellular calcium levels and can kill the cells. Within the intact eye, however, glia and other cell types surrounding the ganglion cells may provide protection and attenuate the effects of receptor stimulation. This investigation thus asks whether stimulation of the P2X(7) receptor can actually kill retinal ganglion cells in vivo. Drugs were injected intravitreally into the superior/nasal region of Long Evans rats. Cell survival was determined by counting the number of remaining ganglion cells labeled with amino-stilbamidine. The P2X(7) receptor agonist BzATP reduced ganglion cell survival as compared to eyes injected with saline solution. Ganglion cell death was inhibited by co-injection of the P2X(7) antagonists Brilliant Blue G and MRS 2540. The loss of ganglion cells following activation of the P2X(7) receptor was also prevented by the adenosine A(3) adenosine receptor agonist MRS 3558. In conclusion, stimulation of the P2X(7) receptor can kill retinal ganglion cells in vivo. The neuroprotective effects of A(3) receptor activation identified in isolated ganglion cells are also apparent in vivo. This implies that the balance between extracellular ATP and its protective metabolite adenosine can influence ganglion cell survival in the living eye. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Lu, Wennan; Argall, Arthur J.; Patel, Shaun; Mitchell, Claire H.] Univ Penn, Dept Physiol, Sch Med, Philadelphia, PA 19104 USA.
[Hu, Huiling; Zhang, Mei; Laties, Alan M.] Univ Penn, Dept Ophthalmol, Sch Med, Philadelphia, PA 19104 USA.
[Lu, Wennan; Argall, Arthur J.; Mitchell, Claire H.] Univ Penn, Dept Anat & Cell Biol, Sch Dent Med, Philadelphia, PA 19104 USA.
[Hu, Huiling; Zhang, Xiulan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
[Lee, Ga Eun; Kim, Yong-Chul] Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.
[Jacobson, Kenneth A.] NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
RP Mitchell, CH (reprint author), Univ Penn, Dept Physiol, Sch Med, 3700 Hamilton Walk, Philadelphia, PA 19104 USA.
EM chm@mail.med.upenn.edu
RI Jacobson, Kenneth/A-1530-2009
OI Jacobson, Kenneth/0000-0001-8104-1493
FU NIH [EY015537, EY013434]; Vision Research Core Grant [EY001583];
Research to Prevent Blindness; Paul and Evanina Bell Mackall Foundation;
Jody Sack Fund; National Natural Science Foundation of China [30872831];
NIDDK, NIH, Bethesda; Ministry of Education, Science and Technology
[2009-0074289]
FX This work is supported by grants from the NIH EY015537 and EY013434
(CHM), Vision Research Core Grant EY001583 (CHM and AML). Research to
Prevent Blindness (AML), the Paul and Evanina Bell Mackall Foundation
Trust (AML), the Jody Sack Fund (HH, MZ and XZ), the National Natural
Science Foundation of China 30872831(XZ), by support from the Intramural
Research Program of NIDDK, NIH, Bethesda, MD (KAJ), and by Basic Science
Research Program through the National Research Foundation of Korea (NRF)
funded by the Ministry of Education, Science and Technology (YCK : grant
number 2009-0074289). The authors would like to thank Mary Leonard and
Gabriel Baltazar for help with the illustrations.
NR 36
TC 50
Z9 54
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2010
VL 91
IS 3
BP 425
EP 432
DI 10.1016/j.exer.2010.06.017
PG 8
WC Ophthalmology
SC Ophthalmology
GA 645XY
UT WOS:000281500700013
PM 20599962
ER
PT J
AU Cokic, V
Bhattacharya, B
Beleslin-Cokic, B
Noguchi, C
Puri, R
Schechter, A
AF Cokic, V.
Bhattacharya, B.
Beleslin-Cokic, B.
Noguchi, C.
Puri, R.
Schechter, A.
TI GLOBIN GENES VERSUS COMMON GENES EXPRESSION PROFILING IN ERYTHROID CELLS
DURING ONTOGENY
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT 39th Annual Scientific Meeting of the ISEH -
Society-for-Hematology-and-Stem-Cells
CY SEP 15-18, 2010
CL Melbourne, AUSTRALIA
SP Soc Hematol Stem Cell
C1 [Cokic, V.] Inst Med Res, Belgrade, Serbia.
[Bhattacharya, B.; Puri, R.] US FDA, Ctr Biol Eval & Res, Div Cellular & Gene Therapies, Bethesda, MD USA.
[Beleslin-Cokic, B.] Inst Endocrinol Diabet & Dis Metab, Belgrade, Serbia.
[Noguchi, C.; Schechter, A.] NIDDK, Mol Med Branch, NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD SEP
PY 2010
VL 38
IS 9
SU 1
MA 060
BP S29
EP S29
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 641YM
UT WOS:000281168900059
ER
PT J
AU Slape, CI
Saw, J
Aplan, PD
Jane, SM
Curtis, DJ
AF Slape, C. I.
Saw, J.
Aplan, P. D.
Jane, S. M.
Curtis, D. J.
TI OVEREXPRESSION OF BCL2 RESCUES APOPTOSIS, CYTOPENIAS AND LEUKEMIC
TRANSFORMATION IN MURINE MYELODYSPLASTIC SYNDROME
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT 39th Annual Scientific Meeting of the ISEH -
Society-for-Hematology-and-Stem-Cells
CY SEP 15-18, 2010
CL Melbourne, AUSTRALIA
SP Soc Hematol Stem Cell
C1 [Slape, C. I.; Saw, J.; Jane, S. M.; Curtis, D. J.] Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
[Aplan, P. D.] NCI, Bethesda, MD 20892 USA.
RI Jane, Stephen/D-6659-2011; Aplan, Peter/K-9064-2016
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD SEP
PY 2010
VL 38
IS 9
SU 1
MA 098
BP S46
EP S47
PG 2
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 641YM
UT WOS:000281168900094
ER
PT J
AU Airavaara, M
Chiocco, MJ
Howard, DB
Zuchowski, KL
Peranen, J
Liu, C
Fang, SY
Hoffer, BJ
Wang, Y
Harvey, BK
AF Airavaara, Mikko
Chiocco, Matt J.
Howard, Doug B.
Zuchowski, Katie L.
Peranen, Johan
Liu, Chao
Fang, Shengyun
Hoffer, Barry J.
Wang, Yun
Harvey, Brandon K.
TI Widespread cortical expression of MANF by AAV serotype 7: Localization
and protection against ischemic brain injury
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Gene therapy; Stroke; AAV; MANF; Neurotrophic factor; Mesencephalic
astrocyte-derived neurotrophic factor; ARMET; CDNF
ID ADENOASSOCIATED VIRUS VECTORS; UNFOLDED PROTEIN RESPONSE; AGE-RELATED
OBESITY; NEUROTROPHIC FACTOR; CELL-LINE; ENDOPLASMIC-RETICULUM;
CEREBRAL-ISCHEMIA; IN-VIVO; RAT MODEL; STROKE
AB Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a secreted protein which reduces endoplasmic reticulum (ER) stress and has neurotrophic effects on dopaminergic neurons. Intracortical delivery of recombinant MANF protein protects tissue from ischemic brain injury in vivo. In this study, we examined the protective effect of adeno-associated virus serotype 7 encoding MANF in a rodent model of stroke. An AAV vector containing human MANF cDNA (AAV-MANF) was constructed and verified for expression of MANF protein. AAV-MANF or an AAV control vector was administered into three sites in the cerebral cortex of adult rats. One week after the vector injections, the right middle cerebral artery (MCA) was ligated for 60 min. Behavioral monitoring was conducted using body asymmetry analysis, neurological testing, and locomotor activity. Standard immunohistochemical and western blotting procedures were conducted to study MANF expression. Our data showed that AAV-induced MANF expression is redistributed in neurons and glia in cerebral cortex after ischemia. Pretreatment with AAV-MANF reduced the volume of cerebral infarction and facilitated behavioral recovery in stroke rats. In conclusion, our data suggest that intracortical delivery of AAV-MANF increases MANF protein production and reduces ischemic brain injury. Ischemia also caused redistribution of MV-mediated MANF protein suggesting an injury-induced release. Published by Elsevier Inc.
C1 [Airavaara, Mikko; Chiocco, Matt J.; Howard, Doug B.; Zuchowski, Katie L.; Hoffer, Barry J.; Wang, Yun; Harvey, Brandon K.] NIDA, Neural Protect & Regenerat Sect, IRP, NIH, Baltimore, MD 21201 USA.
[Peranen, Johan] Univ Helsinki, Viikki Bioctr, Inst Biotechnol, FIN-00014 Helsinki, Finland.
[Liu, Chao; Fang, Shengyun] Univ Maryland, Ctr Biomed Engn & Technol, Baltimore, MD 21201 USA.
RP Harvey, BK (reprint author), NIDA, Neural Protect & Regenerat Sect, IRP, NIH, Baltimore, MD 21201 USA.
EM bharvey@intra.nida.nih.gov
RI Fang, Shengyun/H-3802-2011;
OI Airavaara, Mikko/0000-0002-2026-1609
FU NIDA; DHHS; NIH
FX This research was supported by the intramural research program at NIDA,
NIH, and DHHS. The authors declare that they do not have any conflicts
of interest (financial or otherwise) related to the data presented in
this manuscript.
NR 37
TC 22
Z9 22
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
J9 EXP NEUROL
JI Exp. Neurol.
PD SEP
PY 2010
VL 225
IS 1
SI SI
BP 104
EP 113
DI 10.1016/j.expneurol.2010.05.020
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 643ZD
UT WOS:000281339300016
PM 20685313
ER
PT J
AU Lanuza, MA
Besalduch, N
Gonzalez, C
Santafe, MM
Garcia, N
Tomas, M
Nelson, PG
Tomas, J
AF Lanuza, Maria A.
Besalduch, Nuria
Gonzalez, Carmen
Santafe, Manel M.
Garcia, Neus
Tomas, Marta
Nelson, Phillip G.
Tomas, Josep
TI Decreased phosphorylation of delta and epsilon subunits of the
acetylcholine receptor coincides with delayed postsynaptic maturation in
PKC theta deficient mouse
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Synapse elimination; Synaptogenesis; PKC theta; Neuromuscular junction;
nAChR clustering; KO mouse
ID PROTEIN-KINASE-C; NERVE MUSCLE JUNCTIONS; NEUROMUSCULAR-JUNCTION;
SYNAPSE ELIMINATION; SKELETAL-MUSCLE; IN-VITRO; POSTNATAL MATURATION;
NEURAL INFLUENCE; PHORBOL ESTER; NEONATAL-RAT
AB Protein kinase C (PKC) activity is involved in the nicotinic acetylcholine receptor (nAChR) redistribution at the neuromuscular junction in vivo during postnatal maturation. Here we studied, in PKC theta (PKC theta) deficient mice (KO), how the theta isoform of PKC is involved in the nAChR cluster maturation that is accompanied by the developmental activity-dependent neuromuscular synapse elimination process. We found that axonal elimination and dispersion of nAChR from the postsynaptic plaques and its redistribution to form the mature postsynaptic apparatus were delayed but not totally suppressed in PKC theta deficient mice. Moreover, the delay in the maturation of the morphology of the nAChR clusters during the early postnatal synapse elimination period in the PKC theta deficient mice coincides with a reduction in the PKC theta-mediated phosphorylation on the delta subunit of the nAChR. In addition, we show evidence for PKC theta regulation of PKA in normally phosphorylating the epsilon subunit of nAChR. We have also found that the theta isoform of PKC is located on the postsynaptic component of the neuromuscular junction but is also expressed by motoneurons in the spinal cord and in the motor nerve terminals. The results allow us to hypothesize that a spatially specific and opposing action of PKC theta and PICA may result in activity-dependent alterations to synaptic connectivity at both the nerve inputs and the postsynaptic nAChR clusters. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Lanuza, Maria A.; Besalduch, Nuria; Gonzalez, Carmen; Santafe, Manel M.; Garcia, Neus; Tomas, Marta; Tomas, Josep] Univ Rovira & Virgili, Fac Med & Ciencies Salut, UHN, Reus 43201, Spain.
[Nelson, Phillip G.] NICHHD, NIH, Bethesda, MD 20892 USA.
RP Lanuza, MA (reprint author), Univ Rovira & Virgili, Fac Med & Ciencies Salut, UHN, Carrer St Llorenc 21, Reus 43201, Spain.
EM mariaangel.lanuza@urv.cat; josepmaria.tomas@urv.cat
OI Santafe, Manel/0000-0002-5462-5108
FU MEC [SAF 2008-02836]; Catalan Government (Generalitat) [2009SGR01248]
FX This work was supported by a grant from MEC (SAF 2008-02836) and a grant
from the Catalan Government (Generalitat) (2009SGR01248).
NR 36
TC 7
Z9 7
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
J9 EXP NEUROL
JI Exp. Neurol.
PD SEP
PY 2010
VL 225
IS 1
SI SI
BP 183
EP 195
DI 10.1016/j.expneurol.2010.06.014
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 643ZD
UT WOS:000281339300024
PM 20599977
ER
PT J
AU Kelly, RJ
Giaccone, G
AF Kelly, Ronan J.
Giaccone, Giuseppe
TI The role of talactoferrin alfa in the treatment of non-small cell lung
cancer
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE dendritic cell; immunotherapy; non small cell lung cancer; talactoferrin
alpha
ID LACTOFERRIN INHIBITS GROWTH; CYCLIN-DEPENDENT KINASES; BOVINE
LACTOFERRIN; ORAL LACTOFERRIN; SOLID TUMORS; MICE; CARCINOMA; RECEPTOR;
EPITHELIUM; ARREST
AB Importance of the field: Immunotherapeutic approaches to treating NSCLC via either adoptive transfer of immunity or stimulation of the endogenous immune system have shown increasing promise in recent years.
Areas covered in this review: Talactoferrin alfa is an oral immunomodulatory agent currently in late-stage clinical trials that acts through dendritic cell recruitment and activation in the gut-associated lymphoid tissue.
What the reader will gain: Talactoferrin is a recombinant human lactoferrin that is a member of the transferrin family of iron-binding glycoproteins. Lactoferrins have multiple known biological activities including cancer protection, cellular growth and differentiation and antimicrobial and anti-inflammatory properties. This review discusses the proposed mechanism of action of talactoferrin-alfa and outlines the pre-clinical, Phase I and II data in NSCLC. The ongoing Phase III trials are discussed.
Take home message: The current role of Talactoferrin alpha in the treatment of NSCLC is described and we explore potential future roles for this drug in both early stage and advanced stage disease.
C1 [Kelly, Ronan J.; Giaccone, Giuseppe] NCI, Bethesda, MD 20892 USA.
RP Giaccone, G (reprint author), NCI, Bethesda, MD 20892 USA.
EM giacconeg@mail.nih.gov
RI Giaccone, Giuseppe/E-8297-2017
OI Giaccone, Giuseppe/0000-0002-5023-7562
NR 32
TC 9
Z9 10
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD SEP
PY 2010
VL 10
IS 9
BP 1379
EP 1386
DI 10.1517/14712598.2010.512914
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 647JJ
UT WOS:000281614500008
PM 20684737
ER
PT J
AU Hedrick, MN
Lonsdorf, AS
Hwang, ST
Farber, JM
AF Hedrick, Michael N.
Lonsdorf, Anke S.
Hwang, Sam T.
Farber, Joshua M.
TI CCR6 as a possible therapeutic target in psoriasis
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE autoimmune disease; chemokines; inflammation; psoriasis
ID NATURAL-KILLER-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; INFLAMMATORY PROTEIN 3-ALPHA;
CHEMOKINE RECEPTOR CCR6; MEMORY T-CELLS; HUMAN B-CELLS; DENDRITIC CELLS;
ATOPIC-DERMATITIS; IN-VIVO
AB Importance of the field: Psoriasis is a common, chronic autoimmune disease of the skin. Despite a number of effective treatments, new therapies are needed with enhanced efficacy, safety and convenience. Chemokine receptors are GPCRs that control leukocyte trafficking, and like other GPCRs, are good potential drug targets. The chemokine receptor CCR6 is expressed on the T(H)17 subset of CD4(+) T cells, which produces IL-17A/F, IL-22, TNF-alpha and other cytokines, and which has been implicated in the pathogenesis of psoriasis. CCR6 and its ligand, CCL20/MIP-3 alpha, are highly expressed in psoriatic skin and CCR6 is necessary for the pathology induced in a mouse model of psoriasis-like inflammation.
Areas covered in this review: This review summarizes the evidence for the importance of the IL-23/T(H)17 axis, and in particular CCR6 and CCL20 in psoriasis, dating from 2000 to the present, and discusses the possibility of inhibiting CCR6 as a treatment for the disease.
What the reader will gain: The review informs the reader of the current thinking on the mechanisms of inflammation in psoriasis and the possible roles for CCR6 (and CCL20) in disease pathogenesis.
Take home message: We conclude that CCR6 should be investigated as a potential therapeutic target in psoriasis.
C1 [Hedrick, Michael N.; Farber, Joshua M.] NIAID, NIH, Lab Mol Immunol, Inflammat Biol Sect, Bethesda, MD 20892 USA.
[Lonsdorf, Anke S.] Univ Heidelberg Hosp, Dept Dermatol, Heidelberg, Germany.
[Hwang, Sam T.] Med Coll Wisconsin, Dept Dermatol, Froedtert Clin E, Milwaukee, WI 53226 USA.
RP Farber, JM (reprint author), NIAID, NIH, Lab Mol Immunol, Inflammat Biol Sect, Bldg 10,Rm 11N112, Bethesda, MD 20892 USA.
EM jfarber@niaid.nih.gov
FU NIH, NIAID; National Institutes of Health; German Research Foundation;
NCI
FX This work was supported by the Intramural Research Program of the NIH,
NIAID and NCI, and an NIH/DFG Research Career Transition Award of the
National Institutes of Health and the German Research Foundation to AS
Lonsdorf.
NR 155
TC 25
Z9 28
U1 1
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1472-8222
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD SEP
PY 2010
VL 14
IS 9
BP 911
EP 922
DI 10.1517/14728222.2010.504716
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 647JM
UT WOS:000281614800004
PM 20629596
ER
PT J
AU Vaccari, M
Poonam, P
Franchini, G
AF Vaccari, Monica
Poonam, Poonam
Franchini, Genoveffa
TI Phase III HIV vaccine trial in Thailand: a step toward a protective
vaccine for HIV
SO EXPERT REVIEW OF VACCINES
LA English
DT Article
DE gp120; HIV; neutralizing antibodies; Phase III; prime-boost; T-cell
responses; vaccine trial
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE RESPONSES; RECOMBINANT
CANARYPOX; SIMIAN-IMMUNODEFICIENCY; RHESUS MACAQUES; ALVAC-HIV;
IMMUNE-RESPONSES; SERONEGATIVE ADULTS; POXVIRUS VECTORS; DOUBLE-BLIND
AB The large human efficacy trail in Thailand, RV144, was concluded in the summer of 2009. This is the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition. This trial represents the first sign that a preventive vaccine for HIV may be feasible. The vaccine regimen tested in Thailand consisted of priming with a Canarypox vector carrying three synthetic HIV genes. The priming was followed by booster inoculations with two recombinant envelope proteins from HIV, clade B and E. The need to understand the role in protection from HIV acquisition of the new responses, induced by this vaccine combination, has brought together many researchers with the common goal of improving the development of a safe and effective vaccine for HIV.
C1 [Vaccari, Monica; Poonam, Poonam; Franchini, Genoveffa] NCI, Anim Models & Retroviral Vaccine Sect, NIH, Bethesda, MD 20892 USA.
RP Franchini, G (reprint author), NCI, Anim Models & Retroviral Vaccine Sect, NIH, Bethesda, MD 20892 USA.
EM franchig@mail.nih.gov
NR 77
TC 33
Z9 33
U1 1
U2 3
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1476-0584
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD SEP
PY 2010
VL 9
IS 9
BP 997
EP 1005
DI 10.1586/ERV.10.104
PG 9
WC Immunology
SC Immunology
GA 653SO
UT WOS:000282117200008
PM 20822342
ER
PT J
AU Yi, H
Xue, L
Guo, MX
Ma, JA
Zeng, Y
Wang, W
Cai, JY
Hu, HM
Shu, HB
Shi, YB
Li, WX
AF Yi, Hong
Xue, Lu
Guo, Ming-Xiong
Ma, Jian
Zeng, Yan
Wang, Wei
Cai, Jin-Yang
Hu, Hai-Ming
Shu, Hong-Bing
Shi, Yun-Bo
Li, Wen-Xin
TI Gene expression atlas for human embryogenesis
SO FASEB JOURNAL
LA English
DT Article
DE human embryonic development; gene regulation database; organogenesis;
microarrays; maternal genes
ID HUMAN OOCYTES; HUMAN EMBRYO; DIFFERENTIATION; TRANSCRIPTOME; FEATURES;
BIOLOGY; ZNF268; CELLS
AB Human embryogenesis is believed to involve an integrated set of complex yet coordinated development of different organs and tissues mediated by the changes in the spatiotemporal expression of many genes. Here, we report a genome-wide expression analysis during wk 4-9 of human embryogenesis, a critical period when most organs develop. About half of all human genes are expressed, and 18.6% of the expressed genes were significantly regulated during this important period. We further identified >5000 regulated genes, most of which previously were not known to be associated with animal development. Our study fills an important gap in mammalian developmental studies by identifying functional pathways involved in this critical but previously not studied period. Our study also revealed that the genes involved here are distinct from those during early embryogenesis, which include three groups of maternal genes. Furthermore, we discovered that genes in a given developmental process are regulated coordinately. This led us to develop an easily searchable database of this entire collection of gene expression profiles, allowing for the identification new genes important for a particular developmental process/pathway and deducing the potential function of a novel gene. The validity of the predictions from the database was demonstrated with two examples through spatiotemporal analyses of the two novel genes. Such a database should serve as a highly valuable resource for the molecular analysis of human development and pathogenesis.-Yi, H., Xue, L., Guo, M.-X. Ma, J., Zeng, Y., Wang, W., Cai, J.-Y. Hu, H.-M., Shu, H.-B. Shi, Y.-B., Li, W.-X. Gene expression atlas for human embryogenesis. FASEB J. 24, 3341-3350 (2010). www.fasebj.org
C1 [Li, Wen-Xin] Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China.
[Shi, Yun-Bo] NICHHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.
RP Li, WX (reprint author), Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China.
EM shi@helix.nih.gov; liwxlab@whu.edu.cn
FU National High Technology Research and Development Program of China (863
Program) [2006AA02A306]; National Natural Science Foundation of China
[30871245]; Program of Introducing Talents of Discipline to Universities
[B06018]; National Institute of Child Health and Human Development,
National Institutes of Health
FX This work was supported by National High Technology Research and
Development Program of China (863 Program) grant 2006AA02A306, National
Natural Science Foundation of China grant 30871245, Program of
Introducing Talents of Discipline to Universities grant B06018. Y.-B. S.
was supported by the National Institute of Child Health and Human
Development Intramural Research Program, National Institutes of Health.
NR 33
TC 17
Z9 17
U1 4
U2 10
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD SEP
PY 2010
VL 24
IS 9
BP 3341
EP 3350
DI 10.1096/fj.10-158782
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 645IK
UT WOS:000281446400022
PM 20430792
ER
PT J
AU Goetzl, EJ
Huang, MC
Kon, J
Patel, K
Schwartz, JB
Fast, K
Ferrucci, L
Madara, K
Taub, DD
Longo, DL
AF Goetzl, Edward J.
Huang, Mei-Chuan
Kon, Junko
Patel, Kalpesh
Schwartz, Janice B.
Fast, Katharine
Ferrucci, Luigi
Madara, Karen
Taub, Dennis D.
Longo, Dan L.
TI Gender specificity of altered human immune cytokine profiles in aging
SO FASEB JOURNAL
LA English
DT Article
DE T cells; monocytes; immunodeficiency; autoimmunity
ID REGULATORY T-CELLS; INTERFERON-GAMMA-PRODUCTION; IFN-GAMMA; CLONAL
EXPANSIONS; ELDERLY-PEOPLE; OLD SUBJECTS; IN-VITRO; AGE; LYMPHOCYTES;
ACTIVATION
AB Cytokine generation by T cells and monocytes was determined for 50 subjects aged 65 yr or older and concurrently studied young subjects individually matched to each old subject for sex, race, and national origin. Highly significant differences between cytokine levels of old and young subjects all were gender specific. For T cells stimulated with anti-CD3 plus anti-CD28 antibodies, mean ratios of IFN-gamma generation for healthy old to young subjects were 0.22 for men (P<0.001; n=15) and 3.35 for women (P<0.001; n=13), and those of IL-17 were 0.30 for men (P<0.001) and no difference for women. CD8 T cells were the source of high IFN-gamma in healthy old women. For old men with an inflammatory or immune disease (n=10), mean old to young ratios of T-cell-generated IFN-gamma and IL-17 increased with disease severity up to 5.78 and 2.97 (both P<0.01), respectively, without changes for old women with similar diseases (n=12). For differentiated LPS-stimulated monocytes, old to young ratios of TNF-alpha and IL-6 generation were high only in women with immune or inflammatory disease (2.38, P<0.05 and 1.62, P<0.01, respectively), whereas ratios of IFN-gamma-evoked IP-10 chemokine were low in all groups. Alterations in immune cytokine profiles with aging show significant gender specificity.-Goetzl, E. J., Huang, M.-C., Kon, J., Patel, K., Schwartz, J. B., Fast, K., Ferrucci, L., Madara, K., Taub, D. D., Longo, D. L. Gender specificity of altered human immune cytokine profiles in aging. FASEB J. 24, 3580-3589 (2010). www.fasebj.org
C1 [Goetzl, Edward J.; Huang, Mei-Chuan; Kon, Junko; Schwartz, Janice B.; Fast, Katharine] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Goetzl, Edward J.; Huang, Mei-Chuan; Kon, Junko; Schwartz, Janice B.; Fast, Katharine] Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA.
[Goetzl, Edward J.; Patel, Kalpesh; Ferrucci, Luigi; Madara, Karen; Taub, Dennis D.; Longo, Dan L.] NIA, NIH, Baltimore, MD 21224 USA.
RP Goetzl, EJ (reprint author), Univ Calif San Francisco, Dept Med, Rm UB8B,UC Box 0711,533 Parnassus & 4th Ave, San Francisco, CA 94143 USA.
EM edward.goetzl@ucsf.edu
RI Patel, Kalpesh/G-6685-2012
OI Patel, Kalpesh/0000-0002-2952-6773
FU National Institute on Aging; Kenneth Rainin Foundation; National
Institutes of Health [HL31809]
FX This research was supported by the Intramural Research Program of the
National Institute on Aging, a grant from the Kenneth Rainin Foundation,
and National Institutes of Health RO-1 grant HL31809. E.J.G., M. C. H.,
J.B.S., D. D. T., and D. L. L. designed research; E.J.G., J.B.S., K. F.,
L. F., and K. M. evaluated and selected subjects; E.J.G., M. C. H.,
J.K., and K. P. performed laboratory research; E.J.G., M. C. H., J.B.S.,
and D. L. L. analyzed data and wrote the paper. The authors are grateful
to Judith H. Goetzl for preparation of the figures and tables.
NR 37
TC 39
Z9 39
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD SEP
PY 2010
VL 24
IS 9
BP 3580
EP 3589
DI 10.1096/fj.10-160911
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 645IK
UT WOS:000281446400045
PM 20453111
ER
PT J
AU Wu, YL
Brosh, RM
AF Wu, Yuliang
Brosh, Robert M., Jr.
TI G-quadruplex nucleic acids and human disease
SO FEBS JOURNAL
LA English
DT Review
DE BLM; Bloom's syndrome; FANCJ; Fanconi anemia; genomic instability;
G-quadruplex; helicase; telomere; Werner syndrome; WRN
ID FRAGILE-X-SYNDROME; REPLICATION PROTEIN-A; FAMILIAL BREAST-CANCER;
TELOMERIC G-QUADRUPLEXES; WERNER-SYNDROME HELICASE; SYNDROME DNA
HELICASE; BONE-MARROW FAILURE; HUMAN KRAS PROMOTER; CROSS-LINK REPAIR;
IN-VITRO
AB Alternate DNA structures that deviate from B-form double-stranded DNA such as G-quadruplex (G4) DNA can be formed by sequences that are widely distributed throughout the human genome. G-quadruplex secondary structures, formed by the stacking of planar quartets composed of four guanines that interact by Hoogsteen hydrogen bonding, can affect cellular DNA replication and transcription, and influence genomic stability. The unique metabolism of G-rich chromosomal regions that potentially form quadruplexes may influence a number of biological processes including immunoglobulin gene rearrangements, promoter activation and telomere maintenance. A number of human diseases are characterized by telomere defects, and it is proposed that G-quadruplex structures which form at telomere ends play an important role in telomere stability. Evidence from cellular studies and model organisms suggests that diseases with known defects in G4 DNA helicases are likely to be perturbed in telomere maintenance and cellular DNA replication. In this minireview, we discuss the connections of G-quadruplex nucleic acids to human genetic diseases and cancer based on the recent literature.
C1 [Brosh, Robert M., Jr.] NIA, Lab Mol Gerontol, NIH, NIH Biomed Res Ctr, Baltimore, MD 21224 USA.
RP Brosh, RM (reprint author), NIA, Lab Mol Gerontol, NIH, NIH Biomed Res Ctr, 251 Bayview Blvd, Baltimore, MD 21224 USA.
EM broshr@mail.nih.gov
FU NIH, National Institute on Aging; Fanconi Anemia Research Fund
FX This research was supported in part by the Intramural Research Program
of the NIH, National Institute on Aging and the Fanconi Anemia Research
Fund (RMB).
NR 173
TC 118
Z9 122
U1 9
U2 84
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1742-464X
J9 FEBS J
JI FEBS J.
PD SEP
PY 2010
VL 277
IS 17
BP 3470
EP 3488
DI 10.1111/j.1742-4658.2010.07760.x
PG 19
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 639TB
UT WOS:000280996300004
PM 20670277
ER
PT J
AU Pivovarova, NB
Andrews, SB
AF Pivovarova, Natalia B.
Andrews, S. Brian
TI Calcium-dependent mitochondrial function and dysfunction in neurons
SO FEBS JOURNAL
LA English
DT Review
DE calcium buffering; calcium deregulation; cell death; electron
microscopy; electron probe microanalysis; energy filtering electron
microscopy; excitotoxicity; hippocampal neurons; mitochondria;
permeability transition
ID CEREBELLAR GRANULE CELLS; ACUTE GLUTAMATE EXCITOTOXICITY; PERMEABILITY
TRANSITION PORE; SPARE RESPIRATORY CAPACITY; NMDA RECEPTOR ACTIVATION;
RAT HIPPOCAMPAL-NEURONS; ISCHEMIC BRAIN-INJURY; CYTOCHROME-C RELEASE;
OXIDATIVE STRESS; CNS MITOCHONDRIA
AB Calcium is an extraordinarily versatile signaling ion, encoding cellular responses to a wide variety of external stimuli. In neurons, mitochondria can accumulate enormous amounts of calcium, with the consequence that mitochondrial calcium uptake, sequestration and release play pivotal roles in orchestrating calcium-dependent responses as diverse as gene transcription and cell death. In this review, we consider the basic chemistry of calcium as a 'sticky' cation, which leads to extremely high bound/free ratios, and discuss areas of current interest or controversy. Topics addressed include methodologies for measuring local intracellular calcium, mitochondrial calcium buffering and loading capacity, mitochondrially directed spatial calcium gradients, and the role of calcium overload-dependent mitochondrial dysfunction in glutamate-evoked excitotoxic injury and neurodegeneration. Finally, we consider the relationship between delayed calcium de-regulation, the mitochondrial permeability transition and the generation of reactive oxygen species, and propose a unified view of the 'source specificity' and 'calcium overload' models of N-methyl-d-aspartate (NMDA) receptor-dependent excitotoxicity. Non-NMDA receptor mechanisms of excitotoxicity are discussed briefly.
C1 [Pivovarova, Natalia B.; Andrews, S. Brian] NINDS, Neurobiol Lab, NIH, Bethesda, MD 20892 USA.
RP Andrews, SB (reprint author), NINDS, Neurobiol Lab, NIH, 49-3A62,49 Convent Dr, Bethesda, MD 20892 USA.
EM sba@helix.nih.gov
FU National Institute of Neurological Disorders and Stroke, National
Institutes of Health
FX The authors are indebted to the staff of the National Institute of
Neurological Disorders and Stroke Electron Microscopy facility (Director
Dr Jung-Hwa Tao-Cheng) for excellent technical assistance. This research
was supported by the Intramural Research Program of the National
Institute of Neurological Disorders and Stroke, National Institutes of
Health.
NR 129
TC 86
Z9 92
U1 2
U2 12
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1742-464X
J9 FEBS J
JI FEBS J.
PD SEP
PY 2010
VL 277
IS 18
BP 3622
EP 3636
DI 10.1111/j.1742-4658.2010.07754.x
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 646PX
UT WOS:000281555600002
PM 20659161
ER
PT J
AU Beisel, CL
Storz, G
AF Beisel, Chase L.
Storz, Gisela
TI Base pairing small RNAs and their roles in global regulatory networks
SO FEMS MICROBIOLOGY REVIEWS
LA English
DT Review
DE sRNAs; regulatory circuits; gene regulation; Hfq; network motifs
ID BACTERIAL SMALL RNA; SM-LIKE PROTEIN; ESCHERICHIA-COLI; GENE-EXPRESSION;
MESSENGER-RNA; NEGATIVE FEEDBACK; VIBRIO-HARVEYI; NONCODING RNA;
SOLUBLE-RNA; TRANSCRIPTIONAL REGULATION
AB Bacteria use a range of RNA regulators collectively termed small RNAs (sRNAs) to help respond to changes in the environment. Many sRNAs regulate their target mRNAs through limited base-pairing interactions. Ongoing characterization of base-pairing sRNAs in bacteria has started to reveal how these sRNAs participate in global regulatory networks. These networks can be broken down into smaller regulatory circuits that have characteristic behaviors and functions. In this review, we describe the specific regulatory circuits that incorporate base-pairing sRNAs and the importance of each circuit in global regulation. Because most of these circuits were originally identified as network motifs in transcriptional networks, we also discuss why sRNAs may be used over protein transcription factors to help transduce environmental signals.
C1 [Beisel, Chase L.; Storz, Gisela] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cell Biol & Metab Program, Bethesda, MD 20892 USA.
RP Storz, G (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cell Biol & Metab Program, Bethesda, MD 20892 USA.
EM storz@helix.nih.gov
RI Beisel, Chase/D-4823-2015;
OI Beisel, Chase/0000-0003-0650-9943; Storz, Gisela/0000-0001-6698-1241
FU NICHD
FX We thank S. Gottesman, M. Goulian, B. Janson, M. Thomason, O. Venturelli
and L. Waters for their comments on this review. C.L.B. is a Gordon and
Betty Moore Foundation Fellow of the Life Sciences Research Foundation.
Work carried out in the laboratory of G.S. is supported by the
intramural program of NICHD.
NR 83
TC 133
Z9 137
U1 1
U2 26
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0168-6445
J9 FEMS MICROBIOL REV
JI Fems Microbiol. Rev.
PD SEP
PY 2010
VL 34
IS 5
BP 866
EP 882
DI 10.1111/j.1574-6976.2010.00241.x
PG 17
WC Microbiology
SC Microbiology
GA 635CP
UT WOS:000280633500013
PM 20662934
ER
PT J
AU Choi, YH
Ngamskulrungroj, P
Varma, A
Sionov, E
Hwang, SM
Carriconde, F
Meyer, W
Litvintseva, AP
Lee, WG
Shin, JH
Kim, EC
Lee, KW
Choi, TY
Lee, YS
Kwon-Chung, KJ
AF Choi, Young Hwa
Ngamskulrungroj, Popchai
Varma, Ashok
Sionov, Edward
Hwang, Soo Myung
Carriconde, Fabian
Meyer, Wieland
Litvintseva, Anastasia P.
Lee, Wee Gyo
Shin, Jong Hee
Kim, Eui-Chong
Lee, Kyung Won
Choi, Tae Yeal
Lee, Yeong Seon
Kwon-Chung, Kyung J.
TI Prevalence of the VNIc genotype of Cryptococcus neoformans in
non-HIV-associated cryptococcosis in the Republic of Korea
SO FEMS YEAST RESEARCH
LA English
DT Article
DE epidemiology; cryptococcosis; Cryptococcus neoformans; Cryptococcus
gattii; molecular type; MLST
ID GRUBII SEROTYPE-A; VANCOUVER-ISLAND; VAR. GRUBII; GENETIC DIVERSITY;
BRITISH-COLUMBIA; SEXUAL CYCLE; GATTII; OUTBREAK; CANADA; CHINA
AB PCR fingerprinting and multilocus sequence typing were applied to determine the major molecular types of the Cryptococcus neoformans/Cryptococcus gattii species complex in the Republic of Korea. Of the 78 strains isolated from patients diagnosed with cryptococcosis between 1990 and 2008, 96% were C. neoformans serotype A, mating type MAT alpha and molecular type VNI. The remaining 4% were C. gattii, serotype B, mating type MAT alpha and either molecular type VGIIb or VGIII. Of the 62 strains with known HIV status, only 14 (22.6%) were isolated from HIV-positive patients and belonged to molecular type VNI. Remarkably, 93% of the C. neoformans isolates had identical PCR fingerprint profiles with the VNIc genotype that has been identified recently as the major genotype among C. neoformans strains in China. Most strains (81.8%) of the VNIc genotype were associated with non-HIV patients compared with strains of the non-VNIc genotype (20%) (P=0.009). Unlike the Chinese strains, a majority (60%) of the non-HIV patients infected with strains of the VNIc genotype in the Republic of Korea had serious underlying conditions, with cancer and liver disease being the most common. This study affirms VNIc to be the most prevalent genotype of C. neoformans isolated from non-HIV patients with cryptococcosis.
C1 [Choi, Young Hwa; Ngamskulrungroj, Popchai; Varma, Ashok; Sionov, Edward; Kwon-Chung, Kyung J.] NIAID, Mol Microbiol Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
[Hwang, Soo Myung] Catholic Univ Pusan, Dept Clin Lab Sci, Pusan, South Korea.
[Carriconde, Fabian; Meyer, Wieland] Univ Sydney, Sydney Med Sch Western, Westmead Millennium Inst,Westmead Hosp, Mol Mycol Res Lab,Ctr Infect Dis & Microbiol, Sydney, NSW 2006, Australia.
[Litvintseva, Anastasia P.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA.
[Lee, Wee Gyo] Ajou Univ, Sch Med, Dept Lab Med, Suwon 441749, South Korea.
[Shin, Jong Hee] Chonnam Natl Univ, Coll Med, Dept Lab Med, Kwangju, South Korea.
[Kim, Eui-Chong] Seoul Natl Univ, Dept Lab Med, Seoul, South Korea.
[Lee, Kyung Won] Yonsei Univ, Dept Lab Med, Res Inst Bacterial Resistance, Seoul 120749, South Korea.
[Choi, Tae Yeal] Hanyang Univ Hosp, Dept Lab Med, Seoul, South Korea.
[Lee, Yeong Seon] Natl Inst Hlth, Ctr Infect Dis, Seoul, South Korea.
RP Kwon-Chung, KJ (reprint author), NIAID, Mol Microbiol Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM june_kwon-chung@nih.gov
RI Kim, Eu Chong/J-5424-2012; Meyer, Wieland/G-1204-2015
OI Meyer, Wieland/0000-0001-9933-8340
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health
FX This work was supported by funds from the intramural program of the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health (K.J.K.-C.).
NR 37
TC 41
Z9 41
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1567-1356
J9 FEMS YEAST RES
JI FEMS Yeast Res.
PD SEP
PY 2010
VL 10
IS 6
BP 769
EP 778
DI 10.1111/j.1567-1364.2010.00648.x
PG 10
WC Biotechnology & Applied Microbiology; Microbiology; Mycology
SC Biotechnology & Applied Microbiology; Microbiology; Mycology
GA 639TM
UT WOS:000280997400013
PM 20561059
ER
PT J
AU Alford, CE
Chen, GL
Armstrong, AY
AF Alford, Connie E.
Chen, Grace L.
Armstrong, Alicia Y.
TI 2009 H1N1 influenza prevention and treatment: counseling infertility
patients
SO FERTILITY AND STERILITY
LA English
DT Editorial Material
DE H1N1; H1N1 influenza virus; H1N1 influenza vaccine; H1N1 influenza
treatment; pregnancy; infertility; preconception counseling
ID ANTIBODY; IMMUNIZATION; INFANTS; PROTECTION; PREGNANCY; VACCINE
AB It is known that pregnant women are at high risk for complications from the 2009 H1N1 influenza virus. Reproductive endocrinologists often have the opportunity to evaluate patients before conception and are able to counsel them before they become part of this high-risk obstetrics group. The 2009 H1N1 vaccine data and the current recommendations by the Centers for Disease Control and Prevention, American College of Obstetrics and Gynecology, and American Society of Reproductive Medicine are discussed. There is universal agreement in recommending vaccination for all pregnant women and all women attempting conception. Patients should be counseled regarding the vaccine and consider delaying conception until the immunization has been received. (Fertil Steril (R) 2010;94:1178-80. (C) 2010 by American Society for Reproductive Medicine.)
C1 [Alford, Connie E.; Armstrong, Alicia Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD 20892 USA.
[Chen, Grace L.] NIAID, NIH, Bethesda, MD 20892 USA.
RP Alford, CE (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bldg 10 Clin Resource Ctr,Rm 1E-3140,10 Ctr Dr,MS, Bethesda, MD 20892 USA.
EM alfordco@mail.nih.gov
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development
FX Supported, in part, by the Program in Reproductive and Adult
Endocrinology, Eunice Kennedy Shriver National Institute of Child Health
and Human Development.
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
BP 1178
EP 1180
DI 10.1016/j.fertnstert.2010.04.056
PG 3
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 648FA
UT WOS:000281674600002
PM 20579645
ER
PT J
AU Grossman, LC
Michalakis, KG
Browne, H
Payson, MD
Segars, JH
AF Grossman, Lisa C.
Michalakis, Konstantinos G.
Browne, Hyacinth
Payson, Mark D.
Segars, James H.
TI The pathophysiology of ovarian hyperstimulation syndrome: an
unrecognized compartment syndrome
SO FERTILITY AND STERILITY
LA English
DT Article
DE Ovarian hyperstimulation syndrome (OHSS); abdominal compartment syndrome
(ACS); intraabdominal pressure (IAP); intraabdominal hypertension (IAH);
paracentesis
ID ENDOTHELIAL GROWTH-FACTOR; IN-VITRO FERTILIZATION; STIMULATING-HORMONE
RECEPTOR; JUGULAR-VEIN THROMBOSIS; MASSIVE VULVAR EDEMA;
OF-THE-LITERATURE; ABDOMINAL COMPARTMENT; INTRAABDOMINAL HYPERTENSION;
FACTOR VEGF; PARACENTESIS
AB Objective: To compare and contrast the pathophysiology of ovarian hyperstimualtion syndrome (OHSS) with known syndromes of increased intraabdominal pressure (IAP), and to explore the relationship of increased IAP with symptom severity in OHSS.
Design: Literature review.
Main Outcome Measure(s): Correlation of OHSS symptoms with IAP; effects of paracentesis on IAP in patients with OHSS.
Setting: Academic Research Institution.
Intervention(s): None.
Result(s): OHSS involves a rapid accumulation of volume (from 1.5-17 liters) in the peritoneal cavity that can lead to organ dysfunction, including respiratory impairment and oliguria. In published reports of 20 moderate-to-severe OHSS patients in whom IAP was measured, IAP was found to be elevated to a pathologic range. The increased IAP indicates that OHSS may be considered a compartment syndrome and meets criteria for abdominal compartment syndrome in advanced cases. For this reason, management of OHSS should include reduction of pressure by paracentesis to avoid morbidity and syndrome progression. In addition, measurement of IAP may help to classify the stage of OHSS.
Conclusion(s): IAP was found to be elevated in the few cases of OHSS in which it was measured, substantiating the conclusion that OHSS may be considered a compartment syndrome. An understanding of the pathophysiology of increased intrabdominal pressure is useful in the management of OHSS. (Fertil Steril (R) 2010;94:1392-8. (C) 2010 by American Society for Reproductive Medicine.)
C1 [Segars, James H.] NICHHD, Reprod Biol & Med Branch, NIH, CRC, Bethesda, MD 20892 USA.
[Grossman, Lisa C.] Georgetown Univ, Sch Med, Washington, DC USA.
[Payson, Mark D.] Walter Reed Army Med Ctr, Washington, DC 20307 USA.
RP Segars, JH (reprint author), NICHHD, Reprod Biol & Med Branch, NIH, CRC, 10 Ctr Dr,Bldg 10,1E-3140, Bethesda, MD 20892 USA.
EM segarsj@mail.nih.gov
FU Reproductive Biology and Medicine Branch, NICHD, NIH
FX Supported, in part, by the Intramural Research Program of the
Reproductive Biology and Medicine Branch, NICHD, NIH.
NR 68
TC 18
Z9 19
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
BP 1392
EP 1398
DI 10.1016/j.fertnstert.2009.07.1662
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 648FA
UT WOS:000281674600038
PM 19836016
ER
PT J
AU Baker, VL
Luke, B
Brown, MB
Alvero, R
Frattarelli, JL
Usadi, R
Grainger, DA
Armstrong, AY
AF Baker, Valerie L.
Luke, Barbara
Brown, Morton B.
Alvero, Ruben
Frattarelli, John L.
Usadi, Rebecca
Grainger, David A.
Armstrong, Alicia Y.
TI Multivariate analysis of factors affecting probability of pregnancy and
live birth with in vitro fertilization: an analysis of the Society for
Assisted Reproductive Technology Clinic Outcomes Reporting System
SO FERTILITY AND STERILITY
LA English
DT Article
DE Assisted reproductive technology; in vitro fertilization; race;
ethnicity; ART outcomes; IVF pregnancy rates; pregnancy loss;
spontaneous abortion
ID RATES; IVF
AB Objective: To evaluate factors predictive of clinical pregnancy and of pregnancy loss from assisted reproductive technology (ART) using data from the Society for Assisted Reproductive Technology database for 2004-2006.
Design: Retrospective cohort.
Setting: Clinic-based data.
Patient(s): The study population included 225,889 fresh embryo transfer cycles using autologous oocytes and partner semen.
Intervention(s): None.
Main Outcome Measure(s): Clinical intrauterine gestation (presence of gestational sac) and live birth (>= 22 weeks gestation and >= 300 g birth weight).
Result(s): Increasing maternal age was significantly associated with a reduced odds of conception and increased fetal loss until 19 weeks gestation, but not with later pregnancy loss. Intracytoplasmic sperm injection (ICSI), assisted hatching, and increasing number of embryos transferred had significant positive effects on the odds of conception and pregnancy continuation through the first trimester, but did not affect the risk of later loss. Blacks, Asians, and Hispanics had significantly lower odds of clinical pregnancy compared with whites. Also compared with whites, Hispanics and Asians had a significantly greater risk of pregnancy loss in the second and third trimesters, and blacks had a significantly greater risk of pregnancy loss in all trimesters.
Conclusion(s): Certain demographic and ART treatment parameters influenced chance of conception and early pregnancy loss, whereas black race and Hispanic ethnicity were also significantly associated with late pregnancy loss in ART-conceived pregnancies. (Fertil Steril (R) 2010;94:1410-6. (C) 2010 by American Society for Reproductive Medicine.)
C1 [Baker, Valerie L.] Stanford Univ, Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol, Stanford, CA 94305 USA.
[Luke, Barbara] Michigan State Univ, Dept Obstet Gynecol & Reprod Biol, E Lansing, MI 48824 USA.
[Luke, Barbara] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA.
[Brown, Morton B.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.
[Alvero, Ruben] Univ Colorado Denver, Dept Obstet & Gynecol, Div Reprod Endocrinol, Aurora, CO USA.
[Frattarelli, John L.] Adv Reprod Med & Gynecol Hawaii, Oahu, HI USA.
[Usadi, Rebecca] Carolinas Healthcare, Charlotte, NC USA.
[Grainger, David A.] Univ Kansas, Ctr Reprod Med, Wichita, KS USA.
[Armstrong, Alicia Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol Branch, NIH, Bethesda, MD USA.
RP Baker, VL (reprint author), Stanford Univ, Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol, 300 Pasteur Dr,Room HH333, Stanford, CA 94305 USA.
EM vlbaker@stanford.edu
FU IBSA; Clinical Research/Reproductive Scientist Training (CREST) Program;
Society for Assisted Reproductive Technology
FX V.L.B. has received research support from IBSA. B.L. has nothing to
disclose. M.B.B. has nothing to disclose. R.A. has nothing to disclose.;
Supported by the Clinical Research/Reproductive Scientist Training
(CREST) Program and the Society for Assisted Reproductive Technology.
NR 16
TC 36
Z9 37
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
BP 1410
EP 1416
DI 10.1016/j.fertnstert.2009.07.986
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 648FA
UT WOS:000281674600041
PM 19740463
ER
PT J
AU Jungheim, ES
Ryan, GL
Levens, ED
Cunningham, AF
Macones, GA
Carson, KR
Beltsos, AN
Odem, RR
AF Jungheim, Emily S.
Ryan, Ginny L.
Levens, Eric D.
Cunningham, Alexandra F.
Macones, George A.
Carson, Kenneth R.
Beltsos, Angeline N.
Odem, Randall R.
TI Embryo transfer practices in the United States: a survey of clinics
registered with the Society for Assisted Reproductive Technology
SO FERTILITY AND STERILITY
LA English
DT Article
DE Embryo transfer practices; ASRM embryo transfer guidelines; single
embryo transfer; IVF insurance coverage
ID MULTIPLE GESTATION RATES; IN-VITRO FERTILIZATION; PREGNANCY RATES;
PRETERM BIRTH; SINGLE; OUTCOMES; COST; IVF
AB Objective: To gain a better understanding of factors influencing clinicians' embryo transfer practices.
Design: Cross-sectional survey.
Setting: Web-based survey conducted in December 2008 of individuals practicing IVF in centers registered with the Society for Assisted Reproductive Technology (SART).
Patient(s): None.
Intervention(s): None.
Main Outcome Measure(s): Prevalence of clinicians reporting following embryo transfer guidelines recommended by the American Society for Reproductive Medicine (ASRM), prevalence among these clinicians to deviate from ASRM guidelines in commonly encountered clinical scenarios, and practice patterns related to single embryo transfer.
Result(s): Six percent of respondents reported following their own, independent guidelines for the number of embryos to transfer after IVF. Of the 94% of respondents who reported routinely following ASRM embryo transfer guidelines, 52% would deviate from these guidelines for patient request, 51% for cycles involving the transfer of frozen embryos, and 70% for patients with previously failed IVF cycles. All respondents reported routinely discussing the risks of multiple gestations associated with standard embryo transfer practices, whereas only 34% reported routinely discussing single embryo transfer with all patients.
Conclusion(s): Although the majority of clinicians responding to our survey reported following ASRM embryo transfer guidelines, at least half would deviate from these guidelines in a number of different situations. (Fertil Steril (R) 2010;94:1432-6. (C) 2010 by American Society for Reproductive Medicine.)
C1 [Jungheim, Emily S.; Cunningham, Alexandra F.; Macones, George A.; Odem, Randall R.] Washington Univ, Dept Obstet & Gynecol, St Louis, MO 63108 USA.
[Ryan, Ginny L.] Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA.
[Levens, Eric D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, Bethesda, MD USA.
[Carson, Kenneth R.] Washington Univ, Dept Internal Med, St Louis, MO 63108 USA.
[Beltsos, Angeline N.] Fertil Ctr Illinois, Chicago, IL USA.
RP Jungheim, ES (reprint author), Washington Univ, Dept Obstet & Gynecol, 4444 Forest Pk,Suite 3100,Campus Box 8513, St Louis, MO 63108 USA.
EM jungheime@wudosis.wustl.edu
FU Program in Reproductive and Adult Endocrinology of the Eunice Kennedy
Shriver National Institute of Child Health and Human Development,
Bethesda, MD
FX Supported in part by the Program in Reproductive and Adult Endocrinology
of the Eunice Kennedy Shriver National Institute of Child Health and
Human Development, Bethesda, MD.
NR 30
TC 19
Z9 19
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
BP 1432
EP 1436
DI 10.1016/j.fertnstert.2009.07.987
PG 5
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 648FA
UT WOS:000281674600044
PM 19748089
ER
PT J
AU Pagidas, K
Carson, SA
McGovern, PG
Barnhart, HX
Myers, ER
Legro, RS
Diamond, MP
Carr, BR
Schlaff, WD
Coutifaris, C
Steinkampf, MP
Cataldo, NA
Nestler, JE
Gosman, G
Giudice, LC
AF Pagidas, Kelly
Carson, Sandra A.
McGovern, Peter G.
Barnhart, Huiman X.
Myers, Evan R.
Legro, Richard S.
Diamond, Michael P.
Carr, Bruce R.
Schlaff, William D.
Coutifaris, Christos
Steinkampf, Michael P.
Cataldo, Nicholas A.
Nestler, John E.
Gosman, Gabey
Giudice, Linda C.
CA Natl Inst Child Hlth Human Dev-Rep
TI Intercourse compliance, ovulation, and treatment success in the National
Institute of Child Health and Human Development-Reproductive Medicine
Network's Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial
SO FERTILITY AND STERILITY
LA English
DT Article
DE Intercourse timing; ovulation; intercourse frequency; polycystic ovary
syndrome
ID MENSTRUAL-CYCLE; CLOMIPHENE; METFORMIN; MOOD
AB Objective: To investigate the relationship among intercourse compliance, ovulation, and the occurrence of pregnancy in the Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome (RMNPPCOS) Trial.
Design: Post hoc data analysis of subjects in the Reproductive Medicine Network PPCOS Trial.
Setting: Academic medical centers.
Intervention(s): None.
Patient(s): Six hundred twenty-six infertile women with polycystic ovary syndrome with a mean age of 28.1 +/- 4 years and mean body mass index of 35.2 +/- 8.7 kg/m(2).
Main Outcome Measure(s): Intercourse compliance, ovulation, and pregnancy.
Result(s): Data on 2925 cycles were included in the analysis, of which 1340 were ovulatory cycles and 1585 were nonovulatory cycles. The rates of intercourse compliance in the PPCOS trial were similar across all treatment groups at all cycles except cycle 4. Among cycles with known ovulation status, 81.2% of patients were compliant with intercourse instructions. Patients were more intercourse compliant in those cycles during which ovulation occurred (83.2% vs. 79.4%). With regard to ovulatory cycles, there was no difference in the occurrence of pregnancy when comparing intercourse compliant versus intercourse noncompliant cycles.
Conclusion(s): Intercourse compliance was not associated with the occurrence of pregnancy in ovulatory cycles in the PPCOS Trial. The occurrence of ovulation still remains a critical predictor for the occurrence of pregnancy. (Fertil Steril (R) 2010;94:1444-6. (C) 2010 by American Society for Reproductive Medicine.)
C1 [Pagidas, Kelly; Carson, Sandra A.] Brown Univ, Dept Obstet & Gynecol, Warren Alpert Med Sch, Providence, RI 02905 USA.
[McGovern, Peter G.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Obstet Gynecol & Womens Hlth, Newark, NJ 07103 USA.
[Barnhart, Huiman X.; Myers, Evan R.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Myers, Evan R.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA.
[Legro, Richard S.] Penn State Univ, Dept Obstet & Gynecol, Hershey, PA USA.
[Diamond, Michael P.] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA.
[Carr, Bruce R.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA.
[Schlaff, William D.] Univ Colorado, Dept Obstet & Gynecol, Denver, CO 80202 USA.
[Coutifaris, Christos] Univ Penn, Sch Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA.
[Steinkampf, Michael P.] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA.
[Cataldo, Nicholas A.] Stanford Univ, Palo Alto, CA 94304 USA.
[Nestler, John E.] Virginia Commonwealth Univ, Dept Med, Sch Med, Richmond, VA 23284 USA.
[Giudice, Linda C.] NICHHD, Reprod Sci Branch, Bethesda, MD 20892 USA.
[Giudice, Linda C.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
RP Pagidas, K (reprint author), Brown Univ, Women & Infants Hosp, Warren Alpert Med Sch, Obstet & Gynecol 101 Dudley St, Providence, RI 02905 USA.
EM kpagidas@wihri.org
OI Diamond, Michael/0000-0001-6353-4489
FU National Institutes of Health/National Institute of Child Health and
Human Development [U10 HD27049, U01 HD38997, U10 HD39005, U10 HD27011,
U10 HD33172, U10 HD38988, U10 HD38992, U10 HD38998, U10 HD38999, U54-
HD29834]; General Clinical Research Center (GCRC) [MO1RR00056, MO1 RR
10732, C06 RR016499]
FX Supported by National Institutes of Health/National Institute of Child
Health and Human Development grant nos. U10 HD27049 (to C.C.), U01
HD38997 (to E.R.M.), U10 HD39005 (to M.P.D.), U10 HD27011 to S.A.C.),
U10 HD33172 (to M.P.S.), U10 HD38988 (to B.R.C.), U10 HD38992 (to
R.S.L.), U10 HD38998 (to W.D.S.), U10 HD38999 (to P.G.M.), and U54-
HD29834 to the University of Virginia Center for Research in
Reproduction Ligand Assay and Analysis Core; General Clinical Research
Center (GCRC) grant no. MO1RR00056 to the University of Pittsburgh; and
General Clinical Research Center (GCRC) grant no. MO1 RR 10732 and
construction grant no. C06 RR016499 to Pennsylvania State University.
NR 5
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
BP 1444
EP 1446
DI 10.1016/j.fertnstert.2009.05.047
PG 3
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 648FA
UT WOS:000281674600046
PM 19540477
ER
PT J
AU Pagidas, K
Carson, SA
McGovern, PG
Barnhart, HX
Myers, ER
Legro, RS
Diamond, MP
Carr, BR
Schlaff, WD
Coutifaris, C
Steinkampf, MP
Cataldo, NA
Nestler, JE
Gosman, G
Giudice, LC
AF Pagidas, Kelly
Carson, Sandra A.
McGovern, Peter G.
Barnhart, Huiman X.
Myers, Evan R.
Legro, Richard S.
Diamond, Michael P.
Carr, Bruce R.
Schlaff, William D.
Coutifaris, Christos
Steinkampf, Michael P.
Cataldo, Nicholas A.
Nestler, John E.
Gosman, Gabey
Giudice, Linda C.
CA Natl Inst Child Hlth Human Dev-Rep
TI Body mass index and intercourse compliance
SO FERTILITY AND STERILITY
LA English
DT Article
DE Body mass index; intercourse frequency; ovulation; polycystic ovary
syndrome
AB Objective: To investigate the relationship between body mass index and intercourse compliance in the Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome (RMN PPCOS) Trial.
Design: Post hoc data analysis of subjects in the RMN PPCOS Trial.
Setting: Academic medical centers.
Intervention(s): None.
Patient(s): Six hundred twenty-six infertile women with polycystic ovary syndrome (PCOS) with a mean age of 28.1 +/- 4 years and mean body mass index (BMI) of 35.2 +/- 8.7 kg/m(2).
Main Outcome Measure(s): Intercourse compliance and BMI.
Result(s): Overall, body mass index was not associated with increased intercourse compliance. However, although patients with BMI >= 35 were less likely to ovulate than patients with BMI <35, they tend to be more compliant with intercourse frequency in ovulatory cycles than patients with BMI <35.
Conclusion(s): BMI was not associated with intercourse compliance or noncompliance. An elevated BMI in infertile women with PCOS is not associated with poor intercourse compliance. (Fertil Steril (R) 2010;94:144750. (C) 2010 by American Society for Reproductive Medicine.)
C1 [Pagidas, Kelly; Carson, Sandra A.] Brown Univ, Dept Obstet & Gynecol, Warren Alpert Med Sch, Providence, RI 02905 USA.
[McGovern, Peter G.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Obstet Gynecol & Womens Hlth, Newark, NJ 07103 USA.
[Barnhart, Huiman X.; Myers, Evan R.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Myers, Evan R.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA.
[Legro, Richard S.] Penn State Univ, Dept Obstet & Gynecol, Hershey, PA USA.
[Diamond, Michael P.] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA.
[Carr, Bruce R.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA.
[Schlaff, William D.] Univ Colorado, Dept Obstet & Gynecol, Denver, CO 80202 USA.
[Coutifaris, Christos] Univ Penn, Sch Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA.
[Steinkampf, Michael P.] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA.
[Cataldo, Nicholas A.] Stanford Univ, Palo Alto, CA 94304 USA.
[Nestler, John E.] Virginia Commonwealth Univ, Sch Med, Dept Med, Richmond, VA 23284 USA.
[Giudice, Linda C.] NICHHD, Reprod Sci Branch, Bethesda, MD 20892 USA.
[Giudice, Linda C.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
RP Pagidas, K (reprint author), Brown Univ, Women & Infants Hosp, Warren Alpert Med Sch, Obstet & Gynecol 101 Dudley St, Providence, RI 02905 USA.
EM kpagidas@wihri.org
OI Diamond, Michael/0000-0001-6353-4489
FU National Institutes of Health/National Institute of Child Health and
Human Development [U10 HD27049, U01 HD38997, U10 HD39005, U10 HD27011,
U10 HD33172, U10 HD38988, U10 HD38992, U10 HD38998, U10 HD38999,
U54-HD29834]; General Clinical Research Center (GCRC) [MO1RR00056, MO1
RR 10732, C06 RR016499]
FX Supported by National Institutes of Health/National Institute of Child
Health and Human Development grant nos. U10 HD27049 (to C.C.), U01
HD38997 (to E. R. M.), U10 HD39005 (to M. P. D.), U10 HD27011 (to
S.A.C.), U10 HD33172 (to M.P.S.), U10 HD38988 (to B.R.C.), U10 HD38992
(to R.S.L.), U10 HD38998 (to W.D.S.), U10 HD38999 (to P.G.M.), and
U54-HD29834 to the University of Virginia Center for Research in
Reproduction Ligand Assay and Analysis Core; General Clinical Research
Center (GCRC) grant no. MO1RR00056 to the University of Pittsburgh; and
General Clinical Research Center (GCRC) grant no. MO1 RR 10732 and
construction grant no. C06 RR016499 to Pennsylvania State University.
NR 5
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
BP 1447
EP 1450
DI 10.1016/j.fertnstert.2009.05.048
PG 4
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 648FA
UT WOS:000281674600047
PM 19540480
ER
PT J
AU Alford, CE
Widra, EA
Levy, MJ
Segars, JH
Richter, KS
AF Alford, C. E.
Widra, E. A.
Levy, M. J.
Segars, J. H.
Richter, K. S.
TI DOES OBESITY CAUSE ABNORMAL ENDOMETRIAL DEVELOPMENT?
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 NICHHD, Program Reprod & Adult Endocrinol, Bethesda, MD 20892 USA.
Shady Grove Fertil Reprod Sci Ctr, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S190
EP S190
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000649
ER
PT J
AU Alford, CE
DeCherney, AH
Armstrong, AY
AF Alford, C. E.
DeCherney, A. H.
Armstrong, A. Y.
TI ALL PATIENTS SEEKING INFERTILITY SERVICES SHOULD BE IMMUNIZED AGAINST
H1N1: ESTIMATION OF THE IMPACT OF H1N1 IMMUNIZATION ON MATERNAL
MORBIDITY AND MORTALITY IN INFERTILITY PATIENTS.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 [Alford, C. E.; DeCherney, A. H.; Armstrong, A. Y.] NICHHD, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S227
EP S227
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000778
ER
PT J
AU Alford, CE
Csokmay, JM
Segars, JH
Armstrong, AY
AF Alford, C. E.
Csokmay, J. M.
Segars, J. H.
Armstrong, A. Y.
TI COSTANALYSIS OF IN VITRO FERTILIZATION (IVF) VERSUS BILATERAL TUBAL
REANASTOMOSIS (BTA) TO ACHIEVE A LIVE BIRTH.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 [Alford, C. E.; Csokmay, J. M.; Segars, J. H.; Armstrong, A. Y.] NICHHD, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD 20892 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S34
EP S34
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000114
ER
PT J
AU Banks, NK
Norian, JM
DeCherney, AH
Henne, MB
AF Banks, N. K.
Norian, J. M.
DeCherney, A. H.
Henne, M. B.
TI INSURANCE MANDATES AND ASSISTED REPRODUCTIVE TECHNOLOGY (ART): HOW WERE
TREATMENTS AND OUTCOMES IMPACTED BY IMPLEMENTATION OF A MANDATE IN NEW
JERSEY?
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Georgetown Univ Hosp, Dept Obstet & Gynecol, Washington, DC 20007 USA.
Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Reprod Biol & Med Branch, Bethesda, MD USA.
Walter Reed Army Med Ctr, Assisted Reprod Technol Program, Washington, DC 20307 USA.
Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S167
EP S167
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000568
ER
PT J
AU Catherino, WH
Malik, M
Britten, J
Gilden, M
Segars, J
McCarthy-Keith, D
AF Catherino, W. H.
Malik, M.
Britten, J.
Gilden, M.
Segars, J.
McCarthy-Keith, D.
TI LEIOMYOMA FIBROSIS INHIBITED BY LIAROZOLE, A RETINOIC ACID METABOLIC
BLOCKING AGENT.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD USA.
Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S32
EP S33
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000109
ER
PT J
AU Chason, RJ
Richter, KS
Widra, EA
Segars, JH
AF Chason, R. J.
Richter, K. S.
Widra, E. A.
Segars, J. H.
TI A DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME (PCOS) IS ASSOCIATED WITH AN
INCREASED LIKELIHOOD OF PREGNANCY LOSS WITH ASSISTED REPRODUCTION.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.
Shady Grove Fertil Reprod Sci Ctr, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S25
EP S25
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000083
ER
PT J
AU Kearns, WG
Benner, A
Nguyen, KHD
Chipko, C
Widra, E
Leach, R
AF Kearns, W. G.
Benner, A.
Nguyen, K. -H. D.
Chipko, C.
Widra, E.
Leach, R.
TI VALIDATION OF SINGLE NUCLEOTIDE POLYMORPHISM (SNP) MICROARRAY PGD ON
SINGLE CELL(S) FROM EMBRYOS.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Shady Grove Ctr Preimplantat Genet, Rockville, MD USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
NHGRI, NIH, Bethesda, MD 20892 USA.
Shady Grove Fertil Reprod Sci Ctr, Rockville, MD USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S124
EP S124
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000420
ER
PT J
AU Khachikyan, I
Sinaii, N
Shah, J
Ortiz, R
Segars, J
Stratton, P
AF Khachikyan, I.
Sinaii, N.
Shah, J.
Ortiz, R.
Segars, J.
Stratton, P.
TI CNS SENSITIZATION AND MYOFASCIAL DYSFUNCTION IN PATIENTS WITH
ENDOMETRIOSIS AND CHRONIC PELVIC PAIN.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 NICHD, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.
NIH, Biostatist & Clin Epidemiol Serv, CC, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S40
EP S40
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000135
ER
PT J
AU Louis, GMB
Kim, S
Chen, Z
Sweeney, AM
Barr, D
Schrader, SM
AF Louis, G. M. Buck
Kim, S.
Chen, Z.
Sweeney, A. M.
Barr, D.
Schrader, S. M.
TI POLYCHLORINATED BIPHENYLS AND SEMEN QUALITY - LIFE STUDY.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, Rockville, MD USA.
Texas A&M Rural Sch Publ Hlth, College Stn, TX USA.
Emory Univ, Atlanta, GA 30322 USA.
NIOSH, CDC, Cincinnati, OH 45226 USA.
RI Schrader, Steven/E-8120-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S73
EP S74
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000251
ER
PT J
AU Louis, GMB
Schisterman, EF
Sweeney, AM
Gore-Langton, R
Lynch, CD
Sundaram, R
AF Louis, G. M. Buck
Schisterman, E. F.
Sweeney, A. M.
Gore-Langton, R.
Lynch, C. D.
Sundaram, R.
TI PRECONCEPTION RECRUITMENT OF COUPLES DESIRING PREGNANCY - CASE FOR THE
EXPOSOME.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, Rockville, MD USA.
Texas A&M Rural Sch Publ Hlth, College Stn, TX USA.
EMMES Corp, Rockville, MD USA.
Ohio State Coll Publ Hlth, Columbus, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S229
EP S229
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000785
ER
PT J
AU Maguire, M
Csokmay, J
Hill, M
Segars, J
Armstrong, A
AF Maguire, M.
Csokmay, J.
Hill, M.
Segars, J.
Armstrong, A.
TI OBESITY IS ASSOCIATED WITH LOWER LIVE BIRTH RATES IN FRESH, BUT NOT
FROZEN EMBRYO TRANSFER CYCLES.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
Walter Reed Army Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Washington, DC 20307 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S18
EP S19
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000063
ER
PT J
AU Maguire, MF
Sullivan, SD
Vanderhoof, V
Troendle, J
DeCherney, A
Nelson, L
AF Maguire, M. F.
Sullivan, S. D.
Vanderhoof, V.
Troendle, J.
DeCherney, A.
Nelson, L.
TI PREGNANCY OUTCOME IN WOMEN WITH SPONTANEOUS 46,XX PRIMARY OVARIAN
INSUFFICIENCY.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 [Maguire, M. F.; Sullivan, S. D.; Vanderhoof, V.; Troendle, J.; DeCherney, A.; Nelson, L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S178
EP S178
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000608
ER
PT J
AU Martinez, AM
Chason, RJ
DeCherney, AH
Venkatesan, AM
Elkas, J
Armstrong, A
AF Martinez, A. M.
Chason, R. J.
DeCherney, A. H.
Venkatesan, A. M.
Elkas, J.
Armstrong, A.
TI MEDICAL TREATMENT OF BENIGN METASTASIZING LEIOMYOMA: A CASE SERIES.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 St Barnabas Hosp, Dept Obstet & Gynecol, Livingston, NJ USA.
Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.
No Virginia Pelv Surg Associates, Annandale, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S220
EP S220
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000755
ER
PT J
AU McCarthy-Keith, DM
Britten, J
Malik, M
Segars, JH
Catherino, WH
AF McCarthy-Keith, D. M.
Britten, J.
Malik, M.
Segars, J. H.
Catherino, W. H.
TI AN ENHANCED LEIOMYOMA CELL RESPONSE TO OSMOTIC STRESS IS CENTRAL TO THE
MECHANISM OF GONADOTROPIN RELEASING HORMONE ANALOGUE TREATMENT.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Program Reprod & Adult Endocrinol, Bethesda, MD USA.
Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S75
EP S75
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000257
ER
PT J
AU Moon, KS
Csokmay, JM
Armstrong, AY
Segars, JH
Stegmann, BJ
AF Moon, K. S.
Csokmay, J. M.
Armstrong, A. Y.
Segars, J. H.
Stegmann, B. J.
TI ELEVATED ESTRADIOL LEVELS IN AFRICAN-AMERICAN WOMEN MAY EXPLAIN THE
REDUCED LIVE BIRTH RATES FOLLOWING ASSISTED REPRODUCTION.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the American-Society-for-Reproductive-Medicine
(ASRM 2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproduct Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, Bethesda, MD USA.
Univ Iowa, Hosp & Clin, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Iowa City, IA USA.
Walter Reed Army Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Washington, DC 20307 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S242
EP S242
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000830
ER
PT J
AU Moon, KS
Stegmann, BJ
Yauger, BJ
Segars, JH
AF Moon, K. S.
Stegmann, B. J.
Yauger, B. J.
Segars, J. H.
TI ARE THERE PROVIDER-DEPENDENT DIFFERENCES IN THE LEARNING CURVE FOR
PROFICIENCY WITH OOCYTE RETRIEVALS?
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the American-Society-for-Reproductive-Medicine
(ASRM 2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproduct Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, Bethesda, MD USA.
Univ Iowa, Hosp & Clin, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Iowa City, IA USA.
Walter Reed Army Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Washington, DC 20307 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S242
EP S243
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000832
ER
PT J
AU Moon, KS
Zhou, Y
Mumford, S
Segars, JH
Armstrong, AY
AF Moon, K. S.
Zhou, Y.
Mumford, S.
Segars, J. H.
Armstrong, A. Y.
TI SERUM ANTI-MULLERIAN HORMONE LEVELS DO NOT CORRELATE WITH
CYCLOPHOSPHAMIDE-INDUCED PRIMORDIAL FOLLICULAR DESTRUCTION IN MICE
PRETREATED WITH CETRORELIX.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, Bethesda, MD USA.
Walter Reed Army Med Ctr, Dept Clin Invest, Washington, DC 20307 USA.
Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S104
EP S105
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000354
ER
PT J
AU Muneyyirci-Delale, O
Sinaii, N
Charles, C
Dalloul, M
Osei-Tutu, N
Stratton, P
AF Muneyyirci-Delale, O.
Sinaii, N.
Charles, C.
Dalloul, M.
Osei-Tutu, N.
Stratton, P.
TI PREVALENCE OF METABOLIC SYNDROME AND CHANGES IN LIPID PROFILE OF WOMEN
WITH ENDOMETRIOSIS DURING TREATMENT.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the American-Society-for-Reproductive-Medicine
(ASRM 2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproduct Med
C1 Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
Kings Cty Hosp Ctr, Brooklyn, NY USA.
NIH Clin Ctr, Biostat & Clin Epidemiol Serv, Bethesda, MD USA.
NICHD, Program Reprod & Adult Endocrinol, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S206
EP S206
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000705
ER
PT J
AU Muneyyirci-Delale, O
Sinaii, N
Charles, C
Dalloul, M
Osei-Tutu, N
Stratton, P
AF Muneyyirci-Delale, O.
Sinaii, N.
Charles, C.
Dalloul, M.
Osei-Tutu, N.
Stratton, P.
TI CHANGES IN QUALITY OF LIFE (QOL)IN WOMEN WITH SYMPTOMATIC ENDOMETRIOSIS
BY PAIN TYPE DURING TREATMENT.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the American-Society-for-Reproductive-Medicine
(ASRM 2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproduct Med
C1 Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
Kings Cty Hosp Ctr, Brooklyn, NY USA.
NIH Clin Ctr, Bethesda, MD USA.
NICHD, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S206
EP S206
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000703
ER
PT J
AU Nguyen, KHD
Ross, R
Benner, A
Zhao, Y
Brezina, P
Kearns, WG
AF Nguyen, D. K. -H
Ross, R.
Benner, A.
Zhao, Y.
Brezina, P.
Kearns, W. G.
TI SINGLE NUCLEOTIDE POLYMORPHISM (SNP) MICROARRAY PREIMPLANTATION GENETIC
SCREENING (PGS): A COMPARISON BETWEEN ABNORMAL DAY-3 BLASTOMERES AND
CORRESPONDING INNER CELL MASS AND TROPHECTODERM CELLS.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 NHGRI, NIH, Bethesda, MD 20892 USA.
La Jolla IVF, La Jolla, CA USA.
Shady Grove Ctr Preimplantat Genet, Rockville, MD USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S80
EP S80
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000274
ER
PT J
AU Owen, CM
Norian, JM
Guo, XC
Malik, M
Catherino, WH
Segars, JH
AF Owen, C. M.
Norian, J. M.
Guo, X. C.
Malik, M.
Catherino, W. H.
Segars, J. H.
TI LEIOMYOMA CELLS SHOW ATTENUATED MECHANOSENSING, BUT AN INCREASED
DEPENDENCE ON RHO-GEF ACTIVATION COMPARED TO MYOMETRIAL CELLS.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Program Reprod & Adult Endocrinol, Bethesda, MD USA.
Uniformed Serv Univ Hlth Sci, Bethesda, MD USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S76
EP S76
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000261
ER
PT J
AU Pulanic, TK
Venkatesan, A
Segars, J
Partanen, A
Merino, M
Stratton, P
AF Pulanic, T. Klepac
Venkatesan, A.
Segars, J.
Partanen, A.
Merino, M.
Stratton, P.
TI PILOT STUDY OF MR-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND (MRGHIFU)
ABLATION OF UTERINE FIBROIDS.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 NICHD, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.
NIH, Dept Radiol & Imaging Serv, CC, Bethesda, MD 20892 USA.
Philips Healthcare, Cleveland, OH USA.
NCI, Pathol Lab, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S222
EP S222
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000760
ER
PT J
AU Schlaff, WD
Legro, RS
Diamond, MP
Coutifaris, C
Zhang, H
AF Schlaff, W. D.
Legro, R. S.
Diamond, M. P.
Coutifaris, C.
Zhang, H.
TI OVULATION INDUCTION WITH CLOMIPHENE, METFORMIN, OR A COMBINATION OF THE
TWO DOES NOT AFFECT HIRSUTISM SCORE OVER A STANDARD COURSE OF TREATMENT
IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Univ Colorado, Reprod Med Network, Aurora, CO USA.
Penn State Univ, Hershey, PA USA.
Wayne State Univ, Detroit, MI USA.
Univ Penn, Philadelphia, PA 19104 USA.
Yale Univ, New Haven, CT USA.
NICHD, Data Coordinating Ctr, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S192
EP S193
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000657
ER
PT J
AU Schlaff, WD
Legro, RS
Diamond, MP
Coutifaris, C
Zhang, H
AF Schlaff, W. D.
Legro, R. S.
Diamond, M. P.
Coutifaris, C.
Zhang, H.
TI IMPACT OF THE INSTITUTIONAL RESEARCH REVIEW PROCESS ON INITIATING A
CLINICAL STUDY: THE REPRODUCTIVE MEDICINE NETWORK (RMN) EXPERIENCE WITH
PREGNANCY IN POLYCYSTIC OVARY SYNDROME I AND II
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Univ Colorado, Dept Obstet & Gynecol, Reprod Med Network, Aurora, CO USA.
Penn State Univ, Dept Obstet & Gynecol, Hershey, PA USA.
Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA.
Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA.
Yale Univ, New Haven, CT USA.
NICHD, Data Coordinating Ctr, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S196
EP S197
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000671
ER
PT J
AU Smith, KM
Alnifaidy, R
Wei, Q
Neiman, L
AF Smith, K. M.
Alnifaidy, R.
Wei, Q.
Neiman, L.
TI ENDOMETRIAL INDIAN HEDGEHOG EXPRESSION IS DECREASED IN WOMEN WITH
ENDOMETRIOSIS
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 [Smith, K. M.; Alnifaidy, R.; Wei, Q.; Neiman, L.] NICHHD, Program Reprod & Adult Endocrinol, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S200
EP S200
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000682
ER
PT J
AU Steiner, AZ
Herring, AH
Hoberman, S
Stanczyk, FZ
Baird, DD
AF Steiner, A. Z.
Herring, A. H.
Hoberman, S.
Stanczyk, F. Z.
Baird, D. D.
TI SERUM MARKERS OF OVARIAN AGING ARE ASSOCIATED WITH NATURAL FERTILITY.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Univ N Carolina, Chapel Hill, NC USA.
Univ So Calif, Los Angeles, CA USA.
NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S98
EP S99
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000334
ER
PT J
AU Steiner, AZ
Herring, A
Kesner, J
Meadows, JW
Hoberman, S
Baird, DD
AF Steiner, A. Z.
Herring, A.
Kesner, J.
Meadows, J. W.
Hoberman, S.
Baird, D. D.
TI URINARY MARKERS OF OVARIAN AGING AND PREDICTING NATURAL FERTILITY.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Univ N Carolina, Chapel Hill, NC USA.
NIOSH, Cincinnati, OH 45226 USA.
NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S45
EP S45
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000154
ER
PT J
AU Wolff, EF
Csokmay, J
Segars, JH
Richter, KS
Widra, EA
AF Wolff, E. F.
Csokmay, J.
Segars, J. H.
Richter, K. S.
Widra, E. A.
TI ASSOCIATION BETWEEN ETHNICITY AND PEAK ENDOMETRIAL THICKNESS IN
INTRAUTERINE INSEMINATION CYCLES.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the American-Society-for-Reproductive-Medicine
(ASRM 2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproduct Med
C1 NICHD, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.
Shady Grove Fertil Reprod Sci Ctr, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S209
EP S209
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000714
ER
PT J
AU Wolff, EF
Segars, JH
Richter, KS
Widra, EA
AF Wolff, E. F.
Segars, J. H.
Richter, K. S.
Widra, E. A.
TI DEFINING "ENDOMETRIAL FACTOR'' INFERTILITY: PREGNANCY RATES FOLLOWING
2,090 INTRAUTERINE INSEMINATION CYCLES CORRELATE WITH ENDOMETRIAL
THICKNESS.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the American-Society-for-Reproductive-Medicine
(ASRM 2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproduct Med
C1 NICHD, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.
Shady Grove Fertil Reprod Sci Ctr, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S209
EP S209
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000715
ER
PT J
AU Yu, B
Sullivan, S
Vanderhoof, VH
Segars, JH
DeCherney, A
Nelson, LM
AF Yu, B.
Sullivan, S.
Vanderhoof, V. H.
Segars, J. H.
DeCherney, A.
Nelson, L. M.
TI MEAN SERUM FREE TESTOSTERONE AND ESTRADIOL LEVELS IN WOMEN WITH
SPONTANEOUS 46, XX PRIMARY OVARIAN INSUFFICIENCY REMAIN RELATIVELY
STABLE AS THE TIME SINCE ONSET OF MENSTRUAL IRREGULARITY LENGTHENS.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 [Yu, B.; Sullivan, S.; Vanderhoof, V. H.; Segars, J. H.; DeCherney, A.; Nelson, L. M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Adult & Reprod Endocrinol, NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S181
EP S182
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000620
ER
PT J
AU Yu, B
Chipko, C
Richter, KS
Widra, EA
DeCherney, A
Kearns, WG
AF Yu, B.
Chipko, C.
Richter, K. S.
Widra, E. A.
DeCherney, A.
Kearns, W. G.
TI IMPROVEMENT IN DIAGNOSTIC ACCURACY USING SINGLE NUCLEOTIDE POLYMORPHISM
(SNP) MICROARRAYS VERSUS FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN
PREIMPLANTATION GENETIC SCREENING (PGS) FOR ANEUPLOIDY.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.
Shady Grove Ctr Preimplantat Genet, Rockville, MD USA.
Shady Grove Fertil Reprod Sci Ctr, Rockville, MD USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S126
EP S126
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000426
ER
PT J
AU Yu, B
Richter, KS
Widra, EA
DeCherney, A
Segars, JH
AF Yu, B.
Richter, K. S.
Widra, E. A.
DeCherney, A.
Segars, J. H.
TI THE INCIDENCE OF GENUINE EMPTY FOLLICLE SYNDROME.
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Reproductive-Medicine (ASRM
2010)
CY OCT 23-27, 2010
CL Denver, CO
SP Amer Soc Reproductive Med
C1 Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Adult & Reprod Endocrinol, NIH, Bethesda, MD USA.
Shady Grove Fertil Reprod Sci Ctr, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2010
VL 94
IS 4
SU 1
BP S95
EP S95
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 645GR
UT WOS:000281441000324
ER
PT J
AU Wang, ST
Zderic, V
Frenkel, V
AF Wang, Shutao
Zderic, Vesna
Frenkel, Victor
TI Extracorporeal, low-energy focused ultrasound for noninvasive and
nondestructive targeted hyperthermia
SO FUTURE ONCOLOGY
LA English
DT Review
DE computer simulation; focused ultrasound; heat-sensitive liposome; heat
shock protein promoter; hyperthermia tissue; mimicking phantom
ID TEMPERATURE-SENSITIVE LIPOSOMES; TISSUE-MIMICKING MATERIAL;
GENE-EXPRESSION; DRUG-DELIVERY; IN-VIVO; LOCAL HYPERTHERMIA; THERMAL
THERAPY; SPATIOTEMPORAL CONTROL; TEMPORAL CONTROL; CONTRAST AGENT
AB The benefits of hyperthermia are well known as both a primary treatment modality and adjuvant therapy for treating cancer. Among the different techniques available, high-intensity focused ultrasound is the only noninvasive modality that can provide local hyperthermia precisely at a targeted location at any depth inside the body using image guidance, Traditionally, focused ultrasound exposures have been provided at high rates of energy deposition for thermal ablation of benign and malignant tumors. At present, exposures are being evaluated in pulsed mode, which lower the rates of energy deposition and generate primarily mechanical effects for enhancing tissue permeability to improve local drug delivery. These pulsed exposures can be modified for low-level hyperthermia as an adjuvant therapy for drug and gene delivery applications, as well as for more traditional applications such as radiosensitization. In this review, we discuss the manner by which focused ultrasound exposures at low rates of energy deposition are being developed for a variety of clinically translatable applications for the treatment of cancer. Specific preclinical studies will be highlighted. Additional information will also be provided for optimizing these exposures, including computer modeling and simulations. Various techniques for monitoring temperature elevations generated by focused ultrasound will also be reviewed.
C1 [Wang, Shutao; Frenkel, Victor] NIH, Dept Radiol & Imaging Sci, Ctr Clin, Bethesda, MD 20892 USA.
[Wang, Shutao; Zderic, Vesna] George Washington Univ, Dept Elect & Comp Engn, Washington, DC USA.
RP Frenkel, V (reprint author), NIH, Dept Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
NR 96
TC 11
Z9 11
U1 3
U2 11
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1479-6694
J9 FUTURE ONCOL
JI Future Oncol.
PD SEP
PY 2010
VL 6
IS 9
BP 1497
EP 1511
DI 10.2217/FON.10.101
PG 15
WC Oncology
SC Oncology
GA 666JG
UT WOS:000283110400016
PM 20919832
ER
PT J
AU Noureddin, M
Ghany, MG
AF Noureddin, Mazen
Ghany, Marc G.
TI Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin:
Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis
C
SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Pharmacokinetics; Pharmacodynamics; Peginterferon alfa-2a; Peginterferon
alfa-2b; Ribavirin; Chronic hepatitis C
ID ALPHA-2B PLUS RIBAVIRIN; PEGYLATED INTERFERON-ALPHA-2B;
RANDOMIZED-TRIAL; VIROLOGICAL RESPONSE; TREATMENT DURATION; INITIAL
TREATMENT; VIRUS-INFECTION; VIRAL DYNAMICS; NAIVE PATIENTS; PEG-IFN
AB The pharmacokinetics and pharmacodynamics of standard interferon alfa-2a and interferon alfa-2b are substantially altered by pegylation The size geometry and site of attachment of the PEG moiety affect the pharmacokinetics and pharmacodynamics as evidenced by the different absorption volume of distribution, and clearance of the linear 12-kDa peginterferon alfa-2b and the branched 40-kDa peginterferon alfa-2a Despite these differences the clinical efficacy safety and tolerability of the 2 peginterferons are similar However evidence exists that peginterferon alfa-2 plus ribavirin is associated with small but significantly higher sustained virological response rates compared with peginterferon alfa-2b This article discusses the pharmacokinetics and pharmacodynamics of the 2 peginterferons and their combination with ribavirin
C1 [Noureddin, Mazen; Ghany, Marc G.] NIDDKD, Liver Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Ghany, MG (reprint author), NIDDKD, Liver Dis Branch, NIH, Bldg 10,Room 9B 16,10 Ctr Dr,MSC 1800, Bethesda, MD 20892 USA.
FU National Institute of Diabetes and Digestive and Kidney Diseases;
National Institutes of Health Liver Diseases Branch National Institute
of Diabetes and Digestive and Kidney Diseases National Institutes of
Health
FX This work was supported by the intramural program of the National
Institute of Diabetes and Digestive and Kidney Diseases National
Institutes of Health Liver Diseases Branch National Institute of
Diabetes and Digestive and Kidney Diseases National Institutes of Health
Building 10 Room 9B 16 10 Center Drive MSC 1800 Bethesda MD 20892 1800
USA
NR 33
TC 4
Z9 6
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8553
J9 GASTROENTEROL CLIN N
JI Gastroenterol. Clin. North Am.
PD SEP
PY 2010
VL 39
IS 3
BP 649
EP +
DI 10.1016/j.gtc.2010.08.008
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 681DP
UT WOS:000284291900015
PM 20951922
ER
PT J
AU Vohanka, J
Simeckova, K
Machalova, E
Behensky, F
Krause, MW
Kostrouch, Z
Kostrouchova, M
AF Vohanka, Jaroslav
Simeckova, Katerina
Machalova, Eliska
Behensky, Frantisek
Krause, Michael W.
Kostrouch, Zdenek
Kostrouchova, Marta
TI Diversification of fasting regulated transcription in a cluster of
duplicated nuclear hormone receptors in C. elegans
SO GENE EXPRESSION PATTERNS
LA English
DT Article
DE Caenorhabditis elegans; Caenorhabditis briggsae; Nuclear hormone
receptor; Gene expression; Fasting
ID EARLY LARVAL DEVELOPMENT; CAENORHABDITIS-ELEGANS; NEMATODES;
SUPERFAMILY; NHR-40
AB The genome of Caenorhabditis elegans encodes more than 280 nuclear hormone receptors (NHRs) in contrast to the 48 NHRs in humans and 18 NHRs in Drosophila. The majority of the C. elegans NHRs are categorized as supplementary nuclear receptors (supnrs) that evolved by successive duplications of a single ancestral gene. The evolutionary pressures that lead to the expansion of NHRs in nematodes, as well as the function of the majority of supnrs, are not known. Here, we have studied the expression of seven genes organized in a cluster on chromosome V: nhr-206, nhr-208, nhr-207, nhr-209, nhr-154, nhr-153 and nhr-136. Reverse transcription-quantitative PCR and analyses using transgenic lines carrying GFP fusion genes with their putative promoters revealed that all seven genes of this cluster are expressed and five have partially overlapping expression patterns including in the pharynx, intestine, certain neurons, the anal sphincter muscle, and male specific cells. Four genes in this cluster are conserved between C. elegans and Caenorhabditis briggsae whereas three genes are present only in C elegans, the apparent result of a relatively recent expansion. Interestingly, we find that a subset of the conserved and non-conserved genes in this cluster respond transcriptionally to fasting in tissue-specific patterns. Our results reveal the diversification of the temporal, spatial, and metabolic gene expression patterns coupled with evolutionary drift within supnr family members. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Vohanka, Jaroslav; Simeckova, Katerina; Machalova, Eliska; Behensky, Frantisek; Kostrouchova, Marta] Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Lab Mol Biol & Genet, CZ-12801 Prague 2, Czech Republic.
[Kostrouch, Zdenek] Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Lab Mol Pathol, CZ-12801 Prague, Czech Republic.
[Krause, Michael W.] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Kostrouchova, M (reprint author), Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Lab Mol Biol & Genet, Ke Karlovu 2, CZ-12801 Prague 2, Czech Republic.
EM marta.kostrouchova@lf1.cuni.cz
OI Krause, Michael/0000-0001-6127-3940
FU Czech Science Foundation [304/08/0970, 304/07/0529]; Ministry of
Education, Youth and Sports of the Czech Republic [0021620806]; National
Institutes of Health, USA
FX We thank Dr. A. Fire for vectors pPD95.67, L4440 and HT115 cells host.
The work was supported by Grant 304/08/0970, Grant 304/07/0529 from the
Czech Science Foundation and by Grant 0021620806 from the Ministry of
Education, Youth and Sports of the Czech Republic. M.W.K. was supported
by the Intramural Research Program of the National Institutes of Health,
USA.
NR 26
TC 5
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-133X
J9 GENE EXPR PATTERNS
JI Gene Expr. Patterns
PD SEP
PY 2010
VL 10
IS 6
BP 227
EP 236
DI 10.1016/j.gep.2010.05.001
PG 10
WC Developmental Biology; Genetics & Heredity
SC Developmental Biology; Genetics & Heredity
GA 638RT
UT WOS:000280914300001
PM 20460175
ER
PT J
AU Shi, Q
Nguyen, AT
Angell, Y
Deng, D
Na, CR
Burgess, K
Roberts, DD
Brunicardi, FC
Templeton, NS
AF Shi, Q.
Nguyen, A. T.
Angell, Y.
Deng, D.
Na, C-R
Burgess, K.
Roberts, D. D.
Brunicardi, F. C.
Templeton, N. S.
TI A combinatorial approach for targeted delivery using small molecules and
reversible masking to bypass nonspecific uptake in vivo
SO GENE THERAPY
LA English
DT Article
DE non-viral delivery; liposomes; targeted delivery; tumor vascular
microenvironment; anticancer therapeutics; reversible masking
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TUMOR ENDOTHELIAL MARKERS;
ANTI-ANGIOGENIC THERAPIES; GROWTH-FACTOR VEGF; BETA-TURN MIMICS;
GENE-THERAPY; SYSTEMIC DELIVERY; ANTITUMOR-ACTIVITY; ENVELOPE PROTEIN;
CELLS
AB We have developed a multi-disciplinary approach combining molecular biology, delivery technology, combinatorial chemistry and reversible masking to create improved systemic, targeted delivery of plasmid DNA while avoiding nonspecific uptake in vivo. We initially used a well-characterized model targeting the asialolglycoprotein receptor in the liver. Using our bilamellar invaginated vesicle (BIV) liposomal delivery system with reversible masking, we increased expression in the liver by 76-fold, nearly equaling expression in first-pass organs using non-targeted complexes, with no expression in other organs. The same technology was then applied to efficiently target delivery to a human tumor microenvironment model. We achieved efficient, targeted delivery by attachment of specific targeting ligands to the surface of our BIV complexes in conjunction with reversible masking to bypass nonspecific tissues and organs. We identified ligands that target a human tumor microenvironment created in vitro by co-culturing primary human endothelial cells with human lung or pancreatic cancer cells. The model was confirmed by increased expression of tumor endothelial phenotypes including CD31 and vascular endothelial growth factor-A, and prolonged survival of endothelial capillary-like structures. The co-cultures were used for high-throughput screening of a specialized small molecule library to identify ligands specific for human tumor-associated endothelial cells in vitro. We identified small molecules that enhanced the transfection efficiency of tumor-associated endothelial cells, but not normal human endothelial cells or cancer cells. Intravenous (i.v.) injection of our targeted, reversibly masked complexes into mice, bearing human pancreatic tumor and endothelial cells, specifically increased transfection to this tumor microenvironment approximately 200-fold. Efficacy studies using our optimized targeted delivery of a plasmid encoding thrombospondin-1 eliminated tumors completely after five i.v. injections administered once every week. Gene Therapy (2010) 17, 1085-1097; doi:10.1038/gt.2010.55; published online 13 May 2010
C1 [Shi, Q.; Templeton, N. S.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.
[Nguyen, A. T.; Deng, D.; Na, C-R; Brunicardi, F. C.; Templeton, N. S.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA.
[Angell, Y.; Burgess, K.] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
[Roberts, D. D.] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Templeton, NS (reprint author), Gradalis Inc, Delivery Syst, 2545 Golden Bear Dr,Suite 110, Carrollton, TX 75006 USA.
EM ntempleton@gradalisinc.com
RI Roberts, David/A-9699-2008; Burgess, Kevin/B-5372-2015
OI Roberts, David/0000-0002-2481-2981; Burgess, Kevin/0000-0001-6597-1842
FU GeneExcel, Inc. (now part of Gradalis, Inc.); National Institutes of
Health [MH070040, GM076261]; NIH, NCI, Center for Cancer Research;
Robert A Welch Foundation
FX We thank GeneExcel, Inc. (now part of Gradalis, Inc.), the National
Institutes of Health (MH070040, GM076261), the Intramural Research
Program of the NIH, NCI, Center for Cancer Research, and the Robert A
Welch Foundation for the financial support of this project.
NR 68
TC 11
Z9 11
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THER
JI Gene Ther.
PD SEP
PY 2010
VL 17
IS 9
BP 1085
EP 1097
DI 10.1038/gt.2010.55
PG 13
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Research & Experimental Medicine
GA 649HC
UT WOS:000281757900003
PM 20463761
ER
PT J
AU Das, B
Matsuda, H
Fujimoto, K
Sun, GH
Matsuura, K
Shi, YB
AF Das, Biswajit
Matsuda, Hiroki
Fujimoto, Kenta
Sun, Guihong
Matsuura, Kazuo
Shi, Yun-Bo
TI Molecular and genetic studies suggest that thyroid hormone receptor is
both necessary and sufficient to mediate the developmental effects of
thyroid hormone
SO GENERAL AND COMPARATIVE ENDOCRINOLOGY
LA English
DT Article; Proceedings Paper
CT 6th International Symposium on Amphibian and Reptilian Endocrinology and
Neurobiology
CY 2009
CL Leibniz-Inst Freshwater Ecol & Inland Fisheries, Berlin, GERMANY
HO Leibniz-Inst Freshwater Ecol & Inland Fisheries
DE Thyroid hormone receptor; Chromatin; Histone acetylation; Postembryonic
development; Metamorphosis; Xenopus laevis; Xenopus tropicalis
ID RETINOIC ACID RECEPTORS; XENOPUS-LAEVIS; AMPHIBIAN METAMORPHOSIS;
NUCLEAR RECEPTOR; BETA GENE; POSTEMBRYONIC DEVELOPMENT; COREPRESSOR
COMPLEXES; EMBRYONIC-DEVELOPMENT; FROG METAMORPHOSIS; NONGENOMIC ACTIONS
AB Thyroid hormone (TH) affects diverse biological processes and can exert its effects through both gene regulation via binding the nuclear TH receptors (TRs) and non-genomic actions via binding to cell surface and cytoplasmic proteins. The critical importance of TH in vertebrate development has long been established, ranging from the formation of human cretins to the blockage of frog metamorphosis due the TH deficiency. How TH affects vertebrate development has been difficult to study in mammals due to the complications associated with the uterus-enclosed mammalian embryos. Anuran metamorphosis offers a unique opportunity to address such an issue. Using Xenopus as a model, we and others have shown that the expression of TRs and their heterodimerization partners RXRs (9-cis retinoic acid receptors) correlates temporally with metamorphosis in different organs in two highly related species, Xenopus laevis and Xenopus tropicalis. In vivo molecular studies have shown that TR and RXR are bound to the TH response elements (TREs) located in TH-inducible genes in developing tadpoles of both species. More importantly, transgenic studies in X. laevis have demonstrated that TR function is both necessary and sufficient for mediating the metamorphic effects of TH. Thus, the non-genomic effects of TH have little or no roles during metamorphosis and likely during vertebrate development in general. Published by Elsevier Inc.
C1 [Das, Biswajit; Matsuda, Hiroki; Fujimoto, Kenta; Sun, Guihong; Matsuura, Kazuo; Shi, Yun-Bo] NICHD, Lab Gene Regulat & Dev, Program Cellular Regulat & Metab, NIH, Bethesda, MD 20892 USA.
RP Shi, YB (reprint author), NICHD, Lab Gene Regulat & Dev, Program Cellular Regulat & Metab, NIH, Bldg 18T,Rm 106, Bethesda, MD 20892 USA.
EM shi@helix.nih.gov
FU Intramural NIH HHS [Z01 HD001901-13]
NR 81
TC 16
Z9 21
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0016-6480
J9 GEN COMP ENDOCR
JI Gen. Comp. Endocrinol.
PD SEP 1
PY 2010
VL 168
IS 2
SI SI
BP 174
EP 180
DI 10.1016/j.ygcen.2010.01.019
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 641AF
UT WOS:000281095000003
PM 20138179
ER
PT J
AU Heimeier, RA
Shi, YB
AF Heimeier, Rachel A.
Shi, Yun-Bo
TI Amphibian metamorphosis as a model for studying endocrine disruption on
vertebrate development: Effect of bisphenol A on thyroid hormone action
SO GENERAL AND COMPARATIVE ENDOCRINOLOGY
LA English
DT Article; Proceedings Paper
CT 6th International Symposium on Amphibian and Reptilian Endocrinology and
Neurobiology
CY 2009
CL Leibniz-Inst Freshwater Ecol & Inland Fisheries, Berlin, GERMANY
HO Leibniz-Inst Freshwater Ecol & Inland Fisheries
DE Thyroid hormone receptor; Bisphenol A; Endocrine disrupting compound;
Xenopus laevis; Metamorphosis
ID XENOPUS-LAEVIS METAMORPHOSIS; IODINE-DEFICIENCY DISORDER;
GENE-EXPRESSION INDICATORS; IN-VITRO; TRANSCRIPTIONAL REGULATION;
POSTEMBRYONIC DEVELOPMENT; ENVIRONMENTAL CHEMICALS; INTESTINAL
EPITHELIUM; RECEPTOR SUPERFAMILY; MOLECULAR-MECHANISMS
AB Thyroid hormone (TH) is essential for proper development in vertebrates. TH deficiency during gestation and early postnatal development produces severe neurological, skeletal, metabolism and growth abnormalities. It is therefore important to consider environmental chemicals that may interfere with TH signaling. Exposure to environmental contaminants that disrupt TH action may underlie the increasing incidence of human developmental disorders worldwide. One contaminant of concern is the xenoestrogen bisphenol A (BPA), a chemical widely used to manufacture polycarbonate plastics and epoxy resins. The difficulty in studying uterus-enclosed mammalian embryos has hampered the analysis on the direct effects of BPA during vertebrate development. As TH action at the cellular level is highly conserved across vertebrate species, amphibian metamorphosis serves as an important TH-dependent in vivo vertebrate model for studying potential contributions of BPA toward human developmental disorders. Using Xenopus laevis as a model, we and others have demonstrated the inhibitory effects of BPA exposure on metamorphosis. Genome-wide gene expression analysis revealed that surprisingly. BPA primarily targets the TH-signaling pathway essential for metamorphosis in Xenopus laevis. Given the importance of the genomic effects of TH during metamorphosis and the conservation in its regulation in higher vertebrates, these observations suggest that the effect of BPA in human embryogenesis is through the inhibition of the TH pathway and warrants further investigation. Our findings further argue for the critical need to use in vivo animal models coupled with systematic molecular analysis to determine the developmental effects of endocrine disrupting compounds. Published by Elsevier Inc.
C1 [Heimeier, Rachel A.] Karolinska Inst, Inst Environm Med IMM, S-17177 Stockholm, Sweden.
[Shi, Yun-Bo] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Mol Morphogenesis, Program Cell Regulat & Metab, NIH, Bethesda, MD 20892 USA.
RP Heimeier, RA (reprint author), Karolinska Inst, Inst Environm Med IMM, Nobels Vag 13, S-17177 Stockholm, Sweden.
EM rachel.heimeier@ki.se; shi@helix.nih.gov
FU Intramural NIH HHS
NR 115
TC 22
Z9 23
U1 2
U2 21
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0016-6480
J9 GEN COMP ENDOCR
JI Gen. Comp. Endocrinol.
PD SEP 1
PY 2010
VL 168
IS 2
SI SI
BP 181
EP 189
DI 10.1016/j.ygcen.2010.02.016
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 641AF
UT WOS:000281095000004
PM 20178801
ER
PT J
AU Chambers, DA
Wang, PS
Insel, TR
AF Chambers, David A.
Wang, Philip S.
Insel, Thomas R.
TI Maximizing efficiency and impact in effectiveness and services research
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Editorial Material
C1 [Chambers, David A.; Wang, Philip S.; Insel, Thomas R.] NIMH, Bethesda, MD 20892 USA.
RP Chambers, DA (reprint author), NIMH, Bethesda, MD 20892 USA.
EM dchamber@mail.nih.gov
NR 11
TC 8
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD SEP-OCT
PY 2010
VL 32
IS 5
BP 453
EP 455
DI 10.1016/j.genhosppsych.2010.07.011
PG 3
WC Psychiatry
SC Psychiatry
GA 657CT
UT WOS:000282390500001
PM 20851264
ER
PT J
AU Lagomasino, IT
Zatzick, DF
Chambers, DA
AF Lagomasino, Isabel T.
Zatzick, Douglas F.
Chambers, David A.
TI Efficiency in mental health practice and research
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article; Proceedings Paper
CT Conference on Improving the Efficiency of Research and Mental Health
Service Delivery
CY MAR 20, 2009
CL Natl Inst Mental Hlth, Bethesda, MD
HO Natl Inst Mental Hlth
DE Efficiency; Mental health; Health services research; Intervention
development; Implementation
ID CARE; ILLNESS; INJURY
AB Limited financial resources, escalating mental health-related costs and opportunities for capitalizing on advances in health information technologies have brought the theme of efficiency to the forefront of mental health services research and clinical practice. In this introductory article to the journal series stemming from the 20th NIMH Mental Health Services Research Conference, we first delineate the need for a new focus on efficiency in both research and clinical practice. Second, we provide preliminary definitions of efficiency for the field and discuss issues related to measurement. Finally, we explore the interface between efficiency in mental health services research and practice and the NIMH strategic objectives of developing improved interventions for diverse populations and enhancing the public health impact of research. Case examples illustrate how perspectives from dissemination and implementation research may be used to maximize efficiencies in the development and implementation of new service delivery models. Allowing findings from the dissemination and implementation field to permeate and inform clinical practice and research may facilitate more efficient development of interventions and enhance the public health impact of research. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Lagomasino, Isabel T.] Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.
[Zatzick, Douglas F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA.
[Chambers, David A.] NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA.
RP Lagomasino, IT (reprint author), Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.
EM lagomasi@usc.edu
FU NIMH NIH HHS [P30 MH082760-04, P30 MH082760, R01 MH067949, R01
MH067949-04]
NR 18
TC 10
Z9 10
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD SEP-OCT
PY 2010
VL 32
IS 5
BP 477
EP 483
DI 10.1016/j.genhosppsych.2010.06.005
PG 7
WC Psychiatry
SC Psychiatry
GA 657CT
UT WOS:000282390500004
PM 20851267
ER
PT J
AU Laurie, CC
Doheny, KF
Mirel, DB
Pugh, EW
Bierut, LJ
Bhangale, T
Boehm, F
Caporaso, NE
Cornelis, MC
Edenberg, HJ
Gabriel, SB
Harris, EL
Hu, FB
Jacobs, KB
Kraft, P
Landi, MT
Lumley, T
Manolio, TA
McHugh, C
Painter, I
Paschall, J
Rice, JP
Rice, KM
Zheng, XW
Weir, BS
AF Laurie, Cathy C.
Doheny, Kimberly F.
Mirel, Daniel B.
Pugh, Elizabeth W.
Bierut, Laura J.
Bhangale, Tushar
Boehm, Frederick
Caporaso, Neil E.
Cornelis, Marilyn C.
Edenberg, Howard J.
Gabriel, Stacy B.
Harris, Emily L.
Hu, Frank B.
Jacobs, Kevin B.
Kraft, Peter
Landi, Maria Teresa
Lumley, Thomas
Manolio, Teri A.
McHugh, Caitlin
Painter, Ian
Paschall, Justin
Rice, John P.
Rice, Kenneth M.
Zheng, Xiuwen
Weir, Bruce S.
CA GENEVA Investigators
TI Quality Control and Quality Assurance in Genotypic Data for Genome-Wide
Association Studies
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE GWAS; DNA sample quality; genotyping artifact; Hardy-Weinberg
equilibrium; chromosome aberration
ID DIFFERENTIAL BIAS; COLLABORATION; SUBSTRUCTURE; INFORMATION; GENE
AB Genome-wide scans of nucleotide variation in human subjects are providing an increasing number of replicated associations with complex disease traits. Most of the variants detected have small effects and, collectively, they account for a small fraction of the total genetic variance. Very large sample sizes are required to identify and validate findings. In this situation, even small sources of systematic or random error can cause spurious results or obscure real effects. The need for careful attention to data quality has been appreciated for some time in this field, and a number of strategies for quality control and quality assurance (QC/QA) have been developed. Here we extend these methods and describe a system of QC/QA for genotypic data in genome-wide association studies (GWAS). This system includes some new approaches that (1) combine analysis of allelic probe intensities and called genotypes to distinguish gender misidentification from sex chromosome aberrations, (2) detect autosomal chromosome aberrations that may affect genotype calling accuracy, (3) infer DNA sample quality from relatedness and allelic intensities, (4) use duplicate concordance to infer SNP quality, (5) detect genotyping artifacts from dependence of Hardy-Weinberg equilibrium test P-values on allelic frequency, and (6) demonstrate sensitivity of principal components analysis to SNP selection. The methods are illustrated with examples from the "Gene Environment Association Studies" (GENEVA) program. The results suggest several recommendations for QC/QA in the design and execution of GWAS. Genet. Epidemiol. 34 :591-602, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Laurie, Cathy C.; Bhangale, Tushar; Boehm, Frederick; Lumley, Thomas; McHugh, Caitlin; Rice, Kenneth M.; Zheng, Xiuwen; Weir, Bruce S.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Doheny, Kimberly F.; Pugh, Elizabeth W.] Johns Hopkins Univ, Sch Med, Ctr Inherited Dis Res, Baltimore, MD USA.
[Mirel, Daniel B.; Gabriel, Stacy B.] Broad Inst & Harvard, Cambridge, MA USA.
[Bierut, Laura J.; Rice, John P.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Caporaso, Neil E.; Jacobs, Kevin B.; Landi, Maria Teresa] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Cornelis, Marilyn C.; Hu, Frank B.] Harvard Univ, Dept Nutr, Harvard Sch Publ Hlth, Boston, MA 02115 USA.
[Edenberg, Howard J.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA.
[Harris, Emily L.] NIDCR, Div Extramural Res, Bethesda, MD USA.
[Kraft, Peter] Harvard Univ, Program Mol & Genet Epidemiol, Harvard Sch Publ Hlth, Boston, MA 02115 USA.
[Manolio, Teri A.] NHGRI, Off Populat Gen, Bethesda, MD 20892 USA.
[Paschall, Justin] Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA.
RP Weir, BS (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
EM bsweir@u.washington.edu
RI Weir, Bruce/A-2894-2013; Rice, Kenneth/A-4150-2013;
OI Rice, Kenneth/0000-0001-5779-4495; Boehm, Frederick/0000-0002-1644-5931;
Painter, Ian/0000-0001-7643-1200; Zheng, Xiuwen/0000-0002-1390-0708;
Edenberg, Howard/0000-0003-0344-9690
FU NIH [U01HG004422, HHSN268200782096C]; NIAAA [U10AA008401]; NIDA
[P01CA089392, R01DA013423, T2D, U01HG004399]; NIH GEI [HG-06-033-NCI-01,
U01HG04424]; National Institutes of Health, National Cancer Institute,
Division of Cancer Epidemiology and Genetics; Johns Hopkins University
Center for Inherited Disease Research [U01HG004438]; [U01 HG 004446]
FX Funding support has been provided through the NIH Genes, Environment and
Health Initiative. Additional funding sources for projects are: ( 1)
Addiction, PI Laura J. Bierut, U01HG004422, NIAAA: U10AA008401, NIDA:
P01CA089392, R01DA013423; ( 2) T2D, PI Frank B. Hu, U01HG004399; and (
3) Lung Cancer, PI Neil Caporaso, NIH GEI: HG-06-033-NCI-01 and the
Intramural Research Program of National Institutes of Health, National
Cancer Institute, Division of Cancer Epidemiology and Genetics.;
Genotyping was performed at the Broad Institute of MIT and Harvard, with
funding support from the NIH GEI (U01HG04424), and Johns Hopkins
University Center for Inherited Disease Research, with support from the
NIH GEI (U01HG004438) and the NIH contract "High throughput genotyping
for studying the genetic contributions to human disease"
(HHSN268200782096C). The GENEVA Coordinating Center receives support
from U01 HG 004446 ( PI Bruce S Weir). Assistance with data cleaning was
provided by the National Center for Biotechnology Information; this work
was supported by the Intramural Research Program of the NIH, National
Library of Medicine. LJ Bierut and JP Rice are inventors on the patent
"Markers for Addiction" (US 20070258898) covering the use of certain
SNPs in determining the diagnosis, prognosis, and treatment of
addiction. Dr. Bierut served as a consultant for Pfizer Inc. in 2008.
NR 30
TC 142
Z9 144
U1 0
U2 21
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0741-0395
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD SEP
PY 2010
VL 34
IS 6
BP 591
EP 602
DI 10.1002/gepi.20516
PG 12
WC Genetics & Heredity; Mathematical & Computational Biology
SC Genetics & Heredity; Mathematical & Computational Biology
GA 652VG
UT WOS:000282038200009
PM 20718045
ER
PT J
AU Abedi-Ardekani, B
Kamangar, F
Hewitt, SM
Hainaut, P
Sotoudeh, M
Abnet, CC
Taylor, PR
Boffetta, P
Malekzadeh, R
Dawsey, SM
AF Abedi-Ardekani, Behnoush
Kamangar, Farin
Hewitt, Stephen M.
Hainaut, Pierre
Sotoudeh, Masoud
Abnet, Christian C.
Taylor, Philip R.
Boffetta, Paolo
Malekzadeh, Reza
Dawsey, Sanford M.
TI Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk
of oesophageal squamous cell carcinoma in north-eastern Iran
SO GUT
LA English
DT Article
ID MONOCLONAL-ANTIBODIES; GASTRIC CANCERS; DNA ADDUCTS; TOOTH LOSS;
POPULATION; BENZOPYRENE; TOBACCO; AREA; IMMUNOHISTOCHEMISTRY;
BIOMARKERS
AB Objective To evaluate the association between polycyclic aromatic hydrocarbon (PAH) exposure in oesophageal epithelial tissue and oesophageal squamous cell carcinoma (ESCC) case status in an ESCC case-control study in a high-risk population in north-eastern Iran.
Methods Tissue microarrays (TMAs) of non-tumoral oesophageal biopsies from patients with biopsy-proven ESCC and gastrointestinal clinic patients with no endoscopic or biopsy evidence of ESCC (control subjects) in a rural region in north-eastern Iran were immunohistochemically stained. Immunohistochemistry was performed using monoclonal antibodies 8E11 and 5D11 raised against benzo[ a] pyrene (B[ a] P) diol epoxide (BPDE)-I-modified guanosine and BPDE-I-modified DNA, respectively. Staining intensity was quantified by image analysis and the average staining in three replicates was calculated. The main outcome measure was adjusted ORs with 95% CIs for the association between antibody staining intensity and ESCC case status.
Results Cultured ESCC cells exposed to B[ a] P in vitro showed dose-dependent staining with 8E11 but not with 5D11. With 8E11, sufficient epithelial tissue was available in the TMA cores to analyse 91 cases and 103 controls. Compared with the lowest quintile of 8E11 staining in the controls, adjusted ORs for the 2nd to 5th quintiles were 2.42, 5.77, 11.3 and 26.6 (95% CI 5.21 to 135), respectively (p for trend <0.001). With 5D11, 89 cases and 101 controls were analysed. No association between staining and case status was observed (ORs for the 2nd to 5th quintiles were 1.26, 0.88, 1.06 and 1.63 (95% CI 0.63 to 4.21), p for trend=0.40).
Conclusions Dramatically higher levels of 8E11 staining were observed in non-tumoral oesophageal epithelium from patients with ESCC than from control subjects. This finding strengthens the evidence for a causal role for PAHs in oesophageal carcinogenesis in north-eastern Iran.
C1 [Abedi-Ardekani, Behnoush; Kamangar, Farin; Abnet, Christian C.; Taylor, Philip R.; Dawsey, Sanford M.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Abedi-Ardekani, Behnoush; Kamangar, Farin; Sotoudeh, Masoud; Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Ctr, Tehran, Iran.
[Abedi-Ardekani, Behnoush; Hainaut, Pierre; Boffetta, Paolo] Int Agcy Res Canc, F-69372 Lyon, France.
[Abedi-Ardekani, Behnoush] Social Secur Org, Tehran, Iran.
[Kamangar, Farin] Morgan State Univ, Sch Community Hlth & Policy, Dept Publ Hlth Anal, Baltimore, MD 21239 USA.
[Hewitt, Stephen M.] NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
[Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
RP Dawsey, SM (reprint author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,Rm 3018, Bethesda, MD 20892 USA.
EM dawseys@mail.nih.gov
RI Hainaut, Pierre /B-6018-2012; Abnet, Christian/C-4111-2015;
Abedi-Ardekani, Behnoush/O-7829-2016;
OI Hainaut, Pierre /0000-0002-1303-1610; Abnet,
Christian/0000-0002-3008-7843; Abedi-Ardekani,
Behnoush/0000-0002-0980-0587; Hewitt, Stephen/0000-0001-8283-1788;
Malekzadeh, Reza/0000-0003-1043-3814
FU Digestive Disease Research Center of Tehran University of Medical
Sciences; National Cancer Institute at the National Institutes of
Health; International Agency for Research on Cancer
FX This work was supported by intramural funds from the Digestive Disease
Research Center of Tehran University of Medical Sciences, the National
Cancer Institute at the National Institutes of Health and the
International Agency for Research on Cancer.
NR 34
TC 26
Z9 27
U1 1
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
J9 GUT
JI Gut
PD SEP
PY 2010
VL 59
IS 9
BP 1178
EP 1183
DI 10.1136/gut.2010.210609
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 654SA
UT WOS:000282187100008
PM 20584779
ER
PT J
AU Tumblin, A
Tailor, A
Hoehn, GT
Mack, AK
Mendelsohn, L
Freeman, L
Xu, XL
Remaley, AT
Munson, PJ
Suffredini, AF
Kato, GJ
AF Tumblin, Ashaunta
Tailor, Anitaben
Hoehn, Gerard T.
Mack, A. Kyle
Mendelsohn, Laurel
Freeman, Lita
Xu, Xiuli
Remaley, Alan T.
Munson, Peter J.
Suffredini, Anthony F.
Kato, Gregory J.
TI Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of
acute painful episodes in patients with sickle cell disease
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Article
DE acute painful episode; immunoassay; sickle cell disease
ID ACUTE-PHASE RESPONSE; VASOOCCLUSIVE CRISIS; STEADY-STATE; ANEMIA; HDL;
HYDROXYUREA; EXPRESSION; FREQUENCY; PROTEIN; MICE
AB Background Acute painful episodes are the clinical hallmark of sickle cell disease and have been linked to morbidity and mortality in the sickle cell population.
Design and Methods We undertook exploratory proteomic studies on paired plasma samples collected from a cohort of 26 adult sickle cell patients during steady state and on the first day of an acute painful episode. We screened for changes in abundance of specific protein peaks via surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF MS), and confirmed the identify of candidate protein peaks by specific immunoassays.
Results The levels of hemoglobin, hematocrit, total protein, and albumin were lower and the levels of lactate dehydrogenase and absolute reticulocytes higher during acute painful episodes than during the steady state. Surface-enhanced laser desorption/ionization time of flight mass spectrometry spectral analysis consistently showed a mass-to-charge peak at 11.7 kDa with elevated intensities during acute painful episodes, which correlated significantly with the serum amyloid A immunoassay. Serum amyloid A levels were significantly elevated during acute painful episodes, especially in four patients with marked end-organ complications of such episodes. A second, recurring peak, less abundant during acute painful episodes, was present at 28.1 kDa; this peak was correlated significantly with immunoassay measurements of apolipoprotein A1.
Conclusions On the average, plasma serum amyloid A rises and apolipoprotein AI falls during acute painful episodes. The serum amyloid A/apolipoprotein AI ratio increased in 81% of the patients during acute painful episodes, potentially making it a useful objective marker of such episodes. We propose that these protein alterations, known to contribute to endothelial dysfunction in other settings, might do likewise acutely in acute painful episodes and present a new target for therapeutic intervention in sickle cell disease.
C1 [Hoehn, Gerard T.; Suffredini, Anthony F.; Kato, Gregory J.] NHLBI, Vasc Med Branch, NIH, Bethesda, MD 20892 USA.
[Mack, A. Kyle] NCI, Dept Crit Care Med, Ctr Clin, NIH, Bethesda, MD 20892 USA.
[Munson, Peter J.] NIH, Ctr Informat Technol, Bethesda, MD 20892 USA.
RP Kato, GJ (reprint author), NHLBI, Vasc Med Branch, NIH, 10 Ctr Dr,MSC 1476,Bldg 10 CRC,Room 5-5140, Bethesda, MD 20892 USA.
EM gkato@mail.nih.gov
RI Kato, Gregory/I-7615-2014
OI Kato, Gregory/0000-0003-4465-3217
FU NIH Division of Intramural Research through the National Heart, Lung and
Blood Institute; NIH Clinical Center; NIH Center for Information
Technology
FX Funding: research funding was provided by the NIH Division of Intramural
Research through the National Heart, Lung and Blood Institute, the NIH
Clinical Center, and the NIH Center for Information Technology.
NR 36
TC 9
Z9 10
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD SEP
PY 2010
VL 95
IS 9
BP 1467
EP 1472
DI 10.3324/haematol.2009.018044
PG 6
WC Hematology
SC Hematology
GA 651NA
UT WOS:000281933200007
PM 20378559
ER
PT J
AU Nierenberg, K
Byrne, MM
Fleming, LE
Stephan, W
Reich, A
Backer, LC
Tanga, E
Dalpra, DR
Kirkpatrick, B
AF Nierenberg, Kate
Byrne, Margaret M.
Fleming, Lora E.
Stephan, Wendy
Reich, Andrew
Backer, Lorraine C.
Tanga, Elvira
Dalpra, Dana R.
Kirkpatrick, Barbara
TI Florida red tide perception: Residents versus tourists
SO HARMFUL ALGAE
LA English
DT Article
DE Communication tools; Evaluation of outreach and education; Florida red
tide; Harmful algal blooms and public knowledge; Karenia brevis;
Outreach and education; Resident risk perception; Seafood safety;
Tourist risk perception
ID TOXINS BREVETOXINS; EXPOSURE; ASTHMA; RISK; FISH
AB The west coast of Florida has annual blooms of the toxin-producing dinoflagellate, Karenia brevis with Sarasota, FL considered the epicenter for these blooms. Numerous outreach materials, including Frequently Asked Question (FAQ) cards, exhibits for local museums and aquaria, public beach signs, and numerous websites have been developed to disseminate information to the public about this natural hazard. In addition, during intense onshore blooms, a great deal of media attention, primarily via newspaper (print and web) and television, is focused on red tide. However to date, the only measure of effectiveness of these outreach methods has been counts of the number of people exposed to the information, e.g., visits to a website or number of FAQ cards distributed. No formal assessment has been conducted to determine if these materials meet their goal of informing the public about Florida red tide. Also, although local residents have the opinion that they are very knowledgeable about Florida red tide, this has not been verified empirically. This study addressed these issues by creating and administering an evaluation tool for the assessment of public knowledge about Florida red tide. A focus group of Florida red tide outreach developers assisted in the creation of the evaluation tool. The location of the evaluation was the west coast of Florida, in Sarasota County. The objective was to assess the knowledge of the general public about Florida red tide. This assessment identified gaps in public knowledge regarding Florida red tides and also identified what information sources people want to use to obtain information on Florida red tide. The results from this study can be used to develop more effective outreach materials on Florida red tide. (c) 2010 Elsevier B.V. All rights reserved.
C1 [Nierenberg, Kate] Mote Marine Lab, Environm Hlth Program, Sarasota, FL 34236 USA.
[Byrne, Margaret M.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Fleming, Lora E.; Stephan, Wendy] Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, NSF & NIEHS Oceans & Human Hlth Ctr, Miami, FL 33149 USA.
[Fleming, Lora E.; Stephan, Wendy] Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, NIEHS Marine & Freshwater Biomed Sci Ctr, Miami, FL 33149 USA.
[Reich, Andrew] Florida Dept Hlth & Rehabil Serv, Tallahassee, FL 32399 USA.
[Backer, Lorraine C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA.
[Tanga, Elvira] Wesleyan Coll, Macon, GA 31210 USA.
RP Nierenberg, K (reprint author), Mote Marine Lab, Environm Hlth Program, 1600 Ken Thompson Pkwy, Sarasota, FL 34236 USA.
EM knierenberg@mote.org
FU National Science Foundation [0453955]; DHHS NIH of the National
Institute of Environmental Health Sciences [P01 ES 10594]; National
Institute of Environmental Health Sciences (NIEHS) Oceans and Human
Health Center at the University of Miami Rosenstiel School [NSF
OCE0432368, NSF OCE0911373]; NIEHS [1 P50 ES12736]; Centers for Disease
Control and Prevention; Florida Department of Health [U50/CCU423360-02]
FX Thanks to Erin Griswold and all the Mote Marine Laboratory volunteers
who took time to administer this survey. This research was supported by
the National Science Foundation under The Research Experience for
Undergraduate Program, grant number 0453955 and the P01 ES 10594, DHHS
NIH of the National Institute of Environmental Health Sciences.
Additional support was received from the National Institute of
Environmental Health Sciences (NIEHS) Oceans and Human Health Center at
the University of Miami Rosenstiel School (NSF OCE0432368 and NSF
OCE0911373); (NIEHS 1 P50 ES12736), as well as by the Centers for
Disease Control and Prevention and the Florida Department of Health
(Cooperative Agreement: U50/CCU423360-02). [SS]
NR 31
TC 7
Z9 7
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1568-9883
EI 1878-1470
J9 HARMFUL ALGAE
JI Harmful Algae
PD SEP
PY 2010
VL 9
IS 6
BP 600
EP 606
DI 10.1016/j.hal.2010.04.010
PG 7
WC Marine & Freshwater Biology
SC Marine & Freshwater Biology
GA 652JC
UT WOS:000281999300009
PM 20824108
ER
PT J
AU Zarate, C
Machado-Vieira, R
Henter, I
Ibrahim, L
Diazgranados, N
Salvadore, G
AF Zarate, Carlos, Jr.
Machado-Vieira, Rodrigo
Henter, Ioline
Ibrahim, Lobna
Diazgranados, Nancy
Salvadore, Giacomo
TI Glutamatergic Modulators: The Future of Treating Mood Disorders?
SO HARVARD REVIEW OF PSYCHIATRY
LA English
DT Review
ID MAJOR DEPRESSIVE DISORDER; D-ASPARTATE ANTAGONIST; OPEN-LABEL TRIAL;
MAGNETIC-RESONANCE SPECTROSCOPY; SEROTONIN REUPTAKE INHIBITORS; CELLULAR
PLASTICITY CASCADES; ANTERIOR CINGULATE ACTIVITY; BIPOLAR
AFFECTIVE-DISORDER; GAMMA-AMINOBUTYRIC-ACID; MEDIAL TEMPORAL-LOBE
AB Mood disorders such as bipolar disorder and major depressive disorder are common, chronic, and recurrent conditions affecting millions of individuals worldwide. Existing antidepressants and mood stabilizers used to treat these disorders are insufficient for many. Patients continue to have low remission rates, delayed onset of action, residual subsyndromal symptoms, and relapses. New therapeutic agents able to exert faster and sustained antidepressant or mood-stabilizing effects are urgently needed to treat these disorders. In this context, the glutamatergic system has been implicated in the pathophysiology of mood disorders in unique clinical and neurobiological ways. In addition to evidence confirming the role of the glutamatergic modulators riluzole and ketamine as proof-of-concept agents in this system, trials with diverse glutamatergic modulators are under way. Overall, this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder.3H]Ibogaine, ibogaine, and phencyclidine, and to
Paulina Iacoban for their technical assistance. Xiao Juan Yuan was
supported by a Student Summer Fellowship, Western University of Health
Sciences (Pomona, CA, USA).
NR 43
TC 10
Z9 10
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD SEP
PY 2010
VL 42
IS 9
BP 1525
EP 1535
DI 10.1016/j.biocel.2010.05.011
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 639IE
UT WOS:000280967700020
PM 20684041
ER
PT J
AU Jiang, WD
Wang, XW
Unger, T
Forgues, M
Kim, JW
Hussain, SP
Bowman, E
Spillare, EA
Lipsky, MM
Meck, JM
Cavalli, LR
Haddad, BR
Harris, CC
AF Jiang, Weidong
Wang, Xin Wei
Unger, Tamar
Forgues, Marshonna
Kim, Jin Woo
Hussain, S. Perwez
Bowman, Elise
Spillare, Elisa A.
Lipsky, Michael M.
Meck, Jeanne M.
Cavalli, Luciane R.
Haddad, Bassem R.
Harris, Curtis C.
TI Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in
regulating cell proliferation, anchorage-independent growth and
aneuploidy in a telomerase-immortalized normal human hepatocyte-derived
cell line
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE p53; HBx; cell proliferation; anchorage-independent growth
ID HEPATITIS-B-VIRUS; HUMAN HEPATOCELLULAR CARCINOMAS; BRONCHIAL
EPITHELIAL-CELLS; X-PROTEIN; LIVER-CANCER; GENE-EXPRESSION; TRANSGENIC
MICE; P53 GENE; MUTATIONS; APOPTOSIS
AB Hepatocellular carcinoma (HCC) is a common cancer, and hepatitis B virus (HBV) is a major etiological agent. Convincing epidemiological and experimental evidence also links HCC to aflatoxin, a naturally occurring mycotoxin that produces a signature p53-249(ser) mutation. Recently, we have reported that tumor-derived HBx variants encoded by HBV exhibited attenuated transactivation and proapoptotic functions but retained their ability to block p53-mediated apoptosis. These results indicate that mutations in HBx may contribute to the development of HCC. In this study, we determined whether tumor-derived HBx mutants along, or in cooperation with p53-249(ser), could alter cell proliferation and chromosome stability of normal human hepatocytes. To test this hypothesis, we established a telomerase immortalized normal human hepatocycte line HHT4 that exhibited a near diploid karyotype and expressed many hepatocyte-specific genes. We found that overexpression one of the tumor-derived HBx mutants, CT, significantly increased colony forming efficiency (CFE) while its corresponding wild-type allele CNT significantly decreased CFE in HHT4 cells. p53-249(ser) rescued CNT-mediated inhibition of colony formation. Although HHT4 cells lacked an anchorage independent growth capability as they did not form any colonies in soft agar, the CT-expressing HHT4 cells could form colonies, which could be significantly enhanced by p53-249(ser). Induction of aneuploidy could be observed in HHT4 cells expressing CT, but additionally recurring chromosome abnormalities could only be detected in cells coexpressing CT and p53-249(ser) Our results are consistent with the hypothesis that certain mutations in HBx and p53 at codon 249 may cooperate in contributing to liver carcinogenesis.
C1 [Jiang, Weidong; Wang, Xin Wei; Forgues, Marshonna; Kim, Jin Woo; Hussain, S. Perwez; Bowman, Elise; Spillare, Elisa A.; Harris, Curtis C.] NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA.
[Unger, Tamar] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.
[Lipsky, Michael M.] Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA.
[Meck, Jeanne M.; Cavalli, Luciane R.; Haddad, Bassem R.] Georgetown Univ, Dept Oncol, Washington, DC USA.
[Meck, Jeanne M.; Cavalli, Luciane R.; Haddad, Bassem R.; Harris, Curtis C.] Georgetown Univ, Dept Obstet & Gynecol, Washington, DC USA.
[Meck, Jeanne M.; Cavalli, Luciane R.; Haddad, Bassem R.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
RP Harris, CC (reprint author), Room 3068,Bldg 37,37 Convent Dr, Bethesda, MD 20892 USA.
EM harrisc@mail.nih.gov
RI Cavalli, Luciane/J-6100-2012; Wang, Xin/B-6162-2009
FU NIH; Intramural Research Program
FX Grant sponsor: NIH; Grant number: Intramural Research Program
NR 46
TC 21
Z9 23
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 1
PY 2010
VL 127
IS 5
BP 1011
EP 1020
DI 10.1002/ijc.25118
PG 10
WC Oncology
SC Oncology
GA 635KK
UT WOS:000280653800002
PM 20017137
ER
PT J
AU Swoboda, RK
Somasundaram, R
Caputo, L
Berencsi, K
von Franzke, P
Taylor, DD
Marincola, FM
Meropol, NJ
Sigurdson, E
Miller, E
Herlyn, D
AF Swoboda, Rolf K.
Somasundaram, Rajasekharan
Caputo, Laura
Berencsi, Klara
von Franzke, Paul
Taylor, Douglas D.
Marincola, Francesco M.
Meropol, Neal J.
Sigurdson, Elin
Miller, Eric
Herlyn, Dorothee
TI Nucleophosmin is recognized by a cytotoxic T cell line derived from a
rectal carcinoma patient
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE colorectal carcinoma patients; cytotoxic T cells; antigens; tumor
immunity
ID MALIGNANT-MELANOMA; COLORECTAL-CANCER; LYMPHOCYTE CLONE; COLON-CANCER;
TUMOR-CELLS; EXPRESSION; GENES; NPM; IDENTIFICATION; PROLIFERATION
AB Immunotherapy of colorectal carcinoma (CRC) has great promise as the presence of T lymphocytes in CRC tissues in situ is correlated with reduced recurrence and increased survival. Thus, identification of the antigens recognized by T cells of CRC patients may permit development of vaccines with potential benefit for these patients. Using expression cloning, we identified the antigen, nucleophosmin (Npm), recognized by an HLA-A1 restricted cytotoxic T lymphocyte (CTL) line derived from the peripheral blood mononuclear cells (PBMC) of a rectal cancer patient. A decamer peptide derived from the Npm sequence sensitized peptide-pulsed HLA-A1 positive cells to lysis by the CTL line. The peptide also induced proliferative and cytotoxic T lymphocytes in the PBMC of 4 of 6 CRC patients, which lysed HLA-A1 positive peptide-pulsed target cells and CRC cells endogenously expressing Npm. Overexpression of Npm by tumors of various histological types, recognition of the antigen by T cells derived from different CRC patients and association of the antigen with poor prognostic outcome make it a promising target for immunotherapeutic intervention in cancer patients.
C1 [Swoboda, Rolf K.; Somasundaram, Rajasekharan; Caputo, Laura; Berencsi, Klara; von Franzke, Paul; Herlyn, Dorothee] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
[Taylor, Douglas D.] Univ Louisville, Dept Obstet Gynecol & Womens Hlth, Louisville, KY 40292 USA.
[Marincola, Francesco M.] NIH, Infect Dis & Immunogenet Sect, Dept Transfus, Bethesda, MD 20892 USA.
[Meropol, Neal J.] Univ Hosp Case Med Ctr, Div Hematol Oncol, Cleveland, OH USA.
[Sigurdson, Elin] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA.
[Miller, Eric] Virtua Mem Hosp, Mt Holly, NJ USA.
RP Herlyn, D (reprint author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
EM dherlyn@wistar.org
FU NIH [CA74294, CA10815]; Pennsylvania Department of Health; National
Cancer Institute [CA98166]; Kentucky Science and Technology Corporation
FX Grant sponsors: NIH; Grant numbers: CA74294, CA10815; Grant sponsor:
Pennsylvania Department of Health (Commonwealth Universal Research
Enhancement Program), National Cancer Institute; Grant number: CA98166;
Grant sponsor: Kentucky Science and Technology Corporation
NR 29
TC 4
Z9 4
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 1
PY 2010
VL 127
IS 5
BP 1124
EP 1130
DI 10.1002/ijc.25133
PG 7
WC Oncology
SC Oncology
GA 635KK
UT WOS:000280653800013
PM 20027629
ER
PT J
AU Ebbesson, SOE
Tejero, ME
Lopez-Alvarenga, JC
Harris, WS
Ebbesson, LOE
Devereux, RB
MacCluer, JW
Wenger, C
Laston, S
Fabsitz, RR
Howard, BV
Comuzzie, AG
AF Ebbesson, Sven O. E.
Tejero, M. Elizabeth
Lopez-Alvarenga, Juan Carlos
Harris, William S.
Ebbesson, Lars O. E.
Devereux, Richard B.
MacCluer, Jean W.
Wenger, Charlotte
Laston, Sandra
Fabsitz, Richard R.
Howard, Barbara V.
Comuzzie, Anthony G.
TI Individual saturated fatty acids are associated with different
components of insulin resistance and glucose metabolism: the GOCADAN
study
SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH
LA English
DT Article
DE myristic acid; palmitic acid; stearic acid; Inuit; Alaska Natives;
diabetes; saturated fat
ID DIABETES-MELLITUS; ALASKA NATIVES; ESKIMO; SENSITIVITY;
OMEGA-3-FATTY-ACIDS; PREVENTION; TOLERANCE; DISEASE
AB Objectives. Type 2 diabetes and the consumption of saturated fatty acids (FAs) are on the rise among Alaska Inuits. This analysis, based on a cross-sectional study, explores the possible associations of saturated FA content in red blood cells (RBCs) and parameters of glucose metabolism in a sample of Alaska Natives.
Study design and methods. The sample included 343 women and 282 men aged 35-74. Statistical analyses explored the associations of selected RBC (myristic, palmitic and stearic acids) FAs with fasting glucose (plasma), fasting insulin (plasma), 2h glucose (2-hour glucose tolerance test), 2h insulin and homeostasis model assessment (HOMA) index. The models included sex and glucose metabolism status as fixed factors and age, body mass index (BMI), waist circumference, physical activity (METS) and FA content in RBCs as covariates. Measures of insulin, glucose and HOMA index were used as dependent variables.
Results. Myristic acid was positively associated with fasting insulin (beta=0.47, p < 0.001), 2h insulin (beta=0.53, p=0.02) and HOMA index (beta=0.455, p < 0.001). Palmitic acid was associated with 2h glucose (beta=2.3x10-2, p < 0.001) and 2h insulin (beta=5.6x10-2, p=0.002) and stearic acid was associated with fasting glucose (beta=4.8x10-3, p=0.006).
Conclusions. These results strongly support the hypothesis that saturated fatty acids are associated with insulin resistance and glucose intolerance and that saturated fatty acids are significant risk factors for type 2 diabetes. (Int J Circumpolar Health 2010; 69(4):344-351)
C1 [Ebbesson, Sven O. E.] Norton Sound Hlth Corp, GOCADAN Dept, Nome, AK 99762 USA.
[Tejero, M. Elizabeth; Lopez-Alvarenga, Juan Carlos; MacCluer, Jean W.; Wenger, Charlotte; Laston, Sandra; Comuzzie, Anthony G.] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA.
[Harris, William S.] S Dakota Hlth Res Fdn, Sioux Falls, SD USA.
[Ebbesson, Lars O. E.] Univ Bergen, Dept Biol, Bergen, Norway.
[Devereux, Richard B.] Weill Cornell Med Coll, New York, NY USA.
NHLBI, Bethesda, MD 20892 USA.
[Fabsitz, Richard R.; Howard, Barbara V.] MedStar Res Inst, Hyattsville, MD USA.
RP Ebbesson, SOE (reprint author), Norton Sound Hlth Corp, GOCADAN Dept, POB 966, Nome, AK 99762 USA.
EM soebbesson@alaska.edu
RI Ebbesson, Lars/F-9385-2011
FU National Heart Lung and Blood Institute of the National Institutes of
Health, Bethesda, MD [RO1-HL64244, U01 HL082458, U01 HL082490, MI
0RR0047-34]; Research Resources of the National Institutes of Health,
Bethesda, MD [CO06-RR013556, C06-RR017515]
FX The authors are grateful to the Norton Sound Health Corporation (NSHC)
and the participants of villages participating in this study. The study
was approved by the Research Ethics Review Board of the NSHC, the
Institutional Review Boards of MedStar Research Institute and the
University of Texas Health Science Center, San Antonio. The study was
funded by grants RO1-HL64244, U01 HL082458, U01 HL082490, and MI
0RR0047-34 (GCRC) from National Heart Lung and Blood Institute of the
National Institutes of Health, Bethesda, MD. Work at the Southwest
Foundation for Biomedical Research was conducted in facilities provided
in part by grants CO06-RR013556 and C06-RR017515 from Research Resources
of the National Institutes of Health, Bethesda, MD.
NR 26
TC 23
Z9 24
U1 0
U2 3
PU INT ASSOC CIRCUMPOLAR HEALTH PUBL
PI OULU
PA AAPISTIE1, OULU, FIN-90220, FINLAND
SN 1239-9736
J9 INT J CIRCUMPOL HEAL
JI Int. J. Circumpolar Health
PD SEP
PY 2010
VL 69
IS 4
BP 344
EP 351
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 674AL
UT WOS:000283705400005
PM 20719107
ER
PT J
AU Black, D
Riskind, JH
Kleiman, EM
AF Black, David
Riskind, John H.
Kleiman, Evan M.
TI Lifetime History of Anxiety and Mood Disorders Predicted by Cognitive
Vulnerability to Anxiety
SO INTERNATIONAL JOURNAL OF COGNITIVE THERAPY
LA English
DT Article
ID LOOMING MALADAPTIVE STYLE; SENSITIVITY; DEPRESSION; SELF; INVENTORY;
DIMENSIONS; DEPLETION; COMORBIDITY; VALIDATION; RESOURCE
AB A retrospective behavioral high-risk design with used to test hypotheses about cognitive vulnerability to anxiety with college students who were free of current anxiety or mood disorders. Cognitive risk groups were selected on the basis of two currently studied factors that have conceptualized as cognitive vulnerabilities, looming cognitive style (LCS; Riskind et al., 2000) and anxiety sensitivity (ASI; Reiss & McNally, 1985). Consistent with cognitive vulnerability hypotheses, participants at high cognitive risk had far higher lifetime prevalence (approximately 65%) of anxiety disorders than participants at low cognitive risk (approximately 8%) and were approximately 11 times more likely to have a prior anxiety disorder. When LCS and ASI were looked at separately as risk group factors they had no significant effect on anxiety disorders. Secondary analyses were also done on the whole sample using data from the full continuum of scores. Total cognitive risk on these continuous data no effect on anxiety disorders in general but had a small significant effect on social anxiety disorder. When LCS and ASI were looked at separately as continuous scores, the only finding to emerge was that LCS but not ASI had a significant but small effect on past prevalence of anxiety disorders. Consistent with cognitive specificity predictions, no effects similar to those on lifetime anxiety disorders were found for mood disorders.
C1 [Riskind, John H.] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA.
[Black, David] NIMH, Bethesda, MD 20892 USA.
RP Riskind, JH (reprint author), George Mason Univ, Dept Psychol, Mail Stop 3F5, Fairfax, VA 22030 USA.
EM jriskind@gmu.edu
OI Kleiman, Evan/0000-0001-8002-1167
NR 36
TC 7
Z9 7
U1 0
U2 0
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 1937-1209
J9 INT J COGN THER
JI Int. J. Cogn. Ther.
PD SEP
PY 2010
VL 3
IS 3
BP 215
EP 227
PG 13
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 654II
UT WOS:000282161300003
ER
PT J
AU Jehan, I
Zaidi, S
Rizvi, S
Mobeen, N
McClure, EM
Munoz, B
Pasha, O
Wright, LL
Goldenberg, RL
AF Jehan, Imtiaz
Zaidi, Shahida
Rizvi, Sameera
Mobeen, Naushaba
McClure, Elizabeth M.
Munoz, Breda
Pasha, Omrana
Wright, Linda L.
Goldenberg, Robert L.
TI Dating gestational age by last menstrual period, symphysis-fundal
height, and ultrasound in urban Pakistan
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Gestational age; Last menstrual period; Pakistan; Symphysis-fundal
height; Ultrasound
ID GROWTH-RETARDATION; PREGNANCY; WOMEN; GRAVIDOGRAM; LENGTH
AB Objective: To compare the accuracy of the reported date of the last menstrual period (LMP) with that of symphysis-fundal height (SFH) in the estimation of gestational age (GA), using an ultrasound (US) scan as reference. Methods: Gestational age was concurrently assessed by the 3 methods in this prospective, population-based, pregnancy-outcome study conducted in Hyderabad, Pakistan, from June 18. 2003, through August 31, 2005, with 1128 women between 20 and 26 weeks of a singleton pregnancy. Results: The mean GA was less by ultrasound than by SFH measurement or the reported LMP, and the mean differences with the US result were statistically significant (P<0.001 for both). At delivery, about 75% of the GA values estimated by SFH measurement were within 7 days and almost 91% were within 14 days of the estimation by ultrasound, compared with 65% and 82% for the GA estimated by the reported LMP. Moreover, using the US as reference, the SFH correctly classified 84% of the term, 68% of the preterm, and 86% of the post-term deliveries (weighted kappa=0.58) compared with the corresponding 79%, 61%, and 55% predicted by the reported LMP (Weighted kappa=0.44). Conclusion: The SFH measurement was found to be more accurate than the reported LMP as a tool to estimate GA and therefore date of delivery, but neither were as accurate as a US scan. (C) 2010 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Jehan, Imtiaz] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan.
[McClure, Elizabeth M.; Munoz, Breda] Res Triangle Inst, Durham, NC USA.
[Wright, Linda L.] NICHHD, Bethesda, MD 20892 USA.
[Goldenberg, Robert L.] Drexel Univ, Philadelphia, PA 19104 USA.
RP Jehan, I (reprint author), Aga Khan Univ, Dept Community Hlth Sci, Stadium Rd,POB 3500, Karachi, Pakistan.
EM Imtiaz.jehan@aku.edu
FU Global Network for Women's and Children's Health Research of the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development; Bill and Melinda Gates Foundation
FX This study was supported by grants from the Global Network for Women's
and Children's Health Research of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development and from the Bill and
Melinda Gates Foundation.
NR 25
TC 19
Z9 20
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0020-7292
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD SEP
PY 2010
VL 110
IS 3
BP 231
EP 234
DI 10.1016/j.ijgo.2010.03.030
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 643AV
UT WOS:000281265500013
PM 20537328
ER
PT J
AU Beydoun, HA
Dail, J
Ugwu, B
Boueiz, A
Beydoun, MA
AF Beydoun, Hind A.
Dail, Jessica
Ugwu, Bethrand
Boueiz, Adel
Beydoun, May A.
TI Socio-demographic and behavioral correlates of herpes simplex virus type
1 and 2 infections and co-infections among adults in the USA
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Epidemiology; Infection; Herpes simplex virus; Prevalence; Sexually
transmitted diseases
ID SEXUALLY-TRANSMITTED-DISEASE; RISK-FACTORS; UNITED-STATES;
PREGNANT-WOMEN; SENSATION SEEKING; GENITAL HERPES; ALCOHOL-USE;
DRUG-USERS; PREVALENCE; HIV
AB Objectives: Although herpes simplex virus (HSV)-1 and HSV-2 may co-exist and interact, some epidemiologic features including geographical distribution, secular trends, route of transmission, and established risk factors may distinguish these HSV sub-types. With recent data indicating a link between genital herpes and either strain, a re-evaluation of risk factors for HSV-1/HSV-2 infection and co-infection is needed.
Methods: We used the 1999-2004 National Health and Nutrition Examination Study (NHANES) data and logistic regression modeling to identify socio-demographic and behavioral risk factors that can independently predict HSV-1/HSV-2 infection and co-infection.
Results: Approximately 48% were positive for HSV-1 alone, 7% were positive for HSV-2 alone and 12% were co-infected with HSV-1 and HSV-2. History of genital herpes was found in individuals infected with either or both HSV sub-types. Whereas age, sex, race, and level of education independently predicted all three outcomes, lifetime sexual activity as well as use of tobacco products and recreational drugs mainly correlated with HSV-2 infection and HSV-1/HSV-2 co-infection. Lifetime use of alcohol was not consistently associated with HSV-1/HSV-2 infection and co-infection.
Conclusions: Sexual activity played an important role for HSV-2 and was potentially important for HSV-1, with implications for healthcare practice and vaccine development. (C) 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Beydoun, Hind A.; Dail, Jessica; Ugwu, Bethrand] Eastern Virginia Med Sch, Grad Program Publ Hlth, Norfolk, VA 23501 USA.
[Boueiz, Adel] Johns Hopkins Univ, Dept Internal Med, Baltimore, MD USA.
[Beydoun, May A.] Natl Inst Aging Intramural Res Program, Baltimore, MD USA.
RP Beydoun, HA (reprint author), Eastern Virginia Med Sch, Grad Program Publ Hlth, 700 W Olney Rd,POB 1980, Norfolk, VA 23501 USA.
EM baydouha@evms.edu
FU NIH, National Institute on Aging
FX No funding was provided for this project. However, this research was
supported in part by the intramural research program of the NIH,
National Institute on Aging. We would like to thank the Brickell Library
at Eastern Virginia Medical School for providing access to peer-reviewed
journals.
NR 41
TC 10
Z9 10
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2010
VL 14
SU 3
BP E154
EP E160
DI 10.1016/j.ijid.2009.12.007
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 660LA
UT WOS:000282643000031
PM 20418142
ER
PT J
AU Mussi-Pinhata, MM
Motta, F
Freimanis-Hance, L
de Souza, R
Szyld, E
Succi, RCM
Christie, CDC
Rolon, MJ
Ceriotto, M
Read, JS
AF Mussi-Pinhata, Marisa M.
Motta, Fabrizio
Freimanis-Hance, Laura
de Souza, Ricardo
Szyld, Edgardo
Succi, Regina C. M.
Christie, Celia D. C.
Rolon, Maria J.
Ceriotto, Mariana
Read, Jennifer S.
TI Lower respiratory tract infections among human immunodeficiency
virus-exposed, uninfected infants
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-exposed; Infancy; Infections; Latin America
ID SYNCYTIAL VIRUS; IMMUNE-RESPONSES; PREGNANT-WOMEN; LATIN-AMERICAN; BIRTH
COHORT; RISK-FACTORS; HIV; CHILDREN; MORBIDITY; MOTHERS
AB Objectives: To evaluate whether maternal HIV disease severity during pregnancy is associated with an increased likelihood of lower respiratory tract infections (LRTIs) in HIV-exposed, uninfected infants.
Methods: HIV-exposed, uninfected, singleton, term infants enrolled in the NISDI Perinatal Study, with birth weight >2500 g were followed from birth until 6 months of age. LRTI diagnoses, hospitalizations, and associated factors were assessed.
Results: Of 547 infants, 103 (18.8%) experienced 116 episodes of LRTI (incidence = 0.84 LRTIs/100 child-weeks). Most (81%) episodes were bronchiolitis. Forty-nine (9.0%) infants were hospitalized at least once with an LRTI. There were 53 hospitalizations (45.7%) for 116 LRTI episodes. None of these infants were breastfed. The odds of LRTI in infants whose mothers had CD4% <14 at enrollment were 4.4 times those of infants whose mothers had CD4% >= 29 (p = 0.003). The odds of LRTI in infants with a CD4+ count (cells/ mm(3)) <750 at hospital discharge were 16.0 times those of infants with CD4+ >= 750 (p = 0.002). Maternal CD4+ decline and infant hemoglobin at the 6-12 week visit were associated with infant LRTIs after 6-12 weeks and before 6 months of age.
Conclusions: Acute bronchiolitis is common and frequently severe among HIV-exposed, uninfected infants aged 6 months or less. Lower maternal and infant CD4+ values were associated with a higher risk of infant LRTIs. Further understanding of the immunological mechanisms of severe LRTIs is needed. (C) 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Mussi-Pinhata, Marisa M.; Motta, Fabrizio] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
[Freimanis-Hance, Laura] WESTAT Corp, Rockville, MD 20850 USA.
[de Souza, Ricardo] Univ Caxias Sul, Rio Grande Do Sul, Brazil.
[Szyld, Edgardo] Hosp Diego Paroissien, Buenos Aires, DF, Argentina.
[Succi, Regina C. M.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
[Christie, Celia D. C.] Univ W Indies, Kingston 7, Jamaica.
[Rolon, Maria J.] Hosp Juan Fernandez, Buenos Aires, DF, Argentina.
[Ceriotto, Mariana] Hosp Agudos Dra Cecilia Grierson, Buenos Aires, DF, Argentina.
[Read, Jennifer S.] NICHD, Pediat Adolescent & Maternal AIDS Branch, CRMC, NIH,DHHS, Bethesda, MD USA.
RP Mussi-Pinhata, MM (reprint author), Univ Sao Paulo, Fac Med Ribeirao Preto, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Inca, Inct/K-2204-2013
FU NICHD [N01-HD-3-3345, HHSN267200800001C, N01-DK-8-0001]
FX This study was supported financially by NICHD Contract No. N01-HD-3-3345
and No. HHSN267200800001C (NICHD Control No. N01-DK-8-0001).
NR 30
TC 19
Z9 19
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2010
VL 14
SU 3
BP E176
EP E182
DI 10.1016/j.ijid.2010.01.006
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 660LA
UT WOS:000282643000035
PM 20452798
ER
PT J
AU Moya, PR
Murphy, DL
McMahon, FJ
Wendland, JR
AF Moya, Pablo R.
Murphy, Dennis L.
McMahon, Francis J.
Wendland, Jens R.
TI Increased gene expression of diacylglycerol kinase eta in bipolar
disorder
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Letter
ID GENOME-WIDE ASSOCIATION
C1 [Wendland, Jens R.] NIMH, Genet Basis Mood & Anxiety Disorders Unit, NIH, Bethesda, MD 20892 USA.
[Moya, Pablo R.; Murphy, Dennis L.; Wendland, Jens R.] NIMH, Clin Sci Lab, Bethesda, MD 20892 USA.
RP Wendland, JR (reprint author), NIMH, Genet Basis Mood & Anxiety Disorders Unit, NIH, Bldg 35,Room 1A207, Bethesda, MD 20892 USA.
EM wendlandj@mail.nih.gov
RI Wendland, Jens/A-1809-2012;
OI McMahon, Francis/0000-0002-9469-305X
FU Intramural NIH HHS [ZIA MH000336-30]
NR 10
TC 16
Z9 16
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1461-1457
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD SEP
PY 2010
VL 13
IS 8
SI SI
BP 1127
EP 1128
DI 10.1017/S1461145710000593
PG 2
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 651HS
UT WOS:000281919200013
PM 20519059
ER
PT J
AU Hsu, JCF
Yamada, KM
AF Hsu, Jeff Chi-Feng
Yamada, Kenneth M.
TI Salivary Gland Branching Morphogenesis - Recent Progress and Future
Opportunities
SO INTERNATIONAL JOURNAL OF ORAL SCIENCE
LA English
DT Review
DE salivary gland; epithelium; branching morphogenesis; fibronectin;
E-cadherin; growth factor
ID MOUSE SUBMANDIBULAR-GLAND; GROWTH-FACTOR RECEPTOR; EPITHELIAL
MORPHOGENESIS; E-CADHERIN; GENE-EXPRESSION; CLEFT FORMATION; IN-VITRO;
EGF; CELL; TISSUE
AB Salivary glands provide saliva to maintain oral health, and a loss of salivary gland function substantially decreases quality-of-life. Understanding the biological mechanisms that generate salivary glands during embryonic development may identify novel ways to regenerate function or design artificial salivary glands. This review article summarizes current research on the process of branching morphogenesis of salivary glands, which creates gland structure during development. We highlight exciting new advances and opportunities in studies of cell-cell interactions, mechanical forces, growth factors, and gene expression patterns to improve our understanding of this important process.
C1 [Hsu, Jeff Chi-Feng; Yamada, Kenneth M.] Natl Inst Dent & Craniofacial Res, NIH, Lab Cell & Dev Biol, Bethesda, MD 20892 USA.
RP Yamada, KM (reprint author), Natl Inst Dent & Craniofacial Res, NIH, Lab Cell & Dev Biol, Bldg 30,Room 426,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.
EM kenneth.yamada@nih.gov
OI Yamada, Kenneth/0000-0003-1512-6805
FU National Institute of Dental and Craniofacial Research, NIH
FX Supported by the Intramural Research Program of the National Institute
of Dental and Craniofacial Research, NIH.
NR 49
TC 22
Z9 22
U1 0
U2 2
PU SICHUAN UNIV
PI CHENGDU
PA SICHUAN UNIV, CHENGDU, SICHUAN, 610064 00000, PEOPLES R CHINA
SN 1674-2818
J9 INT J ORAL SCI
JI Int. J. Oral Sci.
PD SEP
PY 2010
VL 2
IS 3
BP 117
EP 126
DI 10.4248/IJOS10042
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 662HQ
UT WOS:000282798700001
PM 21125789
ER
PT J
AU Mettu, P
Agron, E
Samtani, S
Chew, EY
Wong, WT
AF Mettu, Pradeep
Agron, Elvira
Samtani, Sonia
Chew, Emily Y.
Wong, Wai T.
TI Genotype-Phenotype Correlation in Ocular von Hippel-Lindau (VHL)
Disease: The Effect of Missense Mutation Position on Ocular VHL
Phenotype
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; ENDOTHELIAL GROWTH-FACTOR; GERMLINE MUTATIONS;
CAPILLARY HEMANGIOMAS; ELONGIN-C; PROTEIN; CANCER; BINDING;
HEMANGIOBLASTOMAS; IDENTIFICATION
AB PURPOSE. von Hippel-Lindau (VHL) disease is a dominantly inherited, multisystemic tumor syndrome caused by mutations in the VHL gene. This study was conducted to establish genotype-phenotype correlations between the positions of disease-causing missense mutations and the ocular phenotypes of VHL disease.
METHODS. Participants with clinically defined VHL disease and documented germline missense mutations in the VHL gene were identified in a cross-sectional study (n = 412). Statistical analysis was used to correlate the position of the missense mutation in either the alpha- or beta-domain of the VHL protein with the ocular disease phenotype.
RESULTS. Missense mutations among study participants were located in 47 of the 213 possible codons in the VHL gene. Almost all mutations (98.5%) were located in one of two structural domains of the VHL protein: the alpha- and beta-domains. alpha-Domain mutations were significantly associated with a higher prevalence of retinal capillary hemangioblastomas (RCHs) compared with the beta-domain mutations (P = 0.016). Among patients with RCHs, the prevalence of the lesions in the juxtapapillary position was also significantly higher in patients with beta-domain mutations (P = 0.0017). Conversely, beta-domain mutations correlated with a higher prevalence of peripherally located RCHs (P = 0.0104).
CONCLUSIONS. The location of missense mutations in the VHL gene correlates significantly with the prevalence and phenotype of ocular disease, and as such, influences the risk of visual loss in affected patients. These genotype-phenotype correlations can assist in the prognostic counseling and follow-up of VHL patients and may provide a basis for molecular inferences on ocular VHL disease pathogenesis. (Invest Ophthalmol Vis Sci. 2010;51:4464-4470) DOI:10.1167/iovs.10-5223
C1 [Mettu, Pradeep; Samtani, Sonia; Wong, Wai T.] NEI, Unit Neuron Glia Interact Retinal Dis, Off Sci Director, NIH, Bethesda, MD 20892 USA.
[Mettu, Pradeep; Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
RP Wong, WT (reprint author), NEI, Unit Neuron Glia Interact Retinal Dis, Off Sci Director, NIH, 7 Mem Dr,Room 217, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016
FU NEI; NIH; Pfizer, Inc.
FX Supported by the NEI Intramural Research Program. PM is supported by the
Clinical Research Training Program, a public-private partnership
supported jointly by the NIH and Pfizer, Inc.
NR 39
TC 13
Z9 15
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2010
VL 51
IS 9
BP 4464
EP 4470
DI 10.1167/iovs.10-5223
PG 7
WC Ophthalmology
SC Ophthalmology
GA 645YS
UT WOS:000281502700016
PM 20375333
ER
PT J
AU Meade, CS
Weiss, RD
Fitzmaurice, GM
Poole, SA
Subramaniam, GA
Patkar, AA
Connery, HS
Woody, GE
AF Meade, Christina S.
Weiss, Roger D.
Fitzmaurice, Garrett M.
Poole, Sabrina A.
Subramaniam, Geetha A.
Patkar, Ashwin A.
Connery, Hilary S.
Woody, George E.
TI HIV Risk Behavior in Treatment-Seeking Opioid-Dependent Youth: Results
From a NIDA Clinical Trials Network Multisite Study
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE buprenorphine treatment; gender differences; HIV risk; injection drug
use; opioid dependence; youth
ID INJECTION-DRUG USERS; GENDER-DIFFERENCES; BUPRENORPHINE-NALOXONE;
SEXUAL-BEHAVIORS; RANDOMIZED-TRIAL; PREVENTION INTERVENTIONS;
MAINTENANCE TREATMENT; SENSATION-SEEKING; HEROIN DEPENDENCE; ADOLESCENT
BRAIN
AB Objective: To assess baseline rates of and changes in HIV drug and sexual risk behavior as a function of gender and treatment in opioid-dependent youth.
Methods: One hundred fifty participants were randomly assigned to extended buprenorphine/naloxone therapy (BUP) for 12 weeks or detoxification for 2 weeks; all received drug counseling for 12 weeks. HIV risk was assessed at baseline and 4-week, 8-week, and 12-week follow-ups. Behavioral change was examined using generalized estimating equations.
Results: Baseline rates of past-month HIV risk for females/males were 51%/45% for injection drug use (IDU) (ns), 77%/35% for injection risk (P < 0.001), 82%/74% for sexual activity (ns), 14%/24% for multiple partners (ns), and 68%/65% for unprotected intercourse (ns). IDU decreased over time (P < 0.001), with greater decreases in BUP versus detoxification (P < 0.001) and females versus males in BUP (P < 0.05). Injection risk did not change for persistent injectors. Sexual activity decreased in both genders and conditions (P < 0.01), but sexual risk did not.
Conclusions: Overall, IDU and sexual activity decreased markedly, particularly in BUP patients and females, but injection and sexual risk behaviors persisted. Although extended BUP seems to have favorable effects on HIV risk behavior in opioid-dependent youth, risk reduction counseling may be necessary to extend its benefits.
C1 [Meade, Christina S.; Patkar, Ashwin A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
[Weiss, Roger D.; Fitzmaurice, Garrett M.; Connery, Hilary S.] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA.
[Weiss, Roger D.; Fitzmaurice, Garrett M.; Connery, Hilary S.] McLean Hosp, Belmont, MA 02178 USA.
[Poole, Sabrina A.; Woody, George E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Poole, Sabrina A.; Woody, George E.] Treatment Res Inst, Philadelphia, PA USA.
[Subramaniam, Geetha A.] NIDA, Div Clin Neurosci & Behav Res, Bethesda, MD 20892 USA.
RP Meade, CS (reprint author), Duke Global Hlth Inst, Box 90519, Durham, NC 27708 USA.
EM christina.meade@duke.edu
FU National Institutes of Health [P30-AI064518, U10-DA013711, K05-DA017009,
U10-DA013043, K24-DA022288, U10-DA015831, U10-013034, K12-DA000357,
U10-DA015833]
FX Supported by the following grants from the National Institutes of
Health: P30-AI064518 (Weinhold) and U10-DA013711 (Hubbard) to Duke
University, K05-DA017009 (Woody) and U10-DA013043 (Woody) to University
of Pennsylvania, K24-DA022288 (Weiss) and U10-DA015831 (Weiss) to
Harvard University, U10-013034 (Stitzer) and K12-DA000357 (Riggs) to
Johns Hopkins University, and U10-DA015833 (Miller) to University of New
Mexico.
NR 68
TC 12
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2010
VL 55
IS 1
BP 65
EP 72
DI 10.1097/QAI.0b013e3181d916db
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 641YY
UT WOS:000281170500008
PM 20393347
ER
PT J
AU Moster, D
Wilcox, AJ
Vollset, SE
Markestad, T
Lie, RT
AF Moster, Dag
Wilcox, Allen J.
Vollset, Stein Emil
Markestad, Trond
Lie, Rolv Terje
TI Cerebral Palsy Among Term and Postterm Births
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID GESTATIONAL-AGE; EPIDEMIOLOGIC RESEARCH; PERINATAL FACTORS; PRETERM
BIRTH; ANTECEDENTS; OUTCOMES; CHILDREN; COMPLICATIONS; PREVALENCE;
INFANTS
AB Context Although preterm delivery is a well-established risk factor for cerebral palsy (CP), preterm deliveries contribute only a minority of affected infants. There is little information on the relation of CP risk to gestational age in the term range, where most CP occurs.
Objective To determine whether timing of birth in the term and postterm period is associated with risk of CP.
Design, Setting, and Participants Population-based follow-up study using the Medical Birth Registry of Norway to identify 1 682 441 singleton children born in the years 1967-2001 with a gestational age of 37 through 44 weeks and no congenital anomalies. The cohort was followed up through 2005 by linkage to other national registries.
Main Outcome Measures Absolute and relative risk of CP for children surviving to at least 4 years of age.
Results Of the cohort of term and postterm children, 1938 were registered with CP in the National Insurance Scheme. Infants born at 40 weeks had the lowest risk of CP, with a prevalence of 0.99/1000 (95% confidence interval [CI], 0.90-1.08). Risk for CP was higher with earlier or later delivery, with a prevalence at 37 weeks of 1.91/1000 (95% CI, 1.58-2.25) and a relative risk (RR) of 1.9 (95% CI, 1.6-2.4), a prevalence at 38 weeks of 1.25/1000 (95% CI, 1.07-1.42) and an RR of 1.3 (95% CI, 1.1-1.6), a prevalence at 42 weeks of 1.36/1000 (95% CI, 1.19-1.53) and an RR of 1.4 (95% CI, 1.2-1.6), and a prevalence after 42 weeks of 1.44 (95% CI, 1.15-1.72) and an RR of 1.4 (95% CI, 1.1-1.8). These associations were even stronger in a subset with gestational age based on ultrasound measurements: at 37 weeks the prevalence was 1.17/1000 (95% CI, 0.30-2.04) and the relative risk was 3.7 (95% CI, 1.5-9.1). At 42 weeks the prevalence was 0.85/1000 (95% CI, 0.33-1.38) and the relative risk was 2.4 (95% CI, 1.1-5.3). Adjustment for infant sex, maternal age, and various socioeconomic measures had little effect.
Conclusion Compared with delivery at 40 weeks' gestation, delivery at 37 or 38 weeks or at 42 weeks or later was associated with an increased risk of CP. JAMA. 2010; 304(9): 976-982 www.jama.com
C1 [Moster, Dag; Vollset, Stein Emil; Lie, Rolv Terje] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, N-5020 Bergen, Norway.
[Markestad, Trond] Univ Bergen, Dept Clin Med, Sect Pediat, N-5020 Bergen, Norway.
[Moster, Dag; Markestad, Trond] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway.
[Wilcox, Allen J.] NIEHS, Epidemiol Branch, NIH, Durham, NC USA.
[Vollset, Stein Emil; Lie, Rolv Terje] Norwegian Inst Publ Hlth, Med Birth Registry Norway, Bergen, Norway.
RP Moster, D (reprint author), Univ Bergen, Dept Publ Hlth & Primary Hlth Care, POB 7804, N-5020 Bergen, Norway.
EM Dag.Moster@smis.uib.no
OI Wilcox, Allen/0000-0002-3376-1311
FU National Institutes of Health, National Institute of Environmental
Health Sciences; Unger-Vetlesen Charitable Fund; US-Norway Fulbright
Foundation; Norwegian Society of Pediatricians; University of Bergen;
Research Council of Norway
FX This research was supported in part by the Intramural Research Program
of the National Institutes of Health, National Institute of
Environmental Health Sciences; the Unger-Vetlesen Charitable Fund; The
US-Norway Fulbright Foundation; the Norwegian Society of Pediatricians;
the University of Bergen; and the Research Council of Norway.
NR 39
TC 48
Z9 48
U1 1
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 1
PY 2010
VL 304
IS 9
BP 976
EP 982
DI 10.1001/jama.2010.1271
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 645AD
UT WOS:000281422400023
PM 20810375
ER
PT J
AU Hertzano, R
Puligilla, C
Chan, SL
Timothy, C
Depireux, DA
Ahmed, Z
Wolf, J
Eisenman, DJ
Friedman, TB
Riazuddin, S
Kelley, MW
Strome, SE
AF Hertzano, Ronna
Puligilla, Chandrakala
Chan, Siaw-Lin
Timothy, Caroline
Depireux, Didier A.
Ahmed, Zubair
Wolf, Jeffrey
Eisenman, David J.
Friedman, Thomas B.
Riazuddin, Sheikh
Kelley, Matthew W.
Strome, Scott E.
TI CD44 is a Marker for the Outer Pillar Cells in the Early Postnatal Mouse
Inner Ear
SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY
LA English
DT Article
DE CD44; FGFR3; cochlea; outer pillar cells; deafness
ID HEARING-LOSS; HAIR-CELLS; EXPRESSION; GENE; ORGAN; CORTI; COCHLEA;
DIFFERENTIATION; EPITHELIA; DEAFNESS
AB Cluster of differentiation antigens (CD proteins) are classically used as immune cell markers. However, their expression within the inner ear is still largely undefined. In this study, we explored the possibility that specific CD proteins might be useful for defining inner ear cell populations. mRNA expression profiling of microdissected auditory and vestibular sensory epithelia revealed 107 CD genes as expressed in the early postnatal mouse inner ear. The expression of 68 CD genes was validated with real-time RT-PCR using RNA extracted from microdissected sensory epithelia of cochleae, utricles, saccules, and cristae of newborn mice. Specifically, CD44 was identified as preferentially expressed in the auditory sensory epithelium. Immunohistochemistry revealed that within the early postnatal organ of Corti, the expression of CD44 is restricted to outer pillar cells. In order to confirm and expand this finding, we characterized the expression of CD44 in two different strains of mice with loss- and gain-of-function mutations in Fgfr3 which encodes a receptor for FGF8 that is essential for pillar cell development. We found that the expression of CD44 is abolished from the immature pillar cells in homozygous Fgfr3 knockout mice. In contrast, both the outer pillar cells and the aberrant Deiters' cells in the Fgfr3 (P244R/) (+) mice express CD44. The deafness phenotype segregating in DFNB51 families maps to a linkage interval that includes CD44. To study the potential role of CD44 in hearing, we characterized the auditory system of CD44 knockout mice and sequenced the entire open reading frame of CD44 of affected members of DFNB51 families. Our results suggest that CD44 does not underlie the deafness phenotype of the DFNB51 families. Finally, our study reveals multiple potential new cell type-specific markers in the mouse inner ear and identifies a new marker for outer pillar cells.
C1 [Hertzano, Ronna; Chan, Siaw-Lin; Timothy, Caroline; Wolf, Jeffrey; Eisenman, David J.; Strome, Scott E.] Univ Maryland, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA.
[Puligilla, Chandrakala; Kelley, Matthew W.] Natl Inst Deafness & Other Commun Disorders, Sect Dev Neurosci, NIH, Bethesda, MD 20892 USA.
[Depireux, Didier A.] Univ Maryland, Sch Engn, Syst Res Inst, College Pk, MD 20742 USA.
[Ahmed, Zubair] Childrens Hosp Res Fdn, Div Pediat Ophthalmol, Cincinnati, OH 45229 USA.
[Ahmed, Zubair] Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH 45229 USA.
[Friedman, Thomas B.] Natl Inst Deafness & Other Commun Disorders, Sect Human Genet, Mol Genet Lab, NIH, Rockville, MD 20850 USA.
[Riazuddin, Sheikh] Univ Punjab, Natl Ctr Excellence Mol Biol, Lahore, Pakistan.
RP Hertzano, R (reprint author), Univ Maryland, Dept Otorhinolaryngol Head & Neck Surg, 16 S Eutaw St,Suite 500, Baltimore, MD 21201 USA.
EM rhertzano@smail.umaryland.edu
FU American Academy of Otolaryngology-Head and Neck Surgery Foundation;
Deafness Research Foundation; NIDCD [1-Z01-000070, 1-Z01-000039]
FX We are grateful to Janice K. Babus, Yadong Ji, Amiel A. Dror and Dr.
Weise Chang for technical assistance, Dr. Suzi Mansour and Chaoying Li
for sending us the Fgfr3-P244R mutant mice. We thank Dr. Karen B.
Avraham for sharing unpublished data, and Dr. Tomoko Makishima for
critically reviewing this manuscript. Finally, we thank Dr. Strome's
laboratory members for their technical help and advice. This research
was supported by a resident research grant provided by the American
Academy of Otolaryngology-Head and Neck Surgery Foundation (R.H.), a
Deafness Research Foundation grant (R.H.) and by funds from the
Intramural Program at NIDCD 1-Z01-000070 (M.W.K), and 1-Z01-000039
(T.B.F).
NR 41
TC 16
Z9 16
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1525-3961
J9 JARO-J ASSOC RES OTO
JI JARO
PD SEP
PY 2010
VL 11
IS 3
BP 407
EP 418
DI 10.1007/s10162-010-0211-x
PG 12
WC Neurosciences; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 634QO
UT WOS:000280598300006
PM 20386946
ER
PT J
AU Jesus, AA
Oliveira, JB
Hilario, MOE
Terreri, MTRA
Fujihira, E
Watase, M
Carneiro-Sampaio, M
Silva, CAA
AF Jesus, Adriana Almeida
Oliveira, Joao Bosco
Esteves Hilario, Maria Odete
Terreri, Maria Teresa R. A.
Fujihira, Erika
Watase, Mariana
Carneiro-Sampaio, Magda
Almeida Silva, Clovis Artur
TI Pediatric hereditary autoinflammatory syndromes
SO JORNAL DE PEDIATRIA
LA English
DT Review
DE Autoinflammatory syndromes; child; familial Mediterranean fever;
cryopyrinopathies; TRAPS; NOMID
ID FAMILIAL MEDITERRANEAN FEVER; HYPER-IGD SYNDROME; MEVALONATE
KINASE-DEFICIENCY; RECURRENT MULTIFOCAL OSTEOMYELITIS; PERIODIC SYNDROME
TRAPS; MUCKLE-WELLS-SYNDROME; CONGENITAL DYSERYTHROPOIETIC ANEMIA;
HYPERIMMUNOGLOBULINEMIA-D SYNDROME; NERVOUS-SYSTEM INVOLVEMENT; TNF
RECEPTOR
AB Objective: To describe the most prevalent pediatric hereditary autoinflammatory syndromes.
Sources: A review of the literature including relevant references from the PubMed and SciELO was carried out using the keywords autoinflammatory syndromes and child.
Summary of the findings: The hereditary autoinflammatory syndromes are caused by monogenic defects of innate immunity and are classified as primary immunodeficiencies. These syndromes are characterized by recurrent or persistent systemic inflammatory symptoms and must be distinguished from infectious diseases, autoimmune diseases, and other primary immunodeficiencies. This review describes the epidemiological, clinical and laboratory features, prognosis, and treatment of the main autoinflammatory syndromes, namely: familial Mediterranean fever; TNF receptor associated periodic syndrome; the cryopyrinopathies; mevalonate kinase deficiency; pediatric granulomatous arthritis; pyogenic arthritis, pyoderma gangrenosum and acne syndrome; Majeed syndrome; and deficiency of interleukin 1 receptor antagonist. The cryopyrinopathies discussed include neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurologic, cutaneous and articular syndrome) Muckle-Wells syndrome, and familial cold autoinflammatory syndrome.
Conclusions: Pediatricians must recognize the clinical features of the most prevalent autoinflammatory syndromes. Early referral to a pediatric rheumatologist may allow early diagnosis and institution of treatment, with improvement in the quality of life of these patients.
C1 [Almeida Silva, Clovis Artur] Univ Sao Paulo, Fac Med, Hosp Clin, Inst Crianca,Unidade Reumatol Pediat,Disciplina R, BR-09500900 Sao Paulo, Brazil.
[Oliveira, Joao Bosco] NIH, Human Disorders Lymphocyte Homeostasis Unit, Serv Immunol, DLM,CC, Bethesda, MD 20892 USA.
[Esteves Hilario, Maria Odete; Terreri, Maria Teresa R. A.] Univ Fed Sao Paulo, Disciplina Alergia Imunol & Reumatol, Setor Reumatol Pediat, Sao Paulo, Brazil.
[Fujihira, Erika; Watase, Mariana] Univ Sao Paulo, Fac Med, Dept Dermatol, Secao Genet & Imunol Mol,Lab Invest Med 56, BR-09500900 Sao Paulo, Brazil.
[Carneiro-Sampaio, Magda] Univ Sao Paulo, Fac Med, Hosp Clin, Inst Crianca,Unidade Alergia & Imunol Pediat, BR-09500900 Sao Paulo, Brazil.
RP Silva, CAA (reprint author), Rua Araioses 152-81, BR-05442010 Sao Paulo, Brazil.
EM clovis.silva@icr.usp.br
OI Oliveira, Joao/0000-0001-9388-8173
FU Sao Paulo State Research Foundation (Fundacao de Amparo a Pesquisa do
Estado de Sao Paulo, FAPESP) [0568/09]; National Council for Scientific
and Technological Development (Conselho Nacional de Desenvolvimento
Cientifico e Tecnologico, CNPq) [300248/2008-3]
FX This study was supported by grants from the Sao Paulo State Research
Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo,
FAPESP; grant no. 0568/09; recipient, CAAS) and the National Council for
Scientific and Technological Development (Conselho Nacional de
Desenvolvimento Cientifico e Tecnologico, CNPq; grant no. 300248/2008-3;
recipient, CAAS).
NR 129
TC 4
Z9 4
U1 0
U2 2
PU SOC BRASIL PEDIATRIA
PI RIO DE JANEIRO, RJ
PA RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL
SN 0021-7557
EI 1678-4782
J9 J PEDIAT-BRAZIL
JI J. Pediatr.
PD SEP-OCT
PY 2010
VL 86
IS 5
BP 353
EP 366
DI 10.2223/JPED.2015
PG 14
WC Pediatrics
SC Pediatrics
GA 680NQ
UT WOS:000284241400003
PM 20938587
ER
PT J
AU Hernandez, ML
Lay, JC
Harris, B
Esther, CR
Brickey, WJ
Bromberg, PA
Diaz-Sanchez, D
Devlin, RB
Kleeberger, SR
Alexis, NE
Peden, DB
AF Hernandez, Michelle L.
Lay, John C.
Harris, Bradford
Esther, Charles R., Jr.
Brickey, W. June
Bromberg, Philip A.
Diaz-Sanchez, David
Devlin, Robert B.
Kleeberger, Steven R.
Alexis, Neil E.
Peden, David B.
TI Atopic asthmatic subjects but not atopic subjects without asthma have
enhanced inflammatory response to ozone
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Ozone; innate immunity; asthma; atopy; hyaluronic acid; environmental
airways disease; IL-1 beta; IL-10
ID TOLL-LIKE RECEPTOR-4; MILD ALLERGIC-ASTHMA; 0.16 PPM OZONE; AIRWAY
INFLAMMATION; LUNG INJURY; HEALTHY-VOLUNTEERS; INNATE IMMUNITY; IN-VIVO;
EXPOSURE; HYALURONAN
AB Background: Asthma is a known risk factor for acute ozone-associated respiratory disease. Ozone causes an immediate decrease in lung function and increased airway inflammation. The role of atopy and asthma in modulation of ozone-induced inflammation has not been determined.
Objective: We sought to determine whether atopic status modulates ozone response phenotypes in human subjects.
Methods: Fifty volunteers (25 healthy volunteers, 14 atopic nonasthmatic subjects, and 11 atopic asthmatic subjects not requiring maintenance therapy) underwent a 0.4-ppm ozone exposure protocol. Ozone response was determined based on changes in lung function and induced sputum composition, including airway inflammatory cell concentration, cell-surface markers, and cytokine and hyaluronic acid concentrations.
Results: All cohorts experienced similar decreases in lung function after ozone. Atopic and atopic asthmatic subjects had increased sputum neutrophil numbers and IL-8 levels after ozone exposure; values did not significantly change in healthy volunteers. After ozone exposure, atopic asthmatic subjects had significantly increased sputum IL-6 and IL-1 beta levels and airway macrophage Toll-like receptor 4, Fc epsilon RI, and CD23 expression; values in healthy volunteers and atopic nonasthmatic subjects showed no significant change. Atopic asthmatic subjects had significantly decreased IL-10 levels at baseline compared with healthy volunteers; IL-10 levels did not significantly change in any group with ozone. All groups had similar levels of hyaluronic acid at baseline, with increased levels after ozone exposure in atopic and atopic asthmatic subjects.
Conclusion: Atopic asthmatic subjects have increased airway inflammatory responses to ozone. Increased Toll-like receptor 4 expression suggests a potential pathway through which ozone generates the inflammatory response in allergic asthmatic subjects but not in atopic subjects without asthma. (J Allergy Clin Immunol 2010;126:537-44.)
C1 [Hernandez, Michelle L.; Lay, John C.; Harris, Bradford; Esther, Charles R., Jr.; Alexis, Neil E.; Peden, David B.] Univ N Carolina, Dept Pediat, Sch Med, Chapel Hill, NC 27599 USA.
[Hernandez, Michelle L.; Lay, John C.; Harris, Bradford; Alexis, Neil E.; Peden, David B.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Sch Med, Chapel Hill, NC 27599 USA.
[Bromberg, Philip A.; Peden, David B.] Univ N Carolina, Dept Med, Sch Med, Chapel Hill, NC 27599 USA.
[Brickey, W. June; Peden, David B.] Univ N Carolina, Dept Microbiol Immunol, Chapel Hill, NC 27599 USA.
[Kleeberger, Steven R.] Natl Inst Environm Hlth Sci, Lab Resp Biol, Res Triangle Pk, NC USA.
[Diaz-Sanchez, David; Devlin, Robert B.] US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA.
RP Hernandez, ML (reprint author), Univ N Carolina, Dept Pediat, Sch Med, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.
EM Michelle_Hernandez@med.unc.edu
RI Lay, John/A-6380-2012
FU National Institute of Environmental Health Sciences [R01ES012706,
P30ES010126]; National Institute for Allergy and Infectious Diseases
[U19AI077437]; National Center for Complementary and Alternative
Medicine [P01AT002620]; National Institutes of Health [KL2RR025746,
M01RR00046, UL1RR025747]; US Environmental Protection Agency [CR
83346301]; Center for Environmental Medicine and Lung Biology at the
University of North Carolina at Chapel Hill; Environmental Protection
Agency
FX Supported in part by grants R01ES012706 and P30ES010126 from the
National Institute of Environmental Health Sciences, U19AI077437 from
the National Institute for Allergy and Infectious Diseases, P01AT002620
from the National Center for Complementary and Alternative Medicine, and
KL2RR025746, M01RR00046, and UL1RR025747 from the National Center of
Research Resources of the National Institutes of Health, as well as CR
83346301 from the US Environmental Protection Agency.; Although the
research described in this article has been funded wholly or in part by
the United States Environmental Protection Agency through cooperative
agreement CR 83346301 with the Center for Environmental Medicine and
Lung Biology at the University of North Carolina at Chapel Hill, it has
not been subjected to the Agency's required peer and policy review and
therefore does not necessarily reflect the views of the Agency, and no
official endorsement should be inferred.; Disclosure of potential
conflict of interest: P. A. Bromberg has received research support from
the US Environmental Protection Agency. D. B. Peden is a consultant for
Funxional Therapeutics and GlaxoSmithKline and has received research
support from the National Institutes of Health and the Environmental
Protection Agency. The rest of the authors have declared that they have
no conflict of interest.
NR 58
TC 39
Z9 41
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD SEP
PY 2010
VL 126
IS 3
BP 537
EP U228
DI 10.1016/j.jaci.2010.06.043
PG 9
WC Allergy; Immunology
SC Allergy; Immunology
GA 646CF
UT WOS:000281512500020
PM 20816188
ER
PT J
AU Merenstein, DJ
Hu, HH
Robison, E
Levine, AM
Greenblatt, R
Schwartz, R
Weber, K
Young, M
Sharp, G
Liu, CL
AF Merenstein, Daniel J.
Hu, Haihong
Robison, Esther
Levine, Alexandra M.
Greenblatt, Ruth
Schwartz, Rebecca
Weber, Kathleen
Young, Mary
Sharp, Gerald
Liu, Chenglong
TI Relationship Between Complementary/Alternative Treatment Use and Illicit
Drug Use Among a Cohort of Women with, or at Risk for, HIV Infection
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; ALTERNATIVE
MEDICINE USE; SUBSTANCE-ABUSE; AURICULAR ACUPUNCTURE; DISEASE
PROGRESSION; INTERAGENCY HIV; ADHERENCE; ASSOCIATION; COCAINE
AB Objectives: Two of the most pressing public health challenges in the United States are treating human immunodeficiency virus (HIV) infection and illegal substance use. High rates of complementary and alternative medicine (CAM) use have been reported by individuals who suffer from both of these diseases. The goal of this study was to examine the relationship between CAM use and illegal substance use in a cohort of women with HIV or at risk for HIV disease. Based on previous research, it was hypothesized that CAM use may decrease substance use.
Design: This was a longitudinal cohort study.
Subjects: The subjects comprised Women in the Women's Interagency HIV Study.
Outcome measures: The role of CAM use in illegal substance use was examined. Due to the hierarchical structure of the dataset, logistic regression analysis adjusting for repeated measurements (generalized estimating equation model) was carried out to assess associations of CAM use and illicit drug use.
Results: There were 2176 women included in the analysis. After excluding for marijuana use, CAM use was associated with less drug use (odds ratio 0.82; 95% confidence interval: 0.73, 0.90).
Conclusions: The results supported our hypothesis that CAM users are more health conscious and thus less likely to use illicit drugs. Future studies should target both specific drugs and CAM modalities to help finalize this association.
C1 [Merenstein, Daniel J.] Georgetown Univ, Med Ctr, Dept Family Med, Washington, DC 20007 USA.
[Hu, Haihong; Young, Mary; Liu, Chenglong] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA.
[Robison, Esther] Montefiore Med Ctr, Dept Med, Div Gen Internal Med, Bronx, NY 10467 USA.
[Levine, Alexandra M.] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Greenblatt, Ruth] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Schwartz, Rebecca] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
[Weber, Kathleen] CORE Ctr John H Stroger Jr Hosp Cook Cty, Chicago, IL USA.
[Sharp, Gerald] NIAID, Basic Sci Program, NIH, Bethesda, MD 20892 USA.
RP Merenstein, DJ (reprint author), Georgetown Univ, Med Ctr, Dept Family Med, 417 Kober Cogan Hall 3800 Reservoir Rd NW, Washington, DC 20007 USA.
EM djm23@georgetown.edu
FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590];
National Institute of Child Health and Human Development [UO1-HD-32632];
National Cancer Institute; National Institute on Drug Abuse; National
Institute on Deafness and Other Communication Disorders; National Center
for Research Resources [UL1 RR024131]
FX Data in this article were collected by the Women's Interagency HIV Study
(WIHS) Collaborative Study Group with centers (Principal Investigators)
at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY
(Howard Minkoff); Washington DC Metropolitan Consortium (Mary Young);
The Connie Wofsy Study Consortium of Northern California (Ruth
Greenblatt); Los Angeles County/Southern California Consortium
(Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating
Center (Stephen Gange). The WIHS is funded by the National Institute of
Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834,
UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the
National Institute of Child Health and Human Development (UO1-HD-32632).
The study is co-funded by the National Cancer Institute, the National
Institute on Drug Abuse, and the National Institute on Deafness and
Other Communication Disorders. Funding is also provided by the National
Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). The
contents of this publication are solely the responsibility of the
authors and do not necessarily represent the official views of the
National Institutes of Health.
NR 37
TC 4
Z9 4
U1 2
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD SEP
PY 2010
VL 16
IS 9
BP 989
EP 993
DI 10.1089/acm.2009.0584
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 650TG
UT WOS:000281874700012
PM 20738164
ER
PT J
AU Ahn, AC
Nahin, RL
Calabrese, C
Folkman, S
Kimbrough, E
Shoham, J
Haramati, A
AF Ahn, Andrew C.
Nahin, Richard L.
Calabrese, Carlo
Folkman, Susan
Kimbrough, Elizabeth
Shoham, Jacob
Haramati, Aviad
TI Applying Principles from Complex Systems to Studying the Efficacy of CAM
Therapies
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
ID B-CELL LYMPHOMA; MORTALITY; SURVIVAL; DYNAMICS
AB In October 2007, a National Center for Complementary and Alternative Medicine (NCCAM)-sponsored workshop, entitled "Applying Principles from Complex Systems to Studying the Efficacy of CAM Therapies,'' was held at Georgetown University in Washington, DC. Over a 2-day period, the workshop engaged a small group of experts from the fields of complementary and alternative medicine (CAM) research and complexity science to discuss and examine ways in which complexity science can be applied to CAM research. After didactic presentations and small-group discussions, a number of salient themes and ideas emerged. This paper article describes the workshop program and summarizes these emergent ideas, which are divided into five broad categories: (1) introduction to complexity; (2) challenges to CAM research; (3) applications of complexity science to CAM; (4) CAM as a model of complexity applied to medicine; and (5) future directions. This discusses possible benefits and challenges associated with applying complexity science to CAM research. By providing an introductory framework for this collaboration and exchange, it is hoped that this article may stimulate further inquiry into this largely unexplored area of research.
C1 [Ahn, Andrew C.] Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, Boston, MA 02215 USA.
[Ahn, Andrew C.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Nahin, Richard L.] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA.
[Calabrese, Carlo] Natl Coll Nat Med, Helfgott Res Inst, Portland, OR USA.
[Folkman, Susan] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA.
[Kimbrough, Elizabeth] Univ Maryland, Ctr Integrat Med, Baltimore, MD 21201 USA.
[Shoham, Jacob] Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel.
[Haramati, Aviad] Georgetown Univ, Sch Med, Dept Physiol & Biophys, Washington, DC 20007 USA.
[Haramati, Aviad] Georgetown Univ, Sch Med, Dept Med, Washington, DC USA.
RP Ahn, AC (reprint author), Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, 401 Pk Dr Suite 22A W, Boston, MA 02215 USA.
EM aahn@hms.harvard.edu
OI Nahin, Richard/0000-0002-3682-4816
FU National Center for Complementary and Alternative Medicine (NCCAM) at
the National Institutes of Health [R25-AT00419]; Institute for
Integrative Health
FX Support for convening the 21/2-dayworkshop was provided by a grant
(R25-AT00419) from the National Center for Complementary and Alternative
Medicine (NCCAM) at the National Institutes of Health, funds from the
Institute for Integrative Health, a nonprofit organization located in
Baltimore, MD, that aims to catalyze innovative ideas in health care,
and Georgetown University School of Medicine, in Washington, DC.
NR 17
TC 8
Z9 8
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD SEP
PY 2010
VL 16
IS 9
BP 1015
EP 1022
DI 10.1089/acm.2009.0593
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 650TG
UT WOS:000281874700017
PM 20715978
ER
PT J
AU Hild, SA
Attardi, BJ
Koduri, S
Till, BA
Reel, JR
AF Hild, Sheri Ann
Attardi, Barbara J.
Koduri, Sailaja
Till, Bruce A.
Reel, Jerry R.
TI Effects of Synthetic Androgens on Liver Function Using the Rabbit as a
Model
SO JOURNAL OF ANDROLOGY
LA English
DT Article
DE Dimethandrolone-17 beta-undecanoate,11 beta-methyl-19-nortestosterone-17
beta-dodecylcarbonate; bromsulfonphthalein; hepatotoxicity
ID PERFUSED-RAT-LIVER; GLUTAMIC PYRUVIC TRANSAMINASE; ORALLY-ACTIVE
ANDROGEN; SORBITOL DEHYDROGENASE; ANABOLIC-STEROIDS; HEPATIC DISEASE;
HEPATOTOXICITY; BROMOSULFOPHTHALEIN; TOXICITY; METHYLTESTOSTERONE
AB The objective of this study was to determine whether the rabbit was a suitable model to test new synthetic androgens for potential liver toxicity within a short dosing interval. Adult male rabbits were dosed orally daily on days 0-13 with 17 alpha-methyltes-tosterone (MT) as a positive control and testosterone (T) as a negative control to validate this model. Synthetic androgens tested were: 7 alpha-methyl-19-nortestosterone (MENT), dimethandrolone-un-decanote (DMAU), and 11 beta-methyl-19-nortestosterone-17 beta-dodecylcarbonate (11 beta-MNTDC). Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), and sorbitol dehydrogenase (SDH), as well as clearance of intravenous injected bromsulfonphthalein (BSP) from serum on days 0, 7, and 14, were determined. As expected, T (10 mg/kg/d) did not adversely affect BSP retention or serum liver enzymes. MT (10 mg/kg/d) increased BSP retention, and AST, ALT, GGT, and SDH levels, indicating that this model could detect androgens known to be hepatotoxic. DMAU and MENT (10 mg/kg/d) increased BSP retention and all 4 serum liver enzymes as well, but the effects were less than those observed with MT at the same dose. All parameters returned to baseline 2 weeks after cessation of dosing. 11 beta-MNTDC at 10 mg/kg/d did not have an effect on BSP retention or liver enzymes, but a slight increase in serum GGT levels was observed in rabbits treated with 25 mg/kg/d. For the androgens that exhibited liver toxicity at 10 mg/kg/d (MT, DMAU, and MENT), a no-observed-effect level of 1 mg/kg/d was established. Overall ranking of the synthetic androgens from most to least hepatotoxic on the basis of percent BSP retention was: MT >> MAU > MENT > 11 beta-MNTDC. Hence, the rabbit appears to be a promising model for detection of potential liver toxicity by synthetic androgens using BSP clearance and serum liver enzyme levels as early indicators of injury.
C1 [Hild, Sheri Ann; Attardi, Barbara J.; Koduri, Sailaja; Till, Bruce A.; Reel, Jerry R.] BIOQUAL Inc, Div Reprod Endocrinol & Toxicol, Rockville, MD USA.
RP Hild, SA (reprint author), NIH, Off Review, Natl Ctr Res Resources, 6701 Democracy Blvd,Room 1082, Bethesda, MD 20892 USA.
EM hildsa@mail.nih.gov
FU National Institute of Child Health and Human Development [NO1-HD-2-3338]
FX This work was supported by the National Institute of Child Health and
Human Development contract NO1-HD-2-3338 awarded to BIOQUAL Inc.
NR 38
TC 7
Z9 8
U1 0
U2 0
PU AMER SOC ANDROLOGY, INC
PI LAWRENCE
PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA
SN 0196-3635
J9 J ANDROL
JI J. Androl.
PD SEP-OCT
PY 2010
VL 31
IS 5
BP 472
EP 481
DI 10.2164/jandrol.109.009365
PG 10
WC Andrology
SC Endocrinology & Metabolism
GA 676ER
UT WOS:000283893400008
PM 20378929
ER
PT J
AU Visness, CM
London, SJ
Daniels, JL
Kaufman, JS
Yeatts, KB
Siega-Riz, AM
Calatroni, A
Zeldin, DC
AF Visness, Cynthia M.
London, Stephanie J.
Daniels, Julie L.
Kaufman, Jay S.
Yeatts, Karin B.
Siega-Riz, Anna-Maria
Calatroni, Agustin
Zeldin, Darryl C.
TI Association of Childhood Obesity With Atopic and Nonatopic Asthma:
Results From the National Health and Nutrition Examination Survey
1999-2006
SO JOURNAL OF ASTHMA
LA English
DT Article
DE asthma; atopy; BMI; obesity
ID BODY-MASS INDEX; C-REACTIVE PROTEIN; CHILDREN; OVERWEIGHT; SEVERITY;
SYMPTOMS; SAMPLE; COHORT; ADULTS; RISK
AB Background. Obesity and asthma prevalence have both risen among children over the last several decades, and research efforts increasingly suggest that obesity is associated with asthma. Some, but not all, studies have shown that the effect of obesity on asthma is stronger among nonatopic individuals than among those with atopy. Systemic inflammation may be a factor in this relationship. Objective. To examine the association of obesity with atopic and nonatopic asthma among U. S. children and to assess the role of C-reactive protein. Design. Nationally representative data from the National Health and Nutrition Examination Survey (NHANES) were used to examine the relationship of weight to current asthma using logistic regression. Overweight was defined as >= 85th percentile of body mass index (BMI)-for-age and obesity was defined as >= 95th percentile of BMI-for-age. The presence of at least one positive allergen-specific immunoglobulin E (IgE) was used to stratify the relationship by atopic status in 2005-2006 data (n = 3387). Setting and Participants. Stratified, multistage probability sampling was used to identify survey participants. This analysis includes children ages 2-19 (n = 16,074) from the 1999-2006 NHANES who have information on BMI and current asthma. Main Outcome Measure. Self-report of doctor-diagnosed current asthma. Results. Obesity was significantly related to current asthma among children and adolescents (odds ratio [OR]: 1.68, 95% confidence interval [CI]: 1.33, 2.12). The association was stronger in nonatopic children (OR: 2.46, 95% CI: 1.21, 5.02) than in atopic children (OR: 1.34, 95% CI: 0.70, 2.57) (interaction p value = .09). C-reactive protein levels were associated with current asthma in nonatopic children, but not after adjusting for BMI. Conclusion. Excess weight in children is associated with higher rates of asthma, especially asthma that is not accompanied by allergic disease.
C1 [Visness, Cynthia M.; Calatroni, Agustin] Rho Fed Syst Div Inc, Chapel Hill, NC 27517 USA.
[Visness, Cynthia M.; Daniels, Julie L.; Kaufman, Jay S.; Yeatts, Karin B.; Siega-Riz, Anna-Maria] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[London, Stephanie J.; Zeldin, Darryl C.] Natl Inst Environm Hlth Sci, Div Intramural Res, Res Triangle Pk, NC USA.
[Kaufman, Jay S.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
RP Visness, CM (reprint author), Rho Fed Syst Div Inc, 6330 Quadrangle Dr,Suite 500, Chapel Hill, NC 27517 USA.
EM cindy_visness@rhoworld.com
OI Kaufman, Jay/0000-0003-1606-401X; London, Stephanie/0000-0003-4911-5290
FU National Institutes of Health, National Institute of Environmental
Health Sciences (NIEHS) [Z01 ES025041]; National Institute of Allergy
and Infectious Diseases (NIAID), National Institutes of Health [N01
AI-25482]
FX This research was supported in part by the Intramural Research Program
of the National Institutes of Health, National Institute of
Environmental Health Sciences (NIEHS), under grant number Z01 ES025041
and by the National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health, under contract number N01
AI-25482.
NR 30
TC 80
Z9 85
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0277-0903
J9 J ASTHMA
JI J. Asthma
PD SEP
PY 2010
VL 47
IS 7
BP 822
EP 829
DI 10.3109/02770903.2010.489388
PG 8
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA 658VR
UT WOS:000282519500019
PM 20707763
ER
PT J
AU Baudino, L
Yoshinobu, K
Dunand-Sauthier, I
Evans, LH
Izui, S
AF Baudino, Lucie
Yoshinobu, Kumiko
Dunand-Sauthier, Isabelle
Evans, Leonard H.
Izui, Shozo
TI TLR-mediated up-regulation of serum retroviral gp70 is controlled by the
Sgp loci of lupus-prone mice
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE Toll-like receptor; Systemic lupus etythematosus; Endogenous retrovirus;
Acute phase protein
ID MURINE LEUKEMIA-VIRUS; TOLL-LIKE RECEPTORS; NEW-ZEALAND MICE; BXSB MICE;
ENVELOPE GLYCOPROTEIN; AUTOIMMUNE-DISEASE; IMMUNE-COMPLEXES; DNA
METHYLATION; GENE-EXPRESSION; AUTOANTIBODY PRODUCTION
AB The endogenous retroviral envelope glycoprotein, gp70, implicated in murine systemic lupus erythematosus (SLE), has been considered to be a product of xenotropic, polytropic (PT) and modified PT (mPT) endogenous retroviruses. It is secreted by hepatocytes like an acute phase protein, but its response is under a genetic control. Given critical roles of TLR7 and TLR9 in the pathogenesis of SLE, we assessed their contribution to the acute phase expression of serum gp70, and defined a pivotal role of the Sgp3 (serum gp70 production 3) and Sgp4 loci in this response. Our results demonstrated that serum levels of gp70 were up-regulated in lupus-prone NZB mice injected with TLR7 or TLR9 agonist at levels comparable to those induced by injection of IL-1, IL-6 or TNF. In addition, studies of C57BL/6 Sgp3 and/or Sgp4 congenic mice defined the major roles of these two loci in up-regulated production of serum gp70 during acute phase responses. Finally, the analysis of Sgp3 congenic mice strongly suggests the presence of at least two distinct genetic factors in the Sgp3 interval, one of which controlled the basal-level expression of xenotropic, PT and mPT gp70 and the other which controlled the up-regulated production of xenotropic and mPT gp70 during acute phase responses. Our results uncovered an additional pathogenic role of TLR7 and TLR9 in murine lupus nephritis by promoting the expression of nephritogenic gp70 autoantigen. Furthermore, they revealed the involvement of multiple regulatory genes for the expression of gp70 autoantigen under steady-state and inflammatory conditions in lupus-prone mice. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Baudino, Lucie; Yoshinobu, Kumiko; Dunand-Sauthier, Isabelle; Izui, Shozo] Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland.
[Evans, Leonard H.] NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, Hamilton, MT 59840 USA.
RP Izui, S (reprint author), Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland.
EM Shozo.Izui@unige.ch
FU Swiss National Foundation for Scientific Research; National Institute of
Allergy and Infectious Diseases, National Institutes of Health
FX We thank Mr Guy Brighouse and Ms Montserrat Alvarez for their excellent
technical assistance. This work was supported by a grant from the Swiss
National Foundation for Scientific Research. L.H.E. was supported by the
Intramural Research Program of the National Institute of Allergy and
Infectious Diseases, National Institutes of Health.
NR 46
TC 15
Z9 15
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD SEP
PY 2010
VL 35
IS 2
BP 153
EP 159
DI 10.1016/j.jaut.2010.06.001
PG 7
WC Immunology
SC Immunology
GA 652EX
UT WOS:000281986100007
PM 20619604
ER
PT J
AU Shen, Y
Bax, A
AF Shen, Yang
Bax, Ad
TI SPARTA plus : a modest improvement in empirical NMR chemical shift
prediction by means of an artificial neural network
SO JOURNAL OF BIOMOLECULAR NMR
LA English
DT Article
DE Electric field; Hydrogen bonding; Torsion angles; SHIFTX; Structure
database; Camshift; SPARTA
ID PROTEIN-STRUCTURE DETERMINATION; C-13 NMR; SEQUENCE HOMOLOGY; TORSION
ANGLES; NUCLEIC-ACIDS; C-ALPHA; CONFORMATION; DYNAMICS; DATABASE;
C-13(ALPHA)
AB NMR chemical shifts provide important local structural information for proteins and are key in recently described protein structure generation protocols. We describe a new chemical shift prediction program, SPARTA+, which is based on artificial neural networking. The neural network is trained on a large carefully pruned database, containing 580 proteins for which high-resolution X-ray structures and nearly complete backbone and (13)C(beta) chemical shifts are available. The neural network is trained to establish quantitative relations between chemical shifts and protein structures, including backbone and side-chain conformation, H-bonding, electric fields and ring-current effects. The trained neural network yields rapid chemical shift prediction for backbone and (13)C(beta) atoms, with standard deviations of 2.45, 1.09, 0.94, 1.14, 0.25 and 0.49 ppm for delta(15)N, delta(13)C, delta(13)C(alpha), delta(13)C(beta), delta(1)H(alpha) and delta(1)H(N), respectively, between the SPARTA+ predicted and experimental shifts for a set of eleven validation proteins. These results represent a modest but consistent improvement (2-10%) over the best programs available to date, and appear to be approaching the limit at which empirical approaches can predict chemical shifts.
C1 [Shen, Yang; Bax, Ad] NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
RP Bax, A (reprint author), NIDDKD, Chem Phys Lab, NIH, Bldg 5,Room 126, Bethesda, MD 20892 USA.
EM bax@nih.gov
RI Shen, Yang/C-3064-2008
OI Shen, Yang/0000-0003-1408-8034
FU NIDDK; NIH; Office of the Director of the NIH
FX This work was supported by the Intramural Research Program of the NIDDK,
NIH, and by the Intramural AIDS-Targeted Antiviral Program of the Office
of the Director of the NIH.
NR 41
TC 175
Z9 175
U1 1
U2 38
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0925-2738
J9 J BIOMOL NMR
JI J. Biomol. NMR
PD SEP
PY 2010
VL 48
IS 1
BP 13
EP 22
DI 10.1007/s10858-010-9433-9
PG 10
WC Biochemistry & Molecular Biology; Spectroscopy
SC Biochemistry & Molecular Biology; Spectroscopy
GA 653OT
UT WOS:000282102300002
PM 20628786
ER
PT J
AU Butterfoss, GL
DeRose, EF
Gabel, SA
Perera, L
Krahn, JM
Mueller, GA
Zheng, XH
London, RE
AF Butterfoss, Glenn L.
DeRose, Eugene F.
Gabel, Scott A.
Perera, Lalith
Krahn, Joseph M.
Mueller, Geoffrey A.
Zheng, Xunhai
London, Robert E.
TI Conformational dependence of C-13 shielding and coupling constants for
methionine methyl groups
SO JOURNAL OF BIOMOLECULAR NMR
LA English
DT Article
DE Methionine; [methyl-C-13] methionine; Calmodulin; NMR; Karplus relation;
(3)J(CSCC); Scalar coupling constants
ID NUCLEAR-MAGNETIC-RESONANCE; CARDIAC TROPONIN-C; DNA-POLYMERASE-DELTA;
SEQUENCE-INDEPENDENT RECOGNITION; HIV-1 REVERSE-TRANSCRIPTASE;
SPERM-WHALE MYOGLOBIN; MYELIN BASIC-PROTEIN; NMR CHEMICAL-SHIFTS; HUMAN
TRANSFERRIN; SIDE-CHAINS
AB Methionine residues fulfill a broad range of roles in protein function related to conformational plasticity, ligand binding, and sensing/mediating the effects of oxidative stress. A high degree of internal mobility, intrinsic detection sensitivity of the methyl group, and low copy number have made methionine labeling a popular approach for NMR investigation of selectively labeled protein macromolecules. However, selective labeling approaches are subject to more limited information content. In order to optimize the information available from such studies, we have performed DFT calculations on model systems to evaluate the conformational dependence of (3)J(CSCC), (3)J(CSCH), and the isotropic shielding, sigma(iso). Results have been compared with experimental data reported in the literature, as well as data obtained on [methyl-C-13]methionine and on model compounds. These studies indicate that relative to oxygen, the presence of the sulfur atom in the coupling pathway results in a significantly smaller coupling constant, (3)J(CSCC)/(3)J(COCC) similar to 0.7. It is further demonstrated that the (3)J(CSCH) coupling constant depends primarily on the subtended CSCH dihedral angle, and secondarily on the CSCC dihedral angle. Comparison of theoretical shielding calculations with the experimental shift range of the methyl group for methionine residues in proteins supports the conclusion that the intra-residue conformationally-dependent shift perturbation is the dominant determinant of delta C-13(epsilon). Analysis of calmodulin data based on these calculations indicates that several residues adopt non-standard rotamers characterized by very large similar to 100 degrees chi(3) values. The utility of the delta C-13(epsilon) as a basis for estimating the gauchel trans ratio for chi(3) is evaluated, and physical and technical factors that limit the accuracy of both the NMR and crystallographic analyses are discussed.
C1 [DeRose, Eugene F.; Gabel, Scott A.; Perera, Lalith; Krahn, Joseph M.; Mueller, Geoffrey A.; Zheng, Xunhai; London, Robert E.] NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
[Butterfoss, Glenn L.] NYU, Courant Inst Math Sci, New York, NY 10003 USA.
[Butterfoss, Glenn L.] NYU, Ctr Genom & Syst Biol, New York, NY 10003 USA.
RP London, RE (reprint author), NIEHS, Struct Biol Lab, NIH, MR 01,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.
EM London@niehs.nih.gov
RI perera, Lalith/B-6879-2012; Zheng, Xunhai/G-1187-2015
OI perera, Lalith/0000-0003-0823-1631; Zheng, Xunhai/0000-0003-0390-2491
FU National Institutes of Health [Z01-ES050111]; NIEHS [HHSN273200700046U]
FX This research was supported by Research Project Z01-ES050111 (R.E.L.) in
the Intramural Research Program of the National Institutes of Health.
The contributions of E.F.D. and J.M.K. were funded in whole with Federal
funds from NIEHS, under Delivery Order HHSN273200700046U to SRA
International, Inc. The authors also wish to thank Prof. Richard Bonneau
(NYU) for supporting some of the computations included in this study.
NR 101
TC 13
Z9 13
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0925-2738
J9 J BIOMOL NMR
JI J. Biomol. NMR
PD SEP
PY 2010
VL 48
IS 1
BP 31
EP 47
DI 10.1007/s10858-010-9436-6
PG 17
WC Biochemistry & Molecular Biology; Spectroscopy
SC Biochemistry & Molecular Biology; Spectroscopy
GA 653OT
UT WOS:000282102300004
PM 20734113
ER
PT J
AU Arenella, C
Yox, S
Eckstein, DS
Ousley, A
AF Arenella, Cheryl
Yox, Susan
Eckstein, Daniel S.
Ousley, Anita
TI Expanding the Reach of a Cancer Palliative Care Curriculum Through
Web-Based Dissemination: A Public-Private Collaboration
SO JOURNAL OF CANCER EDUCATION
LA English
DT Article
DE Cancer; Palliative care; End-of-life care; Palliative care education;
Health professionals; Web-based continuing education; Online
ID MEDICAL-EDUCATION
AB Deficiencies in palliative and end-of-life care have been well documented by the Institute of Medicine. The National Cancer Institute (NCI), in partnership with Northwestern University, developed an educational curriculum for clinicians who deal with end-of-life issues, the Education in Palliative and End-of-Life Care for Oncology. A live meeting was held to distribute the curriculum to institutional leaders who could take it back to their organizations for broader distribution. To further distribute the materials and ensure they were available whenever a clinician wanted to view them, NCI collaborated with a leading online medical education provider whose websites are visited by over 1,500,000 physicians per month (http://cme.medscape.com) to post one module of the curriculum as an online activity certified for physician and nurse continuing education credit. The module is entitled "Last Hours of Living: Practical Advice for Clinicians." A descriptive analysis of the first 7 months of publication was performed. Twenty thousand sixty-one health professionals completed the activity during this time period and earned continuing education credit. Eighty-four percent completed the post-activity evaluation survey. Satisfaction was very high among participants, and many indicated their intention to incorporate new knowledge into practice. Collaboration with a commonly used online medical education provider such as Medscape is effective at broadly disseminating palliative care education to health professionals.
C1 [Arenella, Cheryl] NCI, Off Communicat & Educ, Dept Hlth & Human Serv, NIH, Rockville, MD 20852 USA.
[Yox, Susan] Medscape LLC, New York, NY 10001 USA.
[Eckstein, Daniel S.] NOVA Res Co, Bethesda, MD 20814 USA.
[Ousley, Anita] NCI, Off Commun & Educ, Dept Hlth & Human Serv, NIH, Rockville, MD 20852 USA.
RP Arenella, C (reprint author), NCI, Off Communicat & Educ, Dept Hlth & Human Serv, NIH, 6116 Execut Blvd,Suite 410 Room 4104, Rockville, MD 20852 USA.
EM arenellac@mail.nih.gov
NR 14
TC 4
Z9 4
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-8195
J9 J CANCER EDUC
JI J. Cancer Educ.
PD SEP
PY 2010
VL 25
IS 3
BP 418
EP 421
DI 10.1007/s13187-010-0066-1
PG 4
WC Oncology; Education, Scientific Disciplines; Public, Environmental &
Occupational Health
SC Oncology; Education & Educational Research; Public, Environmental &
Occupational Health
GA 666HQ
UT WOS:000283105800027
PM 20237885
ER
PT J
AU Kim, C
McGlynn, KA
McCorkle, R
Zheng, TZ
Erickson, RL
Niebuhr, DW
Ma, SG
Zhang, YQ
Bai, YN
Dai, L
Graubard, BI
Kilfoy, B
Barry, KH
Zhang, YW
AF Kim, Christopher
McGlynn, Katherine A.
McCorkle, Ruth
Zheng, Tongzhang
Erickson, Ralph L.
Niebuhr, David W.
Ma, Shuangge
Zhang, Yaqun
Bai, Yana
Dai, Li
Graubard, Barry I.
Kilfoy, Briseis
Barry, Kathryn Hughes
Zhang, Yawei
TI Fertility among testicular cancer survivors: a case-control study in the
US
SO JOURNAL OF CANCER SURVIVORSHIP-RESEARCH AND PRACTICE
LA English
DT Article
DE Fertility; Testicular cancer; Epidemiology
ID GERM-CELL TUMORS; CHEMOTHERAPY; INFERTILITY
AB Introduction Testicular germ cell tumors (TGCT) disproportionately affect men between the ages of 15 and 49 years, when reproduction is typical. Although TGCT treatment directly affects gonadal tissues, it remains unclear whether there are long-term effects on fertility.
Methods To examine post-TGCT treatment fertility, study participants in a previously conducted case-control study were contacted. The men were initially enrolled in the US Servicemen's Testicular Tumor Environmental and Endocrine Determinants (STEED) study between 2002 and 2005. A total of 246 TGCT cases and 236 controls participated in the current study and completed a self-administered questionnaire in 2008-2009.
Results TGCT cases were significantly more likely than controls to experience fertility distress (OR 5.23; 95% CI 1.99-13.76) and difficulty in fathering children (OR 6.41; 2.72-15.13). Cases were also more likely to be tested for infertility (OR 3.65; 95% CI 1.55-8.59). Cases, however, did not differ from controls in actually fathering children (OR 1.37; 95% CI 0.88-2.15). These findings were predominantly observed among nonseminoma cases and cases treated with surgery only or surgery-plus-chemotherapy.
Discussion While expressing greater fertility distress, higher likelihood of fertility testing, and difficulty fathering children, these data suggest that TGCT survivors are no less likely to father children than are other men. It is possible that treatment for TGCT does not permanently affect
C1 [Kim, Christopher; Ma, Shuangge; Zhang, Yaqun; Bai, Yana; Dai, Li; Barry, Kathryn Hughes; Zhang, Yawei] Yale Univ, Yale Sch Publ Hlth, New Haven, CT 06520 USA.
[McGlynn, Katherine A.; Zheng, Tongzhang; Graubard, Barry I.; Kilfoy, Briseis; Barry, Kathryn Hughes] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Rockville, MD USA.
[McCorkle, Ruth] Yale Univ, Yale Sch Nursing, New Haven, CT 06520 USA.
[Erickson, Ralph L.; Niebuhr, David W.] Walter Reed Army Inst Res, Forest Glen, MD USA.
[Zhang, Yawei] Gansu Prov Design & Res Inst Environm Sci, Lanzhou, Gansu, Peoples R China.
[Bai, Yana] Lanzhou Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Lanzhou 730000, Peoples R China.
[Dai, Li] Sichuan Univ, W China Univ Hosp 2, Natl Ctr Birth Defect Monitoring, Chengdu 610064, Peoples R China.
RP Zhang, YW (reprint author), Yale Univ, Yale Sch Publ Hlth, 60 Coll St,LEPH 440, New Haven, CT 06520 USA.
EM yawei.zhang@yale.edu
RI Aschebrook-Kilfoy, Briseis/A-2537-2012
FU National Cancer Institute (NCI) [CA130110]; National Institute of Health
(NIH) [1D43TW008323-01, 1D43TW007864-01]; National Center for Research
Resources (NCRR), NIH [UL1 RR024139]
FX This study is supported by grant CA130110 from the National Cancer
Institute (NCI) and by Fogarty training grants 1D43TW008323-01 and
1D43TW007864-01 from the National Institute of Health (NIH). This
publication was made possible by CTSA Grant number UL1 RR024139 from the
National Center for Research Resources (NCRR), a component of the NIH
and NHL roadmap for medical Research. Its contents are solely the
responsibility of the authors and do not necessarily represent the
official view of NCRR. The authors are greatly indebted to the Study
participants, without whom, there would have been no study. The opinions
or assertions contained herein are the private views of the author, and
are not to be construed as official, or as reflecting true views of the
Department of the Army or the Department of Defense.
NR 23
TC 6
Z9 7
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1932-2259
J9 J CANCER SURVIV
JI J. Cancer Surviv.-Res. Pract.
PD SEP
PY 2010
VL 4
IS 3
BP 266
EP 273
DI 10.1007/s11764-010-0134-x
PG 8
WC Oncology; Social Sciences, Biomedical
SC Oncology; Biomedical Social Sciences
GA 788TZ
UT WOS:000292468600009
PM 20571931
ER
PT J
AU Pischke, CR
Elliott-Eller, M
Li, MM
Mendell, N
Ornish, D
Weidner, G
AF Pischke, Claudia R.
Elliott-Eller, Melanie
Li, Minmin
Mendell, Nancy
Ornish, Dean
Weidner, Gerdi
TI Clinical Events in Coronary Heart Disease Patients With an Ejection
Fraction of 40% or Less 3-Year Follow-up Results
SO JOURNAL OF CARDIOVASCULAR NURSING
LA English
DT Article
DE asymptomatic reduced left ventricular ejection fraction; clinical
events; coronary heart disease; lifestyle
ID VENTRICULAR SYSTOLIC DYSFUNCTION; STYLE DEMONSTRATION PROJECT;
RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; ARTERY-DISEASE;
RISK-FACTORS; FAILURE; MANAGEMENT; CARE; GUIDELINES
AB Background and Research Objective: It is unclear whether lifestyle changes can delay the need for surgical procedures in coronary heart disease (CHD) patients with asymptomatic reduced left ventricular ejection fraction (LVEF). The aim of this pilot study was to examine whether lifestyle changes can delay the need for surgical procedures in this population. Subjects and Methods: We compared 3-year clinical events in 27 CHD patients eligible to receive revascularization (by insurance standards), but underwent lifestyle changes (low-fat diet, exercise, stress management) instead (intervention group [IG], LVEF <= 40%), with those of a historically matched (age, gender, LVEF, and stenosis of the 3 major coronary arteries) control group receiving usual care (UCG; n = 13) who received revascularization at study entry. Both IG and UCG patients were enrolled in the health insurance companies participating in the Multicenter Lifestyle Demonstration Project, an insurance-sponsored, community-based, secondary prevention study implemented at 8 hospital sites in the United States. Results and Conclusion: At 3 months, there were more cardiac events in the UCG (6 events) than in the IG (1 event; P < .006; odds ratio = 13.27; confidence interval = 1.57-111.94). This difference was maintained over 3 years (P < .06; odds ratio = 2.75; confidence interval = 1.05-7.19). Of the 26 surviving (1 cardiac death) IG patients, 23 did not require primary revascularization. In conclusion, CHD patients with asymptomatic reduced LVEF may be able to safely delay revascularization by making changes in lifestyle with no increased risk for cardiac events or overt heart failure over 3 years.
C1 [Pischke, Claudia R.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Pischke, Claudia R.] NCI, Bethesda, MD 20892 USA.
[Elliott-Eller, Melanie] Palm Drive Hosp, Sebastopol, CA USA.
[Li, Minmin; Mendell, Nancy] SUNY Stony Brook, Dept Appl Math & Stat, New York, NY USA.
[Ornish, Dean] Res Inst Prevent Med, Sausalito, CA USA.
[Weidner, Gerdi] San Francisco State Univ, Romberg Tiburon Ctr, Dept Biol, Tiburon, CA 94920 USA.
[Weidner, Gerdi] Johannes Gutenberg Univ Mainz, Mainz, Germany.
RP Pischke, CR (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, 44 Binney St,LW703, Boston, MA 02115 USA.
EM pischcl@gmx.net; gweidner@sfsu.edu
FU NCI NIH HHS [R25 CA 057713-05]; NIMH NIH HHS [MH0711523]
NR 31
TC 1
Z9 1
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0889-4655
J9 J CARDIOVASC NURS
JI J. Cardiovasc. Nurs.
PD SEP-OCT
PY 2010
VL 25
IS 5
BP E8
EP E15
DI 10.1097/JCN.0b013e3181d51f9e
PG 8
WC Cardiac & Cardiovascular Systems; Nursing
SC Cardiovascular System & Cardiology; Nursing
GA 641GK
UT WOS:000281112600059
PM 20714228
ER
PT J
AU Shi, SL
Liang, Y
Li, QF
Liu, QR
Jing, GJ
Wang, SY
Zhang, XY
Wu, FY
AF Shi, Song-Lin
Liang, Ying
Li, Qi-Fu
Liu, Qing-Rong
Jing, Guang-Jun
Wang, San-Ying
Zhang, Xiu-Yan
Wu, Fu-Yun
TI Localization of Nucleophosmin in Nuclear Matrix and Changes in Its
Expression During the Differentiation of Human Neuroblastoma Induced by
Retinoic Acid
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE NUCLEOPHOSMIN; NUCLEAR MATRIX; HUMAN NEUROBLASTOMA; CELL DIFFERENTIATION
ID C-MYC; TRANSCRIPTIONAL ACTIVATION; PROTEIN; CELLS; CANCER; STABILITY;
P53
AB In this article, we selectively extracted the nuclear matrix and intermediate filament system of human neuroblastoma SK-N-SH cells pre- and post-treated with retinoic acid (RA). The distribution of nucleophosmin (NPM) in the nuclear matrix and its colocalization with several products of related genes were investigated. Results from two-dimensional gel electrophoresis and MALDI-TOF showed that NPM was a component of the nuclear matrix and its expression in SK-N-SH cells post-treated with RA was down-regulated Immunofluorescent microscopy observations further showed that NPM was localized in the nuclear matrix of SK-N-SH cells, and its expression level and distribution were altered after treatment with RA. The colocalization of NPM with c-myc. c-fos, p53, and Rb in SK-N-SH cells was observed under a laser scanning confocal microscope, but the colocalization region was changed by RA Our results prove that NPM is a nuclear matrix protein, which is localized in nuclear matrix fibers. The colocalization of NPM with its related genes and oncogenes affect the differentiation of SK-N-SH cells. The expression of NPM and its distribution in the process of cell differentiation deserve more intensive investigation. J Cell. Biochem 111 67-74. 2010. (C) 2010 whey-Liss, Inc
C1 [Shi, Song-Lin; Liang, Ying; Li, Qi-Fu; Jing, Guang-Jun; Wang, San-Ying; Zhang, Xiu-Yan; Wu, Fu-Yun] Xiamen Univ, Sch Life Sci, Minist Educ Cell Biol & Tumor Cell Engn, Key Lab, Xiamen 361005, Fujian Province, Peoples R China.
[Shi, Song-Lin] Xiamen Univ, Coll Med, Xiamen 361005, Peoples R China.
[Liu, Qing-Rong] NIDA, Mol Neurobiol Branch, Intramural Res Program, NIH,DHSS, Baltimore, MD 21224 USA.
RP Li, QF (reprint author), Xiamen Univ, Sch Life Sci, Minist Educ Cell Biol & Tumor Cell Engn, Key Lab, Xiamen 361005, Fujian Province, Peoples R China.
RI Li, QF/G-4604-2010; Liu, Qing-Rong/A-3059-2012
OI Liu, Qing-Rong/0000-0001-8477-6452
FU National Natural Science Foundation of China [30871241]
FX Grant sponsor. National Natural Science Foundation of China. Grant
number 30871241
NR 19
TC 1
Z9 2
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP 1
PY 2010
VL 111
IS 1
BP 67
EP 74
DI 10.1002/jcb.22663
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 648JU
UT WOS:000281690500009
PM 20506166
ER
PT J
AU Hou, SX
AF Hou, Steven X.
TI Intestinal Stem Cell Asymmetric Division in the Drosophila Posterior
Midgut
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
ID JAK/STAT; PROTEIN; NOTCH; GENE; IDENTIFICATION; PROLIFERATION;
MAINTENANCE; MECHANISMS; PATHWAYS; RECEPTOR
AB Over the past 2 years, our understanding of intestinal stem cells in the Drosophila posterior midgut has advanced greatly. In this review, I will focus on the establishment of these stem cells in their niche during development and the molecular mechanisms that regulate their asymmetric division in adults. J. Cell. Physiol. 224: 581-584, 2010. Published 2010 Wiley-Liss, Inc.
C1 NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.
RP Hou, SX (reprint author), NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.
EM hous@mail.nih.gov
NR 30
TC 15
Z9 15
U1 1
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2010
VL 224
IS 3
BP 581
EP 584
DI 10.1002/jcp.22194
PG 4
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 634YG
UT WOS:000280621600003
PM 20578235
ER
PT J
AU Zeng, XK
Singh, SR
Hou, D
Hou, SX
AF Zeng, Xiankun
Singh, Shree Ram
Hou, David
Hou, Steven X.
TI Tumor Suppressors Sav/Scrib and Oncogene Ras Regulate Stem-Cell
Transformation in Adult Drosophila Malpighian Tubules
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID BACTERIAL-INFECTION; PROMOTES APOPTOSIS; MYELOID-LEUKEMIA; HIPPO
PATHWAY; SELF-RENEWAL; CANCER; PROLIFERATION; GROWTH; IDENTIFICATION;
DIVISION
AB An increasing body of evidence suggests that tumors might originate from a few transformed cells that share many properties with normal stem cells. However, it remains unclear how normal stem cells are transformed into cancer stem cells (CSCs). Here, we demonstrated that mutations causing the loss of tumor suppressor Salvador (Say) or Scribble (Scrib) or activation of the oncogene Ras transform normal stem cells into CSCs through a multistep process in the adult Drosophila Malpighian Tubules (MTs). In wild-type MTs, each stem cell generates one self-renewing and one differentiating daughter cell. However, in flies with loss-of-function say or scrib or gain-of-function Ras mutations, both daughter cells grew and behaved like stem cells, leading to the formation of tumors in MTs. Ras functioned downstream of Say and Scrib in regulating the stem-cell transformation. The Ras-transformed stem cells exhibited many of the hallmarks of cancer, such as increased proliferation, reduced cell death, and failure to differentiate. We further demonstrated that several signal transduction pathways (including MEK/MAPK, RhoA, PKA, and TOR) mediate Ras' function in the stem-cell transformation. Therefore, we have identified a molecular mechanism that regulates stem-cell transformation, and this finding may lead to strategies for preventing tumor formation in certain organs. J. Cell. Physiol. 224: 766-774, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Zeng, Xiankun; Singh, Shree Ram; Hou, David; Hou, Steven X.] NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.
RP Zeng, XK (reprint author), NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.
EM zengx2@mail.nih.gov; hous@mail.nih.gov
RI Singh, Shree Ram/B-7614-2008
OI Singh, Shree Ram/0000-0001-6545-583X
FU Intramural NIH HHS [Z99 CA999999]
NR 45
TC 10
Z9 10
U1 4
U2 8
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2010
VL 224
IS 3
BP 766
EP 774
DI 10.1002/jcp.22179
PG 9
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 634YG
UT WOS:000280621600026
PM 20432470
ER
PT J
AU Fleming, JM
Miller, TC
Meyer, MJ
Ginsburg, E
Vonderhaar, BK
AF Fleming, Jodie M.
Miller, Tyler C.
Meyer, Matthew J.
Ginsburg, Erika
Vonderhaar, Barbara K.
TI Local Regulation of Human Breast Xenograft Models
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID ATHYMIC NUDE-MICE; NORMAL MAMMARY-GLANDS; HUMAN-MELANOMA CELLS;
CANCER-CELLS; IN-VIVO; PROMOTER HYPERMETHYLATION;
PROGESTERONE-RECEPTORS; GROWTH-CHARACTERISTICS; IMMUNODEFICIENT MICE;
TUMORS
AB Breast cancer studies implant human cancer cells under the renal capsule, subcutaneously, or orthotopically and often use estrogen supplementation and immune suppressants (etoposide) in xenograft mouse models. However, cell behavior is significantly impacted by signals from the local microenvironment. Therefore, we investigated how the combinatorial effect of the location of injection and procedural differences affected xenograft characteristics. Patient-derived breast cancer cells were injected into mouse abdominal or thoracic mammary glands +/- estrogen and/or etoposide pretreatment. Abdominal xenografts had increased tumor incidence and volume, and decreased latency (P < 0.001) compared to thoracic tumors. No statistically significant difference in tumor volume was found in abdominal xenografts treated estrogen or etoposide; however, etoposide suppressed tumor volume in thoracic xenografts (P < 0.02). The combination of estrogen and etoposide significantly decreased tumor incidence in both sites. In addition, mice treated +/- estradiol were injected orthotopically or subcutaneously with well-characterized breast cancer cell lines (MCF7, ZR75-1, MDA MB-231, or MCF10Calh). Orthotopic injection increased tumor volume; growth varied with estrogen supplementation. Location also altered methylation status of several breast cancer-related gene promoters. Lastly, vascularization of orthotopic tumors was significantly enhanced compared to subcutaneous tumors. These data suggest that optimal xenograft success occurs with orthotopic abdominal injections and illustrate molecular details of the compelling influence of the local microenvironment on in vivo models. J. Cell. Physiol. 224: 795-806, 2010. Published 2010 Wiley-Liss, Inc.(dagger)
C1 [Fleming, Jodie M.; Miller, Tyler C.; Meyer, Matthew J.; Ginsburg, Erika; Vonderhaar, Barbara K.] NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Vonderhaar, BK (reprint author), 37 Convent Dr,Bldg 37,Room 1106A1, Bethesda, MD 20892 USA.
EM bv10w@nih.gov
FU Center for Cancer Research; National Cancer Institute; Breast Cancer
Research
FX This research was supported by the Center for Cancer Research, an
Intramural Research Program of the National Cancer Institute and by
Breast Cancer Research Stamp proceeds awarded through competitive peer
review.
NR 57
TC 20
Z9 20
U1 0
U2 7
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2010
VL 224
IS 3
BP 795
EP 806
DI 10.1002/jcp.22190
PG 12
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 634YG
UT WOS:000280621600029
PM 20578247
ER
PT J
AU Samuel, W
Kutty, RK
Vijayasarathy, C
Pascual, I
Duncan, T
Redmond, TM
AF Samuel, William
Kutty, R. Krishnan
Vijayasarathy, Camasamudram
Pascual, Iranzu
Duncan, Todd
Redmond, T. Michael
TI Decreased Expression of Insulin-Like Growth Factor Binding Protein-5
During N-(4-Hydroxyphenyl) Retinamide-Induced Neuronal Differentiation
of ARPE-19 Human Retinal Pigment Epithelial Cells: Regulation by
CCAAT/Enhancer-Binding Protein
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID INTESTINAL SMOOTH-MUSCLE; FACTOR-I; GENE-EXPRESSION; IGF-I; ADIPOCYTE
DIFFERENTIATION; PHYSIOLOGICAL FUNCTIONS; TRANSCRIPTION FACTORS;
NEUROBLASTOMA-CELLS; MAP KINASE; IGFBP-5
AB Insulin-like growth factor (IGF)-binding protein-5 (IGFBP5), an important member of the IGF axis involved in regulating cell growth and differentiation, acts by modulating IGF signaling and also by IGF-independent mechanisms. We identified IGFBP5 by microarray analysis as a gene differentially regulated during N-(4-hydroxyphenyl)retinamide (4HPR)-induced neuronal differentiation of human retinal pigment epithelial (RPE) cells. IGFBP5 is expressed in human RPE cells, and its expression, mRNA as well as protein, is greatly decreased during the 4HPR-induced neuronal differentiation. Exogenous IGFBP5 does not block the neuronal differentiation indicating that IGFBP5 down-regulation may not be a prerequisite for the neuronal differentiation. IGFBP5 down-regulation, similar to neuronal differentiation, is mediated by the MAPK pathway since U0126, an inhibitor of MEK1/2, effectively blocked it. The overexpression of transcription factor CCAAT/enhancer binding protein-beta (C/EBP beta) inhibited the 4HPR-induced down-regulation of IGFBP5 expression and the neuronal differentiation of RPE cells. Interestingly, the binding of C/EBP beta to the IGFBP5 promoter was decreased by the 4HPR treatment as indicated by gel shift and chromatin immunoprecipitation analyses. Further, the deletion of C/EBP response element from IGFBP5 promoter markedly decreased the basal promoter activity and abolished its responsiveness to 4HPR treatment in reporter assays, suggesting that the expression of IGFBP5 is regulated by C/EBP. Thus, our results clearly demonstrate that the IGFBP5 expression is down-regulated during 4HPR-induced neuronal differentiation of human RPE cells through a MAPK signal transduction pathway involving C/EBP beta. J. Cell. Physiol. 224: 827-836, 2010. Published 2010 Wiley-Liss, Inc.(dagger)
C1 [Samuel, William; Kutty, R. Krishnan; Pascual, Iranzu; Duncan, Todd; Redmond, T. Michael] NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
[Vijayasarathy, Camasamudram] Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD USA.
RP Samuel, W (reprint author), NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Room 112A,6 Ctr Dr, Bethesda, MD 20892 USA.
EM samuelw@nei.nih.gov
OI Redmond, T. Michael/0000-0002-1813-5291
FU National Eye Institute, National Institutes of Health
FX This research work was supported by the Intramural Research Program of
the National Eye Institute, National Institutes of Health.
NR 47
TC 2
Z9 2
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2010
VL 224
IS 3
BP 827
EP 836
DI 10.1002/jcp.22191
PG 10
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 634YG
UT WOS:000280621600032
PM 20583135
ER
PT J
AU Hawkins, BT
Rigor, RR
Miller, DS
AF Hawkins, Brian T.
Rigor, Robert R.
Miller, David S.
TI Rapid loss of blood-brain barrier P-glycoprotein activity through
transporter internalization demonstrated using a novel in situ
proteolysis protection assay
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE blood-brain barrier; endothelium; pharmacology; physiology; vascular
biology
ID PHOSPHORYLATION; LOCALIZATION; MICROVESSELS; MODULATION; ABCB1
AB Blood-brain barrier (BBB) P-glycoprotein activity is rapidly reduced by vascular endothelial growth factor (VEGF) acting via Src and by tumor necrosis factor-a acting via protein kinase C (PKC)beta 1. To probe underlying mechanism(s), we developed an in vivo, immunoblot-based proteinase K (PK) protection assay to assess the changes in the P-glycoprotein content of the BBB's luminal membrane. Infusion of PK into the brain vasculature selectively cleaved luminal membrane P-glycoprotein, leaving intracellular proteins intact. Intracerebroventricular injection of VEGF partially protected P-glycoprotein from proteolytic cleavage, consistent with transporter internalization. Activation of PKC beta 1 did not protect P-glycoprotein. Thus, VEGF and PKC beta 1 reduce P-glycoprotein activity by distinct mechanisms. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 1593-1597; doi:10.1038/jcbfm.2010.117; published online 14 July 2010
C1 [Hawkins, Brian T.; Miller, David S.] NIEHS, Lab Toxicol & Pharmacol, NIH, Res Triangle Pk, NC 27709 USA.
[Rigor, Robert R.] Univ Calif Davis, Sch Med, Dept Surg, Sacramento, CA 95817 USA.
RP Miller, DS (reprint author), NIEHS, Lab Toxicol & Pharmacol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
EM miller@niehs.nih.gov
OI Rigor, Robert/0000-0001-6234-1992; Hawkins, Brian/0000-0001-6719-5402
FU National Institutes of Health, National Institute of Environmental
Health Sciences
FX This work was supported by the Intramural Research Program of the
National Institutes of Health, National Institute of Environmental
Health Sciences.
NR 13
TC 18
Z9 18
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD SEP
PY 2010
VL 30
IS 9
BP 1593
EP 1597
DI 10.1038/jcbfm.2010.117
PG 5
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 646SF
UT WOS:000281562300006
PM 20628400
ER
PT J
AU Morra, G
Neves, MAC
Plescia, CJ
Tsustsumi, S
Neckers, L
Verkhivker, G
Altieri, DC
Colombo, G
AF Morra, Giulia
Neves, Marco A. C.
Plescia, Christopher J.
Tsustsumi, Shinji
Neckers, Len
Verkhivker, Gennady
Altieri, Dario C.
Colombo, Giorgio
TI Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New
Ligands for the C-terminal Domain of Hsp90
SO JOURNAL OF CHEMICAL THEORY AND COMPUTATION
LA English
DT Article
ID MOLECULAR-DYNAMICS; NOVOBIOCIN ANALOGS; PROTEINS; CHAPERONE; SITES;
FLUCTUATIONS; MODULATION; SIMULATION; MECHANICS; ALGORITHM
AB The study of allosteric functional modulation in dynamic proteins is attracting increasing attention. In particular, the discovery of new allosteric sites may generate novel opportunities and strategies for drug development, overcoming the limits of classical active-site oriented drug design. In this paper, we report on the results of a novel, ab initio, fully computational approach for the discovery of allosteric inhibitors based on the physical characterization of signal propagation mechanisms in proteins and apply it to the important molecular chaperone Hsp90. We first characterize the allosteric "hot spots" involved in interdomain communication pathways from the nucleotide-binding site in the N-domain to the distal C-domain. On this basis, we develop dynamic pharmacophore models to screen drug libraries in the search for small molecules with the functional and conformational properties necessary to bind these "hot spot" allosteric sites. Experimental tests show that the selected moelcules bind the Hsp90 C-domain, exhibit antiproliferative activity in different tumor cell lines, while not affecting proliferation of normal human cells, destabilize Hsp90 client proteins, and disrupt association with several cochaperones known to bind the N- and M-domains of Hsp90. These results prove that the hits alter Hsp90 function by affecting its conformational dynamics and recognition properties through an allosteric mechanism. These findings provide us with new insights on the discovery and development of new allosteric inhibitors that are active on important cellular pathways through computational biology. Though based on the specific case of Hsp90, our approach is general and can readily be extended to other target proteins and pathways.
C1 [Morra, Giulia; Neves, Marco A. C.; Colombo, Giorgio] CNR, Ist Chim Riconoscimento Mol, I-20131 Milan, Italy.
[Plescia, Christopher J.; Altieri, Dario C.] Univ Massachusetts, Dept Canc Biol, Sch Med, Worcester, MA 01605 USA.
[Tsustsumi, Shinji; Neckers, Len] NCI, Urol Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Verkhivker, Gennady] Univ Kansas, Dept Pharmaceut Chem, Sch Pharm, Lawrence, KS 66047 USA.
[Verkhivker, Gennady] Univ Kansas, Ctr Bioinformat, Lawrence, KS 66047 USA.
RP Colombo, G (reprint author), CNR, Ist Chim Riconoscimento Mol, Via Mario Bianco 9, I-20131 Milan, Italy.
EM giorgio.colombo@icrm.cnr.it
RI Neves, Marco/K-6630-2012; Colombo, Giorgio/A-2730-2012; Morra,
Giulia/O-2311-2015
OI Colombo, Giorgio/0000-0002-1318-668X; Morra, Giulia/0000-0002-9681-7845
FU Associazione Italiana Ricerca sul Cancro (AIRC)
FX This work was supported by a grant from Associazione Italiana Ricerca
sul Cancro (AIRC) to G.C. G.M. gratefully acknowledges support from a
"L'Oreal-Unesco for Women in Science" grant.
NR 43
TC 28
Z9 28
U1 0
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9618
J9 J CHEM THEORY COMPUT
JI J. Chem. Theory Comput.
PD SEP
PY 2010
VL 6
IS 9
BP 2978
EP 2989
DI 10.1021/ct100334n
PG 12
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 648KQ
UT WOS:000281693000038
PM 26616092
ER
PT J
AU Nieman, LK
AF Nieman, Lynnette K.
TI Approach to the Patient with an Adrenal Incidentaloma
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID SUBCLINICAL CUSHINGS-SYNDROME; CLINICAL-PRACTICE GUIDELINE; NIGHT
SALIVARY CORTISOL; TERM-FOLLOW-UP; LAPAROSCOPIC ADRENALECTOMY; PRIMARY
ALDOSTERONISM; COMPUTED-TOMOGRAPHY; MASS INCIDENTALOMA; DIAGNOSIS;
MANAGEMENT
AB Unsuspected adrenal masses, or incidentalomas, are increasingly found with the widespread use of thoracic and abdominal imaging. These masses may be hormonally active or nonfunctional and malignant or benign. Clinicians must determine the nature of the mass to decide what treatment, if any, is needed. Measurement of precontrast Hounsfield units (HU) and contrast washout on computed tomography scan provide useful diagnostic information. All patients should undergo biochemical testing for pheochromocytoma, either with plasma or urinary catecholamine measurements. This is particularly important before surgical resection, which is routinely recommended for masses larger than 4 cm in diameter without a clear-cut diagnosis and for others with hormonal secretion or ominous imaging characteristics. Hypertensive patients should undergo biochemical testing for hyperaldosteronism. Patients with features consistent with Cushing's syndrome, such as glucose intolerance, weight gain, and unexplained osteopenia, should be evaluated for cortisol excess. Here, the dexamethasone suppression test and late-night salivary cortisol may be preferred over measurement of urine cortisol. The ability of surgical resection to reverse features of mild hypercortisolism is not well established. For masses that appear to be benign (<10 HU; washout, >50%), small (<3 cm), and completely nonfunctioning, imaging and biochemical reevaluation (pheochromocytoma and hypercortisolism only) at 1-2 yr (or more) is appropriate. For more indeterminate lesions, repeat evaluation for growth after 3-12 months is useful, with subsequent testing intervals based on the rate of growth. (J Clin Endocrinol Metab 95: 4106-4113, 2010)
C1 [Nieman, Lynnette K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD 20892 USA.
RP Nieman, LK (reprint author), Bldg 10-CRC 1 E Room 3140,10 Cent Dr, Bethesda, MD 20892 USA.
EM niemanl@nih.gov
NR 50
TC 93
Z9 101
U1 0
U2 8
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2010
VL 95
IS 9
BP 4106
EP 4113
DI 10.1210/jc.2010-0457
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 647SU
UT WOS:000281640300022
PM 20823463
ER
PT J
AU Speiser, PW
Azziz, R
Baskin, LS
Ghizzoni, L
Hensle, TW
Merke, DP
Meyer-Bahlburg, HFL
Miller, WL
Montori, VM
Oberfield, SE
Ritzen, M
White, PC
AF Speiser, Phyllis W.
Azziz, Ricardo
Baskin, Laurence S.
Ghizzoni, Lucia
Hensle, Terry W.
Merke, Deborah P.
Meyer-Bahlburg, Heino F. L.
Miller, Walter L.
Montori, Victor M.
Oberfield, Sharon E.
Ritzen, Martin
White, Perrin C.
TI Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency:
An Endocrine Society Clinical Practice Guideline
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID TANDEM MASS-SPECTROMETRY; BONE-MINERAL DENSITY; QUALITY-OF-LIFE;
DECREASED EPINEPHRINE RESERVE; TOTAL UROGENITAL MOBILIZATION;
EARLY-PRENATAL DEXAMETHASONE; HIGH-INTENSITY EXERCISE; FETAL SEX
DETERMINATION; EMILIA-ROMAGNA REGION; DRIED BLOOD SPOTS
AB Objective: We developed clinical practice guidelines for congenital adrenal hyperplasia (CAH).
Participants: The Task Force included a chair, selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), ten additional clinicians experienced in treating CAH, a methodologist, and a medical writer. Additional experts were also consulted. The authors received no corporate funding or remuneration.
Consensus Process: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments.
Conclusions: We recommend universal newborn screening for severe steroid 21-hydroxylase deficiency followed by confirmatory tests. We recommend that prenatal treatment of CAH continue to be regarded as experimental. The diagnosis rests on clinical and hormonal data; genotyping is reserved for equivocal cases and genetic counseling. Glucocorticoid dosage should be minimized to avoid iatrogenic Cushing's syndrome. Mineralocorticoids and, in infants, supplemental sodium are recommended in classic CAH patients. We recommend against the routine use of experimental therapies to promote growth and delay puberty; we suggest patients avoid adrenalectomy. Surgical guidelines emphasize early single-stage genital repair for severely virilized girls, performed by experienced surgeons. Clinicians should consider patients' quality of life, consulting mental health professionals as appropriate. At thetransition to adulthood, we recommend monitoring for potential complications of CAH. Finally, we recommend judicious use of medication during pregnancy and in symptomatic patients with nonclassic CAH. (J Clin Endocrinol Metab 95: 4133-4160, 2010)
C1 [Speiser, Phyllis W.] Cohen Childrens Med Ctr, New York, NY 11040 USA.
[Speiser, Phyllis W.] Hofstra Univ, Sch Med, New York, NY 11040 USA.
[Azziz, Ricardo] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Baskin, Laurence S.; Miller, Walter L.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ghizzoni, Lucia] Univ Turin, I-10129 Turin, Italy.
[Hensle, Terry W.] Columbia Univ, New York, NY 10032 USA.
[Merke, Deborah P.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Natl Inst Hlth Clin Ctr, Bethesda, MD 20892 USA.
[Meyer-Bahlburg, Heino F. L.] Columbia Univ, New York State Psychiat Inst, New York, NY 10032 USA.
[Oberfield, Sharon E.] Childrens Hosp New York Presbyterian, New York, NY 10032 USA.
[Oberfield, Sharon E.] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.
[Montori, Victor M.] Mayo Clin, Rochester, MN 55905 USA.
[Ritzen, Martin] Karolinska Inst, S-17176 Stockholm, Sweden.
[White, Perrin C.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Speiser, PW (reprint author), Cohen Childrens Med Ctr, New York, NY 11040 USA.
RI Miller, Walter/J-3696-2012; Azziz, Ricardo/N-7229-2014;
OI Azziz, Ricardo/0000-0002-3917-0483; Montori, Victor/0000-0003-0595-2898
FU Pediatric Endocrine Society; Society for Pediatric Research; American
Association of Clinical Endocrinologists; Significant Financial Interest
or Leadership Position: Medical Advisory Board; CARES Foundation;
National Adrenal Diseases Foundation; Phoqus Pharmaceuticals; American
Psychiatric Association; National Institutes of Health, National
Institute of Diabetes and Digestive and Kidney Diseases; Biopartners AG;
Acta Paediatrica; National Institutes of Health
FX Phyllis W. Speiser, M.D. (chair) - Financial or Business/Organizational
Interests: Pediatric Endocrine Society, Society for Pediatric Research,
and American Association of Clinical Endocrinologists; Significant
Financial Interest or Leadership Position: Medical Advisory Board, CARES
Foundation, and National Adrenal Diseases Foundation; Ricardo Azziz,
M.B.A., M.D., M.P.H. - Financial or Business/Organizational Interests:
none declared; Significant Financial Interest or Leadership Position:
none declared; Laurence S. Baskin, M.D. - Financial or
Business/Organizational Interests: none declared; Significant Financial
Interest or Leadership Position: none declared; Lucia Ghizzoni, M.D.,
Ph.D. - Financial or Business/Organizational Interests: none declared;
Significant Financial Interest or Leadership Position: none declared;
Terry W. Hensle, M.D. - Financial or Business/Organizational Interests:
none declared; Significant Financial Interest or Leadership Position:
none declared; * Deborah P. Merke, MS, M.D. - Financial of
Business/Organizational Interests: Phoqus Pharmaceuticals and CARES
Foundation; Significant Financial Interest or Leadership Position: none
declared; Heino F. L. Meyer-Bahlburg, Dr. rer. Nat. - Financial of
Business/Organizational Interests: Pediatric Endocrine Society, World
Professional Association of Transgender Health, and Gender Identity
Disorders for DSM-V of the American Psychiatric Association; Significant
Financial Interest or Leadership Position: none declared; Walter L.
Miller, M.D. - Financial or Business/Organizational Interests: CARES
Foundation and Pediatric Endocrine Society; Significant Financial
Interest or Leadership Position: Medical Advisory Board and CARES
Foundation; dagger Victor M. Montori, M.D.-Financial or
Business/Organizational Interests: KERUnit (Mayo Clinic); Significant
Financial Interest or Leadership Position: none declared; Sharon E.
Oberfield, M.D. - Financial or Business/Organizational Interests:
National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases; Significant Financial Interest or
Leadership Position: Pediatric Endocrine Society, Medical Advisory
Board, and CARES Foundation; Martin Ritzen, M.D. - Financial or
Business/Organizational Interests: Biopartners AG and Acta Paediatrica;
Significant Financial Interest or Leadership Position: none declared;
Perrin C. White, M.D. - Financial or Business/Organizational Interests:
none declared; Significant Financial Interest or Leadership Position:
none declared.; This work was supported by the Intramural Research
Program of the National Institutes of Health.
NR 275
TC 342
Z9 390
U1 4
U2 29
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2010
VL 95
IS 9
BP 4133
EP 4160
DI 10.1210/jc.2009-2631
PG 28
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 647SU
UT WOS:000281640300025
PM 20823466
ER
PT J
AU Lonser, RR
Kindzelski, BA
Mehta, GU
Jane, JA
Oldfield, EH
AF Lonser, Russell R.
Kindzelski, Bogdan A.
Mehta, Gautam U.
Jane, John A., Jr.
Oldfield, Edward H.
TI Acromegaly without Imaging Evidence of Pituitary Adenoma
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID TUMORS; DIAGNOSIS
AB Context: GH-secreting pituitary adenomas are nearly always visible on conventional magnetic resonance (MR) imaging. However, management and outcome of acromegalic patients lacking imaging evidence of GH-secreting pituitary adenomas are undefined.
Objective: The aim was to evaluate surgical exploration for MR-invisible GH-secreting pituitary adenomas.
Design and Setting: We conducted a retrospective review at two tertiary care centers.
Patients or Other Participants: Consecutive acromegalic patients without imaging evidence of a pituitary adenoma on pre- and postcontrast, spin echo T1-weighted MR imaging and who lacked evidence of an ectopic (nonpituitary) source causing GH excess were included.
Interventions: Surgical exploration with identification and resection of a pituitary adenoma was performed.
Main Outcome Measures: Laboratory values (GH, IGF-I), surgical findings, and clinical outcome were analyzed.
Results: Six patients (three males, three females; 3% of all patients) with suspected GH-secreting adenomas did not demonstrate imaging evidence of pituitary adenoma on conventional MR imaging. Three patients underwent a postcontrast, volumetric interpolated breath-hold examination MR-imaging sequence (1.2-mm slice thickness), which revealed a 4-mm pituitary adenoma not seen on the spin echo T1-weighted MR imaging in one patient. A pituitary adenoma was identified and removed in all patients (mean diameter, 5.6 mm; range, 5 to 6.7 mm). Histological analysis confirmed that the lesions were GH-secreting adenomas. All patients achieved biochemical remission after surgical resection.
Conclusion: Acromegaly can be caused by GH-secreting pituitary adenomas that are not evident on conventional MR imaging. Adenomas in some of these patients become evident using volumetric interpolated breath-hold examination MR imaging. Surgical exploration of the pituitary gland in acromegalic patients with endocrine findings consistent with a GH-secreting adenoma but negative MR imaging can lead to identification and removal of an adenoma. (J Clin Endocrinol Metab 95: 4192-4196, 2010)
C1 [Lonser, Russell R.; Kindzelski, Bogdan A.; Mehta, Gautam U.; Oldfield, Edward H.] Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.
[Jane, John A., Jr.; Oldfield, Edward H.] Univ Virginia, Univ Virginia Hlth Syst, Dept Neurosurgery, Charlottesville, VA 22908 USA.
RP Lonser, RR (reprint author), Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bldg 10,Room 3D20, Bethesda, MD 20892 USA.
EM lonserr@ninds.nih.gov
OI Mehta, Gautam/0000-0002-8009-6430
FU National Institute of Neurological Disorders and Stroke at the National
Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Institute of Neurological Disorders and Stroke at the National
Institutes of Health.
NR 16
TC 9
Z9 9
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2010
VL 95
IS 9
BP 4192
EP 4196
DI 10.1210/jc.2010-0570
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 647SU
UT WOS:000281640300031
PM 20610592
ER
PT J
AU Lee, DC
Romero, R
Kim, JS
Yoo, W
Lee, J
Mittal, P
Kusanovic, JP
Hassan, SS
Yoon, BH
Kim, CJ
AF Lee, Deug-Chan
Romero, Roberto
Kim, Jung-Sun
Yoo, Wonsuk
Lee, JoonHo
Mittal, Pooja
Kusanovic, Juan Pedro
Hassan, Sonia S.
Yoon, Bo Hyun
Kim, Chong Jai
TI Evidence for a Spatial and Temporal Regulation of
Prostaglandin-Endoperoxide Synthase 2 Expression in Human Amnion in Term
and Preterm Parturition
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID HUMAN FETAL MEMBRANES; DECIDUAL CELLS; SPONTANEOUS LABOR;
GENE-EXPRESSION; CYCLOOXYGENASE-2; FLUID; INFECTION; TYPE-2; COX-2;
ONSET
AB Context: Prostaglandin-endoperoxide synthase 2 (PTGS2) is a key enzyme involved in parturition. PTGS2 mRNA was found to be differentially expressed between placental amnion (amnion overlying the placental disc) and reflected amnion (amnion of the extraplacental chorioamniotic membranes) in term placentas.
Objective: The aim was to evaluate the spatial and temporal regulation of PTGS2 expression in the amnion and the chorion-decidua.
Design: PTGS2 expression was analyzed in the amnion and chorion-decidua obtained from 32 women: term not in labor (n = 12), term in labor (n = 12), and preterm labor (n = 8), by immunoblotting and densitometry. Prostaglandin E(2) (PGE(2)) in the amnion and chorion-decidua was measured by a specific immunoassay.
Results: Compared to preterm labor cases, PTGS2 expression increased at term before the onset of labor far more prominently in placental amnion (4.5-fold; P = 0.002) than in reflected amnion (1.4-fold; P = 0.007). There was a significant increase in PTGS2 expression in reflected amnion (2.9-fold; P < 0.01) but not in placental amnion with labor at term. PTGS2 expression was higher in reflected amnion than in chorion-decidua in labor at term (2.9-fold; P < 0.01). PTGS2 was barely detected in amnion and chorion-decidua with preterm labor. Expression of PGE2 showed a good correlation with PTGS2 expression (r = 0.722; P < 0.001).
Conclusion: PTGS2 expression in the amnion shows a distinct spatial and temporal regulation. Spontaneous labor at term and pathological preterm labor clearly differ in amniotic PTGS2 and PGE2 abundance. Our observations underscore the biological significance of the amnion and amniotic fluid in human parturition. (J Clin Endocrinol Metab 95: E86-E91, 2010)
C1 [Kim, Jung-Sun; Kim, Chong Jai] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.
[Yoo, Wonsuk] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA.
[Mittal, Pooja; Kusanovic, Juan Pedro; Hassan, Sonia S.] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA.
[Yoon, Bo Hyun] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 110799, South Korea.
[Lee, Deug-Chan; Romero, Roberto; Lee, JoonHo] NICHHD, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Lee, Deug-Chan; Romero, Roberto; Lee, JoonHo] NICHHD, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Detroit, MI 48201 USA.
RP Kim, CJ (reprint author), Wayne State Univ, Sch Med, Hutzel Womens Hosp, Dept Pathol, 3990 John R St, Detroit, MI 48201 USA.
EM prbchiefstaff@med.wayne.edu; cjkim@med.wayne.edu
RI Yoon, Bo Hyun/H-6344-2011
FU Perinatology Research Branch, Division of Intramural Research, Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health, Department of Health and
Human Services
FX This work was supported by the Perinatology Research Branch, Division of
Intramural Research, Eunice Kennedy Shriver National Institute of Child
Health and Human Development, National Institutes of Health, Department
of Health and Human Services.
NR 22
TC 11
Z9 11
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2010
VL 95
IS 9
BP E86
EP E91
DI 10.1210/jc.2010-0203
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 647SU
UT WOS:000281640300015
PM 20519349
ER
PT J
AU Lindstrom, S
Ma, J
Altshuler, D
Giovannucci, E
Riboli, E
Albanes, D
Allen, NE
Berndt, SI
Boeing, H
Bueno-de-Mesquita, HB
Chanock, SJ
Dunning, AM
Feigelson, HS
Gaziano, JM
Haiman, CA
Hayes, RB
Henderson, BE
Hunter, DJ
Kaaks, R
Kolonel, LN
Le Marchand, L
Martinez, C
Overvad, K
Siddiq, A
Stampfer, M
Stattin, P
Stram, DO
Thun, MJ
Trichopoulos, D
Tumino, R
Virtamo, J
Weinstein, SJ
Yeager, M
Kraft, P
Freedman, ML
AF Lindstroem, Sara
Ma, Jing
Altshuler, David
Giovannucci, Edward
Riboli, Elio
Albanes, Demetrius
Allen, Naomi E.
Berndt, Sonja I.
Boeing, Heiner
Bueno-de-Mesquita, H. Bas
Chanock, Stephen J.
Dunning, Alison M.
Feigelson, Heather Spencer
Gaziano, J. Michael
Haiman, Christopher A.
Hayes, Richard B.
Henderson, Brian E.
Hunter, David J.
Kaaks, Rudolf
Kolonel, Laurence N.
Le Marchand, Loic
Martinez, Carmen
Overvad, Kim
Siddiq, Afshan
Stampfer, Meir
Stattin, Paer
Stram, Daniel O.
Thun, Michael J.
Trichopoulos, Dimitrios
Tumino, Rosario
Virtamo, Jarmo
Weinstein, Stephanie J.
Yeager, Meredith
Kraft, Peter
Freedman, Matthew L.
TI A Large Study of Androgen Receptor Germline Variants and Their Relation
to Sex Hormone Levels and Prostate Cancer Risk. Results from the
National Cancer Institute Breast and Prostate Cancer Cohort Consortium
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID CAG-REPEAT POLYMORPHISM; GROWTH-FACTOR-I; MULTIETHNIC COHORT;
GENETIC-VARIATION; REGULATING GENES; STEROID-HORMONES; MEN; NUTRITION;
LENGTH; ASSOCIATION
AB Background: Androgens are key regulators of prostate gland maintenance and prostate cancer growth, and androgen deprivation therapy has been the mainstay of treatment for advanced prostate cancer for many years. Along-standing hypothesis has been that inherited variation in the androgen receptor (AR) gene plays a role in prostate cancer initiation. However, studies to date have been inconclusive and often suffered from small sample sizes.
Objective and Methods: We investigated the association of AR sequence variants with circulating sex hormone levels and prostate cancer risk in 6058 prostate cancer cases and 6725 controls of Caucasian origin within the Breast and Prostate Cancer Cohort Consortium. We genotyped a highly polymorphic CAG microsatellite in exon 1 and six haplotype tagging single nucleotide polymorphisms and tested each genetic variant for association with prostate cancer risk and with sex steroid levels.
Results: We observed no association between AR genetic variants and prostate cancer risk. However, there was a strong association between longer CAG repeats and higher levels of testosterone (P = 4.73 x 10(-5)) and estradiol (P = 0.0002), although the amount of variance explained was small (0.4 and 0.7%, respectively).
Conclusions: This study is the largest to date investigating AR sequence variants, sex steroid levels, and prostate cancer risk. Although we observed no association between AR sequence variants and prostate cancer risk, our results support earlier findings of a relation between the number of CAG repeats and circulating levels of testosterone and estradiol. (J Clin Endocrinol Metab 95: E121-E127, 2010)
C1 [Freedman, Matthew L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Lindstroem, Sara; Hunter, David J.; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
[Lindstroem, Sara; Stampfer, Meir; Trichopoulos, Dimitrios; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward; Stampfer, Meir] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Ma, Jing; Hunter, David J.; Stampfer, Meir] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Altshuler, David] Broad Inst Massachusetts Inst Technol MIT & Harva, Program Med & Populat Genet, Cambridge, MA USA.
[Altshuler, David] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Altshuler, David] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Altshuler, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Altshuler, David] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
[Riboli, Elio; Siddiq, Afshan] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Epidemiol & Publ Hlth, London, England.
[Albanes, Demetrius; Berndt, Sonja I.; Chanock, Stephen J.; Hayes, Richard B.; Weinstein, Stephanie J.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Allen, Naomi E.] Univ Oxford, Canc Epidemiol Unit, Oxford, England.
[Boeing, Heiner] German Inst Human Nutr Potsdam Rehbrucke, Nuthetal, Germany.
[Bueno-de-Mesquita, H. Bas] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
[Dunning, Alison M.] Univ Cambridge, Dept Oncol, Cambridge, England.
[Feigelson, Heather Spencer; Thun, Michael J.] Amer Canc Soc, Dept Epidemiol, Atlanta, GA 30329 USA.
[Feigelson, Heather Spencer] Kaiser Permanente, Denver, CO USA.
[Gaziano, J. Michael] Boston Vet Affairs Healthcare Syst, Massachusetts Vet Epidemiol & Res Informat Ctr, Boston, MA USA.
[Gaziano, J. Michael] Boston Vet Affairs Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
[Haiman, Christopher A.; Henderson, Brian E.; Stram, Daniel O.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Hayes, Richard B.] NYU, Div Epidemiol, Langone Med Ctr, New York, NY USA.
[Kaaks, Rudolf] German Canc Res Ctr, Div Canc Epidemiol, D-6900 Heidelberg, Germany.
[Kolonel, Laurence N.; Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA.
[Martinez, Carmen] Ctr Invest Biomed Red Epidemiol & Salud Publ, Granada, Spain.
[Martinez, Carmen] Andalusian Sch Publ Hlth, Granada, Spain.
[Overvad, Kim] Aarhus Univ Hosp, Aalborg Hosp, Aalborg, Denmark.
[Stattin, Paer] Umea Univ, Umea, Sweden.
[Tumino, Rosario] Canc Registry Azienda Osped Civile MP Arezzo, Ragusa, Italy.
[Virtamo, Jarmo] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland.
[Yeager, Meredith] NCI, Core Genotyping Facil, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21701 USA.
[Freedman, Matthew L.] Broad Inst Harvard & MIT, Cambridge, MA USA.
RP Freedman, ML (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM mfreedman@partners.org
RI Altshuler, David/A-4476-2009; Albanes, Demetrius/B-9749-2015;
OI Altshuler, David/0000-0002-7250-4107; Dunning, Alison
Margaret/0000-0001-6651-7166; Hayes, Richard/0000-0002-0918-661X
FU National Cancer Institute [UO1-CA98233, UO1-CA98710, UO1-CA98216,
UO1-CA98758]; National Institutes of Health/National Cancer Institute,
Division of Cancer Epidemiology and Genetics; Swedish Research Council
(Vetenskapsradet)
FX This work was supported by National Cancer Institute cooperative
agreements UO1-CA98233, UO1-CA98710, UO1-CA98216, and UO1-CA98758, and
by the Intramural Research Program of National Institutes of
Health/National Cancer Institute, Division of Cancer Epidemiology and
Genetics. S. \L. is supported by the Swedish Research Council
(Vetenskapsradet).
NR 32
TC 26
Z9 27
U1 1
U2 9
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2010
VL 95
IS 9
BP E121
EP E127
DI 10.1210/jc.2009-1911
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 647SU
UT WOS:000281640300020
PM 20534771
ER
PT J
AU Mumford, SL
Schisterman, EF
Siega-Riz, AM
Browne, RW
Gaskins, AJ
Trevisan, M
Steiner, AZ
Daniels, JL
Zhang, CL
Perkins, NJ
Wactawski-Wende, J
AF Mumford, Sunni L.
Schisterman, Enrique F.
Siega-Riz, Anna Maria
Browne, Richard W.
Gaskins, Audrey J.
Trevisan, Maurizio
Steiner, Anne Z.
Daniels, Julie L.
Zhang, Cuilin
Perkins, Neil J.
Wactawski-Wende, Jean
TI A Longitudinal Study of Serum Lipoproteins in Relation to Endogenous
Reproductive Hormones during the Menstrual Cycle: Findings from the
BioCycle Study
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN;
PLASMA-LIPIDS; SR-BI; CHOLESTEROL; METABOLISM; DISEASE; TRIAL
AB Context: Exogenous estrogens have been shown to affect the lipid profile, leading to the hypothesis that endogenous estrogens may have similar effects.
Objective: The objective of the study was to evaluate the association between endogenous estrogen and serum lipoproteins across the menstrual cycle.
Design: This was a prospective cohort study.
Setting: The study was conducted at the University at Buffalo, 2005-2007.
Participants: Participants included 259 healthy, regularly menstruating women aged 18-44 yr.
Main Outcome Measures: Serum levels of total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, and triglycerides measured up to eight times per cycle for up to two cycles were measured.
Results: Total and LDL cholesterol were lower during the luteal phase as compared with the follicular phase (P < 0.001), and HDL levels were highest around ovulation (P < 0.001). More women were classified above the desirable range (LDL >= 130 mg/dl or total cholesterol >= 200 mg/dl) when measured during the follicular phase. Estradiol was positively associated with HDL in acute effects models [beta = 0.019, 95% confidence interval (CI) 0.015, 0.022] and inversely associated with total (beta = -0.017, 95% CI -0.020, -0.014) and LDL cholesterol (beta = -0.023, 95% CI -0.027, -0.018) and triglycerides (beta = -0.041, 95% CI -0.054, -0.029) in persistent effects models.
Conclusions: Endogenous estrogen, like exogenous estrogen, appears to have beneficial effects on the lipid profile. Because lipoprotein cholesterol levels vary across the menstrual cycle, cyclic variations in lipoprotein levels may need to be considered in the design and interpretation of studies in reproductive-age women and in the clinical management of women's cholesterol. (J Clin Endocrinol Metab 95: E80-E85, 2010)
C1 [Mumford, Sunni L.; Schisterman, Enrique F.; Gaskins, Audrey J.; Zhang, Cuilin; Perkins, Neil J.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH,Dept Hlth & Human Serv, Rockville, MD 20852 USA.
[Mumford, Sunni L.; Siega-Riz, Anna Maria; Daniels, Julie L.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
[Steiner, Anne Z.] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC 27599 USA.
[Browne, Richard W.; Trevisan, Maurizio; Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14214 USA.
[Trevisan, Maurizio] Univ Nevada Hlth Sci Syst, Las Vegas, NV 89103 USA.
RP Schisterman, EF (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH,Dept Hlth & Human Serv, 6100 Execut Blvd 7B03, Rockville, MD 20852 USA.
EM schistee@mail.nih.gov
OI Perkins, Neil/0000-0002-6802-4733; Schisterman,
Enrique/0000-0003-3757-641X
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health
FX This work was supported by the Intramural Research Program of the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health.
NR 20
TC 22
Z9 22
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2010
VL 95
IS 9
BP E80
EP E85
DI 10.1210/jc.2010-0109
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 647SU
UT WOS:000281640300014
PM 20534764
ER
PT J
AU Xiao, TS
AF Xiao, Tsan Sam
TI Subversion of Innate Immune Signaling Through Molecular Mimicry
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article
DE Microbial subversion of innate signaling; TIR domain; PYD domain;
molecular mimicry
ID TOLL/INTERLEUKIN-1 RECEPTOR DOMAIN; BRUTONS TYROSINE KINASE; TIR-DOMAIN;
CRYSTAL-STRUCTURE; STRUCTURAL BASIS; VACCINIA VIRUS; PROTEIN; ADAPTER;
FAMILY; BRUCELLA
AB Innate immune signaling is mediated by a number of membrane-anchored or cytosolic receptor or sensor molecules. Several receptor families utilize conserved signaling domains such as the Toll/interleukin-1 receptor (TIR) domain and Pyrin domain (PYD) to link microbe recognition to induction of proinflammatory cytokines and interferons. Recent studies have identified a number of bacterial and viral TIR domains and PYD domains that directly target the signaling function of their host homologues. Emerging biochemical and structural studies of these microbial TIR and PYD domains suggest that they are mimics of their host counterparts at the sequence and structure levels. Unraveling the mechanisms of such molecular mimicry is crucial to our understanding and clinical intervention of infectious diseases and inflammatory disorders.
C1 NIAID, Struct Immunobiol Unit, Immunol Lab, NIH, Bethesda, MD 20892 USA.
RP Xiao, TS (reprint author), NIAID, Struct Immunobiol Unit, Immunol Lab, NIH, 4 Mem Dr,Bldg 4,Room 138, Bethesda, MD 20892 USA.
EM Xiaot@niaid.nih.gov
RI Xiao, Tsan/I-7616-2013; Xiao, Tsan/A-8590-2010
OI Xiao, Tsan/0000-0001-9688-475X;
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health
FX The author is supported by the Division of Intramural Research of the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health.
NR 32
TC 10
Z9 10
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD SEP
PY 2010
VL 30
IS 5
BP 638
EP 642
DI 10.1007/s10875-010-9435-0
PG 5
WC Immunology
SC Immunology
GA 648KX
UT WOS:000281693700004
PM 20589422
ER
PT J
AU Caspi, RR
AF Caspi, Rachel R.
TI A look at autoimmunity and inflammation in the eye
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Review
ID REGULATORY T-CELLS; KOYANAGI-HARADA-DISEASE; HLA CLASS-II;
ENDOTOXIN-INDUCED UVEITIS; HLA-A29 TRANSGENIC MICE; RETINAL S-ANTIGEN;
NEO-SELF ANTIGEN; BIRDSHOT RETINOCHOROIDOPATHY; OCULAR AUTOIMMUNITY;
THYMIC EXPRESSION
AB Autoimmune and inflammatory uveitis are a group of potentially blinding intraocular inflammatory diseases that arise without a known infectious trigger and are often associated with immunological responses to unique retinal proteins. In the United States, about 10% of the cases of severe visual handicap are attributed to this group of disorders. As I discuss here, experimental models of ocular autoimmunity targeting retinal proteins have brought about a better understanding of the basic immunological mechanisms involved in the pathogenesis of uveitis and are serving as templates for the development of novel therapies.
C1 NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
RP Caspi, RR (reprint author), NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
EM rcaspi@helix.nih.gov
OI Caspi, Rachel/0000-0002-7140-7671
NR 122
TC 132
Z9 136
U1 1
U2 15
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD SEP
PY 2010
VL 120
IS 9
BP 3073
EP 3083
DI 10.1172/JCI42440
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 645LJ
UT WOS:000281458800009
PM 20811163
ER
PT J
AU Land, SR
Kopec, JA
Julian, TB
Brown, AM
Anderson, SJ
Krag, DN
Christian, NJ
Costantino, JP
Wolmark, N
Ganz, PA
AF Land, Stephanie R.
Kopec, Jacek A.
Julian, Thomas B.
Brown, Ann M.
Anderson, Stewart J.
Krag, David N.
Christian, Nicholas J.
Costantino, Joseph P.
Wolmark, Norman
Ganz, Patricia A.
TI Patient-Reported Outcomes in Sentinel Node-Negative Adjuvant Breast
Cancer Patients Receiving Sentinel-Node Biopsy or Axillary Dissection:
National Surgical Adjuvant Breast and Bowel Project Phase III Protocol
B-32
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; RANDOMIZED CLINICAL-TRIAL; UPPER-LIMB MORBIDITY;
LONG-TERM MORBIDITY; RACS SNAC TRIAL; LYMPH-NODE; ARM MORBIDITY; WOMENS
CHOICE; STAGE-I; MULTICENTER
AB Purpose
Sentinel lymph node resection (SNR) may reduce morbidity while providing the same clinical utility as conventional axillary dissection (AD). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 is a randomized phase III trial comparing SNR immediately followed by AD (SNAD) to SNR and subsequent AD if SN is positive. We report the definitive patient-reported outcomes (PRO) comparisons.
Patients and Methods
Eligible patients had clinically node-negative, operable invasive breast cancer. The PRO substudy included all SN-negative participants enrolled May 2001 to February 2004 at community institutions in the United States (n = 749; 78% age >= 50; 87% clinical tumor size <= 2.0 cm; 84% lumpectomy; 87% white). They completed questionnaires presurgery, 1 and 2 to 3 weeks postoperatively, and every 6 months through year 3. Arm symptoms, arm use avoidance, activity limitations, and quality of life (QOL) were compared with intent-to-treat two-sample t-tests and repeated measures analyses.
Results
Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006). Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P <= .002 all items). From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation.
Conclusion
Arm morbidity was greater with SNAD than with SNR. Despite considerable fears about complications from AD for breast cancer, this study demonstrates that initial problems with either surgery resolve over time.
C1 [Land, Stephanie R.] Univ Pittsburgh, Grad Sch Publ Hlth, Natl Surg Adjuvant Breast & Bowel Project, Dept Biostat,Operat & Biostat Ctr, Pittsburgh, PA 15213 USA.
Allegheny Gen Hosp, Pittsburgh, PA 15212 USA.
Univ British Columbia, Arthritis Res Ctr Canada, Vancouver, BC V5Z 1M9, Canada.
Univ Vermont, Coll Med, Burlington, VT USA.
Univ Vermont, Breast Care Ctr, Burlington, VT USA.
Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
RP Land, SR (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Natl Surg Adjuvant Breast & Bowel Project, Dept Biostat,Operat & Biostat Ctr, 201 N Craig St,Suite 350, Pittsburgh, PA 15213 USA.
EM land@pitt.edu
OI Anderson, Stewart/0000-0001-8948-0650
FU National Cancer Institute, Department of Health and Human Services,
Public Health Service [U10-CA-12027, U10-CA-69651, U10-CA-37377,
U10-CA-69974, 5RO1-CA-074137]; Vermont Cancer Center [P30 CA22435]
FX Supported by the Grants No. U10-CA-12027, U10-CA-69651, U10-CA-37377,
U10-CA-69974, and 5RO1-CA-074137 (D.N.K.) from the National Cancer
Institute, Department of Health and Human Services, Public Health
Service, and by Grant No. P30 CA22435 from the Vermont Cancer Center.
NR 41
TC 53
Z9 56
U1 1
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD SEP 1
PY 2010
VL 28
IS 25
BP 3929
EP 3936
DI 10.1200/JCO.2010.28.2491
PG 8
WC Oncology
SC Oncology
GA 645YQ
UT WOS:000281502500008
PM 20679600
ER
PT J
AU O'Connell, MJ
Lavery, I
Yothers, G
Paik, S
Clark-Langone, KM
Lopatin, M
Watson, D
Baehner, FL
Shak, S
Baker, J
Cowens, JW
Wolmark, N
AF O'Connell, Michael J.
Lavery, Ian
Yothers, Greg
Paik, Soonmyung
Clark-Langone, Kim M.
Lopatin, Margarita
Watson, Drew
Baehner, Frederick L.
Shak, Steven
Baker, Joffre
Cowens, J. Wayne
Wolmark, Norman
TI Relationship Between Tumor Gene Expression and Recurrence in Four
Independent Studies of Patients With Stage II/III Colon Cancer Treated
With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID COLORECTAL-CANCER; THYMIDYLATE SYNTHASE; DUKES-B; DIHYDROPYRIMIDINE
DEHYDROGENASE; MICROSATELLITE-INSTABILITY; PREDICT RECURRENCE;
PROGNOSTIC VALUE; MISMATCH REPAIR; CHROMOSOME 18Q; BREAST-CANCER
AB Purpose
These studies were conducted to determine the relationship between quantitative tumor gene expression and risk of cancer recurrence in patients with stage II or III colon cancer treated with surgery alone or surgery plus fluorouracil (FU) and leucovorin (LV) to develop multigene algorithms to quantify the risk of recurrence as well as the likelihood of differential treatment benefit of FU/LV adjuvant chemotherapy for individual patients.
Patients and Methods
We performed quantitative reverse transcription polymerase chain reaction (RT-qPCR) on RNA extracted from fixed, paraffin-embedded (FPE) tumor blocks from patients with stage II or III colon cancer who were treated with surgery alone (n = 270 from National Surgical Adjuvant Breast and Bowel Project [NSABP] C-01/C-02 and n = 765 from Cleveland Clinic [CC]) or surgery plus FU/LV (n = 308 from NSABP C-04 and n = 508 from NSABP C-06). Overall, 761 candidate genes were studied in C-01/C-02 and C-04, and a subset of 375 genes was studied in CC/C-06.
Results
A combined analysis of the four studies identified 48 genes significantly associated with risk of recurrence and 66 genes significantly associated with FU/LV benefit (with four genes in common). Seven recurrence-risk genes, six FU/LV-benefit genes, and five reference genes were selected, and algorithms were developed to identify groups of patients with low, intermediate, and high likelihood of recurrence and benefit from FU/LV.
Conclusion
RT-qPCR of FPE colon cancer tissue applied to four large independent populations has been used to develop multigene algorithms for estimating recurrence risk and benefit from FU/LV. These algorithms are being independently validated, and their clinical utility is being evaluated in the Quick and Simple and Reliable (QUASAR) study.
C1 [O'Connell, Michael J.] Natl Surg Adjuvant Breast & Bowel Project, Allegheny Ctr 4, Pittsburgh, PA 15212 USA.
Allegheny Gen Hosp, Pittsburgh, PA 15212 USA.
Univ Pittsburgh, Natl Surg Adjuvant Breast & Bowel Project, Ctr Stat, Pittsburgh, PA USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Genom Hlth Inc, Redwood City, CA USA.
RP O'Connell, MJ (reprint author), Natl Surg Adjuvant Breast & Bowel Project, Allegheny Ctr 4, 5th Floor, Pittsburgh, PA 15212 USA.
EM michael.oconnell@nsabp.org
OI Yothers, Greg/0000-0002-7965-7333
FU National Cancer Institute, National Institutes of Health, Department of
Health and Human Services [U10-CA-37377, U10-CA-69974, U10-CA-12027,
U10-CA-69651]; Genomic Health, Inc.
FX Supported by Public Health Service Grants No. U10-CA-37377,
U10-CA-69974, U10-CA-12027, and U10-CA-69651 from the National Cancer
Institute, National Institutes of Health, Department of Health and Human
Services, and by Genomic Health, Inc.
NR 57
TC 128
Z9 131
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD SEP 1
PY 2010
VL 28
IS 25
BP 3937
EP 3944
DI 10.1200/JCO.2010.28.9538
PG 8
WC Oncology
SC Oncology
GA 645YQ
UT WOS:000281502500009
PM 20679606
ER
PT J
AU Widemann, BC
Balis, FM
Kim, A
Boron, M
Jayaprakash, N
Shalabi, A
O'Brien, M
Eby, M
Cole, DE
Murphy, RF
Fox, E
Ivy, P
Adamson, PC
AF Widemann, Brigitte C.
Balis, Frank M.
Kim, AeRang
Boron, Matthew
Jayaprakash, Nalini
Shalabi, Aiman
O'Brien, Michelle
Eby, Michelle
Cole, Diane E.
Murphy, Robert F.
Fox, Elizabeth
Ivy, Percy
Adamson, Peter C.
TI Glucarpidase, Leucovorin, and Thymidine for High-Dose
Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic
Factors Affecting Outcome
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CARBOXYPEPTIDASE G2 RESCUE; CANCER-PATIENTS; INDUCED NEPHROTOXICITY;
G(2) RESCUE; ELIMINATION; FAILURE; THERAPY; PHARMACOKINETICS; TOXICITY;
PATIENT
AB Purpose
To assess the role of the recombinant bacterial enzyme, glucarpidase (carboxypeptidase-G(2)), leucovorin, and thymidine in the management and outcome of patients with high-dose methotrexate (HDMTX)-induced nephrotoxicity.
Methods
Patients with HDMTX-induced nephrotoxicity received one to three doses of intravenous (IV) glucarpidase and leucovorin rescue. The initial cohort (n = 35) also received thymidine by continuous IV infusion. Subsequently, thymidine was restricted to patients with prolonged exposure (> 96 hours) to methotrexate (MTX) or with substantial MTX toxicity at study entry. Plasma MTX, leucovorin, and 5-methyltetrahydrofolate (5-mTHF) concentrations were measured pre- and postglucarpidase. Toxicities were monitored, and logistic regression analysis was used to assess the relationship of baseline characteristics to the development of severe toxicity and death.
Results
Glucarpidase was administered at a median of 96 hours (receiving thymidine, n = 44) and 66 hours (not receiving thymidine, n = 56) after the start of the MTX infusion. Plasma MTX concentrations decreased within 15 minutes of glucarpidase by 98.7%. Plasma 5-mTHF concentrations also decreased more than 98% after administration of glucarpidase. Of 12 deaths, six were directly attributed to irreversible MTX toxicity. Presence of grade 4 toxicity before administration of glucarpidase, inadequate initial increase in leucovorin dosing, and administration of glucarpidase more than 96 hours after the start of the MTX infusion were associated with development of grade 4 and 5 toxicity.
Conclusion
Early intervention with the combination of leucovorin and glucarpidase is highly effective in patients who develop HDMTX-induced renal dysfunction. Severe toxicity and mortality occurred in patients in whom glucarpidase rescue was delayed and occurred despite thymidine administration.
C1 [Widemann, Brigitte C.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
RP Widemann, BC (reprint author), NCI, Pediat Oncol Branch, 10 Ctr Dr,Bldg 10 CRC,Room 1-5750, Bethesda, MD 20892 USA.
EM widemanb@mail.nih.gov
FU National Institutes of Health, National Cancer Institute, Center for
Cancer Research, Bethesda, MD
FX Supported by the Intramural Research Program of the National Institutes
of Health, National Cancer Institute, Center for Cancer Research,
Bethesda, MD.
NR 28
TC 34
Z9 37
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD SEP 1
PY 2010
VL 28
IS 25
BP 3979
EP 3986
DI 10.1200/JCO.2009.25.4540
PG 8
WC Oncology
SC Oncology
GA 645YQ
UT WOS:000281502500015
PM 20679598
ER
PT J
AU Thomas, MB
Jaffe, D
Choti, MM
Belghiti, J
Curley, S
Fong, YM
Gores, G
Kerlan, R
Merle, P
O'Neil, B
Poon, R
Schwartz, L
Tepper, J
Yao, F
Haller, D
Mooney, M
Venook, A
AF Thomas, Melanie B.
Jaffe, Deborah
Choti, Michael M.
Belghiti, Jacques
Curley, Steven
Fong, Yuman
Gores, Gregory
Kerlan, Robert
Merle, Phillipe
O'Neil, Bert
Poon, Ronnie
Schwartz, Lawrence
Tepper, Joel
Yao, Francis
Haller, Daniel
Mooney, Margaret
Venook, Alan
TI Hepatocellular Carcinoma: Consensus Recommendations of the National
Cancer Institute Clinical Trials Planning Meeting
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; ENDOTHELIAL GROWTH-FACTOR; TRANSCATHETER
ARTERIAL CHEMOEMBOLIZATION; ACTIVATED PROTEIN-KINASES; MULTIDETECTOR-ROW
CT; PRIMARY LIVER-CANCER; CHRONIC HEPATITIS-C; LONG-TERM SURVIVAL;
DISEASE MELD SCORE; PHASE-II TRIAL
AB Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. The incidence of HCC in the United States is rising steadily because of the prevalence of hepatitis C viral infection and other causes of hepatic cirrhosis. The majority of patients have underlying hepatic dysfunction, which complicates patient management and the search for safe and effective therapies. The Clinical Trials Planning Meeting (CTPM) in HCC was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to identify the key knowledge gaps in HCC and define clinical research priorities. The CTPM structured its review according to current evidence-based treatment modalities in HCC and prioritized the recommendations on the basis of the patient populations representing the greatest unmet medical need.
C1 [Thomas, Melanie B.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
NCI, Bethesda, MD 20892 USA.
Johns Hopkins Med Inst, Baltimore, MD 21205 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
Mayo Clin, Rochester, MN USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Hop Hotel Dieu, Paris, France.
Univ N Carolina, Chapel Hill, NC USA.
Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
Univ Penn, Philadelphia, PA 19104 USA.
RP Thomas, MB (reprint author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St,Suite 118K, Charleston, SC 29425 USA.
EM thomasmb@musc.edu
FU Genentech BioOncology; Bayer Pharmaceuticals; Genentech; Pfizer
FX Research Funding: Melanie B. Thomas, Genentech BioOncology; Michael M.
Choti, Bayer Pharmaceuticals; Bert O'Neil, Bayer Pharmaceuticals; Alan
Venook, Genentech, Bayer Pharmaceuticals, Pfizer
NR 148
TC 165
Z9 168
U1 2
U2 15
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD SEP 1
PY 2010
VL 28
IS 25
BP 3994
EP 4005
DI 10.1200/JCO.2010.28.7805
PG 12
WC Oncology
SC Oncology
GA 645YQ
UT WOS:000281502500017
PM 20679622
ER
PT J
AU Jobes, ML
Epstein, DH
Preston, KL
AF Jobes, Michelle L.
Epstein, David H.
Preston, Kenzie L.
TI EFFECTS OF CLONIDINE ON COCAINE CRAVING IN RESPONSE TO STRESS- AND
DRUG-RELATED SCRIPTS
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Meeting Abstract
CT 39th Annual Meeting on American-College-of-Clinical-Pharmacology
CY SEP 12-14, 2010
CL Baltimore, MD
SP Amer coll Pharmacol
C1 [Jobes, Michelle L.; Epstein, David H.; Preston, Kenzie L.] Natl Inst Drug Abuse, Intramural Res Program, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0091-2700
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD SEP
PY 2010
VL 50
IS 9
MA 138
BP 1089
EP 1089
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 650OD
UT WOS:000281858000133
ER
PT J
AU Post, RM
Altshuler, LL
Frye, MA
Suppes, T
Keck, PE
McElroy, SL
Leverich, GS
Luckenbaugh, DA
Rowe, M
Pizzarello, S
Kupka, RW
Grunze, H
Nolen, WA
AF Post, Robert M.
Altshuler, Lori L.
Frye, Mark A.
Suppes, Trisha
Keck, Paul E., Jr.
McElroy, Susan L.
Leverich, Gabriele S.
Luckenbaugh, David A.
Rowe, Michael
Pizzarello, Scott
Kupka, Ralph W.
Grunze, Heinz
Nolen, Willem A.
TI Complexity of Pharmacologic Treatment Required for Sustained Improvement
in Outpatients With Bipolar Disorder
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID TREATMENT ENHANCEMENT PROGRAM; I DISORDER; ANTIDEPRESSANT
DISCONTINUATION; CLINICAL-TRIALS; DOUBLE-BLIND; MAINTENANCE TREATMENT;
DEPRESSED-PATIENTS; 18-MONTH TRIAL; STEP-BD; ILLNESS
AB Objective: To evaluate the clinical correlates of and types of naturalistic treatments associated with sustained improvement/remission for at least 6 months in outpatients with bipolar disorder.
Method: Five hundred twenty-five outpatients with bipolar disorder (77.7% bipolar 1) gave informed consent, had their mood rated daily on the National Institute of Mental Health Life Chart Method for a minimum of at least 1 year, and recorded all medications. Demographics and clinical characteristics of patients with a "sustained response" (ratings of "improved" or "very much improved" on the Clinical Global Impressions-Bipolar Version for a period of at least 6 months) versus nonresponders were compared. The study was conducted from 1996 to 2002.
Results: Of the 429 patients who were ill at study entry, 195 (45.5%) showed a sustained response; 54.5% showed no or insufficient response. A mean of 2.98 medications was given at time of improvement, which occurred after a mean of 18 months of participation in the study. Lithium and valproate were the medications most frequently prescribed at the time of improvement and had among the highest overall success rates. Equally complex regimens were employed in the nonresponders who, however, had a more adverse clinical course prior to network entry. Nonresponders were ultimately exposed to more antidepressants and antipsychotics than the sustained responders.
Conclusions: A mean of 1.5 years and at times highly complex medication regimens were required to achieve a sustained response for 6 months during naturalistic outpatient treatment of bipolar disorder. Delineating the clinical and biologic correlates of individual response to combination treatment is a very high clinical research priority, as is developing new treatment strategies for the large proportion of patients who fail to respond in a sustained fashion. J Clin Psychiatry 2010;71(9):1176-1186 (C) Copyright 2010 Physicians Postgraduate Press, Inc.
C1 [Post, Robert M.; Rowe, Michael] Bipolar Collaborat Network, Dept Biostat, Bethesda, MD 20814 USA.
[Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA.
[Altshuler, Lori L.] Univ Calif Los Angeles, Mood Disorders Res Program, Los Angeles, CA USA.
[Altshuler, Lori L.] Vet Affairs Med Ctr, Los Angeles, CA USA.
[Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MN USA.
[Suppes, Trisha] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
[Keck, Paul E., Jr.; McElroy, Susan L.] Univ Cincinnati, Coll Med, Dept Psychiat & Neurosci, Cincinnati, OH USA.
[Keck, Paul E., Jr.; McElroy, Susan L.] Lindner Ctr HOPE, Mason, OH USA.
[Luckenbaugh, David A.] NIMH, Mood & Anxiety Disorders Program, NIH, Bethesda, MD 20892 USA.
[Pizzarello, Scott] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Kupka, Ralph W.] Altrecht Inst Mental Hlth Care, Utrecht, Netherlands.
[Grunze, Heinz] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9700 AB Groningen, Netherlands.
[Kupka, Ralph W.] Free Univ Amsterdam, Dept Psychiat, Med Ctr, NL-1007 MC Amsterdam, Netherlands.
RP Post, RM (reprint author), Bipolar Collaborat Network, Dept Biostat, 5415 W Cedar Lane,Suite 201B, Bethesda, MD 20814 USA.
EM robert.post@speakeasy.net
RI Nolen, Willem/E-9006-2014;
OI Grunze, Heinz/0000-0003-4712-8979
FU Abbott; Pfizer; AstraZeneca; NIMH; Stanley Medical Research Institute;
JDS Pharmaceuticals; CME Outfitters; Medscape; Wolters Kluwer Pharma
Solutions (CNS Drug Supplement); Jones and Bartlett (formerly Compact
Clinicals); Alkermes; Cephalon; GlaxoSmithKline; Eli Lilly; Epi-Q; Jazz;
Marriott Foundation; Orexigen; Shire; Bristol-Myers Squibb; Forest;
Takeda; Johnson & Johnson Pharmaceutical Research Development; UCB
Belgium; Stanley Foundation; NHS National Institute for Health
Research/Medical Research Council UK; The Netherlands Organization for
Health Research and Development; European Union; The Stanley Medical
Research Institute; Wyeth; Servier; The Stanley Medical Research
Institute, Chevy Chase, Maryland; NIMH, Bethesda, Maryland
FX Dr Post has been a consultant to and has been a member of the speakers
or advisory boards for Abbott, AstraZeneca, Bristol-Myers Squibb, and
GlaxoSmithKline. Dr Altshuler has received grant/research support from
Abbott; has received honoraria from Abbott, Forest, and GlaxoSmithKline;
is a member of the advisory board of Abbott and Forest; and is a member
of the speakers board of Forest and GlaxoSmithKline. Dr Frye has
received grant support from Pfizer; has been a consultant to Cephalon,
Dainippon Sumitomo, Ortho McNeil/Janssen, Johnson & Johnson,
Schering-Plough, and Pfizer; and has participated in supported CME
activities for AstraZeneca, Bristol-Myers Squibb, Eli Lilly,
GlaxoSmithKline, Otsuka, Pfizer, and Schering-Plough. Dr Suppes, from
January 2008 to December 2009, received grant support or clinical study
medications from AstraZeneca, NIMH, Stanley Medical Research Institute,
Abbott, and JDS Pharmaceuticals; had consulting agreements with or
served on the advisory board for Orexigen; received honoraria or
speakers fees from CME Outfitters, Medscape, and Wolters Kluwer Pharma
Solutions (CNS Drug Supplement); received support for travel from
AstraZeneca; and received royalties from Jones and Bartlett (formerly
Compact Clinicals). Dr Keck is presently or has been in the past year a
principal or co-investigator on research studies sponsored by Alkermes,
AstraZeneca, Cephalon, GlaxoSmithKline, Eli Lilly, Epi-Q, Jazz, Marriott
Foundation, NIMH, Orexigen, Pfizer, and Shire; has been reimbursed for
consulting to Sepracor, Medco, GlaxoSmithKline, Schering-Plough,
Bristol-Myers Squibb, Pfizer, and QuantiaMD; and is a co-inventor on US
patent no. 6,387,956: Shapira NA, Goldsmith TD, Keck PE Jr. (University
of Cincinnati). Methods of treating obsessive-compulsive spectrum
disorder comprises the step of administering an effective amount of
tramadol to an individual. Filed March 25, 1999; approved May 14, 2002.
Dr Keck has received no financial gain from this patent. Dr McElroy is a
consultant to or member of the scientific advisory boards of
AstraZeneca, Eli Lilly, and Schering-Plough and is a principal or
coinvestigator on research studies sponsored by Abbott, AstraZeneca,
Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline,
Jazz, NIMH, Orexigen, Pfizer, and Takeda. Dr McElroy is also inventor on
US Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating
Impulse Control Disorders, and, along with the patent's assignee, the
University of Cincinnati, Cincinnati, Ohio, has received payments from
Johnson & Johnson Pharmaceutical Research & Development, which has
exclusive rights under the patent. Dr Kupka has been a member of the
speakers or advisory boards of Eli Lilly and AstraZeneca. During the
past 3 years, Dr Grunze has received honoraria for consultancies,
advisory boards, and paid speaker engagements from AstraZeneca,
Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Pfizer,
Sanofi-Aventis, Schering-Plough, Servier, and UBC and has received
research grants from AstraZeneca, UCB Belgium, Stanley Foundation, NHS
National Institute for Health Research/Medical Research Council UK, and
Pfizer. Dr Nolen has received grants from The Netherlands Organization
for Health Research and Development, the European Union, The Stanley
Medical Research Institute, AstraZeneca, Eli Lilly, GlaxoSmithKline, and
Wyeth; has received honoraria or speaker's fees from AstraZeneca, Eli
Lilly, Pfizer, Servier, and Wyeth; and has served on the advisory boards
of AstraZeneca, Cyberonics, Pfizer, and Servier.; Dr Rowe, Ms Leverich,
ad Mssrs Luckenbaugh and Pizzarello have no personal affiliations or
financial relationships with any commercial interest to disclose
relative to the article.; The conduct of this study was supported by The
Stanley Medical Research Institute, Chevy Chase, Maryland. Data analysis
was supported by NIMH, Bethesda, Maryland.
NR 44
TC 54
Z9 54
U1 0
U2 2
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD SEP
PY 2010
VL 71
IS 9
BP 1176
EP 1186
DI 10.4088/JCP.08m04811yel
PG 11
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 661EF
UT WOS:000282705700010
PM 20923622
ER
PT J
AU Alegria, AA
Hasin, DS
Nunes, EV
Liu, SM
Davies, C
Grant, BF
Blanco, C
AF Alegria, Analucia A.
Hasin, Deborah S.
Nunes, Edward V.
Liu, Shang-Min
Davies, Carrie
Grant, Bridget F.
Blanco, Carlos
TI Comorbidity of Generalized Anxiety Disorder and Substance Use Disorders:
Results From the National Epidemiologic Survey on Alcohol and Related
Conditions
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID DSM-III-R; DRUG-USE DISORDERS; PSYCHIATRIC RESEARCH INTERVIEW; SAMPLE
HEAVY DRINKERS; BIPOLAR I DISORDER; UNITED-STATES; MENTAL-DISORDERS;
PERSONALITY-DISORDERS; SCHEDULE AUDADIS; DEPRESSIVE-DISORDERS
AB Objective: Prior research has consistently documented a strong association between generalized anxiety disorder (GAD) and substance use disorder (SUD). Comorbidity of GAD and SUD (GAD-SUD) represents clinical challenges, as the patients' symptoms are often more severe and are frequently prolonged, making their management more complex when compared with individuals with GAD only. The purpose of this study was to examine whether individuals with GAD-SUD differ meaningfully from individuals with GAD and no SUD comorbidity (GAD-NSUD) in terms of demographic characteristics, risk factors, psychiatric comorbidity, and clinical correlates.
Method: Data were derived from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (N = 43,093). Diagnoses were made using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version.
Results: We found that the lifetime prevalence rate of GAD-SUD is about 2.04%, while that of GAD-NSUD is 2.10%. Individuals with GAD-SUD showed higher psychiatric comorbidity rates than those with GAD-NSUD. Treatment-seeking rates for GAD are equally low in individuals with GAD-SUD and GAD-NSUD. Both groups were as likely to receive pharmacologic treatment for anxiety.
Conclusions: The findings of our study indicate that individuals with GAD-SUD constitute half of the lifetime prevalence of GAD and that GAD-SUD is associated with high overall vulnerability for additional psychopathology, particularly in the externalizing spectrum; higher disability; and, higher use of alcohol and drugs to relieve anxiety symptoms. J Clin Psychiatry 2010;71(9):1187-1195 (C) Copyright 2010 Physicians Postgraduate Press, Inc.
C1 [Grant, Bridget F.] NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, NIH, Bethesda, MD 20892 USA.
[Alegria, Analucia A.; Hasin, Deborah S.; Nunes, Edward V.; Liu, Shang-Min; Davies, Carrie; Blanco, Carlos] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Hasin, Deborah S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
[Hasin, Deborah S.; Nunes, Edward V.; Blanco, Carlos] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.
RP Grant, BF (reprint author), NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, NIH, MS 9304,5635 Fishers Lane, Bethesda, MD 20892 USA.
EM bgrant@willco.niaaa.nih.gov
RI Blanco, Carlos/I-4906-2013;
OI Blanco, Carlos/0000-0001-6187-3057; Alegria, Analucia
/0000-0001-6044-3311
FU GlaxoSmithKline; Eli Lilly; Pfizer; NIAAA, NIH; NIH [DA019606, DA020783,
DA023200, MH076051, R01AA08159, K05AA00161, K24 DA022412]; American
Foundation for Suicide Prevention; New York State Psychiatric Institute;
NIAAA
FX Dr Blanco has received grant/research support from GlaxoSmithKline, Eli
Lilly, and Pfizer. Mss Alegria, Liu, and Davies and Drs Hasin, Nunes,
and Grant have no personal affiliations or financial relationships with
any commercial interest to disclose relative to the article.; The
National Epidemiologic Survey on Alcohol and Related Conditions was
sponsored by the NIAAA and was funded, in part, by the Intramural
Program, NIAAA, NIH. This study was supported by NIH grants DA019606,
DA020783, DA023200, and MH076051 (Dr Blanco); R01AA08159 and K05AA00161
(Dr Hasin); and K24 DA022412 (Dr Nunes); the American Foundation for
Suicide Prevention (Dr Blanco); and the New York State Psychiatric
Institute (Drs Blanco, Nunes, and Hasin).
NR 79
TC 31
Z9 32
U1 1
U2 8
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD SEP
PY 2010
VL 71
IS 9
BP 1187
EP 1195
DI 10.4088/JCP.09m05328gry
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 661EF
UT WOS:000282705700011
PM 20923623
ER
PT J
AU Blanco, C
Alegria, AA
Petry, NM
Grant, JE
Simpson, HB
Liu, SM
Grant, BF
Hasin, DS
AF Blanco, Carlos
Alegria, Analucia A.
Petry, Nancy M.
Grant, Jon E.
Simpson, H. Blair
Liu, Shang-Min
Grant, Bridget F.
Hasin, Deborah S.
TI Prevalence and Correlates of Fire-Setting in the United States: Results
From the National Epidemiologic Survey on Alcohol and Related Conditions
(NESARC)
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID GENERAL-POPULATION SAMPLE; PSYCHIATRIC DIAGNOSTIC MODULES; INTERVIEW
SCHEDULE AUDADIS; IMPULSE CONTROL DISORDERS; SUBSTANCE USE DISORDERS;
FAMILY-HISTORY; RELIABILITY; DISABILITIES; PERSONALITY; CONCORDANCE
AB Objective: To estimate the prevalence, sociodemographic correlates, comorbidity, and rates of mental health service utilization of fire-setters in the general population.
Method: A face-to-face survey of more than 43,000 adults aged 18 years and older residing in households was conducted during the 2001-2002 period. Diagnoses of mood, anxiety, substance use disorders, and personality disorders were based on the Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version (AUDADIS-IV).
Results: The prevalence of lifetime fire-setting in the US population was 1.13 (95% CI, 1.0-1.3). Being male, never married, and US-born and having a yearly income over $70,000 were risk factors for lifetime fire-se